FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Wynn, JK Breitmeyer, B Nuechterlein, KH Green, MF AF Wynn, Jonathan K. Breitmeyer, Bruno Nuechterlein, Keith H. Green, Michael F. TI Exploring the short term visual store in schizophrenia using the attentional blink SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article; Proceedings Paper CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat DE schizophrenia; visual processing; attentional blink; short term visual memory ID WORKING-MEMORY CONSOLIDATION; BACKWARD-MASKING; SUPPRESSION; DEFICITS; TASK; PERCEPTION; TRANSIENT; CHANNELS; MODEL AB Schizophrenia patients exhibit numerous deficits on visual processing tasks, ranging from very early stages of visual processing (e.g., backward masking) to the later working memory stages (e.g., delayed match-to-sample, N-back). However, little is known about deficits in an inter-mediate stage of visual information processing, namely short term visual memory (STVM). The attentional blink (AB) paradigm is considered to be a valid way to assess the STVM, and recent studies have reported AB deficits in schizophrenia. However, it is not clear whether the reported AB deficit in schizophrenia patients is due to their increased susceptibility to backward masking or increased vulnerability in the STVM. In this study we first found poorer performance in the AB task in 37 schizophrenia patients compared to 26 normal controls. To examine the effects of increasing and decreasing mask strength on AB performance in patients and controls, we next systematically varied the masking effect by varying the length of the distracters immediately following the targets. The manipulation had relatively little effect on the patient - control differences and patients continued to show an enhanced AB effect across conditions. The findings suggest that the enhanced AB effect in schizophrenia reflects an abnormality in their short term visual memory, as opposed to their enhanced susceptibility to visual masking. (c) 2006 Elsevier Ltd. All rights reserved. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Wynn, JK (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 210, Los Angeles, CA 90073 USA. EM jkwynn@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU NIMH NIH HHS [MH-65707, MH-43292, MH14584] NR 34 TC 17 Z9 17 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIAT RES JI J. Psychiatr. Res. PD OCT PY 2006 VL 40 IS 7 BP 599 EP 605 DI 10.1016/j.jpsychires.2006.06.002 PG 7 WC Psychiatry SC Psychiatry GA 093AU UT WOS:000241140300004 PM 16890242 ER PT J AU Tsai, AG Asch, DA Wadden, TA AF Tsai, Adam Gilden Asch, David A. Wadden, Thomas A. TI Insurance coverage for obesity treatment SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article; Proceedings Paper CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc Gen Internal Med ID IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; BARIATRIC SURGERY; HEALTH-CARE; MANAGEMENT; METFORMIN; SERVICES; THERAPY; SMOKING; ADULTS AB Recent work demonstrates the benefits of weight loss from intensive lifestyle modification. One barrier to counseling may be lack of reimbursement. We sought to quantify the obesity coverage policies of insurers in Pennsylvania. A three-page questionnaire was sent to eligible Pennsylvania health plans. Respondents included company medical directors and administrators from other departments, including public relations, provider relations, disease management, and utilization review. The questionnaire inquired about major treatment modalities for obesity, including details of coverage. Sixteen of 19 eligible plans (84%) responded. All plans provided some coverage for bariatric surgery. Nine out of 16 companies (56%) stated that they covered individual dietary counseling, but only five paid for intensive counseling. Less than 50% of plans reimbursed other forms of lifestyle modification or weight loss medication. Surgery was covered significantly more often than all other treatment modalities (P<0.02 for all comparisons). No differences in reimbursement were found by plan type or by number of enrollees. Insurance reimbursement for obesity in Pennsylvania does not consistently reflect recent evidence for the benefits of lifestyle modification. Given the increasing evidence for the clinical and cost-effectiveness of nonsurgical weight loss therapy, coverage policies may begin to change. C1 Univ Penn, Ctr Weight & Eating Disorders, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Tsai, AG (reprint author), Univ Penn, Ctr Weight & Eating Disorders, 3535 Market St,Suite 3022, Philadelphia, PA 19104 USA. EM gildena@mail.med.upenn.edu OI Asch, David/0000-0002-7970-286X FU NIDDK NIH HHS [K24-DK-065018] NR 25 TC 32 Z9 32 U1 0 U2 3 PU AMER DIETETIC ASSOC PI CHICAGO PA 216 W JACKSON BLVD #800, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD OCT PY 2006 VL 106 IS 10 BP 1651 EP 1655 DI 10.1016/j.jada.2006.07.012 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 090BI UT WOS:000240925200022 PM 17000198 ER PT J AU Steinman, MA Landefeld, CS Rosenthal, GE Berthenthal, D Sen, S Kaboli, PJ AF Steinman, Michael A. Landefeld, C. Seth Rosenthal, Gary E. Berthenthal, Daniel Sen, Saunak Kaboli, Peter J. TI Polypharmacy and prescribing quality in older people SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT 29th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 26-29, 2006 CL Los Angeles, CA SP Soc Gen Internal Med DE aged; drug utilization; quality of health care; polypharmacy; drug therapy ID MEDICATION APPROPRIATENESS INDEX; ADVERSE DRUG-REACTIONS; POTENTIALLY INAPPROPRIATE; ELDERLY PATIENTS; BEERS CRITERIA; CARE PATIENTS; OF-CARE; TOO; RELIABILITY; GUIDELINES AB OBJECTIVES: To evaluate the relationship between inappropriate prescribing, medication underuse, and the total number of medications used by patients. DESIGN: Cross-sectional study. SETTING: Veterans Affairs Medical Center. PARTICIPANTS: One hundred ninety-six outpatients aged 65 and older who were taking five or more medications. MEASUREMENTS: Inappropriate prescribing was assessed using a combination of the Beers drugs-to-avoid criteria (2003 update) and subscales of the Medication Appropriateness Index that assess whether a drug is ineffective, not indicated, or unnecessary duplication of therapy. Underuse was assessed using the Assessment of Underutilization of Medications instrument. All vitamins and minerals, topical and herbal medications, and medications taken as needed were excluded from the analyses. RESULTS: Mean age was 74.6, and patients used a mean standard deviation of 8.1 +/- 2.5 medications (range 5-17). Use of one or more inappropriate medications was documented in 128 patients (65%), including 73 (37%) taking a medication in violation of the Beers drugs-to-avoid criteria and 112 (57%) taking a medication that was ineffective, not indicated, or duplicative. Medication underuse was observed in 125 patients (64%). Together, inappropriate use and underuse were simultaneously present in 82 patients (42%), whereas 25 (13%) had neither inappropriate use nor underuse. When assessed by the total number of medications taken, the frequency of inappropriate medication use rose sharply from a mean of 0.4 inappropriate medications in patients taking five to six drugs, to 1.1 inappropriate medications in patients taking seven to nine drugs, to 1.9 inappropriate medications in patients taking 10 or more drugs (P <.001). In contrast, the frequency of underuse averaged 1.0 underused medications per patient and did not vary with the total number of medications taken (P = .26). Overall, patients using fewer than eight medications were more likely to be missing a potentially beneficial drug than to be taking a medication considered inappropriate. CONCLUSION: Inappropriate medication use and underuse were common, in older people taking five or more medications, with both simultaneously present in more than 40% of patients. Inappropriate medication use is most frequent in patients taking many medications, but underuse is also common and merits attention regardless of the total number of medications taken. C1 San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, Hlth Serv Res & Dev Serv Res Enhancement Award Pr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Iowa City Vet Affairs Med Ctr, Ctr Res Implementat Innovat Strategies Practice, Iowa City, IA USA. Univ Iowa, Carver Coll Med, Div Gen Internal Med, Dept Med, Iowa City, IA USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Box 181-G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU NIA NIH HHS [AG 00912, AG 10418] NR 36 TC 203 Z9 214 U1 5 U2 24 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2006 VL 54 IS 10 BP 1516 EP 1523 DI 10.1111/j.1532-5415.2006.00889.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 096NY UT WOS:000241385300005 PM 17038068 ER PT J AU Beeri, MS Uribarri, J Schmeidler, J Lally, R Wang, J Grossman, HT Langhoff, E Rosendorff, C Silverman, JM AF Beeri, Michal Schnaider Uribarri, Jaime Schmeidler, James Lally, Rachel Wang, Joy Grossman, Hillel T. Langhoff, Erik Rosendorff, Clive Silverman, Jeremy M. TI Normal homocysteine levels in wellfunctioning oldest-old individuals despite low kidney function SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID PLASMA TOTAL HOMOCYSTEINE; DISEASE C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Bronx Vet Affairs Med Ctr, Renal Clin, Bronx, NY USA. Bronx Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Beeri, MS (reprint author), Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. FU NIA NIH HHS [K01 AG023515-01A2, P01-AG02219, P50 AG005138, P50-AG05138, P01 AG002219, K01 AG023515, 1 K01 AG023515-01A2] NR 10 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2006 VL 54 IS 10 BP 1623 EP 1625 DI 10.1111/j.1532-5415.2006.00903.x PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 096NY UT WOS:000241385300025 PM 17038088 ER PT J AU Simmons, SF Schnelle, JF AF Simmons, Sandra F. Schnelle, John F. TI A continuous quality improvement pilot study: Impact on nutritional care quality SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE nutrition; quality; nursing home; assessment ID NURSING-HOME RESIDENTS; FEEDING ASSISTANCE; WEIGHT-LOSS; ACCURACY; STAFF AB Objective: All long-term care facilities are supposed to engage in quality improvement activities in an effort to improve care quality. The purpose of this pilot study was to teach long-term care staff how to conduct continuous quality improvement (CQI) related to nutritional care. Methods: Research staff conducted CQI training in one 48-bed pilot site with designated staff members. Supervisory staff were taught a standardized direct observational protocol, which was implemented weekly by both facility and research staff, to monitor defined nutritional care processes under the control of direct care staff. In addition, direct care staff received feedback on a weekly basis about care process implementation. Results: Following initial training and 12 weeks of CQI implementation, there were improvements in all 5 nutritional care processes related to the adequacy and quality of daily feeding assistance care provision according to both facility and research staff data. Weekly CQI implementation required approximately 1 hour of supervisory staff time and less than 15 minutes of direct care staff time to receive feedback. Implications: Both initial training and weekly CQI implementation were effective and required less than 2 hours of total staff time per week. Long-term care staff in this pilot site were able to improve nutritional care quality using a standardized direct observational protocol to guide CQI activities. C1 Univ Calif Los Angeles, Borun Ctr Gerontol Res, Jewish Home Aging, Sch Med,Div Geriatr, Reseda, CA 91335 USA. Univ Calif Los Angeles, Sch Med, Dept Geriatr, Borun Ctr Gerontol Res, Los Angeles, CA USA. Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda Geriatr Res Educ & Clin Ctr, Sepulveda, CA USA. RP Simmons, SF (reprint author), Univ Calif Los Angeles, Borun Ctr Gerontol Res, Jewish Home Aging, Sch Med,Div Geriatr, 7150 Tampa Ave, Reseda, CA 91335 USA. EM ssimmons@ucla.edu FU NIA NIH HHS [AG01026-01A1, AG10415] NR 22 TC 21 Z9 23 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD OCT PY 2006 VL 7 IS 8 BP 480 EP 485 DI 10.1016/j.jamda.2006.03.002 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 094YM UT WOS:000241275300002 PM 17027624 ER PT J AU Levy, CR Eilertsen, T Kramer, AM Hutt, E AF Levy, Cari R. Eilertsen, Terry Kramer, Andrew M. Hutt, Evelyn TI Which clinical indicators and resident characteristics are associated with health care practitioner nursing home visits or hospital transfer for urinary tract infections? SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE nursing home; hospitalization; practitioner practice patterns ID DO-NOT-RESUSCITATE; OF-LIFE CARE; PHYSICIAN; ORDERS; PREFERENCES; DEATH; BENEFIT; FEVER; SITE AB Objectives: (1) To determine factors associated with practitioner visitation and/or hospital transfer for skilled nursing facility (SNF) patients who develop a urinary tract infection (UTI) and (2) to determine if SNF patients with a Do Not Resuscitate (DNR) directive are less likely to be personally assessed and/or transferred to the hospital in the event of a UTI when compared to patients without a DNR directive. Design: Retrospective cohort study using nursing home medical record review. Participants: Participants were 564 residents from 35 nursing homes in 3 states who became acutely ill with UTI during the first 90 days of their nursing home admission. They were identified from 2832 random nursing home Medicare admissions and divided into 2 groups, those with DNR directives (n = 334) and those without (n = 230). Measurements: Logistic regression was used to determine factors associated with practitioner in-person assessment and/or hospitalization, and to determine differences in the likelihood of practitioner in-person assessment and/or hospitalization among those with DNR directives versus those without DNR directives. Results: Only one third (29%) of patients with unstable vital signs were seen by a practitioner or transferred to a hospital. Factors associated with practitioner assessment or hospital transfer were elevated temperature (OR 1.7, Cl 1.04-2.64), pulse more than 100 beats per minute (OR 1.7, Cl 1.01-2.99), and delirium (OR 2.1, Cl 1.267-3.44). White residents were less likely to be assessed by a practitioner or transferred to a hospital (OR 0.45, Cl 0.22-0.95). DNR directives were not significantly associated with fewer in-person assessments (P =.067). Conclusion: Only one third of SNF patients who developed a UTI with unstable vital signs were personally assessed by a practitioner and/or hospitalized. Patients with delirium were twice as likely to be assessed or transferred to a hospital, suggesting that practitioners use delirium as an indicator of illness severity. However, practitioner visit or transfer was also associated with ethnic background. In the absence of good evidence regarding which nursing home residents are likely to benefit from hospitalization or an urgent practitioner visit, these care decisions will continue to be associated with factors that are unknown. C1 Univ Colorado, Hlth Sci Ctr, Div Hlth Care Policy & Res, Aurora, CO 80011 USA. Univ Colorado, Hlth Sci Ctr, Div Geriatr, Aurora, CO 80011 USA. Denver VA Med Ctr, Program Res Long Term Care, Denver, CO USA. RP Levy, CR (reprint author), Univ Colorado, Hlth Sci Ctr, Div Hlth Care Policy & Res, 13611 E Colfax Ave, Aurora, CO 80011 USA. EM cari.levy@uchsc.edu NR 31 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD OCT PY 2006 VL 7 IS 8 BP 493 EP 498 DI 10.1016/j.jamda.2006.03.001 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 094YM UT WOS:000241275300004 PM 17027626 ER PT J AU Weisbord, SD Chen, HY Stone, RA Kip, KE Fine, MJ Saul, MI Palevsky, PM AF Weisbord, Steven D. Chen, Huanyu Stone, Roslyn A. Kip, Kevin E. Fine, Michael J. Saul, Melissa I. Palevsky, Paul M. TI Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article; Proceedings Paper CT 36th Annual Meeting of the American-Society-of-Nephrology CY NOV 12-17, 2003 CL SAN DIEGO, CA SP Amer Soc Nephrol ID RANDOMIZED CONTROLLED-TRIAL; CONTRAST-INDUCED NEPHROPATHY; ACUTE-RENAL-FAILURE; N-ACETYLCYSTEINE; CARDIAC ANGIOGRAPHY; COMORBIDITY INDEX; RISK-FACTORS; PREVENTION; MEDIA; NEPHROTOXICITY AB The absence of a universally accepted definition of radiocontrast nephropathy (RCN) has hampered efforts to characterize effectively the incidence and the clinical significance of this condition. The objective of this study was to identify a clinically relevant definition of RCN by assessment of the relationships between increases in serum creatinine (Scr) of varying magnitude after coronary angiography and clinical outcomes. An electronic medical database was used to identify all patients who underwent coronary angiography at the University of Pittsburgh Medical Center during a 12-yr period and abstract Scr levels before and after angiography, as well as demographic characteristics and comorbid conditions. Changes in Scr after angiography were categorized into mutually exclusive categories on the basis of absolute and relative changes from baseline levels, with a separate category denoting "unknown" change. Discrete proportional odds models were used to examine the association between increases in Scr and 30-d in-hospital mortality and length of stay. A total of 27,608 patients who underwent coronary angiography were evaluated. Small absolute (0.25 to 0.5 mg/dl) and relative (25 to 50%) increases in Scr were associated with risk-adjusted odds ratios for in-hospital mortality of 1.83 and 1.39, respectively. Larger increases in Scr generally were associated with greater risks for these clinical outcomes. Small increases in Scr after the administration of intravascular radiocontrast are associated with adverse patient outcomes. This observation will help guide the postprocedure care of patients who undergo coronary angiography and has important implications for future studies that investigate RCN. C1 VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Med, Div Renal & Electrolyte, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Ctr Biomed Informat, Dept Med, Sch Med, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Mailstop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu NR 27 TC 106 Z9 113 U1 0 U2 1 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD OCT PY 2006 VL 17 IS 10 BP 2871 EP 2877 DI 10.1681/ASN.2006030301 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 090BV UT WOS:000240926500026 PM 16928802 ER PT J AU Peralta, CA Shlipak, MG Fan, DJ Ordonez, J Lash, JP Chertow, GM Go, AS AF Peralta, Carmen A. Shlipak, Michael G. Fan, Dongjie Ordonez, Juan Lash, James P. Chertow, Glenn M. Go, Alan S. TI Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID HEART-STUDY EVIDENCE; MEXICAN-AMERICANS; UNITED-STATES; RACIAL-DIFFERENCES; NATIONAL-HEALTH; ALL-CAUSE; MORTALITY; POPULATION; PREVALENCE; PARADOX AB Rates of ESRD are rising faster in Hispanic than non-Hispanic white individuals, but reasons for this are unclear. Whether rates of cardiovascular events and mortality differ among Hispanic and non-Hispanic white patients with chronic kidney disease (CKD) also is not well understood. Therefore, this study examined the associations between Hispanic ethnicity and risks for ESRD, cardiovascular events, and death in patients with CKD. A total of 39,550 patients with stages 3 to 4 CKD from Kaiser Permanente of Northern California were included. Hispanic ethnicity was obtained from self-report supplemented by surname matching. GFR was estimated from the abbreviated Modification of Diet in Renal Disease equation, and clinical outcomes, patient characteristics, and longitudinal medication use were ascertained from health plan databases and state mortality files. After adjustment for sociodemographic characteristics, Hispanic ethnicity was associated with an increased risk for ESRD (hazard ratio [HR] 1.93; 95% confidence interval [CI] 1.72 to 2.17) when compared with non-Hispanic white patients, which was attenuated after controlling for diabetes and insulin use (HR 1.50; 95% CI 1.33 to 1.69). After further adjustment for potential confounders, Hispanic ethnicity remained independently associated with an increased risk for ESRD (HR 1.33; 95% CI 1.17 to 1.52) as well as a lower risk for cardiovascular events (HR 0.82; 95% CI 0.76 to 0.88) and death (HR 0.72; 95% CI 0.66 to 0.79). Among a large cohort of patients with CKD, Hispanic ethnicity was associated with lower rates of death and cardiovascular events and a higher rate of progression to ESRD. The higher prevalence of diabetes among Hispanic patients only partially explained the increased risk for ESRD. Further studies are required to elucidate the cause(s) of ethnic disparities in CKD-associated outcomes. C1 Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA. San Francisco Vet Affairs Med Ctr, Gen Internal Med Sect, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Kaiser Permanente, Oakland Med Ctr, Div Nephrol, Oakland, CA USA. Univ Illinois, Dept Med, Div Nephrol, Chicago, IL USA. RP Go, AS (reprint author), Kaiser Permanente No Calif, Div Res, 2000 Broadway St,3rd Floor, Oakland, CA 94612 USA. EM alan.s.go@kp.org FU NIDDK NIH HHS [U01 DK 60902, R01 DK 58411] NR 31 TC 84 Z9 88 U1 0 U2 2 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD OCT PY 2006 VL 17 IS 10 BP 2892 EP 2899 DI 10.1681/ASN.2005101122 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 090BV UT WOS:000240926500029 PM 16959827 ER PT J AU Barbour, JR Stroud, RE Lowry, AS Clark, LL Leone, AM Jones, JA Spinale, FG Ikonomidis, JS AF Barbour, John R. Stroud, Robert E. Lowry, Abigail S. Clark, Leslie L. Leone, Allyson M. Jones, Jeffery A. Spinale, Francis G. Ikonomidis, John S. TI Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID NEUTROPHIL COLLAGENASE; UP-REGULATION; MURINE MODEL; T-CELLS; INFLAMMATION; EXPRESSION; LOCALIZATION; GELATINASE; GAMMA; MICE AB Background: An important component of matrix remodeling during thoracic aortic aneurysm progression is the balance between matrix metalloproteinases and their endogenous inhibitors (tissue inhibitors of metalloproteinases). However, whether and to what degree matrix metalloproteinase/tissue inhibitor of metalloproteinases profiles change over time with an evolving thoracic aortic aneurysm remains unclear. Methods: Descending thoracic aortic aneurysms were induced in mice (FVB strain, 15 minutes of 0.5 mol/L CaCl2 exposure) and followed for 24 hours, 72 hours, 1 week, 2 weeks, 4 weeks, or 8 weeks (each group, n = 13). Thoracic aortic aneurysm size was determined by means of video micrometry, and immunoblotting was used to measure aortic matrix metalloproteinase 2, 8, 9, and 12 and tissue inhibitor of metalloproteinases 1 and 4 levels (expressed as a percentage of control values, n = 13). Results: Increased aortic diameter was detected by 72 hours and reached a maximal size at 4 weeks (135% +/- 4% increase from baseline, P < .05), which is consistent with thoracic aortic aneurysm progression. Active matrix metalloproteinase 8 (collagenase) levels increased at 72 hours (178% +/- 49%, P < .05 from control), and active matrix metalloproteinase 12 (elastase) levels increased by 24 hours (138% +/- 11%, P < .05), whereas active matrix metalloproteinase 2 levels increased at 72 hours and 1 week after thoracic aortic aneurysm induction (72 hours: 158% +/- 12%, 1 week: 162% +/- 19%; P < .05). At 1 week after thoracic aortic aneurysm induction, active matrix metalloproteinase 9 and 12 levels decrease (matrix metalloproteinase 9: 55% +/- 5%; matrix metalloproteinase 12: 63% +/- 5%; P < .05); however, matrix metalloproteinase 9 and 12 levels were increased from these values at 4 and 8 weeks (P < .05). Tissue inhibitor of metalloproteinases 1 levels were decreased at 1 week (52% +/- 15%, P <. 05) and later returned to control values, whereas tissue inhibitor of metalloproteinases 4 levels increased at the late thoracic aortic aneurysm time points (4 weeks: 278% +/- 46%; 8 weeks: 213% +/- 40%; P < .05). Conclusions: These findings show 2 phases of matrix metalloproteinase abundance during murine thoracic aortic aneurysm formation. The late tissue inhibitor of metalloproteinases 4 increase might explain prevention of further aortic dilation past 4 weeks. Unique matrix metalloproteinase/tissue inhibitor of metalloproteinases temporal relationships occurred during the natural history of thoracic aortic aneurysm progression that might hold both diagnostic and therapeutic relevance. C1 Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Ikonomidis, JS (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Suite 409 CSB,96 Jonathan Lucas St, Charleston, SC 29425 USA. EM ikonomij@musc.edu FU NHLBI NIH HHS [R01 HL059165-07, R01 HL075488-01] NR 30 TC 12 Z9 12 U1 0 U2 4 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD OCT PY 2006 VL 132 IS 4 BP 788 EP 795 DI 10.1016/j.jtcvs.2006.05.052 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 090ME UT WOS:000240954600008 PM 17000289 ER PT J AU Chew, RB Chew, LD Bradley, K AF Chew, Ryan B. Chew, Lisa D. Bradley, Katharine TI The association between number of Pap smears performed and self-reported confidence in an internal medicine residency SO JOURNAL OF WOMENS HEALTH LA English DT Article ID WOMENS HEALTH; AMBULATORY GYNECOLOGY; PROCEDURAL SKILLS; PROGRAM; CARE; EDUCATION; IMPACT AB Background: The American Board of Internal Medicine (ABIM) recommends internal medicine residents perform at least 3-5 Pap smears during training. We evaluated whether doing more than the required minimum Pap smears was associated with greater confidence and less desire for more Pap smear training. Methods: We surveyed all 142 internal medicine residents at one university training program. Participants were asked how many Pap smears they had performed during residency and to rank their confidence and desire for more training in performing Pap smears. We compared confidence and desire for more training across three groups of residents reporting varying experience (<= 5, 6-10, > 10 Pap smears performed). Results: Of 101 responding residents (71% eligible), 42 (42%), 19 (19%), and 36 (36%) reported performing <= 5, 6-10, and > 10 Pap smears, respectively. The number of Pap smears performed was significantly related to confidence and desire for more training in Pap smears (p < 0.05). Of residents who reported <= 5 Pap smears, 64% and 57%, respectively, indicated they were not confident and desired more training. Of those reporting 6-10 Pap smears, 42% were not confident, and 42% desired more training, whereas comparable proportions for those reporting > 10 Pap smears were 14% and 17%, respectively. After adjusting for gender, primary care track, year of training, continuity clinic site, women's health rotation experience, and future plans in primary care, those reporting doing > 10 Pap smears were significantly more likely to report confidence (OR 9.08, 95% CI 2.15-36.26) and less likely to want more training (OR 0.23; 0.06-0.93) than those reporting <= 5 Pap smears. Conclusions: Residents who performed over twice the number of Pap smears recommended by ABIM were much more likely to indicate confidence in their Pap smear skills compared with those completing <= 5. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev S 152, Seattle, WA 98101 USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98101 USA. Univ Washington, Div Gen Internal Med, Dept Med, Seattle, WA USA. RP Chew, RB (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev S 152, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM rbchew@hotmail.com FU NIAAA NIH HHS [K23AA00313] NR 14 TC 5 Z9 5 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD OCT PY 2006 VL 15 IS 8 BP 928 EP 933 DI 10.1089/jwh.2006.15.928 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 104VX UT WOS:000241989800006 PM 17087616 ER PT J AU Peterfy, M Mao, HZ Doolittle, MH AF Peterfy, Miklos Mao, Hui Z. Doolittle, Mark H. TI The cld mutation: narrowing the critical chromosomal region and selecting candidate genes SO MAMMALIAN GENOME LA English DT Article ID COMBINED LIPASE DEFICIENCY; MOUSE T-COMPLEX; LIPOPROTEIN-LIPASE; ENDOPLASMIC-RETICULUM; HEPATIC LIPASE; LETHAL MUTATION; T/T COMPLEX; MICE; HAPLOTYPES; EXPRESSION AB Combined lipase deficiency (cld) is a recessive, lethal mutation specific to the t(w73) supercript stop haplotype on mouse Chromosome 17. While the cld mutation results in lipase proteins that are inactive, aggregated, and retained in the endoplasmic reticulum (ER), it maps separately from the lipase structural genes. We have narrowed the gene critical region by about 50% using the t(w18) supercript stop haplotype for deletion mapping and a recombinant chromosome used originally to map cld with respect to the phenotypic marker tf. The region now extends from 22 to 25.6 Mbp on the wild-type chromosome, currently containing 149 genes and 50 expressed sequence tags (ESTs). To identify the affected gene, we have selected candidates based on their known role in associated biological processes, cellular components, and molecular functions that best fit with the predicted function of the cld gene. A secondary approach was based on differences in mRNA levels between mutant (cld/cld) and unaffected (+/cld) cells. Using both approaches, we have identified seven functional candidates with an ER localization and/or an involvement in protein maturation and folding that could explain the lipase deficiency, and six expression candidates that exhibit large differences in mRNA levels between mutant and unaffected cells. Significantly, two genes were found to be candidates with regard to both function and expression, thus emerging as the strongest candidates for cld. We discuss the implications of our mapping results and our selection of candidates with respect to other genes, deletions, and mutations occurring in the cld critical region. C1 Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. RP Doolittle, MH (reprint author), Greater Los Angeles VA Healthcare Ctr, Dept Med, 11301 Wilshire Blvd,Bldg 113,Room 312, Los Angeles, CA 90073 USA. EM markdool@ucla.edu FU NHLBI NIH HHS [HL28481] NR 54 TC 8 Z9 8 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0938-8990 J9 MAMM GENOME JI Mamm. Genome PD OCT PY 2006 VL 17 IS 10 BP 1013 EP 1024 DI 10.1007/s00335-006-0045-3 PG 12 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA 093JS UT WOS:000241165200003 PM 17019649 ER PT J AU Shrank, WH Asch, SM Adams, J Setodji, C Kerr, EA Keesey, J Malik, S McGlynn, EA AF Shrank, William H. Asch, Steven M. Adams, John Setodji, Claude Kerr, Eve A. Keesey, Joan Malik, Shaista McGlynn, Elizabeth A. TI The quality of pharmacologic care for adults in the United States SO MEDICAL CARE LA English DT Article DE quality; prescription drugs; prescribing; underuse ID ADVERSE DRUG EVENTS; MEDICARE BENEFICIARIES; HEART-FAILURE; OF-CARE; RACIAL-DIFFERENCES; AMBULATORY-CARE; HEALTH-CARE; RACE; COST; RISK AB Background: Despite rising annual expenditures for prescription drugs, little systematic information is available concerning the quality of pharmacologic care for adults in the United States. We evaluated how frequently appropriate pharmacologic care is ordered in a national sample of U.S. residents. Methods: The RAND/UCLA Modified Delphi process was used to select quality-of-care indicators for adults across 30 chronic and acute conditions and preventive care. One hundred thirty-three pharmacologic quality-of-care indicators were identified. We interviewed a random sample of adults living in 12 metropolitan areas in the United States by telephone and received consent to obtain copies of their medical records for the most recent 2-year period. We abstracted patient medical records and evaluated 4 domains of the prescribing process that encompassed the entire pharmacologic care experience: appropriate medication prescribing (underuse), avoidance of inappropriate medications (overuse), medication monitoring, and medication education and documentation. A total of 3457 participants were eligible for at least 1 quality indicator, and 10,739 eligible events were evaluated. We constructed aggregate scores and studied whether patient, insurance, and community factors impact quality. Results: Participants received 61.9% of recommended pharmacologic care overall (95% confidence interval 60.3-63.5%). Performance was lowest in education and documentation (46.2%); medication monitoring (54.7%) and under-use of appropriate medications (62.6%) performance were higher. Performance was best for avoiding inappropriate medications (83.5%). Patient race and health services utilization were associated with modest quality differences, while insurance status was not. Conclusions: Significant deficits in the quality of pharmacologic care were seen for adults in the United States, with large shortfalls associated with underuse of appropriate medications. Strategies to measure and improve phannacologic care quality ought to be considered, especially as we initiate a prescription drug benefit for seniors. C1 Brigham & Womens Hosp, Div Pharmacoepideiol & Pharmacoecon, Boston, MA 02120 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Hlth, Santa Monica, CA USA. VA Ann Arbor Healthcare Syst, Ctr Practice Management & Outcomes Res, Ann Arbor, MI USA. Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA USA. Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. Univ Calif Irvine, Dept Med, Div Cardiol, Irvine Sch Med, Irvine, CA 92717 USA. RP Shrank, WH (reprint author), Brigham & Womens Hosp, Div Pharmacoepideiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA. EM wshrank@partners.org RI Kim, Hyung Woo /G-7525-2011 NR 42 TC 51 Z9 51 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD OCT PY 2006 VL 44 IS 10 BP 936 EP 945 DI 10.1097/01.mlr.0000223460.60033.79 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 092RR UT WOS:000241115500008 PM 17001265 ER PT J AU Carlson, MJ Cummings, DE AF Carlson, Molly J. Cummings, David E. TI Prospects for an anti-ghrelin vaccine to treat obesity SO MOLECULAR INTERVENTIONS LA English DT Editorial Material ID HORMONE SECRETAGOGUE RECEPTOR; BROWN ADIPOSE-TISSUE; FOOD-INTAKE; WEIGHT-GAIN; MICE; APPETITE; STOMACH; SECRETION; DELETION; PEPTIDE AB In the battle to treat the pandemic of obesity, one therapeutic strategy is to block endogenous signals that stimulate appetite and control body weight. One such molecule is ghrelin, a gut peptide that is the only known orexigenic hormone and is a likely contributor to mealtime hunger. The relative importance of ghrelin in long-term body-weight regulation (and thus its promise as an anti-obesity target) is uncertain, however, because genetic and pharmacologic blockade of ghrelin signaling have yielded variable results to date. Using a novel approach of vaccinating rats against their own ghrelin, Zorilla et al. report that animals with high ghrelin-specific antibody titers displayed restricted body weight, without evidence of non-specific inflammation following the vaccine. These results favor a meaningful role for ghrelin in energy homeostasis, hinting at a possible new anti-obesity approach. More broadly, the work of Zorilla et al. supports the feasibility of vaccinations directed against specific autologous targets-immunopharmacotherapy that could potentially be developed to target a wide array of medical conditions. C1 Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. RP Cummings, DE (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. EM mollyc@u.washington.edu; davidec@u.washington.edu NR 28 TC 5 Z9 5 U1 2 U2 4 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 1534-0384 J9 MOL INTERV JI Mol. Interv. PD OCT PY 2006 VL 6 IS 5 BP 249 EP + DI 10.1124/mi.6.5.5 PG 5 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 099YO UT WOS:000241634000003 PM 17035664 ER PT J AU Siegel, JM Boehmer, LN AF Siegel, Jerome M. Boehmer, Lisa N. TI Narcolepsy and the hypocretin system - where motion meets emotion SO NATURE CLINICAL PRACTICE NEUROLOGY LA English DT Review DE immunology; major histocompatibility complex class II; narcolepsy; rapid eye movement sleep; sleep ID OREXIN-A; INTRAVENOUS IMMUNOGLOBULINS; SLEEP-DEPRIVATION; NEURONS; CATAPLEXY; ONSET; BRAIN; EXPRESSION; PEPTIDES; BEHAVIOR AB Narcolepsy is a neurological disorder that is characterized by excessive daytime sleepiness and cataplexy - a loss of muscle tone generally triggered by certain strong emotions with sudden onset. The underlying cause of most cases of human narcolepsy is a loss of neurons that produce hypocretin (Hcrt, also know as orexin). These cells normally serve to drive and synchronize the activity of monoaminergic and cholinergic cells. Sleepiness results fro the reduced activity of monoaminergic, cholinergic and other cells that are normally activated by Hcrt neurons, as well as from the loss of Hcrt itself. Cataplexy is caused by an episodic loss of activity in noradrenergic cells that support muscle tone, and a linked activation of a medial medullary cell population that suppresses muscle tone. Current treatments for narcolepsy include stimulants to combat sleepiness and antidepressants to reduce cataplexy. Sodium oxybate produces both reductions in cataplexy and improved waking alertness. Future treatments are likely to include Hcrt or Hcrt agonists to reverse the underlying neurochemical deficit. C1 Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Siegel, JM (reprint author), VA GLAHS Sepulveda, Ctr Sleep Res, Neurobiol Res 151A3,16111 Plummer St, North Hills, CA 91343 USA. EM jsiegel@ucla.edu FU NIMH NIH HHS [MH64109]; NINDS NIH HHS [NS14610] NR 58 TC 51 Z9 53 U1 1 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1745-834X J9 NAT CLIN PRACT NEURO JI Nat. Clin. Pract. Neurol. PD OCT PY 2006 VL 2 IS 10 BP 548 EP 556 DI 10.1038/ncpneuro0300 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 085QQ UT WOS:000240619000010 PM 16990828 ER PT J AU Hunt, MA Muldoon, LL Palmieri, D Steeg, PS Neuwelt, EA AF Hunt, M. A. Muldoon, L. L. Palmieri, D. Steeg, P. S. Neuwelt, E. A. TI HER-2 status influences survival in a rat model of brain metastasis from breast cancer SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 7th Congress of the European-Association-for-Neuro-Oncology (EANO) CY SEP 14-17, 2006 CL Vienna, AUSTRIA SP European Assoc Neuro Oncol C1 Natl Canc Inst, Ctr Canc Res, Womens Canc Sect, Mol Pharmacol Lab, Bethesda, MD USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR 97201 USA. RI Palmieri, Diane/B-4258-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU DUKE UNIV PRESS PI DURHAM PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD OCT PY 2006 VL 8 IS 4 BP 472 EP 472 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 089JS UT WOS:000240877301311 ER PT J AU Knight, KR Kraemer, DF Winter, C Neuwelt, EA AF Knight, K. R. Kraemer, D. F. Winter, C. Neuwelt, E. A. TI Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions in pediatric ototoxicity monitoring SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 7th Congress of the European-Association-for-Neuro-Oncology (EANO) CY SEP 14-17, 2006 CL Vienna, AUSTRIA SP European Assoc Neuro Oncol C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR 97201 USA. Oregon State Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU DUKE UNIV PRESS PI DURHAM PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD OCT PY 2006 VL 8 IS 4 BP 480 EP 480 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 089JS UT WOS:000240877301343 ER PT J AU Neuwelt, EA Varallyay, C Manninger, S Solymosi, D Hunt, MA Jerosch-Herold, M Nesbit, G Hoffman, JM AF Neuwelt, E. A. Varallyay, C. Manninger, S. Solymosi, D. Hunt, M. A. Jerosch-Herold, M. Nesbit, G. Hoffman, J. M. TI Comparison of ferumoxytol, an iron oxide nanoparticle, vs. gadolinium in MR perfusion of malignant brain tumors SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 7th Congress of the European-Association-for-Neuro-Oncology (EANO) CY SEP 14-17, 2006 CL Vienna, AUSTRIA SP European Assoc Neuro Oncol C1 Oregon Hlth & Sci Univ, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. Univ Utah, Sch Med, Salt Lake City, UT USA. RI Jerosch-Herold, Michael/F-2496-2010 NR 0 TC 0 Z9 0 U1 0 U2 0 PU DUKE UNIV PRESS PI DURHAM PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD OCT PY 2006 VL 8 IS 4 BP 496 EP 497 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 089JS UT WOS:000240877301403 ER PT J AU Neuwelt, EA Wu, YJ Varallyay, C Jones, R Muldoon, LL AF Neuwelt, E. A. Wu, Y. J. Varallyay, C. Jones, R. Muldoon, L. L. TI In vivo leukocyte iron labeling with intravenous ferumoxides and protamine sulfate for cellular magnetic resonance imaging SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 7th Congress of the European-Association-for-Neuro-Oncology (EANO) CY SEP 14-17, 2006 CL Vienna, AUSTRIA SP European Assoc Neuro Oncol C1 Oregon Hlth & Sci Univ, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU DUKE UNIV PRESS PI DURHAM PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD OCT PY 2006 VL 8 IS 4 BP 497 EP 497 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 089JS UT WOS:000240877301404 ER PT J AU Soussain, C Muldoon, LL Varallyay, C Jahnke, K Neuwelt, EA AF Soussain, C. Muldoon, L. L. Varallyay, C. Jahnke, K. Neuwelt, E. A. TI Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 7th Congress of the European-Association-for-Neuro-Oncology (EANO) CY SEP 14-17, 2006 CL Vienna, AUSTRIA SP European Assoc Neuro Oncol C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU DUKE UNIV PRESS PI DURHAM PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD OCT PY 2006 VL 8 IS 4 BP 498 EP 498 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 089JS UT WOS:000240877301409 ER PT J AU Filley, CM Ramsberger, G Menn, L Wu, J Reid, BY Reid, AL AF Filley, Christopher M. Ramsberger, Gail Menn, Lise Wu, Jiang Reid, Bessie Y. Reid, Allan L. TI Primary progressive aphasia in a bilingual woman SO NEUROCASE LA English DT Article ID BRAIN AB Multilingual aphasias are common because most people in the world know more than one language, but little is known of these syndromes except in patients who have had a stroke. We present a 76-year-old right-handed woman, fluent in English and Chinese, who developed anomia at age 70 and then progressed to aphasia. Functional neuroimaging disclosed mild left temporoparietal hypometabolism. Neurolinguistic testing was performed in both English and Chinese, representing a unique contribution to the literature. Results revealed conduction-like aphasia that was comparable in the two languages, although English was slightly better preserved. Primary progressive aphasia has disrupted 2 languages in a similar manner, suggesting their close neuroanatomic relationship in this case. C1 Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA. Univ Colorado, Sch Med, Dept Psychiat, Denver, CO USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Univ Colorado, Dept Speech Language & Hearing Sci, Boulder, CO 80309 USA. Univ Colorado, Dept Linguist, Boulder, CO 80309 USA. RP Filley, CM (reprint author), Univ Colorado, Hlth Sci Ctr, Behav Neurol Sect, B-183,4200 E 9th Ave, Denver, CO 80262 USA. EM christopher.filley@uchsc.edu OI Menn, Lise/0000-0003-2583-1292; RAMSBERGER, GAIL/0000-0003-3161-4710 NR 15 TC 10 Z9 11 U1 1 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1355-4794 J9 NEUROCASE JI Neurocase PD OCT PY 2006 VL 12 IS 5 BP 296 EP 299 DI 10.1080/13554790601126047 PG 4 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 120KB UT WOS:000243082500005 PM 17190751 ER PT J AU Garcia, JM Iyer, D Poston, WSC Marcelli, M Reeves, R Foreyt, J Balasubramanyam, A AF Garcia, Jose M. Iyer, Dinakar Poston, Walker S. C. Marcelli, Marco Reeves, Rebecca Foreyt, John Balasubramanyam, Ashok TI Rise of plasma ghrelin with weight loss is not sustained during weight maintenance SO OBESITY LA English DT Article DE overweight; orlistat; Mexican American; leptin; insulin ID GASTRIC BYPASS-SURGERY; INSULIN-RESISTANCE; FOOD-INTAKE; CIRCULATING GHRELIN; MEXICAN-AMERICANS; HUMAN OBESITY; US ADULTS; HUMANS; PREVALENCE; LEPTIN AB Objective: Ghrelin is postulated to be an orexigenic signal that promotes weight regain after weight loss (WL). However, it is not known whether this putative effect of ghrelin is sustained after weight stabilization. The objective of this study was to investigate the relationship of plasma ghrelin concentrations to active WL and weight maintenance in obese subjects. Research Methods and Procedures: This study was a randomized clinical trial, with a 12-month follow-up period. Obese Mexican-American women matched for age and BMI were randomized to a 12-month WL program (n = 25) or no intervention (controls, n = 23). Interventions included diet, exercise, and orlistat. Body weight and fasting ghrelin, leptin, insulin, and glucose concentrations were measured at baseline and 6 and 12 months. Results: The WL group lost 8.5% of body weight after 6 months and maintained the new weight for the next 6 months. Ghrelin concentrations increased significantly at 6 months but returned to baseline at 12 months. Baseline ghrelin concentrations were directly related to the degree of WL achieved after 12 months. Controls experienced no change in BMI or ghrelin levels. There were no associations between plasma ghrelin and leptin or insulin concentrations. Discussion: Consistent with previous results, ghrelin rises in response to WL, perhaps as a counter-regulatory mechanism. However, the present results indicate that ghrelin concentrations return to baseline with sustained weight maintenance, suggesting that its effects are unlikely to regulate long-term energy balance. Baseline ghrelin concentrations are related to the degree of WL that can be achieved by active weight reduction. C1 Baylor Coll Med, Div Endocrinol Diabet & Metab, Translat Metab Unit, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. Univ Missouri, Kansas City, MO 64110 USA. Baylor Coll Med, Sect Behav Med, Houston, TX USA. Ben Taub Gen Hosp, Endocrine Serv, Houston, TX 77030 USA. RP Balasubramanyam, A (reprint author), Baylor Coll Med, Div Endocrinol Diabet & Metab, Translat Metab Unit, Room 700B,1 Baylor Plaza, Houston, TX 77030 USA. EM ashokb@bctn.tmc.edu FU NHLBI NIH HHS [R01 HL73696] NR 39 TC 35 Z9 37 U1 0 U2 1 PU NORTH AMER ASSOC STUDY OBESITY PI SILVER SPRING PA 8630 FENTON ST, SUITE 918, SILVER SPRING, MD 20910 USA SN 1930-7381 J9 OBESITY JI Obesity PD OCT PY 2006 VL 14 IS 10 BP 1716 EP 1723 DI 10.1038/oby.2006.197 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 212OE UT WOS:000249605900006 PM 17062800 ER PT J AU Borello-France, D Burgio, KL Richter, HE Zyczynski, H FitzGerald, MP Kitehead, W Fine, P Nygaard, I Handa, VL Visco, AG Weber, AM Brown, MB AF Borello-France, Diane Burgio, Kathryn L. Richter, Holly E. Zyczynski, Halina FitzGerald, Mary Pat Kitehead, William Fine, Paul Nygaard, Ingrid Handa, Victoria L. Visco, Anthony G. Weber, Anne M. Brown, Morton B. CA Pelvic Floor Disorders Network TI Fecal and urinary incontinence in primiparous women SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID ANAL-SPHINCTER RUPTURE; VAGINAL DELIVERY; POSTPARTUM URINARY; CESAREAN DELIVERY; PREVALENCE; RISK; SYMPTOMS; DISRUPTION; INCREASE; DAMAGE AB OBJECTIVE: To prospectively investigate the relationship between anal sphincter tears and postpartum fecal and urinary incontinence. METHODS: The Childbirth and Pelvic Symptoms study was a prospective cohort study performed by the Pelvic Floor Disorders Network to estimate the prevalence of postpartum fecal and urinary incontinence in primiparous women: 407 with clinically recognized anal sphincter tears during vaginal delivery, 390 without recognized sphincter tears (vaginal controls), and 124 delivered by cesarean before labor. Women were recruited postpartum while hospitalized and interviewed by telephone 6 weeks and 6 months postpartum. We assessed fecal and urinary incontinence symptoms using the Fecal Incontinence Severity Index and the Medical, Epidemiological, and Social Aspects of Aging Questionnaire, respectively. Odds ratios were adjusted for age, race, and clinical site. RESULTS: Compared with the vaginal control group, women in the sphincter tear cohort reported more fecal incontinence (6 weeks, 26.6% versus 11.2%; adjusted odds ratio [AOR] 2.8, 95% confidence interval [CI] 1.84.3; 6 months, 17.0% versus 8.2%; AOR 1.9, 95% CI 1.2-3.2), more fecal urgency and flatal incontinence, and greater fecal incontinence severity at both times. Urinary incontinence prevalence did not differ between the sphincter tear and vaginal control groups. Six months postpartum, 22.9% of women delivered by cesarean reported urinary incontinence, whereas 7.6% reported fecal incontinence. CONCLUSION: Women with clinically recognized anal sphincter tears are more than twice as likely to report postpartum fecal incontinence than women without sphincter tears. Cesarean delivery before labor is not entirely protective against pelvic floor disorders. C1 Duquesne Univ, Dept Phys Therapy, Pittsburgh, PA 15282 USA. Birmingham VA Med Ctr, Birmingham, AL USA. Univ Alabama, Birmingham, AL USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. Loyola Univ, Med Ctr, Maywood, IL 60153 USA. Univ N Carolina, Chapel Hill, NC 27515 USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Iowa, Iowa City, IA 52242 USA. Johns Hopkins Univ, Baltimore, MD USA. Natl Inst Child Hlth & Human Dev, NIH, Bethesda, MD USA. Univ Michigan, Ann Arbor, MI 48109 USA. RP Borello-France, D (reprint author), Duquesne Univ, Dept Phys Therapy, 111 Hlth Sci Bldg, Pittsburgh, PA 15282 USA. EM borellofrance@duq.edu FU NICHD NIH HHS [U10 HD41248, U01 HD41249, U10 HD041261, U10 HD041263, U10 HD41250, U10 HD41261, U10 HD41263, U10 HD41267, U10 HD41268, U10 HD41269] NR 43 TC 133 Z9 136 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD OCT PY 2006 VL 108 IS 4 BP 863 EP 872 DI 10.1097/01.AOG.0000232504.32589.3b PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 171XS UT WOS:000246769300007 PM 17012447 ER PT J AU Mowry, SE LoTempio, MM Sadeghi, A Wang, KH Wang, MB AF Mowry, Sarah E. LoTempio, Maria M. Sadeghi, Ahmad Wang, Kevin H. Wang, Marilene B. TI Quality of life outcomes in laryngeal and oropharyngeal cancer patients after chemoradiation SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article ID NECK-CANCER; ORGAN PRESERVATION; ADVANCED HEAD; CONCOMITANT CHEMORADIOTHERAPY; RADIATION-THERAPY; UW-QOL; CHEMOTHERAPY; PERFORMANCE; CARCINOMA; DIAGNOSIS AB OBJECTIVE: The purpose of this study was to compare quality of life issues in patients with advanced laryngeal versus oropharyngeal cancer after treatment with chemoradiation. DESIGN: A cohort study of 31 patients with laryngeal or oropharyngeal squamous cell carcinoma treated with chemoradiation completed the University of Washington quality of life instrument version 4 (UW-QOL v4). Statistical analysis was performed with Wilcoxon rank sum and chi-square tests. SETTING: Academic tertiary care center. RESULTS: Both groups reported similar impairment in the domains of swallowing, chewing, and taste. Oropharyngeal cancer patients reported significantly worse quality of life in the domain of saliva (P < 0.007). CONCLUSION: Swallowing, chewing, and taste were adversely affected by chemoradiation for both groups. Oropharyngeal patients experienced significantly worse problems with saliva than laryngeal patients. These patients reported high levels of satisfaction with health-related quality of life issues. SIGNIFICANCE: Specific head and neck subsites have different morbidities when treated with primary chemoradiation for advanced tumors. (C) 2006 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Head & Neck Surg, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Dept Radiat Oncol, Los Angeles, CA USA. NYU, Sch Med, Dept Otolaryngol, New York, NY USA. RP Wang, MB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Head & Neck Surg, 10833 Le Conte Ave,CHS 62-132, Los Angeles, CA 90095 USA. EM mbwang@ucla.edu NR 20 TC 16 Z9 18 U1 1 U2 2 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD OCT PY 2006 VL 135 IS 4 BP 565 EP 570 DI 10.1016/j.otohns.2006.06.1266 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 094AD UT WOS:000241210500015 PM 17011418 ER PT J AU Jonker, S Louey, S Thornburg, K Giraud, G AF Jonker, S. Louey, S. Thornburg, K. Giraud, G. TI In vivo administration of U0126 to the sheep fetus blocks acute and chronic cardiac ERK phosphorylation SO PEDIATRIC RESEARCH LA English DT Meeting Abstract CT 47th Annual Meeting of the Midwest Society-for-Pediatric-Research CY OCT 18-20, 2006 CL Indianapolis, IN C1 Oregon Hlth Sci Univ, Heart Res Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT PEDIATRIC RESEARCH FOUNDATION, INC PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA SN 0031-3998 J9 PEDIATR RES JI Pediatr. Res. PD OCT PY 2006 VL 60 IS 4 MA 21 BP 494 EP 494 DI 10.1203/00006450-200610000-00043 PG 1 WC Pediatrics SC Pediatrics GA 086XX UT WOS:000240707500043 ER PT J AU Jonker, S Louey, S Thornburg, K Giraud, G AF Jonker, S. Louey, S. Thornburg, K. Giraud, G. TI Cardiac ERK activation during sustained arterial and venous hypertension in the sheep fetus SO PEDIATRIC RESEARCH LA English DT Meeting Abstract CT 47th Annual Meeting of the Midwest Society-for-Pediatric-Research CY OCT 18-20, 2006 CL Indianapolis, IN C1 Oregon Hlth Sci Univ, Heart Res Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT PEDIATRIC RESEARCH FOUNDATION, INC PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA SN 0031-3998 J9 PEDIATR RES JI Pediatr. Res. PD OCT PY 2006 VL 60 IS 4 MA 30 BP 495 EP 495 DI 10.1203/00006450-200610000-00052 PG 1 WC Pediatrics SC Pediatrics GA 086XX UT WOS:000240707500052 ER PT J AU Haynes, PL McQuaid, JR Ancoli-Israel, S Martin, JL AF Haynes, Patricia L. McQuaid, John R. Ancoli-Israel, Sonia Martin, Jennifer L. TI Disrupting life events and the sleep-wake cycle in depression SO PSYCHOLOGICAL MEDICINE LA English DT Article ID MAJOR DEPRESSION; MOTOR-ACTIVITY; RECURRENT DEPRESSION; CIRCADIAN-RHYTHMS; STRESS ASSESSMENT; WRIST ACTIVITY; ANTIDEPRESSANT; ACTIGRAPHY; DISORDERS; CORTISOL AB Background. Social rhythm disruption life events are significant predictors of mood relapse in bipolar patients. However, no research has examined the relationship between these events and their hypothesized mechanism of action: disrupted sleep-wake patterns. The goal of this study was to test whether participants with major depressive disorder have a greater disruption of daily sleep and motor activity following disrupting life events when compared to normal controls. Method. Over the course of 2 weeks, 39 normal controls and 39 individuals with major depressive disorder completed life events interviews and wore actigraphs to obtain estimates of sleep/wake activity. Results. Statistically significant interactions indicated that the presence of at least one disrupting life event in the previous 4 months correlated with elevations in the amount of time spent awake after sleep onset [beta=0(.)45, Delta F(1,73)=4-80,p < 0(.)05], and decreases in the percentage of time spent asleep [beta=-0(.)53, Delta F(1,73)=6(.)57,p < 0(.)05], in depressed individuals but not in normal controls. Conclusions. The results indicated that depressed individuals may be more susceptible to the effects of life events on sleep than normal controls. This is the first study to date to correlate life events with objective measures of sleep. However, prospective longitudinal research is necessary to clarify the temporal relationship among these variables. C1 Univ Arizona, Dept Psychiat, Tucson, AZ 85724 USA. Univ Calif San Diego, La Jolla, CA 92093 USA. Vet Affairs San Diego Healthcare Syst, La Jolla, CA 92093 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Sepulveda, CA USA. RP Haynes, PL (reprint author), Univ Arizona, Dept Psychiat, 1501 N Campbell Ave,POB 245002, Tucson, AZ 85724 USA. EM thaynes@email.arizona.edu FU NCI NIH HHS [CA85264]; NIA NIH HHS [AG08415]; NIMH NIH HHS [1F31MH064255] NR 55 TC 22 Z9 22 U1 3 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD OCT PY 2006 VL 36 IS 10 BP 1363 EP 1373 DI 10.1017/S0033291706008208 PG 11 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 100LY UT WOS:000241671800003 PM 16834822 ER PT J AU Hoffman, WF Moore, M Templin, R McFarland, B Hitzemann, RJ Mitchell, SH AF Hoffman, William F. Moore, Meredith Templin, Raymond McFarland, Bentson Hitzemann, Robert J. Mitchell, Suzanne H. TI Neuropsychological function and delay discounting in methamphetamine-dependent individuals SO PSYCHOPHARMACOLOGY LA English DT Article; Proceedings Paper CT Dopamine 2002 Conference CY JUL 10-14, 2002 CL Portland, OR DE methamphetamine; impulsivity; delay discounting; memory ID ADJUSTING-AMOUNT PROCEDURE; ILLICIT AMPHETAMINE USERS; NEUROIMAGING EVIDENCE; DECISION-MAKING; IMPULSE CONTROL; SELF-CONTROL; REWARDS; DRUG; IMPAIRMENT; ADDICTION AB Rationale Methamphetamine (MA) dependence accounts for substantial neuropsychiatric morbidity. Furthermore, there is evidence in the literature of psychiatric and cognitive impairment in chronic users. Objectives This report compares the general psychiatric and cognitive functioning, including impulsive decision-making,of individuals dependent on MA and normal controls. Materials and methods Forty-one currently abstinent individuals in treatment for MA dependence and 41 controls participated. Controls were selected to minimize group differences in age and gender. MA users met DSM-IV criteria for MA dependence, had average daily use of 0.5 g/day (0.5-6 g/day), had been abstinent at least 2 weeks (2-24 weeks), and did not currently meet criteria for other Axis I psychiatric disorders. Psychiatric symptoms were rated on standardized scales. Cognitive function was assessed with a battery of standardized neuropsychological tests. Impulsivity was assessed using a delay discounting task, which measured preference for small, immediate, and large delayed rewards. Results The MA group reported more psychiatric symptoms than controls, and was impaired relative to controls on the Babcock Story Recall-Delayed and the Rey Auditory Verbal Learning Test. MA-dependent subjects discounted delayed rewards more than controls, and this measure of impulsivity was correlated with memory impairment in the MA group but not in the controls. Conclusions MA-dependent individuals are more impulsive than controls, and this may be causally related to memory deficits but was unrelated to any other measure of psychiatric or cognitive impairment or any drug use history variable. C1 Vet Affairs Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. Vet Affairs Med Ctr, Methamphetamine Abuse Res Ctr P35C, Portland, OR 97239 USA. Vet Affairs Med Ctr, Mental Hlth & Clin Neurosci Div P35C, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Res Serv, Portland, OR USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Sch Nursing, Portland, OR 97201 USA. Kaiser Permanente, Ctr Hlth Res, Portland, OR USA. RP Hoffman, WF (reprint author), Vet Affairs Med Ctr, Mental Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM hoffmanw@ohsu.edu OI Mitchell, Suzanne/0000-0002-0225-7200; McFarland, Bentson/0000-0001-9149-5616 FU NIAAA NIH HHS [AA11034, AA00281, AA13454]; NIDA NIH HHS [DA015543]; NIMH NIH HHS [MH51372] NR 54 TC 136 Z9 144 U1 8 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD OCT PY 2006 VL 188 IS 2 BP 162 EP 170 DI 10.1007/s00213-006-0494-0 PG 9 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 082IN UT WOS:000240380000004 PM 16915378 ER PT J AU Niederman, MS Anzueto, A Sethi, S Choudhri, S Kureishi, A Haverstock, D Perroncel, R AF Niederman, M. S. Anzueto, A. Sethi, S. Choudhri, S. Kureishi, A. Haverstock, D. Perroncel, R. TI Eradication of H-influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents SO RESPIRATORY MEDICINE LA English DT Article; Proceedings Paper CT 70th Annual Meeting of the American-College-of-Chest-Physicians CY OCT 23-27, 2004 CL Seattle, WA SP Amer Coll Chest Phys DE acute exacerbations of chronic bronchitis; azithromycin; clarithromycin; Haemophilus influenzae; macrolides; moxifloxacin ID OBSTRUCTIVE PULMONARY-DISEASE; ACUTE BACTERIAL EXACERBATIONS; COURSE 5-DAY MOXIFLOXACIN; CHRONIC-BRONCHITIS; STREPTOCOCCUS-PNEUMONIAE; MORAXELLA-CATARRHALIS; EFFICACY; THERAPY; CLARITHROMYCIN; SUSCEPTIBILITY AB Haemophilus influenzae is the most common bacterial pathogen associated with acute exacerbations of chronic bronchitis (AECB). This study determined the rate of bacterial eradication of H. influenzae during AECB treated with either macrolides or moxifloxacin. Adult AECB patients with H. influenzae were included in a pooled analysis of four double-blind; multicentre, randomised trials. Patients received either moxifloxacin (400 mg qd for 5-10 days) or macrolides (azithromycin 500 mg/250 mg qd for 5 days or ctarithromycin 500 mg bid for 5-10 days). Bacterial eradication and clinical success were recorded at the test-of-cure visit (7-37 days post-therapy). Of 2555 patients in the intent-to-treat population, 910 were microbiologically valid and 292 (32%) had H. influenzae cultured at baseline. Bacterial eradication of H. influenzae was significantly higher with moxifloxacin vs. macrolide-treated patients (93.0% [133/143] vs. 73.2% [109/149], respectively, P = 0.001). Moxifloxacin also demonstrated higher eradication rates compared with azithromycin (96.8% vs. 84.6%, P = 0.019) and ctarithromycin (90.1% vs. 64.2%, P = 0.001) analysed separately. Clinical success was 89.5% (128/143) for moxifloxacin vs. 85.2% (127/149) for the macrolide group (P = 0.278); similar results were found when moxifloxacin was compared individually with each macrolide. For patients with AECB due to H. influenzae, moxifloxacin provided superior bacterial eradication rates than macrolide therapy. (c) 2006 Elsevier Ltd. All rights reserved. C1 Winthrop Univ Hosp, Dept Med, Mineola, NY 11501 USA. SUNY Stony Brook, Mineola, NY 11501 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, San Antonio, TX USA. SUNY Buffalo, Dept Vet Affairs, Western New York Healthcare Syst, Div Pulm & Crit Care Med, Buffalo, NY 14260 USA. Bayer Pharmaceut Corp, West Haven, CT USA. RP Niederman, MS (reprint author), Winthrop Univ Hosp, Dept Med, 222 Stn Plaza N,Suite 509, Mineola, NY 11501 USA. EM mniederman@winthrop.org NR 36 TC 14 Z9 14 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 J9 RESP MED JI Respir. Med. PD OCT PY 2006 VL 100 IS 10 BP 1781 EP 1790 DI 10.1016/j.rmed.2006.01.025 PG 10 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA 091PE UT WOS:000241040000013 PM 16531032 ER PT J AU Kee, KS Horan, WP Wynn, JK Mintz, J Green, MF AF Kee, Kimmy S. Horan, William P. Wynn, Jonathan K. Mintz, Jim Green, Michael F. TI An analysis of categorical perception of facial emotion in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; categorical perception; facial emotion; affect perception ID GENERALIZED POOR PERFORMANCE; AFFECT RECOGNITION; AFFECTIVE PROSODY; SOCIAL COGNITION; EXPRESSIONS; DEFICIT; PSYCHOPATHOLOGY; BEHAVIOR AB Background Emotion perception deficits have been extensively documented in schizophrenia and are associated with poor social functioning. Yet fundamental questions about the nature and scope of these impairments remain unanswered from commonly used experimental tasks. An alternative categorical perception paradigm that focuses on distinguishing boundaries between emotions was used to evaluate whether schizophrenia patients demonstrate atypical patterns of categorical perception and a negativity bias in the identification of ambiguous facial expressions. Method: 47 schizophrenia outpatients and 31 nonpsychiatric controls completed a forced-choice emotion identification task. Stimuli consisted of a series of digitized facial images that were morphed in 10% signal intensity increments along continua between pairs of emotions (happy-sad; fearful-happy; angry-fearful; angry-sad) and presented in a random order. For each emotion continuum, measures of the response slope and the location of the boundary shift point between emotions were calculated for each group. Results: The schizophrenia group demonstrated significantly shallower response curves than controls across all emotion continua. Despite these generally less precise demarcations between emotions, patients did not significantly differ from controls in the location of the shift point between emotions on any of the continua. Conclusions: Schizophrenia patients demonstrated impaired categorical perception of facial expressions with generally less sharp categorizations of ambiguous stimuli to one emotion category or another. However, patients did not demonstrate a negativity bias in their processing of ambiguous facial expressions. The emotional continuum paradigm can help to clarify the nature and boundaries of affect perception deficits in schizophrenia. (c) 2006 Elsevier B.V. All rights reserved. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. RP Kee, KS (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,MIRECC 210A,Bldg 210, Los Angeles, CA 90073 USA. EM kee@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU NIMH NIH HHS [MH 65707, MH-43292] NR 41 TC 31 Z9 35 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2006 VL 87 IS 1-3 BP 228 EP 237 DI 10.1016/j.schres.2006.06.001 PG 10 WC Psychiatry SC Psychiatry GA 095LV UT WOS:000241310100026 PM 16859896 ER PT J AU Wirshing, DA Pierre, JM Wirshing, WC Guzik, LH Resnick, SA Goldstein, D Zorick, TS AF Wirshing, Donna A. Pierre, Joseph M. Wirshing, William C. Guzik, Lisa H. Resnick, Seth A. Goldstein, Danielle Zorick, Todd S. TI Community re-entry program training module for schizophrenic inpatients improves treatment outcomes SO SCHIZOPHRENIA RESEARCH LA English DT Letter ID SKILLS C1 W Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. RP Guzik, LH (reprint author), W Los Angeles VA Med Ctr, 11301 Wilshire Blvd B-151H, Los Angeles, CA 90073 USA. EM lisa.guzik@gmail.com NR 4 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2006 VL 87 IS 1-3 BP 338 EP 339 DI 10.1016/j.schres.2006.06.030 PG 2 WC Psychiatry SC Psychiatry GA 095LV UT WOS:000241310100041 PM 16844344 ER PT J AU Morgenthaler, TI Owens, J Alessi, C Boehlecke, B Brown, TM Coleman, J Friedman, L Kapur, VK Lee-Chiong, T Pancer, J Swick, TJ AF Morgenthaler, Timothy I. Owens, Judith Alessi, Cathy Boehlecke, Brian Brown, Terry M. Coleman, Jack, Jr. Friedman, Leah Kapur, Vishesh K. Lee-Chiong, Teofilo Pancer, Jeffrey Swick, Todd J. TI Practice parameters for behavioral treatment of bedtime problems and night wakings in infants and young children - An American Academy of Sleep Medicine report SO SLEEP LA English DT Article DE practice guidelines; practice parameters; bedtime problems; night wakings in young children; treatment; behavioral; non-pharmacological; unmodified extinction; graduated extinction; extinction with parental presence; parent education; positive routines; scheduled awakenings; standardized bedtime routines; positive reinforcement AB Bedtime problems and frequent night wakings are highly prevalent in infants, toddlers, and preschoolers. Evidence suggests that sleep disruption and/or insufficient sleep have potential deleterious effects on children's cognitive development, regulation of affect, attention, health outcomes, and overall quality of life, as well as secondary effects on parental and family functioning. Furthermore, longitudinal studies have demonstrated that sleep problems first presenting in infancy may become chronic, persisting into the preschool and school-aged years. A solid body of literature now exists supporting the use of empirically-based behavioral management strategies to treat bedtime problems and night wakings in infants, toddlers, and preschoolers. The following practice parameters present recommendations for the use of behavioral (i.e., non-pharmacological) treatments of bedtime problems and night walkings in young children (aged 0-4. years 11 months). A companion review paper(1) on which the recommendations are based was prepared by a taskforce appointed by the Standards of Practice Committee (SPC) of the American Academy of Sleep Medicine (AASM), and summarizes the peer-reviewed scientific literature on this topic. The authors of the review paper evaluated the evidence presented by the reviewed studies according to modified Sackett criteria.(2) Using this information and a grading system described by Eddy(3) (i.e., standard, guideline or option), the Standards of Practice Committee and Board of Directors of the American Academy of Sleep Medicine determined levels of treatment recommendation presented in the practice parameters below. These practice parameters provide 3 types of recommendations. First, recommendations are provided indicating that behavioral interventions are effective in the treatment of bedtime problems and night wakings in young children, producing reliable and significant clinical improvement in sleep parameters. Second, recommendations are made regarding specific behavioral therapies, including: (1) unmodified extinction, extinction with parental presence, and preventive parent education are all rated as individually effective therapies in the treatment of bedtime problems and night wakings (Standards), and (2) graduated extinction, bedtime fading/positive routines and scheduled awakenings are rated as individually effective therapies in the treatment of bedtime problems and night wakings but with less certainty (Guidelines). There was insufficient evidence to recommend standardized bedtime routines and positive reinforcement as single therapies. In addition, although behavioral therapies for bedtime problems and night wakings are often combined, there was insufficient evidence available to recommend one individual therapy over another or to recommend an individual therapy over a combination of therapies. Finally, recommendations are provided regarding the beneficial effects of behavioral treatments on secondary outcomes, including daytime functioning (child) and parental well-being. C1 Mayo Clin, Mayo Sleep Disorders Ctr, Rochester, MN 55905 USA. Rhode Isl Hosp, Providence, RI USA. VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Calif Los Angeles, Sepulveda, CA USA. Univ N Carolina, Chapel Hill, NC USA. St Joseph Mem Hosp, Murphysboro, IL USA. Stanford Univ, Stanford, CA 94305 USA. Univ Washington, Seattle, WA 98195 USA. Natl Jewish Med & Res Ctr, Denver, CO USA. Houston Sleep Ctr, Houston, TX USA. RP Morgenthaler, TI (reprint author), Mayo Clin, Mayo Sleep Disorders Ctr, 200 1st St SW, Rochester, MN 55905 USA. EM morgenthaler.timothy@mayo.edu RI Kapur, Vishesh/K-1054-2014 OI Kapur, Vishesh/0000-0002-5417-1097; Morgenthaler, Timothy/0000-0002-2614-3793 NR 4 TC 78 Z9 79 U1 0 U2 17 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD OCT 1 PY 2006 VL 29 IS 10 BP 1277 EP 1281 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 100FL UT WOS:000241653400003 PM 17068980 ER PT J AU Harley, JB Kelly, JA Kaufman, KM AF Harley, John B. Kelly, Jennifer A. Kaufman, Kenneth M. TI Unraveling the genetics of systemic lupus erythematosus SO SPRINGER SEMINARS IN IMMUNOPATHOLOGY LA English DT Review DE SLE; lupus; genetics; gene; polymorphism ID MANNOSE-BINDING LECTIN; MAJOR HISTOCOMPATIBILITY COMPLEX; SINGLE-NUCLEOTIDE POLYMORPHISM; FC-GAMMA-RIIA; LYMPHOID TYROSINE PHOSPHATASE; HLA-CLASS-II; AUTOIMMUNE THYROID-DISEASE; CONNECTIVE-TISSUE DISEASE; HEREDITARY C1Q DEFICIENCY; POPULATION-BASED COHORT AB The capacity to locate polymorphisms on a virtually complete map of the human genome coupled with the ability to accurately evaluate large numbers (by historical standards) of genetic markers has led to gene identification in complex diseases, such as systemic lupus erythematosus (SLE or lupus). While this is a phenotype with enormous clinical variation, the twin studies and the observed familial aggregation, along with the genetic effects now known, suggest a strong genetic component. Unlike type 1 diabetes, lupus genetics is not dominated by the powerful effect of a single locus. Instead, there are at least six known genetic association effects in lupus of smaller magnitude (odds ratio < 2), and at least 17 robust linkages (established and arguably confirmed independently) defining potentially responsible genes that largely remain to be discovered. The more convincing genetic associations include the human leukocyte antigen region (with multiple genes), C1q, PTPN22, PDCD1, Fc receptor-like 3, Fc gamma RIIA, Fc gamma RIIIA, interferon regulatory factor 5, and others. How they contribute to disease risk remains yet to be clarified, beyond the obvious speculation derived from what has previously been learned about these genes. Certainly, they are expected to contribute to lupus risk independently and in combination with each other, with genes not yet identified, and with the environment. A substantial number of genes (> 10) are expected to be identified to contribute to lupus or in its many subsets defined by clinical and laboratory features. C1 Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. Univ Oklahoma, Dept Med, Oklahoma City, OK USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Harley, JB (reprint author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM john-harley@omrf.ouhsc.edu NR 169 TC 85 Z9 92 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0344-4325 J9 SPRINGER SEMIN IMMUN JI Springer Semin. Immunopathol. PD OCT PY 2006 VL 28 IS 2 BP 119 EP 130 DI 10.1007/s00281-006-0040-5 PG 12 WC Immunology; Pathology SC Immunology; Pathology GA 097OC UT WOS:000241456300005 PM 17021721 ER PT J AU Cohen, PL AF Cohen, Philip L. TI Apoptotic cell death and lupus SO SPRINGER SEMINARS IN IMMUNOPATHOLOGY LA English DT Review DE lupus; apoptosis; programmed cell death ID RECEPTOR TYROSINE KINASES; DENDRITIC CELLS; AUTOIMMUNE-DISEASE; IMPAIRED UPTAKE; TNF-ALPHA; LYMPHOPROLIFERATIVE DISEASE; AUTOANTIBODY PRODUCTION; MOUSE STRAINS; IN-VITRO; B-CELLS AB Programmed cell death and the disposal of cell corpses by phagocytic cells are highly regulated ongoing processes essential for the survival and well-being of higher organisms. Abnormalities in the susceptibility of certain cells to receptor-induced death are known to lead to certain human diseases (e.g., autoimmune lymphoproliferative syndrome) and may contribute to the pathogenesis of systemic lupus erythematosus. Impaired clearance of apoptotic cells is also likely to be an important factor in lupus pathogenesis, though the biological basis of such a defect remains elusive. Finally, the process of apoptosis has been shown to contribute to lupus disease effector mechanisms. A better understanding of the role of apoptosis in lupus very likely will lead to improved diagnosis and therapy. C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Cohen, PL (reprint author), Univ Penn, 421 Curie Blvd,Suite 757, Philadelphia, PA 19104 USA. EM philipco@mail.med.upenn.edu NR 68 TC 16 Z9 18 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0344-4325 J9 SPRINGER SEMIN IMMUN JI Springer Semin. Immunopathol. PD OCT PY 2006 VL 28 IS 2 BP 145 EP 152 DI 10.1007/s00281-006-0038-z PG 8 WC Immunology; Pathology SC Immunology; Pathology GA 097OC UT WOS:000241456300007 PM 16941106 ER PT J AU Zhou, XH Qin, GS Lin, HZ Li, G AF Zhou, X. H. Qin, G. S. Lin, H. Z. Li, G. TI Inferences in censored cost regression models with empirical likelihood SO STATISTICA SINICA LA English DT Article DE censored data; empirical likelihood; health care costs; prediction ID ESTIMATING MEDICAL COSTS; COLLABORATIVE CARE; MEDIAN REGRESSION; LINEAR-MODELS; POPULATION; DEPRESSION; SAMPLES; TABLES AB In many studies of health economics, we are interested in the expected total cost over a certain period for a patient with given characteristics. Problems can arise if cost estimation models do not account for distributional aspects of costs. Two such problems are (1) the skewed nature of the data, and (2) censored observations. In this paper we propose an empirical likelihood (EL) method for constructing a confidence region for the vector of regression parameters, and a confidence interval for the expected total cost of a patient with the given covariates. We show that this new method has good theoretical properties and we compare its finite-sample properties with those of the existing method. Our simulation results demonstrate that the new EL-based method performs as well as the existing method when cost data are not so skewed, and outperforms the existing method when cost data are highly skewed. Finally, we illustrate the application of our method to a data set. C1 VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Georgia State Univ, Dept Math & Stat, Atlanta, GA 30303 USA. Sichuan Univ, Sch Math, Chengdu 610064, Peoples R China. Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA. RP Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98108 USA. EM azhou@u.washington.edu; gqin@gsu.edu; huazhenlin@hotmail.com; vli@ucla.edu NR 29 TC 7 Z9 8 U1 0 U2 3 PU STATISTICA SINICA PI TAIPEI PA C/O DR H C HO, INST STATISTICAL SCIENCE, ACADEMIA SINICA, TAIPEI 115, TAIWAN SN 1017-0405 J9 STAT SINICA JI Stat. Sin. PD OCT PY 2006 VL 16 IS 4 BP 1213 EP 1232 PG 20 WC Statistics & Probability SC Mathematics GA 108ZE UT WOS:000242276900008 ER PT J AU Magliocca, JF Held, IKA Odorico, JS AF Magliocca, Joseph F. Held, Inka K. A. Odorico, Jon S. TI Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression SO STEM CELLS AND DEVELOPMENT LA English DT Article ID MHC CLASS-I; TRANSPLANTATION TOLERANCE; T-CELLS; MICE; RAT; DIFFERENTIATION; ANTIBODIES; CHIMERISM; DEFICIENT; RESPONSES AB Induction of donor-specific tolerance using embryonic stem (ES) cells followed by transplantation of ES cell-derived tissues from the same allogeneic strain could theoretically engender successful transplantation without immunosuppression. We sought to induce tolerance using bona fide murine ES cells in immunocompetent mice. ES cells were evaluated for the expression of markers restricted to undifferentiated cells [stage-specific embryonic antigen-1 (SSEA-1) and OCT-4] and the ability to form teratomas in immunodeficient mice. BALB/cByJ mice underwent intraportal inoculation with YC5-EYFP ES cells (129 strain; R1-derived) or saline followed by transplantation with 129X1/SvJ, CBA/J, or BALB/cByJ nonvascularized, neonatal cardiac grafts. Mice were sacrificed at graft failure and underwent histologic evaluation of transplanted grafts and lymphoid organs. ES cells and early differentiated progeny underwent real time (RT)-PCR and fluorescence-activated cell sorting (FACS) analysis to detect major histocompatibility complex (MHC) gene transcription and antigen expression. ES cells expressed markers restricted to undifferentiated cells while maintaining the ability to form teratomas in immunodeficient mice. No prolongation of allograft survival or evidence of lymphoid chimerism was observed in immunocompetent recipient mice despite hepatic teratoma formation. MHC class I, class II, and nonclassical antigens were undetectable on ES cells and early differentiated progeny despite the presence of mRNA transcripts. Class I expression was strongly up-regulated upon exposure to gamma-interferon. Intraportal inoculation with murine ES cells does not produce lymphoid chimerism or induce donor-specific unresponsiveness to neonatal cardiac grafts in unmanipulated immunocompetent hosts. However, specific differentiated cell types such as ES cell-derived dendritic cells, or alternate routes of ES cell administration, may be effective. ES cells appear to have immune privilege, allowing them to form teratomas in immunocompetent mice. C1 Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Div Transplantat, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53792 USA. WiCell Res Inst, Madison, WI 53792 USA. RP Magliocca, JF (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Div Transplantat, 600 Highland Ave,H4-780, Madison, WI 53792 USA. EM drjoemag@yahoo.com FU NIDDK NIH HHS [U19DK61244] NR 37 TC 45 Z9 48 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1547-3287 J9 STEM CELLS DEV JI Stem Cells Dev. PD OCT PY 2006 VL 15 IS 5 BP 707 EP 717 DI 10.1089/scd.2006.15.707 PG 11 WC Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation SC Cell Biology; Hematology; Research & Experimental Medicine; Transplantation GA 105GQ UT WOS:000242018800011 PM 17105406 ER PT J AU Loftis, JM Hauser, P Macey, TA Lowe, JD AF Loftis, Jennifer M. Hauser, Peter Macey, Tara A. Lowe, Janet D. TI Can rodents be used to model interferon-alpha-induced depressive symptoms? SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY LA English DT Letter ID RATS; BRAIN; NEUROENDOCRINE; INHIBITION; MICE; A/D C1 Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Portland VA Med Ctr, JENS Lab, Portland, OR USA. Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Internal Med, Portland, OR 97201 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. RP Loftis, JM (reprint author), Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, P3MHAdm,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM loftisj@ohsu.edu NR 15 TC 12 Z9 13 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-5846 J9 PROG NEURO-PSYCHOPH JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry PD SEP 30 PY 2006 VL 30 IS 7 BP 1364 EP 1365 DI 10.1016/j.pnpbp.2006.04.004 PG 2 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 080WU UT WOS:000240280000034 PM 16682106 ER PT J AU Reeve, JR Rosenquist, GL Keire, DA Chew, P Nicholas, HB Davis, MT Lee, TD Shively, JE Backus, RC AF Reeve, Joseph R., Jr. Rosenquist, Grace L. Keire, David A. Chew, Peter Nicholas, Hugh B. Davis, Michael T., Jr. Lee, Terry D. Shively, John E. Backus, Robert C. TI Crucial role of position 40 for interactions of CCK-58 revealed by sequence of cat CCK-58 SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE pancreas; cholecystokinin; conformations; structure-activity relationships; sequence analysis; mass spectral analysis; molecular forms ID RAT PANCREATIC ACINI; DIFFERENT CONFORMATIONS; MICROSEQUENCE ANALYSIS; CHOLECYSTOKININ; RECEPTOR; INTESTINE; SECRETIN; PERFORMANCE; PEPTIDES; TERMINUS AB Evidence suggests that amino terminal extensions of CCK-8 affect the carboxyl terminal bioactive region of CCK. Cat CCK-58 was purified by low pressure reverse phase and ion-exchange chromatography steps and several reverse phase HPLC steps. The purified peptide and its tryptic fragments were characterized by mass spectral analysis and microsequence analysis. The structure of cat CCK-58 is: AVQKVDGEPRAHLGALLARYIQQARKAPSGRMSVIKNLQSLDPSHRISDRDY(SO3) MGWMDF-amide. Cat and dog CCK-58 are identical except for position 40 which is serine in cat and asparagine in dog. Radioimmunoassay detected cat CCK-58 about 1/10th as well as dog CCK-58, indicating a marked effect on C-terminal immunoreactivity. Cat CCK-58 with a serine at position 40, the same residue found in pig, mouse, cow and rabbit CCK-58, can be used as a unique bioprobe for defining how amino terminal amino acids influence the structure and bioactivity of the carboxyl terminal region of CCK. (c) 2006 Elsevier Inc. All rights reserved. C1 Vet Adm Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Digest Dis Div, Los Angeles, CA 90024 USA. Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA. Univ Pittsburgh, Pittsburgh Supercomp Ctr, Pittsburgh, PA 15203 USA. Beckman Res Inst City Hope, Div Immunol, Duarte, CA 91010 USA. RP Keire, DA (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. EM dkeire@ucla.edu FU NCI NIH HHS [CA3572]; NCRR NIH HHS [R01-RR06217, RR06009]; NIDDK NIH HHS [DK-41301]; PHS HHS [R01-33580] NR 34 TC 2 Z9 2 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD SEP 29 PY 2006 VL 348 IS 3 BP 819 EP 825 DI 10.1016/j.bbrc.2006.07.081 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 079HM UT WOS:000240166500007 PM 16904071 ER PT J AU Thomas, SL Deadwyler, GD Tang, J Stubbs, EB Muir, D Hiatt, KK Clapp, DW De Vries, GH AF Thomas, Stacey L. Deadwyler, Gail D. Tang, Jun Stubbs, Evan B., Jr. Muir, David Hiatt, Kelly K. Clapp, D. Wade De Vries, George H. TI Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE neurofibromatosis; NF1; NF1-GRD; neurofibroma; MPNST; Schwann cell; Ras; morphology; proliferation; angiogenesis ID NERVE SHEATH TUMORS; GROWTH-FACTOR EXPRESSION; WILD-TYPE P53; NEUROFIBROMATOSIS TYPE-1; GENE-PRODUCT; TUMORIGENIC PROPERTIES; ADENYLYL-CYCLASE; ABERRANT GROWTH; DROSOPHILA NF1; IN-VITRO AB Schwann cells derived from peripheral nerve sheath tumors from individuals with Neurofibromatosis Type I (NF1) are deficient for the protein neurofibromin, which contains a GAP-related domain (NF1-GRD). Neurofibromin-deficient Schwarm cells have increased Ras activation, increased proliferation in response to certain growth stimuli, increased angiogenic potential, and altered cell morphology. This study examined whether expression of functional NF1-GRD can reverse the transformed phenotype of neurofibromin-deficient Schwann cells from both benign and malignant peripheral nerve sheath tumors. We reconstituted the NF1-GRD using retroviral transduction and examined the effects on cell morphology, growth potential, and angiogenic potential. NF1-GRD reconstitution resulted in morphologic changes, a 16-33% reduction in Ras activation, and a 53% decrease in proliferation in neurofibromin-deficient Schwarm cells. However, NF1-GRD reconstitution was not sufficient to decrease the in vitro angiogenic potential of the cells. This study demonstrates that reconstitution of the NFI-GRD can at least partially reverse the transformation of human NEI tumor-derived Schwarm cells. Published by Elsevier Inc. C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Hines, IL 60141 USA. Loyola Univ, Med Ctr, Neurosci Program, Maywood, IL 60153 USA. Loyola Univ, Med Ctr, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA. Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA. Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60680 USA. Univ Florida, Div Neurol, Dept Pediat, Gainesville, FL 32611 USA. Univ Florida, McKnight Brain Inst, Gainesville, FL 32611 USA. Univ Florida, UF Shands Canc Ctr, Gainesville, FL 32611 USA. Indiana Univ, Sch Med, Dept Microbiol Immunol, Indianapolis, IN 46202 USA. Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA. RP De Vries, GH (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. EM George.Devries@med.va.gov NR 63 TC 13 Z9 13 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD SEP 29 PY 2006 VL 348 IS 3 BP 971 EP 980 DI 10.1016/j.bbrc.2006.07.159 PG 10 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 079HM UT WOS:000240166500027 PM 16908010 ER PT J AU Carroll, MC Outten, CE Proescher, JB Rosenfeld, L Watson, WH Whitson, LJ Hart, PJ Jensen, LT Culotta, VC AF Carroll, Mark C. Outten, Caryn E. Proescher, Jody B. Rosenfeld, Leah Watson, Walter H. Whitson, Lisa J. Hart, P. John Jensen, Laran T. Culotta, Valeria Cizewski TI The effects of glutaredoxin and copper activation pathways on the disulfide and stability of Cu, Zn superoxide dismutase SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN S-GLUTATHIONYLATION; CHAPERONE CCS; CU,ZN-SUPEROXIDE DISMUTASE; ESCHERICHIA-COLI; OXIDATIVE STRESS; TRANSGENIC MICE; SOD1; MUTANT AB Mutations in Cu, Zn superoxide dismutase (SOD1) can cause amyotrophic lateral sclerosis (ALS) through mechanisms proposed to involve SOD1 misfolding, but the intracellular factors that modulate folding and stability of SOD1 are largely unknown. By using yeast and mammalian expression systems, we demonstrate here that SOD1 stability is governed by post-translational modification factors that target the SOD1 disulfide. Oxidation of the human SOD1 disulfide in vivo was found to involve both the copper chaperone for SOD1 (CCS) and the CCS-independent pathway for copper activation. When both copper pathways were blocked, wild type SOD1 stably accumulated in yeast cells with a reduced disulfide, whereas ALS SOD1 mutants A4V, G93A, and G37R were degraded. We describe here an unprecedented role for the thiol oxidoreductase glutaredoxin in reducing the SOD1 disulfide and destabilizing ALS mutants. Specifically, the major cytosolic glutaredoxin of yeast was seen to reduce the intramolecular disulfide of ALS SOD1 mutant A4V SOD1 in vivo and in vitro. By comparison, glutaredoxin was less reactive toward the disulfide of wild type SOD1. The apo-form of A4V SOD1 was highly reactive with glutaredoxin but not SOD1 containing both copper and zinc. Glutaredoxin therefore preferentially targets the immature form of ALS mutant SOD1 lacking metal co-factors. Overall, these studies implicate a critical balance between cellular reductants such as glutaredoxin and copper activation pathways in controlling the disulfide and stability of SOD1 in vivo. C1 Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA. Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs,S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Culotta, VC (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm E7626, Baltimore, MD 21205 USA. EM vculotta@jhsph.edu OI Jensen, Laran/0000-0003-3199-1743; Outten, Caryn/0000-0003-0335-6531 FU NIEHS NIH HHS [ES 07141, ES012260, K22 ES012260]; NIGMS NIH HHS [F32 GM066594, GM50016, R01 GM050016, R37 GM050016]; NINDS NIH HHS [NS39112, R01 NS039112, R01 NS039112-05]; PHS HHS [F32 66594] NR 56 TC 31 Z9 31 U1 0 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 29 PY 2006 VL 281 IS 39 BP 28648 EP 28656 DI 10.1074/jbc.M600138200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 086NO UT WOS:000240680500018 PM 16880213 ER PT J AU Morton, DL Thompson, JF Cochran, AJ Mozzillo, N Elashoff, R Essner, R Nieweg, OE Roses, DF Hoekstra, HJ Karakousis, CP Reintgen, DS Coventry, BJ Glass, EC Wang, HJ AF Morton, Donald L. Thompson, John F. Cochran, Alistair J. Mozzillo, Nicola Elashoff, Robert Essner, Richard Nieweg, Omgo E. Roses, Daniel F. Hoekstra, Harald J. Karakousis, Constantine P. Reintgen, Douglas S. Coventry, Brendon J. Glass, Edwin C. Wang, He-Jing CA MSLT Grp TI Sentinel-node biopsy or nodal observation in melanoma SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID EARLY-STAGE MELANOMA; AMERICAN JOINT COMMITTEE; IN-TRANSIT METASTASIS; LYMPH-NODE; PROGNOSTIC-FACTORS; CUTANEOUS MELANOMA; MULTICENTER TRIAL; RANDOMIZED-TRIAL; REGIONAL NODES; LYMPHADENECTOMY AB Background: We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly diagnosed melanoma. Methods: Patients with a primary cutaneous melanoma were randomly assigned to wide excision and postoperative observation of regional lymph nodes with lymphadenectomy if nodal relapse occurred, or to wide excision and sentinel-node biopsy with immediate lymphadenectomy if nodal micrometastases were detected on biopsy. Results: Among 1269 patients with an intermediate-thickness primary melanoma, the mean (+/-SE) estimated 5-year disease-free survival rate for the population was 78.3+/-1.6% in the biopsy group and 73.1+/-2.1% in the observation group (hazard ratio for death, 0.74; 95% confidence interval [CI], 0.59 to 0.93; P=0.009). Five-year melanoma-specific survival rates were similar in the two groups (87.1+/-1.3% and 86.6+/-1.6%, respectively). In the biopsy group, the presence of metastases in the sentinel node was the most important prognostic factor; the 5-year survival rate was 72.3+/-4.6% among patients with tumor-positive sentinel nodes and 90.2+/-1.3% among those with tumor-negative sentinel nodes (hazard ratio for death, 2.48; 95% CI, 1.54 to 3.98; P < 0.001). The incidence of sentinel-node micrometastases was 16.0% (122 of 764 patients), and the rate of nodal relapse in the observation group was 15.6% (78 of 500 patients). The corresponding mean number of tumor-involved nodes was 1.4 in the biopsy group and 3.3 in the observation group (P < 0.001), indicating disease progression during observation. Among patients with nodal metastases, the 5-year survival rate was higher among those who underwent immediate lymphadenectomy than among those in whom lymphadenectomy was delayed (72.3+/-4.6% vs. 52.4+/-5.9%; hazard ratio for death, 0.51; 95% CI, 0.32 to 0.81; P=0.004). Conclusions: The staging of intermediate-thickness (1.2 to 3.5 mm) primary melanomas according to the results of sentinel-node biopsy provides important prognostic information and identifies patients with nodal metastases whose survival can be prolonged by immediate lymphadenectomy. (ClinicalTrials.gov number, NCT00275496.) C1 St Johns Hlth Ctr, John Wayne Canc Inst, Dept Surg Oncol, Santa Monica, CA 90404 USA. St Johns Hlth Ctr, John Wayne Canc Inst, Dept Biostat, Santa Monica, CA 90404 USA. Royal Prince Alfred Hosp, Sydney Melanoma Unit, Camperdown, NSW 2050, Australia. Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA. Natl Canc Inst, Dept Surg Oncol, Naples, Italy. Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA. Netherlands Canc Inst, Dept Surg, Amsterdam, Netherlands. NYU, Sch Med, Dept Surg, New York, NY USA. Univ Med Ctr Groningen, Dept Surg Oncol, Groningen, Netherlands. Univ Groningen, Groningen, Netherlands. Millard Fillmore Hosp, Dept Surg, Buffalo, NY USA. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL 33612 USA. Royal Adelaide Hosp, Dept Surg, Adelaide, SA 5000, Australia. Vet Affairs Greater Los Angeles Healthcare Syst, Dept Nucl Med, Los Angeles, CA USA. RP Morton, DL (reprint author), St Johns Hlth Ctr, John Wayne Canc Inst, Dept Surg Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA. EM mortond@jwci.org FU NCI NIH HHS [CA 29605] NR 26 TC 986 Z9 1010 U1 4 U2 26 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 28 PY 2006 VL 355 IS 13 BP 1307 EP 1317 DI 10.1056/NEJMoa060992 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 088EF UT WOS:000240793600004 PM 17005948 ER PT J AU Pardini, AW Nguyen, HT Figlewicz, DP Baskin, DG Williams, DL Kim, F Schwartz, MW AF Pardini, Aaron W. Nguyen, Hong T. Figlewicz, Dianne P. Baskin, Denis G. Williams, Diana L. Kim, Francis Schwartz, Michael W. TI Distribution of insulin receptor substrate-2 in brain areas involved in energy homeostasis SO BRAIN RESEARCH LA English DT Article DE insulin receptor substrate-2; brain; energy regulation; co-localization ID CONDITIONED PLACE PREFERENCE; ARCUATE NUCLEUS; HYPOTHALAMIC NEURONS; SYNAPTIC PLASTICITY; NEUROTROPHIC FACTOR; SIGNALING PATHWAYS; INDUCED ANOREXIA; NERVOUS-SYSTEM; FOOD-INTAKE; BETA-CELLS AB Body weight regulation depends on neuronal signaling by adiposity-related hormones such as insulin and leptin. Activation of receptors for these hormones induces cell signaling via the insulin receptor substrate/phosphatidylinositol 3-kinase (IRS-PI3K) pathway, and growing evidence from knockout models implicates IRS-2 as a key component of this signal transduction mechanism. As a first step towards the identification of brain areas that utilize IRS-PI3K signaling in the control of energy homeostasis, we used immunohistochemical techniques to investigate the neuronal distribution of IRS-2 protein in rat brain. In the hypothalamus, strong IRS-2 staining was detected chiefly in the arcuate (ARC), ventromedial (VMN) nucleus and parvocellular paraventricular nucleus (PVN). Within the ARC, IRS-2 was co-localized with alpha melanocyte stimulating hormone (alpha-MSH) as well as neuropeptide Y (NPY). In the hindbrain, IRS-2 staining was detected in the area postrema (AP), medial nucleus of the solitary tract (mNTS), dorsal motor nucleus of the vagus nerve (DMV) and the hypoglossal nucleus (HN). Co-localization studies in the mNTS demonstrated the presence of IRS-2 in catecholamine neurons. IRS-2 protein was also found in the ventral tegmental area (VTA), an important area for reward perception, and was detected in dopamine neurons in this brain area. In summary, neurons containing IRS-2 immunoreactivity were identified in forebrain, midbrain and hindbrain areas and in cell types that are crucial for the control of food intake and autonomic function. An improved understanding of mechanisms underlying normal and abnormal energy homeostasis may be gained by analysis of the role played by signaling through IRS-2 in these brain areas. (c) 2006 Elsevier B.V. All rights reserved. C1 Univ Washington, Dept Med, Harborview Med Ctr, Seattle, WA 98104 USA. Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Div Metab, Seattle, WA USA. RP Schwartz, MW (reprint author), Univ Washington, Dept Med, Harborview Med Ctr, 325 9th Ave,Box 35967, Seattle, WA 98104 USA. EM mschwart@u.washington.edu RI Schwartz, Michael/H-9950-2012; Williams, Diana/C-1699-2014 OI Williams, Diana/0000-0002-3548-7440 FU NIDDK NIH HHS [DK12829, DK07247, DK40963, DK52989, DK68384]; NINDS NIH HHS [NS32273] NR 38 TC 51 Z9 51 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD SEP 27 PY 2006 VL 1112 BP 169 EP 178 DI 10.1016/j.brainres.2006.06.109 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 092XC UT WOS:000241129900018 PM 16925984 ER PT J AU Heitmann, LM Taylor, AB Hart, PJ Urbach, AR AF Heitmann, Lisa M. Taylor, Alexander B. Hart, P. John Urbach, Adam R. TI Sequence-specific recognition and cooperative dimerization of N-terminal aromatic peptides in aqueous solution by a synthetic host SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY LA English DT Article ID ARTIFICIAL RECEPTORS; SUPRAMOLECULAR CHEMISTRY; CUCURBITURIL HOMOLOGS; SELECTIVE RECOGNITION; SIGNAL-TRANSDUCTION; SMALL MOLECULES; BINDING; COMPLEXATION; DERIVATIVES; INCLUSION AB This article describes the selective recognition and noncovalent dimerization of N-terminal aromatic peptides in aqueous solution by the synthetic host compound, cucurbit[8]uril (Q8). Q8 is known to bind two aromatic guests simultaneously and, in the presence of methyl viologen, to recognize N- terminal tryptophan over internal and C-terminal sequence isomers. Here, the binding of Q8 to aromatic peptides in the absence of methyl viologen was studied by isothermal titration calorimetry (ITC), H-1 NMR spectroscopy, and X-ray crystallography. The peptides studied were of sequence X-Gly-Gly, Gly-X-Gly, and Gly-Gly-X (X = Trp, Phe, Tyr, and His). Q8 selectively binds and dimerizes Trp-Gly-Gly (1) and Phe-Gly-Gly (4) with high affinity (ternary K = 10(9)-10(11) M-2); binding constants for the other 10 peptides were too small to be measured by ITC. Both peptides bound in a stepwise manner, and peptide 4 bound with positive cooperativity. Crystal structures of Q8, 1 and Q8, 42 reveal the basis for selective recognition as simultaneous inclusion of the hydrophobic aromatic side chain into the cavity of Q8 and chelation of the proximal N-terminal ammonium group by carbonyl groups of Q8. The peptide sequence selectivity and positively cooperative dimerization reported here are, to the best of our knowledge, unprecedented for synthetic hosts in aqueous solution. Specific peptide recognition and dimerization by synthetic hosts such as Q8 should be important in the study of dimer-mediated biochemical processes and for the separation of peptides and proteins. C1 Trinity Univ, Dept Chem, San Antonio, TX 78212 USA. Univ Texas, Hlth Sci Ctr, Dept Biochem, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs,S Texas Hlth Care Syst, San Antonio, TX 78229 USA. RP Urbach, AR (reprint author), Trinity Univ, Dept Chem, 1 Trinity Pl, San Antonio, TX 78212 USA. EM aurbach@trinity.edu NR 57 TC 151 Z9 152 U1 3 U2 75 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0002-7863 J9 J AM CHEM SOC JI J. Am. Chem. Soc. PD SEP 27 PY 2006 VL 128 IS 38 BP 12574 EP 12581 DI 10.1021/ja064323s PG 8 WC Chemistry, Multidisciplinary SC Chemistry GA 085OF UT WOS:000240612700059 PM 16984208 ER PT J AU Adair, JC Rudnicki, SA Boudreau, E Weiner, WJ Coyle, PK Corboy, JR AF Adair, J. C. Rudnicki, S. A. Boudreau, E. Weiner, W. J. Coyle, P. K. Corboy, J. R. TI Survey of training programs' means for promoting neurology and attracting trainees SO NEUROLOGY LA English DT Article ID MEDICAL-STUDENTS; LIFE-STYLE; RESIDENCY; COMMITTEE; WORKFORCE; CHOICE AB Objective: To determine neurology training opportunities available to medical students and to define factors that influence program choice. Methods: All neurology residency program directors and a random sample of residents were surveyed. Resident questions related to application, interview, and training experience. Directors' questions focused on ways their department generated interest in clinical neurosciences. Results: Medical schools introduce students to clinical neurology primarily through required clerkships. Contact time averages less than 4 weeks and emphasizes inpatient encounters. Preceptorships with neurology faculty do not exist at almost 40% of schools and only 14% have neuroscience tracks. Nearly all residency applicants matched their first or second choice. The majority declined at least one interview and 39% failed to rank at least one site they visited. When choosing where to apply, the programs' reputation and geographic considerations were paramount. When making a rank list, interactions with faculty and residents at interview were most important. Residents generally reported satisfaction with their programs and attribute morale to supportive relationships with faculty and residents. Conclusions: Neurology programs may be able to enhance students' impression of neurology through changes in their clinical experience and development of venues for more meaningful relationships with faculty. Attention to the residents' personal needs may increase the likelihood of matching the best available candidates and ensuring their satisfaction. C1 Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA. New Mexico Vet Healthcare Syst, Albuquerque, NM USA. Univ Arkansas Med Sci, Dept Neurol, Bethesda, MD USA. NIH, Bethesda, MD 20892 USA. Univ Maryland, Dept Neurol, College Pk, MD 20742 USA. SUNY Stony Brook, Dept Neurol, Stony Brook, NY 11794 USA. Univ Colorado, Dept Neurol, Denver, CO 80202 USA. Hlth Sci Ctr, Denver, CO USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Adair, JC (reprint author), Univ New Mexico Hosp, Dept Neurol, ACC 2nd Floor,2211 Lomas Blvd NE, Albuquerque, NM 87131 USA. EM John.Adair@med.va.gov NR 14 TC 9 Z9 9 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD SEP 26 PY 2006 VL 67 IS 6 BP 936 EP 939 DI 10.1212/01.wnl.0000237324.47522.24 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 087NU UT WOS:000240749900004 PM 17000957 ER PT J AU Beeri, MS Schmeidler, J Sano, M Wang, J Lally, R Grossman, H Silverman, JM AF Beeri, M. S. Schmeidler, J. Sano, M. Wang, J. Lally, R. Grossman, H. Silverman, J. M. TI Age, gender, and education norms on the CERAD neuropsychological battery in the oldest old SO NEUROLOGY LA English DT Article ID ALZHEIMERS-DISEASE; PERFORMANCE; AMERICAN; DEMENTIA; ELDERS; TESTS; CONSORTIUM; ESTABLISH; REGISTRY; SAMPLE AB Objective: To evaluate the performance of nondemented subjects 85 years and older on the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological battery, and to assess its relationship with sociodemographic variables. Methods: We studied 196 subjects enrolled in an Alzheimer's Disease Research Center study who had a complete CERAD neuropsychological assessment. We used multiple regression analysis to predict performance on the neuropsychological tests from age, education, and sex. Eight representative hypothetical individuals were created (for example, an 87-year-old man, with high education). For each test, estimates of performance at the 10th, 25th, 50th, and 75th percentiles were reported for the eight representative hypothetical individuals. Results: Mean age was 89.2 years (SD = 3.2), mean years of education was 14.9 (SD = 3.2), and 66% of the sample were women. For 11 of the 14 neuropsychological tests, there was a significant multiple regression model using education, age, and sex as predictors. Neither the models nor the predictors used individually were significant for Delayed Recall, Savings, or correct Recognition. Among the significant results, seven had education as the strongest predictor. Lower age and higher education were associated with better performance. Women performed better than men in three of four tests with significant results for sex. Conclusions: In a sample of oldest old whose primary language is English, neuropsychological testing is influenced mainly by education and age. Cutoff scores based on younger populations and applied to the oldest old might lead to increased false-positive misclassifications. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA. Bronx Vet Affairs Med Ctr, New York, NY USA. RP Beeri, MS (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave Levy Pl,Box 1230, New York, NY 10029 USA. EM michal.beeri@mssm.edu FU NIA NIH HHS [P01-AG02219, 1 K01 AG023515-01A2, K01 AG023515, K01 AG023515-01A2, P01 AG002219, P50 AG005138, P50-AG05138] NR 18 TC 41 Z9 43 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD SEP 26 PY 2006 VL 67 IS 6 BP 1006 EP 1010 DI 10.1212/01.wnl.0000237548.15734.cd PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 087NU UT WOS:000240749900017 PM 17000969 ER PT J AU Ho, PM Rumsfeld, JS Masoudi, FA McClure, DL Plomondon, ME Steiner, JF Magid, DJ AF Ho, P. Michael Rumsfeld, John S. Masoudi, Frederick A. McClure, David L. Plomondon, Mary E. Steiner, John F. Magid, David J. TI Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 55th Annual Scientific Session of the American-College-of-Cardiology CY MAR 11-14, 2006 CL Atlanta, GA SP Amer Coll Cardiol ID MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; CLINICAL-OUTCOMES; GLYCEMIC CONTROL; BLOOD-PRESSURE; DRUG-THERAPY; RISK-FACTORS; ADHERENCE; CARE; QUALITY AB Background: Medication nonadherence may reduce the effectiveness of therapies. To our knowledge, the association between medication nonadherence and mortality remains unexplored outside the context of clinical trials. Methods: A retrospective cohort study of 11 532 patients with diabetes mellitus in a managed care organization. Medication adherence was calculated as the proportion of days covered for filled prescriptions of oral hypoglycemics, antihypertensives, and statin medications. The primary outcomes of interest were all-cause hospitalization and all-cause mortality. Multivariable regression analyses were performed to assess the independent association between medication adherence and outcomes. Results: Nonadherent patients (proportion of days covered, < 80%; prevalence, 21.3%) were younger and had fewer comorbidities compared with adherent patients. During follow-up, nonadherent patients had higher glycosylated hemoglobin, systolic and diastolic blood pressure, and low-density lipoprotein cholesterol levels. In unadjusted analyses, nonadherent patients had higher all-cause hospitalization (23.2% vs 19.2%, P <.001) and higher all-cause mortality (5.9% vs 4.0%, P <.001). In multivariable analyses, medication nonadherence remained significantly associated with increased risks for all-cause hospitalization (odds ratio, 1.58; 95% confidence interval, 1.38- 1.81; P <.001) and for all-cause mortality (odds ratio, 1.81; 95% confidence interval, 1.46-2.23; P <.001). The findings were consistent across patient subgroups and using different cutoffs for the proportion of days covered. Conclusions: Medication nonadherence is prevalent among patients with diabetes mellitus and is associated with adverse outcomes. Interventions are needed to increase medication adherence so that patients can realize the full benefit of prescribed therapies. C1 Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80220 USA. Univ Colorado, Colorado Hlth Outcomes Program, Hlth Sci Ctr, Denver, CO 80202 USA. Univ Colorado, Dept Emergency Med, Hlth Sci Ctr, Denver, CO 80202 USA. Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA. Kaiser Permanente Colorado, Climat Res Unit, Denver, CO USA. Denver Hlth Med Ctr, Dept Med, Denver, CO USA. RP Ho, PM (reprint author), Denver Vet Affairs Med Ctr, Dept Med, 1055 Clermont St 111B, Denver, CO 80220 USA. EM michael.ho@uchsc.edu FU NIA NIH HHS [K08-AG01011] NR 38 TC 454 Z9 463 U1 2 U2 16 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD SEP 25 PY 2006 VL 166 IS 17 BP 1836 EP 1841 DI 10.1001/archinte.166.17.1836 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 087GI UT WOS:000240730500007 PM 17000939 ER PT J AU Ho, PM Spertus, JA Masoudi, FA Reid, KJ Peterson, ED Magid, DJ Krumholz, HM Rumsfeld, JS AF Ho, P. Michael Spertus, John A. Masoudi, Frederick A. Reid, Kimberly J. Peterson, Eric D. Magid, David J. Krumholz, Harlan M. Rumsfeld, John S. TI Impact of medication therapy discontinuation on mortality after myocardial infarction SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID ASSOCIATION TASK-FORCE; PRACTICE GUIDELINES COMMITTEE; ACUTE CORONARY SYNDROMES; LONG-TERM ADHERENCE; AMERICAN-COLLEGE; SECONDARY PREVENTION; RISK-FACTORS; MANAGEMENT; OUTCOMES; REGISTRY AB Background: Nonadherence to medications is common, but the determinants and consequences are poorly defined. The objectives of this study were to identify patient and myocardial infarction (MI) treatment factors associated with medication therapy discontinuation and to assess the impact of medication discontinuation 1 month after MI on 12-month mortality. Methods: This was a multicenter prospective cohort of patients with MI enrolled in the Prospective Registry Evaluating Myocardial Infarction: Event and Recovery study. The outcomes were use of aspirin, beta-blockers, and statins at 1 month after MI hospitalization among patients discharged with all 3 medications as well as 12-month mortality. Results: Of 1521 patients discharged with all 3 medications, 184 discontinued use of all 3 medications, 56 discontinued use of 2 medications, 272 discontinued use of 1 medication, and 1009 continued taking all 3 medications at 1 month. In multivariable analyses, patients not graduating from high school (odds ratio [OR], 1.76; 95% confidence interval [CI], 1.20- 2.60) were more likely to discontinue use of all medications. The effect of increasing age on medication therapy discontinuation was greater for females (OR, 1.77; 95% CI, 1.34- 2.34) than males (OR, 1.23; 95% CI, 1.02- 1.47). Patients who discontinued use of all medications at 1 month had lower 1-year survival (88.5% vs 97.7%; log-rank P <.001) compared with patients who continued to take 1 or more medication(s). In multivariable survival analysis, medication therapy discontinuation was independently associated with higher mortality (hazards ratio, 3.81; 95% CI, 1.88-7.72). Results were consistent when evaluating discontinuation of use of aspirin, beta-blockers, and statins separately. Conclusions: Medication therapy discontinuation after MI is common and occurs early after discharge. Patients who discontinue taking evidence-based medications are at increased mortality risk. These findings suggest the need to improve the transition of care from the hospital to outpatient setting to ensure that patients continue to take medications that have mortality benefit. C1 Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. Mid Amer Heart Inst, Denver, CO USA. Denver Hlth Med Ctr, Denver, CO USA. Duke Clin Res Inst, Durham, NC USA. Kaiser Permanente Colorado, Clin Res Unit, Aurora, CO USA. Yale Univ, Sch Med, New Haven, CT USA. RP Ho, PM (reprint author), Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, 1055 Clermont St 111B, Denver, CO 80220 USA. EM michael.ho@uchsc.edu NR 28 TC 301 Z9 310 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD SEP 25 PY 2006 VL 166 IS 17 BP 1842 EP 1847 DI 10.1001/archinte.166.17.1842 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 087GI UT WOS:000240730500008 PM 17000940 ER PT J AU Kwong, JMK Lalezary, M Nguyen, JK Yang, C Khattar, A Piri, N Mareninov, S Gordon, LK Caprioli, J AF Kwong, Jacky M. K. Lalezary, Maziar Nguyen, Jessica K. Yang, Christine Khattar, Anuj Piri, Natik Mareninov, Sergey Gordon, Lynn K. Caprioli, Joseph TI Co-expression of heat shock transcription factors 1 and 2 in rat retinal ganglion cells SO NEUROSCIENCE LETTERS LA English DT Article DE heat shock protein; stress rat; heat shock factor; retina; ganglion cell ID HEAT-SHOCK RESPONSE; MOLECULAR CHAPERONES; HIPPOCAMPAL-NEURONS; STRESS-RESPONSE; GLAUCOMA MODEL; GLIAL-CELLS; HYPERTHERMIA; ACTIVATION; INDUCTION; PROTECTS AB Heat shock protein (HSP) plays an important role in the maintenance of neuronal survival during harmful conditions. Previously, we reported that metabolic stress induces HSP72 in retinal ganglion cells (RGCs) and protects against excitotoxicity, hypoxia and experimental glaucoma. To understand heat shock protein transcriptional mechanisms, we examined the cellular expression of heat shock factors 1 (HSF1) and 2 (HSF2) in the unstressed adult rat retina. Western blotting, immunohistochemistry and RT-PCR showed that mRNA and protein of HSF1 and HSF2 were present in the rat retina and predominantly expressed in RGC layer cells. Western blotting of dissociated RGC suspensions harvested with Thy-1 immuno-labeled magnetic beads confirmed that RGCs expressed HSF1, HSF2 and HSP72. Our findings suggest that both heat shock transcription factors I and 2 are linked to the heat shock response in retinal ganglion cells. (c) 2006 Elsevier Ireland Ltd. All rights reserved. C1 Univ Calif Los Angeles, Dept Ophthalmol, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Neurosci, Los Angeles, CA 90095 USA. Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA. Greater Los Angeles VA Healthcare Syst, Ophthalmol Sect, Los Angeles, CA USA. RP Kwong, JMK (reprint author), Univ Calif Los Angeles, Dept Ophthalmol, Jules Stein Eye Inst, David Geffen Sch Med, B-146,100 Stein Plaza, Los Angeles, CA 90095 USA. EM kwong@jsei.ucla.edu OI Caprioli, Joseph/0000-0002-2383-7263 NR 25 TC 13 Z9 13 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD SEP 25 PY 2006 VL 405 IS 3 BP 191 EP 195 DI 10.1016/j.neulet.2006.06.070 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 083PL UT WOS:000240470600008 PM 16889897 ER PT J AU Morton, GJ Cummings, DE Baskin, DG Barsh, GS Schwartz, MW AF Morton, G. J. Cummings, D. E. Baskin, D. G. Barsh, G. S. Schwartz, M. W. TI Central nervous system control of food intake and body weight SO NATURE LA English DT Review ID HYPOTHALAMIC ARCUATE NUCLEUS; PLASMA GHRELIN LEVELS; CAUDAL BRAIN-STEM; LEPTIN RECEPTOR; INSULIN-RECEPTOR; ENERGY-BALANCE; RECOMBINANT LEPTIN; PLACE PREFERENCE; INDUCED ANOREXIA; NEUROPEPTIDE-Y AB The capacity to adjust food intake in response to changing energy requirements is essential for survival. Recent progress has provided an insight into the molecular, cellular and behavioural mechanisms that link changes of body fat stores to adaptive adjustments of feeding behaviour. The physiological importance of this homeostatic control system is highlighted by the severe obesity that results from dysfunction of any of several of its key components. This new information provides a biological context within which to consider the global obesity epidemic and identifies numerous potential avenues for therapeutic intervention and future research. C1 Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA. Univ Washington, Dept Med, Seattle, WA 98104 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. Univ Washington, Dept Biol Struct, Seattle, WA 98104 USA. Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA. Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA. RP Schwartz, MW (reprint author), Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA. EM mschwart@u.washington.edu RI Schwartz, Michael/H-9950-2012 NR 75 TC 1137 Z9 1187 U1 27 U2 239 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD SEP 21 PY 2006 VL 443 IS 7109 BP 289 EP 295 DI 10.1038/nature05026 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 085RL UT WOS:000240622000036 PM 16988703 ER PT J AU Suda, Y Arano, A Fukui, Y Koshida, S Wakao, M Nishimura, T Kusumoto, S Sobel, M AF Suda, Yasuo Arano, Akio Fukui, Yasuhiro Koshida, Shuhei Wakao, Masahiro Nishimura, Tomoaki Kusumoto, Shoichi Sobel, Michael TI Immobilization and clustering of structurally defined oligosaccharides for sugar chips: An improved method for surface plasmon resonance analysis of protein-carbohydrate interactions SO BIOCONJUGATE CHEMISTRY LA English DT Article ID FIBROBLAST-GROWTH-FACTOR; VON-WILLEBRAND-FACTOR; HEPARIN-BINDING; A1 DOMAIN; MICROARRAYS; DISACCHARIDE; COMPLEXES; RECEPTOR; ARRAYS; ACID AB Oligosaccharides are increasingly being recognized as important partners in receptor-ligand binding and cellular signaling. Surface plasmon resonance (SPR) is a very powerful tool for the real-time study of the specific interactions between biological molecules. We report here an advanced method for the immobilization of oligosaccharides in clustered structures for SPR and their application to the analysis of heparin-protein interactions. Reductive amination reactions and linker molecules were designed and optimized. Using mono-, tri-, or tetravalent linker compounds, we incorporated synthetic structurally defined disaccharide units of heparin and immobilized them as ligands for SPR. Their binding to an important hemostatic protein, von Willebrand factor (vWf), and its known heparin-binding domain was quantitatively analyzed. These multivalent ligand conjugates exhibited reproducible binding behavior, with consistency of the surface conditions of the SPR chip. This novel technique for oligosaccharide immobilization in SPR studies is accurate, specific, and easily applicable to both synthetic and naturally derived oligosaccharides. C1 Kagoshima Univ, Dept Nanostruct & Adv Mat, Grad Sch Sci & Engn, Kagoshima 8900065, Japan. Kagoshima Univ, Venture Business Lab, Kagoshima 8900065, Japan. Japan Sci & Technol Agcy, Chiyoda Ku, Tokyo 1028666, Japan. Osaka Univ, Dept Chem, Grad Sch Sci, Osaka 5600043, Japan. Univ Washington, Dept Surg, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Suda, Y (reprint author), Kagoshima Univ, Dept Nanostruct & Adv Mat, Grad Sch Sci & Engn, Kagoshima 8900065, Japan. EM ysuda@eng.kagoshima-u.ac.jp FU NHLBI NIH HHS [HL079812, R01HL39903] NR 30 TC 75 Z9 75 U1 0 U2 7 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1043-1802 J9 BIOCONJUGATE CHEM JI Bioconjugate Chem. PD SEP 20 PY 2006 VL 17 IS 5 BP 1125 EP 1135 DI 10.1021/bc0600620 PG 11 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA 085LX UT WOS:000240606700003 PM 16984119 ER PT J AU Goldberger, JJ Subacius, H Schaechter, A Howard, A Berger, R Shalaby, A Levine, J Kadish, AH AF Goldberger, Jeffrey J. Subacius, Haris Schaechter, Andi Howard, Adam Berger, Ronald Shalaby, Alaa Levine, Joseph Kadish, Alan H. CA DEFINITE Investigators TI Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; CORONARY-ARTERY-DISEASE; LIPID-LOWERING DRUGS; HEART-FAILURE; ATRIAL-FIBRILLATION; INFLAMMATION; CHOLESTEROL; DEATH; MORTALITY; MARKERS AB OBJECTIVES We sought to evaluate whether statins were associated with a survival benefit and significant attenuation in life-threatening arrhythmias in patients with nonischemic dilated cardiomyopathy. BACKGROUND Statins are associated with a reduction in appropriate implantable cardioverter-defibriflator (ICD) therapy in patients with coronary artery disease and improved clinical status in nonischemic dilated cardiomyopathy. METHODS The effect of statin use on time to death or resuscitated cardiac arrest and time to arrhythmic sudden death was evaluated in 458 patients enrolled in the DEFINITE (DEFIbrillators in Non-Ischemic cardiomyopathy Treatment Evaluation) study. The effect of statin use on time to first appropriate shock was analyzed only in the 229 patients who were randomized to ICD therapy. RESULTS The unadjusted hazard ratio (HR) for death among patients on versus those not on statin therapy was 0.22 (95% confidence interval [CII 0.09 to 0.55; p = 0.001). When controlled for statin effects, ICD therapy was associated with improved survival (HR 0.61; 95% CI 0.38 to 0.99; p = 0.04). There was one arrhythmic sudden death in the 110 patients receiving statin therapy (0.9%) versus 18 of 348 patients not receiving statins (5.2%; p = 0.04). The unadjusted HR for arrhythmic sudden death among patients on versus those not on statin therapy was 0.16 (95% CI 0.022 to 1.21; p = 0.08). The HR for appropriate shocks among patients on versus those not on statin therapy was 0.78 (95% CI 0.34 to 1.82) after adjustment for baseline differences in the two groups. CONCLUSIONS Statin use in the DEFINITE study was associated with a 78% reduction in mortality. This reduction was caused, in part, by a reduction in arrhythmic sudden death. These findings should be confirmed in a prospective, randomized clinical trial. C1 Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA. NW Mem Hosp, Bluhm Cardiovasc Inst, Clin Trials Unit, Chicago, IL 60611 USA. Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. St Francis Hosp, Ctr Heart, Roslyn, NY USA. RP Goldberger, JJ (reprint author), Northwestern Univ, Feinberg Sch Med, Div Cardiol, 251 E Huron,Feinberg Pavil 8-542, Chicago, IL 60611 USA. EM j-goldberger@northwestern.edu OI Subacius, Haris/0000-0003-4061-1220 NR 21 TC 71 Z9 77 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD SEP 19 PY 2006 VL 48 IS 6 BP 1228 EP 1233 DI 10.1016/j.jacc.2006.05.053 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 086VQ UT WOS:000240701500020 PM 16979011 ER PT J AU Bernardi, RE Lattal, KM Berger, SP AF Bernardi, Rick E. Lattal, Kennon M. Berger, Stephen P. TI Postretrieval propranolol disrupts a cocaine conditioned place preference SO NEUROREPORT LA English DT Article DE cocaine; conditioned place preference; memory; reconsolidation ID RETROGRADE-AMNESIA; PROTEIN-SYNTHESIS; MEMORY CONSOLIDATION; RECONSOLIDATION; REACTIVATION; RETRIEVAL; AMYGDALA; REWARD; NEUROBIOLOGY; PERSPECTIVE AB The current study examined whether a postretrieval drug memory could be disrupted by the beta-adrenoceptor antagonist propranolol, administered following reactivation in a cocaine-mediated conditioned place preference paradigm. Following cocaine conditioning, rats were given a test of conditioned place preference, followed immediately by intraperitoneal administration of propranolol or saline. Rats that received propranolol following the preference test showed no preference for the cocaine-paired floor during a subsequent test, while vehicle-treated rats continued to express a preference for the cocaine-paired floor. These deficits in behavior were specific to retrieval of the cocaine-mediated memory, suggesting that postretrieval propranolol induced an impairment of drug-seeking behavior that is consistent with the disruption of a reconsolidation phase following retrieval. C1 Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Bernardi, RE (reprint author), Oregon Hlth Sci Univ, Dept Behav Neurosci, Mail Code L470,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM bernardi@ohsu.edu NR 25 TC 75 Z9 78 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD SEP 18 PY 2006 VL 17 IS 13 BP 1443 EP 1447 DI 10.1097/01.wnr.0000233098.20655.26 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 089JQ UT WOS:000240877100015 PM 16932155 ER PT J AU Angel, LF Levine, DJ Restrepo, MI Johnson, S Sako, E Carpenter, A Calhoon, J Cornell, JE Adams, SG Chisholm, GB Nespral, J Roberson, A Levine, SM AF Angel, Luis F. Levine, Deborah J. Restrepo, Marcos I. Johnson, Scott Sako, Edward Carpenter, Andrea Calhoon, John Cornell, John E. Adams, Sandra G. Chisholm, Gary B. Nespral, Joe Roberson, Ann Levine, Stephanie M. TI Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE lung recipients; lung transplantation; organ donation; organ donor; survival ID RESPIRATORY-DISTRESS-SYNDROME; CRITERIA; LIBERALIZATION; RECRUITMENT; EXPERIENCE; ORGANS AB Rationale: One of the limitations associated with lung transplantation is the lack of available organs. Objective: To determine whether a lung donor-management protocol could increase the number of lungs for transplantation without affecting the survival rates of the recipients. Methods: We implemented the San Antonio Lung Transplant protocol for managing potential lung donors according to modifications of standard criteria for donor selection and strategies for donor management. We then compared information gathered during a 4-yr period, during which the protocol was used with information gathered during a 4-yr period before protocol implementation. Primary outcome measures were the procurement rate of lungs and the 30-d and 1-yr survival rates of recipients. Main Results: We reviewed data from 711 potential lung donors. The mean rate of lung procurement was significantly higher (p < 0.0001) during the protocol period (25.5%) than during the preprotocol period (111.5%), with an estimated risk ratio of 2.2 in favor of the protocol period. More patients received transplants during the protocol period (n = 121) than during the pre-protocol period (n = 53; p < 0.0001). Of 98 actual lung donors during the protocol period, 53 (54%) had initially been considered poor donors; these donors provided 64 (53%) of the 121 lung transplants. The type of donor was not associated with significant differences in recipients' 30-d and 1-yr survival rates or any clinical measures of adequate graft function. Conclusions: The protocol was associated with a significant increase in the number of lung donors and transplant procedures without compromising pulmonary function, length of stay, or survival of the recipients. C1 Univ Texas, Hlth Sci Ctr, Div Cardiothorac Surg, Div Pulm & Crit Care Med, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Ctr Biostat & Epidemiol, San Antonio, TX USA. Audie L Murphy Mem Vet Adm Med Ctr, VERDICT, Ctr Excellence, San Antonio, TX 78284 USA. Texas Organ Sharing Alliance, San Antonio, TX USA. RP Angel, LF (reprint author), 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM angel@uthscsa.edu NR 33 TC 83 Z9 85 U1 0 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 15 PY 2006 VL 174 IS 6 BP 710 EP 716 DI 10.1164/rccm.200603-432OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 086HJ UT WOS:000240664100015 PM 16799075 ER PT J AU Bastian, PJ Gonzalgo, ML Aronson, WJ Terris, MK Kane, CJ Amling, CL Presti, JC Mangold, LA Humphreys, E Epstein, JI Partin, AW Freedland, SJ AF Bastian, Patrick J. Gonzalgo, Mark L. Aronson, William J. Terris, Martha K. Kane, Christopher J. Amling, Christopher L. Presti, Joseph C., Jr. Mangold, Leslie A. Humphreys, Elizabeth Epstein, Jonathan I. Partin, Alan W. Freedland, Stephen J. TI Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10 SO CANCER LA English DT Article DE Gleason score 8 to 10; high risk; prostate cancer; recurrence; radical prostatectomy ID RETROPUBIC PROSTATECTOMY; RADIATION-THERAPY; SEARCH DATABASE; RISK; RECURRENCE; DISEASE; ANTIGEN; PROGRESSION; MORTALITY; MEN AB BACKGROUND. Men with a biopsy Gleason sum of 8 to 10 are considered high-risk. The current study sought to identify whether there was a subset of men with high biopsy Gleason sums who would have a good pathologic and biochemical outcome with surgical monotherapy. To increase the generalizability of the findings, data were used from patients treated at 2 very different practice settings: a tertiary care referral center (Johns Hopkins Hospital) and multiple equal-access medical centers (Shared Equal Access Regional Cancer Hospital [SEARCH] Database). METHODS. The data were retrospectively reviewed from men with biopsy Gleason sums 8 to 10 treated by radical prostatectomy at the Johns Hopkins Hospital (n = 220, 3.8% of total cohort) and within the SEARCH Database (n = 149, 7.7% of total cohort). The preoperative clinical characteristics predicting unfavorable pathologic disease (nonorgan-confined and/or positive surgical margins) and time to biochemical recurrence were determined using logistic regression and Cox proportional hazards analysis, respectively. RESULTS. Favorable pathologic outcome (organ-confined and negative surgical margins) was observed in 21% of the men in the Johns Hopkins cohort and 41% from the SEARCH cohort. On multivariate analysis, higher serum prostate-specific antigen (PSA) was the only variable that significantly predicted an unfavorable pathologic outcome from both the Johns Hopkins (P = .047) and SEARCH cohorts (P = .002). The 5-year and 10-year estimated biochemical-free survival rates in the Johns Hopkins cohort were 40% (95% confidence interval [CI], 33-48%) and 27% (95% CI, 18-36%), respectively, and 32% (95% CI, 22-42%) and 28% (95% CI, 18-38%) in the SEARCH cohort, respectively. Among men with favorable pathologic findings, the 5- and 10-year estimated biochemical-free survival rates in the Johns Hopkins cohort were 79% (95% CI, 62-89%) and 50% (95% CI, 25-71%), respectively, and 49% (95% CI, 32-65%) and 49% (95% CI, 32-65%) in the SEARCH cohort, respectively. No single preoperative variable significantly predicted the risk of biochemical progression in both the SEARCH or Johns Hopkins cohorts. CONCLUSIONS. The majority of men with a biopsy Gleason sum of >= 8, regardless of where the patient is treated, had unfavorable pathologic disease and experienced a biochemical progression after radical prostatectomy. Even among men with organ-confined disease and negative surgical margins or pathologic Gleason sum < 8, at least half of the men experienced a PSA recurrence. Patients with biopsy Gleason sum 8 to 10 cancers are good candidates for multimodal therapy. Whereas multimodal therapy has often meant radiation plus hormonal therapy, newer possibilities for multimodal therapy exist such as surgery with neoadjuvant or adjuvant chemohormonal therapy or surgery with adjuvant radiation. C1 Duke Univ, Med Ctr, Div Urol Surg, Duke Prostate Ctr,Sch Med, Durham, NC 27710 USA. Duke Univ, Sch Med, Dept Surg, Duke Prostate Ctr, Durham, NC 27710 USA. Duke Univ, Sch Med, Dept Pathol, Duke Prostate Ctr, Durham, NC 27710 USA. Vet Adm Med Ctr, Urol Sect, Dept Surg, Durham, NC USA. Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA. Vet Adm Greater Los Angeles Healthcare Syst, Urol Sect, Dept Surg, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. Vet Adm Med Ctr, Dept Surg, Augusta, GA 30904 USA. Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. Vet Adm Med Ctr, Urol Sect, Dept Surg, San Francisco, CA 94121 USA. Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. Univ Alabama, Dept Urol, Birmingham, AL USA. Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. Naval Hosp, Dept Urol, San Diego, CA USA. Vet Adm Med Ctr, Urol Sect, Dept Surg, Palo Alto, CA 94304 USA. Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA. RP Freedland, SJ (reprint author), Duke Univ, Med Ctr, Div Urol Surg, Duke Prostate Ctr,Sch Med, Box 3850, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [R01CA100938, P50CA58236, P50CA92131-01A1] NR 32 TC 69 Z9 71 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD SEP 15 PY 2006 VL 107 IS 6 BP 1265 EP 1272 DI 10.1002/cncr.22116 PG 8 WC Oncology SC Oncology GA 084MR UT WOS:000240537700009 PM 16900523 ER PT J AU Pejovic, T Yates, JE Liu, HY Hays, LE Akkari, Y Torimaru, Y Keeble, W Rathbun, RK Rodgers, WH Bale, AE Ameziane, N Zwaan, CM Errami, A Thuillier, P Cappuccini, F Olson, SB Cain, JM Bagby, GC AF Pejovic, Tanja Yates, Jane E. Liu, Hong Y. Hays, Laura E. Akkari, Yassmine Torimaru, Yumi Keeble, Winifred Rathbun, R. Keaney Rodgers, William H. Bale, Allen E. Ameziane, Najim Zwaan, C. Michael Errami, Abdellatif Thuillier, Philippe Cappuccini, Fabio Olson, Susan B. Cain, Joanna M. Bagby, Grover C., Jr. TI Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer SO CANCER RESEARCH LA English DT Article ID FANCONI-ANEMIA PROTEIN; FUNCTIONAL-ACTIVITY; BREAST CARCINOMAS; TUMORS; GENE; EXPRESSION; ONCOGENE; PATHWAY; FANCD2; P53 AB Fanconi anemia is an inherited cancer predisposition disease characterized by cytogenetic and cellular hypersensitivity to cross-linking agents. Seeking evidence of Fanconi anemia protein dysfunction in women at risk of ovarian cancer, we screened ovarian surface epithelial cells from 25 primary cultures established from 22 patients using cross-linker hypersensitivity assays. Samples were obtained from (a) women at high risk for ovarian cancer with histologically normal ovaries, (b) ovarian cancer patients, and (c) a control group with no family history of breast or ovarian cancer. In chromosomal breakage assays, all control cells were mitomycin C (MMC) resistant, but eight samples (five of the six high-risk and three of the eight ovarian cancer) were hypersensitive. Lymphocytes from all eight patients were MMC resistant. Only one of the eight patients had a BRCA1 germ-line mutation and none had BRCA2 mutations, but FANCD2 was reduced in five of the eight. Ectopic expression of normal FANCD2 cDNA increased FANCD2 protein and induced MMC resistance in both hypersensitive lines tested. No FANCD2 coding region or promoter mutations were found, and there was no genomic loss or promoter methylation in any Fanconi anemia genes. Therefore, in high-risk women with no BRCA1 or BRCA2 mutations, tissue-restricted hypersensitivity to cross-linking agents is a frequent finding, and chromosomal breakage responses to MMC may be a sensitive screening strategy because cytogenetic instability identified in this way antedates the onset of carcinoma. Inherited mutations that result in tissue-specific FANCD2 gene suppression may represent a cause of familial ovarian cancer. C1 Oregon Hlth Sci Univ, Dept Obstet & Gynecol, Inst Canc, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Ctr Womens Hlth, Inst Canc, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Med & Mol & Med Genet, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, NW Vet Affairs Canc Res Ctr, Portland, OR USA. Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA. Yale Univ, Sch Med, Dept Genet, New Haven, CT USA. MRC, Amsterdam, Netherlands. Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Pediat Oncol, Rotterdam, Netherlands. RP Pejovic, T (reprint author), Oregon Hlth Sci Univ, Dept Obstet & Gynecol, Inst Canc, L-466,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM pejovict@ohsu.edu FU NHLBI NIH HHS [HL48546]; NICHD NIH HHS [5K12HD043488] NR 40 TC 28 Z9 31 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD SEP 15 PY 2006 VL 66 IS 18 BP 9017 EP 9025 DI 10.1158/0008-5472.CAN-06-0222 PG 9 WC Oncology SC Oncology GA 086CI UT WOS:000240650300016 PM 16982743 ER PT J AU Luong, QT O'Kelly, J Braunstein, GD Hershman, JM Koeffler, HP AF Luong, Quang T. O'Kelly, James Braunstein, Glenn D. Hershman, Jerome M. Koeffler, H. Phillip TI Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo SO CLINICAL CANCER RESEARCH LA English DT Article ID HISTONE-DEACETYLASE INHIBITORS; ANTICANCER AGENTS; DNA METHYLATION; CARCINOMA; APOPTOSIS; DIFFERENTIATION; PROLIFERATION AB Purpose: The histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), has multiple antitumor effects against a variety of human cancers. Experimental design: We treated several anaplastic and papillary thyroid cancer cell lines with SAHA to determine if it could inhibit the growth of these cells in vitro and in vivo. Results: SAHA effectively inhibited 50% clonal growth of the anaplastic thyroid cancer cell lines, ARO and FRO, and the papillary thyroid cancer cell line, BHP 7-13, at 1.3 X 10(-7) to 5 X 10(-7) mol/L, doses that are achievable in patients. In concert with growth inhibition, SAHA down-regulated the expression of cyclin D1 and up-regulated levels of p21(WAF1). Annexin V and cleavage of poly(ADP)ribose polymerase were both increased by exposure of the thyroid cancer cells to SAHA. Expression of the death receptor 5 (DR5) gene was also increased by SAHA, but the combination of the DR5 ligand, tumor necrosis factor-related a poptosis-inducing ligand (TRAIL), with SAHA had little effect compared with SAHA alone. Of note, the combination of paclitaxel, doxorubicin, or paraplatin with SAHA enhanced cell killing of the thyroid cancer cells. In addition, murine studies showed that SAHA administered daily by i.p. injection at 100 mg/kg inhibited the growth of human thyroid tumor cells. Conclusion: Our data indicate that SAHA is a plausible adjuvant therapy for thyroid cancers. C1 Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Med,Div Hematol Oncol, Los Angeles, CA 90048 USA. Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Ctr, Los Angeles, CA 90048 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Endocrinol & Diabet, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Luong, QT (reprint author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Med,Div Hematol Oncol, 8700 Beverly Blvd,Davis Bldg,Room 5022, Los Angeles, CA 90048 USA. EM trong.luong@gmail.com RI Luong, Quang/C-3253-2015 NR 24 TC 67 Z9 75 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD SEP 15 PY 2006 VL 12 IS 18 BP 5570 EP 5577 DI 10.1158/1078-0432.CCR-06-0367 PG 8 WC Oncology SC Oncology GA 087AK UT WOS:000240714400044 PM 17000694 ER PT J AU Guzman-Marin, R Ying, Z Suntsova, N Methippara, M Bashir, T Szymusiak, R Gomez-Pinilla, F McGinty, D AF Guzman-Marin, Ruben Ying, Zhe Suntsova, Natalia Methippara, Melvi Bashir, Tariq Szymusiak, Ronald Gomez-Pinilla, Fernando McGinty, Dennis TI Suppression of hippocampal plasticity-related gene expression by sleep deprivation in rats SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID LONG-TERM POTENTIATION; ELEMENT-BINDING-PROTEIN; LIGHT-DARK CYCLE; NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; PARADOXICAL SLEEP; MESSENGER-RNAS; DENTATE GYRUS; GROWTH-FACTOR; BRAIN AB Previous work shows that sleep deprivation impairs hippocampal-dependent learning and long-term potentiation (LTP). Brain-derived neurotrophic factor (BDNF), cAMP response-element-binding (CREB) and calcium-calmodulin-dependent protein kinase II (CAMKII) are critical modulators of hippocampal-dependent learning and LTP. In the present study we compared the effects of short- (8 h) and intermediate-term (48 h) sleep deprivation (SD) on the expression of BDNF and its downstream targets, Synapsin I, CREB and CAMKII in the neocortex and the hippocampus. Rats were sleep deprived using an intermittent treadmill system which equated total movement in the SD and control treadmill animals (CT), but permitted sustained periods of rest in CT animals. Animals were divided into SD (treadmill schedule: 3 s on/12 s off) and two treadmill control groups, CT1 (15 min on/60 min off) and CT2 (30 min on/120 min off-permitting more sustained sleep). Real-time Taqman RT-PCR was used to measure changes in mRNA; BDNF protein levels were determined using ELISA. In the hippocampus, 8 h treatments reduced BDNF, Synapsin I, CREB and CAMKII gene expression in both SD and control groups. Following 48 h of experimental procedures, the expression of all these four molecular markers of plasticity was reduced in SD and CT1 groups compared to the CT2 and cage control groups. In the hippocampus, BDNF protein levels after 8 h and 48 h treatments paralleled the changes in mRNA. In neocortex, neither 8 h nor 48 h SD or control treatments had significant effects on BDNF, Synapsin I and CAMKII mRNA levels. Stepwise regression analysis suggested that loss of REM sleep underlies the effects of SD on hippocampal BDNF, Synapsin I and CREB mRNA levels, whereas loss of NREM sleep underlies the effects on CAMKII mRNA. C1 VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, North Hills, CA 91343 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA 90024 USA. Rostov State Univ, AB Kogan Res Inst Neurocybernet, Rostov Na Donu 344006, Russia. RP McGinty, D (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91343 USA. EM dmcginty@ucla.edu FU NHLBI NIH HHS [HL 60296, P50 HL060296]; NIMH NIH HHS [MH 47480, R01 MH047480] NR 58 TC 93 Z9 95 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD SEP 15 PY 2006 VL 575 IS 3 BP 807 EP 819 DI 10.1113/jphysiol.2006.115287 PG 13 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 081XH UT WOS:000240350400013 PM 16825295 ER PT J AU Brennan, FX Tieder, JB AF Brennan, Francis X. Tieder, J. Bernard, III TI Centrally administered tumor necrosis factor-alpha facilitates the avoidance performance of Sprague-Dawley rats SO BRAIN RESEARCH LA English DT Article DE escape/avoidance conditioning; tumor necrosis factor-alpha; anxiety; stress; coping ID BEHAVIORAL VARIATIONS; CENTRAL MONOAMINE; INTERLEUKIN-1-BETA; MEMORY; SENSITIZATION; BRAIN; CORTICOSTERONE; CYTOKINES AB In addition to their immunological functions, recent research has indicated that the proinflammatory cytokines can influence learning and memory processes. We have previously shown that a peripheral injection of TNF alpha facilitates the acquisition of a leverpress avoidance task 24 h post-injection. Because the improved acquisition is presumably mediated by central changes, the current experiment involved directly injecting TNF alpha into the third ventricle 24 h prior to training. The data indicate that low (20 ng) but not high (40 ng) doses of TNFa produced improved avoidance performance. Results are discussed in terms of possible monoaminergic sensitization induced by TNF alpha and the relationship of this to acquisition of the avoidance response. (c) 2006 Elsevier B.V. All rights reserved. C1 Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. RP Brennan, FX (reprint author), Philadelphia VA Med Ctr, Med Res 151,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Brennan_f@mail.trc.upenn.edu NR 17 TC 3 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD SEP 13 PY 2006 VL 1109 BP 142 EP 145 DI 10.1016/j.brainres.2006.06.040 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 086ZP UT WOS:000240712100016 PM 16836982 ER PT J AU Gvilia, I Xu, F McGinty, D Szymusiak, R AF Gvilia, Irma Xu, Feng McGinty, Dennis Szymusiak, Ronald TI Homeostatic regulation of sleep: A role for preoptic area neurons SO JOURNAL OF NEUROSCIENCE LA English DT Article DE sleep deprivation; non-REM sleep; ventrolateral preoptic area; median preoptic nucleus; GABA; sleep diurnality ID WAKING DISCHARGE PATTERNS; FOS PROTEIN EXPRESSION; EYE-MOVEMENT SLEEP; C-FOS; OREXIN NEURONS; GALANINERGIC NEURONS; GABAERGIC NEURONS; NUCLEUS NEURONS; BASAL FOREBRAIN; HYPOTHALAMUS AB The median preoptic nucleus (MnPN) and the ventrolateral preoptic area (vlPOA) contain putative sleep-regulatory neurons that exhibit elevated discharge rates during sleep compared with waking. Expression of c-Fos protein immunoreactivity (IR) in GABAergic neurons in the MnPN and the vlPOA is high in spontaneously sleeping rats and in rats undergoing recovery sleep after sleep deprivation. However, it is unclear whether c-Fos-IR in these neurons is evoked by increases in sleep pressure or by increases in sleep amount. We examined c-Fos-IR in MnPN and vlPOA neurons under experimental conditions that dissociated homeostatic sleep pressure, sleep amount, and time of day. Groups of rats with strong diurnal rhythms in sleep-wake organization were killed after (1) spontaneous sleep in the light, (2) spontaneous sleep in the dark, (3) sleep deprivation (SLD) in the light and (4) recovery sleep after SLD in the light. Numbers of GABAergic neurons expressing c-Fos-IR in the MnPN were significantly higher after SLD in the light compared with spontaneous sleep and recovery sleep in the light. In contrast, Fos-IR in vlPOA GABAergic neurons was most prevalent after spontaneous sleep and recovery sleep in the light. No light-dark differences in Fos-IR were observed in the MnPN after SLD in groups of rats with weak or absent diurnal sleep-waking rhythms. Our findings define potential roles for MnPN and vlPOA GABAergic neurons in homeostatic aspects of sleep regulation. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA 91343 USA. I Beritashvili Inst Physiol, Tbilisi, Rep of Georgia. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. RP Gvilia, I (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, 151A3,16111 Plummer St, North Hills, CA 91343 USA. EM irmagvilia@hotmail.com; rszym@ucla.edu FU NHLBI NIH HHS [HL60296]; NIMH NIH HHS [MH63323] NR 28 TC 62 Z9 64 U1 3 U2 11 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD SEP 13 PY 2006 VL 26 IS 37 BP 9426 EP 9433 DI 10.1523/JNEUROSCI.2012-06.2006 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 083YM UT WOS:000240495500010 PM 16971526 ER PT J AU Suzuki, T Delgado-Escueta, AV Alonso, ME Morita, R Okamura, N Sugimoto, Y Bai, DS Medina, MT Bailey, JN Rasmussen, A Ramos-Peek, J Cordova, S Rubio-Donnadieu, F Ochoa, A Jara-Prado, A Inazawa, J Yamakawa, K AF Suzuki, Toshimitsu Delgado-Escueta, Antonio V. Alonso, Maria E. Morita, Ryoji Okamura, Nami Sugimoto, Yoshihisa Bai, Dongsheng Medina, Marco T. Bailey, Julia N. Rasmussen, Astrid Ramos-Peek, Jaime Cordova, Sergio Rubio-Donnadieu, Francisco Ochoa, Adriana Jara-Prado, Aurelio Inazawa, Johji Yamakawa, Kazuhiro TI Mutation analyses of genes on 6p12-p11 in patients with juvenile myoclonic epilepsy SO NEUROSCIENCE LETTERS LA English DT Article DE juvenile myoclonic epilepsy; Myoclonin1/EFHCI1; EJM1; 6p11-p12 ID IDIOPATHIC GENERALIZED EPILEPSY; CHILDHOOD ABSENCE EPILEPSY; CHROMOSOME 6P12; GENOME BROWSER; LINKAGE; LOCUS; CANDIDATE; IDENTIFICATION; HETEROGENEITY; GENETICS AB Juvenile myoclonic epilepsy (JME) is a distinct form of idiopathic generalized epilepsy (IGE). One of the candidate regions for human JME has been mapped on chromosome band 6p11-p12 by linkage analyses and is termed EJM1 (MIM 254770). Recently, we reported the reduction of the EJM1 region to 3.5cM that contains 18 genes, the exclusion of three genes (LRRC1, GCLC, KIAA0057) by mutation analyses, and the identification of Myoclonin1/EFHC1 as the EJM1 gene. Here, we describe detailed physical and transcriptome maps of the 3.5cM EJM1 region, and detailed results of mutation analyses for the remained 14 genes (HELO1, GCMA, KIAA0936, FBX09, GSTA3, GSTA4, PTD011, KIAA0576, LMPB1, ILI7F, MCM3, PKHD1, KIAA0105, TFAP2B) in patients with JME. We identified 49 single nucleotide changes in eight genes. Twelve amino acid substitutions occurred in two genes, I I silent mutations in seven genes, and 26 in the non-coding or intronic regions of seven genes. Twelve amino acid substitutions in the two genes (ILI7F, PKHD1) were also observed in healthy control individuals or did not co-segregate with the disease phenotypes in other family members. Thus, the absence of significant and potentially functional mutations in the remaining 14 genes further supports the concept that Myoclonin1/EFHC1 is the EJM1 gene in chromosome 6p12. (c) 2006 Elsevier Ireland Ltd. All rights reserved. C1 RIKEN, Brain Sci Inst, Neurogenet Lab, Wako, Saitama 3510198, Japan. Univ Calif Los Angeles, Geffen Sch Med, Comprehens Epilepsy Program, Epilepsy Genet Genom Labs, Los Angeles, CA 90073 USA. VA GLAHS W Los Angeles, Los Angeles, CA 90073 USA. Natl Inst Neurol & Neurosurg, Mexico City, DF, Mexico. Natl Autonomous Univ, Tegucigalpa, Honduras. Univ Calif Los Angeles, Semel Inst Neurosci, Los Angeles, CA USA. Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Cytogenet, Tokyo, Japan. RP Delgado-Escueta, AV (reprint author), W Los Angeles DVA Med Ctr, Room 3405 127B,Bldg 500,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM escueta@ucla.edu; yamakawa@brain.riken.jp RI Yamakawa, Kazuhiro/N-5050-2015 FU NINDS NIH HHS [NS42376] NR 33 TC 8 Z9 8 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD SEP 11 PY 2006 VL 405 IS 1-2 BP 126 EP 131 DI 10.1016/j.neulet.2006.06.038 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 079IO UT WOS:000240169500025 PM 16876319 ER PT J AU Patel, DN Bailey, SR Gresham, JK Schuchman, DB Shelhamer, JH Goldstein, BJ Foxwell, BM Stemerman, MB Maranchie, JK Valente, AJ Mummidi, S Chandrasekar, B AF Patel, Devang N. Bailey, Steven R. Gresham, John K. Schuchman, David B. Shelhamer, James H. Goldstein, Barry J. Foxwell, Brian M. Stemerman, Michael B. Maranchie, Jodi K. Valente, Anthony J. Mummidi, Srinivas Chandrasekar, Bysam TI TLR4-NOX4-AP-1 signaling mediates lipopolysaccharide-induced CXCR6 expression in human aortic smooth muscle cells SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE atherosclerosis; coronary disease; endotoxins; signal transduction; MAP kinase ID N-TERMINAL KINASE; SCAVENGER RECEPTOR; KAPPA-B; OXIDIZED LIPOPROTEIN; ENDOTHELIAL-CELLS; CHEMOKINE CXCL16; INTERFERON-GAMMA; CUTTING EDGE; ACTIVATION; LIGAND AB CXCL16 is a transmembrane non-ELR CXC chemokine that signals via CXCR6 to induce aortic smooth muscle cell (ASMC) proliferation. While bacterial lipopolysaccharide (LPS) has been shown to stimulate CXCL16 expression in SMC, its effects on CXCR6 are not known. Here, we demonstrate that LPS upregulates CXCR6 mRNA, protein, and surface expression in human ASMC. Inhibition of TLR4 with neutralizing antibodies or specific siRNA interference blocked LPS-mediated CXCR6 expression. LPS stimulated both AP-1 (c-Fos, c-Jun) and NF-kappa B (p50 and p65) activation, but only inhibition of AP-1 attenuated LPS-induced CXCR6 expression. Using dominant negative expression vectors and siRNA interference, we demonstrate that LPS induces AP-1 activation via MyD88, TRAF6, ERK1/2, and JNK signaling pathways. Furthermore, the flavoprotein inhibitor diphenyleniodonium chloride significantly attenuated LPS-mediated AP-1-dependent CXCR6 expression, as did inhibition of NOX4 NADPH oxidase by siRNA. Finally, CXCR6 knockdown inhibited CXCL16-induced ASMC proliferation. These results demonstrate that LPS-TLR4-NOX4-AP-1 signaling can induce CXCR6 expression in ASMC, and suggest that the CXCL16-CXCR6 axis may be an important proinflammatory pathway in the pathogenesis of atherosclerosis. (c) 2006 Elsevier Inc. All rights reserved. C1 S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA. Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA. Univ London Imperial Coll Sci Technol & Med, London, England. Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA. Univ Massachusetts, Dept Surg, Worcester, MA 01605 USA. Univ Massachusetts, Dept Cell Biol, Worcester, MA 01605 USA. RP Chandrasekar, B (reprint author), S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. EM chandraseka@uthscsa.edu RI Mummidi, Srinivas/C-1004-2008 OI Mummidi, Srinivas/0000-0002-4068-6380; Maranchie, Jodi/0000-0002-8534-9468 FU NHLBI NIH HHS [HL68020] NR 35 TC 38 Z9 41 U1 1 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD SEP 8 PY 2006 VL 347 IS 4 BP 1113 EP 1120 DI 10.1016/j.bbre.2006.07.015 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 072NW UT WOS:000239681100038 PM 16870145 ER PT J AU Burgess, SJ Selzer, A Kelly, JX Smilkstein, MJ Riscoe, MK Peyton, DH AF Burgess, Steven J. Selzer, Audrey Kelly, Jane Xu Smilkstein, Martin J. Riscoe, Michael K. Peyton, David H. TI A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID ANTIMALARIAL-DRUGS; RODENT MALARIA; IN-VITRO; TRANSPORTER; CHABAUDI; BINDING; COMBINATIONS; IMIPRAMINE; MECHANISM; PARASITES AB A class of hybrid molecules which we term 'reversed chloroquines' (RCQs) was designed, and a prototype molecule, N'-(7-chloroquinolin-4-yl)-N-[3-(10,11-dihydrodibenzo[b, f] azepin-5-yl)propyl]-N-methylpropane1,3- diamine ( 1), was synthesized and tested against both chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum. An in vitro assay against the two strains indicated that 1 was effective at low-nM concentrations against both strains. A preliminary study in mice demonstrated oral efficacy against P. chabaudi and the absence of obvious toxicity. The RCQ approach therefore appears to be feasible. C1 Portland State Univ, Dept Chem, Portland, OR 97207 USA. Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. RP Peyton, DH (reprint author), Portland State Univ, Dept Chem, POB 751, Portland, OR 97207 USA. EM peytond@pdx.edu FU NIAID NIH HHS [R21 AI067837-01A2, R21 AI067837] NR 28 TC 83 Z9 88 U1 0 U2 10 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD SEP 7 PY 2006 VL 49 IS 18 BP 5623 EP 5625 DI 10.1021/jm060399n PG 3 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 079AX UT WOS:000240149000026 PM 16942036 ER PT J AU McGinnis, JM Birt, DF Brannon, PM Carroll, RJ Gibbons, RD Hazzard, WR Kamerow, DB Levin, B Ntambi, JM Paneth, N Rogers, D Saftlas, AF Vaughan, W AF McGinnis, J. Michael Birt, Diane F. Brannon, Patsy M. Carroll, Raymond J. Gibbons, Robert D. Hazzard, William R. Kamerow, Douglas B. Levin, Bernard Ntambi, James M. Paneth, Nigel Rogers, Douglas Saftlas, Audrey F. Vaughan, William CA NIH State of Science TI National Institutes of Health state-of-the-science conference statement: Multivitamin/mineral supplements and chronic disease prevention SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; NUTRITION INTERVENTION TRIALS; AGE-RELATED CATARACT; BETA-CAROTENE; VITAMIN-E; CARDIOVASCULAR-DISEASE; ALPHA-TOCOPHEROL; LUNG-CANCER; COLORECTAL-CANCER; PROSTATE-CANCER C1 Natl Acad, Inst Med, Washington, DC USA. Iowa State Univ, Dept Food Sci & Human Nutr, Ctr Res Bot Dietary Supplements, Ames, IA USA. Iowa State Univ, Coll Agr, Ames, IA USA. Iowa State Univ, Coll Human Sci, Ames, IA USA. Cornell Univ, Div Nutrit Sci, Ithaca, NY USA. Texas A&M Univ, Dept Stat, College Stn, TX 77843 USA. Univ Illinois, Ctr Hlth Stat, Chicago, IL USA. Univ Washington, Dept Med, Div Gerontol & Geriatr Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. Georgetown Univ, Washington, DC USA. RTI Int, Washington, DC USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA. Univ Wisconsin, Dept Nutrit Sci, Madison, WI 53705 USA. Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA. Cleveland Clin, Sect Pediat & Adolescent Endocrinol, Cleveland, OH 44106 USA. Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. Consumers Union, Washington, DC USA. NIH, Bethesda, MD 20892 USA. RP McGinnis, JM (reprint author), Natl Acad, Inst Med, Washington, DC USA. NR 27 TC 56 Z9 58 U1 0 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 5 PY 2006 VL 145 IS 5 BP 364 EP 371 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 080NZ UT WOS:000240255900007 ER PT J AU MacIntyre, JC Essock, S Clay, S Zuber, MP Felton, CJ AF MacIntyre, James C., II Essock, Susan Clay, Sally Zuber, Michael P. Felton, Chip J. TI The Kids Oneida project: What happened to services when the payment rules changed SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH LA English DT Article DE children's mental health services; systems of care; wrap-around; finance; payment rules; managed care; program implementation ID OUTCOMES; ADOLESCENTS; CHILDREN; CARE; SYSTEM AB Community-based systems of care may provide high quality, cost-effective alternatives to institutional care for children and adolescents. This report examines Kids Oneida (KO), a not-for-profit managed care entity established in upstate New York in 1998 to serve such children and their families. Changes in payment rules that established the program allowed KO to contract with a wide array of providers to provide and be reimbursed for non-traditional and formerly unreimbursable services, such as mentoring and supervision. By design, emphasis was on highly individualized plans of care in which traditional office-based services played only a small part. During the first 30 months of KO's operation, 228 children, whose severity of emotional disturbances was comparable to those of children placed in residential treatment centers, had average monthly expenditures for first admissions of $2,734 for services and $228 for administrative fees. Median length of stay in the program was 13.5 months, yielding an estimate of $39,987 for typical length of stay. Length of stay and treatment costs were not related to children's gender or race. Length of stay was significantly longer for children with diagnoses indicating attention deficit hyperactivity disorder and behavior disorders. Treatment costs were significantly higher for children with behavior disorders and/or substance use and children who had had prior contact with the juvenile justice system. C1 Carolinas Mental Ctr, Behav Hlth Ctr, Charlotte, NC 28211 USA. NYU, Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY USA. Bronx Vet Adm Med Ctr, MIRECC, Bronx, NY USA. NYU, Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. RP MacIntyre, JC (reprint author), Carolinas Mental Ctr, Behav Hlth Ctr, 501 Billingsley Rd, Charlotte, NC 28211 USA. EM james.macintyre@carolinas.org NR 26 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0894-587X J9 ADM POLICY MENT HLTH JI Adm. Policy. Ment. Health PD SEP PY 2006 VL 33 IS 5 BP 585 EP 597 DI 10.1007/s10488-006-0065-z PG 13 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 094HT UT WOS:000241231200009 PM 16807793 ER PT J AU Crabbe, JC Rhodes, JS AF Crabbe, John C. Rhodes, Justin S. TI Drinking in the dark: A mouse model for high ethanol intake SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT World Congress on Alcohol Research CY SEP 10-13, 2006 CL Sydney, AUSTRALIA SP Int Soc Biomed Res Alcoholism C1 Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD SEP PY 2006 VL 30 IS 9 SU S BP 95A EP 95A PG 1 WC Substance Abuse SC Substance Abuse GA 075XE UT WOS:000239919900205 ER PT J AU Cavusoglu, E Chopra, V Gupta, A Clark, LT Eng, C Marmur, JD AF Cavusoglu, Erdal Chopra, Vineet Gupta, Amit Clark, Luther T. Eng, Calvin Marmur, Jonathan D. TI Usefulness of anemia in men as an independent predictor of two-year cardiovascular outcome in patients presenting with acute coronary syndrome SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; DISEASE; ASSOCIATION; MORTALITY; HEART; RISK AB Anemia has been shown to be an independent risk factor for the development of adverse cardiovascular outcomes in a variety of patient populations. In the case of patients presenting with acute coronary syndrome (ACS), anemia has been demonstrated to be a powerful and independent predictor of 30-day outcomes. However, there are limited and conflicting data about the long-term independent predictive value of anemia in patients with ACS. This is in contrast to non-ACS populations in which anemia has been shown to be an independent predictor of long-term outcomes. The present study investigated the long-term prognostic significance of anemia in a well-characterized cohort of 193 men with ACS who were referred for coronary angiography at a Veterans Affairs Medical Center. All patients were followed prospectively for the development of death or acute myocardial infarction (AMI), and follow-up data were available for all patients at 24 months. After controlling for a variety of baseline clinical, laboratory, and angiographic variables, hemoglobin (analyzed as a continuous variable and as a categorical variable using the World Health Organization cutoff of 13 g/dl for men) was a strong and independent predictor of the composite end point of death or AMI at 24 months when using a Cox proportional hazards model. At 24 months, the event-free survival was 64% in the group with a hemoglobin level < 13 g/dl compared with 81% in the group with a hemoglobin level 13 g/dl (p = 0.0065 by log-rank test). In conclusion, these data demonstrate that baseline anemia is a strong and independent predictor of death or AMI at 2 years in patients with ACS. (c) 2006 Elsevier Inc. C1 Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA. Bronx Vet Affairs Med Ctr, Dept Med, New York, NY USA. RP Marmur, JD (reprint author), Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA. EM jonathan@marmur.com NR 9 TC 39 Z9 46 U1 0 U2 1 PU EXCERPTA MEDICA INC PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD SEP 1 PY 2006 VL 98 IS 5 BP 580 EP 584 DI 10.1016/j.amjcard.2006.03.031 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 081NM UT WOS:000240324300003 PM 16923440 ER PT J AU Lam, MM Clarridge, JE AF Lam, Maggie M. Clarridge, Jill E., III TI The other group G Streptococcus: Increased detection of Streptococcus canis ulcer infections in dog owners. SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Academy-of-Clinical-Laboratory-Physicians-and-Scientists CY JUN 01-03, 2006 CL Chicago, IL SP Acad Clin Lab Phys & Sci C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD SEP PY 2006 VL 126 IS 3 MA 19 BP 459 EP 460 PG 2 WC Pathology SC Pathology GA 075UK UT WOS:000239910500034 ER PT J AU Jensen, DM Pace, SC Soffer, E Comer, GM AF Jensen, Dennis M. Pace, Samuel C. Soffer, Elaine Comer, Gail M. CA 315 Study Grp TI Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: A US Multicenter randomized, double-blind study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID BLEEDING PEPTIC-ULCER; PROTON-PUMP INHIBITORS; UPPER GASTROINTESTINAL HEMORRHAGE; HEATER PROBE THERMOCOAGULATION; PLACEBO-CONTROLLED MULTICENTER; NONBLEEDING VISIBLE VESSELS; ENDOSCOPIC THERAPY; ACID SUPPRESSION; INTRAVENOUS OMEPRAZOLE; COMPARATIVE TRIAL AB OBJECTIVES: No North American randomized study has compared ulcer rebleeding rates after endoscopic hemostasis in high-risk patients treated with high-dose intravenous (IV) proton pump inhibitors (PPIs) or IV histamine-2 receptor antagonists. Our hypothesis was that ulcer rebleeding with IV pantoprazole (PAN) would be lower than with IV ranitidine (RAN). METHODS: This was a multicenter, randomized, double-blind, U.S. study. Patients with bleeding peptic ulcers and major stigmata of hemorrhage had endoscopic hemostasis with thermal probes with or without epinephrine injection, then were randomly assigned to IV PAN 80 mg plus 8 mg/h or IV RAN 50 mg plus 6.25 mg/h for 72 h, and subsequently had an oral PPI (1/day). Patients with signs of rebleeding had repeat endoscopy. Rebleeding rates up to 30 days were compared in an intention-to-treat analysis. RESULTS: The study was stopped early because of slow enrollment (total N = 149, PAN 72, RAN 77). Demographics, APACHE II scores, ulcer type/location, stigmata, and hemostasis used were similar. The 7- and 30-day rebleeding rate was 6.9% (5 of 72 patients) with PAN and 14.3% (11 of 77) for RAN (p = 0.19). Rebleeds occurred within 72 h in 56% and between 4 and 7 days in 44% of patients. The 30-day mortality rate was 4%. Nonbleeding severe adverse events were more common in the RAN than in the PAN group (14 [18.1%] vs 7 [9.7%], p = 0.16). CONCLUSIONS: Because of the small sample size of this study, there was an arithmetic but not significant difference in ulcer rebleeding rates. C1 CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Wyeth Pharmaceut, Collegeville, PA USA. RP Jensen, DM (reprint author), CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst, Bldg 115,Room 318, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [P30 DK41301, K24 DK02650] NR 47 TC 43 Z9 44 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2006 VL 101 IS 9 BP 1991 EP 1999 DI 10.1111/j.1572-0241.2006.00773.x PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 080ZM UT WOS:000240287000009 PM 16968504 ER PT J AU Kanwal, F Farid, M Martin, P Chen, G Gralnek, IM Dulai, GS Spiegel, BMR AF Kanwal, Fasiha Farid, Mary Martin, Paul Chen, Gary Gralnek, Ian M. Dulai, Gareth S. Spiegel, Brennan M. R. TI Treatment alternatives for hepatitis B cirrhosis: A cost-effectiveness analysis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID LONG-TERM LAMIVUDINE; LAMIVUDINE/INTERFERON COMBINATION THERAPY; SEVERELY DECOMPENSATED CIRRHOSIS; LIVER-TRANSPLANT RECIPIENT; IMMUNE GLOBULIN; ADEFOVIR DIPIVOXIL; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; NUCLEOSIDE-NAIVE; SURFACE-ANTIGEN AB BACKGROUND: Hepatitis B virus (HBV) patients with cirrhosis are at risk for developing costly, morbid, or mortal events, and therefore need highly effective therapies. Lamivudine is effective but is limited by viral resistance. In contrast, adefovir and entecavir have lower viral resistance, but are more expensive. The most cost-effective approach is uncertain. METHODS: We evaluated the cost-effectiveness of six strategies in HBV cirrhosis: (1) No HBV treatment ("do nothing"), (2) lamivudine monotherapy, (3) adefovir monotherapy, (4) lamivudine with crossover to adefovir on resistance ("adefovir salvage"), (5) entecavir monotherapy, or (6) lamivudine with crossover to entecavir on resistance ("entecavir salvage"). The primary outcome was the incremental cost per quality-adjusted life-year (QALY) gained. RESULTS: The "do nothing" strategy was least effective yet least expensive. Compared with "do nothing," using adefovir cost an incremental $19,731. Entecavir was more effective yet more expensive than adefovir, and cost an incremental $25,626 per QALY gained versus adefovir. Selecting between entecavir versus adefovir was highly dependent on the third-party payer's "willingess-to-pay" (e.g., 45% and 60% of patients fall within budget if willing-to-pay $10K and $50K per QALY gained for entecavir, respectively). Both lamivudine monotherapy and the "salvage" strategies were not cost-effective. However, between the two salvage strategies, "adefovir salvage" was more effective and less expensive than "entecavir salvage." CONCLUSION: Both entecavir and adefovir are cost-effective in patients with HBV cirrhosis. Choosing between adefovir and entecavir is highly dependent on available budgets. In patients with HBV cirrhosis with previous lamivudine resistance, "adefovir salvage" appears more effective and less expensive than "entecavir salvage." C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, David Geffen Sch Med, VA Ctr Outcomes Res & Educ,Div Gastroenterol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Div Digest Dis, David Geffen Sch Med, Los Angeles, CA 90073 USA. CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Mt Sinai Sch Med, New York, NY USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, David Geffen Sch Med, VA Ctr Outcomes Res & Educ,Div Gastroenterol, 11301 Wilshire Blvd,Bldg 115,Room 215E, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [2P30 DK 041301-17] NR 109 TC 55 Z9 58 U1 0 U2 7 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2006 VL 101 IS 9 BP 2076 EP 2089 DI 10.1111/j.1572-0241.2006.00769.x PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 080ZM UT WOS:000240287000022 PM 16968510 ER PT J AU Pimentel, M Chatterjee, S Chang, C Low, K Song, YL Liu, CX Lezcano, S Conklin, J Finegold, S AF Pimentel, Mark Chatterjee, Sownya Chang, Christopher Low, Kimberly Song, Yuli Liu, Chengxu Lezcano, Sheila Conklin, Jeffery Finegold, Sydney CA GI Motility Program TI Gastrointestinal infection with Campylobacter jejuni 81-176 produces altered bowel function and bacterial overgrowth in rats SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 71st Annual Scientific Meeting of the American-College-of-Gasroenterology CY OCT 20-25, 2006 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 Cedars Sinai Med Ctr, GI Motil Program, Los Angeles, CA 90048 USA. Univ Calif Los Angeles, Geffen Sch Med, Div Gastroenterol, Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90073 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2006 VL 101 IS 9 SU S MA 1216 BP S472 EP S472 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 086EH UT WOS:000240656102217 ER PT J AU Singal, AK Rosman, AS Post, JB Bauman, WA Korsten, MA AF Singal, Ashwani K. Rosman, Alan S. Post, James B. Bauman, William A. Korsten, Mark A. TI Effect of colonoscopy preparation on renal function: A retrospective comparison of oral sodium phosphate versus polyethylene glycol SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 71st Annual Scientific Meeting of the American-College-of-Gasroenterology CY OCT 20-25, 2006 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 James J Peters VA Med Ctr, Spinal Cord Ctr Excellence, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2006 VL 101 IS 9 SU S MA 512 BP S216 EP S217 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 086EH UT WOS:000240656101006 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Geographic and temporal variations in the mortality from Crohn's disease and ulcerative colitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 71st Annual Scientific Meeting of the American-College-of-Gasroenterology CY OCT 20-25, 2006 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 P3 GI, Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2006 VL 101 IS 9 SU S MA 1072 BP S421 EP S421 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 086EH UT WOS:000240656102073 ER PT J AU Webb, A Poy, I Patel, R Ali, O Page, R Kashi, M Herrera, A Schoolfield, J Brock, P Hoyumpa, A AF Webb, Amy Poy, Isela Patel, Rikin Ali, Olga Page, Robert Kashi, Maryam Herrera, Ana Schoolfield, John Brock, Paul Hoyumpa, Anastacio TI Comparison of ribavirin with PEG-interferon alpha-2a or with alpha-2b in treatment-naive patients SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 71st Annual Scientific Meeting of the American-College-of-Gasroenterology CY OCT 20-25, 2006 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 UT Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Healthcare Syst, Hepatol Clin, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2006 VL 101 IS 9 SU S MA 412 BP S181 EP S182 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 086EH UT WOS:000240656100413 ER PT J AU Strom, JA Carabello, BA AF Strom, Joel A. Carabello, Blase A. TI Evaluation and treatment of valvular heart disease in the elderly SO AMERICAN JOURNAL OF GERIATRIC CARDIOLOGY LA English DT Editorial Material C1 Univ S Florida, Dept Internal Med, Tampa, FL 33612 USA. Univ S Florida, Dept Chem Biomed Engn, Tampa, FL USA. Baylor Coll Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Strom, JA (reprint author), Univ S Florida, Dept Chem Engn, 4202 E Fowler Ave,ENB-118, Tampa, FL 33620 USA. EM jstrom@health.usf.edu NR 11 TC 0 Z9 0 U1 0 U2 3 PU LE JACQ LTD PI DARIEN PA 3 PARKLANDS DRIVE, DARIEN, CT 06820 USA SN 1076-7460 J9 AM J GERIATR CARDIOL JI Am. J. Geriatr. Cardiol. PD SEP-OCT PY 2006 VL 15 IS 5 BP 275 EP 276 DI 10.1111/j.1076-7460.2006.04882.x PG 2 WC Cardiac & Cardiovascular Systems; Geriatrics & Gerontology SC Cardiovascular System & Cardiology; Geriatrics & Gerontology GA 079ZN UT WOS:000240216500002 ER PT J AU Strom, JA VanAuker, MD Carabello, BA AF Strom, Joel A. VanAuker, Michael D. Carabello, Blase A. TI Effects of aging on the diagnostic assessment of valvular heart disease SO AMERICAN JOURNAL OF GERIATRIC CARDIOLOGY LA English DT Review ID GRADIENT AORTIC-STENOSIS; REGURGITANT ORIFICE AREA; MITRAL REGURGITATION; PRESSURE RECOVERY; VALVE STENOSIS; SYSTEMIC HYPERTENSION; ECHOCARDIOGRAPHY; DOBUTAMINE; QUANTIFICATION; RESISTANCE AB The diagnostic assessment of the severity of valvular heart disease in the older population is impacted by the anatomic and physiologic changes that accompany normal aging and by the interposition of diseases prevalent in the elderly. In this paper, the impact of those changes on the assessment of valvular heart disease will be reviewed. Special attention will be paid to the effects of age and disease on the measurement of the pressure drop and orifice area. C1 Univ S Florida, Dept Internal Med, Tampa, FL 33612 USA. Univ S Florida, Dept Chem Biomed Engn, Tampa, FL USA. Baylor Coll Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Strom, JA (reprint author), Univ S Florida, Dept Chem Engn, 4202 E Fowler Ave,ENG-118, Tampa, FL 33620 USA. EM jstrom@health.usf.edu NR 39 TC 1 Z9 1 U1 0 U2 0 PU LE JACQ LTD PI DARIEN PA 3 PARKLANDS DRIVE, DARIEN, CT 06820 USA SN 1076-7460 J9 AM J GERIATR CARDIOL JI Am. J. Geriatr. Cardiol. PD SEP-OCT PY 2006 VL 15 IS 5 BP 286 EP 290 DI 10.1111/j.1076-7460.2006.04624.x PG 5 WC Cardiac & Cardiovascular Systems; Geriatrics & Gerontology SC Cardiovascular System & Cardiology; Geriatrics & Gerontology GA 079ZN UT WOS:000240216500004 PM 16957447 ER PT J AU Saint, S Kaufman, SR Rogers, MAM Baker, PD Boyko, EJ Lipsky, BA AF Saint, Sanjay Kaufman, Samuel R. Rogers, Mary A. M. Baker, Paul D. Boyko, Edward J. Lipsky, Benjamin A. TI Risk factors for nosocomial urinary tract-related bacteremia: A case-control study SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article ID BLOOD-STREAM INFECTION; 4-YEAR PROSPECTIVE EVALUATION; CATHETER-RELATED BACTERIURIA; CRITICALLY-ILL PATIENTS; PATIENT SAFETY; EPIDEMIOLOGY; MICROBIOLOGY; SMOKING; BLADDER; HOSPITALS AB Background: Risk factors for bacteremia in patients with hospital-acquired bacteriuria are largely unknown. Given the morbidity and costs associated with nosocomial bacteremia, determining risk factors could enhance the safety of hospitalized patients. Methods: We conducted a case-control study within the Veterans Affairs Puget Sound Health Care System. A patient hospitalized between 1984 and 1999 from whom a urine culture and a blood culture grew the same organism >= 48 hours after admission was considered a case. Control patients were those with significant bacteriuria detected 48 hours after admission who did not have a positive blood culture. We used logistic regression to determine independent risk factors for bacteremia. Results: There were 95 cases and 142 controls. Independent, statistically significant predictors of bacteremia included immunosuppressant therapy within 14 days of bacteriuria (odds ratio [OR], 8.13); history of malignancy (OR, 1.94); male sex (OR, 1.88); cigarette use in the past 5 years (OR, 1.26); number of hospital days before bacteriuria (OR, 1.03); and antibiotic use within 3 days of bacteriuria (OR, 0.76). corticosteroid use within 7 days of bacteriuria predicted bacteremia in patients < 70 years old (OR, 14.24). Similarly, patients < 70 years old were more likely to develop bacteremia if they had diabetes mellitus (OR, 6.19). Conclusion: Delineating risk factors for nosocomial urinary tract-related bacteremia can help target appropriate preventive practices at the highest risk patients. C1 Ann Arbor VA Hlth Serv Res & Dev Ctr Excellence, Ctr Practice Management & Outcomes Res, Ann Arbor, MI USA. Univ Michigan, Dept Internal Med, Div Gen Med, Ann Arbor, MI 48109 USA. UM Patient Safety Enhancement Program, Ann Arbor, MI USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Saint, S (reprint author), Room 7E08,300 NIB,Campus Box 0429, Ann Arbor, MI 48109 USA. EM saint@umich.edu RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114; Boyko, Edward/0000-0002-3695-192X FU AHRQ HHS [P20-HS11540] NR 39 TC 27 Z9 29 U1 0 U2 2 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD SEP PY 2006 VL 34 IS 7 BP 401 EP 407 DI 10.1016/j.ajic.2006.03.001 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 083HM UT WOS:000240447000001 PM 16945684 ER PT J AU Wiederkehr, MR Nicosia, RF Munschauer, C Moe, OW AF Wiederkehr, Michael R. Nicosia, Roberto F. Munschauer, Cary Moe, Orson W. TI An unusual case of urticaria and nephrotic syndrome SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE urticarial vasculitis; hypocomplementemia; nephrotic syndrome; membranous glomerulonephritis; mycophenolate mofetil; anti-C1q antibodies; angiodedema ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; VASCULITIS-SYNDROME; DISEASE; C1Q; AUTOANTIBODIES; ASSOCIATION; DEFICIENCY; NEPHRITIS; ARTHRITIS C1 Baylor Univ, Med Ctr, Dallas Nephrol Associates, Div Nephrol, Dallas, TX 75246 USA. Baylor Univ, Med Ctr, Div Vasc Surg, Dallas, TX 75246 USA. Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA. VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med, Seattle, WA USA. Univ Washington, Dept Pathol, Seattle, WA 98195 USA. RP Wiederkehr, MR (reprint author), Baylor Univ, Med Ctr, Dallas Nephrol Associates, Div Nephrol, 3500 Gaston Ave, Dallas, TX 75246 USA. EM wiederkehrm@dneph.com NR 21 TC 1 Z9 1 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD SEP PY 2006 VL 48 IS 3 BP 506 EP 512 DI 10.1053/j.ajkd.2006.03.087 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 084WY UT WOS:000240566300020 PM 16931227 ER PT J AU Lieberman, D AF Lieberman, David TI Screening for colorectal cancer in average-risk populations SO AMERICAN JOURNAL OF MEDICINE LA English DT Review DE colorectal cancer; colonoscopy; fecal occult blood test; sigmoidoscopy; computed tomographic; colonography ID FECAL-OCCULT-BLOOD; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTRAST BARIUM ENEMA; ASYMPTOMATIC ADULTS; FLEXIBLE SIGMOIDOSCOPY; VIRTUAL COLONOSCOPY; NATIONAL-SURVEY; TASK-FORCE; RECOMMENDATIONS; MORTALITY AB Screening average-risk populations for colorectal cancer can reduce the incidence and mortality of colorectal cancer. Effectiveness depends on programmatic adherence and quality. This review discusses the evidence supporting the use of currently available screening tests. The discussion specifically focuses on programmatic issues and highlights the importance of quality assurance in each program. (c) 2006 Elsevier Inc. All rights reserved. C1 Oregon Hlth Sci Univ, Portland VA Med Ctr, Div Gastroenterol, Portland, OR 97239 USA. RP Lieberman, D (reprint author), Oregon Hlth Sci Univ, Portland VA Med Ctr, Div Gastroenterol, P3-GI,POB 1034, Portland, OR 97239 USA. EM lieberma@ohsu.edu NR 47 TC 17 Z9 19 U1 0 U2 0 PU EXCERPTA MEDICA INC PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD SEP PY 2006 VL 119 IS 9 BP 728 EP 735 DI 10.1016/j.amjmed.2006.03.037 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 079TC UT WOS:000240199800004 PM 16945604 ER PT J AU Bosworth, HB Rockey, DC Paulson, EK Niedzwiecki, D Davis, W Sanders, LL Yee, J Henderson, J Hatten, P Burdick, S Sanyal, A Rubin, DT Sterling, M Akerkar, G Bhutani, MS Binmoeller, K Garvie, J Bini, EJ McQuaid, K Foster, WL Thompson, WM Dachman, A Halvorsen, R AF Bosworth, Hayden B. Rockey, Don C. Paulson, Erik K. Niedzwiecki, Donna Davis, Wendy Sanders, Linda L. Yee, Judy Henderson, Jim Hatten, Paul Burdick, Steve Sanyal, Arun Rubin, David T. Sterling, Mark Akerkar, Geetanjali Bhutani, Manoop S. Binmoeller, Kenneth Garvie, John Bini, Edmund J. McQuaid, Kenneth Foster, William L. Thompson, William M. Dachman, Abe Halvorsen, Robert TI Prospective comparison of patient experience with colon imaging tests SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE air contrast barium enema; virtual colonoscopy; computed tomography; computed tomographic; colonography; colonoscopy; cancer screening; patient preference; colon cancer; satisfaction ID CONTRAST BARIUM ENEMA; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CT COLONOGRAPHY; VIRTUAL COLONOSCOPY; COLORECTAL-CANCER; CONVENTIONAL COLONOSCOPY; PERFORMANCE; PREFERENCES; NEOPLASIA; POLYPS AB PURPOSE: Patient experience varies with the currently available colon imaging tests, including air contrast barium enema, computed tomographic colonography, and colonoscopy. We examined differences in patient experience with colon imaging tests and whether they varied with gender, age, and race. SUBJECTS AND METHODS: Patients with fecal occult blood, hematochezia, iron-deficiency anemia, or a family history of colon cancer underwent air contrast barium enema followed 7 to 14 days later by computed tomographic colonography and colonoscopy. Validated patient experience questionnaires that measured the experience for each test and a separate questionnaire that obtained an overall summary measure were administered after testing. Eleven patient experiences including pain, embarrassment, difficulty with bowel preparation, and satisfaction with tests were examined. RESULTS: A total of 614 subjects completed all 3 imaging tests. The test most patients were willing to repeat was colonoscopy; it also was reported to be the least painful procedure. Patients were least satisfied with air contrast barium enema, and fewer would undergo air contrast barium enema compared with computed tomographic colonography or colonoscopy. There were limited racial and gender differences in perceptions of the tests. Younger adults perceived air contrast barium enema to be more painful than older adults. CONCLUSION: Taking into account a wide variety of patient experience measures, patients preferred colonoscopy to air contrast barium enema and computed tomographic colonography. This finding has important implications for physicians considering different colon imaging tests. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Texas, SW Med Ctr, Dept Internal Med, Div Digest & Liver Dis, Dallas, TX 75390 USA. Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. Duke Univ, Med Ctr, Dept Med, Durham, NC 27706 USA. Duke Univ, Med Ctr, Durham VA Med Ctr, Durham, NC 27706 USA. Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. Troy Internal Med, Troy, MI USA. Indian River Radiol, Vero Beach, FL USA. Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA. Univ Chicago, Chicago, IL 60637 USA. Univ Med & Dent New Jersey, Newark, NJ 07103 USA. Seacoast Gastroenterol, Exeter, NH USA. Univ Texas, Med Branch, Galveston, TX 77550 USA. Calif Pacific Med Ctr, San Francisco, CA USA. Univ Calif San Diego, San Diego, CA 92103 USA. NYU, New York, NY USA. RP Rockey, DC (reprint author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Digest & Liver Dis, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM don.rockey@utsouthwestern.edu FU NCI NIH HHS [R01 CA82344] NR 24 TC 55 Z9 57 U1 0 U2 2 PU EXCERPTA MEDICA INC PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD SEP PY 2006 VL 119 IS 9 BP 791 EP 799 DI 10.1016/j.amjmed.2006.02.013 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 079TC UT WOS:000240199800015 PM 16945615 ER PT J AU Iordanova, B Rosenbaum, D Norman, D Weiner, M Studholme, C AF Iordanova, B. Rosenbaum, D. Norman, D. Weiner, M. Studholme, C. TI MR imaging anatomy in neurodegeneration: A robust volumetric parcellation method of the frontal lobe gyri with quantitative validation in patients with dementia SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID VOXEL-BASED MORPHOMETRY; PREFRONTAL CORTEX; SEGMENTATION METHOD; HUMAN BRAIN; SCHIZOPHRENIA; CINGULATE; SULCI AB BACKGROUND AND PURPOSE: Brain volumetry is widely used for evaluating tissue degeneration; however, the parcellation methods are rarely validated and use arbitrary planes to mark boundaries of brain regions. The goal of this study was to develop, validate, and apply an MR imaging tracing method for the parcellation of 3 major gyri of the frontal lobe, which uses only local landmarks intrinsic to the structures of interest, without the need for global reorientation or the use of dividing planes or lines. METHODS: Studies were performed on 25 subjects- healthy controls and subjects diagnosed with Lewy body dementia and Alzheimer disease-with significant variation in the underlying gyral anatomy and state of atrophy. The protocol was evaluated by using multiple observers tracing scans of subjects diagnosed with neurodegenerative disease and those aging normally, and the results were compared by spatial overlap agreement. To confirm the results, observers marked the same locations in different brains. We illustrated the variabilities of the key boundaries that pose the greatest challenge to defining consistent parcellations across subjects. RESULTS: The resulting gyral volumes were evaluated, and their consistency across raters was used as an additional assessment of the validity of our marking method. The agreement on a scale of 0-1 was found to be 0.83 spatial and 0.90 volumetric for the same rater and 0.85 spatial and 0.90 volumetric for 2 different raters. The results revealed that the protocol remained consistent across different neurodegenerative conditions. CONCLUSION: Our method provides a simple and reliable way for the volumetric evaluation of frontal lobe neurodegeneration and can be used as a resource for larger comparative studies as well as a validation procedure of automated algorithms. C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, Dept Radiol, Magnet Resonance Unit, San Francisco, CA USA. RP Iordanova, B (reprint author), Carnegie Mellon Univ, Mellon Inst 601, 4400 5th Av, Pittsburgh, PA 15213 USA. EM biordano@andrew.cmu.edu FU NIA NIH HHS [R01 AG10897, P01 AG012435, P01 AG19724, P01 AG019724, P01 AG12435, R01 AG010897]; NIAAA NIH HHS [P01 AA011493, P01 AA11493]; NIBIB NIH HHS [R01 EB00822, R01 EB000822]; NIMH NIH HHS [R01 MH065392, R01 MH65392] NR 27 TC 4 Z9 4 U1 1 U2 2 PU AMER SOC NEURORADIOLOGY PI OAK BROOK PA 2210 MIDWEST RD, OAK BROOK, IL 60521 USA SN 0195-6108 J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD SEP PY 2006 VL 27 IS 8 BP 1747 EP 1754 PG 8 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 086AJ UT WOS:000240645200039 PM 16971629 ER PT J AU Paintlia, AS Paintlia, MK Singh, I Singh, AK AF Paintlia, Ajaib S. Paintlia, Manjeet K. Singh, Inderjit Singh, Avtar K. TI Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID ACTIVATED PROTEIN-KINASE; COA REDUCTASE INHIBITOR; REMITTING MULTIPLE-SCLEROSIS; CENTRAL-NERVOUS-SYSTEM; GLATIRAMER ACETATE; ENDOTHELIAL-CELLS; CONTROLLED-TRIAL; PROGRESSIVE MS; TH2 BIAS; EXPRESSION AB Combination therapy with multiple sclerosis (MS) therapeutics is gaining momentum over monotherapy for improving MS. Lovastatin, an HMG-CoA reductase inhibitor (statin), was immunomodulatory in an experimental autoimmune encephalomyelitis (EAE) model of MS. Lovastatin biases the immune response from Th1 to a protective Th2 response in EAE by a different mechanism than 5-aminoimidazole-4-carboxaniide-1-13-D-ribofuranoside, an immunomodulating agent that activates AMP-activated protein kinase. Here we tested these agents in combination in an EAE model of MS. Suboptimal doses of these drugs in combination were additive in efficacy against the induction of EAE; clinical symptoms were delayed and severity and duration of disease was reduced. in the central nervous system, the cellular infiltration and proinflammatory immune response was decreased while the anti-inflammatory immune response was increased. Combination treatment biased the class of elicited myelin basic protein antibodies from IgG2a to IgG1 and IgG2b, suggesting a shift from Th1 to Th2 response. In addition, combination therapy lessened inflammation-associated neurodegeneration in the central nervous system of EAE animals. These effects were absent in EAE animals treated with either drug alone at the same dose. Thus, our data suggest that agents with different mechanisms of action such as lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofruranoside, when used in combination, could improve therapy for central nervous system de-myelinating diseases and provide a rationale for testing them in MS patients. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu OI Paintlia, Ajaib/0000-0003-4525-5333 FU NCRR NIH HHS [C06 RR015455, C06-RR018823, C06-RR015455, C06 RR018823]; NIA NIH HHS [AG-025307, R56 AG025307]; NINDS NIH HHS [R01 NS040144, R37 NS022576, NS-40144, R01 NS037766, NS-34741, R01 NS022576, NS-40810, NS-22576, R01 NS034741, NS-37766, R01 NS040810] NR 52 TC 24 Z9 30 U1 0 U2 0 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD SEP PY 2006 VL 169 IS 3 BP 1012 EP 1025 DI 10.2353/ajpath.2006.051309 PG 14 WC Pathology SC Pathology GA 077RY UT WOS:000240048900026 PM 16936274 ER PT J AU Weaver, FM Smith, B Evans, CT Kurichi, JE Patel, N Kapur, VK Burns, SP AF Weaver, F. M. Smith, B. Evans, C. T. Kurichi, J. E. Patel, N. Kapur, V. K. Burns, S. P. TI Outcomes of outpatient visits for acute respiratory illness in veterans with spinal cord injuries and disorders SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE respiratory care; infection; outcomes; spinal cord injuries; veterans ID COMMUNITY-ACQUIRED PNEUMONIA; MORTALITY; HOSPITALIZATION; DEATH; RISK; POPULATION; INFECTION; ETIOLOGY; TRENDS; IMPACT AB Objective: Respiratory complications are a leading cause of death in persons with spinal cord injuries and disorders (SCI&D). We examined same-day and 60-day hospitalizations and 60-day mortality after acute respiratory illness (ARI) outpatient visits. Design: A longitudinal study was conducted of 8775 ARI visits in the Veterans Health Administration (VA) (October. 1997-September 2002) by persons with SCI&D. ARIs included upper respiratory infections (URI), acute bronchitis, pneumonia, and influenza (P&I). Results: URIs accounted for almost half of all (49%) visits. A total of 14.9% of patients with ARIs were hospitalized the same day; 30.8% were hospitalized within 60 days. Predictors of hospitalization included diagnosis of either P&I or acute bronchitis, comorbid illness, level of injury, age, and VA SCI center visit. Overall 60-day mortality was 2.9% but was 7.9% for pneumonia. Mortality was related to diagnosis (P&I: odds ratio [OR] = 9.80, 95% confidence interval [CI]: 6.27-13.33; acute bronchitis: OR = 2.00, 95% CI: 1.08 -2.93), age (65+: OR = 3.96, 95%, CI: 2.23-5.70), and comorbid conditions (OR = 1.94, 95% Cl: 1.432.46). Conclusions: P&I and acute bronchitis were associated with increased VA hospitalization and mortality rates. The case fatality rate for pneumonia is higher for SCI&D than the general population. Level of injury predicted hospitalization but not death. Efforts to improve prevention and treatment of ARIs in persons with SCI&D are needed. C1 Hines VA Hosp, Midw Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA. Hines VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA. Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA. Northwestern Univ, Inst Heathcare Studies, Chicago, IL 60611 USA. Univ Penn, Sch Med, Dept Rehabil Med, Philadelphia, PA 19104 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Univ Washington, Div Pulm & Crit Care Med, Dept Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Harborview Injury Prevent & Res Ctr, Seattle, WA USA. VA Puget Sound Hlth Care Syst, SCI Serv, Seattle, WA USA. RP Weaver, FM (reprint author), Hines VA Hosp, Midw Ctr Hlth Serv & Policy Res, HSR&D,151H,Bldg 1,Room B260,5th & Roosevelt Rd, Hines, IL 60141 USA. RI Kapur, Vishesh/K-1054-2014 OI Kapur, Vishesh/0000-0002-5417-1097 NR 29 TC 12 Z9 12 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD SEP PY 2006 VL 85 IS 9 BP 718 EP 726 DI 10.1097/01.phm.0000223403.94148.67 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 077PV UT WOS:000240043000003 PM 16924184 ER PT J AU Satoh, A Gukovskaya, AS Reeve, JR Shimosegawa, T Pandol, SJ AF Satoh, Akihiko Gukovskaya, Anna S. Reeve, Joseph R., Jr. Shimosegawa, Tooru Pandol, Stephen J. TI Ethanol sensitizes NF-kappa B activation in pancreatic acinar cells through effects on protein kinase C-epsilon SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE alcoholic pancreatitis; cholecystokinin; inflammatory response; protein kinase C-epsilon translocation activator ID CARDIAC PROTECTION; PKC-EPSILON; CHOLECYSTOKININ; ALCOHOL; DELTA; PHOSPHORYLATION; CCK; TRANSLOCATION; PENETRATIN; INCREASES AB Although ethanol abuse is the most common cause of pancreatitis, the mechanism of alcohol's effect on the pancreas is not well understood. Previously, we demonstrated that in vitro ethanol treatment of pancreatic acinar cells augmented the CCK-8-induced activation of NF-kappa B, a key signaling system involved in the inflammatory response of pancreatitis. In the present study, we determine the role for individual PKC isoforms in the sensitizing effect of ethanol on NF-kappa B activation. Dispersed rat pancreatic acini were treated with and without ethanol and then stimulated with CCK-8; 100 nM CCK-8 caused both NF-kappa B and PKC-delta, -epsilon, and -zeta activation, whereas 0.1 nM CCK-8 did not increase PKC-delta, PKC-delta, or NF-kappa B activity. CCK-8 (0.1 nM) did activate PKC-delta. PKC-epsilon activator alone did not cause NF-kappa B activation; however, together with 0.1 nM CCK-8, it caused NF-kappa B activation. Ethanol activated PKC-epsilon without affecting other PKC isoforms or NF-kappa B activity. Of note, stimulation of acini with ethanol and 0.1 nM CCK-8 resulted in the activation of PKC-epsilon, PKC-epsilon, and NF-kappa B. The NF-kappa B activation to 0.1 nM CCK-8 in ethanol-pretreated acini was inhibited by both PKC-delta inhibitor and PKC-epsilon inhibitor. Taken together, these results demonstrate the different modes of activation of PKC isoforms and NF-kappa B in acini stimulated with ethanol, high-dose CCK-8, and low-dose CCK-8, and furthermore suggest that activation of both PKC-epsilon and -delta is required for NF-kappa B activation. These results suggest that ethanol enhances the CCK-8 induced NF-kappa B activation at least in part through its effects on PKC-epsilon. C1 W LA Healthcare Ctr, VA Greater LA Healthcare Syst, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Tohoku Univ, Grad Sch Med, Div Gastroenterol, Sendai, Miyagi 980, Japan. RP Pandol, SJ (reprint author), W LA Healthcare Ctr, VA Greater LA Healthcare Syst, Res Ctr Alcohol Liver & Pancreat Dis, Bldg 258,Rm 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM stephen.pandol@med.va.gov FU NIAAA NIH HHS [1 U56 AA-0114643]; NIDDK NIH HHS [R01-DK-59508]; PHS HHS [P50-A11999] NR 36 TC 38 Z9 41 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD SEP PY 2006 VL 291 IS 3 BP G432 EP G438 DI 10.1152/ajpgi.00579.2005 PG 7 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 072NH UT WOS:000239679600008 PM 16574982 ER PT J AU Janech, MG Fitzgibbon, WR Nowak, MW Miller, DH Paul, RV Ploth, DW AF Janech, Michael G. Fitzgibbon, Wayne R. Nowak, Mark W. Miller, Donald H. Paul, Richard V. Ploth, David W. TI Cloning and functional characterization of a second urea transporter from the kidney of the Atlantic stingray, Dasyatis sabina SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article; Proceedings Paper CT Satellite Symposium of the 34th World Congress of the International-Union-of-Physiological-Sciences CY AUG 24, 2001 CL AUCKLAND COLL EDUC, AUCKLAND, NEW ZEALAND SP Int Union Physiol Sci HO AUCKLAND COLL EDUC DE elasmobranch; euryhaline; alternative splicing; osmoregulation ID AGONIST-INDUCED DESTABILIZATION; RECEPTOR MESSENGER-RNA; RAT-KIDNEY; MOLECULAR CHARACTERIZATION; MARINE ELASMOBRANCH; SQUALUS-ACANTHIAS; RAJA-ERINACEA; LOCALIZATION; UT-A3; OSMOREGULATION AB The cloning of cDNAs encoding facilitated urea transporters (UTs) from the kidneys of the elasmobranchs indicates that in these fish renal urea reabsorption occurs, at least in part, by passive processes. The previously described elasmobranch urea transporter clones from shark (shUT) and stingray (strUT-1) differ from each other primarily because of the COOH-terminus of the predicted strUT-1 translation product being extended by 51-amino acid residues compared with shUT. Previously, we noted multiple UT transcripts were present in stingray kidney. We hypothesized that a COOH terminally abbreviated UT isoform, homologous to shUT, would also be present in stingray kidney. Therefore, we used 5'/3' rapid amplification of cDNA ends to identify a 3'UTR-variant (strUT-1a) of the cDNA that encodes (strUT-1), as well as three, 3'UTR-variant cDNAs (strUT-2a, b, c) that encode a second phloretin-sensitive, urea transporter (strUT-2). The 5'UTR and the first 1,132 nucleotides of the predicted coding region of the strUT-2 cDNAs are identical to the strUT-1 cDNAs. The remainder of the coding region contains only five novel nucleotides. The strUT-2 cDNAs putatively encode a 379-amino acid protein, the first 377 amino acids identical to strUT-1 plus 2 additional amino acids. We conclude that 1) a second UT isoform is expressed in the Atlantic stingray and that this isoform is similar in size to the UT previously cloned from the kidney of the dogfish shark, and 2) at least five transcripts encoding the 2 stingray UTs are derived from a single gene product through alternative splicing and polyadenylation. C1 Med Univ S Carolina, Dept Med, Div Nephrol, Marine Biomed & Environm Sci Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pharmacol & Expt Therapeut, Marine Biomed & Environm Sci Ctr, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Fitzgibbon, WR (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, Marine Biomed & Environm Sci Ctr, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA. EM fitzgiwr@musc.edu OI Janech, Michael/0000-0002-3202-4811 NR 46 TC 14 Z9 14 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD SEP PY 2006 VL 291 IS 3 BP R844 EP R853 DI 10.1152/ajpregu.00739.2005 PG 10 WC Physiology SC Physiology GA 072FH UT WOS:000239658800046 PM 16614049 ER PT J AU Kramer, BJ Wang, MM Hoang, T Harker, JO Finke, B Saliba, D AF Kramer, B. Josea Wang, Mingming Hoang, Tuyen Harker, Judith O. Finke, Bruce Saliba, Debra TI Identification of American Indian and Alaska native veterans in administrative data of the veterans health administration and the Indian health service SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article AB We sought to determine the extent to which the Indian Health Service (IHS) identified enrollees who also use the Veterans Health Administration (VHA) as veterans. We used a bivariate analysis of administrative data from fiscal years 20022003 to study the target population. Of the 32259 IHS enrollees who received care as veterans in the VHA, only 44% were identified by IHS as veterans. IHS data underestimates the number of veterans, and both IHS and VHA need mechanisms to recognize mutual beneficiaries in order to facilitate better coordination of strategic planning and resource sharing among federal health care agencies. C1 Vet Affairs Greater Los Angeles Healthcare Syst, GRECC, Dept Vet Affairs, North Hills, CA 91343 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. Ctr Geriatr Res Educ & Clin, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Indian Hlth Serv, Elder Care Initiat, Northampton, MA USA. RAND Corp, Los Angeles, CA USA. RP Kramer, BJ (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, GRECC, Dept Vet Affairs, 16 111 Plummer St,11E, North Hills, CA 91343 USA. EM josea.kramer@va.gov NR 8 TC 3 Z9 3 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2006 VL 96 IS 9 BP 1577 EP 1578 DI 10.2105/AJPH.2005.073205 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 079LY UT WOS:000240179100016 PM 16873744 ER PT J AU McFall, M Atkins, DC Yoshimoto, D Thompson, CE Kanter, E Malte, CA Saxon, AJ AF McFall, Miles Atkins, David C. Yoshimoto, Dan Thompson, Charles E. Kanter, Evan Malte, Carol A. Saxon, Andrew J. TI Integrating tobacco cessation treatment into mental health care for patients with posttraumatic stress disorder SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID PREDICTING SMOKING CESSATION; PLACEBO-CONTROLLED TRIAL; VIETNAM COMBAT VETERANS; MAJOR DEPRESSION; FOLLOW-UP; DEPENDENCE TREATMENT; NICOTINE DEPENDENCE; SCHIZOPHRENIA; SMOKERS; INTERVENTION AB The integration of tobacco cessation treatment into mental health care for posttraumatic stress disorder (PTSD), known as Integrated Care (IC), was evaluated in an uncontrolled feasibility and effectiveness study. Veterans (N = 107) in PTSD treatment at two outpatient clinics received IC delivered by mental health practitioners. Outcomes were seven-day point prevalence abstinence measured at two, four, six, and nine months post-enrollment and repeated seven-day point prevalence abstinence (RPPA) obtained across three consecutive assessment intervals (four, six, and nine months). Abstinence rates at the four assessment intervals were 28%, 23%, 25%, and 18%, respectively, and RPPA was 15%. The number of IC sessions and a previous quit history greater than six months predicted RPPA. Stopping smoking was not associated with worsening PTSD or depression. C1 NW Network Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. RP McFall, M (reprint author), VA Puget Sound Hlth Care Syst, PTSD Programs S116 MHC, 1660 S Columbian Way, Seattle, WA 98108 USA. EM miles.mcfall@va.gov OI Atkins, David/0000-0002-5781-9880 NR 60 TC 27 Z9 27 U1 2 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD SEP-OCT PY 2006 VL 15 IS 5 BP 336 EP 344 DI 10.1080/10550490600859892 PG 9 WC Substance Abuse SC Substance Abuse GA 083DN UT WOS:000240436200002 PM 16966189 ER PT J AU Stein, MH Sorscher, M Caroff, SN AF Stein, Mark H. Sorscher, Michelle Caroff, Stanley N. TI Neuroleptic malignant syndrome induced by metoclopramide in an infant with Freeman-Sheldon syndrome SO ANESTHESIA AND ANALGESIA LA English DT Letter ID CHILD C1 Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Anesthesia, Sect Pediat Anesthesia, New Brunswick, NJ USA. Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, Bristol Myers Squibb Childrens Hosp, New Brunswick, NJ USA. Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. RP Stein, MH (reprint author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Anesthesia, Sect Pediat Anesthesia, New Brunswick, NJ USA. EM stanley.caroff@va.gov NR 14 TC 5 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD SEP PY 2006 VL 103 IS 3 BP 786 EP 787 DI 10.1213/01.ANE.0000227135.46049.B7 PG 2 WC Anesthesiology SC Anesthesiology GA 077SG UT WOS:000240049800063 PM 16931708 ER PT J AU Shrank, WH Asch, SM Joseph, GJ Young, HN Ettner, SL Kholodenko, Y Glassman, P Kravitz, RL AF Shrank, William H. Asch, Steven M. Joseph, George J. Young, Henry N. Ettner, Susan L. Kholodenko, Yelena Glassman, Peter Kravitz, Richard L. TI Physicians' perceived knowledge of and responsibility for managing patients' out-of-pocket costs for prescription drugs SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE out-of-pocket costs; pharmacy benefit design; prescription drugs ID PHARMACEUTICALS; INCENTIVES; ADHERENCE; CARE AB BACKGROUND: Most insurers in the US have implemented incentive-based formularies that rely on out-of-pocket costs to influence prescription drug utilization. Medicare Part D plans have broadly adopted such benefit designs. OBJECTIVE: To evaluate physicians' perceptions of their knowledge of formularies and out-of-pocket costs, factors that influence knowledge of costs, physicians' perceived responsibility for helping patients manage their out-of-pocket costs for prescription drugs, and physicians' perceptions of the role of pharmacists in managing these costs. METHODS: A multiple-choice survey was mailed to a random sample of 1200 physician members of the California Medical Association; a phone survey of nonresponders was then conducted. RESULTS: Of 1027 surveys delivered to correct addresses, 509 (49.6%) responses were received. Thirty-three percent of physicians reported that they were usually or always aware of patients' formularies and 20% were usually or always aware of patients' out-of-pocket costs for medications. Surgeons, emergency department physicians, and physicians that prescribe from more formularies than other physicians are less likely to be aware of patients' out-of-pocket costs, while physicians in large practices and those who use computers to prescribe are more aware. While 91% of physicians agreed that it is important that patients' out-of-pocket costs be managed, 40% somewhat or strongly agreed that it is their responsibility to help. Sixty-five percent of physicians believed that it is the responsibility of the pharmacist to be familiar with patients' out-of-pocket costs. CONCLUSIONS: Physicians often lack the knowledge to assist patients in the management of their out-of-pocket costs for prescription drugs and they depend on pharmacists to help patients manage those costs. Computer order entry and resources available in large physician organizations improve physicians' awareness of out-of-pocket costs when prescribing. C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidmiol & Pharmacoecon, Boston, MA 02120 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Hlth Care Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. RAND Hlth, Div Gen Internal Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. Univ Wisconsin, Sch Pharm, Social Adm Sci Div, Madison, WI 53706 USA. Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Hlth Serv, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Dept Gen Internal Med, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA. Univ Calif Davis, Ctr Hlth Serv Res Primary Care, Sacramento, CA 95817 USA. RP Shrank, WH (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidmiol & Pharmacoecon, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA. EM wshrank@partners.org OI Kravitz, Richard/0000-0001-5575-529X NR 25 TC 26 Z9 27 U1 1 U2 3 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD SEP PY 2006 VL 40 IS 9 BP 1534 EP 1540 DI 10.1345/aph.1H158 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 078OG UT WOS:000240112500005 PM 16912246 ER PT J AU Kang, WD Gomez, FE Lan, JG Sano, Y Ueno, C Kudsk, KA AF Kang, Woodae Gomez, F. Enrique Lan, Jinggang Sano, Yoshifumi Ueno, Chikara Kudsk, Kenneth A. TI Parenteral nutrition impairs gut-associated lymphoid tissue and mucosal immunity by reducing lymphotoxin beta receptor expression SO ANNALS OF SURGERY LA English DT Article; Proceedings Paper CT 126th Annual Meeting of the American-Surgical-Association CY APR 20-22, 2006 CL Boston, MA SP Amer Surg Assoc ID UPPER RESPIRATORY-TRACT; MAJOR ABDOMINAL-TRAUMA; SEPTIC COMPLICATIONS; ENTERAL NUTRITION; ENHANCING DIET; IGA SYNTHESIS; ROUTE; CELLS; MORBIDITY; BENEFITS AB Objective: To determine the effects of parenteral nutrition (PN) on LT beta R in gut-associated lymphoid tissue (GALT), particularly the intestine and Peyer's patches (PP). Summary Background Data: Lack of enteral stimulation with PN impairs mucosal immunity and reduces IgA levels through depression of GALT cytokines (IL-4 and IL-10) and GALT specific adhesion molecules. We have shown that each is critical to intact mucosal immunity through effects on lymphocyte homing, IgA production, and resistance to antibacterial and antiviral immunity. IgA is the principal specific immunologic mucosal defense. LT beta R stimulation controls production of IL-4, the adhesion molecule MAdCAM-1, and other key components of GALT, all of which are important in increasing IgA levels and maintaining mucosal defenses. Methods: Experiment 1: LT beta R expression in intestine and PP was analyzed by Western blot after 5 days of chow, a complex enteral diet (CED), or PN. Diets were isocaloric and isonitrogenous except for chow. Experiment 2: After completing pilot experiments to determine the appropriate dose of the LT beta R agonistic antibody, mice received chow, PN + 5 mu g of anti-LT beta R mAb (2 times/d, i.v.) or PN + isotype control antibody. PP lymphocytes and intestinal IgA levels were measured after 2 days. Results: Lack of enteral stimulation with PN significantly decreased LT beta R expression in intestine and PP compared with chow and CED. LT beta R stimulation with an agonistic anti-LT beta R mAb significantly increased PP lymphocyte counts and intestinal IgA in PN fed-mice. Conclusions: LT beta R expression is critical for GALT control mechanisms and intact mucosal immunity. PN reduces LT beta R expression, PP lymphocytes, and intestinal IgA production. Exogenous LT beta R stimulation reverses PN-induced depression of gut mucosal immunity. C1 Univ Wisconsin, Coll Med & Publ Hlth, Dept Surg, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU NIGMS NIH HHS [R01 GM053439, R01 GM53439-06A1] NR 30 TC 28 Z9 29 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD SEP PY 2006 VL 244 IS 3 BP 392 EP 399 DI 10.1097/01.sla.0000234797.42935.46 PG 8 WC Surgery SC Surgery GA 080QB UT WOS:000240261500007 PM 16926565 ER PT J AU Pumbwe, L Glass, D Wexler, HM AF Pumbwe, Lilian Glass, Daniel Wexler, Hannah M. TI Efflux pump overexpression in multiple-antibiotic-resistant mutants of Bacteroides fragilis SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID FLUOROQUINOLONE RESISTANCE; ANTIMICROBIAL RESISTANCE; SELECTION WINDOW; ACTIVE EFFLUX; BACTERIA; MUTATIONS AB Multidrug-resistant mutants of a wild-type Bacteroides fragilis strain (strain ADB77) and a quadruple resistance nodulation division family efflux pump deletion mutant (ADB77 Delta bmeB1 Delta bmeB3 Delta bmeB12 Delta bmeB15) were selected with antimicrobials. Ampicillin, doripenem, imipenem, levofloxacin, and metronidazole selected for mutants from both strains; cefoxitin selected for mutants from strain ADB77 only; and sodium dodecyl sulfate selected mutants from ADB77 Delta bmeB1 Delta bmeB3 Delta bmeB12 Delta bmeB15 only. The mutants overexpressed one or more efflux pumps. C1 Univ Calif Los Angeles, Sch Med, Wadsworth Anaerobe Lab, Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. RP Wexler, HM (reprint author), Univ Calif Los Angeles, Sch Med, Wadsworth Anaerobe Lab, Greater Los Angeles Vet Adm Healthcare Syst, Bldg 304,Room E3-224,GLAVAHCS 691-151J, Los Angeles, CA 90073 USA. EM hwexler@ucla.edu NR 16 TC 24 Z9 26 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2006 VL 50 IS 9 BP 3150 EP 3153 DI 10.1128/AAC.00141-06 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 081DI UT WOS:000240297000036 PM 16940115 ER PT J AU Block, K Rcono, JM Lee, DY Bhandari, B Choudhury, GG Abboud, HE Gorin, Y AF Block, Karen Rcono, Jill M. Lee, Duck-Yoon Bhandari, Basant Choudhury, Goutam Ghosh Abboud, Hanna E. Gorin, Yves TI Arachidonic acid-dependent activation of a p22(phox)-based NAD(P)H oxidase mediates angiotensin II-induced mesangial cell protein synthesis and fibronectin expression via Akt/PKB SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Article ID SMOOTH-MUSCLE-CELLS; AKT/PROTEIN KINASE-B; NADPH OXIDASE; MESSENGER-RNA; DIABETIC-NEPHROPATHY; NOX FAMILY; HYPERTROPHY; MECHANISMS; PATHWAYS; GROWTH AB Angiotensin 11 (Ang 11) induces protein synthesis and hypertrophy through arachidonic acid (AA)- and redox-dependent activation of the serine-threonine kinase Akt/PKB in mesangial cells (MCs). The role of NAD(P)H oxidase component p22(phox) was explored in this signaling pathway and in Ang II-induced expression of the extracellular matrix protein fibronectin. Ang 11 causes activation of Akt/PKB and induces fibronectin protein expression, effects abrogated by phospholipase A 2 inhibition and mimicked by AA. Ang 11 and AA also elicited an increase in fibronectin expression that was reduced with a dominant negative mutant of Akt/PKB. Exposure of the cells to hydrogen peroxide stimulates Akt/PKB activity and fibronectin synthesis. The antioxidant N-acetylcysteine abolished Ang II- and AA-induced Akt/PKB activation and fibronectin expression. Western blot analysis revealed high levels of p22(phox) in MCs. Antisense (AS) but not sense oligonucleotides for p22(phox) prevented ROS generation in response to Ang 11 and AA. AS p22(phox) inhibited Ang II- or AA-induced Akt/PKB as well as protein synthesis and fibronectin expression. These data provide the first evidence, in MCs, of activation by AA of a p22(phox)-based NAD(P)H oxidase and subsequent generation of ROS. Moreover, this pathway mediates the effect of Ang 11 on Akt/PKB-induced protein synthesis and fibronectin expression. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol MC 7882, San Antonio, TX 78229 USA. Audie L Murphy Mem Hosp Div, S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Gorin, Y (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol MC 7882, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM gorin@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU NIDDK NIH HHS [DK 55815, P50 DK 61597, DK 50190, DK 43988, DK 33665] NR 43 TC 28 Z9 28 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD SEP-OCT PY 2006 VL 8 IS 9-10 BP 1497 EP 1508 DI 10.1089/ars.2006.8.1497 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 084HL UT WOS:000240523900008 PM 16987006 ER PT J AU Patel, S Ho, JT Kumar, R Lai, K Ahangar, B Burgar, CG Scremin, AE AF Patel, Sheila Ho, Jeffrey T. Kumar, Rajeswari Lai, Khang Ahangar, Brian Burgar, Charles G. Scremin, Antonia E. TI Changes in motoneuron excitability in hemiplegic subjects after passive exercise when using a robotic arm SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT 65th Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation CY OCT, 2004 CL Phoenix, AZ SP Amer Acad Phys Med & Rehabil DE cerebrovascular accident; H-reflex; rehabilitation; robotics ID MOTOR EVOKED-POTENTIALS; H-REFLEX; HOFFMANN REFLEX; SPASTICITY; HUMANS; STROKE AB Objective: To test the hypothesis that motoneuron excitability in stroke subjects is influenced by peripheral sensory input through passive exercise to the hemiplegic upper extremity. Design: Case-control prospective study. Setting: Physical medicine and rehabilitation inpatient and outpatient clinic at a tertiary Veterans Affairs medical center. Participants: Nineteen hemiplegic adult subjects with a history of a cerebrovascular event. Intervention: A standardized passive exercise program was performed on the right upper extremity by using a robotic arm. Nerve conduction study of the median nerve was obtained before and after the exercise. Maximum onset and peak amplitudes of the Hoffmann reflex (Hmax) and motor response (Mmax) wave were recorded. Main Outcome Measures: Hmax, Mmax, and Hmax/Mmax ratio. Results: Immediately after passive exercise, there was no significant alteration in the Hmax (P=.94), Mmax (P=.60), or Hmax/Mmax ratio (P=.53) as compared with pre-exercise evoked responses. Conclusions: Peripheral proprioceptive input with passive exercise does not cause appreciable change in the Hmax/Mmax ratio, suggesting that motoneuron excitability of the affected upper extremity in stroke subjects is not influenced by passive robotic intervention. C1 Univ Calif Los Angeles, Dept Phys Med & Rehabil, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Cent Texas Vet Hlth Care Syst, Temple, TX USA. RP Scremin, AE (reprint author), Univ Calif Los Angeles, Dept Phys Med & Rehabil, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 500,Mailcode 117, Los Angeles, CA 90073 USA. EM Antonio.Scremin@va.gov NR 24 TC 3 Z9 3 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD SEP PY 2006 VL 87 IS 9 BP 1257 EP 1261 DI 10.1016/j.apmr.2006.05.026 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 082SO UT WOS:000240407700016 PM 16935064 ER PT J AU Jobe, BA Kim, CY Minjarez, RC O'Rourke, R Chang, EY Hunter, JG AF Jobe, Blair A. Kim, Charles Y. Minjarez, Renee C. O'Rourke, Robert Chang, Eugene Y. Hunter, John G. TI Simplifying minimally invasive transhiatal esophagectomy with the inversion approach - Lessons learned from the first 20 cases SO ARCHIVES OF SURGERY LA English DT Article; Proceedings Paper CT 77th Annual Meeting of the Pacific-Coast-Surgical-Association CY FEB 17-20, 2006 CL San Francisco, CA SP Pacific Coast Surg Assoc ID PYLOROPLASTY; ANASTOMOSIS; CANCER; LEAK AB Hypothesis: The laparoscopic transhiatal esophagectomy can be simplified and performed safely and effectively by using a novel esophageal inversion technique. Design: Case series describing technique, initial experience, and learning curve with laparoscopic inversion esophagectomy. Setting: Tertiary care university hospital and veteran's hospital. Patients: Twenty consecutive patients with high-grade dysplasia (n = 16) and esophageal adenocarcinoma (n=4). Intervention: Laparoscopic inversion esophagectomy, a totally laparoscopic approach to transhiatal esophagectomy that incorporates distal to proximal inversion to improve mediastinal exposure and ease of dissection. Main Outcome Measures: Perioperative end points and complications, compared between the first and second groups of 10 patients. Results: There were 19 men and 1 woman. Median operative time was 448 minutes. Median blood loss was 175 cull. Median intensive care unit stay was 4 days, and median total hospital stay was 9 days. Overall anastomotic leak rate was 20%. Five patients developed an anastomotic stricture, all successfully managed with endoscopic dilation. There were 2 recurrent laryngeal nerve injuries, which resolved. There was no intraoperative or 30-day mortality. Between the first 10 consecutive cases and last 10 procedures, the incidence of anastomotic leak and stricture formation decreased from 30% to 10% and 40% to 10%, respectively. During this period, the number of lymph nodes harvested increased 9-fold, and duration of intensive care unit stay decreased from 8.00 to 2.50 days. Conclusions: Laparoscopic inversion esophagectomy is a safe procedure. The learning curve for the inversion approach is approximately 10 operations in the hands of esophageal surgeons with advanced laparoscopic expertise. C1 Oregon Hlth & Sci Univ, Dept Surg, Portland, OR USA. Portland VA Med Ctr, Surg Serv, Portland, OR USA. RP Jobe, BA (reprint author), Vet Adm Med Ctr, Surg Serv P3GS, POB 1034, Portland, OR 97207 USA. EM jobeb@ohsu.edu FU NIDDK NIH HHS [K23 DK066165-01] NR 15 TC 26 Z9 26 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD SEP PY 2006 VL 141 IS 9 BP 857 EP 865 DI 10.1001/archsurg.141.9.857 PG 9 WC Surgery SC Surgery GA 081XN UT WOS:000240351000003 PM 16983029 ER PT J AU Bartels, CM Bell, CL Bridges, AJ Shinki, K AF Bartels, Christie M. Bell, Carolyn L. Bridges, Alan J. Shinki, Kazuhiko TI Declining rates of serious extra-articular RA among US veteran inpatients. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 10-15, 2006 CL Washington, DC SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Univ Wisconsin, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2006 VL 54 IS 9 SU S BP S208 EP S208 PG 1 WC Rheumatology SC Rheumatology GA 089JR UT WOS:000240877200466 ER PT J AU Brey, RL Naqibuddin, M Holliday, SL Padilla, PA Fox, PT Narayana, S Franklin, C Samerdro, M Wallace, DJ Weissman, MH Petri, M AF Brey, Robin L. Naqibuddin, Mohammad Holliday, Stephen L. Padilla, Patricia A. Fox, Peter T. Narayana, Shalini Franklin, Crystal Samerdro, Margaret Wallace, Daniel J. Weissman, Michael H. Petri, Michelle TI Matrix metalloproteinase-9 (MMP-9) level, brain imaging findings and cognitive dysfunction in an SLE inception cohort: Brain CONECTIONS. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 10-15, 2006 CL Washington, DC SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 UTHSCSA, San Antonio, TX USA. Johns Hopkins Univ, Baltimore, MD USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2006 VL 54 IS 9 SU S BP S552 EP S552 PG 1 WC Rheumatology SC Rheumatology GA 089JR UT WOS:000240877203048 ER PT J AU Diaz-Torne, C Schumacher, HR Gomez-Vaquero, C Yu, XX Chen, LX Clayburne, G Einhorn, E Pessler, F AF Diaz-Torne, Cesar Schumacher, H. Ralph Gomez-Vaquero, C. Yu, Xiao-Xia Chen, Lan X. Clayburne, Gilda Einhorn, Eugene Pessler, Frank TI Absence of inflammation in synovial biopsies from patients with "Gulf War Syndrome" and joint pain. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 10-15, 2006 CL Washington, DC SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Bellvitge Hosp, Barcelona, Spain. Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2006 VL 54 IS 9 SU S BP S121 EP S122 PG 2 WC Rheumatology SC Rheumatology GA 089JR UT WOS:000240877200230 ER PT J AU Firooz, N Taylor, CE Nouvong, A Masih, S Yentes, JM Perell, KL Fang, MA AF Firooz, Nazanin Taylor, Connie E. Nouvong, Aksone Masih, Sulabha Yentes, Jennifer M. Perell, Karen L. Fang, Meika A. TI Effects of footwear on medial knee osteoarthritis. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 10-15, 2006 CL Washington, DC SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Calif State Univ Fullerton, Fullerton, CA 92634 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2006 VL 54 IS 9 SU S BP S670 EP S670 PG 1 WC Rheumatology SC Rheumatology GA 089JR UT WOS:000240877203391 ER PT J AU Matzkies, FG Daikh, DI AF Matzkies, Franziska G. Daikh, David I. TI Development of lupus nephritis and IgG autoantibodies in NZB/W lupus prone mice is dependent on T-bet. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 10-15, 2006 CL Washington, DC SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2006 VL 54 IS 9 SU S BP S283 EP S283 PG 1 WC Rheumatology SC Rheumatology GA 089JR UT WOS:000240877201172 ER PT J AU Naqibuddin, M Carson, KA Sampedro, MM Wallace, DJ Weisman, MH Brey, RL Holliday, SL Narayana, S Fox, PT Franklin, C Padilla, PA Petri, M AF Naqibuddin, Mohammad Carson, Kathryn A. Sampedro, Margaret M. Wallace, Daniel J. Weisman, Michael H. Brey, Robin L. Holliday, Stephen L. Narayana, Shalini Fox, Peter T. Franklin, Crystal Padilla, Patricia A. Petri, Michelle TI Brain imaging (MRI and FDG-PET) and cognitive function in newly diagnosed SLE. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 10-15, 2006 CL Washington, DC SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Johns Hopkins Univ, Baltimore, MD USA. Univ Calif Los Angeles, Cedars Sinai Med Ctr, David Geffen Sch Med, Los Angeles, CA 90048 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2006 VL 54 IS 9 SU S BP S623 EP S623 PG 1 WC Rheumatology SC Rheumatology GA 089JR UT WOS:000240877203256 ER PT J AU Naqibuddin, M Carson, KA Sampedro, MM Brey, RL Holliday, SL Narayana, S Fox, PT Franklin, C Padilla, PA Petri, M AF Naqibuddin, Mohammad Carson, Kathryn A. Sampedro, Margaret M. Brey, Robin L. Holliday, Stephen L. Narayana, Shalini Fox, Peter T. Franklin, Crystal Padilla, Patricia A. Petri, Michelle TI Anti-ds DNA and antiphospholipid antibodies are associated with abnormal brain MRI in newly diagnosed SLE patients. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 10-15, 2006 CL Washington, DC SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Johns Hopkins Univ, Baltimore, MD USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2006 VL 54 IS 9 SU S BP S554 EP S554 PG 1 WC Rheumatology SC Rheumatology GA 089JR UT WOS:000240877203053 ER PT J AU Pessler, F Diaz-Tome, C Dai, L Gomez-Vaquero, C Yu, XX Ralph Schumacher, H AF Pessler, Frank Diaz-Tome, Cesar Dai, Lie Gomez-Vaquero, C. Yu, Xiao-Xia Ralph Schumacher, H. TI How inflamed are "Non-Inflamed" surgical synovia? A quantitative immunohistochemical analysis. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 10-15, 2006 CL Washington, DC SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. Bellvitge Hosp, Barcelona, Spain. Sun Yat Sen Univ, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China. Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2006 VL 54 IS 9 SU S BP S568 EP S568 PG 1 WC Rheumatology SC Rheumatology GA 089JR UT WOS:000240877203095 ER PT J AU Pessler, F Gay, S Pandolfi, PP Schumacher, HR AF Pessler, Frank Gay, Steffen Pandolfi, Pier-Paolo Schumacher, H. Ralph TI Immunohistochemical localization of the proto-oncogene product FBI-1 (ZBTB7) in RA synovium and pannus. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 10-15, 2006 CL Washington, DC SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. Univ Zurich, Zurich, Switzerland. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD SEP PY 2006 VL 54 IS 9 SU S BP S219 EP S219 PG 1 WC Rheumatology SC Rheumatology GA 089JR UT WOS:000240877201001 ER PT J AU Pessler, F Dai, L Diaz-Torne, C Menetski, J Lu, M Schumacher, HR AF Pessler, Frank Dai, Lie Diaz-Torne, Cesar Menetski, Joseph Lu, Min Schumacher, H. Ralph TI Widespread expression of the zinc finger transcription factor Egr-1 in RA Synovium. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 10-15, 2006 CL Washington, DC SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. Sun Yat Sen Univ, Hosp 2, Guangzhou, Peoples R China. Bellvitge Hosp, Barcelona, Spain. Merck Res Labs, Rahway, NJ USA. Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD SEP PY 2006 VL 54 IS 9 SU S BP S219 EP S219 PG 1 WC Rheumatology SC Rheumatology GA 089JR UT WOS:000240877201002 ER PT J AU Scalapino, KJ Daikh, DI AF Scalapino, Kenneth J. Daikh, David I. TI Suppression of lupus glomerulonephritis by exogenously expanded regulatory T cells in NZB/W mice. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 10-15, 2006 CL Washington, DC SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2006 VL 54 IS 9 SU S BP S524 EP S525 PG 2 WC Rheumatology SC Rheumatology GA 089JR UT WOS:000240877202400 ER PT J AU Koontz, AM Yang, YS Boninger, TDS Kanaly, J Cooper, RA Boninger, ML Dieruf, K Ewer, L AF Koontz, Alicia M. Yang, Yusheng Boninger, David S. Kanaly, John Cooper, Rory A. Boninger, Michael L. Dieruf, Kathy Ewer, Lynette TI Investigation of the performance of an ergonomic handrim as a pain-relieving intervention for manual wheelchair users SO ASSISTIVE TECHNOLOGY LA English DT Article DE ergonomic intervention; wheelchair handrims; carpal tunnel syndrome; propulsion biomechanics; manual wheelchair ID CARPAL-TUNNEL-SYNDROME; BEARING UPPER EXTREMITY; FORCE APPLICATION; PUSHRIM FORCES; PARAPLEGIC PATIENTS; TECHNICAL NOTE; 2 SPEEDS; PROPULSION; WEIGHT; BIOMECHANICS AB Manual wheelchair users commonly experience pain in their hands and wrists associated with the repetitive stress of propulsion. The objective of this research was to examine the effect of an ergonomic wheelchair handrim as an intervention designed to reduce pain in the hands and wrists and improve functional outcomes for manual wheelchair users. Three studies were conducted to achieve this objective. In the first study, 10 individuals with paraplegia underwent a biomechanical analysis before and after a 2-week practice period with a Natural-Fit (NF) prototype ergonomic handrim. The biomechanical results showed that grip moments were reduced with the NF handrim prototype as compared with the subjects' current handrim (p < .1). Other biomechanical findings were mixed. In the second study, 46 manual wheelchair users who replaced their standard handrim with the commercially available NF handrim completed a questionnaire of retrospective measures of symptom severity. Average duration of use of the NF was 6 months. When asked to compare propelling with the NF to propelling with their prior handrims, 85% of respondents reported less pain in their hands and 80% reported less pain in their wrists. The third study was a replication and extension of Study 2:82 manual wheelchair users who replaced their standard handrim with the NF completed retrospective symptom severity and functional status scales after using the NF for an average of 9 months. Results again confirmed that using the NF led to a reduction in the severity of symptoms and to improved functional outcomes. C1 VA Pittsburgh Hlth Care Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. Three Rivers Holdings LLC, Mesa, AZ USA. Univ Pittsburgh, Med Ctr Hlth Syst, Dept Phys Med & Rehabil, Pittsburgh, PA USA. Univ New Mexico, Phys Therapy Program, Albuquerque, NM 87131 USA. RP Koontz, AM (reprint author), VA Pittsburgh Hlth Care Syst, Human Engn Res Labs, 7180 Highland Dr, Pittsburgh, PA 15206 USA. OI Yang, Yu-Sheng/0000-0002-2767-9354; Boninger, Michael/0000-0001-6966-919X FU NICHD NIH HHS [1R43-HD39962-01] NR 41 TC 9 Z9 9 U1 1 U2 4 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PD FAL PY 2006 VL 18 IS 2 BP 123 EP 145 PG 23 WC Rehabilitation SC Rehabilitation GA 109CJ UT WOS:000242285200001 PM 17236472 ER PT J AU Ohnabe, H AF Ohnabe, Hisaichi TI Current trends in rehabilitation engineering in Japan SO ASSISTIVE TECHNOLOGY LA English DT Article; Proceedings Paper CT 28th International RESNA Conference CY JUN 23-27, 2005 CL Atlanta, GA DE rehabilitation engineering; assistive technology; elderly; disability; trend; Japan ID SYNCHRONIZATION AB In 2005, the elderly generation comprised 20% of the Japanese population. This percentage will grow to approximately 30% in 2030, meaning that nearly one in three people in Japan will be 65 years of age or older. Japan is the first nation in the world to face this situation. This article uses the context of Japanese society to give an overview of the elderly and people with disabilities; the International Classification of Functioning, Disability, and Health model; rehabilitation engineering-related policy; and education. In addition, we examine how governmental programs and Japanese law regarding technical aids may evolve by 2030. Partner robots, intelligent powered wheelchairs, nursing robots, and other technologies are introduced as examples of rehabilitation engineering and assistive technology. We also discuss the volunteer activities of the Rehabilitation Engineering Society of Japan (RESJA) in response to the Asian tsunami disaster and the achievements of a group of students from a Japanese senior high school of industry. C1 Univ Pittsburgh, Dept Rehabil Sci & Technol, Sch Hlth & Rehabil Sci, Pittsburgh, PA 15260 USA. Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. RP Ohnabe, H (reprint author), Niigata Univ Hlth & Welf, Dept Prosthet & Orthot & Assist Technol, Sch Hlth Sci, 1398 Simami Cho, Niigata 9503198, Japan. NR 30 TC 5 Z9 5 U1 1 U2 2 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PD FAL PY 2006 VL 18 IS 2 BP 220 EP 232 PG 13 WC Rehabilitation SC Rehabilitation GA 109CJ UT WOS:000242285200010 PM 17236481 ER PT J AU Cooper, RA AF Cooper, Rory A. TI Recent advances in structural joints and repairs for composite materials. SO ASSISTIVE TECHNOLOGY LA English DT Book Review C1 Univ Pittsburgh, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Cooper, RA (reprint author), Univ Pittsburgh, Pittsburgh, PA USA. EM rcooper@pitt.edu NR 2 TC 0 Z9 0 U1 0 U2 2 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PD FAL PY 2006 VL 18 IS 2 BP 233 EP 234 PG 2 WC Rehabilitation SC Rehabilitation GA 109CJ UT WOS:000242285200011 ER PT J AU Fu, YC Luo, LH Luo, NL Garvey, WT AF Fu, Yuchang Luo, Liehong Luo, Nanlan Garvey, W. Timothy TI Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages SO ATHEROSCLEROSIS LA English DT Article DE lipid binding protein; oxLDL; macrophage; foam cell; atherosclerosis ID FATTY-ACID-BINDING; LOW-DENSITY-LIPOPROTEIN; PPAR-GAMMA; OXIDIZED LDL; CHOLESTEROL EFFLUX; FOAM CELLS; ATHEROSCLEROSIS; RECEPTOR; OXIDATION; PATHWAY AB The critical initiating event in atherogenesis involves the invasion of monocytes through the endothelial wall of arteries, and their transformation from macrophages into foam cells. Human THP-1 monocytic cells can be induced to differentiate into macrophages by phorbol myristate acetate (PMA) treatment, and can then be converted into foam cells by exposure to oxidized low-density lipoprotein (oxLDL). We previously reported that adipocyte lipid binding protein (ALBP/aP2) is a gene that is highly up-regulated in foam cells in response to oxLDL. Here, we showed that overexpression of the ALBP gene using a lentiviral construct in macrophage foam cells enhanced the accumulations of cholesterol and triglyceride, probably due to an increased expression of the scavenger receptor type AI (SR-AI), which plays an important role in cell lipid metabolism. Moreover, we determined that the expression of acyl-coenzyme A: cholesterol-acyltransferase 1 (ACAT1) gene was up-regulated by the overexpression of ALBP gene, and on the other hand, the ATP-binding cassette A1 (ABCA1) gene and hormone sensitive lipase (HSL) gene, which mediate separately cholesterol efflux and cholesterol ester hydrolysis in the macrophage cells, were down-regulated by the overexpression of ALBP gene in these cells. Finally, our data indicated that oxLDL regulates expression of ALBP related to two peroxisome proliferator-responsive elements (PPREs) which are located in ALBP promoter region. These results have determined that ALBP gene expression accelerates cholesterol and triglyceride accumulation in macrophage foam cells and affects some key gene expression for lipid metabolism, suggesting some pivotal roles of ALBP in lipid metabolism for macrophage foam cell formation. (c) 2005 Elsevier Ireland Ltd. All rights reserved. C1 Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Fu, YC (reprint author), Univ Alabama, Dept Nutr Sci, 1676 Univ Blvd, Birmingham, AL 35294 USA. EM yfu@uab.edu FU NCRR NIH HHS [P20 RR16434]; NHLBI NIH HHS [P01-HL55782]; NIDDK NIH HHS [DK38764] NR 37 TC 33 Z9 44 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD SEP PY 2006 VL 188 IS 1 BP 102 EP 111 DI 10.1016/j.atherosclerosis.2005.10.041 PG 10 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 079LP UT WOS:000240178200013 PM 16313911 ER PT J AU Fried-Oken, M Fox, L Rau, MT Tullman, J Baker, G Hindal, M Wile, N Lou, JS AF Fried-Oken, Melanie Fox, Lynn Rau, Marie T. Tullman, Jill Baker, Glory Hindal, Mary Wile, Nancy Lou, Jau-Shin TI Purposes of AAC device use for persons with ALS as reported by caregivers SO AUGMENTATIVE AND ALTERNATIVE COMMUNICATION LA English DT Article DE augmentative and alternative communication; amyotrophic lateral sclerosis; communication purposes; caregivers ID QUALITY-OF-LIFE AB Thirty-four informal caregivers who support 26 persons with ALS reported on AAC technology use. Each caregiver completed the Communication Device Use Checklist, a survey tool developed for this study based on Light's (1988) classification of the purposes of social interaction (Augmentative and Alternative Communication, 4, 66-82). The checklist includes 17 purposes of communication and asks participants to judge importance, mode, and frequency of use for each purpose. Results show that the three communication purposes used most frequently and valued as important by caregivers involve regulating the behavior of others for basic needs and wants ( getting needs met; giving instructions or directions to others; and clarifying needs). Consistent reports of use and frequency for the purposes of staying connected ( social closeness) and discussing important issues ( information transfer) indicate that AAC technology can assist the dyad in maintaining previous relationships. The face-to-face spontaneous conversation mode is used most frequently, despite the slow rate of production, the lack of permanence, and the demands on conversational partners during message generation. Clinical and research implications are discussed. C1 Oregon Hlth & Sci Univ, Oregon Inst Disabil & Dev, Portland, OR 97207 USA. Portland State Univ, Portland, OR 97207 USA. Portland VA Med Ctr, Portland, OR USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. RP Fried-Oken, M (reprint author), Oregon Hlth & Sci Univ, Oregon Inst Disabil & Dev, POB 574, Portland, OR 97207 USA. EM friedm@ohsu.edu FU NICHD NIH HHS [R24HD39629] NR 23 TC 22 Z9 22 U1 1 U2 11 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0743-4618 EI 1477-3848 J9 AUGMENT ALTERN COMM JI Augment. Altern. Commun. PD SEP PY 2006 VL 22 IS 3 BP 209 EP 221 DI 10.1080/07434610600650276 PG 13 WC Audiology & Speech-Language Pathology; Rehabilitation SC Audiology & Speech-Language Pathology; Rehabilitation GA 098AO UT WOS:000241492300005 PM 17114164 ER PT J AU Kulich, SM Horbinski, C Chu, CT AF Kulich, Scott M. Horbinski, Craig Chu, Charleen T. TI Characterization of 6-OHDA-elicited superoxide in cytotoxicity SO BRAIN PATHOLOGY LA English DT Meeting Abstract CT 16th International Congress of Neuropathology CY SEP 10-15, 2006 CL San Francisco, CA C1 Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1015-6305 J9 BRAIN PATHOL JI Brain Pathol. PD SEP PY 2006 VL 16 SU 1 MA 140 BP S64 EP S64 PG 1 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 076EA UT WOS:000239938600141 ER PT J AU Shurin, MR Shurin, GV Lokshin, A Yurkovetsky, ZR Gutkin, DW Chatta, G Zhong, H Han, BH Ferris, RL AF Shurin, Michael R. Shurin, Galina V. Lokshin, Anna Yurkovetsky, Zoya R. Gutkin, Dmitry W. Chatta, Gurkamal Zhong, Hua Han, Baohui Ferris, Robert L. TI Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? SO CANCER AND METASTASIS REVIEWS LA English DT Review DE intratumoral cytokines; chemokines; growth factors; dendritic cells; immunosuppression ID ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; ANTIGEN-PRESENTING CELLS; CD4(+) T-CELLS; CHEMOATTRACTANT PROTEIN-1 EXPRESSION; METASTATIC CANCER-PATIENTS; CHEMOKINE RECEPTOR CXCR4; CYTOKINE MESSENGER-RNA; DRAINING LYMPH-NODES AB The tumor microenvironment consists of a variable combination of tumor cells, stromal fibroblasts, endothelial cells and infiltrating leukocytes, such as macrophages, T lymphocytes, and dendritic cells. A variety of cytokines, chemokines and growth factors are produced in the local tumor environment by different cells accounting for a complex cell interaction and regulation of differentiation, activation, function and survival of multiple cell types. The interaction between cytokines, chemokines, growth factors and their receptors forms a comprehensive network at the tumor site, which is primary responsible for overall tumor progression and spreading or induction of antitumor immune responses and tumor rejection. Although the general thought is that dendritic cells are among the first cells migrating to the tumor site and recognizing tumor cells for the induction of specific antitumor immunity, the clinical relevance of dendritic cells at the site of the tumor remains a matter of debate regarding their role in the generation of successful antitumor immune responses in human cancers. While several lines of evidence suggest that intratumoral dendritic cells play an important role in antitumor immune responses, understanding the mechanisms of dendritic cell/tumor cell interaction and modulation of activity and function of different dendritic cell subtypes at the tumor site is incomplete. This review is limited to discussing the role of intratumoral cytokine network in the understanding immunobiology of tumor-associated dendritic cells, which seems to possess different regulatory functions at the tumor site. C1 Shanghai Chest Hosp, Shanghai, Peoples R China. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh Med Ctr, Dept Otolaryngol, Pittsburgh, PA USA. Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. RP Shurin, MR (reprint author), 5725 CHP MT,200 Lothrop St, Pittsburgh, PA 15213 USA. EM shurinmr@upmc.edu FU NCI NIH HHS [1R01 CA115902, 2R01 CA084270] NR 254 TC 73 Z9 88 U1 0 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0167-7659 J9 CANCER METAST REV JI Cancer Metastasis Rev. PD SEP PY 2006 VL 25 IS 3 BP 333 EP 356 DI 10.1007/s10555-006-9010-6 PG 24 WC Oncology SC Oncology GA 114HK UT WOS:000242657100006 PM 17029028 ER PT J AU Wang, JH Cai, Y Ren, CX Ittmann, M AF Wang, Jianghua Cai, Yi Ren, Chengxi Ittmann, Mchael TI Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer SO CANCER RESEARCH LA English DT Article ID RADICAL PROSTATECTOMY; SERINE-PROTEASE; GENE; PROGRESSION AB Recent studies have reported that the majority of prostate cancers express fusion genes in which the 5' region of the androgen-regulated TMPRSS2 gene is fused to an ETS family transcription factor, most commonly the ERG gene. We have characterized in detail the expression of TMPRSS2/ERG fusion mRNAs and correlated the isoforms expressed and expression levels with clinical outcome in cancers from men undergoing radical prostatectomy. Overall, 59% of clinically localized prostate cancers express the TMPRSS2/ERG fusion gene, confirming the initial observations of high frequency expression of this fusion mRNA in prostate cancer. There was significant variation in the alternatively spliced isoforms expressed in different cancers. Expression of an isoform, in which the native ATG in exon 2 of the TMPRSS2 gene is in frame with exon 4 of the ERG gene, was associated with clinical and pathologic variables of aggressive disease. Expression of other isoforms, in which the native ERG ATG in exon 3 was the first in-frame ATG, was associated with seminal vesicle invasion, which is correlated with poor outcome following radical prostatectomy. Cancers not expressing these isoforms tended to express higher levels of fusion mRNAs, and in this group, higher expression levels of fusion mRNA were present in cancers with early prostate-specific antigen recurrence. Thus, both the isoforms of TMPRSS2/ERG fusions expressed and expression level may affect prostate cancer progression. C1 Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol, 1 Baylor Pl, Houston, TX 77030 USA. EM mittmann@bcm.tme.edu FU NCI NIH HHS [P50CA058204] NR 16 TC 251 Z9 261 U1 2 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD SEP 1 PY 2006 VL 66 IS 17 BP 8347 EP 8351 DI 10.1158/0008-5472.CAN-06-1966 PG 5 WC Oncology SC Oncology GA 081PL UT WOS:000240329400006 PM 16951141 ER PT J AU Huang, Y Wright, CD Merkwan, C Baye, NL Liang, QR Simpson, PC O'Connell, TD AF Huang, Yuan Wright, Casey D. Merkwan, Chastity Baye, Nichole L. Liang, Qiangrong Simpson, Paul C. O'Connell, Timothy D. TI An alpha 1A-adrenergic-ERK signaling pathway mediates survival signaling in cardiac myocytes SO CIRCULATION RESEARCH LA English DT Meeting Abstract CT 3rd Annual Symposium of the American-Heart-Association-Council on Basis Cardiovascular Sciences CY JUL 31-AUG 03, 2006 CL Keystone, CO SP Amer Heart Assoc Council Basic Cardiovasc Sci, AHA Interdisciplinary Working Grp Funct Genom & Translat Biol, Natl Heart, Lung & Blood Inst C1 S Dakota Hlth Rsch Fdn, Sioux Falls, SD USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7330 J9 CIRC RES JI Circ.Res. PD SEP 1 PY 2006 VL 99 IS 5 BP E25 EP E25 PG 1 WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Hematology GA 079WY UT WOS:000240209800052 ER PT J AU Franco, V Chen, YF Feng, JA Li, P Wang, D Hasan, E Oparil, S Perry, GJ AF Franco, Veronica Chen, Yiu-Fai Feng, Ji A. Li, Peng Wang, Dajun Hasan, Erum Oparil, Suzanne Perry, Gilbert J. TI Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY LA English DT Article DE aldosterone; atrial natriuretic peptide; collagen; extracellular matrix; mineralocorticoid receptor antagonist ID GROWTH-FACTOR-BETA; HEART-FAILURE; ALDOSTERONE PRODUCTION; ESSENTIAL-HYPERTENSION; GENE-EXPRESSION; RAT-HEART; INDEPENDENT ENHANCEMENT; MYOCARDIAL-INFARCTION; ANGIOTENSIN-II; DEFICIENT MICE AB Atrial natriuretic peptide (ANP)-null mice (Nppa(-/-)) exhibit cardiac hypertrophy at baseline and adverse cardiac remodelling in response to transverse aortic constriction (TAC)-induced pressure overload stress. Previous studies have suggested that natriuretic peptides could potentially oppose mineralocorticoid signalling at several levels, including suppression of adrenal aldosterone production, inhibition of mineralocorticoid receptor (MR) activation or suppression of MR-mediated production of pro-inflammatory factors. Thus, we hypothesized that the MR blocker eplerenone would prevent the exaggerated left ventricular (LV) remodelling/fibrosis and dysfunction after TAC in Nppa(-/-). In the present study, Nppa(-/-) and wild-type Nppa(+/+) mice fed eplerenone- or vehicle (oatmeal)-supplemented chow since weaning were subjected to TAC or sham operation. The daily dose of eplerenone administered was approximately 200 mg/kg. At 1 week after TAC, LV size and function were evaluated by echocardiogram and LV cross-sections were stained with picrosirius red for collagen volume measurement. Total RNA was extracted from the LV for real-time polymerase chain reaction analysis of osteopontin. Eplerenone had no effect on baseline hypertrophy observed in sham-operated Nppa(-/-) compared with Nppa(+/+) mice. Eplerenone attenuated the TAC-induced increase in LV weight in both genotypes and completely prevented LV dilation, systolic dysfunction and interstitial collagen deposition seen in Nppa(-/-) mice after TAC. However, serum aldosterone levels were lower in Nppa(-/-) compared with Nppa(+/+) wild types. No interaction between eplerenone and genotype in osteopontin mRNA levels was observed. Eplerenone prevents adverse cardiac remodelling related to pressure overload in ANP-deficient mice, mainly due to an antifibrotic effect. The mechanism whereby ANP deficiency leads to excess hypertrophy, fibrosis and early failure following TAC is increased profibrotic signals resulting from excess or unopposed MR activation, rather than increased levels of aldosterone. C1 Univ Alabama, Div Cardiovasc Dis, Vasc Biol & Hypertens Program, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Franco, V (reprint author), Univ Alabama, Div Cardiovasc Dis, Vasc Biol & Hypertens Program, Zeigler Res Bldg 1024,703 19th St S, Birmingham, AL 35294 USA. EM vfranco@uab.edu RI Franco, Veronica/E-3080-2011 OI Li, Peng/0000-0002-9026-9999 FU NHLBI NIH HHS [HL07457, HL44195] NR 40 TC 8 Z9 9 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0305-1870 J9 CLIN EXP PHARMACOL P JI Clin. Exp. Pharmacol. Physiol. PD SEP PY 2006 VL 33 IS 9 BP 773 EP 779 DI 10.1111/j.1440-1681.2006.04434.x PG 7 WC Pharmacology & Pharmacy; Physiology SC Pharmacology & Pharmacy; Physiology GA 072FM UT WOS:000239659300002 PM 16922805 ER PT J AU Fujitani, S Yu, VL AF Fujitani, Shigeki Yu, Victor L. TI Quantitative cultures for diagnosing ventilator-associated pneumonia: A critique SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Symposium on Serious Infections in the Intensive Care Unit - Pseudomonas Aeruginosa and Acinetobacter Baumannii CY MAY, 2004 CL Univ Pittsburgh Med Ctr, Pittsburg, PA HO Univ Pittsburgh Med Ctr ID PROTECTED SPECIMEN BRUSH; TELESCOPING PLUGGED CATHETERS; PERIPHERAL-BLOOD CULTURES; BRONCHOALVEOLAR LAVAGE; NOSOCOMIAL PNEUMONIA; ENDOTRACHEAL ASPIRATION; BACTERIAL PNEUMONIA; BRONCHOPNEUMONIA; POSITIVITY; ACCURACY AB The diagnosis of ventilator-associated pneumonia has been clouded by uncertainty, because a reference standard has never been established. The use of invasive procedures to obtain respiratory tract samples for culture, with quantitation of the bacteria isolated, has been the approach most commonly advocated. Quantitation of bacteria from lower respiratory tract specimens can be used to distinguish colonization from infection. We review the invasive procedures (bronchoalveolar lavage, protected specimen brushing, nonbronchoscopic bronchoalveolar lavage, and blinded bronchial sampling), the methods of quantitation used, the types of catheters used, the sample collection methods, and the criteria used as cutoffs for the quantitative cultures. Quantitation of lower respiratory tract samples is inherently unstable from a mathematical perspective, given the variability in the volume of fluid instilled and reaspirated and the magnitude and complexity of the area being sampled. We also briefly review the use of quantitation for bacterial infections other than pneumonia, including urinary tract infection and catheter-related bacteremia. The variability in both the methods and reference criteria in the studies reviewed show that the quantitation approach is neither standardized nor evidence based. C1 Vet Adm Med Ctr, Infect Dis Sect, Div Infect Dis, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Pittsburgh, PA USA. W Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA. RP Yu, VL (reprint author), Vet Adm Med Ctr, Infect Dis Sect, Div Infect Dis, Univ Dr C, Pittsburgh, PA 15240 USA. EM vly@pitt.edu NR 51 TC 19 Z9 19 U1 1 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2006 VL 43 SU 2 BP S106 EP S113 DI 10.1086/504488 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 071TZ UT WOS:000239627100012 PM 16894512 ER PT J AU Newsome, BB McClellan, WM Coffey, CS Allison, JJ Kiefe, CI Warnock, DG AF Newsome, Britt B. McClellan, William M. Coffey, Christopher S. Allison, Jeroan J. Kiefe, Catarina I. Warnock, David G. TI Survival advantage of black patients with kidney disease after acute myocardial infarction SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article; Proceedings Paper CT Southern Regional Meeting for the Society-for-Clinical-Investigation CY 2005 CL New Orleans, LA SP Soc Clin Invest ID STAGE RENAL-DISEASE; GLOMERULAR-FILTRATION-RATE; COOPERATIVE CARDIOVASCULAR PROJECT; NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; POTENTIAL EXPLANATORY FACTORS; CORONARY HEART-DISEASE; QUALITY-OF-CARE; UNITED-STATES; RACIAL-DIFFERENCES AB Black individuals have a disproportionate incidence of ESRD when compared with white individuals, and among patients with ESRD, black patients experience better survival. The aim of this analysis is to assess, in a nationally representative sample of patients with cardiovascular disease, ethnic differences in survival among predialysis patients with kidney disease. A retrospective cohort analysis was conducted of Cooperative Cardiovascular Project data of Medicare patients who were aged > 65 yr and admitted for incident acute myocardial infarction and had 3 yr of mortality follow-up. Cox regression models and Kaplan Meier estimates were performed to examine differences in survival between black and white patients stratified by severity of kidney disease. Of 57,942 patients, 7.3% were black. Black patients were younger and more likely to be female and were less likely to have decreased kidney function. A significant interaction between race and kidney function existed with respect to mortality among patients who survived to discharge. The adjusted hazard ratios for death, black compared with white patients, were 1.00 (95% confidence interval 0.90 to 1.11) among patients with a GFR >= 60 ml/min per 1.73 m(2) and decreased monotonically among patients with lower GFR to 0.79 (95% confidence interval 0.61 to 0.97) among patients with a GFR 15 to 29 ml/min per 1.73 m(2). Among patients with incident acute myocardial infarction, black patients with more severe kidney disease, when compared with their white counterparts, experience better survival. Further investigation into the reasons for ethnic differences in survival and progression of kidney disease is warranted. C1 Univ Alabama, Ctr Outcomes Effect Res & Educ, Birmingham, AL USA. Univ Alabama, Div Prevent Med, Birmingham, AL USA. Univ Alabama, Div Renal Outcomes Res & Epidemiol Sect, Birmingham, AL USA. Univ Alabama, Div Nephrol, Birmingham, AL USA. Univ Alabama, Div Gen Internal Med, Dept Med, Birmingham, AL USA. Univ Alabama, Dept Biostat, Sch Publ Hlth, Birmingham, AL 35294 USA. Univ Alabama, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. Emory Univ, Sch Med, Dept Med, Div Renal, Atlanta, GA 30322 USA. RP Newsome, BB (reprint author), 1530 3rd Ave S,Mt 401E2, Birmingham, AL 35294 USA. EM bnewsome@uab.edu OI Allison, Jeroan/0000-0003-4472-2112 NR 41 TC 23 Z9 23 U1 0 U2 2 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD SEP PY 2006 VL 1 IS 5 BP 993 EP 999 DI 10.2215/CJN.01251005 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 107LL UT WOS:000242173000016 PM 17699318 ER PT J AU Chertow, GM Palevsky, PM Greene, T AF Chertow, Glenn M. Palevsky, Paul M. Greene, Thomas TI Studying the prevention of acute kidney injury: Lessons from an 18th-century mathematician SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article; Proceedings Paper CT 38th Annual Meeting of the American-Society-of-Nephrology CY NOV 08-13, 2005 CL Philadelphia, PA SP Amer Soc Nephrol ID ACUTE-RENAL-FAILURE; RANDOMIZED CONTROLLED-TRIAL; INDUCED NEPHROPATHY; MORTALITY; ACETYLCYSTEINE; INSUFFICIENCY; ANGIOGRAPHY; COSTS C1 Univ Calif San Francisco, Div Nephrol, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Div Nephrol, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA. RP Chertow, GM (reprint author), Univ Calif San Francisco, Dept Med Res, Laurel Heights Suite 430,3333 Calif St, San Francisco, CA 94118 USA. EM chertowg@medicine.ucsf.edu NR 15 TC 26 Z9 26 U1 0 U2 0 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD SEP PY 2006 VL 1 IS 5 BP 1124 EP 1127 DI 10.2215/CJN.01200406 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 107LL UT WOS:000242173000033 PM 17699335 ER PT J AU Dransfield, MT Bailey, WC AF Dransfield, Mark T. Bailey, William C. TI COPD: Racial disparities in susceptibility, treatment, and outcomes SO CLINICS IN CHEST MEDICINE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; HOME-OXYGEN-THERAPY; STAGE LUNG-CANCER; GENDER-DIFFERENCES; CHRONIC-BRONCHITIS; AFRICAN-AMERICANS; CIGARETTE-SMOKING; UNITED-STATES; MORTALITY; HEALTH AB Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States and mortality continues to increase particularly among African Americans. Although this increase may be caused by changing smoking habits, some studies suggest that African Americans may be more susceptible to tobacco smoke than whites. Unlike other respiratory diseases for which there are significant published data on racial and ethnic disparities in disease outcomes, such information is notably lacking in the COPD literature. This article examines the available data concerning racial disparities in COPD susceptibility and care. C1 Birmingham VA Med Ctr, Pulm Sect, Birmingham, AL 35294 USA. Univ Alabama, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. RP Dransfield, MT (reprint author), Birmingham VA Med Ctr, Pulm Sect, Birmingham, AL 35294 USA. EM mdransfield99@msn.com NR 50 TC 36 Z9 38 U1 2 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-5231 J9 CLIN CHEST MED JI Clin. Chest Med. PD SEP PY 2006 VL 27 IS 3 BP 463 EP + DI 10.1016/j.ccm.2006.04.005 PG 10 WC Respiratory System SC Respiratory System GA 082WK UT WOS:000240417700009 PM 16880056 ER PT J AU Pandol, SJ AF Pandol, Stephen J. TI Acute pancreatitis SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Article DE enteral nutrition; necrosis; pancreatitis; trypsin; unfolded protein response ID NECROTIZING PANCREATITIS; ZYMOGEN ACTIVATION; N-ACETYLCYSTEINE; ENDOPLASMIC-RETICULUM; ACINAR-CELLS; LIVER-INJURY; SUBSTANCE-P; MICE; DECREASES; SEVERITY AB Purpose of review This review presents advances in our understanding of the pathobiologic responses of acute pancreatitis from studies using animal models of experimental pancreatitis as well as results of key clinical trials and observations. Recent findings The reports during the past year show significant advances in our understanding of the pathobiology of acute pancreatitis. In particular, there are findings presented that are relevant to our further understanding of pancreatic intracellular digestive enzyme activation; the pancreatic inflammatory response; and cell death responses such as necrosis and apoptosis. Other reports add to understanding of the control of microcirculatory disturbances in acute pancreatitis, and of the role of the pancreatic neural system in regulating the microcirculation as well as the pain associated with the disorder. Finally, there are clinical trials showing benefits of enteral feeding on outcome of acute pancreatitis as well as the finding that diclofenac prevents endoscopic retrograde cholangiopancreatography-induced pancreatitis. Summary Our understanding of the mechanistic processes that mediate the pathobiologic responses of pancreatitis is rapidly evolving. In addition, we now have initial evidence for potential treatment strategies for this disorder. Testing treatment strategies will lead to improved therapies and outcomes for patients with acute pancreatitis. C1 VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA. RP Pandol, SJ (reprint author), VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Bldg 258 Room 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Stephen.Pandol@med.va.gov NR 42 TC 29 Z9 31 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0267-1379 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD SEP PY 2006 VL 22 IS 5 BP 481 EP 486 DI 10.1097/01.mog.0000239861.89209.5f PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 080XL UT WOS:000240281700002 PM 16891878 ER PT J AU James, JA Harley, JB Scofield, RH AF James, Judith A. Harley, John B. Scofield, R. Hal TI Epstein-Barr virus and systemic lupus erythematosus SO CURRENT OPINION IN RHEUMATOLOGY LA English DT Review DE environmental factors; Epstein-Barr virus; etiology; systemic lupus erythematosus ID ANTI-SM ANTIBODIES; NUCLEAR ANTIGEN-1; HEMOPHAGOCYTIC SYNDROME; COMPLEMENT RECEPTOR-2; RHEUMATOID-ARTHRITIS; PEPTIDE IMMUNIZATION; HUMORAL AUTOIMMUNITY; ADULT PATIENTS; EPITOPE; INFECTION AB Purpose of review Systemic lupus erythematosus is a complex human disease likely influenced by a compilation of necessary, but not individually sufficient, features. Although many genetic and environmental factors are associated, this review will focus on the evolving evidence for key Epstein-Barr virus specific roles. Recent findings Recent studies have shown additional molecular mimicry mechanisms between early events in lupus autoimmunity and specific Epstein-Barr virus responses. in addition, several recent papers have demonstrated increased Epstein-Barr viral load, increased numbers of latently infected peripheral B cells, impaired functional T cell responses, and association of the presence of Epstein-Barr virus DNA in systemic lupus erythematosus patients compared with controls. Additional work has continued to show association of various aspects of Epstein-Barr virus serology with systemic lupus erythematosus and a recent paper outlines differences in the pediatric systemic lupus erythematosus humoral immune response to Epstein-Barr virus nuclear antigen-1 compared with matched controls. Summary This review will briefly outline the recent advances that show serologic, DNA, gene expression, viral load, T cell responses, humoral fine specificity, and molecular mimicry evidence for differences between systemic lupus erythematosus patients and controls and the impact that these findings have on understanding the role of Epstein-Barr virus in systemic lupus. C1 Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA. Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP James, JA (reprint author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM jamesj@omrf.ouhsc.edu FU NCRR NIH HHS [RR 020143, RR 15577]; NIAID NIH HHS [AI 031584, AI 053747, AI 062629]; NIAMS NIH HHS [AR 48204, AR 48940, AR 14467, AR 48045, AR 45451, AR 49084, AR 053734] NR 55 TC 56 Z9 57 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8711 J9 CURR OPIN RHEUMATOL JI CURR. OPIN. RHEUMATOL. PD SEP PY 2006 VL 18 IS 5 BP 462 EP 467 DI 10.1097/01.bor.0000240355.37927.94 PG 6 WC Rheumatology SC Rheumatology GA 086DI UT WOS:000240652900004 PM 16896283 ER PT J AU Dall'Era, M Wofsy, D AF Dall'Era, Maria Wofsy, David TI Clinical trial design in systemic lupus erythematosus SO CURRENT OPINION IN RHEUMATOLOGY LA English DT Review DE clinical trial design; systemic lupus erythematosus; therapeutic agents ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; RECOMMENDATIONS; QUALITY AB Purpose of review The purpose of this review is to discuss the challenges inherent in the design of clinical trials for patients with systemic lupus erythematosus. Recent findings Recent years have witnessed a renewed interest in the conduct of systemic lupus erythematosus clinical trials. Three key design decisions play particularly critical roles in determining the fate of these trials: selection of the study, population from among patients with very heterogeneous disease manifestations; selection of the treatment and control regimens; and selection of the primary endpoint. Four recent randomized, controlled trials dealt with these decisions in the context of a variety of interventions, including new biologic agents, hormonal therapies, and anti-metabolites. These trials are informative about the implications of each approach. Summary Systemic lupus erythematosus investigators are faced with substantial trial design challenges because of the inherently complex nature of this disease. The hope is that lessons learned from prior and ongoing trials will inform future trial design such that the efficacy of new agents can be determined and new therapies will become available for patients with SLE. C1 Univ Calif San Francisco, Div Rheumatol, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Wofsy, D (reprint author), Univ Calif San Francisco, Div Rheumatol, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM wofsyd@medsch.ucsf.edu NR 7 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8711 J9 CURR OPIN RHEUMATOL JI CURR. OPIN. RHEUMATOL. PD SEP PY 2006 VL 18 IS 5 BP 476 EP 480 DI 10.1097/01.bor.0000240357.22680.63 PG 5 WC Rheumatology SC Rheumatology GA 086DI UT WOS:000240652900006 PM 16896285 ER PT J AU Carr, DB Heckbert, SR Utzschneher, KM Boyko, EJ Hull, RL Fujimoto, WY Tong, J Kahn, SE Wallace, TM Kodama, K Shofer, JB AF Carr, Darcy B. Heckbert, Susan R. Utzschneher, Kristina M. Boyko, Edward J. Hull, Rebecca L. Fujimoto, Wilfred Y. Tong, Jenny Kahn, Steven E. Wallace, Tara M. Kodama, Keiichi Shofer, Jane B. CA Amer Diabet Assoc GENNID Study Grp TI Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes SO DIABETES CARE LA English DT Article ID CORONARY-HEART-DISEASE; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; LIFE-STYLE; MORTALITY; PREVENTION; PREVALENCE; METABOLISM; ADULTS; VASODILATATION AB OBJECTIVE - We sought to determine whether a history of gestational diabetes mellitus (GDM) further increases the risk of cardiovascular disease (CVD) in parous women with first-degree relatives with type 2 diabetes. RESEARCH DESIGN AND METHODS - Women with (n = 332) and without (n = 663) a history of GDM were compared regarding 1) the revised National Cholesterol Education Program Adult Treatment Panel III metabolic syndrome criteria, 2) the prevalence of type 2 diabetes, and 3) self-reported CVD. RESULTS -' Women with prior GDM were younger (48.6 +/- 0.7 vs. 52.4 +/- 0.6 years [means - SE]; P < 0.001) and less likely to be postmenopausal (48.3 vs. 57.9%; P < 0.005). Although both groups were obese (BMI 34.4 +/- 1.2 vs. 33.7 +/- 0.6 kg/m(2)), women with prior GDM were more likely to have metabolic syndrome (86.6 vs. 73.5%; P < 0.001) and type 2 diabetes (93.4% vs. 63.3%; P < 0.001). Moreover, they had a higher prevalence of CVD (15.5 vs. 12.4%; adjusted odds ratio 1.85 [95% CI 1.21-2.82]; P = 0.005) that occurred at a younger age (45.5 +/- 2.2 vs. 52.5 +/- 1.9 years; P = 0.02) and was independent of metabolic syndrome (1.74 [1.10-2.76]; P = 0.02) and type 2 diabetes (1.56 [1.002-2.43]; P < 0.05). CONCLUSIONS - Among women with a family history of type 2 diabetes, those with prior GDM were even more likely to not only have CVD risk factors, including metabolic syndrome and type 2 diabetes, but also to have experienced CVD events, which occurred at a younger age. Thus, women with both a family history of type 2 diabetes and personal history of GDM may be especially suitable for early interventions aimed at preventing or reducing their risk of CVD and diabetes. C1 Univ Washington, Dept Obstet & Gynecol, Div Maternal Fetal Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA. Univ Washington, Dept Rehabil Res & Dev, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Cardiovasc Res Unit, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. RP Carr, DB (reprint author), Univ Washington, Dept Obstet & Gynecol, Div Maternal Fetal Med, Box 356460, Seattle, WA 98195 USA. EM darcarr@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002; Hull, Rebecca/0000-0001-9690-4087; Boyko, Edward/0000-0002-3695-192X FU NCRR NIH HHS [RR 16066]; NIDDK NIH HHS [DK 02654, DK 17047] NR 36 TC 108 Z9 112 U1 0 U2 10 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD SEP PY 2006 VL 29 IS 9 BP 2078 EP 2083 DI 10.2337/dc05-2482 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 083LG UT WOS:000240456800014 PM 16936156 ER PT J AU Lipsky, BA AF Lipsky, Benjamin A. TI The Biogun: A novel way of eradicatin methicillin-resistant Staphylococcus aureus colonization in diabetic foot ulcers - Response to Dang et al. SO DIABETES CARE LA English DT Letter C1 VA Puget Sound HCS, Dept Med, Primary & Special Care Med Serv, Seattle, WA 98108 USA. Univ Washington, Sch Med, Seattle, WA 98195 USA. RP Lipsky, BA (reprint author), VA Puget Sound HCS, Dept Med, Primary & Special Care Med Serv, S-111-GIMC,1660 S Columbian Way, Seattle, WA 98108 USA. EM dblipsky@hotmail.com RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 4 TC 3 Z9 4 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD SEP PY 2006 VL 29 IS 9 BP 2181 EP 2181 DI 10.2337/dc06-1086 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 083LG UT WOS:000240456800038 PM 16936181 ER PT J AU Forooghian, F Sproule, M Westall, C Gordon, L Jirawuthiworavong, G Shimazaki, K O'Connor, P AF Forooghian, Farzin Sproule, Melanie Westall, Carol Gordon, Lynn Jirawuthiworavong, Guy Shimazaki, Kaori O'Connor, Paul TI Electroretinographic abnormalities in multiple sclerosis: possible role for retinal autoantibodies SO DOCUMENTA OPHTHALMOLOGICA LA English DT Article DE multiple sclerosis; retina autoantibodies; electroretinogram ID CANCER-ASSOCIATED RETINOPATHY; EXPERIMENTAL AUTOIMMUNE PANENCEPHALITIS; CYSTOID MACULAR EDEMA; RETINITIS-PIGMENTOSA; VITREOUS FLUOROPHOTOMETRY; FLASH ELECTRORETINOGRAM; DISEASE-ACTIVITY; LEWIS RAT; ANTIBODIES; BREAKDOWN AB Background Multiple sclerosis (MS) has been associated with inflammation of the uveal tract, suggesting an immunological link between the uvea and central nervous system (CNS) in this disease. The retina is embryologically derived from the CNS, and it is conceivable that retinal antigens may also be recognized by the immune system in MS. Electroretinographic abnormalities, as well as retinal autoantibodies, have previously been described in MS. We performed this study to further explore the possibility of retinal autoimmunity in MS. Methods Thirty-four patients with clinically definite MS and thirty-seven healthy controls were recruited. All patients and controls had standard electroretinographic (ERG) testing done, as well as a brightflash ERG protocol to isolate rod photoreceptor function. Patient and control sera were analyzed for the presence of antiretinal antibodies using Western blot techniques. Results We found statistically significant differences between MS patients and controls in four ERG parameters. In the MS group, implicit times of the rod-cone b-wave response, cone b-wave response, and rod photoreceptor response were increased. The amplitudes of the photopic oscillatory potentials were reduced in the MS group. Patients with the highest titres of retinal autoantibodies had delayed rod-cone b-wave implicit times and diminished photopic oscillatory potential amplitudes. Conclusions We report ERG evidence of retinal dysfunction in patients with MS. We also report the first use of the brightflash ERG protocol in MS, which demonstrated rod photoreceptor dysfunction. Patients with the highest antiretinal antibody titres had abnormal ERG recordings. Retinal autoimmunity is a possible explanation for these observed ERG abnormalities in MS patients. C1 Hosp Sick Children, Dept Ophthalmol, Toronto, ON M5G 1X8, Canada. Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst, Ophthalmol Sect, Los Angeles, CA USA. St Michaels Hosp, Toronto, ON M5B 1W8, Canada. Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada. Univ Toronto, Dept Neurol, Toronto, ON, Canada. RP Forooghian, F (reprint author), Hosp Sick Children, Dept Ophthalmol, Room 10128 Elm Wing,555 Univ Ave, Toronto, ON M5G 1X8, Canada. EM farzin.forooghian@utoronto.ca NR 37 TC 19 Z9 20 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0012-4486 J9 DOC OPHTHALMOL JI Doc. Ophthalmol. PD SEP PY 2006 VL 113 IS 2 BP 123 EP 132 DI 10.1007/s10633-006-9022-0 PG 10 WC Ophthalmology SC Ophthalmology GA 115GD UT WOS:000242721900006 PM 16972082 ER PT J AU Pletz, MWR Fugit, RV McGee, L Glasheen, JJ Keller, DL Welte, T Klugman, KP AF Pletz, Mathias W. R. Fugit, Randolph V. McGee, Lesley Glasheen, Jeffery J. Keller, Darcie L. Welte, Tobias Klugman, Keith P. TI Fluoroquinolone-resistant Streptococcus pneumoniae SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID QUINOLONE RESISTANCE; TOPOISOMERASE-IV; DNA GYRASE; INFECTIONS; MUTATION C1 Hannover Med Sch, Dept Resp Med, D-30625 Hannover, Germany. Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Univ Missouri, Sch Med, Kansas City, MO 64108 USA. Emory Univ, Sch Med, Atlanta, GA USA. RP Pletz, MWR (reprint author), Hannover Med Sch, Dept Resp Med, Carl Neuberg Str 1, D-30625 Hannover, Germany. EM pletz.mathias@mh-hannover.de RI Pletz, Mathias/C-6848-2009 NR 10 TC 10 Z9 14 U1 0 U2 0 PU CENTER DISEASE CONTROL PI ATLANTA PA ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2006 VL 12 IS 9 BP 1462 EP 1463 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 078DJ UT WOS:000240081400031 PM 17073107 ER PT J AU Kogai, T Taki, K Brent, GA AF Kogai, T. Taki, K. Brent, G. A. TI Enhancement of sodium/iodide symporter expression in thyroid and breast cancer SO ENDOCRINE-RELATED CANCER LA English DT Review ID SODIUM-IODIDE SYMPORTER; CARCINOMA CELL-LINES; PROTEIN-KINASE-A; TISSUE-SPECIFIC EXPRESSION; HUMAN CHORIONIC-GONADOTROPIN; 3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; HISTONE DEACETYLASE INHIBITOR; EXPERIMENTAL I-131 THERAPY; HUMAN NA+/I-SYMPORTER; RETINOID-X-RECEPTORS AB The sodium/iodide symporter (NIS) mediates iodide uptake in the thyroid gland and lactating breast. NIS mRNA and protein expression are detected in most thyroid cancer specimens, although functional iodide uptake is usually reduced resulting in the characteristic finding of a 'cold' or non-functioning lesion on a radioiodine image. Iodide uptake after thyroid stimulating hormone (TSH) stimulation, however, is sufficient in most differentiated thyroid cancer to utilize beta-emitting radioactive iodide for the treatment of residual and metastatic disease. Elevated serum TSH, achieved by thyroid hormone withdrawal in athyreotic patients or after recombinant human thyrotropin administration, directly stimulates NIS gene expression and/or NIS trafficking to the plasma membrane, increasing radioiodide uptake. Approximately 10-20% differentiated thyroid cancers, however, do not express the NIS gene despite TSH stimulation. These tumors are generally associated with a poor prognosis. Reduced NIS gene expression in thyroid cancer is likely due in part, to impaired trans-activation at the proximal promoter and/or the upstream enhancer. Basal NIS gene expression is detected in about 80% breast cancer specimens, but the fraction with functional iodide transport is relatively low. Lactogenic hormones and various, nuclear hormone receptor ligands increase iodide uptake in breast cancer cells in vitro, but TSH has no effect. A wide range of 'differentiation' agents have been utilized to stimulate NIS expression in thyroid and breast cancer using in vitro and in vivo models, and a few have been used in clinical studies. Retinoic acid has been used to stimulate NIS expression in both thyroid and breast cancer. There are similarities and differences in NIS gene regulation and expression in thyroid and breast cancer. The various agents used to enhance NIS expression, in thyroid and breast cancer will be reviewed with a focus on the mechanism of action. Agents that promote tumor differentiation, or directly stimulate NIS gene expression, may result in iodine concentration in 'scan-negative' thyroid cancer and some breast cancer. C1 Yamanashi Univ, Dept Med 3, Yamanashi 4093898, Japan. Univ Calif Los Angeles, David Geffen Sch Med, Mol Endocrinol Lab, VA Greater Los Angeles Healthcare Syst,Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Mol Endocrinol Lab, VA Greater Los Angeles Healthcare Syst,Dept Physi, Los Angeles, CA 90073 USA. RP Brent, GA (reprint author), Yamanashi Univ, Dept Med 3, Yamanashi 4093898, Japan. EM gbrent@ucla.edu FU NCI NIH HHS [R01 CA089364] NR 231 TC 105 Z9 113 U1 0 U2 5 PU SOC ENDOCRINOLOGY PI BRISTOL PA 22 APEX COURT, WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 1351-0088 J9 ENDOCR-RELAT CANCER JI Endocr.-Relat. Cancer PD SEP PY 2006 VL 13 IS 3 BP 797 EP 826 DI 10.1677/erc.1.01143 PG 30 WC Oncology; Endocrinology & Metabolism SC Oncology; Endocrinology & Metabolism GA 103YX UT WOS:000241924200009 PM 16954431 ER PT J AU Moore, K Roubideaux, Y Noonan, C Goldberg, J Shields, R Acton, K AF Moore, Kelly Roubideaux, Yvette Noonan, Carolyn Goldberg, Jack Shields, Ray Acton, Kelly TI Measuring the quality of diabetes care in urban and rural Indian health programs SO ETHNICITY & DISEASE LA English DT Article ID AMERICAN-INDIANS; ALASKA NATIVES AB Objective: The purpose of this study was to compare the quality of diabetes care provided to American Indians/Alaska Natives (AI/AN) by urban and rural Indian health programs. Design: Medical record review data collected by the Indian Health Service as part of the Diabetes Care and Outcomes Audit in 2002. Setting: Seventeen urban Indian health clinics and 225 rural Indian health programs. Patients: All urban AI/AN patients (n = 710) and random sample records of rural AI/AN patients (n = 1420). Main Outcomes Measures: Adherence to guidelines for process measures and intermediate outcomes of diabetes care. Results: Compared to the rural sample, urban patients were more likely to have received diabetes education during the prior year (P <= .05). Annual dental examinations were less common among urban patients than rural patients (19% vs 41%, P <= .001). Completion of laboratory testing and immunizations were similar in both groups. Adjusted mean levels for intermediate outcomes of diabetes care and the percentage achieving recommended levels varied slightly but were not statistically or clinically significant. Conclusions: Few differences in the quality of diabetes care were found between urban and rural Indian health sites. Differences in the receipt of dental examinations may reflect differences in resources and staffing between urban and rural settings. This study serves as a baseline for the assessment of ongoing interventions aimed at improving the quality of care. C1 IHS Div Diabet Treatment & Prevent, Albuquerque, NM USA. Univ Arizona, Coll Publ Hlth, Tucson, AZ USA. Univ Washington, Dept Gen Internal Med, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Vietnam Era Twin Registry, VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Moore, K (reprint author), 5300 Homestead Rd NE, Albuquerque, NM 87110 USA. EM kelly.moore@ihs.gov FU AHRQ HHS [P01 HS10854]; NIA NIH HHS [P30 AG15297]; NIMHD NIH HHS [P60 MD000507] NR 15 TC 7 Z9 7 U1 2 U2 3 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD FAL PY 2006 VL 16 IS 4 BP 772 EP 777 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 094KN UT WOS:000241238400004 PM 17061726 ER PT J AU Hematpour, K Bennett, CJ Rogers, D Head, CS AF Hematpour, Khashayar Bennett, Carol J. Rogers, David Head, Christian S. TI Supraclavicular lymph node: incidence of unsuspected metastatic prostate cancer SO EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY LA English DT Article DE supraclavicular lymph node; prostate cancer; metastasis ID NECK; HEAD AB An uncommon presentation of prostate carcinoma to the supraclavicular lymph nodes is herein reviewed. With prompt diagnosis and treatment, patient survival can be extended. A high index of suspicion is necessary to make the diagnosis. The clinical features of four cases involving metastatic prostate carcinoma will be discussed. C1 Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, Los Angeles, CA 90073 USA. Columbia Univ, Coll Phys & Surg, New York, NY 10025 USA. Greater Los Angeles VA Med Syst, Dept Urol, Los Angeles, CA USA. Greater Los Angeles VA Med Syst, Dept Pathol, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Otolaryngol, David Geffen Sch Med, Los Angeles, CA 90073 USA. RP Bennett, CJ (reprint author), Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, 11301 Wilshire Blvd,Mail Code 10 H2, Los Angeles, CA 90073 USA. EM kh2231@columbia.edu; carol.bennett@med.va.gov; david.rogers5@med.va.gov; chead@mednet.ucla.edu NR 7 TC 8 Z9 8 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0937-4477 J9 EUR ARCH OTO-RHINO-L JI Eur. Arch. Oto-Rhino-Laryn. PD SEP PY 2006 VL 263 IS 9 BP 872 EP 874 DI 10.1007/s00405-006-0066-2 PG 3 WC Otorhinolaryngology SC Otorhinolaryngology GA 067JC UT WOS:000239296900015 PM 16830117 ER PT J AU Zabagoitia, M Gage, B Juul-Moller, S Persson, M Labovitz, A Baruch, L Horrow, J AF Zabagoitia, M. Gage, B. Juul-Moller, S. Persson, M. Labovitz, A. Baruch, L. Horrow, J. TI Predictors of ischaemic stroke in anticoagulant-treated atrial fibrillation patients in the SPORTIF III and V trials SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. Washington Univ, Sch Med, St Louis, MO 63130 USA. Univ Hosp, Molndal, Sweden. AstraZeneca R&D Molndal, Molndal, Sweden. St Louis Univ Hosp, St Louis, MO 63110 USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. Drexel Univ, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1351-5101 J9 EUR J NEUROL JI Eur. J. Neurol. PD SEP PY 2006 VL 13 SU 2 BP 45 EP 45 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 084HE UT WOS:000240523200144 ER PT J AU Xu, RJ Jin, JF Hu, W Sun, W Bielawski, J Szulc, Z Taha, T Obeid, LM Mao, CG AF Xu, Ruijuan Jin, Junfei Hu, Wei Sun, Wei Bielawski, Jacek Szulc, Zdzislaw Taha, Tarek Obeid, Lina M. Mao, Cungui TI Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P SO FASEB JOURNAL LA English DT Article DE placenta; rate-limiting step; serum deprivation; S1P receptor; sphingolipid ID PROTEIN-COUPLED RECEPTORS; MOLECULAR-CLONING; NEUTRAL CERAMIDASE; FUNCTIONAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; OVARIAN-CANCER; EDG-1 FAMILY; GENE FAMILY; SPHINGOSINE-1-PHOSPHATE AB Sphingosine-1-phosphate (S1P), a sphingolipid metabolite, promotes cell proliferation and survival whereas its precursor, sphingosine, has the opposite effects. However, much remains unknown about their regulation. Here we identify a novel human ceramidase (haCER2) that regulates the levels of both sphingosine and S1P by controlling the hydrolysis of ceramides. haCER2 is localized to the Golgi complex and is highly expressed in the placenta. High ectopic expression of haCER2 caused fragmentation of the Golgi complex and growth arrest in HeLa cells due to sphingosine accumulation. Low ectopic expression of haCER2 increased S1P without sphingosine accumulation, promoting cell proliferation in serum-free medium. This proliferative effect was suppressed by dimethylsphingosine, an inhibitor of the S1P formation, or by the RNA interference (RNAi) - mediated inhibition of S1P(1), a G-protein-coupled receptor for S1P. The RNAi-mediated down-regulation of haCER2 enhanced the serum deprivation-induced growth arrest and apoptosis of HeLa cells, which was inhibited by addition of exogenous S1P. Serum deprivation up-regulated both haCER2 mRNA and activity in HeLa cells. haCER2 mRNA is also up-regulated in some tumors. Taken together, these results suggest that haCER2 is important for the generation of S1P and S1P-mediated cell proliferation and survival, but that its overexpression may cause cell growth arrest due to an accumulation of sphingosine. - Xu, R., Jin, J., Hu, W., Sun, W., Bielawski, J., Szulc, Z., Taha, T., Obeid, L. M., Mao, C. Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA. RP Mao, CG (reprint author), 114 Doughty St,Rm 646,STB,POB 250779, Charleston, SC 29425 USA. EM maoc@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [R01 CA104834]; NCRR NIH HHS [P20RR017677] NR 48 TC 72 Z9 76 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD SEP PY 2006 VL 20 IS 11 BP 1813 EP 1825 DI 10.1096/fj.05-5689com PG 13 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 080RZ UT WOS:000240267000009 PM 16940153 ER PT J AU Wang, YM Qiao, M Mieyal, JJ Asmis, LM Asmis, R AF Wang, Yanmei Qiao, Mu Mieyal, John J. Asmis, Lars M. Asmis, Reto TI Molecular mechanism of glutathione-mediated protection from oxidized low-density lipoprotein-induced cell injury in human macrophages: Role of glutathione reductase and glutaredoxin SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE macrophage; atherosclerosis; cell death; glutathione; glutaredoxin; glutathione reductase ID MONOCYTE-DERIVED MACROPHAGES; ATHEROSCLEROTIC PLAQUES; LIPID HYDROPEROXIDE; OXIDATIVE INJURY; HUMAN ATHEROMA; APOPTOSIS; DEATH; IRON; TOXICITY; EXPRESSION AB Macrophage death is a hallmark of advanced atherosclerotic plaque, and oxidized low-density lipoprotein (OxLDL) found in these lesions is believed to contribute to macrophage injury. However, the underlying mechanisms of this phenomenon are only poorly understood. Here we show that in human monocyte-derived macrophages, OxLDL depleted intracellular glutathione (GSH) and inhibited glutathione reductase, resulting in a marked diminution of the glutathione/glutathione disulfide ratio. In the absence of OxLDL, an 80% depletion of intracellular GSH levels did not affect cell viability, but glutathione depletion dramatically increased OxLDL-induced cell death. Conversely, supplementation of intracellular GSH stores with glutathione diethyl ester substantially diminished OxLDL toxicity. OxLDL also promoted protein-S-glutatbionylation, which was increased in macrophages pretreated with the glutathione reductase inhibitor BCNU. Knockdown experiments with siRNA directed against glutathione reductase and glutaredoxin showed that both enzymes are essential for the protection of macrophages against OxLDL. Finally, the peroxyl-radical scavenger Trolox did not prevent GSH depletion but completely blocked OxLDL-induced protein-S-glutathionylation and cell death. These data suggest that OxLDL promotes ROS formation and protein-S-glutathionylation by a mechanism independent from its effect on GSH depletion. Neither mechanism was sufficient to induce macrophage injury, but when stimulated concurrently, these pathways promoted the accumulation of protein-glutathione mixed disulfides and cell death. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Div Nephrol, San Antonio, TX 78229 USA. Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40506 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA. Univ Zurich Hosp, Div Hematol, CH-8091 Zurich, Switzerland. RP Asmis, R (reprint author), Univ Texas, Hlth Sci Ctr, Div Nephrol, 7703 Floyd Curl Dr,MSC 7882, San Antonio, TX 78229 USA. EM asmis@uthscsa.edu FU NHLBI NIH HHS [HL-70963]; NIA NIH HHS [AG-024413] NR 39 TC 36 Z9 36 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD SEP 1 PY 2006 VL 41 IS 5 BP 775 EP 785 DI 10.1016/j.freeradbiomed.2006.05.029 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 079YK UT WOS:000240213600010 PM 16895798 ER PT J AU Ying, WH AF Ying, Weihai TI NAD(+) and NADH in cellular functions and cell death SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Review DE NAD(+); NADH; cell death; aging; mitochondria; calcium; review ID NICOTINAMIDE-ADENINE-DINUCLEOTIDE; DELETERIOUS NETWORK HYPOTHESIS; CYCLIC ADP-RIBOSE; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; MITOCHONDRIAL PERMEABILITY TRANSITION; DEPENDENT HISTONE DEACETYLASE; PERINATAL BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; DNA-DAMAGE; CEREBRAL-ISCHEMIA AB Increasing evidence has indicated that NAD(+) and NADH play critical roles not only in energy metabolism, but also in cell death and various cellular functions including regulation of calcium homeostasis and gene expression. It has also been indicated that NAD(+) and NADH are mediators of multiple major biological processes including aging. NAD(+) and NADH produce the biological effects by regulating numerous NAD(+)/NADH-dependent enzymes, including dehydrogenases, poly(ADP-ribose) polymerases, Sir2 family proteins (sirtuins), mono(ADP-ribosyl) transferases, and ADP-ribosyl cyclases. Of particular interest, NAD(+)-dependent generation of ADP-ribose, cyclic ADP-ribose and O-acetyl-ADP-ribose can mediate calcium homeostasis by affecting TRPM2 receptors and ryanodine receptors; and sirtuins and PARPs appear to play key roles in aging, cell death and a variety of cellular functions. It has also been indicated that NADH and NAD(+) can be transported across plasma membranes of cells, and that extracellular NAD(+) may be a new signaling molecule. Our latest studies have shown that intranasal NAD(+) administration can profoundly decrease ischemic brain damage. These new pieces of information have fundamentally changed our understanding about NAD(+) and NADH, suggesting novel paradigms about the metabolism and biological activities of NAD(+) and NADH. Based on this information, it is tempted to hypothesize that NAD(+) and NADH, together with ATP and Ca2+, may be four most fundamental components in life, which can significantly affect nearly all major biological processes. Future studies on NAD(+) and NADH may not only elucidate some fundamental mysteries in biology, but also provide novel insights for interfering aging and many disease processes. C1 San Francisco VA Med Ctr, Dept Neurol 127, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Ying, WH (reprint author), San Francisco VA Med Ctr, Dept Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA. EM Weihai.Ying@ucsf.edu NR 187 TC 103 Z9 108 U1 1 U2 30 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD SEP 1 PY 2006 VL 11 BP 3129 EP 3148 DI 10.2741/2038 PG 20 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 040ML UT WOS:000237382800097 PM 16720381 ER PT J AU Lugea, A Nan, L French, SW Bezerra, JA Gukovskaya, AS Pandol, SJ AF Lugea, Aurelia Nan, Li French, Samuel W. Bezerra, Jorge A. Gukovskaya, Anna S. Pandol, Stephen J. TI Pancreas recovery following cerulein-induced pancreatitis is impaired in plasminogen-deficient mice SO GASTROENTEROLOGY LA English DT Article ID ACUTE NECROTIZING PANCREATITIS; RENAL INTERSTITIAL FIBROSIS; INDUCED PULMONARY-FIBROSIS; KAPPA-B ACTIVATION; EXTRACELLULAR-MATRIX; STELLATE CELLS; LIVER-INJURY; CELLULAR-LOCALIZATION; FIBRINOLYTIC SYSTEM; IN-VITRO AB Background & AIMS: The plasminogen (plg) system participates in tissue repair in several organs, but its role in pancreas repair remains poorly characterized. To understand better the role of plg in pancreas recovery following injury, we examined the course of cerulein-induced pancreatitis in plg-deficient and -sufficient mice. Methods: Pancreatitis was induced by cerulein administration (50 mu g/kg, 7 intraperitoneal injections). Mice were killed either at the acute phase (7 hours after the first cerulein injection) or during recovery (at 2, 4, and 7 days). in pancreatic sections, we examined pancreatic morphology, trypsin activation, inflammatory cell infiltration, acinar cell death, cell proliferation, extracellular matrix deposition, activation of stellate cells (PSCs), and components of the plg and metalloproteinase systems. Results: In plg-sufficent mice, pancreatic plg levels and plasmin activity increased during the acute phase and remained elevated during recovery. Pancreatitis resolved in plg-sufficient mice within 7 days. Pancreas recovery involved reorganization of the parenchyma structure, removal of necrotic debris, cell proliferation, transient activation of PSCs, and moderate deposition of extracellular matrix proteins. Acute pancreatitis (7 hours) was indistinguishable between plg-deficient and -sufficient mice. In contrast, pancreas recovery was impaired in plg-deficient mice. Pig deficiency led to disorganized parenchyma, extensive acinar cell loss, poor removal of necrotic debris, reduced cell proliferation, and fibrosis. Fibrosis was characterized by deposition of collagens and fibronectin, persistent activation of PSCs, and up-regulation of pancreatic transforming growth factor beta 1. Conclusions: Plg/plasmin deficiency leads to features similar to those found in chronic pancreatitis such as parenchyma 1 atrophy and fibrosis. C1 Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, USC, Res Ctr Alcoholic Liver & Pancreat Dis, Los Angeles, CA 90073 USA. Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90509 USA. Univ Cincinnati, Childrens Hosp, Res Fdn, Cincinnati, OH USA. RP Lugea, A (reprint author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, USC, Res Ctr Alcoholic Liver & Pancreat Dis, Bldg 258,Room 339,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM alugea@ucla.edu FU NIAAA NIH HHS [R21 AA015781-01A1, R21AA15781-01A1, R21 AA015781, P50 AA011999]; PHS HHS [P50-A11999] NR 70 TC 25 Z9 25 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD SEP PY 2006 VL 131 IS 3 BP 885 EP 899 DI 10.1053/j.gastro.2006.06.023 PG 15 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 084VF UT WOS:000240561800026 PM 16952557 ER PT J AU Sonnenberg, A AF Sonnenberg, Anmon TI Is endoscopic screening before major surgical procedures warranted? SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID HELICOBACTER-PYLORI INFECTION; PREVALENCE AB Background: Gastroenterologists are frequently requested to perform endoscopic procedures to rule out cancer or other serious GI disease before major surgical operations. Objective: To assess whether such requests are warranted. Design: Cost benefit analysis by using decision tree and threshold analysis. Patients: Subjects scheduled for liver and kidney transplant or other major surgeries. Main Outcome Measurements: Costs of medical and surgical procedures. The threshold value is defined as the a priori probability for a GI diagnosis, where the benefit of endoscopy changes from unfavorable to favorable as the diagnostic probability increases. Results: For all types of organ transplants, the threshold probability for diagnosing a GI disease by endoscopy is lower than 1%. Such a low threshold suggests that if a disease cannot be ruled out with certainty before transplant operations or any other major surgical operation, endoscopic screening would be warranted. For lesser interventions, such as percutaneous transluminal coronary angioplasty and coronary bypass grafting, the threshold value varies between 3.2% and 6.5%, which suggests that endoscopic screening may be justified if there are sufficient grounds to suspect a comorbid medical condition that could compromise the success of the planned surgical intervention. Limitations: The model only considers procedure costs and assumes no endoscopic complications. Conclusions: Endoscopic screening before costly and invasive surgical or other medical interventions is justified. C1 Oregon Hlth Sci Univ, Div Gastroenterol, Portland VA Med Ctr, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Oregon Hlth Sci Univ, Div Gastroenterol, Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. NR 9 TC 2 Z9 2 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD SEP PY 2006 VL 64 IS 3 BP 375 EP 378 DI 10.1016/j.gie.2006.04.030 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 081GC UT WOS:000240304200013 PM 16923485 ER PT J AU Onitilo, AA Nietert, PJ Egede, LE AF Onitilo, Adedayo A. Nietert, Paul J. Egede, Leonard E. TI Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE depression; cancer; health survey; death; mood disorder ID NATIONAL DEATH INDEX; BREAST-CANCER; MAJOR DEPRESSION; DIAGNOSIS; DISEASE; WOMEN; SURVIVAL; RISK; CARCINOMA; SYMPTOMS AB Objective: The objective of this study was to compare the effect of depression on the risk of death in adults with and without cancer and by specific cancer site among those with cancer. Research Design and Methods: We analyzed data on 10,025 participants in the population-based National Health and Nutrition Examination Survey (NHANES) 1 Epidemiologic Follow-up Study. Four groups were created based on cancer and depression status in 1982: (a) no cancer, no depression (reference group; no CA, no DEP); (b) depression but no cancer (DEP, no CA); (c) cancer but no depression (CA, no DEP); and (d) cancer and depression (CA+DEP). Six CA sites were defined: lung, breast, gastrointestinal (GI), genitourinary (GU), skin and other. Cox proportional models were used to calculate adjusted hazard for death for each group compared with the reference group and by cancer site. Results: Over 8 years (78,433 person-years of follow-up), 1925 deaths were documented. The mortality rate per 1000 person-years of follow-up was highest in the CA+DEP group. Compared to the reference group, the hazard ratios (HRs) for all-cause mortality were as follows: CA, no DEP: 1.43 [95% confidence interval (95% CI)=1.23-1.67]; DEP, no CA: 1.44 (95% CI= 1.28-1.63); CA+DEP: 1.87 (95% CI=1.49-2.34). HRs for depression by site were as follows: lung: 1.30 (95% CI=0.49-3.99); breast: 1.27 (95% CI=0.58-2.79); GI: 1.47 (95% CI=0.58-3.75); GU: 0.93 (95% CI=0.50-1.74); skin: 1.07 (95% CI=0.67-1.69); other: 2.13 (95% CI=0.55-8.25). Conclusion: The coexistence of cancer and depression is associated with a significantly increased risk of death, and the effect of depression on the risk of death differs by cancer site. (c) 2006 Elsevier Inc. All rights reserved. C1 Marshfield Clin Wausau Ctr, Dept Hematol Oncol, Wausau, WI 54401 USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. Med Univ S Carolina, Div Gen Internal Med, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston VA TREP, Charleston, SC 29401 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Disparities Res, Charleston, SC 29425 USA. EM egedel@musc.edu OI Nietert, Paul/0000-0002-3933-4986 NR 59 TC 63 Z9 65 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD SEP-OCT PY 2006 VL 28 IS 5 BP 396 EP 402 DI 10.1016/j.genhosppsych.2006.05.006 PG 7 WC Psychiatry SC Psychiatry GA 086SO UT WOS:000240693500005 PM 16950374 ER PT J AU Roy-Byrne, PP Noonan, C Afari, N Buchwald, D Goldberg, J AF Roy-Byrne, Peter P. Noonan, Carolyn Afari, Niloofar Buchwald, Dedra Goldberg, Jack TI Is the association between posttraumatic stress disorder symptoms and poor health due to a common familial or genetic factor? SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE posttraumatic stress disorder; poor health; familial; genetic; twin ID PRIMARY-CARE PATIENTS; SELF-REPORTED HEALTH; ENVIRONMENTAL CONTRIBUTIONS; FUNCTIONAL IMPAIRMENT; ANXIETY DISORDERS; COSTS; WOMEN; TWIN; DEPRESSION; MORTALITY AB Objective: The objective of this study was to identify genetic, familial and environmental contributions to the association between posttraumatic stress disorder (PTSD) symptoms and poor health. Methods: A community sample of 1852 twin pairs was assessed for symptoms of PTSD [with the Impact of Events Scale (IES)] and self-reported global health status using a single five-level question. An ordinal logistic regression model estimated odds ratio/s (OR) for the association between PTSD and health status. Within-pair analysis assessed confounding by familial and genetic factors and adjusted for the possible confounding influence of age, sex, race, education and self-reported physician diagnosis of depression. Results: The IES was strongly and significantly associated with self-reported health [OR= 1.8; 95% confidence interval (95% CI)=1.5-2.2; highest quartile vs. lowest quartile]. This association remained significant in within-pair analysis (OR= 1.3; 95% CI= 1.0-1.7), but after further adjustment for sociodemographics and depression, it was no longer significant (P-trend=.17). Separate analysis by zygosity did not show differential effect in monozygotic or dizygotic pairs. Conclusion: These findings suggest that the association between PTSD symptoms and poor health is, in part, due to familial confounding and sociodemographic factors. Little evidence of confounding by genetic factors was found. These findings suggest that early prevention efforts would have the greatest potential for improving poor health in PTSD-prone patients, whereas later intervention efforts directed at treating PTSD may have a more limited impact on improving poor health. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Washington, Dept Psychiat & Behav Sci, Harborview Med Ctr, Seattle, WA 98104 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Vietnam Era Twin Registry, Seattle, WA USA. RP Roy-Byrne, PP (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Harborview Med Ctr, Seattle, WA 98104 USA. EM roybyrne@u.washington.edu FU NIAID NIH HHS [U19 AI038429, U19 AI038429-08]; NIAMS NIH HHS [R01 AR051524, R01 AR051524-02] NR 48 TC 4 Z9 4 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD SEP-OCT PY 2006 VL 28 IS 5 BP 408 EP 413 DI 10.1016/j.genhosppsych.2006.05.007 PG 6 WC Psychiatry SC Psychiatry GA 086SO UT WOS:000240693500007 PM 16950376 ER PT J AU Kay, DM Bird, TD Zabetian, CP Factor, SA Samii, A Higgins, DS Nutt, J Roberts, JW Griffith, A Leis, BC Montimurro, JS Philpott, S Payami, H AF Kay, Denise M. Bird, Tom D. Zabetian, Cyrus P. Factor, Stewart A. Samii, Ali Higgins, Donald S. Nutt, John Roberts, John W. Griffith, Alida Leis, Berta C. Montimurro, Jennifer S. Philpott, Sean Payami, Haydeh TI Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease SO GENETIC TESTING LA English DT Article ID AUTOSOMAL-DOMINANT PARKINSONISM; NORTH-AFRICAN FAMILIES; EARLY-ONSET; CLINICAL-DIAGNOSIS; ALZHEIMER-DISEASE; COMMON FOUNDER; GENE; ACCURACY; ASSOCIATION; FREQUENCY AB The G2019S mutation in the LRRK2 gene, the most common known cause of Parkinson's disease (PD), will soon be widely available as a molecular clinical test for PD. The objective of this study was to assess performance characteristics of G2019S as a clinical test for PD in the setting of typical movement disorder clinics in the United States. Subjects included 1518 sequentially recruited PD patients from seven movement disorder clinics in the United States, and 1733 unaffected subjects. All 3251 subjects were genotyped for the G2019S mutation using a TaqMan assay, and mutations were verified by direct sequencing. Test validity estimates were calculated using standard methods. A total of 20/1518 patients and 1/1733 controls carried the G2019S mutation. Specificity was 99.9% (95% CI, 99.6-100%), sensitivity was 1.3% (0.8-2.1%), and the positive likelihood ratio was 22.8. A positive family history of PD increased the positive likelihood ratio to 82.5. Information on gender, age at disease onset, or age at testing did not improve test performance. The gene test was highly accurate in classifying mutation carriers as PD, but it performed poorly in predicting the phenotype of non-mutation carriers. A G2019S molecular test for PD would be highly specific, technically simple, and inexpensive. Test interpretation is straightforward when used for diagnosis of symptomatic individuals, but is more complex for risk assessment and predictive testing in asymptomatic individuals. Test results can have psychological, social, and economical ramifications; thus, proper counseling is essential. C1 New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA. Univ Washington, Sch Med, Ctr Geriatr Res Educ & Clin, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. Albany Med Ctr, Parkinsons Dis & Movement Disorder Clin, Albany, NY USA. Univ Washington, Parkinsons Dis Res Educ & Clin Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Virginia Mason Med Ctr, Seattle, WA 98101 USA. Evergreen Hosp, Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. Alden March Bioeth Inst, Albany, NY USA. RP Payami, H (reprint author), New York State Dept Hlth, Wadsworth Ctr, POB 22002, Albany, NY 12201 USA. EM hpayami@wadsworth.org OI Kay, Denise/0000-0002-9928-2698 FU NIA NIH HHS [AG 08017, U24 AG021886]; NINDS NIH HHS [K08-NS044138, R01-NS36960] NR 42 TC 12 Z9 13 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1090-6576 J9 GENET TEST JI Genet. Test. PD SEP PY 2006 VL 10 IS 3 BP 221 EP 227 DI 10.1089/gte.2006.10.221 PG 7 WC Genetics & Heredity; Medicine, Research & Experimental SC Genetics & Heredity; Research & Experimental Medicine GA 094XI UT WOS:000241272100012 PM 17020475 ER PT J AU Yamaoka, Y AF Yamaoka, Y. TI Helicobacter pylori outer membrane proteins and gastric inflammation - Author's reply SO GUT LA English DT Letter ID OIPA C1 Michael E DeBakey Vet Affair Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. RP Yamaoka, Y (reprint author), Michael E DeBakey Vet Affair Med Ctr, Dept Med Gastroenterol, 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu NR 4 TC 1 Z9 2 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD SEP PY 2006 VL 55 IS 9 BP 1361 EP 1361 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 073DM UT WOS:000239723000027 ER PT J AU Deaton, C Kimble, LP Veledar, E Hartigan, P Boden, WE O'Rourke, RA Weintraub, WS AF Deaton, Christi Kimble, Laura P. Veledar, Emir Hartigan, Pamela Boden, William E. O'Rourke, Robert A. Weintraub, William S. TI The synergistic effect of heart disease and diabetes on self-management, symptoms, and health status SO HEART & LUNG LA English DT Article ID CORONARY-ARTERY DISEASE; QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE; CLINICAL-OUTCOMES; FUNCTIONAL STATUS; ANGINA-PECTORIS; MELLITUS; REVASCULARIZATION; IMPACT; BYPASS AB BACKGROUND: Coronary heart disease (CHD) and diabetes may have synergistic effects on symptoms, self-management, and general and cardiac-specific health status. PURPOSE: We compared symptom distress, self-management difficulties, and general and cardiac-specific health status in patients with CHD by the presence and severity of diabetes. METHODS: We performed a cross-sectional study of 1013 patients enrolled in the COURAGE trial, with the use of clinical data, the Symptom Distress Scale, the Self-Management Difficulties Scale, the Short-Form 36, and the Seattle Angina Questionnaire. RESULTS: Patients with diabetes and greater severity of diabetes had worse findings in symptom distress, self-management difficulties, and general and cardiac-specific health status than patients without diabetes. CONCLUSIONS: A robust effect of diabetes on symptom distress and self-management difficulties was found in patients with CHD. The results from the Seattle Angina Questionnaire illustrate difficulty in attributing physical limitations to specific symptoms or conditions, and show the experience of comorbid conditions to be synergistic. Clinicians' understanding of this synergy and integration of condition-specific care with general treatment and self-management practices are needed. C1 Univ Manchester, Sch Nursing Midwifery & Social Work, Manchester M13 9PL, Lancs, England. Emory Univ, Atlanta, GA 30322 USA. VA Connecticut Healthcare Syst, West Haven, CT USA. Yale Univ, New Haven, CT USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas San Antonio, San Antonio, TX 78285 USA. Christiana Care Hlth Syst, Newark, DE USA. RP Deaton, C (reprint author), Univ Manchester, Sch Nursing Midwifery & Social Work, Coupland 3,Coupland St, Manchester M13 9PL, Lancs, England. RI Deaton, Christi/F-6485-2010; Veledar, Emir/K-2808-2012 OI Veledar, Emir/0000-0002-3831-5433 NR 26 TC 5 Z9 5 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0147-9563 EI 1527-3288 J9 HEART LUNG JI Heart Lung PD SEP-OCT PY 2006 VL 35 IS 5 BP 315 EP 323 DI 10.1016/j.hrting.2006.05.005 PG 9 WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System SC Cardiovascular System & Cardiology; Nursing; Respiratory System GA 085XO UT WOS:000240637900003 PM 16963363 ER PT J AU Peery, JT Klute, GK Blevins, JJ Ledoux, WR AF Peery, Jeffrey T. Klute, Glenn K. Blevins, Joanna J. Ledoux, William R. TI A three-dimensional finite element model of the transibial residual limb and prosthetic socket to predict skin temperatures SO IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING LA English DT Article DE amputation; artificial limbs; biomechanics; heat transfer; prosthetics; rehabilitation ID TISSUE HEAT-TRANSFER; VASCULAR MICROSTRUCTURE; BIOHEAT EQUATION; SURFACE; FOUNDATION; FRICTION; GEOMETRY; BODY AB Amputees who wear prosthetic limbs often experience discomfort from blisters and sores due to mechanical insult; these skin conditions are exacerbated by elevated skin temperatures and excessive perspiration within the prosthetic socket. The goal of this study was to create a tool for developing new prostheses that accommodate varying thermal loads arising from everyday activities. A three-dimensional thermal model of a transtibial residual limb and prosthesis was constructed using the finite element (FE) method. Transverse computerized tomography (CT) scans were used to specify the geometry of the residual limb and socket. Thermal properties from the literature were assigned to both biological tissue and prosthetic socket elements. The purpose of this work was to create a model that would aid in testing the effect of new prosthesis designs on skin temperature. To validate its output, the model was used to predict the skin temperature distribution in a common prosthetic socket system (silicone liner, wool sock, and carbon fiber socket) at rest with no mechanical loading. Skin temperatures were generally elevated near muscle and decreased anteriorly and at the distal end. Experimental temperature measurements taken at the skin-prosthesis interface of five human subjects were used to validate the model. Data extracted from the thermal model at anterior, posterior, lateral, and medial locations were typically within one standard deviation of experimental results; the mean temperatures were within 0.3 degrees C for each section and were within 0.1 degrees C overall. C1 VA Puget Sound, Dept Vet Affairs, Rehabil Res & Dev Ctr Excellence Limb Loss Preven, Seattle, WA 98108 USA. Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA. Univ Washington, Dept Orthoped & Sports Med, Seattle, WA 98195 USA. RP Peery, JT (reprint author), VA Puget Sound, Dept Vet Affairs, Rehabil Res & Dev Ctr Excellence Limb Loss Preven, Seattle, WA 98108 USA. EM jeffpeery@yahoo.com; gklute@u.washington.edu; jjb3@u.washington.edu; wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 NR 25 TC 10 Z9 12 U1 3 U2 21 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 1534-4320 J9 IEEE T NEUR SYS REH JI IEEE Trans. Neural Syst. Rehabil. Eng. PD SEP PY 2006 VL 14 IS 3 BP 336 EP 343 DI 10.1109/TNSRE.2006.881532 PG 8 WC Engineering, Biomedical; Rehabilitation SC Engineering; Rehabilitation GA 086UR UT WOS:000240699000010 PM 17009493 ER PT J AU Patterson, JE AF Patterson, Jan E. TI Multidrug-resistant gram-negative pathogens: Multiple approaches and measures for prevention SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Editorial Material ID INITIAL ANTIMICROBIAL THERAPY; BLOOD-STREAM INFECTIONS; SPECTRUM BETA-LACTAMASES; PSEUDOMONAS-AERUGINOSA; RISK-FACTORS; CLINICAL-OUTCOMES; MORTALITY; MICROBIOLOGY; BACTEREMIA; ORGANISMS C1 S Texas Vet Hlth Care Syst, Med Ctr, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. RP Patterson, JE (reprint author), S Texas Vet Hlth Care Syst, Med Ctr, San Antonio, TX 78229 USA. EM pattersonj@uthscsa.edu NR 23 TC 9 Z9 9 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2006 VL 27 IS 9 BP 889 EP 892 DI 10.1086/507436 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 205AE UT WOS:000249084300001 PM 16941311 ER PT J AU Anstead, GM Graybill, JR AF Anstead, Gregory M. Graybill, John R. TI Coccidioidomycosis SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Review ID CAVITARY PULMONARY COCCIDIOIDOMYCOSIS; AMPHOTERICIN-B; SURGICAL CONSIDERATIONS; TRANSPLANT RECIPIENTS; KETOCONAZOLE THERAPY; SEPTIC SHOCK; RISK-FACTORS; MENINGITIS; ITRACONAZOLE; IMMITIS AB Coccidioidomycosis is an infection caused by dimorphic fungi of the genus Coccidioides, soil-dwelling fungi endemic in semiarid to and life zones in the southwestern United States, northern Mexico, and scattered areas of Latin America. This article discusses populations at particular risk, diagnosis, clinical presentation, outcomes, and treatment of this potentially horrific disease. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. S Texas Vet Healthcare Syst, Res Serv, San Antonio, TX 78229 USA. RP Anstead, GM (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM anstead@uthscsa.edu NR 111 TC 27 Z9 30 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD SEP PY 2006 VL 20 IS 3 BP 621 EP + DI 10.1016/j.idc.2006.06.005 PG 24 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 095JV UT WOS:000241304900008 PM 16984872 ER PT J AU Steinberg, M Corcoran, C Tschanz, J Huber, C Welsh-Bohmer, K Norton, MC Zandi, P Breitner, JCS Steffens, DC Lyketsos, CG AF Steinberg, M. Corcoran, C. Tschanz, J. T. Huber, C. Welsh-Bohmer, K. Norton, M. C. Zandi, P. Breitner, J. C. S. Steffens, D. C. Lyketsos, C. G. TI Risk factors for neuropsychiatric symptoms in dementia: The Cache County Study SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE dementia; neuropsychiatric; Alzheimer; risk factors ID ALZHEIMERS-DISEASE; BEHAVIORAL DISTURBANCES; PSYCHIATRIC-SYMPTOMS; MEDICAL COMORBIDITY; DELUSIONS; HALLUCINATIONS; IMPAIRMENT; PREVALENCE; PSYCHOSIS; INVENTORY AB Objective To investigate the probability of individual neuropsychiatric symptoms in dementia patients as a function of eight risk factors. Methods In the Cache County Study, we administered the Neuropsychiatric Inventory (NPI) to 328 dementia patients at baseline. Approximately 18 months later, we re-administered the NPI to 184 participants available for follow-up. Generalized estimating equation methods were used to model the probability of individual neuropsychiatric symptoms as a function of: gender, age, education, dementia type and severity, APOE status, time of observation, and general medical health. Results Women showed increased tendency toward anxiety, [odds ratio (OR) 2.22, 95% confidence interval (CI) 1.313.76] and delusions (OR 2.15, Cl 1.22-3.78), but older persons of both sexes showed less tendency toward anxiety. Dementia severity increased the tendency toward hallucinations and agitation (OR 2.42, CI 1.81-3.23) and decreased risk of depression. Positive APOE epsilon 4 status increased the tendency toward aberrant motor behavior (OR 1.84, CI 1.05-3.22). Among dementia diagnoses, those with Alzheimer's disease showed decreased tendency toward agitation (OR 0.58, CI 0.350.95), depression (OR 0.56, CI 0.33-0.96) and disinhibition (OR 0.46, CI 0.24-0.88). Later time of observation increased risk of aberrant motor behavior and delusions, and more serious medical comorbidity increased risk of, agitation, irritability, disinhibition, and aberrant motor behavior. Conclusions Gender, age, dementia severity, APOE E4, dementia diagnosis, time of observation, and general medical health appear to influence the occurrence of individual neuropsychiatric symptoms. Copyright (c) 2006 John Wiley & Sons, Ltd. C1 Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. Utah State Univ, Dept Math & Stat, Logan, UT 84322 USA. Utah State Univ, Dept Psychol, Logan, UT 84322 USA. Duke Univ, Dept Psychiat & Behav Sci, Sch Med, Durham, NC USA. Utah State Univ, Dept Family & Human Dev, Logan, UT 84322 USA. Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. Univ Washington, VA Puget Sound Hlth Care Syst, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98195 USA. RP Steinberg, M (reprint author), Johns Hopkins Univ Hosp, 550 N Broadway,Suite 308, Baltimore, MD 21205 USA. EM martins@jhmi.edu RI Corcoran, Chris/F-2155-2010; Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013 FU NIA NIH HHS [AG-11380, AG-21136] NR 34 TC 33 Z9 35 U1 2 U2 7 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD SEP PY 2006 VL 21 IS 9 BP 824 EP 830 DI 10.1002/gps.1567 PG 7 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 091DV UT WOS:000241007400003 PM 16955439 ER PT J AU Eisenstein, EM Eisenstein, D AF Eisenstein, E. M. Eisenstein, D. TI A behavioral homeostasis theory of habituation and sensitization from protozoa to humans SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Meeting Abstract C1 W Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD SEP PY 2006 VL 61 IS 3 SI SI BP 318 EP 318 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 071PT UT WOS:000239614800085 ER PT J AU Steinhauer, SR Siegle, GJ Condray, R Gurklis, JA AF Steinhauer, Stuart R. Siegle, Greg J. Condray, Ruth Gurklis, John A., Jr. TI Pupil dilation during sustained processing: An indicator of intact effortful processing in schizophrenia SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Meeting Abstract C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA 15206 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD SEP PY 2006 VL 61 IS 3 SI SI BP 338 EP 338 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 071PT UT WOS:000239614800152 ER PT J AU Pumbwe, L Chang, A Smith, RL Wexler, HM AF Pumbwe, Lilian Chang, Abraham Smith, Rachel L. Wexler, Hannah M. TI Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE cross-resistance; therapy; susceptibility ID RESISTANT PSEUDOMONAS-AERUGINOSA; II TOPOISOMERASE MUTATIONS; EXTENSIVE DNA INVERSIONS; FLUOROQUINOLONE RESISTANCE; ESCHERICHIA-COLI; ANTIBIOTIC-RESISTANCE; QUINOLONE RESISTANCE; ANAEROBIC-BACTERIA; GENE-EXPRESSION; BETA-LACTAMASE AB Objectives: The aim of the present study was to determine correlation between bmeB efflux pump overexpression and resistance to fluoroquinolones and beta-lactams in Bacteroides fragilis clinical isolates (n = 51) and the effects of broad-spectrum efflux pump inhibitors (EPIs) on the MICs of the test antibiotics. Methods: Susceptibility to garenoxacin, levofloxacin, moxifloxacin, cefoxitin and faropenem +/- EPIs (CCCP, MC-207,110, reserpine and verapamil) was determined. Expression of bmeB efflux pumps was measured, topoisomerase genes were sequenced and beta-lactamase production was determined. Results: Isolates were grouped into categories based on susceptibility patterns, topoisomerase sequence and efflux pump expression. Panel I isolates (19/51, 37.3%) were highly resistant to fluoroquinolones and cefoxitin (resistance to all agents was significantly reduced by EPIs, P < 0.05), had a point mutation in gyrA (C -> T) causing a Ser-82 -> Phe substitution, and overexpressed bmeB4 and bmeB15. Panel II isolates (7/51; 13.7%) had intermediate-level resistance to fluoroquinolones and cefoxitin and a GyrA substitution. Panel IIIA isolates (21/51; 41.2%) had intermediate-level fluoroquinolone resistance and high-level cefoxitin resistance [resistance to all agents was significantly reduced by EPIs (P < 0.05)] and overexpressed bmeB4 and bmeB15. Panel IIIB isolates (4/51; 7.8%) had low-level fluoroquinolone resistance and high-level resistance to cefoxitin [cefoxitin resistance was significantly reduced by EPIs (P < 0.05)] and overexpressed bmeB4, bmeB6, bmeB10 and bmeB14. All isolates were beta-lactamase-positive. Conclusions: These data suggest that bmeB efflux pump overexpression can (i) cause low- to intermediate-level clinically relevant fluoroquinolone resistance; (ii) be coupled with GyrA substitutions to cause high-level fluoroquinolone resistance; (iii) contribute to high-level clinically relevant resistance to beta-lactams. C1 Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Wexler, HM (reprint author), Greater Los Angeles Vet Adm Healthcare Syst, 691-151J,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM hwexler@ucla.edu NR 35 TC 21 Z9 24 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD SEP PY 2006 VL 58 IS 3 BP 543 EP 548 DI 10.1093/jac/dkl278 PG 6 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 075RI UT WOS:000239902500010 PM 16840432 ER PT J AU Kaka, AS Rueda, AM Shelburne, SA Hulten, K Hamill, RJ Musher, DM AF Kaka, Anjum S. Rueda, Adriana M. Shelburne, Samuel A., III Hulten, Kristina Hamill, Richard J. Musher, Daniel M. TI Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE trimethoprim; sulfamethoxazole; linezolid; time-kill; bactrim ID TRIMETHOPRIM-SULFAMETHOXAZOLE; INFECTIONS; VANCOMYCIN AB Background: The recent proliferation of community-acquired (CA) methicillin-resistant Staphylococcus aureus (MRSA) has led to a marked increase in the need for outpatient treatment of MRSA infections. Many oral agents active against MRSA have been available for years, and a paucity of literature compares them, leaving physicians with little guidance for choosing among them. The purpose of the present study was to compare the bactericidal effects of orally available antibiotics against MRSA and to determine whether there were differences in antimicrobial killing activity against CA-MRSA and hospital-acquired (HA) MRSA isolates. Methods: A total of 12 unique patient MRSA isolates were studied. Six strains were CA, carrying the staphylococcal chromosomal cassette (SCCmec) type IVa, while six were HA and carried SCCmec type II. Time-kill methods were used to study the bactericidal activity of the orally available antimicrobials linezolid, rifampicin, trimethoprim/sulfamethoxazole, clindamycin, minocycline, and moxifloxacin alone and in combination in vitro. Results: Trimethoprim/sulfamethoxazole was rapidly bactericidal resulting in > 2 log(10) cfu/mL decrease at 8 h and > 3 log(10) cfu/mL decrease at 24 h in vitro. No antibiotic combination exhibited better killing than trimethoprim/sulfamethoxazole alone. Adding rifampicin to trimethoprim/sulfamethoxazole showed a trend towards antagonism in vitro. There were no differences in the bactericidal activity of any antimicrobial or antimicrobial combination against MRSA isolates carrying SCCmec type IVa versus those carrying SCCmec type II. Conclusion: Trimethoprim/sulfamethoxazole is rapidly bactericidal against MRSA in vitro when compared with most other orally available antimicrobials. No differences in bactericidal activity were detected when activities against CA-MRSA and HA-MRSA were compared. C1 Michael E DeBakey Vet Affairs Med Ctr, Sect Infect Dis 111G, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA. Baylor Coll Med, Dept Pediat, Infect Dis Sect, Houston, TX 77030 USA. RP Musher, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Sect Infect Dis 111G, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM Daniel.Musher@va.gov OI Hulten, Kristina/0000-0001-7446-157X FU NCRR NIH HHS [K12 RR 1766504]; NIAID NIH HHS [5T32AI055413-03] NR 10 TC 61 Z9 62 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD SEP PY 2006 VL 58 IS 3 BP 680 EP 683 DI 10.1093/jac/dkl283 PG 4 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 075RI UT WOS:000239902500033 PM 16840428 ER PT J AU Lammerding, J Fong, LG Ji, JY Reue, K Stewart, CL Young, SG Lee, RT AF Lammerding, Jan Fong, Loren G. Ji, Julie Y. Reue, Karen Stewart, Colin L. Young, Stephen G. Lee, Richard T. TI Lamins A and C but not lamin B1 regulate nuclear mechanics SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID DREIFUSS MUSCULAR-DYSTROPHY; GILFORD-PROGERIA-SYNDROME; DILATED CARDIOMYOPATHY; BUILDING-BLOCKS; HUMAN-DISEASE; PRELAMIN-A; ENVELOPE; CELLS; LAMINOPATHIES; MUTATIONS AB Mutations in the nuclear envelope proteins lamins A and C cause a broad variety of human diseases, including Emery-Dreifuss muscular dystrophy, dilated cardiomyopathy, and Hutchinson-Gilford progeria syndrome. Cells lacking lamins A and C have reduced nuclear stiffness and increased nuclear fragility, leading to increased cell death under mechanical strain and suggesting a potential mechanism for disease. Here, we investigated the contribution of major lamin subtypes (lamins A, C, and B1) to nuclear mechanics by analyzing nuclear shape, nuclear dynamics over time, nuclear deformations under strain, and cell viability under prolonged mechanical stimulation in cells lacking both lamins A and C, cells lacking only lamin A (i.e. "lamin C-only" cells), cells lacking wild-type lamin B1, and wild-type cells. Lamin A/C-deficient cells exhibited increased numbers of misshapen nuclei and had severely reduced nuclear stiffness and decreased cell viability under strain. Lamin C-only cells had slightly abnormal nuclear shape and mildly reduced nuclear stiffness but no decrease in cell viability under strain. Interestingly, lamin B1-deficient cells exhibited normal nuclear mechanics despite having a significantly increased frequency of nuclear blebs. Our study indicates that lamins A and C are important contributors to the mechanical stiffness of nuclei, whereas lamin B1 contributes to nuclear integrity but not stiffness. C1 Harvard Univ, Sch Med, Div Cardiovasc, Dept Med, Cambridge, MA 02139 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Cambridge, MA 02139 USA. Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angelese Healthcare Syst, Los Angeles, CA 90073 USA. NCI, Canc & Dev Biol Lab, Frederick, MD 21702 USA. RP Lammerding, J (reprint author), Partners Res Facil, Rm 283,65 Landsdowne St, Cambridge, MA 02139 USA. EM jlammerding@rics.bwh.harvard.edu RI Lammerding, Jan/A-9498-2016 OI Lammerding, Jan/0000-0003-4335-8611 FU NCI NIH HHS [CA099506]; NHLBI NIH HHS [HL073809, HL64858, R01 HL082792]; NIAID NIH HHS [AI05438]; NIAMS NIH HHS [AR050200] NR 42 TC 199 Z9 203 U1 2 U2 30 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 1 PY 2006 VL 281 IS 35 BP 25768 EP 25780 DI 10.1074/jbc.M513511200 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 077LQ UT WOS:000240031300079 PM 16825190 ER PT J AU Bischoff, DS Zhu, J Makhijani, NS Yamaguchi, DT AF Bischoff, D. S. Zhu, J. Makhijani, N. S. Yamaguchi, D. T. TI Acidic pH stimulates ELR+ CXC chemokine expression in human mesenchymal stem cells. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 28th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 15-19, 2006 CL Philadelphia, PA SP Amer Soc Bone & Mineral Res C1 VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2006 VL 21 SU 1 BP S363 EP S363 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 089FS UT WOS:000240866303076 ER PT J AU Garcia-Palacios, V Subler, MA Patrene, K Zhao, L Choi, SJ Blair, HC Windle, JJ Roodman, GD AF Garcia-Palacios, V. Subler, M. A. Patrene, K. Zhao, L. Choi, S. J. Blair, H. C. Windle, J. J. Roodman, G. D. TI A Disintegrin and Metalloprotease 8 (ADAM8) regulates osteoclast function in vitro and bone mass in vivo. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 28th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 15-19, 2006 CL Philadelphia, PA SP Amer Soc Bone & Mineral Res C1 Univ Pittsburgh, Pittsburgh, PA 15260 USA. Virginia Commonwealth Univ, Richmond, VA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2006 VL 21 SU 1 BP S42 EP S42 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 089FS UT WOS:000240866300157 ER PT J AU Vesco, KK Marshall, L Rizzo, JH Nelson, HD Humphrey, L Antoniucci, D Ensrud, K Hochberg, M Hillier, TA AF Vesco, K. K. Marshall, L. Rizzo, J. H. Nelson, H. D. Humphrey, L. Antoniucci, D. Ensrud, K. Hochberg, M. Hillier, T. A. TI Surgical menopause and risk for hip fracture in older women: The study of osteoporotic fractures. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 28th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 15-19, 2006 CL Philadelphia, PA SP Amer Soc Bone & Mineral Res C1 Kaiser Ctr Hlth Res, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland, OR USA. Portland VA Med Ctr, Portland, OR 94143 USA. Univ Calif San Francisco, San Francisco, CA 55455 USA. Univ Minnesota, Minneapolis, MN 21201 USA. Univ Maryland, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2006 VL 21 SU 1 BP S275 EP S275 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 089FS UT WOS:000240866302184 ER PT J AU Zickmund, SL Blasiole, JA Brase, V Arnold, RM AF Zickmund, Susan L. Blasiole, Julie A. Brase, Venture Arnold, Robert M. TI Congestive heart failure patients report conflict with their physicians SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE congestive heart failure; doctor-patient relationship; communication ID QUALITY-OF-LIFE; RESUSCITATION PREFERENCES; HEPATITIS-C; COMMUNICATION; SATISFACTION; CARE; MANAGEMENT; PREDICTORS; CLINICIAN; SYMPTOMS AB Background: Given the importance of the doctor-patient relationship, we examined the prevalence and nature of patients' perceived conflicts with the physicians caring for their congestive heart failure (CHF). Methods and Results: This cross-sectional study recruited patients with CHF in the outpatient and inpatient service of a tertiary referral hospital. Patients completed demographics, semistructured interviews, and surveys of emotional and health status. CHF physiologic measures and comorbidities were abstracted from the medical record. A team of 2 blinded coders analyzed the interviews. Thirty-one percent of the 289 patients reported difficulties with physicians. In the bivariate analysis, only marital status was significantly associated with conflict. Major problems included the providers' poor communication skills (20%), trust in the physicians' competence (18%), and insufficient medical information (16%). Patients identified care outside the tertiary referral hospital (13%) and inadequate communication between physicians (9%) as additional sources of difficulty. Conclusion: Perceived conflict with providers is common in patients with CHF. Patient-level factors, however, did not predict conflict, which differs from our previous findings with hepatitis C patients. Perceived conflict is troubling because it can undermine the trust in the doctor-patient relationship, thereby weakening the therapeutic bond necessary to care for this sick and often vulnerable population. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA 15260 USA. Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA. RP Zickmund, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151C-U,Univ Dr C, Pittsburgh, PA 15240 USA. FU NHLBI NIH HHS [HL07121] NR 54 TC 10 Z9 10 U1 3 U2 3 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD SEP PY 2006 VL 12 IS 7 BP 546 EP 553 DI 10.1016/j.cardfail.2006.03.008 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 086YI UT WOS:000240708700009 PM 16952789 ER PT J AU Wadhani, N Sarma, JSM Singh, BN Radzik, D Gaud, C AF Wadhani, Nitin Sarma, Jonnalagedda S. M. Singh, Bramah N. Radzik, David Gaud, Christine TI Dose-dependent effects of oral dronedarone on the circadian variation of RR and QT intervals in healthy subjects: Implications for antiarrhythmic actions SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS LA English DT Article DE dronedarone; QT circadian rhythm; antiarrhythmic agent ID ATRIAL-FIBRILLATION; MYOCARDIAL-INFARCTION; AMIODARONE; SR-33589; AGENT; CELLS; HEART; ADRENOCEPTOR; DOGS AB Dronedarone, a non-iodinated benzofuran derivative, was developed as a potentially less toxic alternative to amiodarone. This study describes Holter data of dronedarone in humans. Five groups of healthy subjects were given I of 5 oral doses of dronedarone in a twice-daily regimen or placebo. Holter recordings of circadian rhythmicity of RR and QT intervals were evaluated. Dronedarone prolonged RR and QT intervals as a function of dose, without effect on circadian patterns. The relative prolongation of QT, QTc, and RR by dronedarone was significant. The QTc interval did not exhibit a clearly recognizable circadian pattern, suggesting that the circadian pattern of the QT interval was mostly a reflection of circadian changes in the RR interval in the study population. Dronedarone resembled amiodarone in class III and sympatholytic effects, indicating its potential as a unique antiarrhythmic compound seemingly devoid of the side effects mediated by iodine in amiodarone. C1 VA Greater Los Angeles Area Healthcare Syst, Cardiol Sect, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Sanofi Aventis, Chilly Mazarin, France. RP Singh, BN (reprint author), VA Greater Los Angeles Area Healthcare Syst, Cardiol Sect, 111E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM bsingh@ucla.edu NR 19 TC 8 Z9 9 U1 4 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1074-2484 J9 J CARDIOVASC PHARM T JI J. Cardiovasc. Pharmacol. Ther. PD SEP PY 2006 VL 11 IS 3 BP 184 EP 190 DI 10.1177/1074248406290678 PG 7 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 095NI UT WOS:000241314200004 PM 17056831 ER PT J AU Bini, EJ Currie, SL Shen, H Brau, N Schmidt, W Anand, BS Cheung, R Wright, TL AF Bini, Edmund J. Currie, Sue L. Shen, Hui Brau, Norbert Schmidt, Warren Anand, Bhupinderjit S. Cheung, Ramsey Wright, Teresa L. CA VA HCV 001 Study Grp TI National multicenter study of HIV testing and HIV seropositivity in patients with chronic hepatitis C virus infection SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE HIV; AIDS; hepatitis C; testing; multicenter studies; epidemiology ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; CLINICAL-TRIALS GROUP; UNITED-STATES; LIVER-DISEASE; COINFECTED PATIENTS; COST-EFFECTIVENESS; MORTALITY; PROGRESSION; PREVALENCE AB Background: Although HIV testing is recommended for persons with hepatitis C virus (HCV) infection who are at risk for HIV, little is known about HIV testing in this population. Methods: Data were prospectively collected in 4364 HCV-infected patients at 24 Veterans Affairs medical centers across the United States, including demographics, risk factors for HIV infection, and self-reported information on HIV testing. Results: Overall, 76.8% had been tested for HIV at least once, 14.8% were never tested, 6.6% did not know if they were tested, and 1.8% declined to answer. Multivariable analysis identified injection drug use, needlestick injury, sex with a same-sex partner, a greater number of lifetime sexual partners, and sex with an injection drug user as factors that were independently associated with HIV testing. At least one risk factor for HIV infection was present in 84.5% of the 646 patients who were never HIV tested. Among the 3350 subjects who were tested for HIV, 8.4% were positive, 88.3% were negative, 2.4% did not know the results of their test, and 0.9% declined to answer. Multivariable analysis identified African American and Hispanic race/ethnicity, income <=$10,000, sex with a same-sex partner, and sex with an injection drug user as the only variables that were independently associated with HIV seropositivity. Conclusions: Although a substantial proportion of HCV-infected patients have been tested for HIV, missed opportunities for early diagnosis of HIV infection exist. Public health strategies to improve HIV testing among patients with chronic HCV infection are needed. C1 VA New York Harbor Healthcare Syst, Div Gastroenterol, New York, NY 10010 USA. NYU, Sch Med, New York, NY USA. VA Med Ctr, San Francisco, CA USA. VA Med Ctr, Boston, MA USA. VA Med Ctr, Palo Alto, CA USA. VA Med Ctr, Iowa City, IA USA. VA Med Ctr, Houston, TX USA. RP Bini, EJ (reprint author), VA New York Harbor Healthcare Syst, Div Gastroenterol, 423 E 23rd St, New York, NY 10010 USA. EM Edmund.Bini@med.va.gov NR 45 TC 8 Z9 8 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD SEP PY 2006 VL 40 IS 8 BP 732 EP 739 DI 10.1097/00004836-200609000-00014 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 079FC UT WOS:000240159900014 PM 16940888 ER PT J AU Baron, F Storb, R Storer, BE Maris, MB Niederwieser, D Shizuru, JA Chauncey, TR Bruno, B Forman, SJ McSweeney, PA Maziarz, RT Pulsipher, MA Agura, ED Wade, J Sorror, M Maloney, DG Sandmaier, BM AF Baron, Frederic Storb, Rainer Storer, Barry E. Maris, Michael B. Niederwieser, Dietger Shizuru, Judith A. Chauncey, Thomas R. Bruno, Benedetto Forman, Stephen J. McSweeney, Peter A. Maziarz, Richard T. Pulsipher, Michael A. Agura, Edward D. Wade, James Sorror, Mohamed Maloney, David G. Sandmaier, Brenda M. TI Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 7th Conference on Process Integration Modeling and Optimization for Energy Saving and Pollution Reduction CY AUG, 2004 CL Prague, CZECH REPUBLIC ID GRAFT-VERSUS-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; AUTOLOGOUS TRANSPLANTATION; HOST-DISEASE; HEMATOLOGIC MALIGNANCIES; HODGKINS-LYMPHOMA; MULTIPLE-MYELOMA; BLOOD; ENGRAFTMENT AB Purpose Several studies have investigated the feasibility of allogeneic hematopoietic cell transplantations (HCTs) after reduced-intensity conditioning in patients who experienced relapse after myeloablative HCT. Although most studies showed relatively low nonrelapse mortality (NRM) rates and encouraging short-term results, it has yet to be defined which patients would benefit most from these approaches. Patients and Methods We analyzed data from 147 patients with hematologic malignancies who experienced treatment failure with conventional autologous (n = 135), allogeneic (n = 10), or syngeneic (n = 2) HCT and were treated with HLA-matched related (n = 62) or unrelated (n = 85) grafts after conditioning with 2 Gy of total-body irradiation with or without fludarabine. Results Three-year probabilities of NRM, relapse, and overall survival were 32%, 48%, and 27%, respectively, for related recipients, and 28%, 44%, and 44%, respectively, for unrelated recipients. The best outcomes were observed in patients with non-Hodgkin's lymphoma, whereas patients with multiple myeloma and Hodgkin's disease had worse outcomes as a result of high incidences of relapse and progression. Being in partial remission (PR) or complete remission (CR) at HCT (P = .002) and developing chronic graft-versus-host disease (GVHD; P = .03) resulted in lower risks of relapse and progression. Factors associated with better overall survival were PR or CR (P = .01) and lack of comorbidity (P = .03) at HCT and absence of acute GVHD after HCT (P = .06). Conclusion Encouraging outcomes were seen with allogeneic HCT after nonmyeloablative conditioning in selected patients who had experienced relapse after a high-dose HCT, particularly in patients with non-Hodgkin's lymphoma. Results with unrelated grafts were comparable with results with related grafts. C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. Univ Washington, Sch Med, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Stanford Univ, Stanford, CA 94305 USA. City Hope Comprehens Canc Ctr, Duarte, CA USA. Rocky Mt Canc Ctr, Denver, CO USA. Oregon Hlth & Sci Univ, Portland, OR USA. Univ Utah, Salt Lake City, UT USA. Baylor Univ, Dallas, TX USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Univ Liege, Liege, Belgium. Univ Leipzig, D-7010 Leipzig, Germany. Univ Turin, Turin, Italy. RP Sandmaier, BM (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA. EM bsandmai@fhcrc.org FU NCI NIH HHS [CA18029, CA78902, CA92058, CA49605, P01 CA078902, CA15704]; NHLBI NIH HHS [HL36444] NR 44 TC 67 Z9 68 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD SEP 1 PY 2006 VL 24 IS 25 BP 4150 EP 4157 DI 10.1200/JCO.2006.06.9914 PG 8 WC Oncology SC Oncology GA 081LV UT WOS:000240320000018 PM 16896000 ER PT J AU Hussein, MR Hassan, HI AF Hussein, M. R. Hassan, H. I. TI Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations SO JOURNAL OF CLINICAL PATHOLOGY LA English DT Article ID CANCER-CELLS; GRANZYME-B; T-CELLS; LYMPHOCYTES; EXPRESSION; MUTATIONS; STAGE; RISK; LUNG; P53 AB Background: Mammary carcinogenesis is a multistep process entailing the transition from normal breast to benign proliferative breast disease (ductal hyperplasia) to ductal carcinoma in situ to infiltrating ductal carcinoma. Hypothesis: These transitions are associated with changes in the mononuclear inflammatory cell infiltrate. Materials and methods: A total of 53 mastectomy specimens of normal breast, benign proliferative breast disease, ductal carcinoma in situ and infiltrating ductal carcinoma were evaluated for mononuclear inflammatory cell infiltrate by using immunohistological methods and monoclonal antibodies including CD20, CD68, CD3 and granzyme B, histiocytes, T cells and cytotoxic T cells. Results: Transitions from normal breast to the subsequent tissue with lesions (normal skin v benign proliferative breast disease v ductal carcinoma in situ v infiltrating ductal carcinoma) were associated with significantly (p < 0.01) increased mean (SD) density of mononuclear inflammatory cell infiltrate at the parenchyma (3.2 (1.0) v 26.4 (7.8) v 33.6 (7.9) v 39.1 (4.7) for CD20+ B cells; 2.8 (1.0) v 81.5 (14.0) v 84.0 (14.9) v103.7 (3.9) for CD3; 1.3 (2.0) v 3.8 (4.0) v 12.7 (23) v 22.1 (25.0) for CD68+ macrophages; 2.0 (1.0) v 58.3 (5.0) v 60.0 (10.0) v 74.1 (28.0) for granzyme B+ cytotoxic T cells) and at the stroma (0.7 (1.0) v 3.0 (5.0) v 13.3 (20) v 16.7 (30.0) for CD20+ B cells; 1.0 (2.06) v 4.0 (2.5) v 16.7 (5.0) v 21.7 (15) for CD68+ macrophages; 1.4 (0.6) v 4.2 (1.2) v 46.6 (16.7) v 77.0 (5.0) for CD3+ cells and 0 (0) v 0.5 (1.0) v 0.7 (1.0) v 0.7 (1.0) for granzyme B+ cytotoxic T cells). Conclusions: The increased mononuclear inflammatory cell infiltrate during mammary carcinogenesis may reflect non-specific or specific immunological processes. C1 Assir Cent Hosp, Dept Histopathol, Abha, Saudi Arabia. Assiut Univ, Dept Pathol, Assiut Univ Hosp, Fac Med, Assiut, Egypt. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. Univ Wisconsin, Sch Med, Madison, WI 53705 USA. RP Hussein, MR (reprint author), Assir Cent Hosp, Dept Histopathol, Abha, Saudi Arabia. EM mrh17@swissinfo.org NR 23 TC 39 Z9 41 U1 0 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0021-9746 J9 J CLIN PATHOL JI J. Clin. Pathol. PD SEP PY 2006 VL 59 IS 9 BP 972 EP 977 DI 10.1136/jcp.2005.031252 PG 6 WC Pathology SC Pathology GA 077PQ UT WOS:000240042500014 PM 16935972 ER PT J AU Howard, I Turner, R Olkin, R Mohr, DC AF Howard, Isa Turner, Rebecca Olkin, Rhoda Mohr, David C. TI Therapeutic alliance mediates the relationship between interpersonal problems and depression outcome in a cohort of multiple sclerosis patients SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE working alliance; interpersonal problems; multiple sclerosis; depression ID WORKING ALLIANCE; EXPERIENTIAL THERAPY; RATING-SCALE; INVENTORY; PSYCHOTHERAPY; METAANALYSIS; VALIDITY; RUPTURES AB The relationship among therapeutic alliance, psychotherapy outcomes, and interpersonal problems was examined. The present study hypothesized therapeutic alliance would mediate the relationship between interpersonal functioning and outcome among patients with multiple sclerosis entering psychotherapy for depression. Nineteen clients received 16 weeks of individual cognitive-behavioral therapy (CBT) for depression as described by D. C. Mohr, A. C. Boudewyn, D. E. Goodkin, A. Bostrom, and L. Epstein (2001). Participants completed the Beck Depression Inventory (BDI: Beck, Ward, Mendelson, Mock, & Erbaugh, 1961), the Inventory of Interpersonal Problems-Circumplex (IIP-C: Alden, Wiggins, & Pincus, 1990), and the Working Alliance Inventory-Client Form (WAI-C; Horvath & Greenberg, 1989). The IIP-C significantly predicted Week 16 BDI and the WAI-C at 4 weeks. When controlling for the WAI-C, the relationship between the IIP-C and BDI was no longer significant, supporting the mediational hypothesis. (c) 2006 Wiley Periodicals, Inc. C1 San Francisco Vet Affairs Med Ctr, San Francisco, CA 94131 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Howard, I (reprint author), San Francisco Vet Affairs Med Ctr, 4150 Clement St,116-S, San Francisco, CA 94131 USA. EM Isa.Howard@va.gov FU CSR NIH HHS [RG2719 A1/2] NR 32 TC 17 Z9 18 U1 2 U2 5 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9762 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD SEP PY 2006 VL 62 IS 9 BP 1197 EP 1204 DI 10.1002/jclp.20274 PG 8 WC Psychology, Clinical SC Psychology GA 076BO UT WOS:000239932200011 PM 16810663 ER PT J AU Nelson, KM AF Nelson, Karin M. TI The burden of obesity among a national probability sample of veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT Centers-for-Disease-Control Diabetes and Obesity Conference CY MAY 16-19, 2006 CL Denver, CO SP Ctr Dis Control DE veterans; obesity ID HEALTH-CARE-SYSTEM; BODY-MASS INDEX; QUALITY-OF-LIFE; BARIATRIC SURGERY; US ADULTS; DISEASE BURDEN; WEIGHT-LOSS; FOLLOW-UP; OVERWEIGHT; PREVALENCE AB BACKGROUND: Few national data exist about the prevalence of obesity and the resulting health burden among veterans. METHODS: We analyzed data from the 2003 Behavioral Risk Factor Surveillance System (n=242,362) to compare rates of obesity among veterans who do and do not utilize the VA, compared with nonveterans. We used bivariate analyses to describe the association of obesity with lifestyle factors. disability, and comorbid disease, and multivariate analysis to assess the independent association of obesity with VA care. RESULTS: Veterans who use the VA for health care have the highest rates of obesity compared with veterans who do not use the VA and nonveterans (27.7% vs 23.9% vs 22.8%, P <.00 1). Only 27.8% of veterans who receive health care at the VA are of normal weight (vs 42.6% of the general population, P <.001), 44.5% are overweight, 19.9% have class I obesity. 6% have class II obesity, and 1.8% are morbidly obese (an estimated 82.950 individuals). Obese veterans who utilize the VA for services have higher rates of hypertension (65.8%) and diabetes (31.3%), are less likely to follow diet and exercise guidelines, and more likely to report poor health and disability than their normal-weight counterparts. CONCLUSIONS: Veterans who receive care at the VA have higher rates of overweight and obesity than the general population. At present, less than half of VA medical centers have weight management programs. As the largest integrated U.S. health system, the VA has a unique opportunity to respond to the epidemic of obesity. C1 VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. RP Nelson, KM (reprint author), 1660 S Columbian Way S-111 GIMC, Seattle, WA 98108 USA. EM Karin.Nelson@va.gov NR 43 TC 71 Z9 71 U1 2 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2006 VL 21 IS 9 BP 915 EP 919 DI 10.1111/j.1525-1497.2006.00526.x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 074DG UT WOS:000239792300003 PM 16918734 ER PT J AU McCormick, KA Cochran, NE Back, AL Merrill, JO Williams, EC Bradley, KA AF McCormick, Kinsey A. Cochran, Nancy E. Back, Anthony L. Merrill, Joseph O. Williams, Emily C. Bradley, Katharine A. TI How primary care providers talk to patients about alcohol - A qualitative study SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med DE alcohol drinking; primary care; communication; physician-patient relations ID PRIMARY-HEALTH-CARE; BRIEF PHYSICIAN ADVICE; BEHAVIORAL-COUNSELING INTERVENTIONS; RANDOMIZED CONTROLLED TRIAL; BENEFIT-COST-ANALYSIS; GENERAL-PRACTITIONERS; PROBLEM DRINKING; PROBLEM DRINKERS; CONSUMPTION; ATTITUDES AB BACKGROUND: Alcohol misuse is a common and well-documented source of morbidity and mortality. Brief primary care alcohol counseling has been shown to benefit patients with alcohol misuse. OBJECTIVE: To describe alcohol-related discussions between primary care providers and patients who screened positive for alcohol misuse. DESIGN., An exploratory, qualitative analysis of audiotaped primary care visits containing discussions of alcohol use. PARTICIPANTS: Participants were 29 male outpatients at a Veterans Affairs (VA) General Internal Medicine Clinic who screened positive for alcohol misuse and their 14 primary care providers, all of whom were participating in a larger quality improvement trial. MEASUREMENTS: Audiotaped visits with any alcohol-related discussion were transcribed and coded using grounded theory and conversation analysis, both qualitative research techniques. RESULTS: Three themes were identified: (1) patients disclosed information regarding their alcohol use, but providers often did not explore these disclosures; (2) advice about alcohol use was typically vague and/or tentative in contrast to smoking-related advice, which was more common and usually more clear and firm; and (3) discomfort on the part of the provider was evident during alcohol-related discussions. LIMITATIONS: Generalizability of findings from this single-site VA study is unknown. CONCLUSION: Findings from this single site study suggest that provider discomfort and avoidance are important barriers to evidence-based brief alcohol counseling. Further investigation into current alcohol counseling practices is needed to determine whether these patterns extend to other primary care settings, and to inform future educational efforts. C1 VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. White River Junct VA Hosp, White River Jct, VT USA. Dartmouth Coll Sch Med, Dept Med & Community & Family Med, Hanover, NH USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP McCormick, KA (reprint author), VA Puget Sound Hlth Serv Res & Dev 152, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM kamc@u.washington.edu FU NIAAA NIH HHS [K23 AA000313, K23AA00313] NR 47 TC 55 Z9 56 U1 4 U2 11 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2006 VL 21 IS 9 BP 966 EP 972 DI 10.1111/j.1525-1497.2006.00490.x PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 074DG UT WOS:000239792300012 PM 16918743 ER PT J AU Fung, CH AF Fung, Constance H. TI Computerized condition-specific templates for improving care of geriatric syndromes in a primary care setting SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article ID VULNERABLE ELDERS; INTERVENTIONS; INCONTINENCE; COMMUNITY; QUALITY; HEALTH; TRIAL; FALLS AB INTRODUCTION. As the U.S. population ages, primary care clinicians (PCCs) will encounter more patients with geriatric syndromes, such as urinary incontinence (Ul) and falls. Yet, current evidence suggests that care of these conditions does not meet expected standards and that PCCs would benefit from tools to improve care of these conditions. Little is known about the role of computerized condition-specific templates for improving care of geriatric syndromes. AIM: We sought to develop and assess the usefulness of condition-specific computerized templates in a primary care setting. SETTING: A large academic Veterans Affairs medical center. PROGRAM DESCRIPTION: We developed and tested the usefulness of 2 condition-specific computerized templates (UI and falls) that could be added on to an existing electronic health record system. PROGRAM EVALUATION., Semistructured interviews were used to identify barriers to use of computerized templates. Usefulness and usability were assessed through a randomized-controlled trial involving standardized patients. DISCUSSION: Use of condition-specific templates resulted in improved history and physical exam assessment for both Ul and falls (P <.05). Our computerized, condition-specific templates are a promising method for improving care of geriatric conditions in a primary care setting. but require improvement in usability before widespread implementation. C1 Univ Calif Los Angeles, RAND Corp, David Geffen Sch Med,Div Gen Internal Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Fung, CH (reprint author), 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM cfung@rand.org FU NIA NIH HHS [P60 AG010415, P60 AG10415] NR 26 TC 11 Z9 11 U1 1 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2006 VL 21 IS 9 BP 989 EP 994 DI 10.1111/j.1525-1497.2006.00522.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 074DG UT WOS:000239792300016 PM 16918747 ER PT J AU Siminoff, LA Burant, CJ Ibrahim, SA AF Siminoff, Laura A. Burant, Christopher J. Ibrahim, Said A. TI Racial disparities in preferences and perceptions regarding organ donation SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE decision making; disparities; minorities; organ donation; attitudes; African Americans ID AFRICAN-AMERICANS; UNITED-STATES; PROCUREMENT; ATTITUDES; BLACKS; POLICY; RACE AB OBJECTIVES: To identify reasons for lower organ donation rates by African Americans, we examined knowledge and attitudes about brain death, donation, and transplantation and trust in the health care system. METHODS: Data were collected from 1,283 subjects in Ohio using a random digit dial telephone survey. Items were developed based on focus group results. Willingness-to-donate indicators included a signed donor card and willingness to donate one's own and a loved one's organs. RESULTS: Compared with whites, African-Americans had lower rates of signing a donor card (39.1% vs 64.9%, P <.001), and willingness to donate their own organs (72.6% vs 88.3%, P <.0011 or a loved one's organs (53.0%vs 66.2%, P <.001). African Americans had lower scores on the Trust in the Health Care System scale (mean scores +/- SD, 9.43 +/- 3.05 vs 9.93 +/- 2.88, P <.01) and were more likely to agree that "if doctors know I am an organ donor, they won't try to save my life" (38.6% vs 25.9%, P <.001), the rich or famous are more likely to get a transplant (81.9% vs 75.7%, P <.05), and less likely to agree that doctors can be trusted to pronounce death (68.2% vs 82.9. P <.001). African Americans were also more likely to agree that families should receive money for donating organs (45.6% vs 28.0%, P <.001) and funeral expenses (63.1% vs 46.6%, P <. 001). CONCLUSIONS: African Americans reported greater mistrust in the equity of the donation system and were more favorable about providing tangible benefits to donor families than white respondents. C1 Case Western Reserve Univ, Sch Med, Dept Bioeth, Cleveland, OH 44106 USA. Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Siminoff, LA (reprint author), Case Western Reserve Univ, Sch Med, Dept Bioeth, TA-215,10900 Euclid Ave, Cleveland, OH 44106 USA. EM las5@case.edu RI Siminoff, Laura /H-6277-2012 FU AHRQ HHS [R01 HS010047, R01-HS10047] NR 27 TC 76 Z9 78 U1 0 U2 13 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2006 VL 21 IS 9 BP 995 EP 1000 DI 10.1111/j.1525-1497.2006.00516.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 074DG UT WOS:000239792300017 PM 16918748 ER PT J AU Breitner, JCS AF Breitner, John C. S. TI Dementia - Epidemiological considerations, nomenclature, and a tacit consensus definition SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE dementia; definition; syndrome; neuropathology; epidemiology ID ALZHEIMERS-DISEASE; CACHE COUNTY; OLD PEOPLE; ONSET; PREVALENCE; AGE; METAANALYSIS; PREDICTS; BRAINS; WOMEN AB Epidemiologic inquiry requires the definition of a "case." Dementia may be defined clinically or alternatively by inference of irreversible brain pathology. Several iterations of the Diagnostic and Statistical Manual of Mental Disorders and International Classification of Diseases have skirted this issue by using criteria that are at once syndromic and neuropathological. The limitations of this compromise are revealed by large discrepancies in case identification when the various published criteria are strictly applied. Despite this problem, neuroepidemiologists have produced convergent estimates of the prevalence and incidence of dementia and its association with risk factors. This progress has reflected the tacit reliance of investigators on a simple definition of dementia as the syndrome of substantial global cognitive decline not attributable to alteration in level of consciousness. Beyond this description, our knowledge of pathology and, ultimately, the etiology of individual cases is extremely variable. Whatever its antecedents, syndromically defined dementia presents a looming public health crisis. C1 Univ Washington, Sch Med, Ctr Geriatr Res Educ & Clin, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Sch Med, Div Geriatr Psychiat, Seattle, WA 98108 USA. RP Breitner, JCS (reprint author), Univ Washington, Sch Med, Ctr Geriatr Res Educ & Clin, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM jcsb@u.washington.edu NR 31 TC 11 Z9 12 U1 1 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD SEP PY 2006 VL 19 IS 3 BP 129 EP 136 DI 10.1177/0891988706291081 PG 8 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 077HW UT WOS:000240020900003 PM 16880354 ER PT J AU Best, RG Hysong, SJ Pugh, JA Ghosh, S Moore, FI AF Best, Richard G. Hysong, Sylvia J. Pugh, Jacqueline A. Ghosh, Suvro Moore, Frank I. TI Task overlap among primary care team members: An opportunity for system redesign? SO JOURNAL OF HEALTHCARE MANAGEMENT LA English DT Article ID MANAGEMENT AB This article presents the results of research(1) on a systematic approach to the assignment of primary care work in the Veterans Health Administration. Based on a functional job analysis protocol, the study identified overlap in the performance of primary care tasks among multiple occupational groups as prima facie evidence of opportunities to reallocate work responsibilities. Results show that registered nurses, physicians, advanced practitioners, and licensed vocational nurses reported performing 60 percent to 97 percent of the same tasks, while clerks and health technicians appeared to be underutilized. The frequency and duration with which occupational groups performed each task were also examined, providing additional evidence to be used in improving clinic efficiency. The management of healthcare personnel can be improved through systematic analysis of the work, the worker, and the work organization and through more informed decisions about the appropriateness of task assignment (or reassignment). This article presents an evidence-based approach to personnel management with important implications for clinic efficiency. The approach can be used to guide strategic planning and staffing decisions by identifying not only who currently does the work but, more importantly, who should be doing the work given the full array of data. C1 Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. Houston Ctr Qual Care & Ultiizat Studies, Houston, TX USA. Baylor Coll Med, Houston, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Sch Publ Hlth, San Antonio, TX USA. RP Best, RG (reprint author), Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. EM rbest@satx.rr.com RI Hysong, Sylvia/B-8420-2008 OI Hysong, Sylvia/0000-0002-9063-5207; Pugh, Jacqueline/0000-0003-4933-141X NR 19 TC 10 Z9 10 U1 0 U2 2 PU AMER COLL HEALTHCARE EXEC HEALTH ADMINISTRATION PRESS PI CHICAGO PA ONE NORTH FRANKLIN ST SUITE 1700, CHICAGO, IL 60606 USA SN 1096-9012 J9 J HEALTHC MANAG JI J. Healthc. Manag. PD SEP-OCT PY 2006 VL 51 IS 5 BP 295 EP 306 PG 12 WC Health Policy & Services SC Health Care Sciences & Services GA 087ZH UT WOS:000240780800005 PM 17039689 ER PT J AU McDivitt, RP AF McDivitt, Robert P. TI Practitioner application SO JOURNAL OF HEALTHCARE MANAGEMENT LA English DT Editorial Material C1 US Dept Vet Affairs, VA Midwest Hlth Care Network VISN 23, Minneapolis, MN USA. RP McDivitt, RP (reprint author), US Dept Vet Affairs, VA Midwest Hlth Care Network VISN 23, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL HEALTHCARE EXEC HEALTH ADMINISTRATION PRESS PI CHICAGO PA ONE NORTH FRANKLIN ST SUITE 1700, CHICAGO, IL 60606 USA SN 1096-9012 J9 J HEALTHC MANAG JI J. Healthc. Manag. PD SEP-OCT PY 2006 VL 51 IS 5 BP 306 EP 307 PG 2 WC Health Policy & Services SC Health Care Sciences & Services GA 087ZH UT WOS:000240780800006 ER PT J AU Saad, AF Virella, G Chassereau, C Boackle, RJ Lopes-Virella, MF AF Saad, Antonio F. Virella, Gabriel Chassereau, Charlyne Boackle, Robert J. Lopes-Virella, Maria F. TI OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages SO JOURNAL OF LIPID RESEARCH LA English DT Article DE oxidized low density lipoprotein; autoimmunity; atherosclerosis; activated macrophages; inflammation; oxidized low density lipoprotein immune complexes; oxidized low density lipoprotein antibodies ID LOW-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC LESIONS; CORONARY-ARTERY-DISEASE; OXIDIZED LDL; HUMAN MONOCYTES; IMMUNOHISTOCHEMICAL LOCALIZATION; PITTSBURGH EPIDEMIOLOGY; DIABETES COMPLICATIONS; END-PRODUCTS; ANTIBODIES AB Oxidized low density lipoprotein (OxLDL) is immunogenic and induces autoimmune responses in humans. OxLDL antibodies are predominantly of the proinflammatory IgG1 and IgG3 isotypes. We tested the capacity of immune complexes prepared with copper-oxidized human LDL and affinity chromatography-purified human OxLDL antibodies [OxLDL-immune complexes (ICs)] to activate complement and to induce cytokine release by MonoMac 6 (MM6) cells and by primary human macrophages. The levels of C4d and C3a were significantly higher in human serum incubated with OxLDL-ICs than after incubation with OxLDL or OxLDL antibody, indicating complement activation by the classical pathway. MM6 cells and primary human macrophages were incubated with OxLDL-ICs, with or without prior conditioning with interferon-g. After 18 h of incubation, both MM6 cells and primary human macrophages released significantly higher levels of proinflammatory cytokines after incubation with OxLDL-ICs than after incubation with OxLDL or with OxLDL antibody, both in primed and unprimed cells. OxLDL-ICs were more potent activators of MM6 cells than keyhole limpet hemocyanin-ICs. Blocking Fc gamma receptor I (Fc gamma RI) with monomeric IgG1 significantly depressed the response of MM6 cells to OxLDL-ICs. In conclusion, human OxLDL-ICs have proinflammatory properties, as reflected by their capacity to activate the classical pathway of complement and to induce proinflammatory cytokine release from MM6 cells and primary human macrophages. C1 Ralph H Johnson Med Ctr Dept Vet Affairs, Charleston, SC USA. Med Univ S Carolina, Dept Med, Div Endocrinol Metab Nutr, Charleston, SC USA. Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC USA. Med Univ S Carolina, Coll Dent Med, Dept Stomatol, Charleston, SC USA. RP Lopes-Virella, MF (reprint author), Ralph H Johnson Med Ctr Dept Vet Affairs, Charleston, SC USA. EM virellam@musc.edu FU NHLBI NIH HHS [P01 HL-55782] NR 43 TC 64 Z9 66 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD SEP PY 2006 VL 47 IS 9 BP 1975 EP 1983 DI 10.1194/jlr.M600064-JLR200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 081XV UT WOS:000240351800010 PM 16804192 ER PT J AU Pugh, MJV Hanlon, JT Zeber, JE Bierman, A Cornell, J Berlowitz, DR AF Pugh, Mary Jo V. Hanlon, Joseph T. Zeber, John E. Bierman, Arlene Cornell, John Berlowitz, Dan R. TI Assessing potentially inappropriate prescribing in the elderly veterans affairs population using the HEDIS 2006 quality measure SO JOURNAL OF MANAGED CARE PHARMACY LA English DT Article DE geriatrics; quality of health care; benchmarking; pharmacoepidemiology ID CLINICAL-PRACTICE GUIDELINES; NURSING-HOME RESIDENTS; MEDICATION USE; DRUG-USE; EXPLICIT CRITERIA; CARE PATIENTS; OUTPATIENTS; DEPRESSION; MORTALITY; ENROLLEES AB BACKGROUND: Studies have found that 20% to 25% of older patients receive drugs identified as inappropriate by the 1997 Beers criteria. After the addition of 22 new drugs to the 2003 Beers criteria, the National Committee on Quality Assurance convened an expert consensus panel to identify which drugs from the 2003 Beers criteria should always be avoided in the elderly. The resulting list of drugs to avoid was added to the 2006 Health Plan Employer Data and Information Set (HEDIS) to measure the quality of prescribing for the elderly. OBJECTIVE: To use HEDIS 2006 criteria to determine the rate of potentially inappropriate prescribing in the elderly (PIPE) and to determine if patient risk factors are similar to those found using Beers criteria. METHODS: This cross-sectional database study identified older patients receiving drugs included in the HEDIS 2006 criteria using national data from the Veterans Health Administration. Patients aged 65 years or older on October 1, 1999, with at least 2 outpatient visit days during fiscal year 2000, ending September 30, or outpatient visits in fiscal years 1999 and 2000 were included (N = 1,096,361). Multivariable logistic regression analyses stratified by gender identified patient characteristics associated with increased risk of HEDIS 2006 drug exposure. Since oral estrogens were considered appropriate at the time of this study, they were excluded from the list of HEDIS 2006 drugs. RESULTS: Overall, 19.6% of older veterans were exposed to HEDIS 2006 drugs-23.3% of older veteran women and 19.2% of older veteran men. The most commonly prescribed HEDIS 2006 drugs were antihistamines (received by 9.0% of men and 10.7% of women), opioid analgesics (received by 4.6% of men and 5.8% of women), and skeletal muscle relaxants (received by 4.3% of men and 5.3% of women). Propoxyphene was the most commonly used HEDIS 2006 drug, received by 4.5% of men and 5.7% of women, followed by diphenhydramine, received by 3.5% of men and 4.7% of women, and hydroxyzine, received by 3.2% of both men and women. Patients receiving 10 or more medications of any type were at greatest risk of exposure. Men were 8.2 times more likely to receive at least 1 HEDIS 2006 drug than those taking 1 to 3 drugs of any type (95% confidence interval [CI], 8.0-8.4), while women were 9.6 times more likely (95% Cl, 8.2-11.2). CONCLUSIONS: Even though we included a slightly different list of drugs to avoid, results for the HEDIS 2006 measure were similar to those of the 1997 Beers criteria. The HEDIS 2006 drugs are commonly prescribed, and there is a distinct need for direct evidence linking HEDIS 2006 PIPE exposure to adverse patient outcomes. To reduce PIPE, it seems necessary to provide additional evidence for clinicians through the conducting of a well-designed study to assess patient outcomes associated with PIPE exposure as defined by the HEDIS criteria. C1 VERDICT, S Texas Vet Healthcare Syst, Audie L Murphy Div 11C6, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equit Res, Pittsburgh, PA USA. Univ Pittsburgh, Dept Geriatr Med, Pittsburgh, PA 15260 USA. Univ Toronto, Sch Med, Toronto, ON, Canada. Univ Toronto, Sch Nursing, Toronto, ON, Canada. VA Hlth Serv Res & Dev Serv, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. RP Pugh, MJV (reprint author), VERDICT, S Texas Vet Healthcare Syst, Audie L Murphy Div 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM PughM@uthscsa.edu OI Pugh, Mary Jo/0000-0003-4196-7763 NR 60 TC 71 Z9 72 U1 0 U2 7 PU ACADEMY MANAGED CARE PHARMACY PI ALEXANDRIA PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA SN 1083-4087 J9 J MANAG CARE PHARM JI J. Manag. Care Pharm. PD SEP PY 2006 VL 12 IS 7 BP 537 EP 545 PG 9 WC Health Care Sciences & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA 096DA UT WOS:000241356000001 PM 16981799 ER PT J AU Wang, CH Gold, BG Kaler, LJ Yu, X Afentoulis, ME Burrows, GG Vandenbark, AA Bourdette, DN Offner, H AF Wang, Chunhe Gold, Bruce G. Kaler, Laurie J. Yu, Xiaolin Afentoulis, Michael E. Burrows, Gregory G. Vandenbark, Arthur A. Bourdette, Dennis N. Offner, Halina TI Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE axonal loss; demyelination; multiple sclerosis; T lymphocytes ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; STEM-CELL TRANSPLANTATION; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; T-CELLS; INFLAMMATORY DEMYELINATION; BRAIN-TISSUE; LESIONS; MICE; DISEASES AB Inflammation results in CNS damage in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), an animal model of MS. It is uncertain how much repair of injured myelin and axons can occur following highly selective anti-inflammatory therapy in EAE and MS. In this study, SJL/J mice with established EAE were treated successfully with an antigen-specific recombinant T cell receptor ligand (RTL), RTL401, a mouse I-A(s)/PLP-139-151 construct, after the peak of EAE. To define the mechanisms by which late application of RTL401 inhibits EAE, we evaluated mice at different time points to assess the levels of neuroinflammation and myelin and axon damage in their spinal cords. Our results showed that RTL401 administered after the peak of acute EAE induced a marked reduction in inflammation in the CNS, associated with a significant reduction of demyelination, axonal loss and ongoing damage. Electron microscopy showed that RTL-treated mice had reduced pathology compared with mice treated with vehicle and mice at the peak of disease, as demonstrated by a decrease in continued degeneration, increase in remyelinating axons and the presence of an increased number of small, presumably regenerative axonal sprouts. These findings indicate that RTL therapy targeting encephalitogenic T cells may promote CNS neuroregenerative processes. C1 Portland VA Med Ctr, Neuroimmunol Res, Portland, OR USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. RP Wang, CH (reprint author), Portland VA Med Ctr, Neuroimmunol Res, R&D 31,3710 SW US Vet Hosp Rd, Portland, OR USA. EM wangch@ohsu.edu FU NIAID NIH HHS [R01 AI043960, AI43960]; NINDS NIH HHS [NS46877, NS41965, R42 NS046877, R01 NS047661, NS47661, R41 NS046877, R01 NS041965] NR 35 TC 31 Z9 33 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD SEP PY 2006 VL 98 IS 6 BP 1817 EP 1827 DI 10.1111/j.1471-4159.2006.04081 PG 11 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 077MN UT WOS:000240033600011 PM 16899071 ER PT J AU Vandenbark, AA Chou, YK Burrows, GG Link, JM AF Vandenbark, Arthur A. Chou, Yuan K. Burrows, Gregory G. Link, Jason M. TI B cells with preferential affinity for partial (alpha 1 beta 1) MHC class II molecules may regulate pathogenic T cells in experimental encephalomyelitis SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Meeting Abstract CT 8th International Conference of Neuroimmunology CY OCT 15-19, 2006 CL Nagoya, JAPAN C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD SEP PY 2006 VL 178 SU 1 BP 162 EP 162 PG 1 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 099YG UT WOS:000241633101087 ER PT J AU Hashimoto, H Monserratt, L Nguyen, P Feil, D Harwood, D Mandelkern, MA Sultzer, DL AF Hashimoto, Hiroshi Monserratt, Lorena Nguyen, Peter Feil, Denise Harwood, Dylan Mandelkern, Mark A. Sultzer, David L. TI Anxiety and regional cortical glucose metabolism in patients with Alzheimer's disease SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article; Proceedings Paper CT 16th Annual Meeting of the American-Neuropsychiatry-Association CY FEB-MAR -, 2005 CL Bal Harbour, FL SP Amer Neuropsychiat Assoc ID POSTTRAUMATIC-STRESS-DISORDER; PANIC DISORDER; PSYCHOLOGICAL SYMPTOMS; NEUROPSYCHIATRIC INVENTORY; HUMAN AMYGDALA; SOCIAL PHOBIA; SPECT; ACTIVATION; AGITATION; PERFUSION AB In this study, the authors investigated the relationship between anxiety and regional cortical metabolism in Alzheimer's disease. Using the Neuropsychiatric Inventory (NPI), the authors evaluated anxiety in 41 patients with Alzheimer's disease. Regional cortical glucose metabolism was measured using [F-18] fluorodeoxyglucose positron emission tomography in the resting state. Relationships were assessed using voxel-based (SPM2) and anatomic region-based analyses. Higher NPI anxiety score (frequency X severity) was associated with lower metabolism in bilateral entorhinal cortex, anterior parahippocampal gyrus, and left superior temporal gyrus and insula. Functional activity changes in distinct regions of the cortex contribute to the expression of anxiety in Alzheimer's disease. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Hashimoto, H (reprint author), Osaka City Univ, Sch Med, Dept Neuropsychiat, Abeno Ku, 1-4-3 Asahi Machi, Osaka, Osaka 5458585, Japan. EM hashimotoh@med.osaka-cu.ac.jp FU NIMH NIH HHS [MH56031] NR 41 TC 15 Z9 16 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD FAL PY 2006 VL 18 IS 4 BP 521 EP 528 DI 10.1176/appi.neuropsych.18.4.521 PG 8 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 103BX UT WOS:000241861800008 PM 17135378 ER PT J AU Shaw, LJ Heller, GV Casperson, P Miranda-Peats, R Slornka, P Friedman, J Hayes, SW Schwartz, R Weintraub, WS Maron, DJ Dada, M King, S Teo, K Hartigan, P Boden, WE O'Rourke, RA Berman, DS AF Shaw, Leslee J. Heller, Gary V. Casperson, Paul Miranda-Peats, Romalisa Slornka, Piotr Friedman, John Hayes, Sean W. Schwartz, Ronald Weintraub, William S. Maron, David J. Dada, Marcin King, Spencer Teo, Koon Hartigan, Pamela Boden, William E. O'Rourke, Robert A. Berman, Daniel S. CA COURAGE Investigators TI Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424 SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE randomized trial; gated myocardial perfusion SPECT; prognosis; secondary prevention ID CORONARY-ARTERY-DISEASE; AMERICAN-HEART-ASSOCIATION; PRACTICE GUIDELINES COMMITTEE; LONG-TERM; MEDICAL THERAPY; TASK-FORCE; HYPERCHOLESTEROLEMIC PATIENTS; PREVENTIVE CARDIOLOGY; PROGNOSTIC VALUE; SILENT ISCHEMIA AB Background: Stress gated myocardial perfusion single photon emission computed tomography (gSPECT) is increasingly used before and after intercurrent therapeutic intervention and is the basis for ongoing evaluation in the Department of Veterans Affairs clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial. Methods and Results: The COURAGE trial is a North American multicenter randomized clinical trial that enrolled 2287 patients to aggressive medical therapy vs percutaneous coronary intervention plus aggressive medical therapy. Three COURAGE nuclear substudies have been designed. The goals of substudy 0 are to examine the diagnostic accuracy of the extent and severity of inducible ischemia at baseline in COURAGE patients compared with patient symptoms and quantitative coronary angiography and to explore the relationship between inducible ischemia and the benefit from revascularization when added to medical therapy. Substudy 1 will correlate the extent and severity of provocative ischemia with the frequency, quality, and instability of recurrent symptoms in postcatheterization patients. Substudy 2 (n = 300) will examine the usefulness of sequential gSPECT monitoring 6 to 18 months after therapeutic intervention. Together, these nuclear substudies will evaluate the role of gSPECT to determine the effectiveness of aggressive risk-factor modifications, lifestyle interventions, and anti-ischemic medical therapies with or without revascularization in reducing patients' ischemic burdens. Conclusions: The unfolding of evidence on the application of gSPECT in trials such as COURAGE defines a new era for nuclear cardiology. We hope the evidence that emerges from the COURAGE trial will further establish the role of nuclear imaging in the evidence-based management of patients with stable coronary disease. C1 Univ Calif Los Angeles, Cedars Sinai Med Ctr, David Geffen Sch Med, Los Angeles, CA 90048 USA. Hartford Hosp, Hartford, CT 06115 USA. S Texas Vet Healthcare Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. Univ Rochester, Med Ctr, Rochester, NY 14627 USA. Vanderbilt Univ, Med Ctr, Christiana Med Ctr, Nashville, TN USA. McMaster Univ, Hamilton, ON L8S 4L8, Canada. RP Berman, DS (reprint author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, David Geffen Sch Med, Room 1258,Taper Bldg,8700 Beverly Blvd, Los Angeles, CA 90048 USA. EM daniel.berman@cshs.org NR 61 TC 26 Z9 28 U1 1 U2 3 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 1071-3581 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD SEP-OCT PY 2006 VL 13 IS 5 BP 685 EP 698 DI 10.1016/j.nuclcard.2006.06.134 PG 14 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 081ME UT WOS:000240320900014 PM 16945749 ER PT J AU Spinale, FG Escobar, GP Hendrick, JW Clark, LL Camens, SS Mingoia, JP Squires, CG Stroud, RE Ikonomidis, JS AF Spinale, Francis G. Escobar, G. Patricia Hendrick, Jennifer W. Clark, Leslie L. Camens, Sarah S. Mingoia, Joseph P. Squires, Christina G. Stroud, Robert E. Ikonomidis, John S. TI Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: Differential effects on short and long-term survival SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID LEFT-VENTRICULAR ENLARGEMENT; PREVENTS CARDIAC RUPTURE; HEART-FAILURE; TARGETED DELETION; MATRIX-METALLOPROTEINASE-9; MOLECULES; STRESS; TRIALS; CANCER AB Left ventricular (LV) remodeling occurs after myocardial infarction (MI), and the matrix metalloproteinases ( MMPs) contribute to adverse LV remodeling after MI. Short-term pharmacological MMP inhibition (MMPi; days to weeks) in animal models of MI have demonstrated a reduction in adverse LV remodeling. However, the long-term effects (months) of MMPi on survival and LV remodeling after MI have not been examined. MI was induced in adult mice (n = 131) and, at 3 days post-MI, assigned to MMPi [MI- MMPi: (s)-2-(4-bromo-biphenyl-4-sulfonylamino)3- methyl-butyric acid (PD200126), 7.5 mg/day/ p.o., n = 64] or untreated (MI-only, n = 67). Unoperated mice ( n = 16) served as controls. The median survival in the MI- only group was 5 days, whereas median survival was significantly greater in the MI-MMPi group at 38 days ( p < 0.05). However, with prolonged MMPi ( > 120 days), a significant divergence in the survival curves occurred in which significantly greater mortality was observed with prolonged MMPi ( p < 0.05). LV echo-cardiography at 6 months revealed LV dilation in the MI- only and MI- MMPi groups ( 154 +/- 14 and 219 +/- 24 mu l) compared with control (67 +/- 14 mu l, p < 0.05), with a greater degree of dilation in the MI- MMPi group ( p < 0.05). MMPi conferred a beneficial effect on survival early post-MI, but prolonged MMPi ( > 3 months) was associated with higher mortality and adverse LV remodeling. These unique results suggest that an optimal temporal window exists with respect to pharmacological interruption of MMP activity in the post-MI period. C1 Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. EM wilburnm@musc.edu FU NCRR NIH HHS [P20 RR16434]; NHLBI NIH HHS [P01 HL48788-08, HL59165] NR 37 TC 22 Z9 26 U1 1 U2 3 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD SEP PY 2006 VL 318 IS 3 BP 966 EP 973 DI 10.1124/jpet.106.104455 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 075IT UT WOS:000239878900005 PM 16757539 ER PT J AU Mukhin, YV Gooz, M Raymond, JR Garnovskaya, MN AF Mukhin, Yurii V. Gooz, Monika Raymond, John R. Garnovskaya, Maria N. TI Collagenase-2 and-3 mediate epidermal growth factor receptor transactivation by bradykinin B-2 receptor in kidney cells SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID ACTIVATED PROTEIN-KINASE; GONADOTROPIN-RELEASING-HORMONE; COLONIC EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; MATRIX METALLOPROTEINASES; ANGIOTENSIN-II; RENAL FIBROSIS; MAP KINASE; TRANSFORMING GROWTH; COUPLED RECEPTORS AB We have previously shown that stimulation of extracellular signal-regulated protein kinase (ERK) by bradykinin (BK) in murine inner medullary collecting duct (mIMCD)-3 cells is mediated by epidermal growth factor receptor ( EGFR) transactivation. The mechanism of EGFR transactivation seemed to be novel, because it does not require phospholipase C, Ca2+, calmodulin, protein kinase C, G alpha(i) subunits, or EGFR-B-2 receptor heterodimerization. In this study, we demonstrated the involvement of matrix metalloproteinases ( MMPs) in B-2 receptor-induced EGFR transactivation using their broad-spectrum inhibitors batimastat and N-[(2R)-2-( hydroxamidocarbonylmethyl)4- methylpentanoyl]-L-tryptophan methylamide ( Galardin) (GM-6001). Selective inhibitors for collagenase-2 and -3 (MMP-8 and MMP-13, respectively) blocked BK-induced EGFR phosphorylation and ERK activation, whereas inhibitors for MMP-1, -2, -3, - 7, or - 9 were without effect. Transfection of mIMCD- 3 cells with MMP-8 small interfering RNA ( siRNA) resulted in similar to 50% decrease of BK-induced ERK activation. A neutralizing antibody against MMP-13 as well as transfection with MMP-13 siRNA produced a similar effect. Inhibition of both collagenases resulted in similar to 65% decrease of BK-induced ERK activation, supporting roles for both enzymes. Stimulation of mIMCD-3 cells with 10 nM BK increased the activity of collagenases in concentrated culture media within 10 min. Moreover, recombinant MMP-13 and MMP-8, when applied to mIMCD-3 cells for 10 min without BK, stimulated tyrosine phosphorylation of EGFR and caused similar to 250% increase over basal ERK phosphorylation comparable with BK-induced ERK activation. Collagenases-induced ERK activation was inhibited by 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (AG-1478) and thus dependent on EGFR tyrosine kinase activity. This study demonstrates a novel role for collagenase-2 and -3 in signaling of the G(q)-coupled BK B-2 receptor in mIMCD-3 cells. C1 Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. RP Garnovskaya, MN (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, 96 Jonathan Lucas St,Room 829 CSB,POB 250623, Charleston, SC 29425 USA. EM garnovsk@musc.edu FU NCRR NIH HHS [S10RR013005]; NIDDK NIH HHS [DK52448-02, DK02694] NR 40 TC 14 Z9 16 U1 0 U2 1 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD SEP PY 2006 VL 318 IS 3 BP 1033 EP 1043 DI 10.1124/jpet.106.104000 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 075IT UT WOS:000239878900012 PM 16717107 ER PT J AU Lopez-Meraz, ML Neri-Bazan, L Rocha, L AF Lopez-Meraz, M. L. Neri-Bazan, L. Rocha, L. TI Indorenate modifies a(1)-adrenergic and benzodiazepine receptor binding in the rat brain: an autoradiography study SO JOURNAL OF PHARMACY AND PHARMACOLOGY LA English DT Article ID DORSAL RAPHE NUCLEUS; ANXIOLYTIC ACTION; 5-HT1A RECEPTOR; SEROTONIN; SUBTYPES; AGONISTS; GABA; RECOMBINANT; INVOLVEMENT; ANTAGONISTS AB Indorenate (5-methoxytryptamine-ss-methylcarboxylate) is a 5-HT1A receptor agonist that produces anti hypertensive, anxiolytic, antidepressant and anticonvulsant effects. However, there is evidence suggesting that these effects could involve the activation of benzodiazepine (BZD) receptors but not the activation of a(1)-adrenergic receptors. The goal of this study was to analyse the effect of inclorenate on a(1)-adrenergic and BZD receptor binding in specific rat brain areas by using in-vitro autoradiography. Coronal brain sections from male Wistar rats were used for labelling 5-HT1A (H-3-8-OH-DFAT, 2 nM), a(1)-adrenergic (H-3-prazosin, 2 nM) and BZD (H-3-flunitrazepam, 2 nM) receptor binding in the presence or absence of inclorenate (1 mu m). Indorenate totally displaced H-3-8-OH-DPAT binding in all the brain areas evaluated. It decreased H-3-prazosin binding just in the frontal (30%) and sensorimotor (32%) cortices and in the thalamus (21%). Additionally, inclorenate diminished H-3-flunitrazepam binding only in the cingulate (16%) and piriform (18%) cortices as well as in the dorsal raphe nucleus (18%). These results confirm that inclorenate is a 5-HT1A ligand and suggest the possible participation of a(1)-adrenergic and BZD receptors in its pharmacological properties. C1 Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, Los Angeles, CA USA. Ctr Invest & Estudios Avanzados, Dept Farmacobiol, Mexico City, DF, Mexico. RP Lopez-Meraz, ML (reprint author), VA Med Ctr, 11301 Wilshire Blvd,Bldg 114,Room 139,W, Los Angeles, CA 90073 USA. EM lopezmerazml@ucla.edu NR 38 TC 2 Z9 2 U1 0 U2 0 PU PHARMACEUTICAL PRESS-ROYAL PHARMACEUTICAL SOC GREAT BRITIAN PI LONDON PA 1 LAMBETH HIGH ST, LONDON SE1 7JN, ENGLAND SN 0022-3573 J9 J PHARM PHARMACOL JI J. Pharm. Pharmacol. PD SEP PY 2006 VL 58 IS 9 BP 1243 EP 1248 DI 10.1211/jpp.58.9.0011 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 085DG UT WOS:000240582800011 PM 16945183 ER PT J AU Gvilia, I Mcginty, D Szymusiak, R AF Gvilia, I. Mcginty, D. Szymusiak, R. TI Neuronal activation in the preoptic area during different levels of sleep drive SO JOURNAL OF SLEEP RESEARCH LA English DT Meeting Abstract CT 18th Congress of the European-Sleep-Research-Society CY SEP 12-16, 2006 CL Innsbruck, AUSTRIA SP European Sleep Res Soc C1 I Beritashvili Inst Physiol, Tbilisi, Rep of Georgia. VA Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0962-1105 J9 J SLEEP RES JI J. Sleep Res. PD SEP PY 2006 VL 15 SU 1 BP 66 EP 66 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 076NW UT WOS:000239966000157 ER PT J AU Costello, RM AF Costello, Raymond M. TI Long-term mortality from alcoholism: A descriptive analysis SO JOURNAL OF STUDIES ON ALCOHOL LA English DT Article ID FOLLOW-UP; CONSUMPTION; COHORT; MEN AB Objective: Short-term alcoholism mortality studies are limited in their ramifications for long-term, comprehensive treatment program planning. Therefore, this study was pursued for more than 33 years to answer questions such as how, when, and why alcoholics die after discharge from an intermediate care component of a comprehensive community-based treatment program. Method: A cohort of 500 alcoholics admitted in five groups of 100 in the years 1963, 1964, 1967, 1970, and 1972 to an intermediate care unit of a community-based, comprehensive treatment program was tracked for 33-42 years to document deaths. Case-fatality rate (CFR) and cause-specific mortality rate were computed and correlated with follow-up lag and ethnicity. Results: Four hundred and forty nine subjects died within 39 years, with 50% of the deaths occurring by Year 11. Average annual CFR was .057. Cause-specific mortality varied over time and with ethnicity. Deaths attributable to lifestyle causes (i.e., suicide, homicide, accidents, and AIDS) occurred disproportionately in the earlier years of the follow-up, claiming the youngest and ethnic minority (black and Hispanic) persons disproportionately to white. Whites tended to live longer, but all three racial/ethnic groups died of lifestyle causes at young ages, early in the follow-up series, and at relatively older ages from cancer and diseases of the lung late in the follow-up series. Conclusions: Comprehensive treatment programs must prepare for lifestyle crises soon after discharge from intermediate care and for organ diseases later. Ethnicity is a significant predictor of early death in alcoholic cohorts and must be considered in comprehensive treatment program planning. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Kerrville, TX 78028 USA. RP Costello, RM (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM costello@uthscsa.edu NR 19 TC 7 Z9 8 U1 1 U2 2 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 0096-882X J9 J STUD ALCOHOL JI J. Stud. Alcohol PD SEP PY 2006 VL 67 IS 5 BP 694 EP 699 PG 6 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 068JB UT WOS:000239368700006 PM 16847537 ER PT J AU Gray, SH Vick, C Graham, L Finan, K Neumayer, L Catarina, K Hawn, M AF Gray, Stephen H. Vick, Catherine Graham, Laura Finan, Kelly Neumayer, Leigh Catarina, Kiefe Hawn, Mary TI Unplanned enterotomy or bowel resection during elective hernia repair increases complications SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT 61st Annual Session of the Surgical Forum 2006 Clinical Congress CY OCT 08-12, 2006 CL Chicago, IL C1 Univ Alabama, Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2006 VL 203 IS 3 SU S BP S69 EP S69 PG 1 WC Surgery SC Surgery GA 082SF UT WOS:000240406800142 ER PT J AU Ochoa, O Shireman, PK McManus, LM AF Ochoa, Oscar Shireman, Paula K. McManus, Linda M. TI Altered inflammation increases intramuscular fat accumulation and impairs skeletal muscle regeneration following ischemic injury in CCR2-/-mice SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT 61st Annual Session of the Surgical Forum 2006 Clinical Congress CY OCT 08-12, 2006 CL Chicago, IL C1 UTHSCSA, S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2006 VL 203 IS 3 SU S BP S101 EP S101 DI 10.1016/j.jamcollsurg.2006.05.265 PG 1 WC Surgery SC Surgery GA 082SF UT WOS:000240406800221 ER PT J AU Friedlander, AH Norman, DC Mahler, ME Norman, KM Yagiela, JA AF Friedlander, Arthur H. Norman, Dean C. Mahler, Michael E. Norman, Keith M. Yagiela, John A. TI Alzheimer's disease - Psychopathology, medical management and dental implications SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Review DE dental treatment; Alzheimer's disease ID ADVERSE DRUG-INTERACTIONS; DOUBLE-BLIND; LATE-LIFE; CHOLINESTERASE-INHIBITORS; ASPIRATION PNEUMONIA; ADVANCED DEMENTIA; RISK-FACTORS; ORAL HEALTH; TRIAL; NEURODEGENERATION AB Background. The authors review the clinical features, epidemiology, pathophysiology, medical management, dental findings and dental treatment of patients with Alzheimer's disease (AD). Studies Reviewed. The authors conducted MEDLINE searches for 2000 through 2005 using the terms "Alzheimer's disease," "geriatric," "epidemiology," "pathophy iology," "treatment" and "dentistry." Reports selected for further review included those published in English peer-reviewed journals. The authors gave preference to articles reporting randomized, controlled trials. Results. AD is a progressive and fatal neurodegenerative disorder characterized by cognitive dysfunctions, particularly in learning. and, memory, and the emergence of behavioral abnormalities. Deficiencies in the cells responsible for storage and processing of information underlie the cognitive, functional and behavioral changes seen in, patients with the disorder. Clinical Implications. As the elderly population grows, increasing numbers of Americans with AD will require dental treatment. The prevalence of dental disease likely will be extensive, because of diminished salivary flow and patients' inability to perform appropriate oral hygiene techniques. Preventive dental education for the caregiver and use of saliva substitutes and anticaries agents by the patient are indicated. C1 VA Greater Los Angeles Healthcare Syst, Neurobehav Clin, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Hosp Dent Serv, Med Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Neurobehav Clin, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@med.va.gov NR 112 TC 28 Z9 30 U1 1 U2 11 PU AMER DENTAL ASSN PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD SEP PY 2006 VL 137 IS 9 BP 1240 EP 1251 PG 12 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 086IX UT WOS:000240668100020 PM 16946428 ER PT J AU Levine, DA Saag, KG Casebeer, LL Colon-Emeric, C Lyles, KW Shewchuk, RM AF Levine, Deborah A. Saag, Kenneth G. Casebeer, Linda L. Colon-Emeric, Cathleen Lyles, Kenneth W. Shewchuk, Richard M. TI Using a modified nominal group technique to elicit director of nursing input for an osteoporosis intervention SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE osteoporosis; nominal group technique; intervention; quality improvement ID CONTINUING MEDICAL-EDUCATION; BONE-MINERAL DENSITY; HIP FRACTURE; HOME RESIDENTS; OLDER-PEOPLE; MANAGEMENT; HEALTH; OPPORTUNITY; PHYSICIANS; OUTCOMES AB Background. Barriers prevent osteoporosis care in nursing homes. Successful interventions designed to circumvent these barriers benefit from target recipient input during development. Objective: To elicit suggestions for an osteoporosis quality improvement intervention designed for use by nursing home health care professionals. Design: Modified nominal group technique Setting: Convenience sample of Alabama nursing home directors. Participants: Fifteen Alabama nursing home directors of nursing were recruited by mailing. Sixty percent of respondents participated (n = 9). Measurements: In the first phase conducted via teleconference, an experienced moderator used a preformulated question and elicited 41 suggestions to improve osteoporosis care in nursing homes. Substantively similar suggestions were combined and idiosyncratic suggestions were discarded resulting in the retention of 20 suggestions. In the second phase conducted by mail, the same participants rated the 20 suggestions based on perceived practicality and helpfulness. Elements were grouped into tertiles based on the ranking of the mean ratings of the 2 attributes and then cross-tabulated. Results: All director of nursing (n = 9) participants completed both phases. The most practical, most helpful suggestions were information on fall prevention program implementation, osteoporosis treatment protocols, and osteoporosis medication information. Conclusions: A modified nominal group technique provided useful information from nursing home directors of nursing for an osteoporosis intervention. The technique proved efficient and facile to perform. C1 Univ Alabama, Div Gen Internal Med, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, HSR&D REAP, Deep S Ctr Effectiveness Res, Birmingham, AL USA. Univ Alabama, Dept Med, Ctr Educ & Res Therapeut Musculoskeletal Disorder, Birmingham, AL 35294 USA. Duke Univ, Med Ctr, Durham, NC USA. Durham VA Med Ctr, Durham, NC USA. Univ Alabama, Dept Hlth Adm, Birmingham, AL USA. RP Levine, DA (reprint author), Univ Alabama, Div Gen Internal Med, 1530 3rd Ave S,FOT 720, Birmingham, AL 35294 USA. EM dlevine@uab.edu FU NIA NIH HHS [K23 AG024787] NR 47 TC 12 Z9 13 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD SEP PY 2006 VL 7 IS 7 BP 420 EP 425 DI 10.1016/j.jamda.2006.05.004 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 090CX UT WOS:000240929300004 PM 16979085 ER PT J AU Bagby, SP AF Bagby, Susan P. TI Developmental origins of hypertension: Biology meets statistics SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID BLOOD-PRESSURE; BIRTH-WEIGHT; FETAL ORIGINS; CHILDHOOD GROWTH; ADULT LIFE; INSULIN-RESISTANCE; DISEASE; OBESITY; SIZE; ASSOCIATION C1 Oregon Hlth Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Bagby, SP (reprint author), Oregon Hlth Sci Univ, Div Nephrol & Hypertens, 3314 SW US Vet Hosp Rd,Suite PP 262, Portland, OR 97239 USA. EM bagbys@ohsu.edu NR 32 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2006 VL 17 IS 9 BP 2356 EP 2358 DI 10.1681/ASN.2006070744 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 078OP UT WOS:000240113400004 PM 16899513 ER PT J AU Schutzer, WE Hong, X Reed, JF Mader, SL AF Schutzer, William E. Hong Xue Reed, John F. Mader, Scott L. TI Effect of age on vascular beta(2)-adrenergic receptor desensitization is not mediated by the receptor coupling to G alpha i proteins SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID BETA-ADRENERGIC-RECEPTORS; SENSITIVE G-PROTEINS; SMOOTH-MUSCLE; RAT AORTA; KINASE-A; RESPONSES; ISOPROTERENOL; SYSTEM; PHOSPHORYLATION; EXPRESSION AB Beta-adrenergic receptor (beta-AR)-mediated vasorelaxation declines with age. In the vasculature, beta(2)-AR undergoes protein kinase A-mediated desensitization that causes a switch in the G protein coupled to beta(2)-AR; God links instead of G alpha s. We exposed Fischer 344 rat aortae of increasing age to a desensitizing dose of isoproterenol, and determined its effect on beta(2)-AR-mediated vasorelaxation. Desensitization decreased beta(2)-AR-mediated vasorelaxation in young aortae only. Subsequently, we used pertussis toxin to block God to determine whether changes in beta(2)-AR/G protein coupling occurred. God inhibition did not reverse desensitization or the age-related change, but there appears to be a population of beta(2)-AR linked to G alpha i, as pertussis toxin treatment improved beta(2)-AR-mediated vasorelaxation in aortae from animals of all ages. These findings suggest aortic beta(2)-AR in older animals may be maximally desensitized, which would explain impaired vasorelaxation. Our results also imply that protein kinase A-mediated beta(2)-AR desensitization may not be responsible for the age-related decline. C1 Portland VA Med Ctr, Res Serv, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Sch Med, Portland, OR USA. RP Mader, SL (reprint author), Portland VA Med Ctr, Res Serv, R&D 26,3710 SW US Vet Hosp Rd, Portland, OR 97201 USA. EM scott.mader@med.va.gov NR 48 TC 6 Z9 8 U1 1 U2 1 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD SEP PY 2006 VL 61 IS 9 BP 899 EP 906 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 085CP UT WOS:000240581100003 PM 16960020 ER PT J AU Calvert, JF Hollander-Rodriguez, J Kaye, J Leahy, M AF Calvert, James F., Jr. Hollander-Rodriguez, Joyce Kaye, Jeffrey Leahy, Marjorie TI Dementia-free survival among centenarians: An evidence-based review SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Review ID OLDEST-OLD; EXTREME LONGEVITY; EXCEPTIONAL LONGEVITY; DANISH CENTENARIANS; ALZHEIMER-DISEASE; FUNCTIONAL STATUS; PREVALENCE; AGE; HEALTH; MORBIDITY AB Background. The 2000 U.S. census identified 50,454 Americans older than 100 years (18 per 100,000). Increased longevity is only of benefit if accompanied by the maintenance of physical, social, and cognitive function into advanced age. The goal of this review was to identify research describing centenarians to find the prevalence of dementia-free survival. Methods. We reviewed 650 publications to find studies that described the prevalence of dementia in centenarians, were community-based, had data that were specific to persons older than 100 years, and were published in peer-reviewed journals. For each study, we identified the prevalence of dementia, the completeness of the sample, the number of study participants, the method used to diagnose dementia, and the duration of the study. Results. We identified 20 research groups from 14 countries with publications meeting our search criteria. The studies showed substantial variation in methods of assessing cognitive status, assuring a complete cohort, and sample size. Few studies reported longitudinal data or attempted diagnosis of the cause of dementia. The prevalence of dementia-free survival past 100 years of age varied between 0 and 50 percent. Conclusions. The methodology used in studies regarding dementia prevalence among centenarians is sufficiently varied that combination of existing studies into a meta-analysis is not possible. Suggestions for assuring quality in future centenarian research are presented. C1 Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. Merle W Ctr Med Res, Klamath Falls, OR USA. RP Calvert, JF (reprint author), 1453 Esplanade, Klamath Falls, OR 97601 USA. EM calvertj@ohsu.edu OI Kaye, Jeffrey/0000-0002-9971-3478 FU NIA NIH HHS [AG08017] NR 59 TC 10 Z9 10 U1 1 U2 5 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD SEP PY 2006 VL 61 IS 9 BP 951 EP 956 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 085CP UT WOS:000240581100009 PM 16960026 ER PT J AU Mowry, SE Ho, A LoTempio, MM Sadeghi, A Blackwell, KE Wang, MB AF Mowry, Sarah E. Ho, Allen LoTempio, Maria M. Sadeghi, Ahmad Blackwell, Keith E. Wang, Marilene B. TI Quality of life in advanced oropharyngeal carcinoma after chemoradiation versus surgery and radiation SO LARYNGOSCOPE LA English DT Article; Proceedings Paper CT 109th Annual Meeting of the Triological-Society CY MAY, 2006 CL Chicago, IL SP Triol Soc DE quality of life; oropharyngeal carcinoma ID NECK-CANCER; HEAD; CHEMOTHERAPY; RADIOTHERAPY AB Objective: The objective of this cohort study from a tertiary academic university practice was to identify differences in patients' perceived quality of life after either chemoradiation or surgery and radiation for advanced-stage oropharyngeal carcinoma. Methods: From institutional databases, thirty-five patients were identified who had undergone either primary chemoradiation or primary surgery and postoperative radiation for advanced oropharyngeal cancer (stage II-IV). Patients voluntarily responded by mail using the University of Washington quality-of-life instrument version 4 (UW-QOL). Data were analyzed using chi(2) and Wilcogon tests. Results: There were 17 patients who underwent chemoradiation and 18 patients who underwent surgery and postoperative radiation. All surgical patients had undergone free-flap reconstruction. Patients completed the UW-QOL an average of 25 months after treatment. There was no statistically significant difference between the two groups with regard to any specific domain, including pain, appearance, swallowing, chewing, speech, saliva, or mood. There was a trend toward significance for taste (P =.07) with chemoradiation patients reporting poorer taste function. The lack of difference in the patients' perception of appearance and swallowing was rather surprising given the vastly different treatment modalities. Respondents reported equivalent overall quality of life in response to global quality-of-life questions. Conclusion: Most patients with advanced oropharyngeal carcinoma report good quality of life after treatment, regardless of treatment modality. Although the short-term side effects of treatment may be different between the groups, long-term quality of life is remarkably similar whether the patients choose primary chemoradiation or surgery with postoperative radiation. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Head & Neck Surg, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Dept Radiat Oncol, Los Angeles, CA USA. RP Wang, MB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Head & Neck Surg, 10833 Le Conte Ave,CHS 62-132, Los Angeles, CA 90095 USA. EM mbwang@ucla.edu NR 13 TC 50 Z9 51 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD SEP PY 2006 VL 116 IS 9 BP 1589 EP 1593 DI 10.1097/01.mlg.0000233244.18901.44 PG 5 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 081OD UT WOS:000240326000012 PM 16954985 ER PT J AU Walters, DK Goss, VL Stoffregen, EP Gu, TL Lee, K Nardone, J McGreevey, L Heinrich, MC Deininger, MW Polakiewicz, R Druker, BJ AF Walters, Denise K. Goss, Valerie L. Stoffregen, Eric P. Gu, Ting-Lei Lee, Kimberly Nardone, Julie McGreevey, Laura Heinrich, Michael C. Deininger, Michael W. Polakiewicz, Roberto Druker, Brian J. TI Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes SO LEUKEMIA RESEARCH LA English DT Article DE AML; phosphopeptide; tyrosine kinases; leukemia ID ACUTE MYELOID-LEUKEMIA; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; CONSTITUTIVE ACTIVATION; MYELOGENOUS LEUKEMIA; PHOSPHORYLATION; MUTATION; INHIBITOR; GROWTH; STAT5 AB STAT5 is constitutively phosphorylated in leukemic cells in approximately 70% of acute myeloid leukemia (AML) patients. To identify kinase candidates potentially responsible for STAT5 phosphorylation, we used liquid chromatography-tandem mass spectrometry (LC-MS/MS) mass spectrometry to detect phosphoproteins in AML cell lines. We established TEL-ARG and BCR-ABL fusion proteins as the mechanism underlying STAT5 phosphorylation in HT-93 and KBM-3 cells, respectively. In addition, we identified a JAK2 pseudokinase domain mutation in HEL cells and using siRNA downregulation, established JAK2 as the kinase responsible for phosphorylating STAT5. This study illustrates the benefit of LC-MS/MS mass spectrometry and siRNA for the identification of novel targets and mutations. (c) 2006 Elsevier Ltd. All rights reserved. C1 Oregon Hlth Sci Univ, Inst Canc, Howard Hughes Med Inst, Dept Hematol & Oncol, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. Cell Signaling Technol Inc, Beverly, MA 01915 USA. RP Walters, DK (reprint author), Oregon Hlth Sci Univ, Inst Canc, Howard Hughes Med Inst, Dept Hematol & Oncol, 3181 Sam Jackson Pk Rd, Portland, OR 97239 USA. EM waltersd@ohsu.edu NR 26 TC 42 Z9 44 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2126 J9 LEUKEMIA RES JI Leuk. Res. PD SEP PY 2006 VL 30 IS 9 BP 1097 EP 1104 DI 10.1016/j.leukres.2006.01.001 PG 8 WC Oncology; Hematology SC Oncology; Hematology GA 071RV UT WOS:000239620500010 PM 16464493 ER PT J AU Pietz, K Byrne, MM Petersen, LA AF Pietz, Kenneth Byrne, Margaret M. Petersen, Laura A. TI A decision-theoretic approach to identifying future high-cost patients SO MEDICAL CARE LA English DT Article DE risk adjustment; logistic regression; decision theory; cost; diagnostic cost groups ID HEALTH PLANS; MEDICAL-CARE; OUTCOMES; USERS AB Objective: The objective of this study was to develop and evaluate a method of allocating funding for very-high-cost (VHC) patients among hospitals. Research Design: Diagnostic cost groups (DCGs) were used for risk adjustment. The patient population consisted of 253,013 veterans who used Department of Veterans Affairs (VA) medical care services in fiscal year (FY) 2003 (October 1, 2002-September 30, 2003) in a network of 8 VA hospitals. We defined VHC as greater than $75,000 (0.81%). The upper fifth percentile was also used for comparison. Methods: A Bayesian decision rule for classifying patients as VHC/not VHC using DCGs was developed and evaluated. The method uses FY 2003 DCGs to allocate VHC funds for FY 2004. We also used FY 2002 DCGs to allocate VHC funds for FY 2003 for comparison. The resulting allocation was compared with using the allocation of VHC patients among the hospitals in the previous year. Results: The decision rule identified DCG 17 as the optimal cutoff for identifying VHC patients for the next year. The previous year's allocation came closest to the actual distribution of VHC patients. Conclusions: The decision-theoretic approach may provide insight into the economic consequences of classifying a patient as VHC or not VHC. More research is needed into methods of identifying future VHC patients so that capitation plans can fairly reimburse healthcare systems for appropriately treating these patients. C1 Houston Vet Affairs Med Ctr, Div Hlth Policy & Qual, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33152 USA. RP Pietz, K (reprint author), Houston Vet Affairs Med Ctr, Div Hlth Policy & Qual, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Ctr Excellence, Hlth Serv Res & Dev 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM kpietz@bcm.tmc.edu NR 19 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD SEP PY 2006 VL 44 IS 9 BP 842 EP 849 DI 10.1097/01.mlr.0000220680.19667.da PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 080PV UT WOS:000240260900007 PM 16932136 ER PT J AU Garcia, AD Thomas, DR AF Garcia, Aimee Dinorah Thomas, David R. TI Assessment and management of chronic pressure ulcers in the elderly SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Review ID RISK-ASSESSMENT SCALES; PROVISIONAL MATRIX; DECUBITUS ULCERS; SORE PREVENTION; NURSING-HOME; HUMAN SKIN; FIBRONECTIN; NUTRITION; PATHOPHYSIOLOGY; MALNUTRITION AB The aging population is increasing the number of individuals at risk for pressure ulcer formation. Risk factors, such as immobility, poor nutrition, comorbidities, and aging skin, make the elderly more susceptible to pressure ulcer formation. The key to management is prevention, but once pressure ulcers occur, it is important to understand the principles of wound healing including debridement, bacterial management, moist wound healing, pressure relief, and nutritional support. C1 Baylor Coll Med, VA Med Ctr, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. St Louis Univ, Div Geriatr Med, St Louis, MO 63104 USA. RP Garcia, AD (reprint author), Baylor Coll Med, VA Med Ctr, Michael E DeBakey VA Med Ctr, 2002 Holcombe ECL 110, Houston, TX 77030 USA. EM aimeeg@bcm.tmc.edu NR 103 TC 27 Z9 27 U1 2 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD SEP PY 2006 VL 90 IS 5 BP 925 EP + DI 10.1016/j.mcna.2006.05.018 PG 22 WC Medicine, General & Internal SC General & Internal Medicine GA 089MV UT WOS:000240885600011 PM 16962850 ER PT J AU Lewinsohn, DM Tydeman, IS Frieder, M Grotzke, JE Lines, RA Ahmed, S Prongay, KD Primack, SL Colgin, LMA Lewis, AD Lewinsohn, DA AF Lewinsohn, David M. Tydeman, Ian S. Frieder, Marisa Grotzke, Jeff E. Lines, Rebecca A. Ahmed, Sheela Prongay, Kamm D. Primack, Steven L. Colgin, Lois M. A. Lewis, Anne D. Lewinsohn, Deborah A. TI High resolution radiographic and fine immunologic definition of TB disease progression in the rhesus macaque SO MICROBES AND INFECTION LA English DT Article DE tuberculosis; CT scanning; macaque ID MYCOBACTERIUM-TUBERCULOSIS INFECTION; PULMONARY TUBERCULOSIS; CELLS; RESPONSES; LYMPHOCYTES; RESEMBLES; THERAPY; PROTEIN AB Mycobacterium tuberculosis infection in non-human primates parallels human tuberculosis, and provides a valuable vaccine evaluation model. However. this model is limited by the availability of real-time, non-invasive information regarding disease progression. Consequently, we have combined computed tomography scanning with enumeration of antigen-specific T cell responses. Four rhesus monkeys were infected with M. tuberculosis strain H37Rv (1000 cfu) in the right lower lobe via a bronchoscope. All uniformly developed progressive tuberculosis, and required euthanasia at 12 weeks. Computed tomography scanning provided detailed real-time imaging of disease progression. At necropsy, computed tomography and pathohistologic findings were tightly correlated, and characteristic of human disease. Immunologic monitoring demonstrated progressive evolution of high frequency M. tuberculosis-specific CD4(+) and CD8(+) T cell responses. Peripheral blood effector cell frequencies were similar to those observed in tissues. In summary, computed tomography scanning in conjunction with immunologic monitoring provides a non-invasive, accurate, and rapid assessment of tuberculosis in the non-human primate. Published by Elsevier Masson SAS. C1 Portland VA Med Ctr, Pulm & CCM, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA. Oregon Hlth Sci Univ, Dept Pediat, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Comparat Med, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Radiol, Portland, OR 97239 USA. Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA. RP Lewinsohn, DM (reprint author), Portland VA Med Ctr, Pulm & CCM, R&D 11,3710 SW US Vet Rd, Portland, OR 97239 USA. EM lewinsod@ohsu.edu RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 FU NCRR NIH HHS [RR15104]; NIAID NIH HHS [1K08AI01644, 1K08AI01645, R01AI48090]; NICHD NIH HHS [HD33703] NR 25 TC 40 Z9 40 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1286-4579 J9 MICROBES INFECT JI Microbes Infect. PD SEP PY 2006 VL 8 IS 11 BP 2587 EP 2598 DI 10.1016/j.micinf.2006.07.007 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 107YO UT WOS:000242207100003 PM 16952476 ER PT J AU Zarnitz, P Malone, E AF Zarnitz, Patricia Malone, Ellen TI Surgical nurse practitioners as registered nurse first assists: The role, historical perspectives, and educational training SO MILITARY MEDICINE LA English DT Article AB Advanced practice nurses (APN) who practice in the surgical subspecialty areas may have the opportunity to expand their scope of practice to include first assistant at surgery. Surgical APNs who practice as registered nurse first assistants (RNFA) should seek credentialing and apply for institutional privileges to assure the consumer of competent providers. Credentialing as an RNFA documents the educational learning process and skills acquired, and recognizes this area of expertise. The role of the APN as an RNFA at surgery is practiced within the specialty area of perioperative nursing which includes preoperative, intraoperative, and postoperative care. In this study, the nurse practitioners describe the role of the RNFA, its historical evolution over wartime, the required educational training, and the benefits of the role for patient care. The surgical nurse practitioner who undertakes training and education as a surgical RNFA is in an excellent position to provide patient care across the surgical continuum. C1 Philadelphia Vet Affairs Med Ctr, Dept Surg Sci, Philadelphia, PA 19104 USA. RP Zarnitz, P (reprint author), Philadelphia Vet Affairs Med Ctr, Dept Surg Sci, Univ & Woodland Ave, Philadelphia, PA 19104 USA. NR 23 TC 0 Z9 0 U1 0 U2 2 PU ASSN MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD SEP PY 2006 VL 171 IS 9 BP 875 EP 878 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 084LN UT WOS:000240534500015 PM 17036610 ER PT J AU Jackson, L Tabatabai, ZL AF Jackson, Lorren Tabatabai, Z. Laura TI Utility of fine needle aspiration cytology (FNAC) in the evaluation of superficial, palpable masses clinically presumed to be lymph nodes: A 5-year retrospective review with histopathological and clinical correlation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 26th International Congress of the International-Academy-of-Pathology CY SEP 16-21, 2006 CL Montreal, CANADA SP Int Acad Pathol, United States & Canadian Acad Pathol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD SEP PY 2006 VL 19 SU 3 MA 142 BP 34 EP 34 PG 1 WC Pathology SC Pathology GA 077AF UT WOS:000239999400143 ER PT J AU Posligua, L Michael, I Bhuvaneswari, K AF Posligua, Lorena Michael, Ittmann Bhuvaneswari, Krishnan TI Cellular angiofibroma of the corpus spongiosum: Case report SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 26th International Congress of the International-Academy-of-Pathology CY SEP 16-21, 2006 CL Montreal, CANADA SP Int Acad Pathol, United States & Canadian Acad Pathol C1 Baylor Coll Med, Houston, TX 77030 USA. Baylor Sch Med, Michael E DE Bakey VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD SEP PY 2006 VL 19 SU 3 MA 202 BP 47 EP 47 PG 1 WC Pathology SC Pathology GA 077AF UT WOS:000239999400203 ER PT J AU Brodsky, MA Hogarth, P Nutt, JG AF Brodsky, Matthew A. Hogarth, Penelope Nutt, John G. TI OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; dyskinesia; deep brain stimulation ID HIGH-FREQUENCY STIMULATION; GLOBUS-PALLIDUS; LEVODOPA AB A 61-year-old man with Parkinson's disease (PD), motor fluctuations, and dyskinesias underwent bilateral implantation of deep brain stimulation (DBS) electrodes in the subthalamic nucleus (STN). One month after surgery, DBS was optimized to bilateral monopolar settings at the most proximal electrode just superior to the STN, which improved motor fluctuations and dyskinesias. At several postoperative evaluations off medications overnight, both stimulators were turned off and within 60 seconds he developed severe dyskinesias. When the stimulators were turned back on, the dyskinesias soon resolved. This article is a first report of a unique pattern of rebound-type dyskinesia that occurred in the off medication state produced by stopping STN DBS. (c) 2006 Movement Disorder Society. C1 Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Care Ctr, Portland, OR USA. RP Brodsky, MA (reprint author), Oregon Hlth & Sci Univ, Parkinson Ctr Oregon, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM brodskym@ohsu.edu NR 15 TC 7 Z9 7 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP PY 2006 VL 21 IS 9 BP 1487 EP 1490 DI 10.1002/mds.20964 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 091AO UT WOS:000240998100031 PM 16721730 ER PT J AU Samii, A Kelly, VE Slimp, JC Shumway-Cook, A Goodkin, R AF Samii, A. Kelly, V. E. Slimp, J. C. Shumway-Cook, A. Goodkin, R. TI Unilateral vs. bilateral subthalamic nucleus deep brain stimulation in Parkinson's disease SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 20th Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinsons Disease and Other Movement Disorders CY OCT 08, 2006 CL Chicago, IL C1 Univ Washington, Dept Neurol, PADRECC, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP PY 2006 VL 21 IS 9 BP 1552 EP 1553 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 091AO UT WOS:000240998100080 ER PT J AU Walker, M Kim, HM Samii, A AF Walker, M. Kim, H. M. Samii, A. TI Lower limb Holmes tremor with hypertrophic olivary degeneration SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 20th Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinsons Disease and Other Movement Disorders CY OCT 08, 2006 CL Chicago, IL C1 Univ Washington, Dept Neurol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. VA Puget Sound Hlth Care Syst, PADRECC, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP PY 2006 VL 21 IS 9 BP 1556 EP 1556 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 091AO UT WOS:000240998100092 ER PT J AU Bergmann, C Sano, M AF Bergmann, Christine Sano, Mary TI Cardiac risk factors and potential treatments in Alzheimer's disease SO NEUROLOGICAL RESEARCH LA English DT Review DE Alzheimer's disease; risk factor; hypertension; diabetes mellitus; hyperlipidemia; cognition ID ANTIHYPERTENSIVE-MEDICATION-USE; ISOLATED SYSTOLIC HYPERTENSION; LIPID-LOWERING AGENTS; IMPROVED GLYCEMIC CONTROL; IMPAIRED FASTING GLUCOSE; CALCIUM-CHANNEL BLOCKERS; TOTAL CHOLESTEROL LEVEL; POPULATION-BASED COHORT; ELDERLY PROGRAM SHEP; AGED 75 YEARS AB Dementia is one of the commonest neurological disorders in the elderly population. In regards to the increasing longevity of populations worldwide, prevention of dementia has become a major public health challenge. There has been an intense research in the identification of modifiable risk factors for dementia. These risk factors could then be used as targets for intervention, pharmacologic or non-pharmacologic. Numerous reports of the relation between cardiovascular risk factors and cognitive decline and dementia have been published over the past years. This review focuses on the cardiovascular risk factors hypertension, hyperlipidemia and diabetes mellitus as targets for prevention of cognitive decline, overall dementia and Alzheimer's disease. Observational studies and clinical trials regarding the association between antihypertensive, lipid lowering and antidiabetic medications and the risk of impaired cognition, dementia or Alzheimer's disease are reviewed. Based on these data, we propose that early interventions at reducing these cardiovascular risk factors may have an impact on future incidence and prevalence of cognitive deficits of many etiologies including Alzheimer's disease. C1 Mt Sinai Sch Med, Alzheimer Dis Res Ctr, New York, NY USA. James J Peters VAMC, Bronx, NY USA. RP Sano, M (reprint author), Mt Sinai Sch Med, 130 Kingsbridge Rd,Rm1F01, Bronx, NY 10468 USA. EM mary.sano@mssm.edu NR 135 TC 24 Z9 25 U1 2 U2 7 PU MANEY PUBLISHING PI LEEDS PA HUDSON RD, LEEDS LS9 7DL, ENGLAND SN 0161-6412 J9 NEUROL RES JI Neurol. Res. PD SEP PY 2006 VL 28 IS 6 BP 595 EP 604 DI 10.1179/016164106X130498 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 078YI UT WOS:000240142300004 PM 16945210 ER PT J AU Buchsbaum, MS Buchsbaum, BR Chokron, S Tang, C Wei, TC Byne, W AF Buchsbaum, Monte S. Buchsbaum, Bradley R. Chokron, Sylvie Tang, Cheuk Wei, Tse-Chung Byne, William TI Thalamocortical circuits: fMRI assessment of the pulvinar and medial dorsal nucleus in normal volunteers SO NEUROSCIENCE LETTERS LA English DT Article DE attention; blood oxygen level; cerebral blood flow; flanker task ID POSITRON-EMISSION-TOMOGRAPHY; ATTENTIONAL CONTROL; EFFECTIVE CONNECTIVITY; MEDIODORSAL NUCLEUS; GLUCOSE-METABOLISM; PREFRONTAL CORTEX; RHESUS-MONKEY; FRONTAL-LOBE; HUMAN BRAIN; SCHIZOPHRENIA AB This fMRI study investigates the activation of the thalamic nuclei in a spatial focusing-of-attention task previously shown to activate the pulvinar with FDG-PET and assesses the connectivity of the thalamic nuclei with cortical areas. Normal right-handed subjects (eight men, eight women, average age=32 years) viewed four types of stimuli positioned to the right or left of the central fixation point (left hemifield-large letter, left hemitield-small letter display with flanking letters; fight hemifield-large letter, fight hemifield-small letter display with flankers). BOLD responses to small letters surrounded by flankers were compared with responses to large isolated letters. To examine maximum functional regional connectivity, we modeled "subject" as a random effect and attained fixed effect parameter estimates and t-statistics for functional connectivity between each of the thalamic nuclei (pulvinar, medial dorsal, and anterior) as the seed region and each non-seed voxel. Greater BOLD activation for letters surrounded by flankers than for large letters was observed in the pulvinar as anticipated and was also marked in the medial dorsal nucleus (MDN), anterior and superior cingulate (BA24 and BA24' dorsolateral prefrontal cortex, and frontal operculum and insula. For the MDN, maximal functional connectivity was with the dorsolateral prefrontal cortex; correlations with left superior temporal, parietal, posterior frontal, and occipital regions were also observed. For the pulvinar, maximal functional connectivity was with parietal BA39; for anterior thalamus, with anterior cingulate. (c) 2006 Published by Elsevier Ireland Ltd. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. NIMH, Unit Integrat Neuroimaging, Clin Brain Disorders Branch, NIH, Bethesda, MD 20892 USA. CNRS, Expt Psychol Lab, UMR 5105, Grenoble, France. Fdn Ophthalmol Rothschild, Neurol Serv, Paris, France. Mt Sinai Sch Med, Dept Radiol, New York, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. RP Buchsbaum, MS (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1505, New York, NY 10029 USA. EM monte.buchsbaum@mssm.edu FU NIMH NIH HHS [MH-60023] NR 38 TC 29 Z9 29 U1 1 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD SEP 1 PY 2006 VL 404 IS 3 BP 282 EP 287 DI 10.1016/j.neulet.2006.05.063 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 079GM UT WOS:000240163800008 PM 16860474 ER PT J AU Khan, M Jatana, M Elango, C Paintlia, AS Singh, AK Singh, I AF Khan, Mushfiquddin Jatana, Manu Elango, Chinnasamy Paintlia, Ajaib Singh Singh, Avtar K. Singh, Inderjit TI Cerebrovascular protection by various nitric oxide donors in rats after experimental stroke SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY LA English DT Article DE cerebral ischemia; nitric oxide; nitrosoglutathione; vasculature; NO donors; endothelial dysfunction ID FOCAL CEREBRAL-ISCHEMIA; BRAIN DOPAMINE NEURONS; S-NITROSOGLUTATHIONE; SODIUM-NITROPRUSSIDE; LIPID-PEROXIDATION; OXIDATIVE STRESS; ENDOTHELIAL DYSFUNCTION; REDUCES INFLAMMATION; REPERFUSION INJURY; L-ARGININE AB The efficacy of nitric oxide (NO) treatment in ischemic stroke, though well recognized, is yet to be tested in clinic. NO donors used to treat ischemic injury are structurally diverse compounds. We have shown that treatment of S-nitrosoglutathione (GSNO) protects the brain against injury and inflammation in rats after experimental stroke [M. Khan, B. Sekhon, S. Giri, M. Jatana, A. G. Gilg, K. Ayasolla, C. Elango, A. K. Singh, I. Singh, S-Nitrosoglutathione reduces inflammation and protects brain against focal cerebral ischemia in a rat model of experimental stroke, J. Cereb. Blood Flow Metab. 25 (2005) 177-192.]. In this study, we tested structurally different NO donors including GSNO, S-nitroso-N-acetyl-penicillamine (SNAP), sodium nitroprusside (SNP), methylamine hexamethylene methylamine NONOate (MAHMA), propylamine propylamine NONOate (PAPA), 3-morpholinosydnonimine (SIN-1) and compared their neuroprotective efficacy and antioxidant property in rats after ischemia/reperfusion (I/R). GSNO, in addition to neuroprotection, decreased nitrotyrosine formation and lipid peroxidation in blood and increased the ratio of reduced versus oxidized glutathione (GSH/GSSG) in brain as compared to untreated animals. GSNO also prevented the I/R-induced increase in mRNA expression of ICAM-1 and E-Selectin. SNAP and SNP extended limited neuroprotection, reduced nitrotyrosine formation in blood and blocked increase in mRNA expression of ICAM-1 and E-Selectin in brain tissue. PAPA, MAHMA, and SIN-I neither protected the brain nor reduced oxidative stress. We conclude that neuroprotective action of NO donors in experimental stroke depends on their ability to reduce oxidative stress both in brain and blood. (c) 2006 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. EM khanm@musc.edu FU NCRR NIH HHS [C06 RR015455]; NINDS NIH HHS [NS-22576, NS-34741, NS-37766, NS-40144, NS-40810] NR 60 TC 53 Z9 56 U1 0 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1089-8603 J9 NITRIC OXIDE-BIOL CH JI Nitric Oxide-Biol. Chem. PD SEP PY 2006 VL 15 IS 2 BP 114 EP 124 DI 10.1016/j.niox.2006.01.008 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 077DG UT WOS:000240007300003 PM 16524750 ER PT J AU Lin, AL Johnson, DA Sims, CA Stephan, KT Yeh, CK AF Lin, Alan L. Johnson, Dorthea A. Sims, Carol Ann Stephan, Kevin T. Yeh, Chih-Ko TI Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART) SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS LA English DT Article ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; ANTICANDIDAL ACTIVITIES; PROTEASE INHIBITORS; PAROTID-SALIVA; AIDS; TRIMETHOPRIM; HYPOURICEMIA; CANDIDIASIS; IMPACT AB Objective. This study was undertaken to determine if HAART alters salivary oral host defense in HIV(+) men. Study design. Whole, parotid, and submandibular/sublingual saliva was collected from 39 healthy men and 147 HIV(+) patients with mild to moderate immune dysfunction (69 treated with HAART [HAART(+)]; 78 not treated [HAART(-)]). Salivary flow rates, anticandidal activities, electrolytes, and antimicrobial/antifungal proteins were determined. Results. While CD4(+) cell counts were not different between the HIV(+) groups, the median viral load for HAART(-) was 15 times greater than HAART(+). For both HAART groups, salivary yeast carriage rates and concentration were comparable and both showed similar reductions in salivary flow rates. Salivary anticandidal activities were not altered. Saliva composition of both HIV(+) groups was different from control, but only uric acid in parotid saliva of HAART(+) differed from HAART(-). Conclusions. HAART does not adversely affect inherent salivary oral host defense in HIV(+) patients with mild to moderate immune dysfunction. C1 S Texas Vet Hlth Care Syst, Audie Murphy Div, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, San Antonio, TX 78285 USA. Univ Texas, Hlth Sci Ctr, Dept Community Dent, San Antonio, TX 78285 USA. Wilford Hall USAF Med Ctr, Dept Infect Dis, San Antonio, TX 78236 USA. RP Yeh, CK (reprint author), S Texas Vet Hlth Care Syst, Audie Murphy Div, Ctr Geriatr Res Educ & Clin, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Yeh@uthscsa.edu FU NCRR NIH HHS [M01-RR-01346]; NIDCR NIH HHS [DE12188] NR 33 TC 13 Z9 13 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 1079-2104 J9 ORAL SURG ORAL MED O JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. PD SEP PY 2006 VL 102 IS 3 BP 318 EP 324 DI 10.1016/j.tripleo.2005.07.021 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 084AA UT WOS:000240502600009 PM 16920540 ER PT J AU Raphael, KG Janal, MN Nayak, S Schwartz, JE Gallagher, RM AF Raphael, Karen G. Janal, Malvin N. Nayak, Sangeetha Schwartz, Joseph E. Gallagher, Rollin M. TI Psychiatric comorbidities in a community sample of women with fibromyalgia SO PAIN LA English DT Article DE fibromyalgia; epidermology; comorbidity; depression; psychiatric disorder; anxiety disorders; community study; minority women ID POSTTRAUMATIC-STRESS-DISORDER; CHRONIC WIDESPREAD PAIN; STRUCTURED CLINICAL INTERVIEW; CARE-SEEKING BEHAVIOR; DIAGNOSTIC-INTERVIEW; GENERAL-POPULATION; MAJOR DEPRESSION; PSYCHOLOGICAL DISTRESS; RHEUMATOID-ARTHRITIS; FAMILIAL AGGREGATION AB Prior studies of careseeking fibromyalgia (FM) patients often report that they have an elevated risk of psychiatric disorders, but biased sampling may distort true risk. The current investigation utilizes state-of-the-art diagnostic procedures for both FM and psychiatric disorders to estimate prevalence rates of FM and the comorbidity of FM and specific psychiatric disorders in a diverse community sample of women. Participants were screened by telephone for FM and MDD, by randomly selecting telephone numbers from a list of households with women in the NY/NJ metropolitan area. Eligible women were invited to complete physical examinations for FM and clinician-administered psychiatric interviews. Data were weighted to adjust for sampling procedures and population demographics. The estimated overall prevalence of FM among women in the NY/NJ metropolitan area was 3.7% (95% CI = 3.2, 4.4), with higher rates among racial minorities. Although risk of current MDD was nearly 3-fold higher in community women with than without FM, the groups had similar risk of lifetime MDD. Risk of lifetime anxiety disorders, particularly obsessive compulsive disorder and post-traumatic stress disorder, was approximately 5-fold higher among women with FM. Overall, this study found a community prevalence for FM among women that replicates prior North American studies, and revealed that FM may be even more prevalent among racial minority women. These community-based data also indicate that the relationship between MDD and FM may be more complicated than previously thought, and call for an increased focus on anxiety disorders in FM. (c) 2006 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07103 USA. SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA. Vet Affairs Med Ctr, Pain Management Serv, Philadelphia, PA 19104 USA. RP Raphael, KG (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07103 USA. EM raphaekg@umdnj.edu OI Raphael, Karen/0000-0002-2804-8124 FU NIDCR NIH HHS [R01 DE13486] NR 61 TC 62 Z9 65 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD SEP PY 2006 VL 124 IS 1-2 BP 117 EP 125 DI 10.1016/j.pain.2006.04.004 PG 9 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 085CV UT WOS:000240581700019 PM 16698181 ER PT J AU Arguelles, LM Afari, N Buchwald, DS Clauw, DJ Furrier, S Goldberg, J AF Arguelles, Lester M. Afari, Niloofar Buchwald, Dedra S. Clauw, Daniel J. Furrier, Sylvia Goldberg, Jack TI A twin study of posttraumatic stress disorder symptoms and chronic widespread pain SO PAIN LA English DT Article DE chronic widespread pain; fibromyalgia; genetic; posttraurnatic stress disorder; twins ID CARE-SEEKING BEHAVIOR; FIBROMYALGIA SYNDROME; GENERAL-POPULATION; RISK-FACTORS; FOLLOW-UP; FUNCTIONAL IMPAIRMENT; MUSCULOSKELETAL PAIN; MUTUAL MAINTENANCE; PERSISTENT PAIN; MENTAL-DISORDER AB Previous studies of the association between posttraumatic stress disorder (PTSD) and chronic widespread pain (CWP) or fibromyalgia have not examined the role of familial or genetic factors. The goals of this study were to determine if symptoms of PTSD are related to CWP in a genetically informative community-based sample of twin pairs, and if so, to ascertain if the association is due to familial or genetic factors. Data were obtained from the University of Washington Twin Registry, which contains 1042 monozygotic and 828 dizygotic twin pairs. To assess the symptoms of PTSD, we used questions from the Impact of Events Scale (IES). IES scores were partitioned into terciles. CWP was defined as pain located in 3 body regions lasting at least I week during the past 3 months. Random-effects regression models, adjusted for demographic features and depression, examined the relationship between IES and CWP. IES scores were strongly associated with CWP (P < 0.0001). Compared to those in the lowest IES tercile, twins in the highest tercile were 3.5 times more likely to report CWP. Although IES scores were associated with CWP more strongly among dizygotic than among monozygotic twins, this difference was not significant. Our findings suggest that PTSD symptoms, as measured by IES, are strongly linked to CWP, but this association is not explained by a common familial or genetic vulnerability to both conditions. Future research is needed to understand the temporal association of PTSD and CWP, as well as the physiological underpinnings of this relationship. (c) 2006 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA. Univ Washington, Dept Med, Seattle, WA USA. Univ Michigan, Dept Internal Med, Chron Pain & Fatigue Res Ctr, Ann Arbor, MI 48109 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Vietnam Era Twin Registry, Seattle, WA USA. RP Afari, N (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM afari@u.washington.edu FU NIAID NIH HHS [5 U19 AI38429-08, U19 AI038429-07, U19 AI038429]; NIAMS NIH HHS [R55 AR051524, R01 AR051524-01A2, R55AR051524, R01 AR051524, R55 AR051524-01] NR 67 TC 31 Z9 31 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD SEP PY 2006 VL 124 IS 1-2 BP 150 EP 157 DI 10.1016/j.pain.2006.04.008 PG 8 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 085CV UT WOS:000240581700023 PM 16701954 ER PT J AU Gallagher, RM AF Gallagher, Rollin M. TI Pulsed radiofrequency treatment: What is the evidence of its effectiveness and should it be used in clinical practice? SO PAIN MEDICINE LA English DT Article C1 Univ Penn, Pain Med Serv, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Pain Med Serv, Philadelphia VA Med Ctr, Univ & Woodland, Philadelphia, PA 19104 USA. EM rgallagh@mail.med.upenn.edu NR 8 TC 10 Z9 10 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD SEP-OCT PY 2006 VL 7 IS 5 BP 408 EP 410 DI 10.1111/j.1526-4637.2006.00211.x PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 087KJ UT WOS:000240741000008 PM 17014599 ER PT J AU Haidet, P Kroll, TL Sharf, BF AF Haidet, Paul Kroll, Tony L. Sharf, Barbara F. TI The complexity of patient participation: Lessons learned from patients' illness narratives SO PATIENT EDUCATION AND COUNSELING LA English DT Article; Proceedings Paper CT AAPP 2005 Forum/ International Conference on Communication in Healthcare CY OCT, 2005 CL Northwestern Univ Feinberg Sch Med, Chicago, IL SP AAPP HO Northwestern Univ Feinberg Sch Med DE (MeSH): physician-patient relations; primary health care; patient-centered care; communication; persuasive communication; qualitative research; patient participation; narration ID MEDICAL DECISION-MAKING; SELF-MANAGEMENT; COMMUNICATION; CARE; INTERVENTION; INVOLVEMENT; PHYSICIANS; ENCOUNTER; SURGERY; BELIEFS AB Objective: To describe the meaning of active participation from the patient's perspective. Methods: We used a narrative framework to analyze transcripts generated from 16 qualitative open-ended, semi-structured interviews with primary care patients in Houston, Texas. Results: Patients' illness narratives reflected several themes related to patient participation. These included patients' perspectives of illness (i.e., how central the illness is in the patient's overall life story and how changeable the patient believes their illness to be) and aspects of actions pursued in the context of patients' illness narratives (i.e., the degree of illness-related activity that a patient engages in and the role of partnership with the patient's physician in health decision making and illness management). The relationships among these themes explained a limited number of distinct illness-management strategies pursued by patients. Conclusion: Our findings revealed a level of complexity to patients' healthcare participation that has not been previously described. Patients' illness-management strategies were explained by four thematic story elements in dynamic interplay with unique variations for each individual. Further research is needed to explore how these story elements influence communication between patients and physicians. Practice implications: By understanding the nature of and relationships between the thematic elements in patients' illness narratives, practitioners will be able to better inform their negotiations with patients regarding participation in healthcare. Published by Elsevier Ireland Ltd. C1 DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. So Methodist Univ, Meadows Sch Arts, Dallas, TX 75275 USA. Texas A&M Univ, Dept Commun, College Stn, TX USA. RP Haidet, P (reprint author), DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd,152, Houston, TX 77030 USA. EM phaidet@bcm.tmc.edu FU AHRQ HHS [P01HS10876] NR 37 TC 39 Z9 39 U1 1 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD SEP PY 2006 VL 62 IS 3 SI SI BP 323 EP 329 DI 10.1016/j.pec.2006.06.005 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 082KP UT WOS:000240386000007 PM 16887319 ER PT J AU Covell, NH Jackson, CT Weissman, EM AF Covell, Nancy H. Jackson, Carlos T. Weissman, Ellen M. TI Health monitoring for patients who have schizophrenia Summary of the Mount Sinai Conference recommendations SO POSTGRADUATE MEDICINE LA English DT Article AB Schizophrenia is associated with several chronic medical illnesses and a reduced life expectancy. This paper summarizes findings and recommendations from "The Mount Sinai Conference," held at the Mount Sinai School of Medicine in New York on October 17-18, 2002, and discusses the implications for improving medical monitoring of patients with schizophrenia who are managed in outpatient settings from the initiation of treatment. The Mount Sinai Conference involved a diverse panel of experts, including specialists on schizophrenia, obesity, diabetes, cardiology, endocrinology, and ophthalmology. Consensus recommendations included baseline measurement and regular monitoring of body mass index, blood glucose, lipid profiles, signs of prolactin elevation or sexual dysfunction, and movement disorders. Information from such measurements should be considered when selecting or switching antipsychotic agents and should trigger an evaluation of medication when abnormalities are detected. C1 [Covell, Nancy H.] Mt Sinai Sch Med, Div Hlth Serv Res, Dept Psychiat, Connecticut DMHAS Res Div, Hartford, CT 06134 USA. [Jackson, Carlos T.] Mt Sinai Sch Med, Div Hlth Serv Res, Dept Psychiat, New York, NY 10029 USA. [Weissman, Ellen M.] James J Peters Vet Affairs Med Ctr, Educ & Clin Ctr Vet Integrated Serv Network 3, Bronx, NY 10468 USA. RP Covell, NH (reprint author), Mt Sinai Sch Med, Div Hlth Serv Res, Dept Psychiat, Connecticut DMHAS Res Div, 410 Capitol Ave,MS 14RSD,POB 341431, Hartford, CT 06134 USA. EM Nancy.covell@po.state.ct.us NR 38 TC 7 Z9 8 U1 1 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0032-5481 EI 1941-9260 J9 POSTGRAD MED JI Postgrad. Med. PD SEP PY 2006 SI SI BP 20 EP 26 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA V06EE UT WOS:000207176100003 ER PT J AU Donahue, SA Lanzara, CB Felton, CJ Essock, SM Carpinello, S AF Donahue, Sheila. A. Lanzara, Carol B. Felton, Chip J. Essock, Susan M. Carpinello, Sharon TI Project Liberty: New York's crisis counseling program created in the aftermath of September 11, 2001 SO PSYCHIATRIC SERVICES LA English DT Article C1 CUNY Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. RP Essock, SM (reprint author), CUNY Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM susan.essock@mssm.edu NR 15 TC 17 Z9 18 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1253 EP 1258 DI 10.1176/appi.ps.57.9.1253 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800002 PM 16968752 ER PT J AU Donahue, SA Covell, NH Foster, MJ Felton, CJ Essock, SM AF Donahue, Sheila A. Covell, Nancy H. Foster, M. Jameson Felton, Chip J. Essock, Susan M. TI Demographic characteristics of individuals who received Project Liberty crisis counseling services SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH-SERVICE; NEW-YORK-CITY; TERRORIST ATTACKS; SEPTEMBER-11; COMORBIDITY; NEEDS AB Objectives: This article describes demographic characteristics of service recipients and their patterns of use of crisis counseling services provided under Project Liberty during the 27 months after the September 11, 2001, attacks on the World Trade Center. It also examines the extent to which service recipients reflected the demographic characteristics of their home communities. Methods: A total of 753,015 service encounter logs submitted by 177 providers were analyzed to determine rates of use by different demographic groups and to evaluate patterns of use over time with goodness-of-fit and logistic regression models. Results: A total of 687,848 individual crisis counseling sessions were provided to an estimated 465,428 individuals, including large numbers of persons from racial or ethnic minority groups and non-English-speaking individuals. Most of these services were provided to residents of the five New York City boroughs, with a small percentage of services to residents from the ten surrounding counties. Most services were provided in community settings rather than provider offices. African-American and Hispanic individuals showed the greatest increase in rates of accessing services over time. Follow-up visits were significantly more likely to be by Caucasians than by non-Caucasians, and children were more likely than adults to receive follow-up visits. Demographic characteristics of individuals using Project Liberty crisis counseling services generally were representative of the five boroughs and ten other counties constituting the greater metropolitan region and representative of estimated need. Conclusions: Project Liberty provided services that were accessible to individuals of diverse racial and ethnic backgrounds. C1 CUNY Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. RP Essock, SM (reprint author), CUNY Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM susan.essock@mssm.edu NR 18 TC 10 Z9 10 U1 2 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1261 EP 1267 DI 10.1176/appi.ps.57.9.1261 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800003 PM 16968753 ER PT J AU Covell, NH Donahue, SA Allen, G Foster, MJ Felton, CJ Essock, SM AF Covell, Nancy H. Donahue, Sheila. A. Allen, George Foster, M. Jameson Felton, Chip J. Essock, Susan M. TI Use of Project Liberty counseling services over time by individuals in various risk categories SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; TERRORIST ATTACKS; RESCUE WORKERS; DISASTER; TRAUMA AB Objective: The authors examined temporal changes in the rates at which people sought access to Project Liberty services after the attacks of September 11, 2001, according to risk category (family of missing or deceased, persons directly affected, uniformed personnel, other rescue or recovery workers, schoolchildren, displaced employed and unemployed workers, persons with disabilities, and the general population). Methods: First visits to individual counseling services, as determined from logs of 465,428 service encounters, were proportioned among risk categories and plotted across 27 months. Results: Individuals who lost family members accounted for 40 percent of visits in the first month but dropped to 5 percent or fewer visits by five months. Uniformed personnel used disproportionately larger percentages of services after the first year. Occupationally displaced and unemployed workers sought counseling at relatively steady rates. Conclusions: Postdisaster counseling should be made available for extended periods, with shifting emphases to meet the changing needs of high-risk groups. C1 CUNY Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. Univ Connecticut, Dept Psychol, Storrs, CT USA. James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. RP Essock, SM (reprint author), CUNY Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM susan.essok@mssm.edu NR 10 TC 11 Z9 11 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1268 EP 1270 DI 10.1176/appi.ps.57.9.1268 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800004 PM 16968754 ER PT J AU Jackson, CT Allen, G Essock, SM Foster, MJ Lanzara, CB Felton, CJ Donahue, SA AF Jackson, Carlos T. Allen, George Essock, Susan M. Foster, M. Jameson Lanzara, Carol B. Felton, Chip J. Donahue, Sheila. A. TI Clusters of event reactions among recipients of Project Liberty mental health counseling SO PSYCHIATRIC SERVICES LA English DT Article ID SEPTEMBER-11 TERRORIST ATTACKS; NEW-YORK-CITY; NEEDS AB Objective: This study aimed to determine a pattern in the frequency with which individuals who manifested distress reactions resembling diagnostic syndromes of posttraumatic stress disorder (PTSD) and major depressive disorder accessed services provided by Project Liberty. Methods: Hierarchical cluster analysis was applied to 31 reactions to stress (event reactions) shown by 465,428 recipients of Project Liberty counseling, to determine how well event reactions mapped onto traditional diagnostic criteria. Service recipients were tracked when they first sought Project Liberty counseling during the 27 months after the attacks. Those who reported three or more reactions associated with these clusters were characterized as having possible diagnosable conditions. Results: Strong consistent clusters corresponding to traumatic stress and depressive symptoms emerged, with 26 percent, 16 percent, and 8 percent of service recipients rated as having possible PTSD, major depressive disorder, or both, respectively. Taken together, this group constituted over 40 percent of service recipients served by Project Liberty almost every month throughout the 27 months of its existence. Conclusions: Event reactions, as reported by Project Liberty crisis counselors, many of whom were nonclinicians, mapped coherently onto diagnostic syndromes, suggesting that a checklist of such reactions may be useful to disaster counselors as a cost-effective screening and planning instrument. The steady entry over time into Project Liberty counseling by a substantial number of individuals experiencing high levels of distress underscores the need for providing long-term access to mental health services postdisaster. C1 Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. Univ Connecticut, Dept Psychol, Storrs, CT USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. RP Essock, SM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM susan.essock@mssm.edu NR 14 TC 8 Z9 8 U1 2 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1271 EP 1276 DI 10.1176/appi.ps.57.9.1271 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800005 PM 16968755 ER PT J AU Covell, NH Allen, G Essock, SM Pease, EA Felton, CJ Lanzara, CB Donahue, SA AF Covell, Nancy H. Allen, George Essock, Susan M. Pease, Elizabeth A. Felton, Chip J. Lanzara, Carol B. Donahue, Sheila A. TI Service utilization and event reaction patterns among children who received Project Liberty counseling services SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; WORLD-TRADE-CENTER; NEW-YORK-CITY; DEPRESSIVE REACTIONS; SCHOOL-CHILDREN; ADOLESCENTS; ATTACKS; SEPTEMBER-11; TERRORISM; DISASTER AB Objectives: This study examined service utilization and event reaction patterns among children who used crisis counseling services provided under Project Liberty for 27 months after the September 11, 2001, terrorist attacks on the World Trade Center. Methods: The authors analyzed logs of 681,318 service encounters submitted by Project Liberty counselors, paying particular attention to demographic characteristics and reported event reactions. Results: Nine percent of service recipients reached by community-based Project Liberty providers were children, whereas census data for the 15 counties and boroughs served by Project Liberty indicated that children constituted 25 percent of the population. Service use as a function of race or ethnicity and of gender was consistent with census data. Similar to findings for adults, the most common emotional event reactions reported for children were experiencing sadness and tearfulness, being anxious and fearful, having difficulty concentrating, experiencing irritability and anger, having intrusive thoughts or images, and having difficulty sleeping. Behavioral event reactions listed on service logs suggested that older children (12 to 17 years) were more likely to use drugs whereas elementary school-age children were more likely to display signs of anxiety, isolation and withdrawal, and difficulties with concentration and memory. Conclusions: Sensitivity to differences in the event reaction patterns shown by younger and older children may be useful in refining treatments to help reduce the psychological impact of children's trauma after terrorist incidents. C1 Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. Univ Connecticut, Dept Psychol, Storrs, CT USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. RP Essock, SM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM susan.essock@mssm.edu NR 25 TC 8 Z9 8 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1277 EP 1282 DI 10.1176/appi.ps.57.9.1277 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800006 PM 16968756 ER PT J AU Jackson, CT Covell, NH Shear, KM Zhu, C Donahue, SA Essock, SM Felton, CJ AF Jackson, Carlos T. Covell, Nancy H. Shear, Katherine M. Zhu, Carolyn Donahue, Sheila. A. Essock, Susan M. Felton, Chip J. TI The road back: Predictors of regaining preattack functioning among Project Liberty clients SO PSYCHIATRIC SERVICES LA English DT Article ID NEW-YORK-CITY; SEPTEMBER-11 TERRORIST ATTACKS; MENTAL-HEALTH-SERVICE; NEEDS AB Objectives: This study determined the likelihood and predictors of Project Liberty counseling recipients' reporting their return to satisfactory life functioning 16 to 26 months after the September 11, 2001, attacks. Methods: Using anonymous brief paper-and-pencil questionnaires or structured telephone interviews, 452 respondents provided retrospective ratings of their functioning in five life domains during the month before the World Trade Center attacks and the month immediately before the assessment. Information on demographic characteristics and exposure to risk during the World Trade Center attacks also was obtained and used in logistic regression models. The 153 respondents who were interviewed by telephone also rated helpfulness of various coping strategies. Results: In the five domains, 77 to 87 percent of the sample reported good to excellent functioning in the month before the attacks; 55 to 68 percent reported returning to at least the same level of daily functioning after the attacks. African Americans were two to four times more likely than respondents of all other races to report a return to good or excellent functioning after the attack in four domains. Compared with respondents who did not lose their job as a result of the attacks, those who did lose their job were less likely to return to good preattack functioning in two domains. Project Liberty counseling reportedly helped 90 percent of respondents return to predisaster levels of functioning. Conclusions: Responses to future terrorist attacks should consider demographic characteristics and the impact of the attack because they can affect return to preattack functioning. Counselors should support activities that facilitate positive responses and ameliorate negative psychological responses. C1 Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. Mental Illness Res Educ & Clin Care Ctr, Bronx, NY USA. James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. Columbia Univ, Coll Phys & Surg, Sch Social Work, New York, NY USA. Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. RP Essock, SM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM susan.essock@mssm.edu NR 21 TC 8 Z9 8 U1 3 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1283 EP 1290 DI 10.1176/appi.ps.57.9.1283 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800007 PM 16968757 ER PT J AU Shear, KM Jackson, CT Essock, SM Donahue, SA Felton, CJ AF Shear, Katherine M. Jackson, Carlos T. Essock, Susan M. Donahue, Sheila A. Felton, Chip J. TI Screening for complicated grief among Project liberty service recipients 18 month after September 11, 2001 SO PSYCHIATRIC SERVICES LA English DT Article ID TERRORIST ATTACKS; TRAUMATIC GRIEF; BEREAVEMENT; DISORDER; ADAPTATION; ATTACHMENT; CRITERIA; DISTINCT; HEALTH AB Objective: The authors surveyed a sample of Project Liberty crisis counseling recipients approximately 1.5 years after the terrorist attacks on September 11, 2001, to determine the proportion of respondents who screened positive for complicated grief, a recently identified condition marked by symptoms of continuing separation distress and accompanying bereavement-related traumatic distress. Methods: A total of 149 service recipients drawn from eight high-volume providers responded to a telephone survey that included questions to screen for complicated grief. Results: Approximately half of the recipients knew someone who had been killed in the attacks. Of those recipients, 44 percent screened positive for complicated grief. Individuals who lost a family member were more likely than those who lost an acquaintance to screen positive for complicated grief. Positive screens were associated with functional impairment independent of the presence of symptoms consistent with full or subthreshold major depression or posttraumatic stress disorder (PTSD). Thirty-two percent of those who screened positive for complicated grief did not meet even subthreshold criteria for major depression or PTSD. Conclusions: Results affirmed the importance of complicated grief as a unique condition and indicated the need to attend to the psychological consequences of bereavement in disaster-related mental health services. C1 Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. Columbia Univ Coll Phys & Surg, Sch Social Work, Dept Psychiat, New York, NY 10032 USA. James J Peters Vet Affairs Med Syst, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. RP Essock, SM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM susan.essock@mssm.edu NR 25 TC 63 Z9 63 U1 5 U2 11 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1291 EP 1297 DI 10.1176/appi.ps.57.9.1291 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800008 PM 16968758 ER PT J AU Donahue, SA Jackson, CT Shear, KM Felton, CJ Essock, SM AF Donahue, Sheila A. Jackson, Carlos T. Shear, Katherine M. Felton, Chip J. Essock, Susan M. TI Outcomes of enhanced counseling services provided to adults through Project liberty SO PSYCHIATRIC SERVICES LA English DT Article ID SEPTEMBER-11 TERRORIST ATTACKS; NEW-YORK-CITY; DISORDER AB Objective: Project Liberty provided brief crisis counseling to 753,015 residents of New York City and surrounding counties after the attacks on the World Trade Center. Most regained predisaster functioning after counseling. For those who did not, Project Liberty provided enhanced services by specially trained, licensed mental health professionals. Individuals receiving crisis counseling and enhanced services responded to confidential telephone interviews about 18 and 24 months, respectively, after the attacks. Impairment was compared between groups to determine whether enhanced services recipients reported improved functioning and fewer symptoms of depression, posttraumatic stress, and complicated grief. Methods: Crisis counseling recipients (N=153) were interviewed once and enhanced services recipients (N=76) were interviewed twice about symptomatology and daily functioning. Results: The samples did not differ in age or gender. Significantly greater proportions of enhanced services recipients reported knowing someone who died as a result of the attacks, having been involved in rescue efforts, or having lost their job because of the attacks. Compared with crisis counseling respondents, enhanced services recipients at their first interview reported significantly more symptoms of depression, grief, and traumatic stress and significantly poorer daily functioning in five life areas. At follow-up, enhanced services respondents reported significant improvement in three of five functioning domains, significantly fewer symptoms of depression and grief, and marginally less traumatic stress. Conclusions: Recipients of enhanced services were more impaired than people who received only crisis counseling. On the basis of reports from service recipients, meaningful improvements in functioning and symptoms may be associated with the receipt of enhanced services. C1 Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. Columbia Univ Coll Phys & Surg, Sch Social Work, New York, NY 10032 USA. Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. RP Essock, SM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM susan.essock@mssm.edu FU NIMH NIH HHS [MH-30915, MH-52247, MH-60783] NR 18 TC 19 Z9 19 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1298 EP 1303 DI 10.1176/appi.ps.57.9.1298 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800009 PM 16968759 ER PT J AU Frank, RG Pindyck, T Donahue, SA Pease, EA Foster, MJ Felton, CJ Essock, SM AF Frank, Richard G. Pindyck, Talia Donahue, Sheila A. Pease, Elizabeth A. Foster, M. Jameson Felton, Chip J. Essock, Susan M. TI Impact of a media campaign for disaster mental health counseling in post-September 11 New York SO PSYCHIATRIC SERVICES LA English DT Article AB Objective: After the September 11, 2001, terrorist attacks on the World Trade Center, the New York State Office of Mental Health (NYOMH) initiated a three-phase multifaceted, multilingual media campaign that advertised the availability of counseling services. This study evaluated the association between patterns of spending within this campaign and the volume of calls received and referred to a counseling program. Methods: Spending on television, radio, print, and other advertising was examined, as was the corresponding volume of calls to the NetLife hotline seeking referrals to counseling services. Results: From September 2001 to December 2002, $9.38 million was spent on Project Liberty media campaigns. Call volumes increased during months when total monthly expenditures peaked. Initially, flyers, billboards, and other material items accounted for most monthly expenses. Over time, spending for television and radio advertisements increased, whereas other advertising declined. Temporal patterns show that in periods after an increase in media spending, call volumes increased independently of other sentinel events such as the one-year anniversary of the attacks. Conclusions: Sustained advertising through multiple media outlets appeared to be effective in encouraging individuals to seek mental health services. C1 Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. Harvard Univ, Dept Hlth Care Policy, Boston, MA 02115 USA. Univ Massachusetts, Sch Med, Worcester, MA 01605 USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. RP Essock, SM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM susan.essock@mssm.edu NR 8 TC 14 Z9 15 U1 0 U2 8 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1304 EP 1308 DI 10.1176/appi.ps.57.9.1304 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800010 PM 16968760 ER PT J AU Gomes, C McGuire, TG Foster, MJ Donahue, SA Felton, CJ Essock, SM AF Gomes, Carla McGuire, Thomas G. Foster, M. Jameson Donahue, Sheila A. Felton, Chip J. Essock, Susan M. TI Did Project Liberty displace community-based Medicaid services in New York? SO PSYCHIATRIC SERVICES LA English DT Article ID MENTAL-HEALTH RESPONSE; TERRORIST ATTACKS; LESSONS; NEEDS; CITY AB Objective: This study analyzed how the introducion of Project Liberty services after the September 11, 2001, terrorist attacks affected agencies' provision of community-based Medicaid mental health services in the New York metropolitan area. Methods: Provision of Medicaid mental health services was tracked between January 2000 and June 2003 for provider agencies participating in Project Liberty (N=164) and for a comparison group of mental health provider agencies that did not participate in this program (N=94). Results: Overall, participation in Project Liberty did not significantly affect the volume of Medicaid services provided. However, for agencies with one site, a statistically significant difference was seen; compared with agencies in the comparison group, agencies that participated in Project Liberty claimed a mean SE decrease of $4.66 +/- 3.57 less in Medicaid services per month per Project Liberty visit. Conclusions: Project Liberty permitted rapid expansion of the total volume of services provided by community-based organizations without interfering with the provision of traditional services, although a modest effect was seen for smaller agencies. Although the results do not imply that "supply side" planning for disaster needs would not improve system response, they do imply that implementation of flexible "demand side" financing can call forth a large volume of new services rapidly and without interfering with other community services. C1 Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. RP Essock, SM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM susan.essock@mssm.edu NR 5 TC 6 Z9 6 U1 3 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1309 EP 1312 DI 10.1176/appi.ps.57.9.1309 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800011 PM 16968761 ER PT J AU Covell, NH Essock, SM Felton, CJ Donahue, SA AF Covell, Nancy H. Essock, Susan M. Felton, Chip J. Donahue, Sheila. A. TI Characteristics of Project Liberty clients that predicted referrals to intensive mental health services SO PSYCHIATRIC SERVICES LA English DT Article ID TERRORIST ATTACKS AB Objective: The authors describe characteristics of Project Liberty crisis counseling recipients that predicted referral to more intensive professional mental health treatments over the two-year period after the terrorist attacks on the World Trade Center. Methods: Random-effects ordinal regression models were applied to data from 684,500 logs of Project Liberty service encounters for individual counseling sessions. Results: Overall, about 9 percent of individual counseling visits ended with a referral to professional mental health services. Individuals needing intensive mental health treatment continued to enter Project Liberty for two years after the World Trade Center attacks. The strongest predictor of referral was having reactions to the attack that fell into a greater number of the four domains assessed-behavioral, emotional, physical, or cognitive domains. Individuals with reactions in four domains were most likely to be referred. Those who had greater attack-related exposure were also more likely to be referred. Conclusions: It is important to provide long-term access to brief counseling and triage services and to target these interventions specifically to individuals displaying greater distress or impairment and having more traumatic exposure. C1 Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Care Ctr, Bronx, NY USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. RP Essock, SM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM susan.essock@mssm.edu NR 10 TC 10 Z9 10 U1 3 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1313 EP 1315 DI 10.1176/appi.ps.57.9.1313 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800012 PM 16968762 ER PT J AU Jackson, CT Allen, G Essock, SM Felton, CJ Donahue, SA AF Jackson, Carlos T. Allen, George Essock, Susan M. Felton, Chip J. Donahue, Sheila A. TI Clients' satisfaction with Project Liberty counseling services SO PSYCHIATRIC SERVICES LA English DT Article ID SEPTEMBER-11 TERRORIST ATTACKS; NEW-YORK-CITY; CONSUMER-REPORTS; PSYCHOTHERAPY AB Objective: Satisfaction with 11 aspects of service quality and four domains of effectiveness was assessed for counseling services offered through Project Liberty after the September 11, 2001, attacks on the World Trade Center. Methods: A total of 607 Project Liberty service recipients completed anonymous questionnaires, telephone interviews, or both. The 11 aspects of quality were counselor respect for client, willingness to listen, cultural sensitivity, speaking the same language as the client, amount of counseling time, convenience of meeting time and location, information received, whether the service would be used again, whether the service would be recommended to friends or family, and overall quality of service. The four effectiveness domains were daily responsibilities, relationships, physical health, and community involvement. Results: At least 89 percent of service recipients rated Project Liberty as either good or excellent across 11 service quality dimensions and four effectiveness domains. The counselor's respect for clients and his or her cultural sensitivity were rated particularly favorably. Conclusions: These ratings suggest that, from the viewpoint of these recipients of counseling services, Project Liberty counselors were largely successful in providing accessible, acceptable, and useful services after the World Trade Center disaster. Such evaluations can be conducted in a cost-effective manner and integrated with evidence-based practice to ultimately ensure that recipients of counseling receive the most efficient and effective interventions. C1 Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. Univ Connecticut, Dept Psychol, Storrs, CT USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. RP Essock, SM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM susan.essock@mssm.edu NR 11 TC 9 Z9 9 U1 3 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1316 EP 1319 DI 10.1176/appi.ps.57.9.1316 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800013 PM 16968763 ER PT J AU Essock, SM Covell, NH Shear, KM Donahue, SA Felton, CJ AF Essock, Susan M. Covell, Nancy H. Shear, Katherine M. Donahue, Sheila A. Felton, Chip J. TI Use of clients' self-reports to monitor Project Liberty clinicians' fidelity to a cognitive-behavioral intervention SO PSYCHIATRIC SERVICES LA English DT Article AB Objective: This study examined outcomes associated with clinicians' fidelity to key elements of a cognitive-behavioral treatment intervention developed for Project Liberty's enhanced services counseling program. Methods: In telephone interviews 60 individuals reported how often their clinicians provided six components considered central to the intervention by the intervention developers. Respondents received services at sites where some (25 to 50 percent) or all clinicians had received training in the intervention. Results: Compared with respondents who received services where only some clinicians had received training (N=19), those who received services where all clinicians had received training (N=41) were significantly more likely to report that their clinicians applied techniques central to the intervention (p <.01). Additionally, those who received services from sites where all clinicians were trained were significantly more likely to report that they had been given homework (p <.05). Conclusions: Brief questions to service recipients are a useful and cost-effective way to monitor intervention fidelity. C1 Mt Sinai Sch Med, Div Hlth Serv Res, Dept Psychiat, New York, NY 10029 USA. James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. Columbia Univ Coll Phys & Surg, Sch Social Work, New York, NY 10032 USA. Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. RP Essock, SM (reprint author), Mt Sinai Sch Med, Div Hlth Serv Res, Dept Psychiat, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM susan.essock@mssm.edu FU NIMH NIH HHS [MH-52247, MH-30915, MH-60783] NR 11 TC 10 Z9 11 U1 0 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1320 EP 1323 DI 10.1176/appi.ps.57.9.1320 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800014 PM 16968764 ER PT J AU Covell, NH Donahue, SA Ulaszek, WR Dunakin, L Essock, SM Felton, CJ AF Covell, Nancy H. Donahue, Sheila A. Ulaszek, Wendy R. Dunakin, Linda Essock, Susan M. Felton, Chip J. TI Effectiveness of two methods of obtaining feedback on mental health services provided to anonymous recipients SO PSYCHIATRIC SERVICES LA English DT Article ID SEPTEMBER-11 TERRORIST ATTACKS; NEW-YORK-CITY AB Objective: The authors examined alternative methods for obtaining feedback from people receiving anonymous mental health services via Project Liberty, an initiative that provided free counseling to residents of the New York City area after the 2001 attacks on the World Trade Center. Methods: Counselors offered all English-speaking and Spanish-speaking adults who used Project Liberty crisis counseling services the opportunity to evaluate Project Liberty via a telephone interview (eight sites) or a brief questionnaire (four sites). Results: A total of 107 service recipients provided feedback via a brief 32-item questionnaire, and 153 gave feedback via a 45-minute telephone interview. Although the overall participation rates were modest (less than 20 percent), nearly threequarters of those who volunteered to participate in the telephone interview (for which they received $20) did so. Neither gender nor racial or ethnic group was associated with a greater likelihood of participating in one method over another. Conclusions: Responses to items on the brief questionnaire and in the telephone interview were similar, and offering multiple response methods increased participation rates. Although telephone interviews were more costly than the questionnaire to administer, they provided important additional information about ongoing symptoms and problems that individuals experienced after the attacks. The modest response rates obtained in the evaluation indicate that future evaluations of postdisaster services need to use methods to maximize response rates and provider adherence to administrative tasks that are critical to the evaluation. C1 Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. New York State Off Mental Hlth, Ctr Informat Technol & Evaluat Res, Albany, NY USA. Univ Connecticut, Dept Psychol, Storrs, CT USA. State Connecticut Dept Mental Hlth & Addict Serv, Hartford, CT USA. RP Essock, SM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM susan.essock@mssm.edu NR 6 TC 5 Z9 5 U1 3 U2 6 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP PY 2006 VL 57 IS 9 BP 1324 EP 1327 DI 10.1176/appi.ps.57.9.1324 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 081PF UT WOS:000240328800015 PM 16968765 ER PT J AU Siddiqa, A Cavazos, DA Marciniak, RA AF Siddiqa, Aisha Cavazos, David A. Marciniak, Robert A. TI Targeting telomerase SO REJUVENATION RESEARCH LA English DT Article ID IMMORTAL HUMAN-CELLS; HUMAN CANCER-CELLS; IN-VITRO; SACCHAROMYCES-CEREVISIAE; ALTERNATIVE MECHANISM; MAMMALIAN TELOMERES; CELLULAR SENESCENCE; LENGTH MAINTENANCE; GENE-EXPRESSION; ALT CELLS AB Given the constitutive expression of telomerase in the majority of human tumors, telomerase inhibition is an attractive, broad-spectrum therapeutic target for cancer treatment. Therapeutic strategies for inhibiting telomerase activity have included both targeting components of telomerase (the protein component, TERT, or the RNA component, TERC) or by directly targeting telomere DNA structures. Recently a combination telomerase inhibition therapy has been studied also. The TERT promoter has been used to selectively express cytotoxic gene(s) in cancer cells and a TERT vaccine for immunization against telomerase has been tested. The 10% to 15% of immortalized cancer cells that do not express telomerase use a recombination-based mechanism for maintaining telomere structures that has been called the alternative lengthening of telomeres (ALT). In view of the increasing study of telomerase inhibitors as anticancer treatments, it will be crucial to determine whether inhibition of telomerase will select for cancer cells that activate ALT mechanisms of telomere maintenance. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Marciniak, RA (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM marciniak@uthscsa.edu FU NIA NIH HHS [1T32AG021890]; NIDCR NIH HHS [DE14318] NR 78 TC 10 Z9 11 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1549-1684 J9 REJUV RES JI Rejuv. Res. PD FAL PY 2006 VL 9 IS 3 BP 378 EP 390 DI 10.1089/rej.2006.9.378 PG 13 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 074TN UT WOS:000239834800003 PM 16859479 ER PT J AU Adams, SG Anzueto, A Briggs, DD Menjoge, SS Kesten, S AF Adams, Sandra G. Anzueto, Antonio Briggs, Dick D., Jr. Menjoge, Shailendra S. Kesten, Steven TI Tiotropium in COPD patients not previously receiving maintenance respiratory medications SO RESPIRATORY MEDICINE LA English DT Article DE chronic obstructive pulmonary disease; dyspnea; forced expiratory volume in 1 s; lung function; quality of life; tiotropium ID OBSTRUCTIVE-PULMONARY-DISEASE; TRANSITION DYSPNEA INDEX; QUALITY-OF-LIFE; OFFICE SPIROMETRY; DIAGNOSIS; PROGRAM AB Introduction: Use of maintenance bronchodilator therapy is currently recommended in symptomatic patients with Chronic obstructive pulmonary disease (COPD) and in those with Stage 11 or greater COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Because no prospective data describe when rescue therapy alone is insufficient or the optimal time to start maintenance therapy, it is unclear whether maintenance therapy has benefits in milder disease. To explore potential benefits we asked: Does once-daily tiotropium improve lung function, health status, and/or symptoms in "undertreated" COPD patients (i.e., those who are not receiving maintenance bronchodilator therapy) or patients considered by their health care providers as having milder disease? Methods: A post-hoc analysis of data from COPD patients participating in two, 1-year, placebo-controtted trials with tiotropium was performed. Patients were defined as "undertreated" if they received no respiratory medication or only as needed short-acting beta-agonists prior to enrollment. Measures included serial spirometry, Transition Dyspnea Index (TDI), and St. George's Respiratory Questionnaire (SGRQ). Results: Of 921 patients enrolled, 218 (23.7%) were "undertreated": 130 received tiotropium; 88 received placebo. Demographics for the two treatment groups were comparable. Tiotropium-treated patients had significantly improved forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) compared with patients using placebo on all study days. Additionally, TDI and SGRQ scores significantly improved with tiotropium compared with placebo. Conclusions: Once-daily tiotropium provides significant improvement in lung function, health status, and dyspnea when used as maintenance therapy in undertreated COPD patients who were not previously receiving maintenance bronchodilator therapy. (c) 2006 Elsevier Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. Univ Alabama, Birmingham, AL 35294 USA. Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA. RP Adams, SG (reprint author), Univ Texas, Hlth Sci Ctr, 7400 Merton Minter 111E, San Antonio, TX 78229 USA. EM adamssg@uthscsa.edu NR 29 TC 16 Z9 16 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 J9 RESP MED JI Respir. Med. PD SEP PY 2006 VL 100 IS 9 BP 1495 EP 1503 DI 10.1016/j.rmed.2006.03.034 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA 074TE UT WOS:000239833900002 PM 16698259 ER PT J AU Wang, X Hsu, HC Wang, Y Edwards, CK Yang, P Wu, Q Mountz, JD AF Wang, X. Hsu, H. -C. Wang, Y. Edwards, C. K., III Yang, P. Wu, Q. Mountz, J. D. TI Phenotype of genetically regulated thymic involution in young BXD RI strains of mice SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY LA English DT Article ID T-CELL DEVELOPMENT; OXIDATIVE STRESS; INTERLEUKIN-7 RECEPTOR; DEFICIENT MICE; APOPTOSIS; AGE; IL-7; EXPRESSION; THYMOPOIESIS; MOUSE AB Age-related thymic involution is a multifactorial process related to age-related changes in intrathymic T-cell development and cytokines. In contrast, early thymic involution, because of genetic differences that cause rapid or slow thymic involution at younger age, is less well characterized. Here, we analysed three representative rapid-involuting strains of mice, BXD 8, 18 and 32, compared with three representative slow-involuting strains, BXD 9, 19 and 29, all at 2 months of age. In rapid-involuting strains compared with slow involution strains, thymocyte production, as indicated by CD4(+) and CD8(+) T-cell receptor recombination excision circle (TREC), were decreased. Rapid-involution strains of mice exhibited a developmental block at the DN1 to DN2 and CD4(-)CD8(-) (DN) to CD4(+)CD8(+) (double positive, DP) transition stages. There was also increased susceptibility to H2O2-induced apoptosis, decreased thymic expression of IL-7, decreased expression of an IL-7 downstream anti-apoptosis gene, Bcl-2, and increased expression of a pro-apoptotic gene, Bad. In contrast, IL-7R expression was higher on DN thymocytes of rapid-involution strains. The increased expression of IL-7R was associated with an increased thymocyte proliferation in response to anti-CD3 + IL-7 or anti-CD3 + IL-12 + IL-7. These findings indicate that, even at young age, genetic differences of IL-7/IL-7R regulation pathway in BXD strains of mice can lead to characteristic phenotypic changes that have been previously associated with age-related thymic involution. C1 Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. Univ Colorado, Dept Dermatol, Aurora, CO USA. Hlth Sci Ctr Fitzsimmons, Aurora, CO USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Mountz, JD (reprint author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, 701 S 19th St,LHRB 473, Birmingham, AL 35294 USA. EM john.mountz@ccc.uab.edu FU NIAID NIH HHS [R01 AI 046990-05, R01 AI046990]; NIAMS NIH HHS [P30 AR050948, P30 AR 50948] NR 44 TC 9 Z9 10 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0300-9475 J9 SCAND J IMMUNOL JI Scand. J. Immunol. PD SEP PY 2006 VL 64 IS 3 BP 287 EP 294 DI 10.1111/j.1365-3083.2006.01813.x PG 8 WC Immunology SC Immunology GA 072GI UT WOS:000239661500017 PM 16918698 ER PT J AU Chang, VW AF Chang, Virginia W. TI Racial residential segregation and weight status among US adults SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE racial segregation; obesity; body mass index; socioeconomic factors; contextual analysis; health inequalities; USA ID BODY-MASS-INDEX; BLACK-AND-WHITE; UNITED-STATES; AFRICAN-AMERICANS; INFANT-MORTALITY; OBESITY; HEALTH; RACE; POVERTY; DISPARITIES AB While the segmentation of residential areas by race is well known to affect the social and economic well-being of the segregated minority group in the United States, the relationship between segregation and health has received less attention. This study examines the association between racial residential segregation, as measured by the isolation index, and individual weight status in US metropolitan areas. Multi-level, nationally representative data are used to consider the central hypothesis that segregation is positively associated with weight status among African Americans, a group that is hyper-segregated and disproportionately affected by unhealthy weight outcomes. Results show that among non-Hispanic blacks, higher racial isolation is positively associated with both a higher body mass index (BMI) and greater odds of being overweight, adjusting for multiple covariates, including measures of individual socioeconomic status. An increase of one standard deviation in the isolation index is associated with a 0.423 unit increase in BMI (p < 0.01), and a 14% increase in the odds of being overweight (p < 0.01). Among whites, there is no significant association between the isolation index and weight status. These findings suggest that in addition to differences among people, differences among places and, in particular, differences in the spatial organization of persons may be relevant to health policy and promotion efforts. (c) 2006 Elsevier Ltd. All rights reserved. C1 Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA. Univ Penn, Populat Studies Ctr, Philadelphia, PA 19104 USA. VAMC, Ctr Hlth Eqi Res & Promot, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Chang, VW (reprint author), Univ Penn, Sch Med, Dept Med, 1233 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM vwchang@mail.med.upenn.edu FU NICHD NIH HHS [K12-HD-043459] NR 47 TC 104 Z9 104 U1 4 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD SEP PY 2006 VL 63 IS 5 BP 1289 EP 1303 DI 10.1016/j.socscimed.2006.03.049 PG 15 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 075HS UT WOS:000239876000016 PM 16707199 ER PT J AU Avansino, JR Chen, DC Hoagland, VD Woolman, JD Stelzner, M AF Avansino, Jeffrey R. Chen, David C. Hoagland, Vicki D. Woolman, Jacob D. Stelzner, Matthias TI Orthotopic transplantation of intestinal mucosal organoids in rodents SO SURGERY LA English DT Article ID BILE-ACID MALABSORPTION; STEM-CELL TRANSPLANTATION; NUTRIENT TRANSPORT; ILEAL RESECTION; SMALL-BOWEL; RAT; DIFFERENTIATION; IDENTIFICATION; ENTEROCYTES; ONTOGENY AB Background. Orthotopic transplantation of intestinal mucosal organoids that contain putative mucosal stem cells serves as an important step toward implementing intestinal gene therapy and treatment for malabsorption syndromes in animals and humans. We hypothesized that intestinal mucosal organoids can be transplanted along the axis of the small bowel giving rise to a neomucosa expressing proteins of its donor origin. Methods. Epithelial organoids were harvested from neonatal mice or rat small intestine with the use of a combination of enzymatic digestion with dispose and collagenase, and gravity sedimentation. In adult syngeneic recipients, a 7-cm segment of midjejunum was isolated, leaving its vascular pedicle intact. The remaining proximal and distal segments were anastomosed to restore intestinal continuity. The isolated segments were randomly subjected to surgical or chemical mucosectomy with a chelator solution for 30, 45, or 60 minutes and then compared. Histologic examination was used to confirm the presence of enterocytes, goblet cells, enteroendocrine cells, and Paneth cells in the neomucosal segments. To confirm the presence of ileal bile acid transporter (IBAT) gene message and function, we measured sodium-dependent We acid uptake and IBAT-messenger RNA. Immunohistochemical examination using anti-IBAT antibodies was performed to demonstrate the expression of IBAT in the neomucosal segments. Experiments were repeated in a murine model transgenic for the green fluorescent protein to verify donor origin of the engrafted mucosa expressing IBAT. Results. The area of peak IBAT function was found to be located in the terminal ileum. Organoid units harvested from this region were capable of generating a small-bowel neoileal mucosa after being seeded into the jejunum. This mucosa was histologically confirmed to differentiate into all 4 intestinal lineages and to express MAT signal, confirming its donor-derived origin. Optimal engraftment of mucosa expressing the IBAT protein was found in isolated jejunal segments debrided for 45 minutes. Sodium-dependent bile acid uptake was 5 fold higher in the neoileum, compared with the jejunum. IBAT-mRNA levels in the neoileum were 18-100-fold higher than those in the jejunum. Areas of green fluorescent protein-positive mucosa stained positively with anti-IBAT antibody in adjacent sections,. suggesting that the regenerated mucosa is from transplanted ileal stem cells. Conclusions. Orthotopic transplantation of epithelial organoids containing ileal stem cells was used to generate a neoileal mucosa that expressed all 4 intestinal lineages along with a new zone of active bile acid uptake and IBA T expression in a recipient jejunal segment. C1 Univ Calif Los Angeles, Dept Surg, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90024 USA. Univ Washington, Dept Surg, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Chen, DC (reprint author), Univ Calif Los Angeles, Dept Surg, VA Greater Los Angeles Hlth Care Syst, 10833 Le Conte Ave, Los Angeles, CA 90024 USA. EM dcchen@mednet.ucla.edu NR 38 TC 21 Z9 21 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0039-6060 J9 SURGERY JI Surgery PD SEP PY 2006 VL 140 IS 3 BP 423 EP 434 DI 10.1016/j.surg.2006.03.012 PG 12 WC Surgery SC Surgery GA 084ED UT WOS:000240513900018 PM 16934605 ER PT J AU Greenberg, JH Reivich, M Gordon, JT Schoenhoff, MB Patlak, CS Dratman, MB AF Greenberg, Joel H. Reivich, Martin Gordon, Janice T. Schoenhoff, Monika B. Patlak, Clifford S. Dratman, Mary B. TI Imaging triiodothyronine binding kinetics in rat brain: A model for studies in human subjects SO SYNAPSE LA English DT Article DE thyroid; autoradiography; receptors; triiodothyronine ID POSITRON-EMISSION-TOMOGRAPHY; THYROID-HORMONE RECEPTORS; TIME UPTAKE DATA; C-ERB; REGIONAL DISTRIBUTION; GRAPHICAL EVALUATION; TRANSFER CONSTANTS; AXONAL-TRANSPORT; MOOD DISORDERS; LOCALIZATION AB Many lines of evidence indicate a role for thyroid hormones in the expression of cognitive and affective disorders. These conditions constitute a large proportion of the illness burden in the general population. Unfortunately, presently available diagnostic procedures cannot adequately identify these problems. To determine whether imaging studies of thyroid hormone kinetics in brain might be feasible in patients with these disorders, an autoradiographic method for measuring thyroid hormone kinetics was developed. Twenty-five awake adult rats received high specific activity [I-125]-triiodothyronine (T-3*). Brains were obtained at intervals from 5 through 300 min after i.v, hormone administration. Every 5th frozen section was thaw mounted and exposed to film. To determine whether T-3 was responsible for the autoradiographic images, the intervening sections were assembled while frozen in regional tissue pools and were extracted and then analyzed by high-performance liquid chromatography. The results demonstrated that radioactivity was almost entirely due to T-3*(similar to 90%) while small amounts of hormone metabolites, including [I-125]iodine accounted for the remainder. Regional concentrations of label in autoradiograms were measured by densitometry in hippocampus (CA1, CA2, CA3, and dentate gyrus), cerebellum (molecular and granular cell layers), caudate nucleus, and amygdala. Unexpectedly and interestingly, the results demonstrated that binding through 5 h was mainly irreversible. Regional values of the net uptake rate constant of T-3* or influx constant, K-i, were determined from the time course of the T-3* data, showing significant differences among regions. These results suggest that imaging of labeled thyroid hormone ligands by positron emission tomography or single photon emission computed tomography may be feasible and would potentially provide useful information relevant to T-3 processing in the brain during a variety of drug and disease-induced conditions. C1 Univ Penn, Cerebrovasc Res Ctr, Dept Neurol, Philadelphia, PA 19104 USA. Univ Penn, Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Greenberg, JH (reprint author), Univ Penn, Cerebrovasc Res Ctr, Dept Neurol, 415 Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA. EM joel@mail.med.upenn.edu FU NIMH NIH HHS [MH45252, MH44210]; NINDS NIH HHS [NS33875, NS10939] NR 54 TC 5 Z9 5 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0887-4476 J9 SYNAPSE JI Synapse PD SEP 1 PY 2006 VL 60 IS 3 BP 212 EP 222 DI 10.1002/syn.20293 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 061SY UT WOS:000238894100004 PM 16739120 ER PT J AU El Sayed, HF Kougias, P Zhou, W Lin, PH AF El Sayed, Hosarn F. Kougias, Panos Zhou, Wei Lin, Peter H. TI Utility of retrievable vena cava filters and mechanical thrombectomy in the endovascular management of acute deep venous thrombosis SO VASCULAR LA English DT Article DE deep venous thrombosis; inferior vena cava filter; retrievable inferior vena cava filter; thrombectomy; thrombolysis AB Endovascular interventions of symptomatic deep venous thrombosis (DVT) using various therapeutic modalities, such as thrombolysis, mechanical thrombectomy, and inferior vena cava (lVC) filter placement, have received increased focus owing in part to advances in catheter-based interventional technologies. Although systemic anticoagulation remains the primary treatment modality in DVT, catheter-based interventions can provide rapid removal of large thrombus burden and possibly preserve venous valvular function in patients with symptomatic DVT. This article reviews current endovascular treatment strategies for acute DVT. Specifically, the utility of mechanical thrombectomy along with various temporary lVC filters in the setting of DVT is examined. Lastly, an illustrative case of acute DVT that was treated with endovascular intervention with lVC filter placement is presented. C1 Baylor Coll Med, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Dept Surg, N Florida S Georgia VA Med Ctr, Houston, TX 77030 USA. RP Lin, PH (reprint author), Baylor Coll Med, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Dept Surg, Houston VAMC, 2002 Holcomb Blvd 112, Houston, TX 77030 USA. EM plin@bcm.tmc.edu NR 26 TC 7 Z9 7 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1708-5381 J9 VASCULAR JI Vascular PD SEP-OCT PY 2006 VL 14 IS 5 BP 305 EP 312 DI 10.2310/6670.2006.00046 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V44FY UT WOS:000202989800009 PM 17038301 ER PT J AU Yano, EM Goldzweig, C Canelo, I Washington, DL AF Yano, Elizabeth M. Goldzweig, Caroline Canelo, Ismelda Washington, Donna L. TI Diffusion of innovation in women's health care delivery: The department of veterans affairs' adoption of women's health clinics SO WOMENS HEALTH ISSUES LA English DT Article ID MEDICAL-CENTER; NATIONAL-CENTERS; FEMALE VETERANS; QUALITY; EXCELLENCE; PHYSICIANS; PROJECT AB Background. In response to concerns about the availability and quality of women's health services in Department of Veterans Affairs (VA) medical centers in the early 1990s, Congress approved landmark legislation earmarking funds to enhance women's health services. A portion of the appropriation was used to launch Comprehensive Women's Health Centers as exemplars for the development of VA women's health care throughout the system. We report on the diffusion and characteristics of VA women's health clinics (WHCs) 10 years later. Methods. In 2001, we surveyed the senior women's health clinician at each VA medical center serving 400 women veterans (83% response rate) regarding their internal organizational characteristics in relation to factors associated with organizational innovation (centralization, complexity, formalization, interconnectedness, organizational slack, size). We evaluated the comparability of WHCs (n = 66) with characteristics of the original comprehensive women's health centers (CWHCs; n = 8). Results. Gender-specific service availability in WHCs was comparable to that of CWHCs with important exceptions in mental health, mammography and osteoporosis management. WHCs were less likely to have same-gender providers (p < .05), women's health training programs (p < .01), separate women's mental health clinics (p < .001), separate space (p < .05), or adequate privacy (p < .05); however, they were less likely to have experienced educational program closures (p < .001) and staffing losses (p < .05 ) compared to CWHCs. Conclusions. Diffusion of comprehensive women's health care is as yet incomplete. More research is needed to examine the quality of care associated with these models and to establish the business case for managers faced with small female patient caseloads. C1 VA Greater Los Angeles, HSR&D, Ctr Excellence, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Med, Los Angeles, CA 90024 USA. RP Yano, EM (reprint author), VA Greater Los Angeles, HSR&D, Ctr Excellence, 16111 Plummer St 152, Sepulveda, CA 91343 USA. EM elizabeth.yano@va.gov NR 49 TC 42 Z9 42 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD SEP-OCT PY 2006 VL 16 IS 5 BP 226 EP 235 DI 10.1016/j.whi.2006.07.002 PG 10 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA 099MH UT WOS:000241598500001 PM 17055375 ER PT J AU Cummings, DE AF Cummings, David E. TI Ghrelin and the short- and long-term regulation of appetite and body weight SO PHYSIOLOGY & BEHAVIOR LA English DT Article; Proceedings Paper CT 3rd Food Summit Meeting on Making Sense of Food CY DEC, 2005 CL Wageningen, NETHERLANDS SP Wageningen Ctr Food Sci DE ghrelin; obesity; body-weight regulation; energy homeostasis; weight loss; cachexia; reward; meals; meal initiation ID PRADER-WILLI-SYNDROME; GROWTH-HORMONE SECRETAGOGUE; GASTRIC BYPASS-SURGERY; HYPOTHALAMIC ARCUATE NUCLEUS; AGOUTI-RELATED PROTEIN; INCREASES FOOD-INTAKE; FASTING PLASMA GHRELIN; DEPENDENT INSULINOTROPIC POLYPEPTIDE; LEFT-VENTRICULAR FUNCTION; PLACEBO-CONTROLLED TRIAL AB Ghrelin, an acylated upper gastrointestinal peptide, is the only known orexigenic hormone. Considerable evidence implicates ghrelin in mealtime hunger and meal initiation. Circulating levels decrease with feeding and increase before meals, achieving concentrations sufficient to stimulate hunger and food intake. Preprandial ghrelin surges occur before every meal on various fixed feeding schedules and also among individuals initiating meals voluntarily without time- or food-related cues. Ghrelin injections stimulate food intake rapidly and transiently, primarily by increasing appetitive feeding behaviors and the number of meals. Preprandial ghrelin surges are probably triggered by sympathetic nervous output. Postprandial suppression is not mediated by nutrients in the stomach or duodenum, where most ghrelin is produced. Rather, it results from post-ingestive increases in lower intestinal osmolarity (information probably relayed to the foregut via enteric nervous signaling), as well as from insulin surges. Consequently, ingested lipids suppress ghrelin poorly compared with other macronutrients. Beyond a probable role in meal initiation, ghrelin also fulfills established criteria for an adiposity-related hormone involved in long-term body-weight regulation. Ghrelin levels circulate in relation to energy stores and manifest compensatory changes in response to body-weight alterations. Ghrelin crosses the bloodbrain barrier and stimulates food intake by acting on several classical body-weight regulatory centers, including the hypothalamus, hindbrain, and mesolimbic reward system. Chronic ghrelin administration increases body weight via diverse, concerted actions on food intake, energy expenditure, and fuel utilization. Congenital ablation of the ghrelin or ghrelin-receptor gene causes resistance to diet-induced obesity, and pharmacologic ghrelin blockade reduces food intake and body weight. Ghrelin levels are high in Prader-Willi syndrome and low after gastric bypass surgery, possibly contributing to body-weight alterations in these settings. Extant evidence favors roles for ghrelin in both short-term meal initiation and long-term energy homeostasis, making it an attractive target for drugs to treat obesity and/or wasting disorders. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Cummings, DE (reprint author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-111 Endo, Seattle, WA 98108 USA. EM davidec@u.washington.edu FU NIDDK NIH HHS [P01 DK68384, R01 DK61516, U01 DK66568] NR 263 TC 353 Z9 365 U1 2 U2 47 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD AUG 30 PY 2006 VL 89 IS 1 BP 71 EP 84 DI 10.1016/j.physbeh.2006.05.022 PG 14 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 078FK UT WOS:000240087400014 PM 16859720 ER PT J AU Gukovskaya, AS AF Gukovskaya, Anna S. TI Supramaximal cholecystokinin stimulates apoptosis and necrosis in pancreatic acinar cells: Role in pancreatitis SO REGULATORY PEPTIDES LA English DT Meeting Abstract CT 16th International Symposium on Regulatory Peptides CY AUG 31-SEP 02, 2006 CL Hakone, JAPAN C1 Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-0115 J9 REGUL PEPTIDES JI Regul. Pept. PD AUG 30 PY 2006 VL 135 IS 3 BP 105 EP 106 DI 10.1016/j.regpep.2006.06.009 PG 2 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 083ZB UT WOS:000240499800010 ER PT J AU Tache, Y Yuan, PQ Wu, V Million, M AF Tache, Yvette Yuan, Pu-Qing Wu, Vincent Million, Mulugeta TI Corticotropin releasing factor (CRF) receptors 1 and 2 (CRF1 and CRF2): Differential distribution and action in upper and lower gut function SO REGULATORY PEPTIDES LA English DT Meeting Abstract CT 16th International Symposium on Regulatory Peptides CY AUG 31-SEP 02, 2006 CL Hakone, JAPAN C1 Univ Calif Los Angeles, David Geffen Sch Med, Digest Dis Res Ctr,Div Digest Dis, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-0115 J9 REGUL PEPTIDES JI Regul. Pept. PD AUG 30 PY 2006 VL 135 IS 3 BP 109 EP 109 PG 1 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 083ZB UT WOS:000240499800020 ER PT J AU Wu, SV Yuan, P Jiang, M Lin, P Wang, L Tache, Y AF Wu, S. V. Yuan, P. Jiang, M. Lin, P. Wang, L. Tache, Y. TI Characterization of corticotropin-releasing factor (CRF) receptor isoforms identified from human and rodent GI endocrine cells SO REGULATORY PEPTIDES LA English DT Meeting Abstract CT 16th International Symposium on Regulatory Peptides CY AUG 31-SEP 02, 2006 CL Hakone, JAPAN C1 Univ Calif Los Angeles, David Geffen Sch Med, CURE, Dept Med,Dept Pharmacol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, CNS WH, Dept Med,Dept Pharmacol, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-0115 J9 REGUL PEPTIDES JI Regul. Pept. PD AUG 30 PY 2006 VL 135 IS 3 BP 168 EP 168 PG 1 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 083ZB UT WOS:000240499800181 ER PT J AU Zhou, XH Li, SM AF Zhou, Xiao-Hua Li, Sierra M. TI ITT analysis of randomized encouragement design studies with missing data SO STATISTICS IN MEDICINE LA English DT Article DE causal inference; flu shots; non-compliance; intention-to-treat analysis; missing data ID BAYESIAN-INFERENCE; NONCOMPLIANCE AB In this paper, we considered a missing outcome problem in causal inferences for a randomized encouragement design study. We proposed both moment and maximum likelihood estimators for the marginal distributions of potential outcomes and the local complier average causal effect (CACE) parameter. We illustrated our methods in a randomized encouragement design study on the effectiveness of flu shots. Copyright (c) 2005 John Wiley & Sons, Ltd. C1 Univ Washington, Dept Biostat, HOB, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, HOB, F600,Box 357232, Seattle, WA 98195 USA. EM azhou@u.washington.edu FU NHLBI NIH HHS [R01HL62567] NR 13 TC 26 Z9 27 U1 1 U2 4 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD AUG 30 PY 2006 VL 25 IS 16 BP 2737 EP 2761 DI 10.1002/sim.2388 PG 25 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 073NS UT WOS:000239750500003 PM 16287216 ER PT J AU Oh, J Feldman, MD Kim, J Condit, C Emelianov, S Milner, TE AF Oh, Junghwan Feldman, Marc D. Kim, Jeehyun Condit, Chris Emelianov, Stanislav Milner, Thomas E. TI Detection of magnetic nanoparticles in tissue using magneto-motive ultrasound SO NANOTECHNOLOGY LA English DT Article ID SUPERPARAMAGNETIC IRON-OXIDE; MICROBUBBLE CONTRAST AGENT; LYMPH-NODE METASTASES; ATHEROSCLEROTIC PLAQUES; ENHANCED MRI; IN-VIVO; PARTICLES; CANCER; VISUALIZATION; EXPERIENCE AB The purpose of this study was to demonstrate the magneto-motive ultrasonic detection of superparamagnetic iron oxide (SPIO) nanoparticles as a marker of macrophage recruitment in tissue. The capability of ultrasound to detect SPIO nanoparticles ( core diameter similar to 20 nm) taken up by murine liver macrophages was investigated. Eight mice were sacrificed two days after the intravenous administration of four SPIO doses (1.5, 1.0, 0.5, and 0.1 mmol Fe/kg body weight). In the iron-laden livers, ultrasound Doppler measurements showed a frequency shift in response to an applied time-varying magnetic field. M-mode scan and colour power Doppler images of the iron-laden livers also demonstrated nanoparticle movement under focused magnetic field excitation. In the livers of two saline injected control mice, no movement was observed using any ultrasound imaging modes. The results of our experiments indicate that ultrasound imaging of magneto-motive excitation is a candidate imaging modality to identify tissue-based macrophages containing SPIO nanoparticles. C1 Univ Texas, Dept Biomed Engn, Austin, TX 78712 USA. S Texas Audie Murphy Hosp, Dept Vet Affairs, San Antonio, TX USA. Univ Calif Irvine, Beckman Laser Inst & Med Clin, Irvine, CA 92715 USA. RP Oh, J (reprint author), Univ Texas, Dept Biomed Engn, Austin, TX 78712 USA. EM jhoh@mail.utexas.edu NR 33 TC 83 Z9 88 U1 1 U2 16 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 0957-4484 J9 NANOTECHNOLOGY JI Nanotechnology PD AUG 28 PY 2006 VL 17 IS 16 BP 4183 EP 4190 DI 10.1088/0957-4484/17/16/031 PG 8 WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied SC Science & Technology - Other Topics; Materials Science; Physics GA 077FE UT WOS:000240012600031 PM 21727557 ER PT J AU Higgs, MH Slee, SJ Spain, WJ AF Higgs, Matthew H. Slee, Sean J. Spain, William J. TI Diversity of gain modulation by noise in neocortical neurons: Regulation by the slow afterhyperpolarization conductance SO JOURNAL OF NEUROSCIENCE LA English DT Article DE noise; gain; pyramidal neuron; interneuron; sAHP; coincidence detection ID ACTION-POTENTIAL INITIATION; RAT VISUAL-CORTEX; PYRAMIDAL NEURONS; IN-VIVO; SENSORIMOTOR CORTEX; LAYER 5; PHYSIOLOGICAL-PROPERTIES; COINCIDENCE DETECTION; SOMATOSENSORY CORTEX; SHUNTING INHIBITION AB Neuronal firing is known to depend on the variance of synaptic input as well as the mean input current. Several studies suggest that input variance, or "noise," has a divisive effect, reducing the slope or gain of the firing frequency-current (f-I) relationship. We measured the effects of current noise on f-I relationships in pyramidal neurons and fast-spiking (FS) interneurons in slices of rat sensorimotor cortex. In most pyramidal neurons, noise had a multiplicative effect on the steady-state f-I relationship, increasing gain. In contrast, noise reduced gain in FS interneurons. Gain enhancement in pyramidal neurons increased with stimulus duration and was correlated with the amplitude of the slow afterhyperpolarization (sAHP), a major mechanism of spike-frequency adaptation. The 5-HT2 receptor agonist alpha-methyl-5-HT reduced the sAHP and eliminated gain increases, whereas augmenting the sAHP conductance by spike-triggered dynamic-current clamp enhanced the gain increase. These results indicate that the effects of noise differ fundamentally between classes of neocortical neurons, depending on specific biophysical properties including the sAHP conductance. Thus, noise from background synaptic input may enhance network excitability by increasing gain in pyramidal neurons with large sAHPs and reducing gain in inhibitory FS interneurons. C1 Univ Washington, Dept Physiol & Biophys, Seattle, WA 98105 USA. Univ Washington, Dept Neurol, Seattle, WA 98105 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Spain, WJ (reprint author), Dept Neurol 128, 1660 S Columbian Way, Seattle, WA 98108 USA. EM spain@u.washington.edu FU BLRD VA [I01 BX000386] NR 67 TC 83 Z9 84 U1 3 U2 4 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD AUG 23 PY 2006 VL 26 IS 34 BP 8787 EP 8799 DI 10.1523/JNEUROSCI.1792-06.2006 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 077CV UT WOS:000240006200016 PM 16928867 ER PT J AU Zabetian, CP Morino, H Ujike, H Yamamoto, M Oda, M Maruyama, H Izumi, Y Kaji, R Griffith, A Leis, BC Roberts, JW Yearout, D Samii, A Kawakami, H AF Zabetian, C. P. Morino, H. Ujike, H. Yamamoto, M. Oda, M. Maruyama, H. Izumi, Y. Kaji, R. Griffith, A. Leis, B. C. Roberts, J. W. Yearout, D. Samii, A. Kawakami, H. TI Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease SO NEUROLOGY LA English DT Article ID COMMON FOUNDER; MUTATION AB LRRK2 G2019S is the most common known cause of Parkinson disease (PD) in patients of European origin, but little is known about its distribution in other populations. The authors identified two of 586 Japanese patients with PD heterozygous for the mutation who shared a haplotype distinct from that observed in Europeans. This suggests that G2019S originated from separate founders in Europe and Japan and is more widely dispersed than previously recognized. C1 Ctr Geriatr Res Educ & Clin, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, NW Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. Hiroshima Univ, Grad Sch Biomed Sci, Res Inst Radiat Biol & Med, Dept Epidemiol, Hiroshima 730, Japan. Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Neurosci & Therapeut, Hiroshima 730, Japan. Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neuropsychiat, Okayama 7008530, Japan. Kagawa Prefectural Cent Hosp, Dept Neurol, Takamatsu, Kagawa, Japan. Sumimoto Hosp, Dept Neurol, Osaka, Japan. Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Clin Neurosci, Tokushima 770, Japan. Evergreen Hosp, Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. Virginia Mason Med Ctr, Seattle, WA 98101 USA. RP Zabetian, CP (reprint author), Ctr Geriatr Res Educ & Clin, VA Puget Sound Hlth Care Syst, S-182 ,1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu RI Maruyama, Hirofumi/B-9333-2011; Kawakami, Hideshi/A-2086-2009; Morino, Hiroyuki/H-9583-2013 OI Kawakami, Hideshi/0000-0002-1405-0901; Morino, Hiroyuki/0000-0002-5190-3547; Zabetian, Cyrus/0000-0002-7739-4306 FU NINDS NIH HHS [K08-NS044138] NR 10 TC 42 Z9 43 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD AUG 22 PY 2006 VL 67 IS 4 BP 697 EP 699 DI 10.1212/01.wnl.0000227732.37801.d4 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 075XG UT WOS:000239920100034 PM 16728648 ER PT J AU Martini, SR Hill, MD Alexandrov, AV Molina, CA Kent, TA AF Martini, S. R. Hill, M. D. Alexandrov, A. V. Molina, C. A. Kent, T. A. TI Outcome in hyperglycemic stroke with ultrasound-augmented thrombolytic therapy SO NEUROLOGY LA English DT Article ID ACUTE ISCHEMIC-STROKE; OXIDE SYNTHASE ACTIVITY AB Hyperglycemia independently predicts poor outcome after acute ischemic stroke. CLOTBUST ( Combined Lysis Of Thrombus in Brain ischemia using transcranial Ultrasound and Systemic tPA) demonstrated that ultrasound-augmented thrombolysis improves recanalization and 24-hour outcome in patients with acute ischemic stroke. We hypothesized that ultrasound would preferentially benefit hyperglycemic patients, and reviewed CLOTBUST with respect to admission glucose and good outcome. We found that ultrasound's benefit on 90-day outcome was primarily apparent at higher glucose levels, suggesting that ultrasound therapy may improve outcome following hyperglycemic stroke. C1 Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Stroke Program, Houston, TX USA. Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 1N4, Canada. Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada. Univ Calgary, Dept Med, Calgary, AB T2N 1N4, Canada. Univ Texas, Sch Med, Stroke Treatment Team, Houston, TX USA. Hosp Gen Valle Hebron, Neurovasc Unit, Barcelona, Spain. RP Kent, TA (reprint author), Baylor Coll Med, Dept Neurol, 2002 Holocombe Blvd,Room 2B223, Houston, TX 77030 USA. EM tkent@bcm.tmc.edu OI Alexandrov, Andrei V/0000-0001-8871-1023; Kent, Thomas/0000-0002-9877-7584; Hill, Michael/0000-0002-6269-1543 FU NINDS NIH HHS [1K23NS02229-01, 1P50NS044227] NR 10 TC 9 Z9 10 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD AUG 22 PY 2006 VL 67 IS 4 BP 700 EP 702 DI 10.1212/01.wnl.0000229926.85117.75 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 075XG UT WOS:000239920100035 PM 16924029 ER PT J AU Hase, H Ando, T Eldeiry, L Brebene, A Peng, YZ Liu, LY Amano, H Davies, TF Sun, L Zaidi, M Abe, E AF Hase, Hidenori Ando, Takao Eldeiry, Leslie Brebene, Alina Peng, Yuanzhen Liu, Lanying Amano, Hitoshi Davies, Terry F. Sun, Li Zaidi, Mone Abe, Etsuko TI TNF alpha mediates the skeletal effects of thyroid-stimulating hormone SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE bone remodeling; osteoclast; macrophage; cytokine ID NECROSIS-FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; THYROTROPIN RECEPTOR; BONE METABOLISM; GRAVES-DISEASE; UP-REGULATION; TSH RECEPTOR; T-CELL; HYPERTHYROIDISM; EXPRESSION AB We have shown recently that by acting on the thyroid-stimulating hormone (TSH) receptor (TSHR), TSH negatively regulates osteoclast differentiation. Both heterozygotic and homozygotic TSHR null mice are osteopenic with evidence of enhanced osteoclast differentiation. Here, we report that the accompanying elevation of TNF alpha, an osteoclastogenic cytokine, causes the increased osteoclast differentiation. This enhancement in TSHR-/- and TSHR+/- mice is abrogated in compound TSHR-/-/TNF alpha(-/-) and TSHR+/-/ TNF alpha(+/-) mice, respectively. In parallel studies, we find that TSH directly inhibits TNFa production, reduces the number of TNF alpha- producing osteoclast precursors, and attenuates the induction of TNF alpha expression by IL-1, TNF alpha, and receptor activator of NF-kappa B ligand. TSH also suppresses osteoclast formation in murine macrophages and RAW-C3 cells. The suppression is more profound in cells that overexpress the TSHR than those transfected with empty vector. The overexpression of ligand-independent, constitutively active TSHR abrogates osteoclast formation even under basal conditions and in the absence of TSH. Finally, IL-1/TNF alpha and receptor activator of NF-kappa B ligand fail to stimulate AM and NF-kappa B binding to DNA in cells transfected with TSHR or constitutively active TSHR. The results suggest that TNFa is the critical cytokine mediating the downstream antiresorptive effects of TSH on the skeleton. C1 Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. Showa Univ, Sch Dent, Dept Pharmacol, Tokyo 142, Japan. RP Abe, E (reprint author), Mt Sinai Sch Med, Dept Med, 1 Gustave L Levy Pl,Box 1055, New York, NY 10029 USA. EM etsuko.abe@mssm.edu FU NIA NIH HHS [R01 AG023176, AG14917, AG23176]; NIAMS NIH HHS [AR 052258]; NIDDK NIH HHS [R01 DK052464, R01 DK070526, DK52464, DK70526] NR 35 TC 53 Z9 57 U1 0 U2 3 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD AUG 22 PY 2006 VL 103 IS 34 BP 12849 EP 12854 DI 10.1073/pnas.0600427103 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 077NI UT WOS:000240035900038 PM 16908863 ER PT J AU Hammer, SM Saag, MS Schechter, M Montaner, JSG Schooley, RT Jacobsen, DM Thompson, MA Carpenter, CCJ Fischl, MA Gazzard, BG Gatell, JM Hirsch, MS Katzenstein, DA Richman, DD Vella, S Yeni, PG Volberding, PA AF Hammer, Scott M. Saag, Michael S. Schechter, Mauro Montaner, Julio S. G. Schooley, Robert T. Jacobsen, Donna M. Thompson, Melanie A. Carpenter, Charles C. J. Fischl, Margaret A. Gazzard, Brian G. Gatell, Jose M. Hirsch, Martin S. Katzenstein, David A. Richman, Douglas D. Vella, Stefano Yeni, Patrick G. Volberding, Paul A. TI Treatment for adult HIV infection - 2006 recommendations of the International AIDS Society-USA panel SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; HEPATITIS-B-VIRUS; TENOFOVIR DISOPROXIL FUMARATE; EARLY VIROLOGICAL FAILURE; DRUG-RESISTANCE; HIV-1-INFECTED PATIENTS; COMBINATION THERAPY; DISEASE PROGRESSION; INITIAL TREATMENT AB Context Guidelines for antiretroviral therapy are important for clinicians worldwide given the complexity of the field and the varied clinical situations in which these agents are used. The International AIDS Society - USA panel has updated its recommendations as warranted by new developments in the field. Objective To provide physicians and other human immunodeficiency virus (HIV) clinicians with current recommendations for the use of antiretroviral therapy in HIV-infected adults in circumstances for which there is relatively unrestricted access to drugs and monitoring tools. The recommendations are centered on 4 key issues: when to start antiretroviral therapy; what to start; when to change; and what to change. Antiretroviral therapy in special circumstances is also described. Data Sources and Study Selection A 16-member noncompensated panel was appointed, based on expertise in HIV research and patient care internationally. Data published or presented at selected scientific conferences from mid 2004 through May 2006 were identified and reviewed by all members of the panel. Data Extraction and Synthesis Data that might change previous guidelines were identified and reviewed. New guidelines were drafted by a writing committee and reviewed by the entire panel. Conclusions Antiretroviral therapy in adults continues to evolve rapidly, making delivery of state-of-the-art care challenging. Initiation of therapy continues to be recommended in all symptomatic persons and in asymptomatic persons after the CD4 cell count falls below 350/mu L and before it declines to 200/mu L. A nonnucleoside reverse transcriptase inhibitor or a protease inhibitor boosted with low-dose ritonavir each combined with 2 nucleoside ( or nucleotide) reverse transcriptase inhibitors is recommended with choice being based on the individual patient profile. Therapy should be changed when toxicity or intolerance mandate it or when treatment failure is documented. The virologic target for patients with treatment failure is now a plasma HIV-1 RNA level below 50 copies/mL. Adherence to antiretroviral therapy in the short-term and the long-term is crucial for treatment success and must be continually reinforced. C1 Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA. Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ Fed Rio de Janeiro, Dept Prevent Med, BR-21941 Rio De Janeiro, Brazil. Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. Int AIDS Soc USA, San Francisco, CA USA. AIDS Res Consortium, Atlanta, GA USA. Brown Univ, Sch Med, Dept Biomed, Providence, RI 02912 USA. Univ Miami, Sch Med, Dept Med, Coral Gables, FL 33124 USA. Chelsea & Westminster Hosp, Dept HIV Med, London, England. Univ Barcelona, Hosp Clin, IDIBAPS, Dept Med, Barcelona, Spain. Harvard Univ, Sch Med, Dept Med, Boston, MA USA. Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA. Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA. San Diego Vet Affairs Healthcare Syst, San Diego, CA USA. Ist Super Sanita, Dept Drug Discovery & Evaluat, I-00161 Rome, Italy. Hop Bichat Claude Bernard, X Bichat Med Sch, Dept Infect Dis, F-75877 Paris 18, France. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Hammer, SM (reprint author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St,Box 82, New York, NY 10032 USA. EM smh48@columbia.edu RI Vella, Stefano/D-4912-2015 OI Vella, Stefano/0000-0003-2347-5984 NR 133 TC 568 Z9 593 U1 2 U2 24 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 16 PY 2006 VL 296 IS 7 BP 827 EP 843 DI 10.1001/jama.296.7.827 PG 17 WC Medicine, General & Internal SC General & Internal Medicine GA 073SR UT WOS:000239763400023 PM 16905788 ER PT J AU Butt, AA Justice, AC Skanderson, M Good, C Kwoh, CK AF Butt, A. A. Justice, A. C. Skanderson, M. Good, C. Kwoh, C. K. TI Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID ALPHA-2A PLUS RIBAVIRIN; HEPATOCELLULAR-CARCINOMA; PEGINTERFERON ALPHA-2A; INTERFERON THERAPY; INFECTED VETERANS; POST-HAART; CIRRHOSIS; RISK; COHORT; CANCER AB Background True treatment rates and the impact of comorbidities on treatment rates for hepatitis C virus in the HCV-HIV-coinfected subjects are unknown. Aim To quantify the rates of treatment prescription and the effect of comorbidities on hepatitis C virus treatment rates in HCV-HIV-coinfected veterans. Methods The Veterans Affairs National Patient Care Database was used to identify all hepatitis C virus-infected subjects between 1999 and 2003 using ICD-9 codes. Demographics, comorbidities and pharmacy data were retrieved. We used logistic regression to compare the predictors of hepatitis C virus treatment in hepatitis C virus-monoinfected and HCV-HIV-coinfected subjects. Findings We identified 120 507 hepatitis C virus-infected subjects, of which 6502 were HIV coinfected. 12% of the hepatitis C virus-monoinfected and 7% of the -coinfected subjects were prescribed hepatitis C virus treatment (P < 0.0001). Those not prescribed treatment were older (48.6 years vs. 47.7 years, P = 0.007) and more likely to be black (52% vs. 32%, P < 0.0001). HIV coinfected was less likely to be prescribed hepatitis C virus treatment (OR 0.74, 95% CI: 0.67-0.82). Among the coinfected subjects, the following were associated with non-treatment (OR, 95% CI): black race (0.45, 0.35-0.57); Hispanic race (0.56, 0.38-0.82); drug use (0.68, 0.53-0.88); anaemia (0.17, 0.11-0.26); bipolar disorder (0.63, 0.40-0.99); major depression (0.72, 0.53-0.99); mild depression (0.47, 0.35-0.62). Conclusions A small number of HCV-HIV-coinfected veterans are prescribed treatment for hepatitis C virus. Non-treatment is associated with increasing age, minority race, drug use and psychiatric illness. Further studies are needed to determine the eligibility for treatment and reasons for non-treatment for hepatitis C virus. C1 Univ Pittsburgh, Med Ctr, Sch Med, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Yale Univ, Sch Med, Ctr Hlth Equ Res & Promot, New Haven, CT 06520 USA. RP Butt, AA (reprint author), Univ Pittsburgh, Med Ctr, Sch Med, 3601 5th Ave,Suite 3A,Falk Med Bldg, Pittsburgh, PA 15213 USA. EM butta@dom.pitt.edu FU NIDA NIH HHS [DA016175-01A1] NR 24 TC 30 Z9 30 U1 2 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD AUG 15 PY 2006 VL 24 IS 4 BP 585 EP 591 DI 10.1111/j.1365-2036.2006.03020.x PG 7 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 067MJ UT WOS:000239306800003 PM 16907891 ER PT J AU Shlipak, MG Katz, R Sarnak, MJ Fried, LF Newman, AB Stehman-Breen, C Seliger, SL Kestenbaum, B Psaty, B Tracy, RP Siscovick, DS AF Shlipak, Michael G. Katz, Ronit Sarnak, Mark J. Fried, Linda F. Newman, Anne B. Stehman-Breen, Catherine Seliger, Stephen L. Kestenbaum, Brian Psaty, Bruce Tracy, Russell P. Siscovick, David S. TI Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID GLOMERULAR-FILTRATION-RATE; RENAL-FUNCTION; HEART-FAILURE; CREATININE CLEARANCE; THYROID-DYSFUNCTION; RISK-FACTOR; HEALTH; MORTALITY; EVENTS; DEFINITION AB Background: Cystatin C is an alternative measure of kidney function that may have prognostic importance among elderly persons who do not meet standard criteria for chronic kidney disease (estimated glomerular filtration rate [GFR] >= 60 mL/min per 1.73 m(2)). Objective: To evaluate cystatin C as a prognostic biomarker for death, cardiovascular disease, and incident chronic kidney disease among elderly persons without chronic kidney disease. Design: Cohort study. Setting: The Cardiovascular Health Study, a population-based cohort recruited from 4 communities in the United States. Participants: 4663 elderly persons Measurements: Measures of kidney function were creatinine-based estimated GFR by using the Modification of Diet in Renal Disease equation and cystatin C concentration. Outcomes were death, cardiovascular death, noncardiovascular death, heart failure, stroke, myocardial infarction, and incident chronic kidney disease during follow-up (median, 9.3 years). Results: At baseline, 78% of participants did not have chronic kidney disease (estimated GFR 60 mL/min per 1.73 m(2)) and mean cystatin C concentration, creatinine concentration, and estimated GFR were 1.0 mg/L, 79.6 mu mol/L (0.9 mg/dL, and 83 mL/min per 1.73 m(2), respectively. Cystatin C concentrations (per SD, 0.18 mg/L) had strong associations with death (hazard ratio, 1.33 [95% CI, 1.25 to 1.40]), cardiovascular death (hazard ratio, 1.42 [CI, 1.30 to 1.54]), noncardiovascular death (hazard ratio, 1.26 [CI, 1.17 to 1.36]), incident heart failure (hazard ratio, 1.28 [CI, 1.17 to 1.401), stroke (hazard ratio, 1.22 [CI, 1.08 to 1.381), and myocardial infarction (hazard ratio, 1.20 [CI, 1.06 to 1.36]) among these participants. Serum creatinine concentrations had much weaker associations with each outcome and only predicted cardiovascular death. Participants without chronic kidney disease who had elevated cystatin C concentrations (>= 1.0 mg/L) had a 4-fold risk for progressing to chronic kidney disease after 4 years of follow-up compared with those with cystatin C concentrations less than 1.0 mg/L. Limitations: Because this study did not directly measure GFR or albuminuria, the extent to which cystatin C may be influenced by nonrenal factors was not determined and participants with albuminuria might have been misclassified as having no kidney disease. Conclusions: Among elderly persons without chronic kidney disease, cystatin C is a prognostic biomarker of risk for death, cardiovascular disease, and chronic kidney disease. In this setting, cystatin C seems to identify a "preclinical" state of kidney dysfunction that is not detected with serum creatinine or estimated GFR. C1 Vet Adm Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Washington, Seattle, WA 98195 USA. Tufts Univ, New England Med Ctr, Boston, MA 02111 USA. Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Pittsburgh, PA USA. Amgen Inc, Thousand Oaks, CA 91320 USA. Univ Vermont, Coll Med, Burlington, VT USA. RP Shlipak, MG (reprint author), Vet Adm Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NHLBI NIH HHS [N01-HC-15103, N01-HC-35129, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, R01 HL073208-01]; NIA NIH HHS [R01 AG027002]; NIDDK NIH HHS [R01 DK066488] NR 41 TC 307 Z9 333 U1 1 U2 10 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD AUG 15 PY 2006 VL 145 IS 4 BP 237 EP 246 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 075CC UT WOS:000239858800001 PM 16908914 ER PT J AU Geiger, GA Parker, SE Beothy, AP Tucker, JA Mullins, MC Kao, GD AF Geiger, Geoffrey A. Parker, Sharon E. Beothy, Andrew P. Tucker, Jennifer A. Mullins, Mary C. Kao, Gary D. TI Zebrafish as a "biosensor"? Effects of ionizing radiation and amifostine on embryonic viability and development SO CANCER RESEARCH LA English DT Article ID DNA FRAGMENTATION; NERVOUS-SYSTEM; APOPTOSIS; PROTECTION; STAUROSPORINE; INDUCTION; TOXICITY; DAMAGE; MODEL AB The zebrafish (Danio rerio) has emerged as a popular vertebrate model system for cancer and treatment-related research. Benefits include ease of care, rapid development, optical clarity of embryos, which allows visualization of major organ systems, and opportunities for genetic manipulation. However, specific parameters of radiation sensitivity have not been systematically documented. We investigated the effects of radiation and a radiomodifier on zebrafish viability and embryonic development. Embryos were exposed toy-radiation (5, 10, or 20 Gy) at sequential times postfertilization and serially assessed for viability and morphologic abnormalities. As expected, lethality and morphologic perturbations were more pronounced earlier in embryogenesis and with higher radiation doses and were partially reversed by amifostine. The effects of radiation and concurrent treatment with amifostine on the developmental organization of the eye and brain were striking. Radiation resulted in hypocellularity and disorganization of the cellular layers of the retina, effects partially reversed by arnifostine, as well as lens opacification. Radiation strikingly reduced the volume of brain, but the volume loss was substantially blocked by amifostine. Increased terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling signal was noted in both the irradiated eye and brain, but reduced by amifostine. Finally, irradiating embryos resulted in caspase activation detectable in 96-well microplates, which was proportional to the number of embryos and radiation dose; the degree of activation was markedly reduced by arnifostine. These results together suggest the power and versatility of the zebrafish in assessing the effects of radiation and radiomodifiers on organ and tissue development. C1 Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Dept Radiat Oncol, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA. RP Kao, GD (reprint author), John Morgan 180 H,Hamilton Walk, Philadelphia, PA 19104 USA. EM Kao@xyt.upenn.edu FU NCI NIH HHS [P01CA075138, C5T32CA009677, CA107956] NR 30 TC 59 Z9 61 U1 1 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD AUG 15 PY 2006 VL 66 IS 16 BP 8172 EP 8181 DI 10.1158/0008-5472.CAN-06-0466 PG 10 WC Oncology SC Oncology GA 074QZ UT WOS:000239828200045 PM 16912196 ER PT J AU Louie, TJ Peppe, J Watt, CK Johnson, D Mohammed, R Dow, G Weiss, K Simon, S John, JF Garber, G Chasan-Taber, S Davidson, DM AF Louie, Thomas J. Peppe, Jennifer Watt, C. Kevin Johnson, David Mohammed, Rasheed Dow, Gordon Weiss, Karl Simon, Stuart John, Joseph F., Jr. Garber, Gary Chasan-Taber, Scott Davidson, David M. CA Tolevamer Study Investigator Grp TI Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile - Associated diarrhea SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 1st International Clostridium Difficile Symposium CY MAY 05-07, 2004 CL Kranjska Gora, SLOVENIA ID ANTIBIOTIC-ASSOCIATED DIARRHEA; ANTIBODY-RESPONSE; TOXIN BINDING; COLITIS; METRONIDAZOLE; INFECTION; DISEASE; MANAGEMENT; DIAGNOSIS; STRAIN AB Background. Current antibiotic therapies for Clostridium difficile - associated diarrhea have limitations, including progression to severe disease, recurrent C. difficile - associated diarrhea, and selection for nosocomial pathogens. Tolevamer, a soluble, high - molecular weight, anionic polymer that binds C. difficile toxins A and B is a unique nonantibiotic treatment option. Methods. In this 3-arm, multicenter, randomized, double-blind, active-controlled, parallel-design phase II study, patients with mild to moderately severe C. difficile - associated diarrhea were randomized to receive 3 g of tolevamer per day (n = 97), 6 g of tolevamer per day (n = 95), or 500 mg of vancomycin per day (n = 97). The primary efficacy parameter was time to resolution of diarrhea, defined as the first day of 2 consecutive days when the patient had hard or formed stools (any number) or <= 2 stools of loose or watery consistency. Results. In the per-protocol study population, resolution of diarrhea was achieved in 48 (67%) of 72 patients receiving 3 g of tolevamer per day (median time to resolution of diarrhea, 4.0 days; 95% confidence interval, 2.0-6.0 days), in 58 (83%) of 70 patients receiving 6 g of tolevamer per day ( median time to resolution of diarrhea, 2.5 days; 95% confidence interval, 2.0-3.0 days), and in 73 (91%) of 80 patients receiving vancomycin (median time to resolution of diarrhea, 2.0 days; 95% confidence interval, 1.0-3.0 days). Tolevamer administered at a dosage of 6 g per day was found to be noninferior to vancomycin administered at a dosage of 500 mg per day with regard to time to resolution of diarrhea (P = .02) and was associated with a trend toward a lower recurrence rate. Tolevamer was well tolerated but was associated with an increased risk of hypokalemia. Conclusions. Tolevamer, a novel polystyrene binder of C. difficile toxins A and B, effectively treats mild to moderate C. difficile diarrhea and merits further clinical development. C1 Univ Calgary, Calgary, AB, Canada. Moncton Hosp, Moncton, NB, Canada. Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada. Univ Ottawa, Ottawa, ON K1N 6N5, Canada. Genzyme Corp, Cambridge, MA USA. Bio Test Clin, Springfield, MO USA. Bay Pines Vet Affairs Med Ctr, Bay Pines, FL USA. Radiant Res, Austell, GA USA. Georgia Lung Associates, Austell, GA USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Louie, TJ (reprint author), Foothills Med Ctr, AGW5,1403 29th St NW, Calgary, AB T2N 2T9, Canada. EM louie@ucalgary.ca NR 36 TC 112 Z9 116 U1 1 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2006 VL 43 IS 4 BP 411 EP 420 DI 10.1086/506349 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 063XN UT WOS:000239053300004 PM 16838228 ER PT J AU Smyk-Pearson, S Tester, IA Lezotte, D Sasaki, AW Lewinsohn, DM Rosen, HR AF Smyk-Pearson, Susan Tester, Ian A. Lezotte, Dennis Sasaki, Anna W. Lewinsohn, David M. Rosen, Hugo R. TI Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: Implications for vaccine design SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID T-CELL RESPONSES; IMMUNE-RESPONSES; EFFECTOR FUNCTION; DENDRITIC CELLS; VIRAL CLEARANCE; HCV INFECTION; CD4(+); PERSISTENCE; EVASION; HELP AB Background. Cellular immune responses play a central role in the control of hepatitis C virus (HCV) infection, and in some individuals the adaptive immune response can spontaneously eradicate HCV infection. The development of vaccine candidates to prevent the spread of this infection remains a top priority; however, understanding the correlates of effective immunological containment is an important prerequisite. Methods. Using 750 overlapping peptides, we directly characterized ex vivo total and subgenomic HCV-specific CD4(+) and CD8(+) T cell responses in a large cohort of participants with either chronic infection or spontaneously resolved infection. Results. In chronic infection, the frequency of total CD4(+) T cells specific for HCV averaged 0.06%, compared with 0.38% in resolved infection. Total HCV-specific CD4(+) and CD8(+) T cell responses were strongly correlated in the setting of spontaneous resolution but not in the setting of viral persistence. NS3 protein-specific responses comprised a significantly greater proportion of the total response in resolved infection than in chronic infection, whereas responses to different regions comprised a larger proportion of responses in chronic infection. Conclusion. Because these data comprehensively define the breadth, specificity, and threshold of the T cell response associated with spontaneous recovery from HCV infection, they have important implications in the development of multigenic vaccine candidates for this common infection. C1 Univ Colorado, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Hepatitis C Ctr, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Integrated Program, Denver, CO 80262 USA. Univ Colorado, Natl Jewish Hosp, Denver, CO 80202 USA. Univ Colorado, Dept Prevent Med, Denver, CO 80202 USA. Portland Vet Affairs Med Ctr, Div Pulm & Crit Care Med, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Rosen, HR (reprint author), Univ Colorado, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Hepatitis C Ctr, 4200 E 9th Ave,No B-158, Denver, CO 80262 USA. EM Hugo.Rosen@UCHSC.edu RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 FU NIDDK NIH HHS [R01 DK060590] NR 40 TC 47 Z9 50 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD AUG 15 PY 2006 VL 194 IS 4 BP 454 EP 463 DI 10.1086/505714 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 064WO UT WOS:000239121000007 PM 16845628 ER PT J AU Prasad, R Giri, S Nath, N Singh, I Singh, AK AF Prasad, Ratna Giri, Shailendra Nath, Narender Singh, Inderjit Singh, Avtar K. TI 5-aminoimidazole-4-carboxamide-1-beta4-ribofurano side attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE EAE; AICAR; endothelial; monocyte; cell adhesion molecules ID ACTIVATED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; NF-KAPPA-B; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NITRIC-OXIDE SYNTHASE; ADHESION MOLECULE EXPRESSION; DEVELOPING RAT-BRAIN; MULTIPLE-SCLEROSIS; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS AB Experimental autoimmune encephalomyelitis (EAE) is a model for studying multiple sclerosis (MS), a chronic demyelinating disorder of the CNS. 5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR), an activator of AMP-activated protein kinase (AMPK), has been reported to show antiinflammatory and immunomodulatory effects in various models of inflammation. Recently, we have reported AICAR-mediated attenuation of active and passive EAE in mouse model [Nath et al. (2005) J. Immunol. 175:566-574]. Here we used a rat model of acute EAE to show anti inflammatory effects of AICAR after daily treatment starting at onset of the disease. By maintaining the blood-brain barrier (BBB), AICAR-administered animals showed lower clinical scores compared with untreated EAE animals. AICAR inhibited the infiltration of inflammatory cells across the BBB, resulting in lowered expression of proinflammatory mediators in the CNS and protection from severe demyelination. By using in vitro model of endothelial-leukocyte interaction, we showed that AICAR inhibited adhesion of monocytes to tumor necrosis factor-alpha-activated endothelial cells. One of the mechanisms of this action is through down-regulation of expression of endothelial cell adhesion molecules via modulation of nuclear factor kappa B activation. The data suggest that AICAR attenuates EAE progression by limiting infiltration of leukocytes across the BBB, thereby controlling the consequent inflammatory reaction in the CNS. (c) 2006 Wiley-Liss, Inc. C1 Med Univ S Carolina, Dept Pathol & Lab Med, Ralph Johnson Vet Affairs Med Ctr, Childrens Res Inst 505, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, Ralph Johnson Vet Affairs Med Ctr, Childrens Res Inst 505, 173 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu FU NINDS NIH HHS [NS-22576, NS-37766, NS-40144, NS-34741, NS-40810] NR 55 TC 37 Z9 38 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD AUG 15 PY 2006 VL 84 IS 3 BP 614 EP 625 DI 10.1002/jnr.20953 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 071FR UT WOS:000239584700015 PM 16770773 ER PT J AU Georgieva, L Moskvina, V Peirce, T Norton, N Bray, NJ Jones, L Holmans, P MacGregor, S Zammit, S Wilkinson, J Williams, H Nikolov, I Williams, N Ivanov, D Davis, KL Haroutunian, V Buxbaum, JD Craddock, N Kirov, G Owen, MJ O'Donovan, MC AF Georgieva, Lyudmila Moskvina, Valentina Peirce, Tim Norton, Nadine Bray, Nicholas J. Jones, Lesley Holmans, Peter MacGregor, Stuart Zammit, Stanley Wilkinson, Jennifer Williams, Hywel Nikolov, Ivan Williams, Nigel Ivanov, Dobril Davis, Kenneth L. Haroutunian, Vahram Buxbaum, Joseph D. Craddock, Nick Kirov, George Owen, Michael J. O'Donovan, Michael C. TI Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE association; oligodentrocyte/myelin-related genes ID MULTIPLE TESTING CORRECTION; NYHOLTS PROCEDURE; PROBE LEVEL; EXPRESSION; MYELIN; PROTEIN; DYSFUNCTION; CORTEX; BRAIN; DISEQUILIBRIUM AB Abnormal oligodendrocyte function has been postulated as a primary etiological event in schizophrenia. Oligodendrocyte lineage transcription factor 2 (OLIG2) encodes a transcription factor central to oligodendrocyte development. Analysis of OLIG2 in a case-control sample (n = approximate to 1,400) in the U.K. revealed several SNPs to be associated with schizophrenia (minimum P = 0.0001, genewide P = 0.0009). To obtain independent support for this association, we sought evidence for genetic interaction between OLIG2 and three genes of relevance to oligodendrocyte function for which we have reported evidence for association with schizophrenia: CNP, NRG1, and ERBB4. We found interaction effects on disease risk between OLIG2 and CNP (minimum P = 0.0001, corrected P = 0.008) for interaction with ERBB4 (minimum P = 0.002, corrected P = 0.04) but no evidence for interaction with NRG1. To investigate the biological plausibility of the interactions, we sought correlations between the expression of the genes. The results were similar to those of the genetic interaction analysis. OLIG2 expression significantly correlated in cerebral cortex with CNP (P < 10(-7)) and ERBB4 (P = 0.002, corrected P = 0.038) but not NRG1. In mouse striatum, O1ig2 and Cnp expression also was correlated, and linkage analysis for trans-effects on gene expression suggests that each locus regulates the other's expression. Our data provide strong convergent evidence that variation in OLIG2 confers susceptibility to schizophrenia alone and as part of a network of genes implicated in oligodendrocyte function. C1 Univ Cardiff Wales, Sch Med, Dept Psychol Med, Cardiff CF14 4XN, Wales. Univ Cardiff Wales, Sch Med, Biostat & Bioinformat Unit, Cardiff CF14 4XN, Wales. Mt Sinai Sch Med, Dept Psychiat, New York, NY 10021 USA. Bronx Vet Affairs Med Ctr, Mental Illness Res Ctr, Bronx, NY 10468 USA. Bronx Vet Affairs Med Ctr, Educ Ctr, Bronx, NY 10468 USA. Bronx Vet Affairs Med Ctr, Ctr Clin, Bronx, NY 10468 USA. RP Owen, MJ (reprint author), Univ Cardiff Wales, Sch Med, Dept Psychol Med, Heath Pk, Cardiff CF14 4XN, Wales. EM owenmj@cf.ac.uk; odonovanmc@cf.ac.uk RI Macgregor, Stuart/C-6442-2009; turton, miranda/F-4682-2011; Holmans, Peter/F-4518-2015 OI Macgregor, Stuart/0000-0001-6731-8142; Holmans, Peter/0000-0003-0870-9412; Zammit, Stanley/0000-0002-2647-9211; O'Donovan, Michael/0000-0001-7073-2379; Ivanov, Dobril/0000-0001-6271-6301; Buxbaum, Joseph/0000-0001-8898-8313; Escott-Price, Valentina/0000-0003-1784-5483 FU Medical Research Council [G9309834, G9810900] NR 54 TC 69 Z9 70 U1 0 U2 1 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD AUG 15 PY 2006 VL 103 IS 33 BP 12469 EP 12474 DI 10.1073/pnas.0603029103 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 075EW UT WOS:000239867500049 PM 16891421 ER PT J AU Shores, MM Matsumoto, AM Sloan, KL Kivlahan, DR AF Shores, Molly M. Matsumoto, Alvin M. Sloan, Kevin L. Kivlahan, Daniel R. TI Low serum testosterone and mortality in male veterans SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID HORMONE-BINDING GLOBULIN; CORONARY-ARTERY-DISEASE; MIDDLE-AGED MEN; OLDER MEN; CARDIOVASCULAR-DISEASE; PREMATURE MORTALITY; CRITICAL ILLNESS; HEART-DISEASE; POPULATION; HYPOPITUITARISM AB Background: Low serum testosterone is a common condition in aging associated with decreased muscle mass and insulin resistance. This study evaluated whether low testosterone levels are a risk factor for mortality in male veterans. Methods: We used a clinical database to identify men older than 40 years with repeated testosterone levels obtained from October 1, 1994, to December 31, 1999, and without diagnosed prostate cancer. A low testosterone level was a total testosterone level of less than 250 ng/dL (< 8.7 nmol/L) or a free testosterone level of less than 0.75 ng/dL (< 0.03 nmol/L). Men were classified as having a low testosterone level ( 166 [ 19.3%]), an equivocal testosterone level ( equal number of low and normal levels) ( 240 [ 28.0%]), or a normal testosterone level ( 452 [ 52.7%]). The risk for all-cause mortality was estimated using Cox proportional hazards regression models, adjusting for demographic and clinical covariates over a follow-up of up to 8 years. Results: Mortality in men with normal testosterone levels was 20.1%( 95% confidence interval [ CI], 16.2%-24.1%) vs 24.6%( 95% CI, 19.2%-30.0%) in men with equivocal testosterone levels and 34.9% ( 95% CI, 28.5%-41.4%) in men with low testosterone levels. After adjusting for age, medical morbidity, and other clinical covariates, low testosterone levels continued to be associated with increased mortality ( hazard ratio, 1.88; 95% CI, 1.34-2.63; P < . 001) while equivocal testosterone levels were not significantly different from normal testosterone levels ( hazard ratio, 1.38; 95% CI, 0.99%-1.92%; P=.06). In a sensitivity analysis, men who died within the first year( 50[ 5.8%]) were excluded to minimize the effect of acute illness, and low testosterone levels continued to be associated with elevated mortality. Conclusions: Low testosterone levels were associated with increased mortality in male veterans. Further prospective studies are needed to examine the association between low testosterone levels and mortality. C1 Univ Washington, VA Puget Sound Hlth Care Syst, Dept Psychiat & Behav Sci, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Shores, MM (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Psychiat & Behav Sci, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way,Mailstop S-182GRECC, Seattle, WA 98108 USA. EM mxs@u.washington.edu NR 47 TC 279 Z9 284 U1 1 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD AUG 14 PY 2006 VL 166 IS 15 BP 1660 EP 1665 DI 10.1001/archinte.166.15.1660 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 073QM UT WOS:000239757700018 PM 16908801 ER PT J AU Giri, S Rattan, R Haq, E Khan, M Yasmin, R Won, JS Key, L Singh, AK Singh, I AF Giri, Shailendra Rattan, Ramandeep Haq, Ehtishamul Khan, Mushfiquddin Yasmin, Rifat Won, Je-song Key, Lyndon Singh, Avtar K. Singh, Inderjit TI AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model SO NUTRITION & METABOLISM LA English DT Article ID ACTIVATED PROTEIN-KINASE; ENHANCER-BINDING-PROTEIN; FATTY-ACID OXIDATION; INSULIN-RESISTANCE; GENE-EXPRESSION; ADIPOSE-TISSUE; MITOCHONDRIAL BIOGENESIS; SKELETAL-MUSCLE; TRANSCRIPTIONAL COACTIVATOR; 3T3-L1 ADIPOCYTES AB Background: Obesity is one of the principal causative factors involved in the development of metabolic syndrome. AMP-activated protein kinase ( AMPK) is an energy sensor that regulates cellular metabolism. The role of AMP-activated protein kinase in adipocyte differentiation is not completely understood, therefore, we examined the effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside ( AICAR), a pharmacological activator of AMP-activated protein kinase ( AMPK) on adipocyte differentiation in 3T3L1 cells and in a mouse Diet induced obesity (DIO) model. Methods: To examine the effect of AICAR on adipocyte differentiation in 3T3L1 cells and in a mouse Diet induced obesity ( DIO) model, 3T3L1 cells were differentiatied in the presence or absence of different concentration of AICAR and neutral lipid content and expression of various adipocyte-specific transcription factors were examined. In vivo study, treated and untreated mice with AICAR (0.1 - 0.5 mg/g body weight) were fed high-fat diet (60% kcal% fat) to induce DIO and several parameters were studied. Results: AICAR blocked adipogenic conversion in 3T3L1 cells along with significant decrease in the neutral lipid content by downregulating several adipocyte-specific transcription factors including peroxisome proliferators-activated receptor gamma (PPAR gamma), C/EBP alpha and ADD1/ SREBP1, which are critical for adipogenesis in vitro. Moreover, intraperitoneal administration of AICAR ( 0.5 mg g/body weight) to mice fed with high-fat diet ( 60% kcal% fat) to induce DIO, significantly blocked the body weight gain and total content of epididymal fat in these mice over a period of 6 weeks. AICAR treatment also restored normal adipokine levels and resulted in significant improvement in glucose tolerance and insulin sensitivity. The reduction in adipose tissue content in AICAR treated DIO mice was due to reduction in lipid accumulation in the pre-existing adipocytes. However, no change was observed in the expression of PPAR gamma, C/EBP alpha and ADD1/ SREBP1 transcription factors in vivo though PGC1 alpha expression was significantly induced. Conclusion: This study suggests that AICAR inhibits adipocyte differentiation via downregulation of expression of adipogenic factors in vitro and reduces adipose tissue content in DIO mice by activating expression of PGC1a without inhibiting adipocyte-specific transcription factors in DIO mice. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA. Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA. Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. EM giris@musc.edu; rattanr@musc.edu; shahe@musc.edu; khanm@musc.edu; yasmin@musc.edu; wonj@musc.edu; keyl@musc.edu; singhak@musc.edu; singhi@musc.edu OI Haq, Ehtishamul/0000-0002-4195-0606 FU NCRR NIH HHS [C06 RR015455, C06 RR018823]; NINDS NIH HHS [R01 NS022576, R01 NS034741, R01 NS037766, R01 NS040144, R01 NS040810, R37 NS022576] NR 62 TC 92 Z9 94 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1743-7075 J9 NUTR METABOLISM JI Nutr. Metab. PD AUG 10 PY 2006 VL 3 AR 31 DI 10.1186/1743-7075-3-31 PG 20 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 083UN UT WOS:000240483800001 PM 16901342 ER PT J AU Lee, SJ Covinsky, KE AF Lee, Sei J. Covinsky, Kenneth E. TI Prognostic index for 4-year mortality in older adults - Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94143 USA. RP Lee, SJ (reprint author), San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94143 USA. EM sei.lee@med.va.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 9 PY 2006 VL 296 IS 6 BP 648 EP 649 DI 10.1001/jama.296.6.648-c PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 071LN UT WOS:000239603800016 ER PT J AU Xia, T Kovochich, M Brant, J Hotze, M Sempf, J Oberley, T Sioutas, C Yeh, JI Wiesner, MR Nel, AE AF Xia, Tian Kovochich, Michael Brant, Jonathan Hotze, Matt Sempf, Joan Oberley, Terry Sioutas, Constantinos Yeh, Joanne I. Wiesner, Mark R. Nel, Andre E. TI Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm SO NANO LETTERS LA English DT Article ID DIESEL EXHAUST PARTICLES; DIRECT ELECTRON-TRANSFER; ULTRAFINE PARTICLES; CARBON-NANOTUBES; FULLERENE DERIVATIVES; EPITHELIAL-CELLS; STATE PROPERTIES; AQUEOUS-SOLUTION; GLUCOSE-OXIDASE; IN-VIVO AB Nanomaterial properties differ from those bulk materials of the same composition, allowing them to execute novel activities. A possible downside of these capabilities is harmful interactions with biological systems, with the potential to generate toxicity. An approach to assess the safety of nanomaterials is urgently required. We compared the cellular effects of ambient ultrafine particles with manufactured titanium dioxide (TiO2), carbon black, fullerol, and polystyrene (PS) nanoparticles (NPs). The study was conducted in a phagocytic cell line ( RAW 264.7) that is representative of a lung target for NPs. Physicochemical characterization of the NPs showed a dramatic change in their state of aggregation, dispersibility, and charge during transfer from a buffered aqueous solution to cell culture medium. Particles differed with respect to cellular uptake, subcellular localization, and ability to catalyze the production of reactive oxygen species (ROS) under biotic and abiotic conditions. Spontaneous ROS production was compared by using an ROS quencher (furfuryl alcohol) as well as an NADPH peroxidase bioelectrode platform. Among the particles tested, ambient ultrafine particles (UFPs) and cationic PS nanospheres were capable of inducing cellular ROS production, GSH depletion, and toxic oxidative stress. This toxicity involves mitochondrial injury through increased calcium uptake and structural organellar damage. Although active under abiotic conditions, TiO2 and fullerol did not induce toxic oxidative stress. While increased TNF-alpha production could be seen to accompany UFP-induced oxidant injury, cationic PS nanospheres induced mitochondrial damage and cell death without inflammation. In summary, we demonstrate that ROS generation and oxidative stress are a valid test paradigm to compare NP toxicity. Although not all materials have electronic configurations or surface properties to allow spontaneous ROS generation, particle interactions with cellular components are capable of generating oxidative stress. C1 Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol & Allergy, Los Angeles, CA 90095 USA. Duke Univ, Dept Civil & Environm Engn, Durham, NC 27708 USA. William S Middleton Mem Vet Adm Med Ctr, Pathol Serv, Madison, WI 53792 USA. Univ So Calif, Dept Civil & Environm Engn, Los Angeles, CA 90089 USA. Univ Calif Los Angeles, So Calif Particle Ctr, Los Angeles, CA 90095 USA. Univ Pittsburgh, Sch Med, Dept Bioengn, Dept Biol Struct, Pittsburgh, PA 15260 USA. RP Nel, AE (reprint author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol & Allergy, 52-175 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM anel@mednet.ucla.edu RI Nel, Andre/J-2808-2012; xia, tian/C-3158-2013 OI xia, tian/0000-0003-0123-1305 FU NIAID NIH HHS [GM/AI66466]; NIEHS NIH HHS [R01 ES015498, R01 ES10253, R01 ES10553, R01 ES13432]; PHS HHS [U19 A1070453] NR 53 TC 896 Z9 936 U1 32 U2 346 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1530-6984 J9 NANO LETT JI Nano Lett. PD AUG 9 PY 2006 VL 6 IS 8 BP 1794 EP 1807 DI 10.1021/nl061025k PG 14 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter SC Chemistry; Science & Technology - Other Topics; Materials Science; Physics GA 071SY UT WOS:000239623900039 PM 16895376 ER PT J AU Blasiole, JA Shinkunas, L LaBrecque, DR Arnold, RM Zickmund, SL AF Blasiole, Julie A. Shinkunas, Laura LaBrecque, Douglas R. Arnold, Robert M. Zickmund, Susan L. TI Mental and physical symptoms associated with lower social support for patients with hepatitis C SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE hepatitis C; social support; depression; anxiety; quality of life; stigmatization ID QUALITY-OF-LIFE; PEGINTERFERON ALPHA-2A; INTERFERON-ALPHA; RECEIVING INTERFERON-ALPHA-2B; DEPRESSIVE SYMPTOMS; ANTIVIRAL THERAPY; INFECTED PATIENTS; VIRUS-INFECTION; PLUS RIBAVIRIN; DISEASE AB AIM: To systematically examine the impact of the hepatitis C virus (HCV) diagnosis on patients' level of social support in a large-scale study. METHODS: Patients evaluated and treated for HCV in a tertiary referral center were enrolled in a cross-sectional study. Demographic data, functional and emotional status as measured by the Hospital Anxiety and Depression Scale (HAD) and the Sickness Impact Profile (SIP), severity of liver disease, mode of acquisition, and physical and psychiatric comorbidities were collected from patients or abstracted from the medical record. All participants completed a semi-structured interview, addressing questions of social support. RESULTS: A total of 342 patients (mean age 45.2 years; 37% women) were enrolled. Ninety-two (27%) patients described lower levels of support by family and friends. Nearly half of the participants (45%) noted the loss of at least one relationship due to the disease. Fears related to transmitting the disease (25%) were common and often associated with ignorance or even discrimination by others (19%). Nearly one fifth of the patients did not share information about their disease with others to avoid being stigmatized. Lower levels of social support were significantly associated with living alone, being unemployed, being excluded from antiviral therapy, having psychiatric comorbidities, contracting HCV through intravenous drug use, having high levels of anxiety and depression as measured by the HAD and negative mood state as measured by the SIR Patients reporting lower levels of social support also noted more physical symptoms as measured by the SIP. CONCLUSION: Patients with hepatitis C often face significant social problems, ranging from social isolation to familial stress. The most common concerns reflect a limited insight of patients and their relatives and friends about the disease, the risk factors for its spread, and about potential consequences. Our data suggest that educational interventions targeting support persons and the stressors identified in our findings may lessen or alleviate the social strains patients with hepatitis C experience. (c) 2006 The WJG Press. All rights reserved. C1 Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot,Dept Med, Pittsburgh, PA 15240 USA. Univ Iowa, Sch Publ Hlth, Dept Epidemiol, Iowa City, IA USA. Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA. RP Zickmund, SL (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot,Dept Med, 151C-U,Univ Dr C, Pittsburgh, PA 15240 USA. EM susan.zickmund@med.va.gov FU NHLBI NIH HHS [HL07121, T32 HL007121] NR 53 TC 28 Z9 29 U1 3 U2 4 PU W J G PRESS PI BEIJING PA APT 1066, YISHOU GARDEN, NO 58, NORTH LANGXINZHUANG RD, PO BOX 2345, BEIJING 100023, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD AUG 7 PY 2006 VL 12 IS 29 BP 4665 EP 4672 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 076IH UT WOS:000239949900010 PM 16937437 ER PT J AU Qin, WP Yang, TL Ho, L Zhao, Z Wang, J Chen, LH Zhao, W Thiyagarajan, M MacGrogan, D Rodgers, JT Puigserver, P Sadoshima, J Deng, HT Pedrini, S Gandy, S Sauve, AA Pasinetti, GM AF Qin, Weiping Yang, Tianle Ho, Lap Zhao, Zhong Wang, Jun Chen, Linghong Zhao, Wei Thiyagarajan, Meenakshisundaram MacGrogan, Donal Rodgers, Joseph T. Puigserver, Pere Sadoshima, Junichi Deng, Haiteng Pedrini, Steven Gandy, Samuel Sauve, Anthony A. Pasinetti, Giulio M. TI Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID DEPENDENT HISTONE DEACETYLASE; TRANSGENIC MICE; PROTEIN; FAMILY; LONGEVITY; NICOTINAMIDE; INHIBITION; REGULATOR AB Nicotinamide adenine dinucleotide(NAD)(+)-dependent sirtuins have been identified to be key regulators in the lifespan extending effects of calorie restriction (CR) in a number of species. In this study we report for the first time that promotion of the NAD(+)-dependent sirtuin, SIRT1-mediated deacetylase activity, may be a mechanism by which CR influences Alzheimer disease (AD)-type amyloid neuropathology. Most importantly, were port that the predicted attenuation of beta-amyloid content in the brain during CR can be reproduced in mouse neurons in vitro by manipulating cellular SIRT1 expression/activity through mechanisms involving the regulation of the serine/threonine Rho kinase ROCK1, known in part for its role in the inhibition of the non-amyloidogenic alpha-secretase processing of the amyloid precursor protein. Conversely, we found that the expression of constitutively active ROCK1 in vitro cultures significantly prevented SIRT1-mediated response, suggesting that alpha-secretase activity is required for SIRT1-mediated prevention of AD-type amyloid neuropathology. Consistently we found that the expression of exogenous human ( h) SIRT1 in the brain of hSIRT1 transgenics also resulted in decreased ROCK1 expression and elevated alpha-secretase activity in vivo. These results demonstrate for the first time a role for SIRT1 activation in the brain as a novel mechanism through which CR may influence AD amyloid neuropathology. The study provides a potentially novel pharmacological strategy for AD prevention and/or treatment. C1 Cornell Univ, Weill Med Coll, Dept Pharmacol, Tri Inst Program Chem Biol, New York, NY 10021 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. Bronx Vet Affairs Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY 10468 USA. Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Newark, NJ 07103 USA. Rockefeller Univ, Proteom Resource Ctr, New York, NY 10021 USA. Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA. RP Pasinetti, GM (reprint author), Cornell Univ, Weill Med Coll, Dept Pharmacol, Tri Inst Program Chem Biol, New York, NY 10021 USA. EM as2004@med.cornell.edu; giulio.pasinetti@mssm.edu RI Zhao, Wei/B-3220-2010; Zhao, Wei/A-2206-2010 FU NIA NIH HHS [P01 AG010491, P01 AG010491-14] NR 31 TC 330 Z9 340 U1 3 U2 28 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD AUG 4 PY 2006 VL 281 IS 31 BP 21745 EP 21754 DI 10.1074/jbc.M602909200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 068PO UT WOS:000239387100020 PM 16751189 ER PT J AU Pines, JM Hollander, JE Localio, AR Metlay, JP AF Pines, Jesse M. Hollander, Judd E. Localio, A. Russell Metlay, Joshua P. TI The association between emergency department crowding and hospital performance on antibiotic timing for pneumonia and percutaneous intervention for myocardial infarction SO ACADEMIC EMERGENCY MEDICINE LA English DT Article DE pneumonia; emergency department crowding; acute myocardial infarction; quality; timing ID OUTCOMES; QUALITY; CARE AB Background: Antibiotics within four hours of arrival for patients with pneumonia and percutaneous intervention (PCI) within two hours for patients with acute myocardial infarction (AMI) are standard measures of emergency department (ED) quality. Objectives: To assess the institutional-level association between measures of ED crowding and process measures for pneumonia and AMI. Methods: The authors used summary data from 24 academic hospitals in the University Health Consortium. Analysis included the 2004 ED cycle time survey and performance data from January to December 2004 regarding the Joint Commission for Accreditation of Healthcare Organizations' PN-5b (initial antibiotic administration within four hours) for pneumonia and AMI-8a (PCI received within 120 minutes). Spearman correlation coefficients were used to determine associations between crowding and performance measures. Results: Across all institutions, 59% (range 43%-77%) of pneumonia patients received antibiotics within four hours, and 57% (range 22%-95%) of AMI patients received PCI within two hours. An increase in overall ED length of stay (-0.44, p = 0.04) and for admitted patients (-0.37, p = 0.08) was associated with a decrease in the proportion of pneumonia patients receiving antibiotics within four hours. An increase in chest x-ray turnaround time (-0.83, p < 0.001) and an increase in the left-without-being-seen rate (-0.51, p = 0.01) were also associated with a decrease in the proportion of pneumonia patients receiving antibiotics within four hours. No measures of crowding exhibited an association with time to PCI for AMI patients. Conclusions: Administrative measures of ED crowding showed an association with poorer performance on pneumonia quality of care measures but not with AMI quality of care measures. Hospitals might consider improving ED throughput, reducing boarding times for admitted patients, and reducing chest x-ray turnaround times to improve pneumonia care. C1 Hosp Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Pines, JM (reprint author), 3400 Spruce St,Ground Ravdin, Philadelphia, PA 19104 USA. EM pinesjes@uphs.upenn.edu OI Hollander, Judd/0000-0002-1318-2785 NR 21 TC 122 Z9 123 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD AUG PY 2006 VL 13 IS 8 BP 873 EP 878 DI 10.1197/j.aem.2006.03.568 PG 6 WC Emergency Medicine SC Emergency Medicine GA 118UK UT WOS:000242967300010 PM 16766743 ER PT J AU Deswal, A Petersen, NJ Urbauer, DL Wright, SM Beyth, R AF Deswal, Anita Petersen, Nancy J. Urbauer, Diana L. Wright, Steven M. Beyth, Rebecca TI Racial variations in quality of care and outcomes in an ambulatory heart failure cohort SO AMERICAN HEART JOURNAL LA English DT Article ID HEALTH-CARE; VETERANS-AFFAIRS; RACE; AMERICAN; HOSPITALIZATIONS; RACE/ETHNICITY; DISPARITIES; DYSFUNCTION; MANAGEMENT; COMMITTEE AB Background Few recent studies have demonstrated similar quality of care for hospitalized black and white patients with heart failure (HF). However, systematic evaluation of racial differences in both the quality of care and outcomes is needed in the outpatient setting, where most patients with HF are treated and where care may be more fragmented. Methods We examined racial differences in quality-of-care measures and outcomes of 1-year mortality and hospitalization in a national cohort of 18 611 ambulatory patients with HF treated at Veterans Affairs medical centers between October 2000 and September 2002. Results Black patients were more likely to have left ventricular ejection fraction assessment than whites (risk-adjusted OR 1.29, 95% CI 1.11-1.49). In patients with left ventricular ejection fraction < 40%, blacks were as likely as whites to be on treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (risk-adjusted OR 1.06, 95% CI 0.85-1.33) and beta-blockers (risk-adjusted OR 0.92, 95% CI 0.79-1.07). However, black patients more frequently had uncontrolled hypertension and were more likely to be hospitalized for any cause (OR 1.20, 95% CI 1.08-1.33) or for HF (OR 1.43, 95% CI 1.23-1.66), although 1-year mortality did not differ by race (OR 1.03, 95% CI 0.89-1.20). Conclusions In a financially "equal access" health care system, the quality of outpatient HF care assessed by select quality measures and 1-year mortality was similar in black compared to white patients. However, blacks were more likely to be hospitalized, especially with HF. Identifying and targeting potentially modifiable factors such as uncontrolled hypertension in black patients may narrow the racial gap in hospitalizations. C1 Baylor Coll Med, Michael E DeBakey Vet Affaris Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Michael E DeBakey Vet Affaris Med Ctr, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. Vet Hlth Adm, Off Qual & Performance, Washington, DC USA. Univ Florida, Coll Med Geriatr, Rehabil Outcomes Res Ctr, NF SG Vet Hlth Syst, Gainesville, FL USA. RP Deswal, A (reprint author), VA Med Ctr, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM adeswal@bcm.tmc.edu NR 27 TC 40 Z9 40 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD AUG PY 2006 VL 152 IS 2 BP 348 EP 354 DI 10.1016/j.ahj.2005.12.004 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 071BU UT WOS:000239573000027 PM 16875921 ER PT J AU Spertus, JA Dawson, J Masoudi, FA Krumholz, HM Reid, KJ Peterson, ED Rumsfeld, JS AF Spertus, John A. Dawson, Jill Masoudi, Frederick A. Krumholz, Harlan M. Reid, Kimberly J. Peterson, Eric D. Rumsfeld, John S. CA Cardiovascular Outcomes Res Consor TI Prevalence and predictors of angina pectoris one month after myocardial infarction SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID QUALITY-OF-LIFE; CORONARY-ARTERY-DISEASE; HEALTH-STATUS; FUNCTIONAL STATUS; SURGERY TRIAL; ANGIOPLASTY; INTERVENTION; OUTCOMES; IMPACT; COLLEGE AB Angina pectoris (AP) is a treatable symptom that is associated with mortality and decreased quality of life. The prevalence and predictors of AP 1 month after a myocardial infarction (MI), a time when additional treatments might be offered, have not been described. We prospectively enrolled 2,094 patients with MI from 19 centers in the United States and evaluated angina symptoms 1 month after discharge with the Seattle Angina Questionnaire. Multivariable logistic regression analysis was performed to identify patient and treatment characteristics associated with 1-month AP. At 1 month, 571 patients, (27.3%) had AP. Women (odds ratio [OR] 1.37, 95% confidence interval [CI] 1.09 to 1.74), younger patients (OR 1.33 per 10-year increment, 95% CI 1.20 to 1.47), those with previous coronary artery bypass (OR 1.47, 95% CI 1.05 to 2.05), smokers (OR 1.35, 95% CI 1.09 to 1.77), and those who developed postinfarct AP during the index hospitalization (OR 1.85, 95% CI 1.20 to 2.65) were more likely to have AP at follow-up. In contrast, patients who were treated with coronary artery bypass surgery during their index admission were less likely to have AP at 1 month (OR 0.5, 95% CI 0.33 to 0.77). The strongest correlate was the frequency of AP before patients' MI., Compared with those without AP before MI, those with AP < 1 time per week (OR 1.86, 95% CI 1.45 to 2.41), weekly (OR 4.24, 95% CI 3.09 to 5.82), and daily (OR 6.12, 95% CI 3.62 to 10.3) were more likely to have AP I month later. In conclusion, > 1 in 4 patients reported AP 1 month after an MI. (c) 2006 Elsevier Inc. All rights reserved. C1 Mid Amer Heart Inst, Kansas City, MO USA. Univ Missouri, Kansas City, MO 64110 USA. Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Denver, CO 80202 USA. Denver Hlth Med Syst, Denver, CO USA. Yale Univ, New Haven, CT USA. Duke Univ, Durham, NC USA. RP Spertus, JA (reprint author), Mid Amer Heart Inst, Kansas City, MO USA. EM spertusj@umkc.edu NR 20 TC 21 Z9 21 U1 0 U2 1 PU EXCERPTA MEDICA INC PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD AUG 1 PY 2006 VL 98 IS 3 BP 282 EP 288 DI 10.1016/j.amjcard.2006.01.099 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 069VT UT WOS:000239477600002 PM 16860010 ER PT J AU El-Serag, HB AF El-Serag, Hashem B. TI Temporal trends in new and recurrent esophageal strictures in department of veterans affairs SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID GASTROESOPHAGEAL-REFLUX-DISEASE; EOSINOPHILIC ESOPHAGITIS; CONCEPTUAL-FRAMEWORK; TIME TRENDS; OMEPRAZOLE; ADULTS AB BACKGROUND: Anecdotal experience suggests that gastroenterologists are encountering fewer patients with esophageal strictures; however, the temporal trends of esophageal strictures have not been well examined in large studies. METHODS: We examined the incidence rates of new esophageal strictures as well as esophageal dilations among patients presenting to VA facilities between 1998 and 2003 as a proportion of the annual frequency of all endoscopic procedures and/or imaging procedures. Recurrent strictures were defined as those recorded at least 3 months after the index date of a new stricture or the date of the preceding recurrent stricture. Stricture was defined only in the presence of an upper endoscopy or upper gastrointestinal (UGI) contrast imaging within 30 days before or after the date of diagnosis. This algorithm was validated by manually reviewing the medical records of 180 patients; the positive predictive value was approximately 84%. The risk of recurrent strictures was examined using Cox proportional hazards model for multiple failures. RESULTS: There were 19,157 patients identified between fiscal year (FY) 1998 and FY 2003 with new esophageal strictures. New strictures comprised a constant annual proportion of total EGD and UGI imaging studies. New strictures declined by 11.6% as a proportion of all upper endoscopies (not including UGI imaging). However, esophageal dilations associated with new stricture diagnoses declined among patients with new esophageal strictures, 16.8% had at least one episode of recurrence. The 1-yr incidence rate of recurrent strictures declined significantly (-36.0%) from 13.9 per 100 person-years for patients diagnosed with new strictures in 1998 to 8.9 per 100 person-years in patients diagnosed with new strictures in 2003. In the full multivarlable model, new strictures diagnoses during 2001-2003 were associated with a reduced risk of having recurrent strictures (19% in the first year and 13% throughout follow-up) independent of age, gender, race, geographic region, or the presence of Barrett's esophagus. CONCLUSION: The incidence of recurrent strictures has declined between 1998 and 2003 by approximately one-third. Although there has been only a small decline in the incidence of new esophageal strictures among patients undergoing endoscopy, the use of esophageal dilations has declined considerably among these patients. The role of proton pump inhibitors needs to be examined. C1 Houston Dept Vet Affairs Med Ctr, Sect Gastroenterol & Hlth Serv Res, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston Dept Vet Affairs Med Ctr, Sect Gastroenterol & Hlth Serv Res, Houston, TX USA. NR 16 TC 13 Z9 13 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD AUG PY 2006 VL 101 IS 8 BP 1727 EP 1733 DI 10.1111/j.1572-0241.2006.00618.x PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 076MI UT WOS:000239962000006 PM 16817844 ER PT J AU Peskind, ER Potkin, SG Pomara, N Ott, BR Graham, SM Olin, JT McDonald, S AF Peskind, Elaine R. Potkin, Steven G. Pomara, Nunzio Ott, Brian R. Graham, Stephen M. Olin, Jason T. McDonald, Scott CA MEM-MD-10 Study Grp TI Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT Annual Meeting of the International-College-of-Geriatric-Psychoneuropharmacology CY NOV 02-05, 2005 CL Pittsburg, PA SP Int Coll Geriatr Psychoneuropharmacol DE memantine; Alzheimer disease; dementia ID VASCULAR DEMENTIA; INVENTORY; DONEPEZIL; EFFICACY; SCALE AB Objective: The objective of this study was to compare the efficacy and safety of the moderate-affinity, uncompetitive N-methyl-d-aspartate receptor antagonist, memantine, versus placebo in patients with mild to moderate Alzheimer disease ( AD). Method: This was a randomized, double-blind, placebo-controlled clinical trial conducted at 42 U. S. sites. Participants were 403 outpatients with mild to moderate AD and Mini-Mental State Examination scores of 10 - 22 randomized to memantine (20 mg/day; N = 201) or placebo (N = 202) for 24 weeks. Primary outcomes were change from baseline at 24 weeks on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog), a measure of cognition, and on the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus), a global measure. Secondary outcomes included change on the Neuropsychiatric Inventory (NPI) and the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL(23)), measures of behavior and function, respectively. Results: Most (82.4%) participants completed the trial. Memantine resulted in significantly better outcomes than placebo on measures of cognition, global status, and behavior when based on the protocol-specified primary last observation carried forward imputation as well as a mixed-models repeated-measures approach applied to the continuous outcomes. Treatment discontinuations because of adverse events for memantine versus placebo were 19 (9.5%) and 10 (5.0%), respectively. Conclusions: These results support the safety and efficacy of memantine for the treatment of mild to moderate AD. C1 Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Vet Affairs NW Network, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA. Nathan S Kline Inst Psychiat Res, Jersey City, NJ USA. Brown Univ, Dept Clin Neurosci, Jersey City, NJ USA. Forest Res Inst, Jersey City, NJ USA. RP Peskind, ER (reprint author), VA Puget Sound Hlth Care Syst, S-1166 E,1660 So Columbian Way, Seattle, WA 98108 USA. EM peskind@u.washington.edu RI Potkin, Steven/A-2021-2013 NR 22 TC 168 Z9 179 U1 2 U2 38 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD AUG PY 2006 VL 14 IS 8 BP 704 EP 715 DI 10.1097/01.JGP.0000224350.82719.83 PG 12 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 066BV UT WOS:000239205500009 PM 16861375 ER PT J AU Ancoli-Israel, S Alessi, C AF Ancoli-Israel, Sonia Alessi, Cathy TI Response to Fetveit and Bjorvatn's letter to the editor SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Letter ID SLEEP C1 Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Ancoli-Israel, S (reprint author), Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. NR 5 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD AUG PY 2006 VL 14 IS 8 BP 716 EP 716 DI 10.1097/01.JGP.0000227962.31646.48 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 066BV UT WOS:000239205500010 PM 16861377 ER PT J AU Pinninti, NR Datto, CJ AF Pinninti, Narsimha R. Datto, Catherine J. TI Cognitive behavior therapy and clozapine synergy in an older adult with schizophrenia? SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Letter C1 Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Psychiat, Cherry Hill, NJ USA. Univ Penn, Dept Psychiat, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Pinninti, NR (reprint author), Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Psychiat, Cherry Hill, NJ USA. NR 4 TC 0 Z9 0 U1 0 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD AUG PY 2006 VL 14 IS 8 BP 717 EP 718 DI 10.1097/01.JGP.0000209606.27969.5e PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 066BV UT WOS:000239205500013 PM 16864560 ER PT J AU Dicianno, BE Spaeth, DM Cooper, RA Fitzgerald, SG Boninger, ML AF Dicianno, Brad E. Spaeth, Donald M. Cooper, Rory A. Fitzgerald, Shirley G. Boninger, Michael L. TI Advancements in power wheelchair joystick technology: Effects of isometric joysticks and signal conditioning on driving performance SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE assistive technology; isometric; joystick; movement disorders; rehabilitation; wheelchairs ID POSITION; TREMOR; SUPPRESSION AB Objective: An estimated 125 000 Americans with movement disorders; that preclude independent mobility in a power wheelchair could benefit from improved control devices. We developed variable gain algorithm (VGA) software for our isometric Joystick OX that allows it to emulate a commercially available motion-sensing joystick (MSX 'in performance but retain the unique customizable features of an isometric control. Force sensing algorithm (FSA) software allowed the IJ to function as a simple isometric device. Design: Using a Fitts' Law paradigm, we compared driving performance with floor targets using a standard MSJ and an U with both FSA and VGA software in 11 electric power wheelchair users with a variety of impairments. Outcome measures were reaction time (RT), movement time (MT), and driving accuracy (DA). Results: The IJ with FSA had a significantly shorter RT than the MSJ (P < 0.0020). The IJ with FSA had a significantly longer MT than the MSJ to far targets (P < 0.0159). No differences were found between the IJ with VGA and the MSJ with respect to RT or MT. No differences in DA were found among any of the joysticks. Conclusions: VGA software allowed the IJ to function similarly to the MSJ with respect to RT, MT, and DA. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Ctr Excellence Wheelchairs & Associated Rehabil E, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Human Engn Res Labs, Pittsburgh, PA USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Ctr Excellence Wheelchairs & Associated Rehabil E, 7180 Highland Dr,Bldg 4,2nd Floor E,151R1-H, Pittsburgh, PA 15206 USA. OI Boninger, Michael/0000-0001-6966-919X; Dicianno, Brad/0000-0003-0738-0192 FU NICHD NIH HHS [K12HD01097] NR 26 TC 18 Z9 18 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD AUG PY 2006 VL 85 IS 8 BP 631 EP 639 DI 10.1097/01.phm.0000228519.54763.b4 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 073AK UT WOS:000239714400001 PM 16865017 ER PT J AU Chang, L Mayer, EA Labus, JS Schmulson, M Lee, OY Olivas, TI Stains, J Naliboff, BD AF Chang, Lin Mayer, Emeran A. Labus, Jennifer S. Schmulson, Max Lee, Oh Young Olivas, Teresa I. Stains, Jean Naliboff, Bruce D. TI Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE visceral perception; gender ID GENDER-RELATED DIFFERENCES; QUALITY-OF-LIFE; TEMPORAL SUMMATION; COLONIC TRANSIT; FIBROMYALGIA SYNDROME; RECTAL DISTENSION; PRIMARY-CARE; IBS PATIENTS; WIND-UP; PAIN AB In irritable bowel syndrome (IBS) patients, the relationship between sex and sensitivity to visceral stimuli is incompletely understood. Our aim was to evaluate the effect of sex on perceptual responses to visceral stimulation in IBS. Fifty-eight IBS patients (mean age 42 +/- 1 yr; 34 men, 24 women) and 26 healthy controls (mean age 38 +/- 3 yr; 9 men, 17 women) underwent barostat-assisted distensions of the rectum and sigmoid colon. Rectal discomfort thresholds were measured using a randomized, phasic distension paradigm before and after repeated noxious sigmoid stimulation (SIG, 60-mmHg pulses). Sex had a significant effect on rectal discomfort thresholds. Women with IBS were the most sensitive ( lower thresholds [27 +/- 2.7 mmHg] and higher ratings), with significantly lower rectal discomfort thresholds compared with men with IBS (38 +/- 2.3 mmHg) and healthy women who were the least sensitive (41.9 +/- 3.2 mmHg; both P < 0.01). There were no significant differences in rectal discomfort thresholds between healthy men (34 +/- 4.3 mmHg) and men with IBS. Across both IBS and control groups, women demonstrated a significant lowering of discomfort thresholds after noxious sigmoid stimulation (P < 0.01), while men did not. Sex significantly influences perceptual sensitivity to rectosigmoid distension. Women show greater perceptual responses to this paradigm. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. Univ Nacl Autonoma Mexico, Sch Med, Dept Expt Med, Mexico City 04510, DF, Mexico. Hanyang Univ, Coll Med, Dept Internal Med, Seoul 133791, South Korea. RP Chang, L (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Neurovisceral Sci & Womens Hlth, CURE Bldg 115,RM 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM linchang@ucla.edu FU NCCIH NIH HHS [R24 AT-002681]; NIAMS NIH HHS [AR-41622]; NIDDK NIH HHS [DK-48351, P50 DK-64539] NR 60 TC 53 Z9 54 U1 1 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 EI 1522-1490 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD AUG PY 2006 VL 291 IS 2 BP R277 EP R284 DI 10.1152/ajpregu.00729.2005 PG 8 WC Physiology SC Physiology GA 060LF UT WOS:000238803000005 PM 16574882 ER PT J AU Matthews, AM Fireman, M Zucker, B Sobel, M Hauser, P AF Matthews, Annette M. Fireman, Marian Zucker, Betsy Sobel, Michelle Hauser, Peter TI Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material ID INJECTION-DRUG USERS; METHADONE-MAINTENANCE; VIRUS-INFECTION; SUBSTANCE USE; DISORDERS; THERAPY C1 Portland VA Med Ctr, NW Hepatitis Resource Ctr C, JENS Lab, Gastroenterol Sect, Portland, OR 97202 USA. Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97202 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97202 USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97202 USA. RP Matthews, AM (reprint author), Portland VA Med Ctr, NW Hepatitis Resource Ctr C, JENS Lab, Gastroenterol Sect, 3710 SW US Vet Hosp Rd,POB 1035 V3MHC, Portland, OR 97202 USA. EM annette.matthews@med.va.gov NR 22 TC 5 Z9 5 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD AUG PY 2006 VL 163 IS 8 BP 1342 EP 1347 DI 10.1176/appi.ajp.163.8.1342 PG 6 WC Psychiatry SC Psychiatry GA 068FT UT WOS:000239358800009 PM 16877644 ER PT J AU Burman, WJ Goldberg, S Johnson, JL Muzanye, G Eagle, M Mosher, AW Choudhri, S Daley, CL Munsiff, SS Zhao, Z Vernon, A Chaisson, RE AF Burman, William J. Goldberg, Stefan Johnson, John L. Muzanye, Grace Eagle, Melissa Mosher, Ann W. Choudhri, Shurjeel Daley, Charles L. Munsiff, Sonal S. Zhao, Zhen Vernon, Andrew Chaisson, Richard E. CA Tuberculosis Trials Consortium TI Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE efficacy; moxifloxacin; randomized trial; toxicity; tuberculosis ID EARLY BACTERICIDAL ACTIVITY; MYCOBACTERIUM-TUBERCULOSIS; MURINE TUBERCULOSIS; CONTAINING REGIMENS; WEEKLY RIFAPENTINE; GATIFLOXACIN; OFLOXACIN; DURATION; THERAPY; CULTURE AB Rationale: Moxifloxacin has promising preclinical activity against Mycobacterium tuberculosis, but has not been evaluated in multidrug treatment of tuberculosis in humans. Objective: To compare the impact of moxifloxacin versus ethambutol, both in combination with isoniazid, rifampin, and pyrazinamide, on sputum culture conversion at 2 mo as a measure of the potential sterilizing activity of alternate induction regimens. Methods: Adults with smear-positive pulmonary tuberculosis were randomized in a factorial design to receive moxifloxacin (400 mg) versus ethambutol given 5 d/wk versus 3 d/wk (after 2 wk of daily therapy). All doses were directly observed. Measurements: The primary endpoint was sputum culture status at 2 mo of treatment. Results: Of 336 patients enrolled, 277 (82%) were eligible for the efficacy analysis, 186 (67%) were male, 175 (63%) were enrolled at African sites, 206 (74%) had cavitation on chest radiograph, and 60 (22%) had HIV infection. Two-month cultures were negative in 71% of patients (99 of 139) treated with moxifloxacin versus 71% (98 of 138) treated with ethambutol (p = 0.97). Patients receiving moxifloxacin, however, more often had negative cultures after 4 wk of treatment. Patients treated with moxifloxacin more often reported nausea (22 vs. 9%, p = 0.002), but similar proportions completed study treatment (88 vs. 89%). Dosing frequency had little effect on 2-mo culture status or tolerability of therapy. Conclusions: The addition of moxifloxacin to isoniazid, rifampin, and pyrazinamide did not affect 2-mo sputum culture status but did show increased activity at earlier time points. C1 Denver Publ Hlth, Denver, CO USA. Natl Jewish Med & Res Ctr, Denver, CO USA. Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. Case Western Reserve Univ, Dept Med, Div Infect Dis, Cleveland, OH 44106 USA. Univ Hosp Cleveland, Cleveland, OH 44106 USA. Uganda Case Western Res Univ Res Collobarat, Kampala, Uganda. S Tex Vet Hlth Care Syst, San Antonio, TX USA. Duke Univ, Med Ctr, Durham, NC USA. Bayer Inc, West Haven, CT USA. New York City Dept Hlth & Mental Hyg, New York, NY USA. Johns Hopkins Univ, Ctr TB Res, Baltimore, MD USA. RP Burman, WJ (reprint author), 605 Bannock St, Denver, CO 80204 USA. EM bburman@dhha.org NR 34 TC 184 Z9 197 U1 1 U2 8 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD AUG 1 PY 2006 VL 174 IS 3 BP 331 EP 338 DI 10.1164/rccm.200603-360OC PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 068ZW UT WOS:000239415200018 PM 16675781 ER PT J AU Finan, KR Leeth, RR Whitley, BM Klapow, JC Hawn, MT AF Finan, Kelly R. Leeth, Ruth R. Whitley, Bryan M. Klapow, Joshua C. Hawn, Mary T. TI Improvement in gastrointestinal symptoms and quality of life after cholecystectomy SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE laparoscopic cholecystectomy; symptom improvement; biliary symptom; quality of life; effectiveness ID LAPAROSCOPIC CHOLECYSTECTOMY; ABDOMINAL SYMPTOMS; ACUTE CHOLECYSTITIS; RANDOMIZED-TRIAL; IMPACT; GALLSTONES; SURGERY; PATTERNS; OUTCOMES; DISEASE AB Background: Laparoscopic cholecystectomy (LC) is the accepted treatment for symptomatic cholelithiasis but has been criticized as an over-used procedure. This study assesses the effectiveness of LC on reduction in gastrointestinal (GI) symptoms and the impact on quality of life (QOL). Methods: A prospective cohort of subjects evaluated for gallstone disease between August 2001 and July 2004 completed preoperative and postoperative GI gallbladder symptom surveys (GISS) and SF36 QOL surveys. The GISS was developed to quantify the magnitude, severity, and distressfulness of 16 GI symptoms. Surveys were scored and evaluated using paired t tests. Results: Fifty-five subjects were included in the final analysis. The GISS revealed significant improvement in biliary type symptoms but not reflux or irritable bowel symptoms after LC (P > .05). Significant improvement was seen in QOL (P < .01). Conclusion: This study supports the utility of LC by showing not only a significant reduction of GI symptoms but also marked improvement in patients' general QOL. (c) 2006 Excerpta Medica Inc. All rights reserved. C1 Univ Alabama, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA. Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Deep S Ctr Effectiveness Res, Birmingham, AL USA. RP Hawn, MT (reprint author), Univ Alabama, Dept Surg, Sect Gastrointestinal Surg, KB 429,1530 3rd Ave S, Birmingham, AL 35294 USA. EM mhawn@uab.edu NR 37 TC 18 Z9 18 U1 1 U2 4 PU EXCERPTA MEDICA INC PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD AUG PY 2006 VL 192 IS 2 BP 196 EP 202 DI 10.1016/j.amjsurg.2006.01.020 PG 7 WC Surgery SC Surgery GA 071EK UT WOS:000239580900010 PM 16860629 ER PT J AU Saab, S Shpaner, A Zhao, Y Brito, I Durazo, F Han, S Farmer, DG Ghobrial, RM Yersiz, H Goldstein, LI Tong, MJ Busuttil, RW AF Saab, S. Shpaner, A. Zhao, Y. Brito, I. Durazo, F. Han, S. Farmer, D. G. Ghobrial, R. M. Yersiz, H. Goldstein, L. I. Tong, M. J. Busuttil, R. W. TI Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE diabetes mellitus; liver transplantation ID HEPATITIS-C; RECIPIENTS; DISEASE; IMPACT; COMPLICATIONS; METABOLISM; MANAGEMENT; INFECTION; CIRRHOSIS; THERAPY AB The prevalence and risk factors for diabetes mellitus after liver transplantation are not well understood. Thus, we sought to identify independent risk factors for the development of diabetes after liver transplantation using currently accepted medical criteria. We studied the prevalence and risk factors in 253 adult recipients transplanted at UCLA between January 1998 and December 2002. Analysis of the retrospective data was performed using demographic, immunosuppression and liver disease variables. Factors found to be significant on a univariate analysis were further studied in a multivariate analysis. There were 158 men and 95 women in our study. The mean age was 51.4 +/- 11.0 years. The mean [+/- standard deviation (SD) pretransplant body mass index was 26.7 (+/- 5.1). Most patients were transplanted for hepatitis C (HCV). The prevalence of diabetes after transplantation was 17.8%. In a multivariate analysis only gender [odds ratio (OR) = 0.37; p = 0.02] was independently predictive of the development of diabetes. This study in a large liver transplant recipient population identifies male gender as an independent risk factor for the development of diabetes. Follow-up studies are needed to assess the impact of diabetes, and its intervention on post-transplant morbidity and mortality. C1 Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Liver Transplant Ctr, Los Angeles, CA 90024 USA. W Los Angeles Vet Adm Med Ctr, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA. Huntington Med Res Inst, Pasadena, CA USA. RP Saab, S (reprint author), Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA 90024 USA. EM Ssaab@mednet.ucla.edu NR 42 TC 37 Z9 40 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD AUG PY 2006 VL 6 IS 8 BP 1890 EP 1895 DI 10.1111/j.1600-6143.2006.01385.x PG 6 WC Surgery; Transplantation SC Surgery; Transplantation GA 061NQ UT WOS:000238879700020 PM 16889544 ER PT J AU Halpern, SD Asch, DA Shaked, A Stock, P Blumberg, EA AF Halpern, Scott D. Asch, David A. Shaked, Abraham Stock, Peter Blumberg, Emily A. TI Inadequate hepatitis B vaccination and post-exposure evaluation among transplant surgeons - Prevalence, correlates, and implications SO ANNALS OF SURGERY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; OCCUPATIONAL EXPOSURES; BLOODBORNE PATHOGENS; RISK; TRANSMISSION; INFECTION; HIV; PROPHYLAXIS; PREVENTION AB Objectives: To identify the proportion of U.S. transplant surgeons who are adequately vaccinated against hepatitis B virus (HBV), identify characteristics associated with inadequate vaccination, and assess the proportion who had been evaluated for immunization following potential HBV exposures. Summary Background Data: It is unknown what proportion of transplant surgeons are appropriately vaccinated against HBV or evaluated for immunization following operative exposures. Methods: We mailed questionnaires and to all active U.S. transplant surgeons. We compared demographic characteristics of responders and nonresponders to evaluate the potential for nonresponse bias. Results: Of 619 eligible respondents, 347 (56.1%) returned completed questionnaires. Of the 311 surgeons for whom HBV vaccination was indicated (all surgeons with neither a prior history of HBV infection nor a prior adverse reaction to the vaccine itself), 70 (22.5%; 95% confidence interval [CI], 18.0-27.6%) received fewer than the recommended 3 injections. Surgeon characteristics associated with inadequate vaccination included length of clinical practice (odds ratio [OR], 1.5 per 10-year increment in duration of practice; 95% Cl 1.1-2.2), increased fear of infection (OR, 1.2 for each unit increase in fear out of 10; 95% Cl, 1.1-1.4), and lack of recent testing for HBV infection (OR, 2.0; 95% Cl, 1.1-3.8). Of the 94 surgeons (27.3%) reporting at least one needle-stick exposure while operating on an HBV-infected patient, 14 (14.9%) were inadequately vaccinated; of these 14, only 5 (35.7%) sought appropriate serologic testing and counseling for active immunization. Surgeons underestimated both the risks of percutaneous exposure while operating, and of becoming infected with HBV if exposed. Conclusions: Many transplant surgeons are inadequately vaccinated against HBV and fail to seek evaluation following possible exposures. Underestimation of the risks of HBV exposure and transmission may relate to these failures. Requiring documentation of HBV vaccination and immunity to maintain operating room privileges may protect surgeons, their patients, and operating room staff. C1 Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. RP Halpern, SD (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 115 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM scott.halpern@uphs.upenn.edu OI Asch, David/0000-0002-7970-286X FU AHRQ HHS [U18 HS010399, HS10399] NR 27 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD AUG PY 2006 VL 244 IS 2 BP 305 EP 309 DI 10.1097/01.sla.0000217641.53330.e8 PG 5 WC Surgery SC Surgery GA 068FS UT WOS:000239358700019 PM 16858195 ER PT J AU Apple, KA McLean, JE Squires, CE Schaeffer, B Sample, JA Murphy, RL Deschamps, AM Leonardi, AH Allen, CM Hendrick, JW Stroud, RE Mukherjee, R Spinale, FG AF Apple, Kimberly A. McLean, Julie E. Squires, Christina E. Schaeffer, Brooke Sample, Jeffrey A. Murphy, Rebecca L. Deschamps, Anne M. Leonardi, Amy H. Allen, Claire M. Hendrick, Jennifer W. Stroud, Robert E. Mukherjee, Rupak Spinale, Francis G. TI Differential effects of protein kinase C isoform activation in endothelin-mediated myocyte contractile dysfunction with cardioplegic arrest SO ANNALS OF THORACIC SURGERY LA English DT Article ID CARDIAC TROPONIN-I; CARDIOPULMONARY BYPASS; VENTRICULAR MYOCYTES; REPERFUSION; ISCHEMIA; EPSILON; PHOSPHORYLATION; ANTAGONISM; EXPRESSION; ISOZYMES AB Background. Increased myocardial interstitial levels of endothelin (ET) occur during cardioplegic arrest (CA) and may contribute to contractile dysfunction. Endothelin receptor transduction involves the protein kinase-C (PKC) family comprised of multiple isoforms with diverse functions. Which PKC isoforms may be involved in ET-induced contractile dysfunction after CA remains unknown. Methods. Shortening velocity was measured in isolated left ventricular porcine myocytes and randomized (minimum of 30 per group): normothermia (cell culture media for 2 hours at 37 degrees C); CA (2 hours in CA solution [4 degrees C, 24 mEq K+] followed by reperfusion in cell media); ET/CA (100 pM ET incubated during CA and reperfusion). These studies were carried out in the presence and absence of PKC inhibitors (500 nM) and directed against members of the classical PKC subfamily (beta I, beta II, gamma) and the novel subfamily (epsilon, eta). Results. Cardiac arrest reduced shortening velocity by approximately 50%, which was further reduced in the presence of ET. Inhibition of either the beta II or gamma PKC isoform significantly increased shortening velocity from ET/CA as well as CA only values. In separate studies (n = 3), total beta II and phosphorylated beta II increased by over 150% with ET/CA (p < 0.05). Taken together, these results suggest that a predominant intracellular effector for the negative contractile effects mediated by ET in the context of CA is the PKC isoform beta II. Conclusions. Targeted inhibition of specific PKC isoforms relieves the negative inotropic effects of ET after simulated CA. These findings provide important mechanistic support for the development of targeted inhibitory strategies with respect to ET signaling and myocyte contractile dysfunction in the context of CA and reperfusion. C1 Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Room 625,Strom Thurmond Res Bldg,770 MUSC Complex, Charleston, SC 29425 USA. EM wilburnm@musc.edu FU NHLBI NIH HHS [HL57952, HL56603] NR 26 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD AUG PY 2006 VL 82 IS 2 BP 664 EP 671 DI 10.1016/j.athoracsur.2006.03.021 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 070UM UT WOS:000239550600043 PM 16863782 ER PT J AU Marra, DE Yip, D Fincher, EF Moy, RL AF Marra, Diego E. Yip, Darwin Fincher, Edgar F. Moy, Ronald L. TI Systemic toxicity from topically applied lidocaine in conjunction with fractional photothermolysis SO ARCHIVES OF DERMATOLOGY LA English DT Article ID ANESTHESIA; PHARMACOKINETICS AB Background: Topical anesthetics, unlike injectable anesthetics, can be applied painlessly and can provide sufficient pain control to maintain patient comfort throughout a variety of laser procedures. Although the use of topical lidocaine is considered relatively safe, instances of cardiotoxic and neurotoxic adverse events have been reported to occur. Observations: A 52-year-old woman underwent fractional photo thermolysis for management of severe hypopigmentation and scarring of several years' duration. Shortly after termination of treatment to her face and neck, which required prolonged exposure to a 30% lidocaine gel compound both before and during surgery, she developed clinical signs and symptoms consistent with systemic lidocaine toxicity. The results of laboratory studies confirmed serum lidocaine levels within the toxic range. We postulate that the combination of the high concentration of topical lidocaine required to achieve sufficient anesthesia, together with the laser-induced disruption in epidermal barrier function, may have been responsible for this phenomenon. Conclusions: Application of a 30% topical lidocaine gel to a limited area in conjunction with fractional photothermolysis may generate serum lidocaine levels high enough to elicit systemic toxicity. Laser surgeons should be alert to this phenomenon, particularly in patients with underlying hepatic, endocrine, cardiac, or central nervous system/ psychiatric dysfunction; in patients with a low body mass index; and in patients who are taking medications that may interfere with hepatic lidocaine metabolism. C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. RP Moy, RL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 100 UCLA Med Plaza,Suite 590, Los Angeles, CA 90024 USA. EM rmoy@ucla.edu NR 16 TC 45 Z9 47 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD AUG PY 2006 VL 142 IS 8 BP 1024 EP 1026 DI 10.1001/archderm.142.8.1024 PG 3 WC Dermatology SC Dermatology GA 073SK UT WOS:000239762700010 PM 16924052 ER PT J AU Turner, AP Williams, RM Bowen, JD Kivlahan, DR Haselkorn, JK AF Turner, Aaron P. Williams, Rhonda M. Bowen, James D. Kivlahan, Daniel R. Haselkorn, Jodie K. TI Suicidal ideation in multiple sclerosis SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE depression; multiple sclerosis; rehabilitation; suicide ID COGNITIVE-BEHAVIOR THERAPY; RISK-FACTORS; PRIMARY-CARE; UNITED-STATES; DEPRESSION; PREVALENCE; MS; HOPELESSNESS; VALIDITY; LIFE AB Objective: To examine risk factors for suicidal ideation among people with multiple sclerosis (MS). Design: Cohort study linking computerized medical records with a mailed self-report survey. Setting: Veteran's Health Administration (VHA) region covering the northwestern United States. Participants: VHA patients with MS (N=445) who returned mailed surveys. Interventions: Not applicable. Main Outcome Measure: Suicidal ideation is assessed by the Patient Health Questionnaire (PHQ) suicide item with suicidal ideation more than half the days considered persistent. Results: One hundred thirty-one (29.4%) of 445 respondents (95% confidence interval [CI], 25.4%-33.9%) endorsed suicidal ideation, and 35 (7.9%; 95% CI, 5.7%-10.8%) endorsed persistent suicidal ideation over the last 2 weeks. In bivariate analyses, suicidal ideation was associated with younger age, earlier disease course, progressive disease subtype, lower income, not being married, lower social support, not driving, higher levels of physical disability (mobility, bowel, bladder), and depression. Analyses on persistent suicidal ideation yielded similar results. In fully adjusted multivariate logistic regression, only depression severity and bowel disability were independently associated with suicidal ideation. Only depression severity was independently associated with persistent suicidal ideation. By using the 2-question depression screen (U.S. Preventive Services Task Force) consisting of the depression and anhedonia items from the PHQ-9, sensitivity and specificity were marginal for suicidal ideation (65.6% and 79.9%) but acceptable for persistent suicidal ideation (88.6% and 71.2%). Conclusions: Suicidal ideation is common among VHA patients with MS, and depression severity is the best risk marker. Brief screening for depression in MS should include the assessment of suicidal ideation. C1 VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117,1660 S Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@med.va.gov OI Turner, Aaron/0000-0001-6897-8003 NR 50 TC 36 Z9 37 U1 4 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD AUG PY 2006 VL 87 IS 8 BP 1073 EP 1078 DI 10.1016/j.apmr.2006.04.021 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 072KW UT WOS:000239673300008 PM 16876552 ER PT J AU Shen, WT Lee, J Kebebew, E Clark, OH Duh, QY AF Shen, Wen T. Lee, James Kebebew, Electron Clark, Orlo H. Duh, Quan-Yang TI Selective use of steroid replacement after adrenalectomy - Lessons from 331 consecutive cases SO ARCHIVES OF SURGERY LA English DT Article; Proceedings Paper CT 77th Annual Meeting of the Pacific-Coast-Surgical-Association CY FEB 17-20, 2006 CL San Francisco, CA SP Pacific Coast Surg Assoc ID SUBCLINICAL CUSHINGS-SYNDROME; BILATERAL ADRENALECTOMY; INSUFFICIENCY; INCIDENTALOMAS; MANAGEMENT; TUMORS AB Hypothesis: Only selected patients require steroid replacement therapy following adrenalectomy. Design: Retrospective review. Settings: University tertiary care center and veterans' hospital. Patients: A total of 331 patients who underwent adrenalectomy by 1 surgeon (Q.-Y.D.) between April 1, 1993, and August 31, 2005. Interventions: Laparoscopic, open, and hand-assisted adrenalectomy. Steroid replacement therapy was administered using a standardized hydrocortisone taper protocol. Main Outcome Measures: Indications for adrenalectomy, operative approach, requirement for postoperative steroid replacement, and episodes of acute adrenocortical insufficiency. Results: Of the 331 adrenalectomies, 304 were laparoscopic, 23 were open, and 4 were hand assisted. There were 299 unilateral adrenalectomies and 32 bilateral adrenalectomies performed. Fifty-seven (17%) of the 331 patients required steroid replacement after adrenalectomy. Of the 57 patients requiring steroid replacement, 52 had Cushing syndrome and 5 had bilateral pheochromocytomas. The 52 patients with Cushing syndrome included 16 with pituitary tumors who had failed pituitary resection and/or medical therapy, 14 with unilateral adrenal adenomas, 9 with ectopic corticotropin-secreting tumors who had failed resection and/or medical therapy, 7 with incidentalomas and subclinical Cushing syndrome, 4 with macronodular hyperplasia, and 2 with adrenocortical carcinoma. No patients undergoing unilateral adrenalectomy for non-Cushing adrenal disease required steroid replacement. Four (7%) of the 57 patients receiving steroid replacement had episodes of acute adrenocortical insufficiency following operation and required increased steroid supplementation. There were no cases of acute adrenocortical insufficiency in the 274 patients who did not receive steroid replacement. Conclusions: Steroid replacement therapy after adrenalectomy should be reserved for patients with Cushing syndrome (overt or subclinical) and patients undergoing bilateral adrenalectomy. Patients undergoing aldrenalectomy for unilateral non-Cushing adrenal tumors do not require postoperative steroid replacement. C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. RP Duh, QY (reprint author), San Francisco Vet Affairs Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM quan-yang.duh@med.va.gov NR 19 TC 29 Z9 35 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD AUG PY 2006 VL 141 IS 8 BP 771 EP 774 DI 10.1001/archsurg.141.8.771 PG 4 WC Surgery SC Surgery GA 072FB UT WOS:000239657600010 PM 16924084 ER PT J AU Leonardi, MJ McGory, ML Ko, CY AF Leonardi, Michael J. McGory, Marcia L. Ko, Clifford Y. TI The rate of bleeding complications after pharmacologic deep venous thrombosis prophylaxis - A systematic review of 33 randomized controlled trials SO ARCHIVES OF SURGERY LA English DT Article; Proceedings Paper CT 77th Annual Meeting of the Pacific-Coast-Surgical-Association CY FEB 17-20, 2006 CL San Francisco, CA SP Pacific Coast Surg Assoc ID LOW-MOLECULAR-WEIGHT; LOW-DOSE HEPARIN; VEIN THROMBOSIS; GENERAL-SURGERY; STANDARD HEPARIN; UNFRACTIONATED HEPARIN; ABDOMINAL-SURGERY; MULTICENTER TRIAL; POSTOPERATIVE THROMBOEMBOLISM; KABI 2165 AB Hypothesis: Major bleeding complications from pharmacologic deep venous thrombosis (DVT) prophylaxis are infrequent. Design: Systematic review of the MEDLINE database from 1965 to August 2005, using the terms DVT, prophylaxis, general surgery, and heparin. Setting and Patients: Randomized controlled trials evaluating pharmacologic DVT prophylaxis in patients undergoing general surgery. Main Outcome Measures: Eight complication categories: injection site bruising, wound hematoma, drain site bleeding, hematuria, gastrointestinal tract bleeding, retroperitoneal bleeding, discontinuation of prophylaxis, and subsequent operation. Results: Fifty-two randomized controlled trials studied DVT prophylaxis; 33 randomized controlled trials with 33 813 patients undergoing general surgery evaluated pharmacologic prophylaxis and quantified bleeding complications. Of the minor complications, injection site bruising (6.9%), wound hematoma (5.7%), drain site bleeding (2.0%), and hematuria (1.6%) were most common. Major bleeding complications, such as gastrointestinal tract (0.2%) or retroperitoneal (< 0.1%) bleeding, were infrequent. Discontinuation of prophylaxis occurred in 2.0% of patients and subsequent operation in less than 1% of patients. When analyzed by high-vs low-dose unfractionated heparin, the lower dose had a smaller rate of discontinuation of prophylaxis (P=.02) and subsequent operation (P=.06). Conclusions: Knowledge of bleeding complication rates is important for surgeons because DVT prophylaxis may soon be implemented by Medicare as a quality measure. This level 1 evidence report shows that bleeding complications requiring a change in care occur less than 3% of the time and seem reduced with lower-dose prophylaxis. Given these findings, most patients undergoing general surgery could receive pharmacologic prophylaxis safely. C1 Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Ctr Hlth Sci 72 215, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Ctr Surg Outcomes & Qual, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Leonardi, MJ (reprint author), Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Ctr Hlth Sci 72 215, 10833 Le Conte Ave,POB 956904, Los Angeles, CA 90095 USA. EM mjleonardi@mednet.ucla.edu NR 39 TC 59 Z9 65 U1 2 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0004-0010 EI 1538-3644 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD AUG PY 2006 VL 141 IS 8 BP 790 EP 797 DI 10.1001/archsurg.141.8.790 PG 8 WC Surgery SC Surgery GA 072FB UT WOS:000239657600016 PM 16924087 ER PT J AU Levin, J Werth, VP AF Levin, Joshua Werth, Victoria P. TI Skin disorders with arthritis SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY LA English DT Review DE skin; joints; arthritis; arthralgias ID FEBRILE NEUTROPHILIC DERMATOSIS; ERYTHEMA-ELEVATUM-DIUTINUM; HYPEROSTOSIS-OSTEITIS SAPHO; INTERSTITIAL LUNG-DISEASE; PLACEBO-CONTROLLED TRIAL; PSORIATIC-ARTHRITIS; PYODERMA-GANGRENOSUM; SWEETS-SYNDROME; MULTICENTRIC RETICULOHISTIOCYTOSIS; ACNE FULMINANS AB Many inflammatory, metabolic and infectious diseases affect the skin and joints. Most of these, such as rheumatoid arthritis and systemic lupus erythaematosus, are considered to be rheumatic conditions with secondary skin involvement. However, several primary cutaneous diseases are associated with arthritis and may even present with joint symptoms prior to cutaneous lesions. Common skin disorders, such as acne and psoriasis, have well-known musculoskeletal manifestations. Other less common conditions, such as dermatomyositis, multicentric reticulohistiocytosis, pyoderma gangrenosum, Sweet's syndrome and various cutaneous vasculitides, also have frequent joint involvement. This review will discuss the clinical presentation, both cutaneous and musculoskeletal, diagnosis and management of these disorders. C1 Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Werth, VP (reprint author), Hosp Univ Penn, 2 Rhoads Pavil,36th & Spruce St, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu NR 146 TC 19 Z9 20 U1 0 U2 3 PU BAILLIERE TINDALL PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1521-6942 J9 BEST PRACT RES CL RH JI Best Pract. Res. Clin. Rheumatol. PD AUG PY 2006 VL 20 IS 4 BP 809 EP 826 DI 10.1016/j.berh.2006.05.001 PG 18 WC Rheumatology SC Rheumatology GA 095BK UT WOS:000241283000013 PM 16979539 ER PT J AU Glahn, DC Bearden, CE Barguil, M Barrett, J Soares, JC Velligan, DI AF Glahn, David C. Bearden, Carrie E. Barguil, Marcela Barrett, Jennifer Soares, Jair C. Velligan, Dawn I. TI Sensitivity and specificity of cognitive defects for bipolar disorder SO BIPOLAR DISORDERS LA English DT Meeting Abstract CT 2nd Biennial Conference of the International-Society-for-Bipolar-Disorders CY AUG 02-04, 2006 CL Edinburgh, SCOTLAND C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD AUG PY 2006 VL 8 SU 1 MA 5 BP 2 EP 3 PG 2 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 065UV UT WOS:000239186300006 ER PT J AU Post, RM Altshuler, LL Leverich, GS Frye, MA Nolen, WA Kupka, RW Suppes, T McElroy, S Keck, PE Denicoff, KD Grunze, H Kitchen, CMR Mintz, J AF Post, R. M. Altshuler, L. L. Leverich, G. S. Frye, M. A. Nolen, W. A. Kupka, R. W. Suppes, T. McElroy, S. Keck, P. E. Denicoff, K. D. Grunze, H. Kitchen, C. M. R. Mintz, J. TI Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline SO BRITISH JOURNAL OF PSYCHIATRY LA English DT Article ID DOUBLE-BLIND; ANTIDEPRESSANT DISCONTINUATION; SYMPTOMATOLOGY IDS; NUCLEUS-ACCUMBENS; NATURAL-HISTORY; DISORDER; NETWORK; 1-YEAR; IMIPRAMINE; TRIAL AB Background: Few studies have examined the relative risks of switching into hypomania or mania associated with second-generation antidepressant drugs in bipolar depression. Aims: To examine the relative acute effects of bupropion, sertraline and venlafaxine as adjuncts to mood stabilisers. Method: In a 10-week trial, participants receiving out-patient treatment for bipolar disorder (stratified for rapid cycling) were randomly treated with a flexible dose of one of the antidepressants, or their respective matching placebos, as adjuncts to mood stabilisers. Results: A total of 174 adults with bipolar disorder 1, 11 or not otherwise specified, currently in the depressed phase, were included. All three antidepressants were associated with a similar range of acute response (49-53%) and remission (34-41%). There was a significantly increased risk of switches into hypomania or mania in participants treated with venlafaxine compared with bupropion or sertraline. Conclusions: More caution appears indicated in the use of venlafaxine rather than bupropion or sertraline in the adjunctive treatment of bipolar depression, especially if there is a prior history of rapid cycling. Declaration of interest: None. C1 NIMH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA. W Los Angeles VA Med Ctr, Los Angeles, CA USA. Univ Groningen Hosp, Groningen, Netherlands. Altrecht Inst Mental Hlth Care, Utrecht, Netherlands. Univ Texas, SW Med Ctr, Dallas, TX 75230 USA. Univ Cincinnati, Coll Med, Dept Psychiat, Psychopharmacol Res Program, Cincinnati, OH USA. Univ Munich, Munich, Germany. Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. RP Post, RM (reprint author), Bldg 10,Room 3S239,10 Ctr Dr MSC 1272, Bethesda, MD 20892 USA. EM postr@mail.nih.gov RI Nolen, Willem/E-9006-2014; Mintz, Jim/N-7385-2014 OI Mintz, Jim/0000-0002-8299-5851 NR 37 TC 196 Z9 202 U1 1 U2 6 PU ROYAL COLLEGE OF PSYCHIATRISTS PI LONDON PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND SN 0007-1250 J9 BRIT J PSYCHIAT JI Br. J. Psychiatry PD AUG PY 2006 VL 189 BP 124 EP 131 PG 8 WC Psychiatry SC Psychiatry GA 074UH UT WOS:000239836800006 PM 16880481 ER PT J AU Cabelof, DC Ikeno, Y Nyska, A Busuttil, RA Anyangwe, N Vijg, J Matherly, LH Tucker, JD Wilson, SH Richardson, A Heydari, AR AF Cabelof, Diane C. Ikeno, Yuji Nyska, Abraham Busuttil, Rita A. Anyangwe, Njwen Vijg, Jan Matherly, Larry H. Tucker, James D. Wilson, Samuel H. Richardson, Arlan Heydari, Ahmad R. TI Haploinsufficiency in DNA polymerase beta increases cancer risk with age and alters mortality rate SO CANCER RESEARCH LA English DT Article ID BASE EXCISION-REPAIR; CALORIC RESTRICTION; GENOME MAINTENANCE; OXIDATIVE STRESS; MICE LACKING; IN-VIVO; MOUSE; MECHANISMS; SENESCENCE; PARAMETERS AB This study uses a base excision repair (BER)-deficient model, the DNA polymerase heterozygous mouse, to investigate the effect of BER deficiency on tumorigenicity and aging. Aged beta-pol(+/-) mice express 50% less beta-pol transcripts and protein (P < 0.05) than aged beta-pol(+/+) mice, showing maintenance of the heterozygous state over the life span of the mouse. This reduction in beta-pol expression was not associated with an increase in mutation rate but was associated with a 100% increase in the onset of hypoploidy. Aged beta-pol(+/-) mice exhibited a 6.7-fold increase in developing lymphoma (P < 0.01). Accordingly, 38% of beta-pol(+/-) mice exhibited lymphoid hyperplasia, whereas none of the beta-pol(+/-) exhibited this phenotype. beta-pol(+/-) mice were also more likely to develop adenocarcinoma (2.7-fold increase; P < 0.05) and more likely to develop multiple tumors, as 20% of the beta-pol(+/-) animals died bearing multiple tumors compared with only 5% of the beta-pol(+/-) animals (P < 0.05). In spite of accelerated tumor development, no gross effect of O-pol heterozygosity was seen with respect to life span. However, the survival curves for the beta-pol(+/-) and beta-pol(+/-) mice are not identical. A maximum likelihood estimation analysis showed a modest but significant (P < 0.05) acceleration of the age-dependent mortality rate in beta-pol(+/-) mice. Thus, the beta-pol(+/-) mouse represents a model in which mortality rate and tumor development are accelerated and provides evidence supporting the role of genomic maintenance in both aging and carcinogenesis. C1 Wayne State Univ, Karmanos Canc Inst, Sch Med, Dev Therapeut Program, Detroit, MI 48201 USA. Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA. Wayne State Univ, Dept Nutr & Food Sci, Detroit, MI 48201 USA. Wayne State Univ, Dept Biol Sci, Detroit, MI 48201 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX USA. Natl Inst Environm Hlth Sci, Struct Biol Lab, Res Triangle Pk, NC USA. RP Cabelof, DC (reprint author), Wayne State Univ, Karmanos Canc Inst, Sch Med, Dev Therapeut Program, 110 E Warren, Detroit, MI 48201 USA. EM d.cabelof@wayne.edu FU NIA NIH HHS [1P01 AG 14674, P01 AG 19316, 1P30 AG 13319, R01 AG 20438, P01 AG 17242]; NIDDK NIH HHS [1R21 DK 62256]; NIEHS NIH HHS [ES 06639, ES 11044, 1F32 ES 013643] NR 35 TC 42 Z9 48 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD AUG 1 PY 2006 VL 66 IS 15 BP 7460 EP 7465 DI 10.1158/0008-5472.CAN-06-1177 PG 6 WC Oncology SC Oncology GA 069XU UT WOS:000239483500013 PM 16885342 ER PT J AU Scholz, D McDermott, P Garnovskaya, M Gallien, TN Huettelmaier, S DeRienzo, C Cooper, G AF Scholz, Dimitri McDermott, Paul Garnovskaya, Maria Gallien, Thomas N. Huettelmaier, Stefan DeRienzo, Christina Cooper, George TI Microtubule-associated protein-4 (MAP-4) inhibits microtubule-dependent distribution of mRNA in isolated neonatal cardiocytes SO CARDIOVASCULAR RESEARCH LA English DT Article DE mRNA; microtubule; cardiocyte; translocation ID CONTAINING RIBONUCLEOPROTEIN-PARTICLES; OVERLOAD CARDIAC-HYPERTROPHY; GREEN FLUORESCENT PROTEIN; HIPPOCAMPAL-NEURONS; PRESSURE-OVERLOAD; BINDING PROTEIN; CONTRACTILE DYSFUNCTION; STAUFEN PROTEIN; NUCLEAR-PORE; SOMATODENDRITIC DOMAIN AB Objectives: Active mRNA distribution in the form of ribonucleoprotein particles moving along microtubules has been shown in several cell types, but not yet in cardiocytes. This study addresses two hypotheses: 1) a similar mRNA distribution mechanism operates in cardiocytes; 2) decoration of microtubules with microtubule-associated proteins compromises this distribution. Methods: To visualize ribonucleoproteins in cultured neonatal rat cardiocytes, they were transfected with vectors encoding zipcode binding protein-1 and Staufen fused with GFP. The velocity of microtubular transport and elongation were calculated on time-lapse confocal pictures. Results: ZBP-1 and Staufen labeled particles co-localized with each other and with microtubules and moved along microtubules over a distance of 1-20 mu m with a mean speed of 80 nm/s. The average speed decreased about 50% after decoration of microtubules by adenoviral microtubule-associated protein-4 (MAP-4). The elongation speed measured using the GFP-tagged end-binding protein-1 exceeded 200 nm/s and was not influenced by MAP-4. Conclusions: We demonstrate for the first time ribonucleoprotein particles in cardiocytes, their microtubular-related movement, and its inhibition (but not of the microtubular elongation), by the MAP-4 decoration of microtubules. (c) 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved. C1 Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Charleston, SC 29403 USA. Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Div Nephrol, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Div Nephrol, Charleston, SC 29425 USA. Dept Vet Affairs Med Ctr, Charleston, SC 29401 USA. Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA. RP Scholz, D (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, 114 Doughty St,Rm 302, Charleston, SC 29403 USA. EM scholzd@musc.edu FU NHLBI NIH HHS [HL-48788] NR 91 TC 9 Z9 10 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0008-6363 J9 CARDIOVASC RES JI Cardiovasc. Res. PD AUG 1 PY 2006 VL 71 IS 3 BP 506 EP 516 DI 10.1016/j.cardiores.2006.04.001 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 075KM UT WOS:000239883900015 PM 16750521 ER PT J AU Williams, DL Goldstein, G Minshew, NJ AF Williams, Diane L. Goldstein, Gerald Minshew, Nancy J. TI Neuropsychologic functioning in children with autism: Further evidence for disordered complex information-processing SO CHILD NEUROPSYCHOLOGY LA English DT Article ID PERVASIVE DEVELOPMENTAL DISORDERS; DIAGNOSTIC OBSERVATION SCHEDULE; IMPAIRED MEMORY FUNCTIONS; NEOCORTICAL SYSTEMS; EXECUTIVE FUNCTIONS; SPECTRUM DISORDERS; INFANTILE-AUTISM; JOINT ATTENTION; INDIVIDUALS; PERFORMANCE AB A wide range of abilities was assessed in 56 high-functioning children with autism and 56 age- and IQ-matched controls. Stepwise discriminant analyses produced good group discrimination for sensory-perceptual, motor, complex language, and complex memory domains but lower agreement for the reasoning domain than previously obtained for adults. Group discrimination did not occur for attention, simple language, simple memory, and visuospatial domains. Findings provide additional support for a complex information-processing model for autism, previously based on adult data, demonstrating a pattern across domains of selective impairments on measures with high demands for integration of information and sparing when demands were low. Children as compared to adults with autism exhibited more prominent sensory-perceptual symptoms and less pronounced reasoning deficits reflecting brain maturation. C1 Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. VA PIttsburgh Healthcare Syst, Pittsburgh, PA USA. RP Minshew, NJ (reprint author), Webster Hall,Suite 300,3811 OHara St, Pittsburgh, PA 15213 USA. EM minshewnj@upmc.edu RI Williams, Diane/B-4128-2017 FU NICHD NIH HHS [U19 HD035469-06, U19 HD035469, U19 HD035469-07, U19 HD035469-08, U19 HD035469-09, U19 HD035469-10, U19HD35469]; NIDCD NIH HHS [K23 DC006691, K23DC00691] NR 97 TC 89 Z9 90 U1 5 U2 33 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0929-7049 J9 CHILD NEUROPSYCHOL JI Child Neuropsychol. PD AUG PY 2006 VL 12 IS 4-5 BP 279 EP 298 DI 10.1080/09297040600681190 PG 20 WC Clinical Neurology SC Neurosciences & Neurology GA 073UL UT WOS:000239768000004 PM 16911973 ER PT J AU Ahmed, A Rich, MW Fleg, JL Zile, MR Young, JB Kitzman, DW Love, TE Aronow, WS Adams, KF Gheorghiade, M AF Ahmed, Ali Rich, Michael W. Fleg, Jerome L. Zile, Michael R. Young, James B. Kitzman, Dalane W. Love, Thomas E. Aronow, Wilbert S. Adams, Kirkwood F., Jr. Gheorghiade, Mihai TI Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary Digitalis Investigation Group trial SO CIRCULATION LA English DT Article DE digoxin; heart failure; morbidity; mortality ID VENTRICULAR SYSTOLIC FUNCTION; EJECTION FRACTION; DIG TRIAL; OLDER-ADULTS; DYSFUNCTION; ASSOCIATION; GLYCOSIDES; OUTCOMES AB Background - About half of the 5 million heart failure patients in the United States have diastolic heart failure (clinical heart failure with normal or near-normal ejection fraction). Except for candesartan, no drugs have been tested in randomized clinical trials in these patients. Although digoxin was tested in an appreciable number of diastolic heart failure patients in the Digitalis Investigation Group ancillary trial, detailed findings from this important study have not previously been published. Methods and Results - Ambulatory chronic heart failure patients (n = 988) with normal sinus rhythm and ejection fraction > 45% (median, 53%) from the United States and Canada (1991 to 1993) were randomly assigned to digoxin (n = 492) or placebo (n = 496). During follow-up with a mean length of 37 months, 102 patients (21%) in the digoxin group and 119 patients (24%) in the placebo group (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.63 to 1.07; P = 0.136) experienced the primary combined outcome of heart failure hospitalization or heart failure mortality. Digoxin had no effect on all-cause or cause-specific mortality or on all-cause or cardiovascular hospitalization. Use of digoxin was associated with a trend toward a reduction in hospitalizations resulting from worsening heart failure (HR, 0.79; 95% CI, 0.59 to 1.04; P = 0.094) but also a trend toward an increase in hospitalizations for unstable angina (HR, 1.37; 95% CI, 0.99 to 1.91; P = 0.061). Conclusions - In ambulatory patients with chronic mild to moderate diastolic heart failure and normal sinus rhythm receiving angiotensin-converting enzyme inhibitor and diuretics, digoxin had no effect on natural history end points such as mortality and all-cause or cardiovascular hospitalizations. C1 Univ Alabama, Birmingham, AL 35294 USA. Washington Univ, St Louis, MO USA. VA Med Ctr, Birmingham, AL USA. NHLBI, Bethesda, MD 20892 USA. Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Wake Forest Univ, Winston Salem, NC 27109 USA. Case Western Reserve Univ, Cleveland, OH 44106 USA. New York Med Coll, Valhalla, NY 10595 USA. Univ N Carolina, Chapel Hill, NC USA. Northwestern Univ, Chicago, IL 60611 USA. RP Ahmed, A (reprint author), Univ Alabama, 1530 3rd Ave S,CH-19,Suite 219, Birmingham, AL 35294 USA. EM aahmed@uab.edu RI Ahmed, Ali/A-2934-2008 OI Ahmed, Ali/0000-0002-6832-6424 FU NIA NIH HHS [1-K23-AG19211-04, K23 AG019211, K23 AG019211-04, R01 AG018915, R37 AG018915] NR 29 TC 242 Z9 264 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD AUG 1 PY 2006 VL 114 IS 5 BP 397 EP 403 DI 10.1161/CIRCULATIONAHA.106.628347 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 069CK UT WOS:000239422500011 PM 16864724 ER PT J AU Kobayashi, N Barnard, RJ Henning, SM Elashoff, D Reddy, ST Cohen, P Leung, P Hong-Gonzalez, J Freedland, SJ Said, J Gui, D Seeram, NP Popoviciu, LM Bagga, D Heber, D Glaspy, JA Aronson, WJ AF Kobayashi, Naoko Barnard, R. James Henning, Susanne M. Elashoff, David Reddy, Srinivasa T. Cohen, Pinchas Leung, Pak Hong-Gonzalez, Jenny Freedland, Stephen J. Said, Jonathan Gui, Dorina Seeram, Navindra P. Popoviciu, Laura M. Bagga, Dilprit Heber, David Glaspy, John A. Aronson, William J. TI Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E-2 SO CLINICAL CANCER RESEARCH LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MESSENGER-RNA; GROWTH-FACTOR; TUMOR-GROWTH; CELL-GROWTH; EICOSAPENTAENOIC ACID; DOCOSAHEXAENOIC ACID; CARCINOMA-CELLS; SCID MICE; IN-VITRO AB Purpose: To determine whether altering the dietary content of omega-6 (n-6) ando)-3 (n-3) polyunsaturated fatty acids affects the growth of androgen-sensitive prostate cancer xenografts, tumor membrane fatty acid composition, and tumor cyclooxygenase-2 and prostaglandin E-2 (PGE(2)) levels. Experimental Design: Individually caged male severe combined immunodeficiency mice were fed isocaloric 20% kcal fat diets with the fat derived either primarily from n-6 fatty acids (n-6 group) or with the fat consisting of n-6 and n-3 fatty acids in a ratio of 1:1 (n-3 group), and injected s.c. with Los Angeles Prostate Cancer 4 (LAPC-4) cells. Tumor volumes and mouse weights were measured weekly, caloric intake was measured 3 days per week, and tumors and serum were harvested at 8 weeks postinjection. Results: Tumor growth rates, final tumor volumes, and serum prostate-specific antigen levels were reduced in the n-3 group relative to the n-6 group. The n-3 group tumors had decreased proliferation (Ki67 staining) and increased apoptosis (terminal nucleotidyl transferase-mediated nick end labeling staining). In vitro proliferation of LAPC-4 cells in medium containing n-3 group serum was reduced by 22% relative to LAPC-4 cells cultured in medium containing serum from the n-6 group. The n-6/n-3 fatty acid ratios in serum and tumor membranes were lower in the n-3 group relative to the n-6 group. In addition, n-3 group tumors had decreased cyclooxygenase-2 protein and mRNA levels, an 83% reduction in PGE(2) levels, and decreased vascular endothelial growth factor expression. Conclusion: These results provide a sound basis for clinical trials evaluating the effect of dietary n-3 fatty acids from fish oil on tumor PGE(2) and membrane fatty acid composition, and serum and tumor biomarkers of progression in men with prostate cancer. C1 Univ Calif Los Angeles, Dept Urol, Ctr Hlth Sci 66 124, Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Biostat, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Div Clin Nutr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Pediat Endocrinol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. Boston Univ, Sch Med, Boston, MA 02118 USA. Duke Univ, Sch Med, Vet Adm Med Ctr, Dept Surg, Durham, NC USA. Duke Univ, Sch Med, Urol Sect, Dept Surg, Durham, NC USA. Univ Calif Los Angeles, Sch Med, Dept Cardiol, Los Angeles, CA 90095 USA. RP Aronson, WJ (reprint author), Univ Calif Los Angeles, Dept Urol, Ctr Hlth Sci 66 124, Sch Med, Box 951738, Los Angeles, CA 90095 USA. EM waronson@ucla.edu FU NCCIH NIH HHS [AT00151, P50 AT000151]; NCI NIH HHS [1R01CA100938, 5P01 CA42710, P01 CA042710, P50 CA092131, P50 CA92131-01A1, R01 CA100938] NR 50 TC 90 Z9 96 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD AUG 1 PY 2006 VL 12 IS 15 BP 4662 EP 4670 DI 10.1158/1078-0432.CCR-06-0459 PG 9 WC Oncology SC Oncology GA 073NR UT WOS:000239750400029 PM 16899616 ER PT J AU Spiegel, BMR Dulai, GS Lim, BS Mann, N Kanwal, F Gralnek, IM AF Spiegel, Brennan M. R. Dulai, Gareth S. Lim, Brian S. Mann, Neel Kanwal, Fasiha Gralnek, Ian M. TI The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID PROSPECTIVE RANDOMIZED-TRIAL; UPPER GASTROINTESTINAL HEMORRHAGE; HYPERTONIC SALINE-EPINEPHRINE; SUCCESSFUL ENDOSCOPIC THERAPY; BLEEDING ULCERS; DOUBLE-BLIND; BIPOLAR ELECTROCOAGULATION; ADRENALINE INJECTION; AGGRESSIVE CARE; HEATER PROBE AB Background & Aims: The most cost-effective route of administering proton pump inhibitor (PPI) therapy in peptic ulcer hemorrhage remains uncertain. Oral (PO) PPI therapy may be less effective than intravenous (IV) PPI therapy, but is less expensive and does not mandate a 72-hour posthemostasis hospital stay to complete a full therapeutic course. Because there are currently no published head-to-head clinical trials comparing IV vs PO PPIs, we used decision analysis with budget impact modeling to measure the clinical and economic outcomes of these competing modes of administration. Methods: We compared 3 postendoscopic strategies for high-risk peptic ulcer hemorrhage: (1) PO PPI therapy, (2) IV PPI therapy, and (3) IV histamine(2) receptor antagonist therapy. The primary outcomes were cost per quality-adjusted life-year gained, and per-member per-month cost in a hypothetical managed care organization with 1,000,000 covered lives. Results: Compared with the PPI strategies, the histamine2 receptor antagonist strategy was more expensive and less effective. Of the 2 PPI strategies, using IV instead of PO PPI cost an incremental $708,735 per year to gain 1 additional quality-adjusted life-year. Substituting IV in lieu of PO PPI cost each member $2.86 per month to subsidize. The IV PPI strategy became dominant when the rebleed rate with PO PPIs exceeded 24% (base case = 13%), and when the hospital stay on IV PPIs decreased to less than 72 hours. Conclusions: The higher effectiveness of IV PPI therapy may not offset its increased costs vs PO PPI therapy in ulcer hemorrhage. The managed care budget impact of IV PPIs exceeds most benchmarks. C1 Technion Israel Inst Technol, Rappaport Fac Med, Rambam Med Ctr, GI Outcomes Unit,Dept Gastroenterol, Haifa, Israel. Vet Adm Greater Los Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA USA. Univ Calif Los Angeles, Vet Adm Ctr Outcomes Res & Educ, Los Angeles, CA USA. CURE Digest Dis Res Ctr, Los Angeles, CA USA. RP Gralnek, IM (reprint author), Technion Israel Inst Technol, Rappaport Fac Med, Rambam Med Ctr, GI Outcomes Unit,Dept Gastroenterol, Haifa, Israel. EM i_gralnek@rambam.health.gov.il FU NCRR NIH HHS [K23 RR-16188] NR 64 TC 27 Z9 27 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD AUG PY 2006 VL 4 IS 8 BP 988 EP 997 DI 10.1016/j.cgh.2006.05.019 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 073BX UT WOS:000239718600009 PM 16844422 ER PT J AU Kudolo, GB Wang, W Javors, M Blodgett, J AF Kudolo, George B. Wang, Wen Javors, Martin Blodgett, Janet TI The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects - A double blind placebo-controled, crossover study SO CLINICAL NUTRITION LA English DT Article DE Ginkgo biloba extract; type 2 diabetes; metformin; pharmacokinetics; drug-herb interaction ID BETA-CELL FUNCTION; INSULIN SENSITIVITY; GLUCOSE-TOLERANCE; MELLITUS; INDIVIDUALS; RESISTANCE; EFFICACY; HEALTHY; DISEASE; NIDDM AB Background & aims: Ginkgo biloba extract (EGb 761) has been shown to ameliorate some defects associated with the insulin resistance syndrome and so patients with Type 2 diabetes mellitus (T2DM) may be inclined to co-ingest the herb with their medications, such as metformin. This study was designed to determine if the coingestion of EGb 761 and metformin would alter the pharmacokinetic properties of metformin in T2DM patients and persons without diabetes, who may ingest it for other purposes. Method: Normal glucose tolerance (NGT) subjects (n = 10; age, 39.2+/-14.0 years; fasting plasma glucose (FPG), 90+/-7 mg/dl; body mass index (BMI), 24.1 +/- 3.7 kg/m(2)) and 10 T2DM patients (n = 10; age, 51.7 +/- 8.9 years; FPG, 150 +/- 7 mg/dl; BMI, 33.7 +/- 5.7 kg/m(2)) completed a randomized, double-blind, placebo - control led crossover study. They ingested either EGb 761 (120 mg/day as a single dose) or a vegetable-based placebo during each arm for 3 months. At the end of each arm, the NGT subject ingested a single 500 mg dose of metformin (non-diabetics) and the T2DM subject took his/her prescribed metformin dose (250-850 mg) with 120 mg EGb 761. Blood and urine samples were collected over an 8-h period, and in the case of T2DM subjects, additionally over the first 2 h of the subsequent 3 days. Results: Ingestion of EGb 761 produced no significant changes in diagnostic laboratory tests in either group, except reducing glycosylated hemoglobin A(1c) levels (from 7.7+/-1.2 to 7.2+/-0.9%, P<0.05) in T2DM the subjects. The pharmacokinetic parameters of metformin were all significantly different (P<0.05) between the NGT (500 mg) and 8 out of 10 of the T2DM subjects who were prescribed 500 mg of metformin during the placebo cycles. During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117 +/- 0.085 to 0. 141 +/- 0.100, P < 0.05). Conclusion: The co-ingestion of 120 mg of EGb 761 and 500 mg of metformin did not significantly affect the pharmacokinetic properties of metformin. Further studies are required to verify this observation for smaller and larger dose of metformin with other doses of EGb 761, since T2DM patients on medication constitute a very heterogeneous group. (C) 2006 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Clin Sci Lab, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA. Audie L Murphy Vet Affairs Hosp, San Antonio, TX 78284 USA. RP Kudolo, GB (reprint author), Univ Texas, Hlth Sci Ctr, Dept Clin Sci Lab, MSC 6246,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM Kudolo@uthscsa.edu FU NCCIH NIH HHS [R01-AT-00832]; NCRR NIH HHS [M01-RR-01346] NR 27 TC 22 Z9 22 U1 1 U2 4 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0261-5614 J9 CLIN NUTR JI Clin. Nutr. PD AUG PY 2006 VL 25 IS 4 BP 606 EP 616 DI 10.1016/j.clnu.2005.12.012 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 082NA UT WOS:000240392300008 PM 16698134 ER PT J AU Doan, TL Fung, HB Mehta, D Riska, PF AF Doan, Thien-Ly Fung, Horatio B. Mehta, Dhara Riska, Paul F. TI Tigecycline: A glycylcycline antimicrobial agent SO CLINICAL THERAPEUTICS LA English DT Review DE tigecycline; glycylcycline; complicated skin and skin-structure infection; complicated intraabdominal infection ID RESISTANT STAPHYLOCOCCUS-AUREUS; IN-VITRO ACTIVITY; SKIN-STRUCTURE INFECTIONS; COMPLICATED INTRAABDOMINAL INFECTIONS; GRAM-NEGATIVE BACTERIA; ACQUIRED RESPIRATORY-TRACT; MULTIDRUG EFFLUX PUMP; HEALTHY-SUBJECTS; ANTIBACTERIAL ACTIVITIES; KLEBSIELLA-PNEUMONIAE AB Background: Tigecycline, the first glycylcycline to be approved by the US Food and Drug Administration, is a structural analogue of minocycline that was designed to avoid tetracycline resistance mediated by ribosomal protection and drug efflux. It is indicated for the treatment of complicated skin and skin-structure infections and complicated intra-abdominal infections and is available for intravenous administration only. Objective: This article summarizes the in vitro and in vivo activities and pharmacologic and pharmacokinetic properties of tigecycline, and reviews its clinical efficacy and tolerability profile. Methods: Relevant information was identified through a search of MEDLINE (1966-April 2006), Iowa Drug Information Service (1966-April 2006), and International Pharmaceutical Abstracts (1970-April 2006) using the terms tigecycline, GAR-936, and glycylcycline. Also consulted were abstracts and posters from meetings of the Infectious Diseases Society of America and the Interscience Conference on Antimicrobial Agents and Chemotherapy (19992006) and documents provided for formulary consideration by the US manufacturer of tigecycline. Results: Like the tetracyclines, tigecycline binds to the 30S subunit of bacterial ribosomes and inhibits protein synthesis by preventing the incorporation of amino acid residues into elongating peptide chains. In vitro, tigecycline exhibits activity against a wide range of clinically significant gram-positive and gram-negative bacteria, including multi drug-resistant strains (eg, oxacillin-resistant Stapbylococcus aureus, vancomycin-resistant enterococci, extended-spectrum beta-lactamase-producing Enterobacteriaceae), and anaerobes (eg, Bacteroides spp). In pharmacokinetic studies in human adults, tigecycline had a large Vd (7-9 L/kg), was moderately bound to plasma protein (71%-89%), had an elimination t(1/2) of 42.4 hours, and was eliminated primarily by biliary/fecal (59%) and renal (33%) excretion. Dose adjustment did not appear to be necessary based on age, sex, renal function, or mild to moderate hepatic impairment (Child-Pugh class A-B). In patients with severe hepatic impairment (Child-Pugh class Q, the maintenance dose should be reduced by 50%. In 4 Phase III clinical trials in patients with complicated skin and skin-structure infections and complicated intra-abdominal infections, tigecycline was reported to be noninferior to its comparators (vancomycin + aztreonam in 2 studies and imipenem/cilastatin in 2 studies), with clinical cure rates among clinically evaluable patients of > 80% (P < 0.001 for noninferiority). The most frequently reported ( >= 5%) adverse events with tigecycline were nausea (28.5%), vomiting (19.4%), diarrhea (11.6%), local IV-site reaction (8.2%), infection (6.7%), fever (6.3%), abdominal pain (6.0%), and headache (5.6%). The recommended dosage of tigecycline is 100 mg IV given as a loading dose, followed by 50 mg IV q12h for 5 to 14 days. Conclusions: In clinical trials, tigecycline was effective for the treatment of complicated skin and skin-structure infections and complicated intra-abdominal infections. With the exception of gastrointestinal adverse events, tigecycline was generally well tolerated. With a broad spectrum of activity that includes multidrug-resistant gram-positive and gram-negative pathogens, tigecycline may be useful in the treatment of conditions caused by these pathogens. C1 James Peters VA Med Ctr, Med Surg Patient Care Ctr, Bronx, NY 10468 USA. Long Isl Jewish Med Ctr, Dept Pharm, New Hyde Pk, NY 11042 USA. James Peters VA Med Ctr, Serv Pharm, Bronx, NY 10468 USA. James Peters VA Med Ctr, Infect Dis Sect, Bronx, NY 10468 USA. RP Fung, HB (reprint author), James Peters VA Med Ctr, Med Surg Patient Care Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM horatio.fung@va.gov NR 101 TC 82 Z9 87 U1 0 U2 17 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD AUG PY 2006 VL 28 IS 8 BP 1079 EP 1106 DI 10.1016/j.clinthera.2006.08.011 PG 28 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 084GP UT WOS:000240521000002 PM 16982286 ER PT J AU Lindblad, CI Hanlon, JT Gross, CR Sloane, RJ Pieper, CF Hajjar, ER Ruby, CM Schmader, KE AF Lindblad, Catherine I. Hanlon, Joseph T. Gross, Cynthia R. Sloane, Richard J. Pieper, Carl F. Hajjar, Emily R. Ruby, Christine M. Schmader, Kenneth E. CA Multidisciplinary Consensus Panel TI Clinically important drug-disease interactions and their prevalence in older adults SO CLINICAL THERAPEUTICS LA English DT Article; Proceedings Paper CT Annual Meeting of the American-College-of-Clinical-Pharmacy CY OCT 23-26, 2005 CL San Francisco, CA SP Amer Coll Clin Pharm DE drug-disease interactions; epidemiology; aged ID INAPPROPRIATE MEDICATION USE; URINARY-INCONTINENCE; PSYCHOTROPIC-DRUGS; EXPLICIT CRITERIA; CONSENSUS PANEL; COMMUNITY; MANAGEMENT; PEOPLE; BENZODIAZEPINES; DEPRESSION AB Background: Older adults may have decreased homeostatic reserve, have multiple chronic diseases, and take multiple medications. Therefore, they are at risk for adverse outcomes after receiving a drug that exacerbates a chronic disease. Objectives: The aims of this study were to compile a list of clinically important drug-disease interactions in older adults, obtain the consensus of a multidisciplinary panel of geriatric health care professionals on these interactions, and determine the prevalence of these interactions in a sample of outpatients. Methods: This analysis included a 2-round modified Delphi survey and cross-sectional study. Possible drug-disease interactions in patients aged >= 65 years were identified through a search of the English-language literature indexed on MEDLINE and International Pharmaceutical Abstracts (1966-July 2004) using terms that included drug-disease interaction, medication errors, and inappropriate prescribing. Nine health care professionals with expertise in geriatrics (2 geriatricians, 7 geriatric clinical pharmacist specialists) were selected based on specialty training and continuing clinical work in geriatrics, academic appointments, and geographic location. The panel rated the importance of the potential drug-disease interactions using a 5-point Likert scale (from 1 = definitely not serious to 5 = definitely serious). Consensus on a drug-disease interaction was defined as a lower bound of the 95% CI >= 4.0. The prevalence of drug-disease interactions was determined by applying the consensus criteria to a convenience sample of frail older veterans at hospital discharge who were enrolled in a health services intervention trial. Results: The panel reached consensus on 28 individual drug-disease interactions involving 14 diseases or conditions. Overall, 205 (15.3%) of the 1340 veterans in the sample had >= 1 drug-disease interaction. The 2 most common drug-disease interactions were use of first-generation calcium channel blockers in patients with congestive heart failure and use of aspirin in patients with peptic ulcer disease (both, 3.7%) Conclusions: A survey of multidisciplinary geriatric health care professionals resulted in a concise consensus list of clinically important drug-disease interactions in older adults. Further research is needed to examine the impact of these drug-disease interactions on health outcomes and their applicability as national measures for the prevention of drug-related problems. C1 Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA. Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Minneapolis, MN USA. Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC USA. Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA. Univ Sci Philadelphia, Philadelphia Coll Pharm, Philadelphia, PA USA. Duke Univ, Med Ctr, Dept Med, Div Geriatr Med, Durham, NC 27710 USA. Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. RP Lindblad, CI (reprint author), Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA. EM lindb047@umn.edu FU NIA NIH HHS [P30 AG024827, P30 AG 024827, R01 AG 14158, R01 AG 15432]; NIAID NIH HHS [K24 AI 51324] NR 64 TC 51 Z9 52 U1 1 U2 8 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD AUG PY 2006 VL 28 IS 8 BP 1133 EP 1143 DI 10.1016/j.clinthera.2006.08.006 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 084GP UT WOS:000240521000006 PM 16982290 ER PT J AU Bice-Stephens, WM AF Bice-Stephens, Wynona M. TI Guest editorial - Ownership in the intensive care unit SO CRITICAL CARE NURSE LA English DT Editorial Material C1 VA PUget Sound Hlth Care Syst, Seattle, WA USA. RP Bice-Stephens, WM (reprint author), VA PUget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 0279-5442 J9 CRIT CARE NURSE JI Crit. Care Nurse PD AUG PY 2006 VL 26 IS 4 BP 10 EP + PG 2 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA 069LG UT WOS:000239447400001 PM 16857996 ER PT J AU Zoghbi, GJ Iskandrian, AE AF Zoghbi, Gilbert J. Iskandrian, Ami E. TI Adenosine myocardial perfusion imaging SO CURRENT MEDICAL IMAGING REVIEWS LA English DT Review DE adenosine; SPECT; myocardial perfusion imaging ID CORONARY-ARTERY-DISEASE; EMISSION COMPUTED-TOMOGRAPHY; TRANSIENT ISCHEMIC DILATION; ST-SEGMENT DEPRESSION; BUNDLE-BRANCH BLOCK; SIGNIFICANT AORTIC-STENOSIS; TC-99M SESTAMIBI SPECT; DOPPLER GUIDE-WIRE; PHARMACOLOGICAL STRESS; BLOOD-FLOW AB Adenosine myocardial perfusion imaging is a commonly used modality for the evaluation of patients with known or suspected coronary artery disease (CAD). In this review we discuss the pharmacology of adenosine and its effects on myocardial blood flow and the generation of perfusion defects during myocardial perfusion imaging (MPI), the indications and contraindications of MPI, stress protocols, side effects, hemodynamic and electrocardiographic changes, comparison to other stress MPI modalities, the role of adenosine MPI in special patient populations and the recent advances in the field with the emergence of the new selective adenosine agonists. C1 Univ Alabama, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Iskandrian, AE (reprint author), Univ Alabama, Dept Med, Div Cardiovasc Dis, 318 LHRB,1900 Univ Blvd, Birmingham, AL 35294 USA. EM aiskand@uab.edu NR 112 TC 0 Z9 0 U1 0 U2 0 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1573-4056 J9 CURR MED IMAGING REV JI Curr. Med. Imaging Rev. PD AUG PY 2006 VL 2 IS 3 BP 315 EP 327 PG 13 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 063LV UT WOS:000239020600003 ER PT J AU Kahn, SE Zinman, B Haffner, SM O'Neill, MC Kravitz, BG Yu, DH Freed, MI Herman, WH Holman, RR Jones, NP Lachin, JM Viberti, GC AF Kahn, Steven E. Zinman, Bernard Haffner, Steven M. O'Neill, M. Colleen Kravitz, Barbara G. Yu, Dahong Freed, Martin I. Herman, William H. Holman, Rury R. Jones, Nigel P. Lachin, John M. Viberti, Giancarlo C. CA ADOPT Study Grp TI Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes SO DIABETES LA English DT Article ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; INSULIN-RESISTANCE ATHEROSCLEROSIS; CHOLESTEROL EDUCATION-PROGRAM; CARDIOVASCULAR-DISEASE; WEIGHT-LOSS; HEART-DISEASE; RISK-FACTORS; ACUTE-PHASE; INFLAMMATION; MELLITUS AB The inflammatory factor C-reactive protein (CRP) and the fibrinolytic variables fibrinogen and plasminogen activator-1 (PAI-1) are associated with long-term cardiovascular morbidity. To determine the contribution of body adiposity (BMI), insulin sensitivity (homeostasis model assessment of insulin resistance [HOMA-IR], and glycemia (HbA(1c) [A1C]) to the levels of these inflammatory and fibrinolytic variables in recently diagnosed (<= 3 years), drug-naive, type 2 diabetic subjects (fasting plasma glucose <= 10 mmol/l), we examined a representative subgroup (n = 921) of the U.S. cohort in ADOPT (A Diabetes Outcome Progression Trial). The relationship between levels of CRP, fibrinogen, PAI-1 antigen and PAI-1 activity, and baseline variables including National Cholesterol Education Program Adult Treatment Panel III metabolic syndrome phenotype were explored. All four factors increased significantly with increasing numbers of metabolic syndrome components (P = 0.0136 to P < 0.0001). BMI (P < 0.0001) and HOMA-IR (P < 0.0001) but not A1C (P = 0.65) increased with increasing numbers of metabolic syndrome components. Adjustment of CRP levels for BMI eliminated the association between CRP and the number of metabolic syndrome components, while adjusting for HOMA-IR did not (P = 0.0028). The relationships of PAI-1 antigen and PAI-1 activity with the number of metabolic syndrome components were maintained after adjusting for BMI (P = 0.0002 and P = < 0.0001, respectively) or HOMA-IR (P = 0.0008 and P = < 0.0001, respectively), whereas that with fibrinogen was eliminated after adjusting for BMI but not after adjusting for HOMA-IR (P = 0.013). Adjustment for A1C had no effect on any of the relationships between the inflammatory and fibrinolytic factors and the metabolic syndrome. We conclude that in recently diagnosed, drugnaive type 2 diabetic subjects, markers of inflammation and fibrinolysis are strongly related to the number of metabolic syndrome components. Further, for CRP and fibrinogen this relationship is determined by body adiposity and not by insulin sensitivity or glucose control. C1 VA Puget Sound Hlth Care Syst, Dept Internal Med, Div Metab, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON, Canada. Univ Toronto, Toronto, ON, Canada. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. GlaxoSmithKline Inc, King Of Prussia, PA USA. Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, Oxford, England. George Washington Univ, Ctr Biostat, Washington, DC 20052 USA. Kings Coll London, Sch Med, London WC2R 2LS, England. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst, Dept Internal Med, Div Metab, 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@u.washington.edu RI Zinman, Bernard/E-7266-2013 OI Lachin, John/0000-0001-9838-2841; Kahn, Steven/0000-0001-7307-9002 NR 37 TC 106 Z9 112 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD AUG PY 2006 VL 55 IS 8 BP 2357 EP 2364 DI 10.2337/db06-0116 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 069SK UT WOS:000239468300024 PM 16873701 ER PT J AU Draznin, B AF Draznin, Boris TI Molecular mechanisms of insulin resistance: Serine phosphorylation of insulin receptor substrate-1 and increased expression of p85 alpha - The two sides of a coin SO DIABETES LA English DT Article ID NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE B; P70 S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; SKELETAL-MUSCLE; MAMMALIAN TARGET; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAYS; GLUCOSE-TRANSPORT; MICE LACKING AB Initial attempts to unravel the molecular mechanism of insulin resistance have strongly suggested that a defect responsible for insulin resistance in the majority of patients lies at the postreceptor level of insulin signaling. Subsequent studies in insulin-resistant animal models and humans have consistently demonstrated a reduced strength of insulin signaling via the insulin receptor substrate (IRS)-1/phosphatidylinositol (PI) 3-kinase pathway, resulting in diminished glucose uptake and utilization in insulin target tissues. However, the nature of the triggering event(s) remains largely enigmatic. Two separate, but likely, complementary mechanisms have recently emerged as a potential explanation. First, it became apparent that serine phosphorylation of IRS proteins can reduce their ability to attract PI 3-kinase, thereby minimizing its activation. A number of serine kinases that phosphorylate serine residues of IRS-1 and weaken insulin signal transduction have been identified. Additionally, mitochondrial dysfunction has been suggested to trigger activation of several serine kinases, leading to a serine phosphorylation of IRS-1. Second, a distinct mechanism involving increased expression of p85 alpha has also been found to play an important role in the pathogenesis of insulin resistance. Conceivably, a combination of both increased expression of p85a and increased serine phosphorylation of IRS-1 is needed to induce clinically apparent insulin resistance. C1 Denver VA Med Ctr, Res Serv 151, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Boulder, CO 80309 USA. RP Draznin, B (reprint author), Denver VA Med Ctr, Res Serv 151, 1055 Clermont St, Denver, CO 80220 USA. EM boris.draznin@med.va.gov NR 94 TC 153 Z9 170 U1 1 U2 25 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD AUG PY 2006 VL 55 IS 8 BP 2392 EP 2397 DI 10.2337/db06-0391 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 069SK UT WOS:000239468300029 PM 16873706 ER PT J AU Metlay, JP Fishman, NO Joffe, MM Kallan, MJ Chittams, JL Edelstein, PH AF Metlay, Joshua P. Fishman, Neil O. Joffe, Marshall M. Kallan, Michael J. Chittams, Jesse L. Edelstein, Paul H. TI Macrolide resistance in adults with bacteremic pneumococcal pneumonia SO EMERGING INFECTIOUS DISEASES LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; PENICILLIN-RESISTANT; RISK-FACTORS; ANTIMICROBIAL RESISTANCE; UNITED-STATES; INFECTIONS; THERAPY; RECALL; ANTIBIOTICS AB We conducted a case-control study of adults with bacteremic pneumococcal pneumonia to identify factors associated with macrolide resistance. Study participants were identified through population-based surveillance in a 5-county region surrounding Philadelphia. Forty-three hospitals contributed 444 patients, who were interviewed by telephone regarding potential risk factors. In multivariable analyses, prior exposure to a macrolide antimicrobial agent (odds ratio [OR] 2.8), prior flu vaccination (OR 2.0), and Hispanic ethnicity (OR 4.1) were independently associated with an increased probability of macrolide resistance, and a history of stroke was independently associated with a decreased probability of macrolide resistance (OR 0.2). Fifty-five percent of patients with macrolide-resistant infections reported no antimicrobial drug exposure in the preceding 6 months. Among patients who reported taking antimicrobial agents in the 6 months preceding infection, failure to complete the course of prescribed drugs was associated with an increased probability of macrolide resistance (OR 3.4). C1 Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Metlay, JP (reprint author), Ctr Clin Epidemiol & Biostat, 712 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jmetlay@cceb.med.upenn.edu FU NIAID NIH HHS [R01 AI 46645, R01 AI046645] NR 31 TC 12 Z9 13 U1 1 U2 1 PU CENTER DISEASE CONTROL PI ATLANTA PA ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2006 VL 12 IS 8 BP 1223 EP 1230 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 068FQ UT WOS:000239358500007 PM 16965701 ER PT J AU Giraud, GD Louey, S Jonker, S Schultz, J Thornburg, KL AF Giraud, G. D. Louey, S. Jonker, S. Schultz, J. Thornburg, K. L. TI Cortisol stimulates cell cycle activity in the cardiomyocyte of the sheep fetus SO ENDOCRINOLOGY LA English DT Article ID RENIN-ANGIOTENSIN SYSTEM; GROWTH-HORMONE RECEPTOR; NEONATAL RAT-HEART; FETAL SHEEP; LATE-GESTATION; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; BLOOD-PRESSURE; CARDIAC MYOCYTES; OVINE FETUS; CORTICOSTEROID RECEPTORS AB The role of cortisol in regulating cardiac myocyte growth in the near-term fetal sheep is unknown. We hypothesized that cortisol would suppress cardiomyocyte proliferation and stimulate cardiomyocyte binucleation and enlargement, signs of terminal differentiation. Cardiomyocyte dimensions and percent binucleation were determined in isolated cardiac myocytes from seven cortisol-treated and seven control fetuses; percentage of myocytes positive for Ki-67 was determined in an additional four cortisol-treated and four control hearts. Cortisol was infused into the circumflex coronary artery at subpressor rates (0.5 mu g/kg center dot min, 7 d). Cortisol infusion had no hemodynamic effects, compared with controls or pretreatment conditions. Cortisol treatment increased heart weight (44.0 +/- 8.7 g vs. control, 34.9 +/- 9.1 g, P < 0.05). Heart to body weight ratio was greater in treated hearts, compared with controls (10.3 +/- 1.9 vs. 7.7 +/- 0.9 g/kg, P < 0.01). Ventricular myocyte length, width, and percent binucleation were not different between groups. The proportion of treated myocytes in the cell cycle staining for Ki-67 was higher in the left ventricle (5.5 +/- 0.1 vs. 2.7 +/- 0.4%, P < 0.005) and right ventricle (4.4 +/- 0.4 vs. 3.7 +/- 0.7%, P < 0.05), compared with controls. Wet weight to dry weight ratios from cortisol-treated and control hearts were not different. In conclusion, whereas cortisol infused into the fetal sheep heart has no effect on cardiomyocyte size or maturational state, it stimulates entry of cardiomyocytes in the cell cycle. Thus, increases in fetal heart mass associated with subpressor doses of cortisol are due to cardiomyocyte proliferation and not hypertrophic growth. C1 Oregon Hlth Sci Univ, Heart Res Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Med Cardiovasc Med, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Surg Cardiothorac, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. RP Thornburg, KL (reprint author), Oregon Hlth Sci Univ, Heart Res Ctr, L464,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM thornbur@ohsu.edu OI Jonker, Sonnet/0000-0002-1097-2562 FU NICHD NIH HHS [P01HD34430] NR 55 TC 55 Z9 55 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD AUG PY 2006 VL 147 IS 8 BP 3643 EP 3649 DI 10.1210/en.2006-0061 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 064FH UT WOS:000239074100002 PM 16690807 ER PT J AU Swartz, BE Houser, CR Tomiyasu, U Walsh, GO DeSalles, A Rich, JR Delgado-Escueta, A AF Swartz, Barbara E. Houser, Carolyn R. Tomiyasu, Uwami Walsh, Gregory O. DeSalles, Antonio Rich, J. Ronald Delgado-Escueta, Antonio TI Hippocampal cell loss in posttraumatic human epilepsy SO EPILEPSIA LA English DT Article DE temporal lobe epilepsy; traumatic brain injury; hippocampal sclerosis; dentate gyrus ID TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; DENTATE GYRUS; HEAD TRAUMA; SURGICAL OUTCOMES; DUAL PATHOLOGY; NEURON LOSS; REORGANIZATION; RAT; PATHOGENESIS AB Purpose: We performed this study to determine whether significant head trauma in human adults can result in hippocampal cell loss, particularly in hilar (polymorph) and CA3 neurons, similar to that observed in animal models of traumatic brain injury. We examined the incidence of hippocampal pathology and its relation to temporal neocortical pathology, neuronal reorganization, and other variables. Methods: Twenty-one of 200 sequential temporal lobectomies had only trauma as a risk factor for epilepsy. Tissue specimens from temporal neocortex and hippocampus were stained with glial fibrillary acidic protein (GFAP) and hematoxylin and eosin (H&E). Eleven hippocampal specimens had additional analysis of neuronal distributions by using cresyl violet and immunolabeling of a neuron-specific nuclear protein. Results: The median age at onset of trauma was 19 years, the median time between trauma and onset of seizures was 2 years, and the median epilepsy duration was 16 years. The length of the latent period was inversely related to the age at the time of trauma (r = 0.75; Spearman). The neocortex showed gliosis in all specimens, with hemosiderosis (n = 8) or heterotopias (n = 6) in some, a distribution differing from chance (p = 0.02; Fisher). Hippocampal neuronal loss was found in 94% of specimens, and all of these had cell loss in the polymorph (hilar) region of the dentate gyrus. Hilar cell loss ranged from mild, when cell loss was confined to the hilus, to severe, when cell loss extended into CA3 and CA1. Some degree of mossy fiber sprouting was found in the dentate gyrus of all 10 specimens in which it was evaluated. Granule cell dispersion (n = 4) was seen only in specimens with moderate to severe neuronal loss. Conclusions: Neocortical pathology was universally present after trauma. Neuronal loss in the hilar region was the most consistent finding in the hippocampal formation, similar to that found in the fluid-percussion model of traumatic head injury. These findings support the idea that head trauma can induce hippocampal epilepsy in humans in the absence of other known risk factors. C1 Hoag Mem Hosp, Epilepsy Ctr, Newport Beach, CA 92658 USA. VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Pathol Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Calif Comprehens Epilepsy Program, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA USA. RP Swartz, BE (reprint author), Hoag Mem Hosp, Epilepsy Ctr, 1 Hoag Dr,POB 6100, Newport Beach, CA 92658 USA. EM BSwartz@Hoaghospital.org OI Delgado-Escueta, Antonio V./0000-0002-1581-6999 FU BLRD VA [I01 BX000404] NR 53 TC 59 Z9 68 U1 1 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD AUG PY 2006 VL 47 IS 8 BP 1373 EP 1382 DI 10.1111/j.1528-1167.2006.00602.x PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 071XB UT WOS:000239636100015 PM 16922884 ER PT J AU McDonald, CR Swartz, BE Halgren, E Patell, A Daimes, R Mandelkern, M AF McDonald, Carrie R. Swartz, Barbara E. Halgren, Eric Patell, Ashok Daimes, Richard Mandelkern, Mark TI The relationship of regional frontal hypometabolism to executive function: A resting fluorodeoxyglucose PET study of patients with epilepsy and healthy controls SO EPILEPSY & BEHAVIOR LA English DT Article DE frontal lobe epilepsy; executive functioning; fluorodeoxyglucose positron emission tomography; cognition; juvenile myoclonic epilepsy ID TEMPORAL-LOBE EPILEPSY; CARD SORTING TEST; POSITRON EMISSION TOMOGRAPHY; COMPARATIVE CYTOARCHITECTONIC ANALYSIS; CORTICOCORTICAL CONNECTION PATTERNS; INTERICTAL GLUCOSE HYPOMETABOLISM; PRIMARY GENERALIZED EPILEPSY; COMPLEX PARTIAL SEIZURES; FOCAL CORTICAL-LESIONS; PREFRONTAL CORTEX AB Executive dysfunction is common in patients with frontal lobe damage and may depend on the location of pathology within the frontal lobes. However, it is unclear how specific brain regions contribute to different aspects of executive functioning. Eighteen patients with frontal lobe epilepsy, 10 patients with juvenile myoclonic epilepsy, and 14 controls completed a series of tests that measure a broad range of executive functions. Resting fluorodeoxyglucose positron emission tomography scans were collected and regional cerebral rates of glucose uptake values were regressed on test scores. Results revealed that frontal lobe metabolic values were strong predictors of executive functioning in patients with epilepsy, but not in healthy controls. However, nonfrontal regions also contributed unique variance on several measures, suggesting that (1) a network of frontal and nonfrontal regions subserve many executive functions and (2) resting hypometabolism can be a useful predictor of executive dysfunction in patients with epilepsy. (C) 2006 Elsevier Inc. All rights reserved. C1 Univ Calif San Diego, Multimodal Imaging Lab, La Jolla, CA 92093 USA. Hoag Mem Hosp, Epilepsy Ctr, Newport Beach, CA USA. W Los Angeles Vet Adm Res Serv & PET Lab, Los Angeles, CA USA. Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP McDonald, CR (reprint author), Vet Adm San Diego Healthcare Syst, Psychol Serv 116B, Delis Lab, 3350 La Jolla Village Dr, La Jolla, CA 92611 USA. EM camcdonald@ucsd.edu FU NIMH NIH HHS [T32 MH018399, T32-MH18399] NR 83 TC 20 Z9 21 U1 3 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD AUG PY 2006 VL 9 IS 1 BP 58 EP 67 DI 10.1016/j.yebeh.2006.04.007 PG 10 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 068MR UT WOS:000239378900008 PM 16713363 ER PT J AU Van Hirtum-Das, M Licht, EA Koh, S Wu, JY Shields, WD Sankar, R AF Van Hirtum-Das, Michele Licht, Eliot A. Koh, Susan Wu, Joyce Y. Shields, W. Donald Sankar, Raman TI Children with ESES: Variability in the syndrome SO EPILEPSY RESEARCH LA English DT Article; Proceedings Paper CT International Symposium on Epileptic Syndromes in Infancy and Early Childhood CY APR 29-MAY 01, 2005 CL Tokyo, JAPAN SP Infantile Seizure Soc DE electrical status epilepticus in sleep; continuous spikes and waves during slow wave sleep; Landau-Kleffner syndrome; EEG; developmental delay ID LANDAU-KLEFFNER-SYNDROME; ELECTRICAL STATUS EPILEPTICUS; SLOW-WAVE SLEEP; LANGUAGE REGRESSION; CONVULSIVE DISORDER; CONTINUOUS SPIKES; ACQUIRED APHASIA; LEVETIRACETAM; EPILEPSY; EEG AB Objective: We under-took a retrospective study of children who present with significant activation of paroxysmal discharges during sleep to examine the clinical spectrum of disorders that present with such an EEG abnormality. Background: Electrical status epilepticus in sleep (ESES) is an electrographic pattern characterized by nearly continuous spike-wave discharges in slow wave sleep, usually with a frequency of 1.5-3 Hz and usually diffuse and bilateral in distribution. A variety of neurocognitive and behavioral problems have been associated with this EEG pattern. Methods: We conducted a retrospective review of 1497 EEG records of patients admitted to University of California, Los Angeles (UCLA) for overnight video-EEG monitoring during a 5 year interval. Demographic, clinical and electroencephalographic variables were evaluated. Results: EEG records for 102 patients meeting criteria were identified. Clinical information was available for 90 of those patients. Eighteen of these patients could be diagnosed with Landau-Kleffner syndrome (LKS). Key findings include: (1) neuroimaging abnormalities were uncommon in our LKS patients; (2) among children who do not fit the specific diagnostic criteria for LKS, a spike-wave index (SWI) > 50% was more likely to be associated with global developmental disturbances than SWI <= 50% (p < 0.05); (3) Children with generalized discharges were more likely to experience severe or global developmental disturbance than those with focal abnon-nalities, without reaching statistical significance (P = 0.07). Conclusions: Severity of ESES can vary over time between and within patients and clinical status does not always directly correlate with SWI. However, the prognosis of LKS is substantially better than CSWS and these two disorders could be classified in a dichotomous manner rather than be seen as two points along a continuum. (c) 2006 Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat & Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Mattel Childrens Hosp, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Dept Neurol, Neurobehavior Unit, Los Angeles, CA USA. RP Sankar, R (reprint author), Univ Calif Los Angeles, Med Ctr, Room 22-474 MDCC, Los Angeles, CA 90095 USA. EM RSankar@ucla.edu FU NINDS NIH HHS [NS45911, NS051637, NS046516] NR 37 TC 60 Z9 60 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 J9 EPILEPSY RES JI Epilepsy Res. PD AUG PY 2006 VL 70 SU 1 BP S248 EP S258 DI 10.1016/j.eplepsyres.2006.01.020 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 083PE UT WOS:000240469900029 PM 16806829 ER PT J AU Anand, IS Rector, T Deswal, A Iverson, E Anderson, S Mann, D Cohn, JN Demets, D AF Anand, I. S. Rector, T. Deswal, A. Iverson, E. Anderson, S. Mann, D. Cohn, J. N. Demets, D. TI Relationship between proinflammatory cytokines and anemia in heart failure SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT 28th Congress of the European-Society-of-Cardiology/World Congress of Cardiology CY SEP 02-06, 2006 CL Barcelona, SPAIN SP European Soc Cardiol, World Heart Federat C1 Univ Minnesota, Minneapolis, MN 55455 USA. VA Med Ctr, Minneapolis, MN USA. VA Med Ctr, Houston, TX USA. Univ Massachusetts, Boston, MA 02125 USA. NR 0 TC 9 Z9 9 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD AUG PY 2006 VL 27 SU 1 BP 485 EP 485 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 086JA UT WOS:000240668403267 ER PT J AU Wong, M Staszewsky, L Carretta, E Barlera, S Latini, R Chiang, YT Glazer, RD Cohn, JN AF Wong, Maylene Staszewsky, Lidia Carretta, Elisa Barlera, Simona Latini, Roberto Chiang, Yann-Tong Glazer, Robert D. Cohn, Jay N. TI Signs and symptoms in chronic heart failure: Relevance of clinical trial results to point of care - data from Val-HeFT SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE orthopnoea; resting and paroxysmal nocturnal dyspnoea ID ANGIOTENSIN-RECEPTOR BLOCKER; RANDOMIZED-TRIAL; FUNCTIONAL CLASS; MORBIDITY; MORTALITY; VALSARTAN AB Background: Clinical trials emphasize mortality and morbidity endpoints. Aims: To bring relevance of trial results to point of care by examining the prognostic and therapeutic value of individual signs and symptoms (S&S). Methods: We analysed data from 5010 patients with stable chronic heart failure and left ventricular dysfunction who were participants in the Val-HeFT study Individual S&S were stratified by severity. Treatment differences between valsartan and placebo were analysed by S&S strata at baseline and endpoint by logistical regression, and an overall S&S score by ANCOVA. Hazard ratios of S&S strata were calculated for mortality and heart failure hospitalisation. Prognostic contributions of S&S to other variables were determined by multivariate analysis. Results: At endpoint, there were significantly fewer valsartan and more placebo patients with severe symptoms. Over time, improvement in the S&S overall score was significantly more favourable for valsartan than placebo. S&S strata were significantly predictive of risk for hospitalisation and death. S&S were each independent and incremental predictors of mortality compared to other variables. Symptom strata separated out moderately symptomatic patients with a mortality rate which was intermediate between that for N_YHA Class II and III. Conclusion: Risk stratification of individual S&S defined prognosis, identified patients with an intermediate mortality between Class II and III, and treatment benefits of valsartan over placebo. (c) 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. Ist Ric Farmacol Mario Negri, Milan, Italy. Novartis Pharmaceut Corp, E Hanover, NJ USA. Univ Minnesota, Minneapolis, MN 55455 USA. RP Wong, M (reprint author), 1661 Pine St,819, San Francisco, CA 94109 USA. EM maylene617@yahoo.com NR 12 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1388-9842 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD AUG PY 2006 VL 8 IS 5 BP 502 EP 508 DI 10.1016/j.ejheart.2005.11.001 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 083BI UT WOS:000240430500008 PM 16386464 ER PT J AU Restrepo, MI Mortensen, EM Pugh, JA Anzueto, A AF Restrepo, M. I. Mortensen, E. M. Pugh, J. A. Anzueto, A. TI COPD is associated with increased mortality in patients with community-acquired pneumonia SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article DE chronic obstructive pulmonary disease; community-acquired pneumonia; mortality ID PROGNOSTIC FACTORS; RISK-FACTORS; SEVERITY; ADULTS; VALIDATION; MANAGEMENT; GUIDELINES; ADMISSION; ETIOLOGY; OUTCOMES AB Patients with chronic obstructive pulmonary disease (COPD) who develop community-acquired pneumonia (CAP) may experience worse clinical outcomes. However, COPD is not included as a distinct diagnosis in validated instruments that predict mortality in patients with CAP. The aim of the present study was to evaluate the impact of COPD as a comorbid condition on 30- and 90-day mortality in CAP patients. A retrospective observational study was conducted at two hospitals. Eligible patients had a discharge diagnosis and radiological confirmation of CAP. Among 744 patients with CAP, 215 had a comorbid diagnosis of COPD and 529 did not have COPD. The COPD group had a higher mean pneumonia severity index score (105 +/- 32 versus 87 +/- 34) and were admitted to the intensive care unit more frequently (25 versus 18%). After adjusting for severity of disease and processes of care, CAP patients with COPD showed significantly higher 30- and 90-day mortality than non-COPD patients. Chronic obstructive pulmonary disease patients hospitalised with community-acquired pneumonia exhibited higher 30- and 90-day mortality than patients without chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease should be evaluated for inclusion in community-acquired pneumonia prediction instruments. C1 Univ Texas, Hlth Sci Ctr, Div Pulm & Crit Care Med, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Div Gen Med, San Antonio, TX USA. Audie L Murphy Vet Hosp, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. RP Restrepo, MI (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Div, VERDICT 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM restrepom@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 OI Pugh, Jacqueline/0000-0003-4933-141X; Mortensen, Eric/0000-0002-3880-5563 NR 26 TC 113 Z9 116 U1 0 U2 2 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD AUG PY 2006 VL 28 IS 2 BP 346 EP 351 DI 10.1183/0903936.06.00131905 PG 6 WC Respiratory System SC Respiratory System GA 070LW UT WOS:000239525000016 PM 16611653 ER PT J AU Doran, N VanderVeen, J McChargue, D Spring, B Cook, JW AF Doran, Neal VanderVeen, Joe McChargue, Dennis Spring, Bonnie Cook, Jessica Werth TI Effect of nicotine on negative affect among more impulsive smokers SO EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE impulsivity; nicotine; negative affect ID FAGERSTROM TOLERANCE QUESTIONNAIRE; STRUCTURED CLINICAL INTERVIEW; MAJOR DEPRESSED-PATIENTS; CIGARETTE-SMOKING; TRYPTOPHAN DEPLETION; PROLACTIN RESPONSE; WEIGHT CONCERNS; PERSONALITY; MOOD; CESSATION AB In the present study, the authors tested the hypothesis that nicotine would provide greater relief from negative affect for more impulsive smokers than for less impulsive smokers. Euthymic adult smokers (N = 70) participated in 2 laboratory sessions, during which they underwent a negative mood induction (music + autobiographical memory), then smoked either a nicotinized or de-nicotinized cigarette. Mixed-effects regression yielded a significant Impulsivity X Condition (nicotinized vs. de-nicotinized) X Time interaction. Simple effects analyses showed that heightened impulsivity predicted greater negative affect relief after smoking a nicotinized cigarette but not after smoking a de-nicotinized cigarette. These data suggest that nicotine may be a disproportionately powerful negative reinforcer for highly impulsive smokers, promoting higher levels of nicotine dependence and inhibiting smoking cessation. C1 Univ Illinois, Dept Psychol, Chicago, IL 60607 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Psychol Serv, Hines, IL 60141 USA. Puget Sound Vet Affairs Hosp, Seattle, WA USA. RP Doran, N (reprint author), Univ Illinois, Dept Psychol, MC 285,1007 W Harrison St, Chicago, IL 60607 USA. EM ndoran1@uic.edu RI Doran, Neal/E-5653-2013 FU NIDA NIH HHS [DA14144] NR 73 TC 21 Z9 23 U1 3 U2 4 PU AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1064-1297 J9 EXP CLIN PSYCHOPHARM JI Exp. Clin. Psychopharmacol. PD AUG PY 2006 VL 14 IS 3 BP 287 EP 295 DI 10.1037/1064-1297.14.3.287 PG 9 WC Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy; Psychiatry SC Psychology; Pharmacology & Pharmacy; Psychiatry GA 076IP UT WOS:000239950700002 PM 16893271 ER PT J AU Naliboff, BD Berman, S Suyenobu, B Labus, JS Chang, L Stains, J Mandelkern, MA Mayer, EA AF Naliboff, Bruce D. Berman, Steve Suyenobu, Brandall Labus, Jennifer S. Chang, Lin Stains, Jean Mandelkern, Mark A. Mayer, Emeran A. TI Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients SO GASTROENTEROLOGY LA English DT Article ID ANTERIOR CINGULATE CORTEX; IBS PATIENTS; CEREBRAL ACTIVATION; RECTAL DISTENSION; AMYGDALA RESPONSE; PAIN PERCEPTION; MECHANISMS; SENSITIVITY; MODULATION; HYPERSENSITIVITY AB Background & Aims: Symptom-related fears and associated hypervigilance toward visceral stimuli may play a role in central pain amplification and irritable bowel syndrome (IBS) pathophysiology. Repeated stimulus exposure leads to decreased salience of threat and reduction of hypervigilance. We sought to evaluate hypervigilance in IBS visceral hypersensitivity and associated brain activity. Methods: Twenty IBS patients (14 female; moderate to severe symptoms) and 14 healthy controls participated in symptom and rectal distention assessments 6 times over 12 months. In a subset of 12 IBS patients, H(2)(15)O-positron emission tomography images were obtained during baseline, rectal distentions, and anticipation of an aversive distention during the first and last session. Statistical parametric mapping (SPM99) was used to identify areas and networks activated during each session as well as those with differential activation across the 2 sessions. Results: Perceptual ratings of the rectal inflations normalized over 12 months, whereas IBS symptom severity did not. There were no sex-related differences in these response patterns. Stable activation of the central pain matrix was observed over 12 months, and activity in limbic, paralimbic, and pontine regions decreased. During the anticipation condition, there were significant decreases in amygdala, dorsal anterior cingulate cortex, and dorsal brainstem activation at 12 months. Covariance analysis supported the hypothesis of changes in an arousal network including limbic, pontine, and cortical areas underlying the decreased perception seen over the multiple stimulations. Conclusions: In IBS patients, repeated exposure to experimental aversive visceral stimuli results in the habituation of visceral perception and central arousal, despite stable activation of networks processing visceral pain and its anticipation. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA USA. Univ Calif Irvine, Dept Nucl Med, Irvine, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA USA. RP Naliboff, BD (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM naliboff@ucla.edu FU NCCIH NIH HHS [R24 AT002681]; NIDDK NIH HHS [DK 48351, P50 DK64539]; NINR NIH HHS [NR04881] NR 60 TC 120 Z9 122 U1 2 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD AUG PY 2006 VL 131 IS 2 BP 352 EP 365 DI 10.1053/j.gastro.2006.05.014 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 072WX UT WOS:000239704800008 PM 16890589 ER PT J AU Wei, II Virnig, BA John, DA Morgan, RO AF Wei, Iris I. Virnig, Beth A. John, Dolly A. Morgan, Robert O. TI Using a Spanish surname match to improve identification of Hispanic women in medicare administrative data SO HEALTH SERVICES RESEARCH LA English DT Article DE women; minorities; Medicare race code; Spanish surname; sensitivity and specificity ID BENEFICIARIES; ACCURACY; TRENDS; CODES AB Objective. To assess the effectiveness of a Spanish surname match for improving the identification of Hispanic women in Medicare administrative data in which Hispanics are historically underrepresented. Data Sources. We collected self-identified race/ethnicity data (N=2,997) from a mailed survey sent to elderly Medicare beneficiaries who resided in 11 geographic areas consisting of eight metropolitan counties and three nonmetropolitan areas ( 171 counties) in the fall of 2004. The 1990 Census Spanish Surname list was used to identify Hispanics in the Medicare data. In addition, we used data published on the U. S. Census Bureau website to obtain estimates of elderly Hispanics. Study Design. We used self-identified race/ethnicity as the gold standard to examine the agreement with Medicare race code alone, and with Medicare race code+Spanish surname match. Additionally, we estimated the proportions of Hispanic women and men, in each of the 11 geographic areas in our survey, using the Medicare race code alone and the Medicare race code+Spanish surname match, and compared those estimates with estimates derived from U. S. Census 2000 data. Principal Findings. The Spanish surname match dramatically increased the accuracy of the Medicare race code for identifying both Hispanic and white women, producing improvements comparable with those seen for men. Conclusions. We recommend the addition of a proxy race code in the Medicare data using the Spanish surname match to improve the accuracy of racial/ethnic representation. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Univ Minnesota, Sch Publ Hlth, Div Hlth Serv Res & Policy, Minneapolis, MN 55455 USA. Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA. Baylor Coll Med, Dept Med, Hlth Serv Res Sect, Houston, TX 77030 USA. RP Wei, II (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. RI Morgan, Robert/A-8577-2009 FU NIA NIH HHS [R01 AG019284, R01/AG019284-01A2] NR 16 TC 35 Z9 35 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD AUG PY 2006 VL 41 IS 4 BP 1469 EP 1481 DI 10.1111/j.1475-6773.2006.00550.x PN 1 PG 13 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 065VQ UT WOS:000239188400019 PM 16899019 ER PT J AU Aqel, RA Lloyd, SG Gupta, H Zoghbi, GJ AF Aqel, Raed A. Lloyd, Steven G. Gupta, Himanshu Zoghbi, Gilbert J. TI Three-vessel coronary artery disease, aortic stenosis, and constrictive pericarditis 27 years after chest radiation therapy: A case report SO HEART SURGERY FORUM LA English DT Article ID HODGKINS-DISEASE; CARDIAC-DISEASE; HEART-DISEASE; FOLLOW-UP; IRRADIATION AB A patient with a history of Hodgkin's lymphoma presented with recurrent left pleural effusions and dyspnea on exertion 27 years after radiation therapy. Further evaluation disclosed suspected radiation-induced constrictive pericarditis, aortic stenosis and regurgitation, and severe coronary artery disease. He underwent successful 3-vessel coronary artery bypass grafting, aortic valve replacement, and pericardiectomy. C1 Univ Alabama, Div Cardiovasc Dis, Dept Internal Med, Birmingham, AL 35233 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Zoghbi, GJ (reprint author), Univ Alabama, Div Cardiovasc Dis, Dept Internal Med, BVAMC Heart Stn 6th Floor,700 19th St S, Birmingham, AL 35233 USA. EM gzoghbi@uab.edu NR 10 TC 3 Z9 3 U1 0 U2 0 PU FORUM MULTIMEDIA PUBLISHING, LLC PI CHARLOTTESVILLE PA 375 GREENBRIER DR, CHARLOTTESVILLE, VA 22901 USA SN 1098-3511 J9 HEART SURG FORUM JI Heart Surg. Forum PD AUG PY 2006 VL 9 IS 4 BP E728 EP E730 DI 10.1532/HSF98.20061031 PG 3 WC Cardiac & Cardiovascular Systems; Surgery SC Cardiovascular System & Cardiology; Surgery GA 077ZH UT WOS:000240069900014 PM 16844629 ER PT J AU Malaty, HM Abudayyeh, S Graham, DY Gilger, MA Rabeneck, L O'Malley, K AF Malaty, Hoda M. Abudayyeh, Suhaib Graham, David Y. Gilger, Mark A. Rabeneck, Linda O'Malley, Kimberly TI A prospective study for the association of Helicobacter pylori infection to a multidimensional measure for recurrent abdominal pain in children SO HELICOBACTER LA English DT Article DE recurrent abdominal pain; children; Helicobacter pylori; epidemiology ID UNITED-STATES; SOCIOECONOMIC-STATUS; CHILDHOOD; POPULATION; COMMUNITY; SYMPTOMS; AGE; EPIDEMIOLOGY; SOMATIZATION; ADOLESCENTS AB Background: There is a controversial association between Helicobacter pylori infection and recurrent abdominal pain (RAP) in childhood and inconsistent information on specific symptomatology of the infection. Aim: To examine the prevalence of H. pylori infection among children with RAP compared to asymptomatic children. Methods: Two prospective studies were conducted. The first study enrolled 223 children diagnosed with RAP from two pediatric gastroenterology clinics in Houston, Texas. Children were qualified if they were identified by their physician as having RAP. A new multidimensional measure for RAP (MM-RAP) consisting of four scales (pain intensity scale, symptoms scale, disability scale, and satisfaction scale) was administered to each child/parent. The second study enrolled 330 asymptomatic children from the same community who did not have any upper gastrointestinal symptoms. Symptomatic and asymptomatic children underwent C-13-urea breath testing. Results: In the first study, the prevalence of H. pylori in children with RAP was 11% and fell with age from 20% at age <= 5 years to 7% for children > 10 years (OR = 2.7, 95% CI = 0.7-11.2). There was no association between the mother's educational level and H. pylori prevalence; (12% among children whose mothers completed college versus 11% among those who had elementary school, p = .8). No relationship was found between H. pylori and mean scores of the RAP scales. In the second study, the prevalence of H. pylori in asymptomatic children was 17% and increased with age from 11% for children <= 5 years to 40% for children > 10 years (OR = 5.4, 95% CI = 2.0-13.8). The mother's educational level was inversely correlated with H. pylori (OR = 3.0, 95% CI = 2.2-6.1, p < .01). Conclusions: The epidemiologic patterns of H. pylori infection differed significantly between symptomatic and asymptomatic children. Younger children suffering from RAP are more likely to be infected with H. pylori than older children with the same complaint, suggesting that early acquisition may manifest in symptoms that lead to clinic visits. C1 Baylor Coll Med, Vet Affairs Med Ctr 111D, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA. Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada. RP Malaty, HM (reprint author), Baylor Coll Med, Vet Affairs Med Ctr 111D, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM Hmalaty@bcm.tmc.edu NR 39 TC 12 Z9 13 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD AUG PY 2006 VL 11 IS 4 BP 250 EP 257 DI 10.1111/j.1523-5378.2006.00412.x PG 8 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 063GC UT WOS:000239005100006 PM 16882328 ER PT J AU Oleastro, M Cordeiro, R Menard, A Queiroz, D Yamaoka, Y Megraud, F Monteiro, L AF Oleastro, M. Cordeiro, R. Menard, A. Queiroz, D. Yamaoka, Y. Megraud, F. Monteiro, L. TI Distribution and allelic diversity of a novel peptic ulcer marker candidate in different geographical regions SO HELICOBACTER LA English DT Meeting Abstract CT 19th International Workshop on Helicobacter and Related Bacteric in Chronic Digestive Inflammation CY SEP 07-09, 2006 CL Wroclaw, POLAND C1 Inst Nacl Saude Dr Ricardo Jorge, Ctr Bacteriol, Lisbon, Portugal. Univ Victor Segalen, Lab Bacteriol, Bordeaux, France. Univ Fed Minas Gerais, Fac Med, Lab Pesquisa Bacteriol, Belo Horizonte, MG, Brazil. Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD AUG PY 2006 VL 11 IS 4 BP 336 EP 336 PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 063GC UT WOS:000239005100058 ER PT J AU Kudo, T Lu, H Ohno, T Graham, DY Genta, RM Yamaoka, Y AF Kudo, T. Lu, H. Ohno, T. Graham, D. Y. Genta, R. M. Yamaoka, Y. TI Pattern of transcription factor activation in Helicobacter pylori-infected Mongolian gerbils SO HELICOBACTER LA English DT Meeting Abstract CT 19th International Workshop on Helicobacter and Related Bacteric in Chronic Digestive Inflammation CY SEP 07-09, 2006 CL Wroclaw, POLAND C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX USA. Univ Geneva, Dept Pathol, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD AUG PY 2006 VL 11 IS 4 BP 347 EP 347 PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 063GC UT WOS:000239005100090 ER PT J AU Vilaichone, R Mahachai, V Yamaoka, Y Graham, D AF Vilaichone, R. Mahachai, V. Yamaoka, Y. Graham, D. TI Evaluation of rapid antibody tests for the diagnosis of Helicobacter pylori infection in Thailand, Japan, and United States SO HELICOBACTER LA English DT Meeting Abstract CT 19th International Workshop on Helicobacter and Related Bacteric in Chronic Digestive Inflammation CY SEP 07-09, 2006 CL Wroclaw, POLAND C1 Thammasat Univ Hosp, Bangkok, Thailand. Chulalongkorn Univ Hosp, Bangkok, Thailand. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD AUG PY 2006 VL 11 IS 4 BP 383 EP 383 PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 063GC UT WOS:000239005100192 ER PT J AU Horowitz, RE AF Horowitz, Richard E. TI Expectations and essentials for the community practice of pathology SO HUMAN PATHOLOGY LA English DT Article; Proceedings Paper CT Annual Meeting of the Association-of-Pathology-Chairs CY JUL 28, 2005 CL Mt Tremblant, CANADA SP Assoc Pathol Chairs DE pathology residency training; pathology private practice; community hospital pathology AB In 3 surveys during the past 10 years, community hospital pathologists were asked what they want, need, or look for when employing a pathologist and, more specifically, what skills and knowledge a newly minted pathologist should have to be successful in the community practice of pathology. The most recent survey, done in spring of 2005, cited surgical pathology diagnosis, frozen section diagnosis, dissection, and fine-needle aspiration as essentials in anatomic pathology. For clinical gross, cytology, pathology, knowledge of clinical medicine and test strategies that use the laboratory for clinical problem solving was paramount. New expectations in the latest survey were knowledge of molecular pathology and experience in quality assurance procedures. New pathologists generally meet the expectations of the community hospital workplace; however, there were some deficiencies: they were not proficient in gross pathology or autopsy pathology, they were slow, and many lack the clinical knowledge and experience to be effective consultants. The principal attribute that determines success in the practice of pathology, however, is skill in communication and interpersonal relations, and this remains the major deficiency of the fledgling pathologist. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA. Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Horowitz, RE (reprint author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA. EM r.e.horowitz@ucla.edu NR 3 TC 21 Z9 21 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0046-8177 J9 HUM PATHOL JI Hum. Pathol. PD AUG PY 2006 VL 37 IS 8 BP 969 EP 973 DI 10.1016/j.humpath.2006.01.035 PG 5 WC Pathology SC Pathology GA 072SW UT WOS:000239694300007 PM 16867856 ER PT J AU Smith, NJ Luttrell, LM AF Smith, Nicola J. Luttrell, Louis M. TI Signal switching, crosstalk, and arrestin scaffolds - Novel G protein-coupled receptor signaling in cardiovascular disease SO HYPERTENSION LA English DT Review ID EPIDERMAL-GROWTH-FACTOR; CHRONIC HEART-FAILURE; II TYPE-1 RECEPTOR; PROMOTES CARDIOMYOCYTE HYPERTROPHY; PRESSURE-OVERLOAD HYPERTROPHY; A-MEDIATED PHOSPHORYLATION; Q-OVEREXPRESSING MICE; ANGIOTENSIN-II; BETA-ARRESTIN; EGF RECEPTOR C1 Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Baker Heart Res Inst, Mol Endocrinol Lab, Melbourne, Vic, Australia. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA. EM luttrell@musc.edu RI Smith, Nicola/D-2541-2010 OI Smith, Nicola/0000-0002-7247-9562 FU NIDDK NIH HHS [DK58283, DK55524, DK64353] NR 75 TC 35 Z9 36 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD AUG PY 2006 VL 48 IS 2 BP 173 EP 179 DI 10.1161/01.HYP.0000232641.84521.92 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 069DZ UT WOS:000239427900001 PM 16818801 ER PT J AU Moore, WH Holschneider, DP Givrad, TK Maarek, JMI AF Moore, William H. Holschneider, Daniel P. Givrad, Tina K. Maarek, Jean-Michel I. TI Transcutaneous RF-powered implantable minipump driven by a class-E transmitter SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE infusion pump; implantable device; radio-frequency field; transcutaneous coupling; wireless energy transfer ID NONTETHERED RATS; COUPLED COILS AB We describe the design and testing of an inductive coupling system used to power an implantable minipump for applications in ambulating rats. A 2 MHz class-E oscillator driver powered a coil transmitter wound around a 33-cm-diameter rat cage. A receiver coil, a filtered rectifier, and a voltage-sensitive switch powered the implant. The implant DC current at the center of the primary coil (5.1 V) exceeded the level required to activate the solenoid valve in the pump. The variations of the implant current in the volume of the primary coil reflected the variations of the estimated coupling coefficient between the two coils. The pump could be activated in-vivo, while accommodating the vertical and horizontal movements of the animal. Advantages of this design include a weight reduction for the implant, an operation independent from a finite power source, and a remote activation/deactivation. C1 Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA. Univ So Calif, Alfred E Mann Inst, Los Angeles, CA 90089 USA. Univ So Calif, Dept Psychiat, Los Angeles, CA 90089 USA. Univ So Calif, Dept Neurol, Los Angeles, CA 90089 USA. Univ So Calif, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA. Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA. Greater Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. RP Maarek, JMI (reprint author), Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA. EM Holschne@usc.edu; maarek@usc.edu FU NINDS NIH HHS [R01 NS050171, R01 NS050171-01A1, 1 R01 NS050171] NR 11 TC 18 Z9 18 U1 2 U2 7 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0018-9294 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD AUG PY 2006 VL 53 IS 8 BP 1705 EP 1708 DI 10.1109/TBME.2006.873698 PG 4 WC Engineering, Biomedical SC Engineering GA 066XH UT WOS:000239263400028 PM 16916107 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Causes underlying the birth-cohort phenomenon of peptic ulcer: analysis of mortality data 1911-2000, England and Wales SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE duodenal ulcer; gastric ulcer; Helicobacter pylori; mortality rates; time trends of peptic ulcer ID HELICOBACTER-PYLORI INFECTION; GASTRIC-ACID SECRETION; DUODENAL-ULCER; TIME TRENDS; NEW-YORK; DISEASE; AGE; EPIDEMIOLOGY; STOMACH; EUROPE AB Background Since humans have been infected with Helicobacter pylori for millennia, it has remained an enigma why the occurrence of gastric and duodenal ulcer rose suddenly during 19th century. The study aim is to present a mathematical model of H. pylori epidemiology that explains the peculiar long-term trends of ulcer disease. Methods Gastric and duodenal ulcer mortality data from England and Wales between 1911 and 2000 were used to validate a model based on two simple and straightforward assumptions about H. pylori infection. First, the infection rate fell in the general population between 1800 and 2000. Second, gastric ulcer was caused by H. pylori infection contracted between the ages 5 and 15 and duodenal ulcer was caused by H. pylori infection contracted after the age of 15. As the infection receded in the general population, the two fractions of subjects who became infected between the ages 5 and 15 or after the age of 15 increased among. consecutive birth cohorts. Results The analysis of the actual long-term mortality from gastric and duodenal ulcer indicates an underlying birth-cohort pattern. These birth-cohort patterns of gastric and duodenal ulcer could be simulated by the interaction of two opposing time trends, namely a declining infection rate and a rising fraction of individuals acquiring their infection at increasingly older ages. The superimposition of a declining and a rising trend resulted in a bell-shaped curve of ulcer occurrence affecting consecutive birth-cohorts born between 1830 and 1970. Similar to the real data, the modelled cohort pattern of gastric ulcer preceded that of duodenal ulcer by 20 years. Conclusion The birth-cohort phenomenon of ulcer disease can be explained by a receding H. pylori infection accompanied by a simultaneous shift in its age of acquisition. C1 Portland VA Med Ctr, Gastroenterol Sect, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Gastroenterol Sect, P3GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 60 TC 27 Z9 27 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD AUG PY 2006 VL 35 IS 4 BP 1090 EP 1097 DI 10.1093/ije/dyl093 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 090GR UT WOS:000240939300044 PM 16709617 ER PT J AU McCasland, LD Budiman-Mak, E Weaver, FM Adams, E Miskevics, S AF McCasland, Leslie D. Budiman-Mak, Elly Weaver, Frances M. Adams, Elaine Miskevics, Scott TI Shoulder pain in the traumatically injured spinal cord patient - Evaluation of risk factors and function SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article DE spinal cord injury; shoulder pain; disability; tetraplegia; paraplegia ID UPPER EXTREMITY PAIN; WHEELCHAIR USERS; IMPINGEMENT SYNDROME; DISABILITY INDEX; INDIVIDUALS; RELIABILITY; PARAPLEGIA; VALIDITY; WUSPI AB Background: Shoulder pain in individuals with traumatic spinal cord injury (TSCI) is common and frequently results in chronic debilitating pain recalcitrant to treatment. Objective: Our objectives were to identify the risk factors associated with shoulder pain in the TSCI population. Methods: A telephone survey and medical record review were conducted on a convenience sample of patients with TSCI. Data variables included: Shoulder Pain and Disability Index (SPADI), demographics, injury type, treatment histories for shoulder pain/ dysfunction, assistive device use, and radiographic imaging. Results: Respondents (n = 63) were male (96%) and tetraplegia (51%) with a mean age of 58.1 years. The majority of patients (70%) currently had shoulder pain, one third had previous injury to the shoulder, and 52% reported bilateral pain. Tetraplegics had higher prevalence (80%) of shoulder pain and higher total SPADI scores than paraplegics (P = 0.001). Previous shoulder trauma increased the likelihood of shoulder pain. Self-care posed their most difficult task. Use of a manual wheelchair (71%) and/or trapeze bar (51%) was common. However, no differences were found in wheelchair or trapeze bar use or average body mass index between groups with and without pain. Respondents with pain tended to use trapeze bars less. Of the respondents reporting shoulder pain, an estimated 57% received physical therapy and massage with most reporting some benefit; 53% had pharmaceutical treatment with variable effect. Conclusion: Shoulder pain is common in patients with TSCI. Tetraplegics fared worse than paraplegics. Pain may limit transfer because respondents with pain used trapeze bars less. Understanding and addressing the factors contributing to shoulder pain in this vulnerable population is sorely needed. C1 Loyola Univ, Med Ctr, Dept Rheumatol, Maywood, IL 60153 USA. Dept Vet Affairs, Hines VA Hosp, Hines, IL USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Midwest Ctr Hlth Serv & Policy Res, SCI QUERI, Hines, IL USA. RP Budiman-Mak, E (reprint author), Dept Vet Affairs, POB 5000 151-H, Hines, IL 60141 USA. EM elly.mak@va.gov NR 32 TC 23 Z9 24 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD AUG PY 2006 VL 12 IS 4 BP 179 EP 186 DI 10.1097/01.rhu.0000230532.54403.25 PG 8 WC Rheumatology SC Rheumatology GA 071OK UT WOS:000239611300005 PM 16891921 ER PT J AU Tsuang, DW Riekse, RG Purganan, KM David, AC Montine, TJ Schellenberg, GD Steinbart, EJ Petrie, EC Bird, TD Leverenz, JB AF Tsuang, Debby W. Riekse, Robert G. Purganan, Kristina M. David, Andrew C. Montine, Thomas J. Schellenberg, Gerard D. Steinbart, Ellen J. Petrie, Eric C. Bird, Thomas D. Leverenz, James B. TI Lewy body pathology in late-onset familial Alzheimer's disease: A clinicopathological case series SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Lewy body; alpha-synuclein; Alzheimer's disease; amygdala ID ALPHA-SYNUCLEIN; APOLIPOPROTEIN-E; PARKINSONS-DISEASE; BODIES; DEMENTIA; BRAINS; PROGRESSION; CONSORTIUM; ANTIBODIES; DIAGNOSIS AB Background: Lewy body pathology (LBP) is a common finding in Alzheimer's disease (AD), but the pathophysiology for this coexistent pathology remains unclear. Methods: We ascertained late-onset dementia (mean age > 60 years old) families with at least 3 autopsies. We then conducted systematic alpha-synuclein (SNCA) immunostaining to determine the frequency and distribution of LBP in families with late-onset AD. Results: All 32 subjects met NIA-Reagan neuropathological criteria for "high likelihood" of having AD. Hematoxylin and eosin staining detected LBP in the substantia nigra (SN) in 8 (25%) individuals. SNCA immunostaining detected LBP in 21 individuals (66%). While all subjects with SN LBP had co-existent amygdala LBP, many (9/21, 43%) of the cases with amygdala LBP did not have coexistent SN LBP (McNemar's chi-square test, p = 0.008). Each family had at least two cases with LBP, but no family had LBP in all autopsied cases. Conclusions: Presence of significant AD pathology in one family member was highly predictive of similar pathology in other family members. However, despite the use of more sensitive SNCA immunohistochemistry, the presence of LBP was variable within all 7 families. Consistent with previous studies in sporadic and familial AD, the amygdala appeared to be the most vulnerable region for LBP in AD. Additional clinical, neuropathologic, and genetic studies are necessary to determine the clinical and pathological significance of LBP in AD. C1 VA Puget Sound Hlth Care Syst, Mental Illness Res Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Educ Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Ctr Clin, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Geriatr Res Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Ctr, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med Gerontol Geroiatr Neurol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Pathol Neuropathol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Tsuang, DW (reprint author), VA Puget Sound Hlth Care Syst, Mental Illness Res Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM dwt1@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU NIA NIH HHS [U01 AG016976, U01-AG16976]; NINDS NIH HHS [R01 NS48595] NR 26 TC 14 Z9 14 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PD AUG PY 2006 VL 9 IS 3 BP 235 EP 242 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 091HC UT WOS:000241016700002 PM 16914833 ER PT J AU Liu, Z Lin, YE Stout, JE Hwang, CC Vidic, RD Yu, VL AF Liu, Z. Lin, Y. E. Stout, J. E. Hwang, C. C. Vidic, R. D. Yu, V. L. TI Effect of flow regimes on the presence of Legionella within the biofilm of a model plumbing system SO JOURNAL OF APPLIED MICROBIOLOGY LA English DT Article DE biofilm; Legionella; stagnation ID WATER DISTRIBUTION-SYSTEMS; SHEAR-STRESS; PNEUMOPHILA; CONTAMINATION AB Aims: Stagnation is widely believed to predispose water systems to colonization by Legionella. A model plumbing system was constructed to determine the effect of flow regimes on the presence of Legionella within microbial biofilms. Methods and Results: The plumbing model contained three parallel pipes where turbulent, laminar and stagnant flow regimes were established. Four sets of experiments were carried out with Reynolds number from 10 000 to 40 000 and from 355 to 2000 in turbulent and laminar pipes, respectively. Legionella counts recovered from biofilm and planktonic water samples of the three sampling pipes were compared with to determine the effect of flow regime on the presence of Legionella. Significantly higher colony counts of Legionella were recovered from the biofilm of the pipe with turbulent flow compared with the pipe with laminar flow. The lowest counts were in the pipe with stagnant flow. Conclusions: We were unable to demonstrate that stagnant conditions promoted Legionella colonization. Significance and Impact of the Study: Plumbing modifications to remove areas of stagnation including deadlegs are widely recommended, but these modifications are tedious and expensive to perform. Controlled studies in large buildings are needed to validate this unproved hypothesis. C1 Univ Pittsburgh, Dept Mech Engn, Pittsburgh, PA 15261 USA. Natl Kaohsiung Normal Univ, Grad Inst Environm Educ, Kaohsiung, Taiwan. VA Pittsburgh Healthcare Syst, Infect Dis Sect, Special Pathogens Lab, Pittsburgh, PA USA. Univ Pittsburgh, Dept Civil & Environm Engn, Pittsburgh, PA 15260 USA. RP Lin, YE (reprint author), 62 Shen Chong Rd, Kaohsiung, Taiwan. EM easonlin@nknucc.nknu.edu.tw OI Vidic, Radisav/0000-0001-7969-6845 NR 16 TC 22 Z9 25 U1 1 U2 11 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1364-5072 J9 J APPL MICROBIOL JI J. Appl. Microbiol. PD AUG PY 2006 VL 101 IS 2 BP 437 EP 442 DI 10.1111/j.1365-2672.2006.02970.x PG 6 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 063GL UT WOS:000239006200020 PM 16882152 ER PT J AU Aguilar, D Bozkurt, B Pritchett, AM Petersen, NJ Deswal, A AF Aguilar, David Bozkurt, Biykem Pritchett, Allison M. Petersen, Nancy J. Deswal, Anita TI Thiazolidinediones are not associated with increased risk of heart failure hospitalizations in ambulatory patients with diabetes mellitus and heart failure SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 10th Annual Scientific Meeting of the Heart-Failure-Society-of-America CY SEP 10-13, 2006 CL Seattle, WA SP Heart Failure Soc Amer C1 Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2006 VL 12 IS 6 SU 1 MA 299 BP S93 EP S93 DI 10.1016/j.cardfail.2006.06.316 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 079VC UT WOS:000240205000299 ER PT J AU Bart, BA Teerlink, JR Costanzo, MR Saltzberg, MT Sobotka, PA AF Bart, Bradley A. Teerlink, John R. Costanzo, Maria Rosa Saltzberg, Mitchell T. Sobotka, Paul A. TI Changes in serum creatinine during treatment of heart failure and volume overload with ultrafiltration or intravenous diuretics SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 10th Annual Scientific Meeting of the Heart-Failure-Society-of-America CY SEP 10-13, 2006 CL Seattle, WA SP Heart Failure Soc Amer C1 Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA. San Francisco Vet Affairs Med Ctr, Dept Med, San Francisco, CA USA. Midwest Heart Fdn, Naperville, IL USA. CHF Solut, Brooklyn Pk, MN USA. RI Teerlink, John/D-2986-2012 NR 0 TC 1 Z9 1 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2006 VL 12 IS 6 SU 1 MA 375 BP S114 EP S114 DI 10.1016/j.cardfail.2006.06.394 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 079VC UT WOS:000240205000375 ER PT J AU Shalaby, A ElSaeed, A Saba, S AF Shalaby, Alaa ElSaeed, Aiman Saba, Samir TI Intracardiac ultrasound utilization to facilitate coronary sinus cannulation in cardiac resynchronization device implantation SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 10th Annual Scientific Meeting of the Heart-Failure-Society-of-America CY SEP 10-13, 2006 CL Seattle, WA SP Heart Failure Soc Amer C1 VA Pittsburgh Hlth Care Syst, Div Cardiol, Pittsburgh, PA USA. Univ Pittsburgh, Div Cardiol, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2006 VL 12 IS 6 SU 1 MA 205 BP S64 EP S64 DI 10.1016/j.cardfail.2006.06.218 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 079VC UT WOS:000240205000205 ER PT J AU Van Kleek, EJ Schwartz, JM Rayhill, SC Rosen, HR Cotler, SJ AF Van Kleek, Erik J. Schwartz, Jonathan M. Rayhill, Stephen C. Rosen, Hugo R. Cotler, Scott J. TI Liver transplantation for hepatocellular carcinoma - A survey of practices SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE hepatocellular carcinoma; liver transplantation; survey of practices ID UNITED-STATES; CHEMOEMBOLIZATION; CIRRHOSIS; CANCER; RESECTION; BIOPSY AB Goal: To survey physician practices regarding liver transplantation for patients with hepatocellular carcinoma (HCC). Background: Many issues surrounding liver transplantation for HCC are controversial and physician practices have not been well characterized. Methods: Transplant physicians and surgeons were electronically surveyed regarding surveillance, diagnosis, selection criteria for deceased and living donor transplantation, and use of adjunctive therapy for HCC. Results: Eighty-nine of 174 (51%) physicians completed the survey (39 hepatologists, 41 transplant surgeons, and 9 others). Most respondents were from large US transplant centers. All reported screening for HCC during transplant evaluation, and 98% surveyed patients awaiting transplant. Sixty percent of respondents would biopsy lesions under selective conditions, whereas 32% never biopsy lesions, and 8% biopsy all lesions. Eighty two percent of respondents claimed to adhere to the Milan criteria (single lesion <= 5 cm or no more than 3 lesions each <= 3 cm without vascular invasion) for patient selection, however, 36% would transplant patients with tumors that invade a small portal branch. Forty one percent of respondents would consider living donor transplantation for patients with tumors exceeding the Milan criteria. Ninety-six percent of respondents treat HCC before transplantation, and 87% would transplant patients down-staged to meet the Milan criteria. Conclusions: There is consistency related to HCC surveillance and treatment in liver transplant candidates. Variations of responses regarding biopsy of lesions, patient selection for deceased donor and living donor transplantation highlight a need for evidence-based guidelines. C1 Oregon Hlth & Sci Univ, Dept Med, Div Gastroenterol & Hepatol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Surg, Div Liver & Pancreas Transplantat, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. Univ Illinois, Dept Med, Sect Hepatol MC 787, Chicago, IL 60612 USA. RP Schwartz, JM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Gastroenterol & Hepatol, PV 310,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM schwajon@ohsu.edu NR 17 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD AUG PY 2006 VL 40 IS 7 BP 643 EP 647 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 073YG UT WOS:000239778000017 PM 16917411 ER PT J AU Brawman-Mintzer, O Knapp, RG Nietert, PJ AF Brawman-Mintzer, Olga Knapp, Rebecca G. Nietert, Paul J. TI Sedative effects of low-dose risperidone in GAD patients and risk of drug interactions - Dr. Brawman-Mintzer and colleagues reply SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Letter C1 Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA. RP Brawman-Mintzer, O (reprint author), Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD AUG PY 2006 VL 67 IS 8 BP 1308 EP 1309 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 080MQ UT WOS:000240252400023 ER PT J AU Hornberger, J Torriani, FJ Dieterich, DT Brau, N Sulkowski, MS Torres, MR Green, J Patel, K AF Hornberger, John Torriani, Francesca J. Dieterich, Douglas T. Brau, Norbert Sulkowski, Mark S. Torres, Maribel Rodriguez Green, Jesse Patel, Kavita TI Cost-effectiveness of peginterferon alfa-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE HIV; economics; costs; cost-effectiveness; interferon; peginterferon alfa-2a; ribavirin ID ACTIVE ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; INTERFERON-ALPHA; MORTALITY; MORBIDITY; LIVER; POPULATION; CIRRHOSIS; SURVIVAL; DURATION AB Background: A multinational trial (APRICOT) showed that peginterferon alfa-2a (40 kDa) plus ribavirin is efficacious for treatment of HIV-HCV co-infection. The cost-effectiveness of treating these patients with peginterferon alfa-2a/ribavirin has yet to be explored from a US societal perspective. Objective: To predict the cost-effectiveness of peginterferon alfa-2a/ribavirin with interferon/ribavirin (IFN/RBV) or no treatment in HIV-HCV co-infected patients. Study design: A Markov model was constructed with liver progression estimates based on published literature. Sustained virological response and baseline characteristics of the reference case were based on APRICOT. Quality of life and costs in 2004 US dollars (US$) were based on literature estimates and discounted at 3%. Results: Peginterferon alfa-2a/ribavirin compared with IFN/RBV or no treatment is predicted to increase quality-adjusted life-years (QALYs) by 0.73 and 0.94 years, respectively, in HCV-genotype-1 patients. The incremental cost-effectiveness ratio of peginterferon alfa-2a/ribavirin compared with IFN/RBV and no treatment for all patients is respectively US$ 2082 and 5187/QALY gained. Conclusions: Anti-HCV treatment is predicted to decrease the risk of cirrhosis and increase quality-adjusted survival of HIV-HCV co-infected patients compared with IFN/RBV and no treatment. Peginterferon alfa-2a/ribavirin's cost per QALY gained relative to these options falls within the cost-effectiveness level of many health technologies commonly adopted in the US. (C) 2006 Elsevier B.V. All rights reserved. C1 SPHERE Inst Acumen LLC, Burlingame, CA 94010 USA. Dept Vet Affairs, Palo Alto, CA USA. Stanford Univ, Dept Med, Stanford, CA 94305 USA. Mt Sinai Sch Med, New York, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. Johns Hopkins Univ, Baltimore, MD USA. Fdn Invest Diego, Santurce, PR USA. Ponce Sch Med, Ponce, PR USA. Hoffmann La Roche Inc, Nutley, NJ 07110 USA. RP Hornberger, J (reprint author), SPHERE Inst Acumen LLC, 500 Airport Blvd,Suite 365, Burlingame, CA 94010 USA. EM jhornberger@sphereinstitute.org NR 45 TC 20 Z9 20 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD AUG PY 2006 VL 36 IS 4 BP 283 EP 291 DI 10.1016/j.jcv.2006.04.008 PG 9 WC Virology SC Virology GA 075BR UT WOS:000239857700007 PM 16765638 ER PT J AU Schnurr, PP Hayes, AF Lunney, CA McFall, M Uddo, M AF Schnurr, Paula P. Hayes, Andrew F. Lunney, Carole A. McFall, Miles Uddo, Madeline TI Longitudinal analysis of the relationship between symptoms and quality of life in veterans treated for posttraumatic stress disorder SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE posttraumatic stress disorder; quality of life; military veterans; group psychotherapy ID ANXIETY DISORDERS; GROUP-THERAPY; TRAUMA; PTSD; INJURY; TRIAL AB This study examined how change in posttraumatic stress disorder (PTSD) symptoms relates to change in quality of life. The sample consisted of 325 male Vietnam veterans with chronic PTSD who participated in a randomized trial of group psychotherapy. Latent growth modeling was used to test for synchronous effects of PTSD symptom change on psychosocial and physical health-related quality of life within the same time period and lagged effects of initial PTSD symptom change on later change in quality of life. PTSD symptoms were associated with reduced quality of life before treatment. There were synchronous effects of symptom change on change in quality of life but no significant lagged effects. Results indicate the importance of measuring quality of life in future investigations of PTSD treatment. C1 US Vet Affairs Med Ctr, Natl Ctr PostTraumat Stress Disorder, White River Jct, VT 05009 USA. Dartmouth Coll Sch Med, Dept Psychiat, Dartmouth, NS, Canada. Ohio State Univ, Sch Commun, Columbus, OH 43210 USA. Univ Washington, Sch Med, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. New Orleans VA Med Ctr, New Orleans, LA USA. RP Schnurr, PP (reprint author), US Vet Affairs Med Ctr, Natl Ctr PostTraumat Stress Disorder, 116D, White River Jct, VT 05009 USA. EM paula.schnurr@dartmouth.edu RI Hayes, Andrew/A-5936-2008; Lunney, Carole/A-1366-2010 OI Hayes, Andrew/0000-0002-8329-1696; Lunney, Carole/0000-0002-0077-1281 NR 31 TC 86 Z9 87 U1 0 U2 15 PU AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD AUG PY 2006 VL 74 IS 4 BP 707 EP 713 DI 10.1037/0022-006X.74.4.707 PG 7 WC Psychology, Clinical SC Psychology GA 071NM UT WOS:000239608900008 PM 16881778 ER PT J AU Kripalani, S Paasche-Orlow, MK Parker, RM Saha, S AF Kripalani, Sunil Paasche-Orlow, Michael K. Parker, Ruth M. Saha, Somnath TI Advancing the field of health literacy SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID ADHERENCE C1 Emory Univ, Sch Med, Div Gen Med, Atlanta, GA 30303 USA. Boston Univ, Sch Med, Boston, MA 02215 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Kripalani, S (reprint author), Emory Univ, Sch Med, Div Gen Med, 49 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA. EM skripal@emory.edu OI Paasche-Orlow, Michael/0000-0002-9276-7190 NR 6 TC 5 Z9 5 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2006 VL 21 IS 8 BP 804 EP 805 DI 10.1111/j.1525-1497.2006.00568.x PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 061QZ UT WOS:000238888800002 ER PT J AU Saha, S AF Saha, Somnath TI Improving literacy as a means to reducing health disparities SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID MORTALITY; INCOME; POLICIES C1 Oregon Hlth Sci Univ, Dept Med, Portland VA Med Ctr, Gen Internal Med Sect,Portland VAMC P3MED, Portland, OR 97239 USA. RP Saha, S (reprint author), Oregon Hlth Sci Univ, Dept Med, Portland VA Med Ctr, Gen Internal Med Sect,Portland VAMC P3MED, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sahas@ohsu.edu NR 18 TC 26 Z9 26 U1 0 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2006 VL 21 IS 8 BP 893 EP 895 DI 10.1111/j.1525-1497.2006.00546.x PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 061QZ UT WOS:000238888800020 PM 16881955 ER PT J AU Scalapino, KJ Tang, QZ Bluestone, JA Bonyhadi, ML Daikh, DI AF Scalapino, Kenneth J. Tang, Qizhi Bluestone, Jeffrey A. Bonyhadi, Mark L. Daikh, David I. TI Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo, expanded regulatory T cells SO JOURNAL OF IMMUNOLOGY LA English DT Article ID VERSUS-HOST-DISEASE; IN-VITRO; AUTOIMMUNE ENCEPHALOMYELITIS; CD25(+); TOLERANCE; INTERLEUKIN-2; ERYTHEMATOSUS; GLOMERULONEPHRITIS; DAMAGE AB An increasing number of studies indicate that a subset of CD4(+) T cells with regulatory capacity (regulatory T cells; T-regs) can function to control organ-specific autoimmune disease. To determine whether abnormalities of thymic-derived T,,g, play a role in systemic lupus erythematosus, we evaluated T-reg prevalence and function in (New Zealand Black X New Zealand White)F-1 (B/W) lupus-prone mice. To explore the potential of T-g to suppress disease, we evaluated the effect of adoptive transfer of purified, ex vivo expanded thymic-derived T-regs on the progression of renal disease. We found that although the prevalence of Tregs is reduced in regional lymph nodes and spleen of prediseased B/W mice compared with age-matched non-autoimmune mice, these cells increase in number in older diseased mice. In addition, the ability of these cells to proliferate in vitro was comparable to those purified from non-autoimmune control animals. Purified CD4(+)CD25(+)CD62L(high) B/W T-regs were expanded ex vivo 80-fold, resulting in cells with a stable suppressor phenotype. Adoptive transfer of these exogenously expanded cells reduced the rate at which mice developed renal disease; a second transfer after treated animals had developed proteinuria further slowed the progression of renal disease and significantly improved survival. These studies indicate that thymic-derived T-regs may have a significant role in the control of autoimmunity in lupus-prone B/W mice, and augmentation of these cells may constitute a novel therapeutic approach for systemic lupus erythematosus. C1 Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA 94121 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, Ctr Diabet, Dept Med, San Francisco, CA 94121 USA. Xcyte, Seattle, WA 98104 USA. RP Daikh, DI (reprint author), Univ Calif San Francisco, Dept Med, Div Rheumatol, Arthrit Immunol 111R,4150 Clement St, San Francisco, CA 94121 USA. EM daikh@itsa.ucsf.edu NR 29 TC 128 Z9 138 U1 3 U2 10 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD AUG 1 PY 2006 VL 177 IS 3 BP 1451 EP 1459 PG 9 WC Immunology SC Immunology GA 065DT UT WOS:000239140300017 PM 16849451 ER PT J AU Bachmann, MP Bartsch, H Gross, JK Maier, SM Gross, TF Workman, JL James, JA Farris, AD Jung, B Franke, C Conrad, K Schmitz, M Buttner, C Buyon, JP Semsei, M Harley, JB Rieber, EP AF Bachmann, Michael P. Bartsch, Holger Gross, Joanne K. Maier, Shannon M. Gross, Timothy F. Workman, Jennifer L. James, Judith A. Farris, A. Darise Jung, Bettina Franke, Claudia Conrad, Karsten Schmitz, Marc Buettner, Cordula Buyon, Jill P. Semsei, Mre Harley, John B. Rieber, E. Peter TI Autoimmunity as a result of escape from RNA surveillance SO JOURNAL OF IMMUNOLOGY LA English DT Article ID INTERNAL TRANSLATION INITIATION; TERMINATION FACTOR LA; AUTOANTIGEN LA/SS-B; MESSENGER-RNA; POLYMERASE-III; IN-VITRO; TRANSCRIPTION TERMINATION; POLIOVIRUS RNA; VIRUS-RNA; SS-B AB In previous studies, we detected a frame shift mutation in the gene encoding the autoantigen La of a patient with systemic lupus erythematosus. The mutant La mRNA contains a premature termination codon. mRNAs that prematurely terminate translation should be eliminated by RNA quality control mechanisms. As we find Abs specific for the mutant La form in similar to 30% of sera from anti-La-positive patients, we expected that mutant La mRNAs circumvent RNA control and the expression of mutant La protein could become harmful. Indeed, real-time PCR, immunostaining, and immunoblotting data of mice transgenic for the mutant La form show that mutant La mRNAs are not repressed in these animals and are translated to mutant La protein. In addition to the mutant La protein, we detected a minor portion of native human La in the mutant La-transgenic mice. Therefore, ribosomal frame shifting may allow the mutant La mRNA to escape from RNA control. Interestingly, expression of the mutant La mRNA results in a lupus-like disease in the experimental mice. Consequently, escape of mutant La mRNA from RNA control can have two effects: it 1) results in the expression of an immunogenic (neo)epitope, and 2) predisposes to autoimmunity. C1 Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Immunol, D-01307 Dresden, Germany. Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA. Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73104 USA. NYU, Sch Med, Hosp Joint Dis, New York, NY 10003 USA. Univ Debrecen, Dept Med 3, Med & Hlth Sci Ctr, Debrecen, Hungary. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK 73104 USA. RP Bachmann, MP (reprint author), Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Immunol, Fiedlerstr 42, D-01307 Dresden, Germany. EM michael.bachmann@mailbox.tu-dresden.de RI Bachmann, Michael/E-8850-2010 OI Bachmann, Michael/0000-0002-8029-5755 FU NCRR NIH HHS [IP20RR15577, P20 RR015577, P20 RR020143, RR020143]; NIAID NIH HHS [AI053747, AI054117, AI131584, AI24717, AI48097, AI51647, K02 AI051647, R01 AI024717, R01 AI031584, R01 AI048097, R21 AI053747, R37 AI024717, R41 AI054117]; NIAMS NIH HHS [P50 AR048940, AR049084, AR42460, AR48940, P01 AR049084, R01 AR042460]; NIDCR NIH HHS [DE015223, R01 DE015223]; NIGMS NIH HHS [GM63497, R01 GM063497] NR 39 TC 10 Z9 10 U1 0 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD AUG 1 PY 2006 VL 177 IS 3 BP 1698 EP 1707 PG 10 WC Immunology SC Immunology GA 065DT UT WOS:000239140300045 PM 16849479 ER PT J AU Underhill, HR Kerwin, WS Hatsukami, TS Yuan, C AF Underhill, Hunter R. Kerwin, William S. Hatsukami, Thomas S. Yuan, Chun TI Automated measurement of mean wall thickness in the common carotid artery by MRI: A comparison to intima-media thickness by B-mode ultrasound SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE carotid artery MRI; atherosclerosis; intima-media thickness; stastical shape modelling; B-mode ultrasound ID HIGH-RESOLUTION MRI; IN-VIVO; MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS; PLAQUE; TRIAL; REPRODUCIBILITY; HEMORRHAGE; ACCURACY; STROKE AB Purpose: To determine whether the mean wall thickness (MWT) of the common carotid artery (CCA) measured by MRI is comparable to B-mode ultrasound (US) measurement of the intima-media thickness (IMT), an established marker of cardiovascular risk. Materials and Methods: As part of the two-year ORION trial, 43 patients with 16-79% stenosis by duplex US underwent high-resolution MRI and B-mode US examinations of their carotid arteries. Twenty-eight carotid arteries were identified as having both sufficient proximal coverage and adequate image quality of the CCA on MRI and a corresponding US. A novel algorithm utilizing statistical shape modeling was developed to automatically detect and measure MWT to within subpixel accuracy. The interrater and interscan reproducibility of the MWT measurement was computed as the root-mean-square (RMS) difference. The MWT and IMT measurements were compared via the Pearson correlation coefficient. Results: The MWT and IMT had a high Pearson correlation coefficient (r = 0.93; P < 0.001). The RMS difference between readers and between scans was 0.01 mm and 0.04 mm,respectively. Our automated algorithm correctly identified the lumen in 28 cases (100%) and the outer-wall boundary in 26 cases (93%). Conclusion: Automated measurements of the MWT by MRI are reproducible and have a high correlation with the IMT by B-mode US. C1 Univ Washington, Dept Radiol, Vasc Imaging Lab, Seattle, WA 98109 USA. Univ Washington, Dept Surg, Seattle, WA 98109 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98109 USA. RP Underhill, HR (reprint author), Univ Washington, Dept Radiol, Vasc Imaging Lab, 815 Mercer St,Box 358050, Seattle, WA 98109 USA. EM hunterru@gmail.com FU NHLBI NIH HHS [T32 HL07828] NR 30 TC 36 Z9 36 U1 1 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD AUG PY 2006 VL 24 IS 2 BP 379 EP 387 DI 10.1002/jmri.20636 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 068YG UT WOS:000239410300017 PM 16786590 ER PT J AU Rodriguez, KL Young, AJ AF Rodriguez, K. L. Young, A. J. TI Perceptions of patients on the utility or futility of end-of-life treatment SO JOURNAL OF MEDICAL ETHICS LA English DT Article ID MEDICAL FUTILITY; ADVANCE DIRECTIVES; CARE; RESOURCE; DECIDES; TERM AB Background and objectives: Definitions of medical futility, offered by healthcare professionals, bioethicists and other experts, have been rigorously debated by many investigators, but the perceptions of patients of futility have been explored only by a few. Patients were allowed to discuss their concerns about end-of-life care, so that their ideas about treatment futility or utility could be extrapolated by us. Methods: In this cross-sectional study, in-depth, semistructured interviews were conducted with 30 elderly people who were receiving outpatient care in a large, urban Veterans Affairs medical centre in the US. Each of their healthcare providers was also interviewed. Participants were asked to consider four terms commonly used in advance directive forms (ie, life-sustaining treatment, terminal condition, state of permanent unconsciousness and decision-making capacity) and to discuss what these terms meant to them. Audiotapes of the open-ended interviews were transcribed and responses were coded and categorised by constant comparison, a commonly used qualitative method. Results: The following four factors were taken into account by the participants when discussing end-of-life interventions and outcomes: (1) expected quality of life; (2) emotional and financial costs of treatment; (3) likelihood of treatment success; and (4) expected effect on longevity. C onclusions: Although the terms "utility'' or "futility'' were not generally used by the participants, segments of speech indicating their perceptions of these terms were identified. Treatment was not always discussed in the same way by patients and providers, but seemed to reflect the same four concerns. Therefore, it may be fruitful for providers to focus on these concerns when discussing end-of-life treatment options with their patients. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Memphis, Dept Commun, Memphis, TN 38152 USA. RP Rodriguez, KL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151CU,Univ Dr C,Bldg 28,MB-1A129, Pittsburgh, PA 15240 USA. EM Rodriguez@med.va.gov NR 37 TC 20 Z9 21 U1 2 U2 6 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0306-6800 J9 J MED ETHICS JI J. Med. Ethics PD AUG 1 PY 2006 VL 32 IS 8 BP 444 EP 449 DI 10.1136/jme.2005.014118 PG 6 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA 068HK UT WOS:000239363800003 PM 16877622 ER PT J AU McCaslin, SE Rogers, CE Metzler, TJ Best, SR Weiss, DS Fagan, JA Liberman, A Marmar, CR AF McCaslin, Shannon E. Rogers, Cynthia E. Metzler, Thomas J. Best, Suzanne R. Weiss, Daniel S. Fagan, Jeffrey A. Liberman, Akiva Marmar, Charles R. TI The impact of personal threat on police officers' responses to critical incident stressors SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE police; personal threat; traumatic stress; peritraumatic dissociation; peritraumatic distress ID EMERGENCY SERVICES PERSONNEL; POSTTRAUMATIC-STRESS; PERITRAUMATIC DISSOCIATION; PSYCHOLOGICAL DISTRESS; EVENT SCALE; SYMPTOMS; DISORDER; EXPOSURE AB The relationship of type of critical incident (CI) stressor with peritraumatic responses and posttraumatic stress disorder symptoms was examined in police. Officers (N = 662) provided narratives of their most distressing CI experienced during police service and completed measures of related peritraumatic responses and posttraumatic stress disorder symptoms. Narratives were reliably rated (kappa = .80-1.0) on seven categories emerging from a series of factor analyses of a measure of critical incident stressors. Additional analysis revealed that the classification of primary narrative features required only five categories (personal life threat, duty-related violence, encountering physical or sexual assault victims, exposure to civilian death, other). When analyzed by further collapsing these five categories into high versus low personal threat, officers whose narratives contained high personal threat reported more peritraumatic dissociation, peritraumatic emotional distress, and current hyperarousal symptoms. Results suggest that greater personal threat during a CI may place an officer at greater risk for subsequent distress. C1 San Francisco VA Med Ctr, PTSD Res Program, Psychiat Serv 116P, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. No Calif Inst Res & Educ, San Francisco, CA USA. Washington Univ, St Louis, MO USA. Columbia Univ, New York, NY USA. Natl Inst Justice, Washington, DC USA. RP McCaslin, SE (reprint author), San Francisco VA Med Ctr, PTSD Res Program, Psychiat Serv 116P, 4150 Clement St, San Francisco, CA 94121 USA. EM shannon.mccaslin@ucsf.edu FU NIMH NIH HHS [MH56350-01A1] NR 33 TC 25 Z9 25 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD AUG PY 2006 VL 194 IS 8 BP 591 EP 597 DI 10.1097/01.nmd.0000230641.43013.68 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 076SH UT WOS:000239977500006 PM 16909067 ER PT J AU Polanczyk, MJ Hopke, C Vandenbark, AA Offner, H AF Polanczyk, Magdalena J. Hopke, Corwyn Vandenbark, Arthur A. Offner, Halina TI Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE estrogen; Treg; costimulation; dendritic cells; PD-1 ID DENDRITIC CELLS; MULTIPLE-SCLEROSIS; PROGRAMMED DEATH-1; B7 FAMILY; RECEPTOR; ANTIGEN; MICE; 17-BETA-ESTRADIOL; AUTOIMMUNITY; LYMPHOCYTES AB Estrogen (E2)-induced immunomodulation involves dual effects on antigen-presenting cells (APC) and CD4(+)CD25(+) regulatory T cells (Treg) but not a direct effect on effector T cells. In this report, we further investigated the effects of E2 on APC and Treg function. We found that E2 treatment in vivo strongly reduced recovery of APC from the peritoneal cavity and inhibited induction of the inflammatory cytokines interleukin (IL)-12 and interferon-gamma but enhanced secretion of IL-10. Moreover, E2-conditioned bone marrow-derived dendritic cells (BM-DC) could both enhance Treg activity and directly inhibit responder T cells in the absence of Treg cells. We examined whether this E2-induced inhibitory activity of BM-DC might involve costimulation through the recently described PD-1 pathway. Both E2 and pregnancy markedly enhanced PD-1 expression in several types of APC, including macrophages, B cells, and especially dendritic cells (DC). Similarly to E2-induced enhancement of FoxP-3 expression and experimental autoimmune encephalomyelitis protection, E2-induced enhancement of PD-1(+) cells was also mediated through estrogen receptor alpha (Esr1) in DC and macrophages but not in B cells. Based on antibody inhibition studies, PD-1 interaction with its ligands, PDL-1 and especially PDL-2, could mediate either positive or negative regulatory signaling in both mature and immature E2-conditioned DC, depending, respectively, on a relatively high (10:1) or low (1:1) ratio of T cells:BM-DC. These novel findings indicate that E2-induced immunomodulation is mediated in part through potentiation in BM-DC of the PD-1 costimulatory pathway. (c) 2006 Wiley-Liss, Inc. C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Agr Univ Warsaw, Fac Vet Med, Dept Food Hyg, Warsaw, Poland. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, R&D-31,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NINDS NIH HHS [NS23444, NS45445, NS49210] NR 35 TC 74 Z9 79 U1 2 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD AUG 1 PY 2006 VL 84 IS 2 BP 370 EP 378 DI 10.1002/jnr.20881 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 069NY UT WOS:000239456700014 PM 16676326 ER PT J AU Penrod, JD Deb, P Luhrs, C Dellenbaugh, C Zhu, CW Hochman, T Maciejewski, ML Granieri, E Morrison, RS AF Penrod, Joan D. Deb, Partha Luhrs, Carol Dellenbaugh, Cornelia Zhu, Carolyn W. Hochman, Tsivia Maciejewski, Matthew L. Granieri, Evelyn Morrison, R. Sean TI Cost and utilization outcomes of patients receiving hospital-based palliative care consultation SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; PROPENSITY SCORE METHODS; END; PERSPECTIVES; CAREGIVERS; MEDICINE; SUPPORT; MODELS; GROWTH; TRIAL AB Objective: To compare per them total direct, ancillary (laboratory and radiology) and pharmacy costs of palliative care (PC) compared to usual care (UC) patients during a terminal hospitalization; to examine the association between PC and ICU admission. Design: Retrospective, observational cost analysis using a VA (payer) perspective. Setting: Two urban VA medical centers. Measurements: Demographic and health characteristics of 314 veterans admitted during two years were obtained from VA administrative data. Hospital costs came from the VA cost accounting system. Analysis: Generalized linear models (GLM) were estimated for total direct, ancillary and pharmacy costs. Predictors included patient age, principal diagnosis, comorbidity, whether patient stay was medical or surgical, site and whether the patient was seen by the palliative care consultation team. A probit regression was used to analyze probability of ICU admission. Propensity score matching was used to improve balance in observed covariates. Results: PC patients were 42 percentage points (95% CI, -556% to -31%) less likely to be admitted to ICU. Total direct costs per day were $239 (95% CI, -387 to -122) lower and ancillary costs were $98 (95% CI, -133 to -57) lower than costs for UC patients. There was no difference in pharmacy costs. The results were similar using propensity score matching. Conclusion: PC was asssociated with significantly lower likelihood of ICU use and lower inpatient costs compared to UC. Our findings coupled with those indicating better patient and family outcomes with PC suggest both a cost and quality incentive for hospitals to develop PC programs. C1 CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, James J Peters VA Med Ctr, Program Res Serious Phys & Mental Illness, New York, NY 10029 USA. CUNY Hunter Coll, Dept Econ, New York, NY 10021 USA. VA NY Harbor Healthcare Syst, Brooklyn, NY USA. James J Peters VA Med Ctr, Program Res Serious Phys & Mental Ill, Bronx, NY USA. James J Peters VA Med Ctr, Bronx NY Harbor VA Geriatr Res Educ & Clin Ctr, Bronx, NY USA. Univ Washington, Dept Hlth Serv, Vet Affairs Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA 98195 USA. CUNY Mt Sinai Sch Med, Dept Geriatr, New York, NY 10029 USA. RP Penrod, JD (reprint author), CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, James J Peters VA Med Ctr, Program Res Serious Phys & Mental Illness, New York, NY 10029 USA. EM joan.penrod@mssm.edu FU NIA NIH HHS [K24 AG022345] NR 42 TC 120 Z9 120 U1 0 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD AUG PY 2006 VL 9 IS 4 BP 855 EP 860 DI 10.1089/jpm.2006.9.855 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 078AT UT WOS:000240074000010 PM 16910799 ER PT J AU Fromme, EK Bascom, PB Smith, MD Tolle, SW Hanson, L Hickam, DH Osborne, ML AF Fromme, Erik K. Bascom, Paul B. Smith, M. D. Tolle, Susan W. Hanson, Lissi Hickam, David H. Osborne, Molly L. TI Survival, mortality, and location of death for patients seen by a hospital-based palliative care team SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID PHYSICIAN-ASSISTED SUICIDE; LIFE-SUSTAINING TREATMENT; HOUSE CALLS; SERVICE; OREGON; CONSULTATION; READMISSIONS; QUALITY AB Background: Little is known about patient outcomes after discharge planning by inpatient palliative care teams. A major difficulty is that successful discharge planning often effectively limits or ends the team's relationship with the patient and family. The goal of this study was to gather a clearer picture of what happened to our palliative care consult patients after discharge. Methods: This was a longitudinal survey of all patients seen over a one year period by the inpatient palliative care team at Oregon Health & Science University (OHSU). Data were recorded by team members at the time of consultation and supplemented by data from administrative databases and death certificates. Results: The team provided consults to 292 unique patients: 60% were younger than age 65, 39% were female, and 16% were members of an ethnic or racial minority. Almost three quarters of patients carried a non-cancer diagnosis. Of the 292 patients, 37% died in hospital and 63% were discharged alive, either to home (54%), nursing facilities (20%), or inpatient hospice (26%). Of the 183 patients discharged alive, 38% died within 2 weeks, 32% died between 2 weeks and 6 months, 25% were alive at 6 months, and 4% were unknown. Of note, only 10% of patients seen by the consult service were readmitted to OSHU within 30 days, and only 5% of those discharged alive from OHSU ultimately died in an acute care hospital. Discussion: We characterized patient outcomes following inpatient palliative care consultation: where patients are discharged, how long they live, and where they die. Two thirds of patients were able to be discharged, even when death occurred within two weeks. The low rates of readmission and death in an acute care hospital support that the decision to discharge the patients was reasonable and the discharge plan was adequate. Hospital based palliative care teams can play an important and unique role in discharge planning-allowing even patients very near death to leave the hospital if they wish. C1 Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Dept Med, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Med, Div Gen Med & Geriatr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Fromme, EK (reprint author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Dept Med, 3181 SW Sam Jackson Pk Rd,L586, Portland, OR 97239 USA. EM frommee@ohsu.edu NR 35 TC 38 Z9 38 U1 1 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD AUG PY 2006 VL 9 IS 4 BP 903 EP 911 DI 10.1089/jpm.2006.9.903 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 078AT UT WOS:000240074000016 PM 16910805 ER PT J AU Cohen, LM Moss, AH Wetsbord, SD Germain, MJ AF Cohen, Lewis M. Moss, Alvin H. Wetsbord, Steven D. Germain, Michael J. TI Renal palliative care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Review ID QUALITY-OF-LIFE; HOSPITALIZED MEDICAL PATIENTS; SLEEP-APNEA SYNDROME; HEMODIALYSIS-PATIENTS; UREMIC PRURITUS; ERECTILE DYSFUNCTION; DIALYSIS PATIENTS; PERITONEAL-DIALYSIS; RISK-FACTORS; SUBTOTAL PARATHYROIDECTOMY AB Patients with chronic kidney disease have a shortened life expectancy and carry a high symptom burden. Clinicians need sophisticated expertise in pain and symptom management and skills in communication to meet the many needs of this population. This article reviews the literature and discusses prognosis, ethical and legal considerations, symptoms, treatment, and end-of-life issues. The field of nephrology is shifting from an exclusive focus on increasing survival to one that provides greater attention to quality of life. There is an opportunity to integrate many of the advances of palliative medicine into the comprehensive treatment of these patients. C1 Baystate Med Ctr, Renal Palliat Care Initiat, Springfield, MA 01199 USA. W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Nephrol Sect, Morgantown, WV 26506 USA. W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Ctr Hlth Eth & Law, Morgantown, WV 26506 USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Cohen, LM (reprint author), Baystate Med Ctr, Renal Palliat Care Initiat, 759 Chestnut St,S2669, Springfield, MA 01199 USA. EM lewis.cohen@bhs.org NR 125 TC 52 Z9 54 U1 1 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD AUG PY 2006 VL 9 IS 4 BP 977 EP 992 DI 10.1089/jpm.2006.9.977 PG 16 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 078AT UT WOS:000240074000024 PM 16910813 ER PT J AU Erdie-Lalena, CR Holm, VA Kelly, PC Frayo, RS Cummings, DE AF Erdie-Lalena, Christine R. Holm, Vanja A. Kelly, Patrick C. Frayo, R. Scott Cummings, David E. TI Ghrelin levels in young children with Prader-Willi syndrome SO JOURNAL OF PEDIATRICS LA English DT Article ID GROWTH-HORMONE DEFICIENCY; FASTING PLASMA GHRELIN; BODY-MASS INDEX; FOOD-INTAKE; CIRCULATING GHRELIN; UNIPARENTAL DISOMY; INSULIN-RESISTANCE; OBESE SUBJECTS; ACTIVE FORM; SECRETION AB Objective To explore the hypothesis that high ghrelin levels contribute to obesity in Prader-Willi syndrome (PWS), we assessed whether the increased levels observed in older persons with PWS exist in very young children, before the onset of hyperphagia. Study design We measured ghrelin levels in nine children with PWS (17-60 months of age) and eight healthy control subjects of equivalent body mass index (BMI), age, and sex. Results PWS and control groups had equivalent BMI (16.8 +/- 1.4 vs 16.1 +/- 0.9 kg/m(2), respectively; P = .24), age (37.8 +/- 15.4 vs 50.3 +/- 17.7 months; P = .14), and sex. PWS and control groups also had equivalent fasting levels of total ghrelin (787 242 vs 716 135 pg/mL, respectively; P = .24), bioactive ghrelin (102 +/- 35 vs 91 +/- 23 pg/mL; P = .45), insulin, and glucose. Ghrelin correlated negatively with BMI among controls (r = -0.760, P = .029) but not PWS (r = 0.015, P = .97). Conclusions Children < 5 years of age with PWS, who had not yet developed hyperphagia or excessive obesity, had normal ghrelin levels, in contrast with the hyperghrelinemia of older, hyperphagic people with PWS. It is possible that ghrelin levels increase suddenly before hyperphagia develops. C1 Univ Washington, VA Puget Sound Hlth Care Syst, SIII Endo, Dept Med,Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Madigan Army Med Ctr, Dept Pediat, Div Dev & Behav Pediat, Ft Lewis, WA USA. Univ Washington, Sch Med, Ctr Human Dev & Disabil, Dept Pediat, Seattle, WA 98195 USA. RP Cummings, DE (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, SIII Endo, Dept Med,Div Metab Endocrinol & Nutr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM davidec@u.washington.edu FU NIDDK NIH HHS [P01 DK68384, R01 DK61516] NR 54 TC 29 Z9 33 U1 2 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD AUG PY 2006 VL 149 IS 2 BP 199 EP 204 DI 10.1016/j.jpeds.2006.04.011 PG 6 WC Pediatrics SC Pediatrics GA 073JG UT WOS:000239738300013 PM 16887433 ER PT J AU Brody, AL AF Brody, AL TI Functional brain imaging of tobacco use and dependence SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Review DE tobacco dependence; functional magnetic resonance imaging; positron emission tomography; autoradiography; prefrontal cortex; review ID NICOTINIC ACETYLCHOLINE-RECEPTORS; CEREBRAL-BLOOD-FLOW; VENTRAL TEGMENTAL AREA; INDUCED DOPAMINE RELEASE; MONOAMINE-OXIDASE-B; ANTERIOR CINGULATE CORTEX; RAT NUCLEUS-ACCUMBENS; FREELY-MOVING RATS; CIGARETTE-SMOKING; CHOLINERGIC-RECEPTORS AB While most cigarette smokers endorse a desire to quit smoking, only about 14% to 49% will achieve abstinence after 6 months or more of treatment. A greater understanding of the effects of smoking on brain function may (in conjunction with other lines of research) result in improved pharmacological (and behavioral) interventions. Many research groups have examined the effects of acute and chronic nicotine/cigarette exposure on brain activity using functional imaging; the purpose of this paper is to synthesize findings from such studies and present a coherent model of brain function in smokers. Responses to acute administration of nicotine/smoking include: a reduction in global brain activity; activation of the prefrontal cortex, thalamus, and visual system; activation of the thalamus and visual cortex during visual cognitive tasks; and increased dopamine (DA) concentration in the ventral striatum/nucleus accumbens. Responses to chronic nicotine/cigarette exposure include decreased monoamine oxidase (MAO) A and B activity in the basal ganglia and a reduction in alpha(4)beta(2) nicotinic acetylcholine receptor (nAChR) availability in the thalamus and putamen. Taken together, these findings indicate that smoking enhances neurotransmission through cortico-basal ganglia-thalamic circuits either by direct stimulation of nAChRs, indirect stimulation via DA release or MAO inhibition, or a combination of these factors. Activation of this circuitry may be responsible for the effects of smoking seen in tobacco dependent subjects, such as improvements in attentional performance, mood, anxiety, and irritability. (c) 2005 Elsevier Ltd. All rights reserved. C1 Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Greater Los Angeles VA Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst, Res Dept, Los Angeles, CA USA. RP Brody, AL (reprint author), Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM abrody@ucla.edu FU NIDA NIH HHS [R01 DA015059-04, R01 DA015059, R01 DA020872, R01 DA020872-01, R01 DA15059] NR 172 TC 101 Z9 104 U1 2 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIAT RES JI J. Psychiatr. Res. PD AUG PY 2006 VL 40 IS 5 BP 404 EP 418 DI 10.1016/j.jpsychires.2005.04.012 PG 15 WC Psychiatry SC Psychiatry GA 059ZB UT WOS:000238769600004 PM 15979645 ER PT J AU Mahlberg, MJ McGinnis, KS Draft, KS Fakharzadeh, SS AF Mahlberg, Matthew J. McGinnis, Karen S. Draft, Karla S. Fakharzadeh, Steven S. TI Multiple eccrine poromas in the setting of total body irradiation and immunosuppression SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article ID SKIN-CANCER; P53 PROTEIN; POROCARCINOMA; EXPRESSION; TUMORS; CHILD AB Eccrine poromas are benign, adnexal tumors that most often occur as a solitary lesion on the palm or sole. The occurrence of multiple eccrine poromas is extremely rare. In this report, we describe the development of several eccrine poromas in an acral distribution in a 42-year-old man. Before the appearance of these tumors, the patient had received total body irradiation and allogeneic bone marrow transplantation for treatment of acute lymphocytic leukemia. As a complication of the bone marrow transplant, the patient developed chronic graft-versus-host disease, which was treated with immunosuppressive therapy. We discuss this patient and review the available literature regarding multiple eccrine poromas. C1 Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. NYU, Sch Med, New York, NY USA. Vet Affairs Med Ctr, Philadelphia, PA USA. RP Fakharzadeh, SS (reprint author), 415 Curie Blvd,Room 235 B,Clin Res Bldg, Philadelphia, PA 19104 USA. EM ssf@mail.med.upenn.edu NR 21 TC 13 Z9 15 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD AUG PY 2006 VL 55 IS 2 SU S BP S46 EP S49 DI 10.1016/j.jaad.2006.02.052 PG 4 WC Dermatology SC Dermatology GA 069RA UT WOS:000239464700011 PM 16843124 ER PT J AU Foster, NM McGory, ML Zingmond, DS Ko, CY AF Foster, Nova M. McGory, Marcia L. Zingmond, David S. Ko, Clifford Y. TI Small bowel obstruction: A population-based appraisal SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article; Proceedings Paper CT 91st Annual Clinical Congress of the American-College-of-Surgeons CY OCT 16-20, 2005 CL San Francisco, CA SP Amer Coll Surg ID NATURAL-HISTORY; MANAGEMENT; OPERATION; DEATH AB BACKGROUND: Small bowel obstruction (SBO) is a common reason for surgical consultation, but little is known about the natural history of SBO. We performed a population-based analysis to evaluate SBO frequency, type of operation, and longterm outcomes. STUDY DESIGN: Using the California Inpatient File, we identified all patients admitted in 1997 with a diagnosis of SBO. Patients were excluded if they had a diagnosis of bowel obstruction in the previous 6 years (1991 to 1996). Of the remaining cohort, the natural history of SBO over the subsequent 5 years (1998 to 2002) was analyzed. Index hospitalization outcomes (eg, surgical versus nonsurgical management, length of stay, in-hospital mortality), and longterm outcomes, including SBO readmissions and 1-year mortality, were evaluated. RESULTS: We identified 32,583 patients with an index admission for SBO in 1997; 24% had surgery during the index admission. The distribution of surgical procedures was: 38% lysis of adhesions, 38% hernia repair, 18% small bowel resection with lysis of adhesions, and 6% small bowel resection with hernia repair. Patients who underwent operations during index admission had longer lengths of stay, lower mortality, fewer SBO readmissions, and longer time to readmission than patients treated nonsurgically. Regardless of treatment during the index admission, 81% of surviving patients had no additional SBO readmissions over the subsequent 5 years. CONCLUSIONS: Most of the 32,583 patients requiring admission for index SBO in 1997 were treated nonsurgically, and few of these patients were readmitted. This is the first longitudinal population-based analysis of SBO evaluating surgical versus nonsurgical management and outcomes, including mortality and readmissions. C1 Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Ctr Surg Outcomes & Qual, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP McGory, ML (reprint author), Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Ctr Surg Outcomes & Qual, 10833 Le Conte Ave,72-215 Ctr Hlth Sci,Box 956904, Los Angeles, CA 90095 USA. NR 12 TC 71 Z9 74 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD AUG PY 2006 VL 203 IS 2 BP 170 EP 176 DI 10.1016/j.jamcollsurg.2006.04.020 PG 7 WC Surgery SC Surgery GA 071ZP UT WOS:000239642700004 PM 16864029 ER PT J AU Johansen, KL Painter, PL Sakkas, GK Gordon, P Doyle, J Shubert, T AF Johansen, Kirsten L. Painter, Patricia L. Sakkas, Giorgos K. Gordon, Patricia Doyle, Julie Shubert, Tiffany TI Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID STAGE RENAL-DISEASE; MORTALITY; DIALYSIS; CAPACITY; STRENGTH; ANEMIA; HEALTH AB Patients who are on hemodialysis commonly experience muscle wasting and weakness, which have a negative effect on physical functioning and quality of life. The objective of this study was to determine whether anabolic steroid administration and resistance exercise training induce anabolic effects among patients who receive maintenance hemodialysis. A randomized 2 X 2 factorial trial of anabolic steroid administration and resistance exercise training was conducted in 79 patients who were receiving maintenance hemodialysis at University of California, San Francisco-affiliated dialysis units. Interventions included double-blinded weekly nandrolone decanoate (100 mg for women; 200 mg for men) or placebo injections and lower extremity resistance exercise training for 12 wk during hemodialysis sessions three times per week using ankle weights. Primary outcomes included change in lean body mass (LBM) measured by dual-energy x-ray absorptiometry, quadriceps muscle cross-sectional area measured by magnetic resonance imaging, and knee extensor muscle strength. Secondary outcomes included changes in physical performance, self-reported physical functioning, and physical activity. Sixty-eight patients completed the study. Patients who received nandrolone decanoate increased their LBM by 3.1 +/- 2.2 kg (P < 0.0001). Exercise did not result in a significant increase in LBM. Quadriceps muscle cross-sectional area increased in patients who were assigned to exercise (P = 0.01) and to nandrolone (P < 0.0001) in an additive manner. Patients who exercised increased their strength in a training-specific fashion, and exercise was associated with an improvement in self-reported physical functioning (P = 0.04 compared with nonexercising groups). Nandrolone decanoate and resistance exercise produced anabolic effects among patients who were on hemodialysis. Further studies are needed to determine whether these interventions improve survival. C1 San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94143 USA. Univ Thessaly, Dept Med, Thessaly, Greece. No Calif Inst Res & Educ, San Francisco, CA USA. Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu FU NIDDK NIH HHS [DK-56182] NR 25 TC 166 Z9 174 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD AUG PY 2006 VL 17 IS 8 BP 2307 EP 2314 DI 10.1681/ASN.2006010034 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 069LV UT WOS:000239449000033 PM 16825332 ER PT J AU Simpson, T Jakupcak, M Luterek, JA AF Simpson, Tracy Jakupcak, Matthew Luterek, Jane A. TI Fear and avoidance of internal experiences among patients with substance use disorders and PTSD: The centrality of anxiety sensitivity SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; THOUGHT CONTROL QUESTIONNAIRE; PSYCHOMETRIC PROPERTIES; TRAIT ANXIETY; ALCOHOL-USE; HYPERVENTILATION; ALEXITHYMIA; TRAUMA; SCALE; EXPECTANCIES AB This study evaluated anxiety sensitivity, cognitive avoidance, and alexithymia and their relationship to posttraumatic stress disorder (PTSD) and alcohol use indices concurrently and prospectively in an outpatient substance abuse treatment sample that screened positive for PTSD (N=58). Anxiety sensitivity accounted for substantial variance in the PTSD clusters, reexperiencing. avoidance, and hyperarousal, both concurrently and prospectively. Cognitive avoidance accounted for additional variance with concurrent PTSD avoidance symptoms. Anxiety sensitivity and cognitive avoidance were largely not associated with alcohol use indices. Alexithymia was largely redundant with cognitive avoidance and was, therefore, not included in the regression analyses. Theoretical and treatment implications of these findings are discussed in the context of individuals with dually diagnosed PTSD and substance abuse disorders. C1 VA Puget Sound Hlth Care Syst, Seattle Div, Dept Vet Affairs, Off Acad Affiliat,VA MIRECC Fellowship Program Ad, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Simpson, T (reprint author), 1660 S Columbia Way 1160MHC, Seattle, WA 98108 USA. EM Tracy.Simpson@va.gov NR 58 TC 23 Z9 23 U1 1 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD AUG PY 2006 VL 19 IS 4 BP 481 EP 491 DI 10.1002/jts.20128 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 084FO UT WOS:000240518000006 PM 16929503 ER PT J AU Subramanya, AR Yang, CL McCormick, JA Ellison, DH AF Subramanya, A. R. Yang, C-L McCormick, J. A. Ellison, D. H. TI WNK kinases regulate sodium chloride and potassium transport by the aldosterone-sensitive distal nephron SO KIDNEY INTERNATIONAL LA English DT Review DE WNK; NCC; ROMK; ENaC; distal convoluted tubule ID ACTIVATES SGK1; MUTANT WNK4; HYPERTENSION; HYPERKALEMIA; ISOFORM; CHANNEL; PSEUDOHYPOALDOSTERONISM; COTRANSPORTERS; PERMEABILITY; REABSORPTION AB With-No-Lysine [K] (WNKs) are a recently discovered family of serine/threonine protein kinases that contain a uniquely structured catalytic domain. Mutations in the genes encoding two family members, WNK1 and WNK4, cause a chloride-dependent, thiazide-sensitive inherited syndrome of hypertension and hyperkalemia. Over the past 5 years, physiologic studies have demonstrated that these proteins regulate transcellular and paracellular epithelial ion flux. In this mini review, we discuss WNK1 and WNK4 gene products and their regulatory effects on sodium chloride and potassium handling in the aldosterone-sensitive distal nephron. Experimental observations regarding the effects of these proteins on transport processes mediated by the thiazide-sensitive Na-Cl co-transporter, the epithelial sodium channel, the renal outer medullary potassium channel, and the paracellular pathway integrate into a model that suggests an essential role for WNKs in coordinating renal Na-Cl reabsorption and K+ secretion. C1 Oregon Hlth Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Ellison, DH (reprint author), Oregon Hlth Sci Univ, Dept Med, Div Nephrol & Hypertens, PP262,33134 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM ellisond@ohsu.edu OI Ellison, David/0000-0003-2915-265X FU NIDDK NIH HHS [DK51496, F32-DK72895] NR 28 TC 47 Z9 48 U1 2 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD AUG PY 2006 VL 70 IS 4 BP 630 EP 634 DI 10.1038/sj.ki.5001634 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 077FW UT WOS:000240015100010 PM 16820787 ER PT J AU Conigliaro, J Justice, AC Gordon, AJ Bryant, K AF Conigliaro, Joseph Justice, Amy C. Gordon, Adam J. Bryant, Kendall CA VACS Alcohol Behavior Change Res G TI Role of alcohol in determining human immunodeficiency virus (HIV)-relevant outcomes - A conceptual model to guide the implementation of evidence-based interventions into practice SO MEDICAL CARE LA English DT Editorial Material ID HIV-INFECTION; SUBSTANCE USE; ANTIRETROVIRAL MEDICATIONS; REPORTED ADHERENCE; SEXUAL-BEHAVIOR; RISK BEHAVIOR; USE DISORDERS; CONSUMPTION; PREDICTORS; DRINKING C1 Univ Kentucky, Program Qual Safety & Patient Rights, Dept Med, Lexington, KY 40536 USA. Yale Univ, VA Connecticut Healthcare Syst, New Haven, CT USA. Univ Pittsburgh, Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NIAAA, Rockville, MD 20852 USA. RP Conigliaro, J (reprint author), Univ Kentucky, Program Qual Safety & Patient Rights, Dept Med, 800 Rose St,N118, Lexington, KY 40536 USA. EM jconigliaro@uky.edu FU NIAAA NIH HHS [U01-AA13566] NR 45 TC 32 Z9 33 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD AUG PY 2006 VL 44 IS 8 SU 2 BP S1 EP S6 DI 10.1097/01.mlr.0000223659.36369.cf PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 069IB UT WOS:000239438500001 PM 16849963 ER PT J AU Fultz, SL Skanderson, M Mole, LA Gandhi, N Bryant, K Crystal, S Justice, AC AF Fultz, Shawn L. Skanderson, Melissa Mole, Larry A. Gandhi, Neel Bryant, Kendall Crystal, Stephen Justice, Amy C. TI Development and verification of a "virtual" cohort using the national VA health information system SO MEDICAL CARE LA English DT Article DE cohort studies; databases; HIV; information systems; validation studies; veterans ID HUMAN-IMMUNODEFICIENCY-VIRUS; ADMINISTRATIVE DATA; MEDICAID CLAIMS; DRUG-USERS; VETERANS; AIDS; SCHIZOPHRENIA; MORTALITY; HOSPITALIZATION; BENEFICIARIES AB Background: The VA's integrated electronic medical record makes it possible to create a "virtual" cohort of veterans with and without HIV infection to monitor trends in utilization, toxicity, and outcomes. Objectives: We sought to develop a virtual cohort of HIV-infected veterans by adapting an existing algorithm, verifying this algorithm against independent clinical data, and finally identifying demographically-similar HIV-uninfected comparators. Research Design: Subjects were identified from VA administrative data in fiscal years 1998-2003 using a modified existing algorithm, then linked with Immunology Case Registry (ICR, the VA's HIV registry) and Pharmacy Benefits Management (centralized database of outpatient prescriptions) to verify accuracy of identification. The algorithm was modified to maximize positive predictive value (PPV) against ICR. Finally, 2 HIV-uninfected comparators were matched to each HIV-infected subject. Results: Using a single HIV code, 30,564 subjects were identified (positive predictive value 69%). Modification to require > 1 outpatient or I inpatient code improved the positive predictive value to 88%. The lack of confirmatory laboratory and pharmacy data for the majority of subjects with a single outpatient code also supported this change. Of subjects identified with the modified algorithm, 89% had confirmatory evidence. When the modified algorithm was applied to fiscal years 1997-2004, 33,420 HIV-infected subjects were identified. Two HIV-uninfected comparators were matched to each subject for an overall cohort sample of 100,260. Conclusions: In the HAART era, HIV-related codes are sufficient for identifying HIV-infected subjects from administrative data when patients with a single outpatient code are excluded. A large cohort of HIV-infected subjects and matched comparators can be identified from existing VA administrative datasets. C1 VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. Yale Univ, Sch Med, New Haven, CT USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Ctr Qual Management Publ Hlth, VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. Emory Univ, Sch Med, Atlanta, GA USA. NIAAA, NIH, Bethesda, MD USA. Rutgers State Univ, New Brunswick, NJ 08903 USA. RP Justice, AC (reprint author), VA Connecticut Healthcare Syst, Bldg 35A,Room 2-212 11 ACSLG,950 Campbell Ave, West Haven, CT 06516 USA. EM amy.justice2@va.gov FU NIA NIH HHS [K08 AG00826]; PHS HHS [U01-13566] NR 27 TC 102 Z9 103 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD AUG PY 2006 VL 44 IS 8 SU 2 BP S25 EP S30 DI 10.1097/01.mlr.0000223670.00890.74 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 069IB UT WOS:000239438500004 PM 16849965 ER PT J AU Gordon, AJ McGinnis, KA Conigliaro, J Rodriguez-Barradas, MC Rabeneck, L Justice, AC AF Gordon, Adam J. McGinnis, Kathleen A. Conigliaro, Joseph Rodriguez-Barradas, Maria C. Rabeneck, Linda Justice, Amy C. CA VACS 3 Project Team TI Associations between alcohol use and homelessness with healthcare utilization among human immunodeficiency virus-infected veterans SO MEDICAL CARE LA English DT Article DE homelessness; HIV; alcoholism and addictive behavior; utilization ID URBAN HOMELESS; UNITED-STATES; SERVICES UTILIZATION; PROTEASE INHIBITORS; SHELTER UTILIZATION; HOUSING STATUS; HIV-INFECTION; MENTAL-HEALTH; AGING COHORT; RISK-FACTORS AB Background: Alcohol use is a frequent root cause of homelessness, and both homelessness and alcohol use influence the quality and quantity of interactions with health care providers. Objective: The objectives of this study are to compare rates of homelessness and alcohol use in a cohort of human immunodeficiency virus (HIV)-infected persons and to evaluate the influence of homelessness and alcohol use on utilization of health services. Research Design and Measures: Data were obtained from the Veterans Aging Cohort 3-Site Study, a cohort study of 881 HIV-infected veterans at 3 VA hospitals. In a baseline survey, we assessed current and past history of homelessness and levels of alcohol consumption. Health care service utilization (ambulatory visits, emergency room visits, and hospital admissions) for the preceding 6 months was determined by self-report and VA administrative records. Logistic regression was used to assess whether homelessness and drinking variables were associated with health care visits in the past 6 months. Results: Among HIV-infected veterans with complete data (n = 839), 62 (7%) were currently homeless, and 212 (25.3%) had a past, but not current, history of homelessness. Among the currently homeless, 36% reported alcohol consumption, 34% were hazardous drinkers, 46% were binge drinkers, and 26% had a diagnosis of alcohol abuse. When adjusting for age, severity of HIV disease, and use of illicit drugs, hazardous drinking (adjusted odds ratio [AOR] 0.68, 95% confidence interval [CI] 0.49-0.93) and current homelessness (AOR 0.56, 95% CI 0.32-0.97) were associated with less than 2 outpatient clinic visits. HIV-infected veterans who were homeless in the past were more likely to be hospitalized in the prior 6 months than those never homeless (AOR 1.51, 95% CI 1.07-2.11). Conclusions: Although homeless HIV-infected veterans tend to use inpatient services more than nonhomeless HIV infected veterans, they were less likely to achieve optimum outpatient care. Alcohol use complicates the effect of homelessness on adherence to outpatient care and is associated with increased inpatient utilization among HIV-infected veterans. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. Univ Pittsburgh, Ctr Social & Urban Res, Pittsburgh, PA USA. Univ Kentucky, Albert B Chandler Med Ctr, Lexington, KY 40536 USA. Houston VA Med Ctr, Houston, TX USA. Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada. Yale Univ, VA Connecticut Healthcare Syst, New Haven, CT USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Bldg 28,Mailcode 151-C,Univ Dr C, Pittsburgh, PA 15240 USA. EM adam.gordon@va.gov FU NIA NIH HHS [K23 AG00826-03]; NIAAA NIH HHS [U01 AA13566-02] NR 39 TC 17 Z9 17 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD AUG PY 2006 VL 44 IS 8 SU 2 BP S37 EP S43 DI 10.1097/01.mlr.0000223705.00175.3d PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 069IB UT WOS:000239438500006 PM 16849967 ER PT J AU Justice, AC Dombrowski, E Conigliaro, J Fultz, SL Gibson, D Madenwald, T Goulet, J Simberkoff, M Butt, AA Rimland, D Rodriguez-Barradas, MC Gibert, CL Oursler, KAK Brown, S Leaf, DA Goetz, MB Bryant, K AF Justice, Amy C. Dombrowski, Elizabeth Conigliaro, Joseph Fultz, Shawn L. Gibson, Deborah Madenwald, Tamra Goulet, Joseph Simberkoff, Michael Butt, Adeel A. Rimland, David Rodriguez-Barradas, Maria C. Gibert, Cynthia L. Oursler, Kris Ann K. Brown, Sheldon Leaf, David A. Goetz, Matthew B. Bryant, Kendall TI Veterans Aging Cohort Study (VACS) - Overview and description SO MEDICAL CARE LA English DT Article DE HIV/AIDS; alcohol; aging veterans; data management/research design ID MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; PRIMARY-CARE; PSYCHOMETRIC PROPERTIES; ALCOHOL-CONSUMPTION; REPORTED ADHERENCE; CLINICAL-TRIALS; DISORDERS; AFFAIRS; RELIABILITY; VALIDATION AB Background: The Veterans Aging Cohort Study (VACS) is a study of human immunodeficiency virus (HIV) infected and uninfected patients seen in infectious disease and general medical clinics. VACS includes the earlier 3 and 5 site studies (VACS 3 and VACS 5) as well as the ongoing 8 site study. Objectives: We sought to provide background and context for analyses based upon VACS data, including study design and rationale as well as its basic protocol and the baseline characteristics of the enrolled sample. Research Design: We undertook a prospectively consented multisite observational study of veterans in care with and without HIV infection. Measures: Data were derived from patient and provider self report, telephone interviews, blood and DNA samples, focus groups, and full access to the national VA "paperless" electronic medical record system. Results: More than 7200 veterans have been enrolled in at least one of the studies. The 8 site study (VACS) has enrolled 2979 HIV-infected and 3019 HIV-uninfected age-race-site matched comparators and has achieved stratified enrollment targets for race/ethnicity and age and 99% of its total target enrollment as of October 30, 2005. Participants in VACS are similar to other veterans receiving care within the VA. VACS participants are older and more predominantly black than those reported by the Centers for Disease Control. Conclusions: VACS has assembled a rich, in-depth, and representative sample of veterans in care with and without HIV infection to conduct longitudinal analyses of questions concerning the association between alcohol use and related comorbid and AIDS-defining conditions. C1 VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. Yale Univ, Sch Med, Sect Gen Med, New Haven, CT USA. Yale Univ, Sch Med, Dept Internal Med, Program Aging, New Haven, CT 06510 USA. Univ Kentucky, Med Ctr, Lexington, KY USA. Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. NYU, Sch Med, New York, NY USA. VA New York Harbor Healthcare Syst, New York, NY USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Pittsburgh, PA USA. Emory Univ, Sch Med, Atlanta, GA USA. VA Med Ctr, Atlanta, GA USA. Baylor Coll Med, Houston, TX 77030 USA. Michael E DeBakey VAMC, Houston, TX USA. George Washington Univ, Med Ctr, Washington, DC 20037 USA. VA Med Ctr, Washington, DC USA. Univ Maryland, Sch Med, Baltimore, MD 21201 USA. Baltimore VA Med Ctr, Baltimore, MD USA. Bronx Vet Adm Med Ctr, New York, NY USA. Mt Sinai Sch Med, New York, NY USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NIAAA, HIV AIDS Res, Rockville, MD 20852 USA. RP Justice, AC (reprint author), VA Connecticut Healthcare Syst, Bldg 35A,Room 212,950 Campbell Ave 11-ACLSG, West Haven, CT 06516 USA. EM amy.justice2@va.gov FU NIA NIH HHS [K23 AG024896-01A2, K23 AG024896]; NIAAA NIH HHS [U01 AA 13566, U01 AA013566] NR 43 TC 123 Z9 123 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD AUG PY 2006 VL 44 IS 8 SU 2 BP S13 EP S24 DI 10.1097/01.mlr.0000223741.02074.66 PG 12 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 069IB UT WOS:000239438500003 PM 16849964 ER PT J AU Justice, AC Lasky, E McGinnis, KA Skanderson, M Conigliaro, J Fultz, SL Crothers, K Rabeneck, L Rodriguez-Barradas, M Weissman, SB Bryant, K AF Justice, Amy C. Lasky, Elaine McGinnis, Kathleen A. Skanderson, Melissa Conigliaro, Joseph Fultz, Shawn L. Crothers, Kristina Rabeneck, Linda Rodriguez-Barradas, Maria Weissman, Sharon B. Bryant, Kendall CA VACS 3 Project Team TI Medical disease and alcohol use among veterans with human immunodeficiency infection - A comparison of disease measurement strategies SO MEDICAL CARE LA English DT Article DE alcohol; HIV; comorbid disease; ICD-9 codes; chart review ID CANCER THERAPY; HIV-INFECTION; ADMINISTRATIVE DATA; USE DISORDERS; AGING COHORT; PRIMARY-CARE; EPIDEMIOLOGY; CONSUMPTION; OUTCOMES; TIME AB Background: Many people with human immunodeficiency (HIV) infection drink alcohol. We asked whether level of exposure to alcohol is associated with medical disease in a linear,or nonlinear manner, whether the association depends upon the proximity of alcohol use, and whether it varies by source used to measure disease (chart review vs. ICD-9 Diagnostic Codes). Methods: The Veterans Aging 3 Site Cohort Study (VACS 3) enrolled 881 veterans, 86% of all HIV-positive patients seen, at 3 VA sites from June 23, 1999, to July 28, 2000. To maximize the sensitivity for alcohol exposure, alcohol use was measured combining data from patient self-report, chart review, and ICD-9 codes. We assigned the greatest exposure level reported from any source. Alcohol use within the past 12 months was considered current. Data on comorbid and AIDS-defining medical diseases were collected via chart review and ICD-9 diagnostic codes. The association of alcohol use (level and timing) and disease was modeled only for diseases demonstrating >= 10% prevalence. Linearity was compared with nonlinearity of association using nested multivariate models and the likelihood ratio test. All multivariate models were adjusted for age, CD4 cell count, viral load, intravenous drug use, exercise, and smoking. Results: Of 881 subjects enrolled, 866 (98%) had sufficient data for multivariate analyses, and 876 (99%) had sufficient data for comparison of chart review with ICD-9 Diagnostic Codes. Of the 866, 42 (5%) were lifetime abstainers; 247 (29%) were past drinkers; and 577 (671/6) were current users. Among the 824 reporting past or current alcohol use, 341 (41%) drank in moderation, 192 (23%) drank hazardously, and 291 (35%) carried a diagnosis of abuse or dependence. ICD-9 codes showed limited sensitivity, but overall agreement with chart review was good for 15 of 20 diseases (kappa > 0.4). The following diseases demonstrated a >= 10% prevalence with both measures (hepatitis C, hypertension, diabetes, obstructive lung disease, candidiasis, and bacterial pneumonia). All of these were associated with alcohol use (P < 0.05). Hepatitis C, hypertension, obstructive lung disease, candidiasis, and bacterial pneumonia demonstrated linear associations with level of alcohol use (P < 0.03). Past alcohol use increased the risk of hepatitis C and diabetes after adjustment for level of exposure (P < 0.01). With the exception of candidiasis, the associations between level and timing of alcohol use were similar when measured by ICD-9 codes or by chart review. Conclusions: Past and current use of alcohol is common among those with HIV infection. Estimates of disease risk associated with alcohol use based upon ICD-9 Diagnostic Codes appear similar to those based upon chart review. After adjustment for level of alcohol exposure, past use is associated with similar (or higher) prevalence of disease as among current drinkers. Finally, level of alcohol use is linearly associated with medical disease. We find no evidence of a "safe" level of consumption among those with HIV infection. C1 VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. Yale Univ, Sch Med, Sect Gen Med, New Haven, CT USA. Univ Pittsburgh, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Kentucky, Med Ctr, Lexington, KY USA. Univ Toronto, Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada. Baylor Coll Med, Houston, TX 77030 USA. Michael E DeBakey VAMC, Houston, TX USA. Hosp St Raphael, Haelen Ctr, New Haven, CT USA. NIAAA, HIV AIDS Res, Bethesda, MD USA. RP Justice, AC (reprint author), VA Connecticut Healthcare Syst, Bldg 35A,Room 212,950 Campbell Ave 11-ACLSG, West Haven, CT 06516 USA. EM amy.justice2@va.gov NR 45 TC 92 Z9 95 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD AUG PY 2006 VL 44 IS 8 SU 2 BP S52 EP S60 DI 10.1097/01.mlr.0000228003.08925.8c PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 069IB UT WOS:000239438500008 PM 16849969 ER PT J AU Kraemer, KL McGinnis, KA Skanderson, M Cook, R Gordon, A Conigliaro, J Shen, YJ Fiellin, DA Justice, AC AF Kraemer, Kevin L. McGinnis, Kathleen A. Skanderson, Melissa Cook, Robert Gordon, Adam Conigliaro, Joseph Shen, Yujing Fiellin, David A. Justice, Amy C. TI Alcohol problems and health care services use in human immunodeficiency virus (HIV)-infected and HIV-uninfected veterans SO MEDICAL CARE LA English DT Article DE alcohol; drinking; HIV disease/AIDS; health services; utilization ID SUBSTANCE-ABUSE TREATMENT; AGING COHORT 3-SITE; UNITED-STATES; MEDICAL-CARE; PROBLEM DRINKING; EMERGENCY-ROOM; COST; INFECTION; ORGANIZATION; DISORDERS AB Background: Although alcohol problems are common in human immunodeficiency virus (HIV)-infected patients, their impact on health care services use in HIV-infected patients is not well understood. Objective: We sought to examine the association between alcohol problems and health care services use in HIV-infected and HIV-uninfected patients. Design, Setting, and Subjects: We undertook a prospective analysis of 16,048 HIV-infected veterans and 32,096 age-, race-, gender-, and region-matched HIV-uninfected controls identified through the national Veterans Affairs electronic administrative medical record database. We identified subjects with alcohol problems using ICD-9-CM codes for alcohol diagnoses and/or alcohol-related complications. Main Outcome Measures: We measured outpatient visits, emergency department visits, and inpatient hospitalizations over 12 months of follow-up. Results: In adjusted analyses, HIV-infected veterans with alcohol problems were significantly more likely than HIV-uninfected veterans without alcohol problems to have at least I outpatient visit and at least I inpatient hospitalization and, among those with any health services use, to have significantly greater rates for outpatient visits (Incidence rate ratio [IRR] 2.17; 95% confidence interval [CI] 2.06-2.28; P < 0.001), emergency department visits (IRR 1.46; 95% CI 1.35-1.58; P < 0.001), and inpatient hospitalizations (IRR 1.46; 95% CI 1.30-1.64; P < 0.001). The incidence rates for outpatient visits, mental health visits, emergency department visits, and inpatient hospitalizations were significantly higher in HIV-infected veterans with alcohol problems than in HIV-infected veterans without alcohol problems. We did not find a consistent interaction effect between alcohol problems and HIV status. Conclusion: Alcohol problems are associated with greater outpatient, emergency department, and inpatient healthcare utilization in HIV-infected and HIV-uninfected veterans. However alcohol does not appear to have a stronger effect on health services use in HIV-infected veterans compared with HIV-uninfected veterans. C1 Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Div Gen Internal Med, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Ctr Social & Urban Res, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Vet Aging Cohort Study Ctr, Pittsburgh, PA USA. Univ Kentucky, Med Ctr, Lexington, KY USA. Lexington VA Med Ctr, Lexington, KY USA. Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA. Yale Univ, Sch Med, Div Gen Internal Med, New Haven, CT USA. W Haven VA Healthcare Syst, Vet Aging Cohort Study Coordinating Ctr, West Haven, CT USA. RP Kraemer, KL (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Div Gen Internal Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM kraemerkl@upmc.edu FU NIAAA NIH HHS [U01 AA 13566] NR 31 TC 24 Z9 24 U1 6 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD AUG PY 2006 VL 44 IS 8 SU 2 BP S44 EP S51 DI 10.1097/01.mlr.0000223703.91275.78 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 069IB UT WOS:000239438500007 PM 16849968 ER PT J AU Wright, SM Levine, RB Beasley, B Haidet, P Gress, TW Caccamese, S Brady, D Marwaha, A Kern, DE AF Wright, Scott M. Levine, Rachel B. Beasley, Brent Haidet, Paul Gress, Todd W. Caccamese, Suzanne Brady, Donald Marwaha, Ajay Kern, David E. TI Personal growth and its correlates during residency training SO MEDICAL EDUCATION LA English DT Article DE multicentre study [publication type]; internship and residency, organisation & administration; education, medical, undergraduate, organisation & administration; staff development; United States; cross-sectional studies; questionnaires ID SELF-AWARENESS; MEDICAL RESIDENCY; PATIENT-CARE; PHYSICIANS; STRESS; INTERNSHIP; ERRORS AB OBJECTIVES To explore the characteristics of and factors associated with personal growth during residency training. METHODS In 2003, 359 house officers on 7 internal medicine residency training programmes in the USA were surveyed about their training experiences and issues related to their personal growth. Factor analysis and internal reliability testing were used to develop a 'personal growth scale'. Logistic regression models were then used to identify independent associations between individual variables and 'high' versus 'low' personal growth scores. RESULTS A total of 281 house officers (80%) responded. The personal growth scale had a Cronbach's alpha of 0.81. Factors that were independently associated with achieving high amounts of personal growth during residency training included: agreeing that reflection is important during residency training (odds ratio [OR] 2.9, 95% confidence interval [CI] 1.1-7.4); being male (OR 2.6, 95% CI 1.4-4.5); being non-white (OR 2.2, 95% CI 1.3-3.9); having a strong desire to develop personally and professionally (OR 2.2, 95% CI 1.1-4.1), and feeling highly supported by one's programme director (OR 2.1, 95% CI 1.2-3.9). Independent predictors of scoring below the median on the personal growth scale included feeling emotionally isolated at work (OR 0.4, 95% CI 0.2-0.7) and noting that negative or disappointing experiences had been powerful (OR 0.4, 95% CI 0.2-0.9). CONCLUSIONS Disparate amounts of personal growth occur among trainees during residency training. Residency programmes interested in promoting personal growth among their trainees may wish to focus on modifiable factors that are associated with personal growth, such as fostering supportive relationships and encouraging reflection. C1 Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Div Gen Internal Med, Baltimore, MD 21224 USA. Univ Missouri, Dept Med, Kansas City, MO 64110 USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Marshall Univ, Dept Med, Huntington, WV USA. Greater Baltimore Med Ctr, Baltimore, MD USA. Emory Univ, Dept Med, Atlanta, GA 30322 USA. York Hosp, York, PA USA. RP Wright, SM (reprint author), Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Div Gen Internal Med, 4940 Eastern Ave, Baltimore, MD 21224 USA. EM smwright@jhmi.edu NR 32 TC 19 Z9 19 U1 0 U2 7 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0308-0110 J9 MED EDUC JI Med. Educ. PD AUG PY 2006 VL 40 IS 8 BP 737 EP 745 DI 10.1111/j.1365-2929.2006.02499.x PG 9 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 067XI UT WOS:000239335500005 PM 16869918 ER PT J AU Clancy, CJ Nguyen, MH Alandoerffer, R Cheng, SJ Iczkowski, K Richardson, M Graybil, JR AF Clancy, Cornelius J. Nguyen, M. Hong Alandoerffer, Ruth Cheng, Shaoji Iczkowski, Kenneth Richardson, Malcolm Graybil, John R. TI Cryptococcus neoformans var. grubii isolates recovered from persons with AIDS demonstrate a wide range of virulence during murine meningoencephalitis that correlates with the expression of certain virulence factors SO MICROBIOLOGY-SGM LA English DT Article ID CAPSULE-ASSOCIATED GENE; PHOSPHOLIPASE-ACTIVITY; HUMAN MONOCYTES; IN-VITRO; STRAINS; MICE; POLYSACCHARIDE; SECRETION; INFECTION; MELANIN AB Cryptococcus neoformans is a common cause of meningoencephalitis among AIDS patients. Several C. neoformans virulence factors have been identified, but the relative importance of particular factors is unknown. This study examined the corrrelation of the virulence of 18 C. neoformans var. grubii isolates from AIDS patients with the expression of several well-described virulence factors. The LD50 at 15 days after intracranial inoculation of ICR mice was < 100 c.f.u. for 22% of isolates, 100-1000 for 28 %, 1000-10000 for 11 % and > 20 000 for 39 %. Higher cryptococcal concentrations in brains were noted for isolates with lower LD50 (P= 0(.)002). In survival studies, no immunocompetent BALB/c mice (nul-) infected with 3 x LD50 of three virulent isolates (LD50 = 62, 99, 1280) survived beyond 23 days, whereas 100 %, 90 % and 90 % of mice infected with 20 000 c.f.u. of three hypovinulent isolates (LD50 > 20 000) survived for 60 days (P < 0(.)0001). Even among BALB/c nude (nu/nu) mice, survival rates over 60 days were 100%, 70%and 50%, respectively, for the hypovirulent isolates. Growth rate at 37 degrees C and capsule size within brains correlated with LD50 by univariate (P=0(.)0001 and 0(.)028, respectively) and multivariate (P= 0(.)017 and 0(.)016, respectively) analyses. There was no correlation between LD50 and capsule size in vitro, phospholipase activity, melanin formation, proteinase activity and fluconazole MIC. In conclusion, AIDS patients are susceptible to infection by C. neoformans isolates of wide-ranging virulence, including isolates that are markedly hypovirulent. The virulence of a given isolate reflects a composite of factors rather than the contribution of a dominant factor. Growth at 37 degrees C and capsule size in vivo make particularly important contributions. C1 VA Med Ctr, Gainesville, FL USA. Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32611 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. Univ Florida, Coll Med, Dept Med, Div Infect Dis, Gainesville, FL 32611 USA. RP Clancy, CJ (reprint author), Univ Florida, Coll Med, Dept Med, Div Infect Dis, Gainesville, FL 32611 USA. EM clancyn@medicine.ufl.edu OI Richardson, Malcolm/0000-0001-5672-9552 NR 53 TC 21 Z9 21 U1 0 U2 1 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1350-0872 J9 MICROBIOL-SGM JI Microbiology-(UK) PD AUG PY 2006 VL 152 BP 2247 EP 2255 DI 10.1099/mic.0.28798-0 PN 8 PG 9 WC Microbiology SC Microbiology GA 074PF UT WOS:000239823600006 PM 16849791 ER PT J AU Imam, SZ Karahalil, B Hogue, BA Souza-Pinto, NC Bohr, VA AF Imam, SZ Karahalil, B Hogue, BA Souza-Pinto, NC Bohr, VA TI Mitochondrial and nuclear DNA-repair capacity of various brain regions in mouse is altered in an age-dependent manner SO NEUROBIOLOGY OF AGING LA English DT Article DE DNA repair; glycosylases; mitochondria; aging; neurodegeneration ID OXIDATIVE DAMAGE; ALZHEIMERS-DISEASE; AGING BRAIN; LYASE ACTIVITY; STRESS; GLYCOSYLASES; RESTRICTION; INCREASES; CHEMISTRY; DELETIONS AB Aging is associated with increased susceptibility to neuronal loss and disruption of cerebral function either as a component of senescence, or as a consequence of neurodegenerative disease or stroke. Here we report differential changes in the repair of oxidative DNA damage in various brain regions during aging. We evaluated mitochondrial and nuclear incision activities of oxoguanine DNA glycosylase (OGG1), uracil DNA glycosylase (UDG) and the endonuclease Ill homologue (NTH1) in the caudate nucleus (CN), frontal cortex (FC), hippocampus (Hip), cerebellum (CE) and brain stem (BS) of 6- and 18-month-old male C5781/6 mice. We observed a significant age-dependent decrease in incision activities of all three glycosylases in the mitochondria of all brain regions, whereas variable patterns of changes were seen in nuclei. No age- or region-specific changes were observed in the mitochondrial repair synthesis incorporation of uracil-initiated base-excision repair (BER). We did not observe any age or region dependent differences in levels of BER proteins among the five brain regions. In summary, our data suggest that a decreased efficiency of mitochondrial BER-glycosylases and increased oxidative damage to mitochondrial DNA might contribute to the normal aging process. These data provide a novel characterization of oxidative DNA damage processing in different brain regions implicated in various neurodegenerative disorders, and suggest that this process is regulated in an age-dependent manner. Manipulation of DNA repair mechanisms may provide a strategy to prevent neuronal loss during age-dependent neurodegenerative disorders. (c) 2005 Elsevier Inc. All rights reserved. C1 NIA, Gerontol Res Ctr, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA. Gazi Univ, Fac Pharm, Dept Toxicol, TR-06330 Ankara, Turkey. Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. RP Bohr, VA (reprint author), NIA, Gerontol Res Ctr, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA. EM vbohr@nih.gov RI Souza-Pinto, Nadja/C-3462-2013 OI Souza-Pinto, Nadja/0000-0003-4206-964X NR 34 TC 111 Z9 114 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD AUG PY 2006 VL 27 IS 8 BP 1129 EP 1136 DI 10.1016/j.neurobiolaging.2005.06.002 PG 8 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 057YV UT WOS:000238632000011 PM 16005114 ER PT J AU Mendez, MF McMurtray, A Licht, E Shapira, JS Saul, RE Miller, BL AF Mendez, Mario F. McMurtray, Aaron Licht, Eliot Shapira, Jill S. Saul, Ronald E. Miller, Bruce L. TI The scale for emotional blunting in patients with frontotemporal dementia SO NEUROCASE LA English DT Article ID ALZHEIMERS-DISEASE; PICKS-DISEASE; CLINICAL-FEATURES; TEMPORAL VARIANTS; PREFRONTAL CORTEX; WORK GROUP; CRITERIA; DEGENERATION; DIAGNOSIS; CONSENSUS AB Emotional blunting may underlie many of the behavioral features of frontotemporal dementia (FTD). The Scale for Emotional Blunting (SEB) was evaluated in 12 patients with early FTD, 12 patients with Alzheimer's disease (AD), and 12 normal controls. There were overall group differences on the SEB, and the FTD patients had greater emotional blunting than the AD patients. The SEB had good inter-rater reliability and a sensitivity of 92%, and a specificity of 83.5% for FTD. These findings suggest that the SEB may be a good instrument for the early detection and quantification of emotional blunting in patient with FTD. C1 Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, 691-116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu FU NIA NIH HHS [AG19724-01, P01 AG019724] NR 31 TC 10 Z9 12 U1 4 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1355-4794 J9 NEUROCASE JI Neurocase PD AUG PY 2006 VL 12 IS 4 BP 242 EP 246 DI 10.1080/13554790600910375 PG 5 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 087NS UT WOS:000240749700008 PM 17000595 ER PT J AU Kimmel, SE Chen, Z Price, M Parker, CS Metlay, JP Christie, JD Brensinger, CM Newcomb, CW Samaha, FF Gross, R AF Kimmel, Stephen E. Chen, Zhen Price, Maureen Parker, Catherine S. Metlay, Joshua P. Christie, Jason D. Brensinger, Colleen M. Newcomb, Craig W. Samaha, Frederick F. Gross, Robert TI The effects of adherence on anticoagulation control with warfarin SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2006 VL 15 SU 1 MA 111 BP S52 EP S53 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 080XG UT WOS:000240281200112 ER PT J AU Meropol, SB Glick, HA Asch, DA AF Meropol, Sharon B. Glick, Henry A. Asch, David A. TI Alternative strategies for diagnosis and treatment of pediatric acute otitis media SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2006 VL 15 SU 1 MA 643 BP S299 EP S299 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 080XG UT WOS:000240281200644 ER PT J AU Faber, JJ Anderson, DF Jonker, SS Davis, LE Giraud, GD AF Faber, J. J. Anderson, D. F. Jonker, S. S. Davis, L. E. Giraud, G. D. TI Fetal infusions of plasma cause an increase in umbilical vascular resistance in sheep SO PLACENTA LA English DT Article DE fetal arterial pressure; fetal placental flow; fetal placental resistance; plasma ID BLOOD-FLOW; RESPONSES; CIRCULATION; PRESSURE AB Earlier studies suggested that the fetal placental circulation is relatively inert with fetal placental flow increasing or decreasing with perfusion pressure. Subsequent studies have demonstrated that the placenta may not be an unreactive vascular bed. The present study was undertaken to determine if plasma infusion-induced hypertension increased fetal placental flow in proportion to the driving pressure across the fetal placental circulation. Six fetal sheep were operated on at 118-122 days to place intravascular catheters and a flow sensor on the common umbilical artery. Starting 6 days later, the fetuses were infused with adult sheep plasma. During the 7-day-long infusion period, they received a total of 1515 +/- 217 (SD) ml of fluid and 93.2 +/- 12.0 g of protein. Fetal plasma protein concentrations increased from 34.2 +/- 2.3 to 77.0 +/- 9.7 g/l (P < 0.0001). Fetal arterial blood pressures rose from 42 +/- 3 to 59 +/- 4 mmHg (P < 0.01) and venous pressures rose from 2.2 +/- 0.5 to 4.8 +/- 0.8 mmHg (P < 0.01). In spite of the large increase in driving pressure, fetal placental blood flow remained (statistically) constant (627 +/- 299 ml/min and 552 +/- 221 ml/min) while fetal umbilical resistance increased from 0.077 +/- 0.038 to 0.115 +/- 0.053 mmHg min/ml (P < 0.01). On day 7, plasma renin activity had fallen from 6.7 +/- 4.2 ng/(ml/h) at preinfusion control to 0.6 +/- 0.6 ng/(ml/h) (P < 0.05) and plasma anglotensin-II concentration had fallen from 33.2 +/- 26.6 to 6.2 +/- 3.9 pg/ml, although this fall was not statistically significant (P = 0.07). Fetal placental flow did not increase with increased driving pressure across the fetal placental circulation. The increase in fetal placental resistance may be a response to the increase in arterial pressure since there was no increase in flow. C1 Oregon Hlth Sci Univ, Sch Med, Dept Physiol & Pharmacol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Sch Med, Dept Obstet & Gynecol, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. RP Giraud, GD (reprint author), Oregon Hlth Sci Univ, Heart Res Ctr, Sch Med, L334, Portland, OR 97239 USA. EM giraudg@ohsu.edu OI Jonker, Sonnet/0000-0002-1097-2562 FU NICHD NIH HHS [5R01-HD37376, 5P01-HD34430] NR 13 TC 5 Z9 5 U1 0 U2 1 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0143-4004 J9 PLACENTA JI Placenta PD AUG PY 2006 VL 27 IS 8 BP 876 EP 881 DI 10.1016/j.placenta.2005.09.003 PG 6 WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology GA 062XU UT WOS:000238981000012 PM 16289267 ER PT J AU Haake, DA AF Haake, David A. TI Molecular epidemiology of leptospirosis in the Amazon SO PLOS MEDICINE LA English DT Editorial Material ID PATHOGENIC LEPTOSPIRA C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. RP Haake, DA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. EM dhaake@ucla.edu FU NIAID NIH HHS [R01 AI034431-09, R21 AI034431, AI-34431, R29 AI034431, R01 AI034431] NR 11 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD AUG PY 2006 VL 3 IS 8 BP 1214 EP 1215 AR e302 DI 10.1371/journal.pmed.0030302 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 079YG UT WOS:000240213200008 PM 16933961 ER PT J AU Goveas, JS Caroff, SN AF Goveas, Joseph S. Caroff, Stanley N. TI Post-ictal symptoms and neuroleptic malignant syndrome SO PSYCHIATRIC ANNALS LA English DT Article ID NONCONVULSIVE STATUS EPILEPTICUS; CATATONIA; EPILEPSY C1 Franciscan Skemp Healthcare Mayo Hlth Syst, Dept Psychiat, La Crosse, WI USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Inpatient Psychiat Serv, Philadelphia, PA USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD AUG PY 2006 VL 36 IS 8 BP 530 EP 534 PG 5 WC Psychiatry SC Psychiatry GA 072UN UT WOS:000239698600003 ER PT J AU Perlick, DA Rosenheck, RA Kaczynski, R Swartz, MS Canive, JM Lieberman, JA AF Perlick, Deborah A. Rosenheck, Robert A. Kaczynski, Richard Swartz, Marvin S. Canive, Jose M. Lieberman, Jeffrey A. TI Components and correlates of family burden in schizophrenia SO PSYCHIATRIC SERVICES LA English DT Article ID CLINICAL ANTIPSYCHOTIC TRIALS; EFFECTIVENESS CATIE PROJECT; SOCIAL SUPPORT; MENTAL-HEALTH; ALZHEIMERS-DISEASE; CAREGIVER BURDEN; SPOUSE CAREGIVERS; RATING-SCALE; STRESS; RELATIVES AB Objective: Components and correlates of caregiver burden in schizophrenia were studied. Methods: The family caregivers of 623 ( 43 percent) of 1,460 patients with schizophrenia enrolled in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) were interviewed about resources they provided and experiences with patient behavior over the previous month. Patients were independently evaluated on symptoms, quality of life, neurocognition, medication side effects, and service use. Factor analysis reduced the caregiver data into four orthogonal factors assessing perceptions of patient problem behavior, patient impairment in activities of daily living, patient helpfulness, and resource demands and disruptions in the caregiver's personal routine. Results: Hierarchical regression analyses demonstrated differential correlates of burden for each factor, explaining 34 percent of variance each for problem behavior and resource demands and disruption, 21 percent for impairment in activities of daily living, and 38 percent for patient helpfulness. Demographic characteristics and patient symptoms explained the greatest proportion of variance, whereas quality of life and service use explained modest variance and patient neurocognition and medication side effects were not significantly associated with burden. Conclusions: Results underscore the need for continued intervention with family members after the acute inpatient phase of treatment to address the impacts of symptoms as well as incorporation of skills training into consumer treatment programs to improve consumer contributions to household maintenance. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Bronx Vet Affairs Med Ctr, Bronx, NY USA. W Haven Vet Affairs Med Ctr, NE Program, Evaluat Ctr, West Haven, CT USA. Yale Univ, Dept Psychiat, Sch Med, New Haven, CT 06520 USA. Yale Univ, Dept Epidemiol, Sch Med, New Haven, CT 06520 USA. Yale Univ, Dept Publ Hlth, Sch Med, New Haven, CT 06520 USA. Duke Univ, Dept Psychiat & Behav Sci, Durham, NC 27706 USA. Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA. New Mexico VA Hlth Care Syst, Albuquerque, NM USA. Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10027 USA. RP Perlick, DA (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM deborah.perlick@mssm.edu FU NIMH NIH HHS [N01-MH-90001] NR 64 TC 53 Z9 57 U1 3 U2 10 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD AUG PY 2006 VL 57 IS 8 BP 1117 EP 1125 DI 10.1176/appi.ps.57.8.1117 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 067NF UT WOS:000239309200008 PM 16870962 ER PT J AU Glahn, DC Barrett, J Bearden, CE Mintz, J Green, MF Monkul, ES Najt, P Soares, JC Velligan, DI AF Glahn, David C. Barrett, Jennifer Bearden, Carrie E. Mintz, Jim Green, Michael F. Monkul, E. Serap Najt, Pablo Soares, Jair C. Velligan, Dawn I. TI Dissociable mechanisms for memory impairment in bipolar disorder and schizophrenia SO PSYCHOLOGICAL MEDICINE LA English DT Article ID DORSOLATERAL PREFRONTAL CORTEX; WORKING-MEMORY; NEUROCOGNITIVE FUNCTION; RATING-SCALE; I DISORDER; STRATEGIES; TASKS; ENDOPHENOTYPES; METAANALYSIS; INFORMATION AB Background. Although memory deficits are consistently reported in schizophrenia and bipolar disorder, the mechanisms underlying these impairments are poorly understood. Clarifying the nature and degree of overlap in memory deficits between the two illnesses could help to distinguish brain systems disrupted in these illnesses, and indicate cognitive remediation strategies to improve patient outcomes. Method. We examined performance on a non-verbal memory task in clinically stable out-patients with bipolar disorder (n = 40), schizophrenia (n = 40), and healthy comparison subjects (n = 40). This task includes conditions in which distinct mnemonic strategies-namely, using context to organize familiar stimuli or using holistic representation of novel stimuli - facilitate performance. Result. When compared to a reference condition, bipolar patients had deficits consistent with organizational dysfunction and poor detection of novel information. Although patients with schizophrenia performed worse than the other groups, they were only differentially impaired when organizational demands were significant. Task performance was not correlated with severity of clinical symptomatology. Conclusions. This pattern of distinct memory impairments implies disturbances in partially overlapping neural systems in bipolar disorder and schizophrenia. Evidence of impairment in detection of novel stimuli that is unique to bipolar disorder suggests that, while the absolute level of cognitive dysfunction is less severe in bipolar disorder as compared to schizophrenia, subtle disruptions in memory are present. These findings can be used to plan targeted cognitive remediation programs by helping patients to capitalize on intact functions and to learn new strategies that they do not employ without training. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Glahn, DC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, 7703 Floyd Curl Dr,Mail Code 7792, San Antonio, TX 78229 USA. EM glahn@uthscsa.edu RI Mintz, Jim/N-7385-2014 OI Mintz, Jim/0000-0002-8299-5851 FU NCRR NIH HHS [M01 RR 01346]; NIMH NIH HHS [MH 62850] NR 46 TC 21 Z9 21 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD AUG PY 2006 VL 36 IS 8 BP 1085 EP 1095 DI 10.1017/S0033291706007902 PG 11 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 074QO UT WOS:000239827100005 PM 16734948 ER PT J AU Inslicht, SS Marmar, CR Neylan, TC Metzler, TJ Hart, SL Otte, C McCaslin, SE Larkin, GL Hyman, KB Baum, A AF Inslicht, Sabra S. Marmar, Charles R. Neylan, Thomas C. Metzler, Thomas J. Hart, Stacey L. Otte, Christian McCaslin, Shannon E. Larkin, G. Luke Hyman, Kelly B. Baum, Andrew TI Increased cortisol in women with intimate partner violence-related posttraumatic stress disorder SO PSYCHONEUROENDOCRINOLOGY LA English DT Article; Proceedings Paper CT Meeting on Psychobiology of Post-Traumatic Stress Disorder CY SEP 11-13, 2005 CL New York, NY SP New York Acad Sci DE posttraumatic stress disorder; cortisol; HPA axis; epinephrine; norepinephrine; intimate partner violence ID 24-HOUR URINARY CORTISOL; MOTOR-VEHICLE ACCIDENTS; MIDDLE-AGED WOMEN; PLASMA NOREPINEPHRINE; CEREBROSPINAL-FLUID; DEPRESSED-PATIENTS; SALIVARY CORTISOL; DOMESTIC VIOLENCE; COMMUNITY SAMPLE; CATECHOLAMINES AB Background: Alterations of hypothalamic-pituitary-adrenal (HPA) axis function and sympathetic-ad renal activity have been proposed as key factors in biological models of posttraumatic stress disorder (PTSD). Methods: We examined neuroendocrine function in female survivors of intimate partner violence (IPV) with lifetime (current or remitted) PTSD (n=29) and in women who were exposed to IPV but never developed PTSD (n=20). Salivary cortisol was collected as a marker of HPA axis function at 1, 4, 9, and 11 h after awakening. Platelet epinephrine and norepinephrine were assayed as markers of sympathetic-adrenal activation. Results: Women with lifetime PTSD had significantly higher cortisol. levels across the day compared to abuse-exposed participants without PTSD, after controlling for age, depression, severity, and latency of abuse. There were no significant group differences in levels of platelet catecholamines. Conclusions: Elevated cortisol levels may be a biomarker of IPV-related lifetime PTSD, reflecting tong-tasting changes associated with trauma-exposure or possibly a reflection of risk for PTSD in women. (c) 2006 Elsevier Ltd. All rights reserved. C1 Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Canc Inst, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA. Affairs Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. Univ Hosp Hamburg Eppendorf, Dept Psychiat & Psychotherapy, D-20246 Hamburg, Germany. Univ Texas, Mem Hosp, SW Med Ctr, Dept Surg,Div Emergency Med, Dallas, TX 75390 USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equit Res & Promot, Pittsburgh, PA 15240 USA. RP Inslicht, SS (reprint author), Univ Pittsburgh, Dept Psychol, Sennott Sq,3rd Floor,210 S Bouquet St, Pittsburgh, PA 15260 USA. EM sabra.inslicht@ucsf.edu RI Hart, Stacey/E-4819-2011 OI LARKIN, GREGORY LUKE/0000-0002-8655-7824 FU NIMH NIH HHS [MH54837]; NIOSH CDC HHS [OH3306] NR 75 TC 49 Z9 50 U1 0 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD AUG PY 2006 VL 31 IS 7 BP 825 EP 838 DI 10.1016/j.psyneuen.2006.03.007 PG 14 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 069UW UT WOS:000239475100004 PM 16716530 ER PT J AU Kern, RS Green, MF Cornblatt, BA Owen, JR McQuade, RD Carson, WH Ali, M Marcus, R AF Kern, Robert S. Green, Michael F. Cornblatt, Barbara A. Owen, J. Randall McQuade, Robert D. Carson, William H. Ali, Mirza Marcus, Ron TI The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine SO PSYCHOPHARMACOLOGY LA English DT Article DE schizophrenia; aripiprazole; olanzapine; neurocognition; learning; memory; dopamine; agonists ID NEUROPSYCHOLOGICAL CHANGE; SCHIZOAFFECTIVE DISORDER; ANTIPSYCHOTIC TREATMENT; PROPENSITY SCORE; PARTIAL AGONIST; SCHIZOPHRENIA; RISPERIDONE; CLOZAPINE; MEMORY; HALOPERIDOL AB Rationale Cognitive deficits are a core feature of schizophrenia. As a target of intervention, improvements in cognition may lead to improvements in functional outcome. Objectives The present paper is the first report, to our knowledge, on the neurocognitive effects of aripiprazole. Unlike other second-generation antipsychotics, aripiprazole is a D-2 and D-3 receptor partial agonist. It is unknown what effects this unusual pharmacological profile may yield on neurocognition. Materials and methods The present open-label study included data on 169 patients with schizophrenia or schizoaffective disorder who were randomly treated with aripiprazole or olanzapine. Subjects received a neurocognitive battery at baseline, week 8, and 26. Results The aripiprazole group had a significantly greater dropout rate than the olanzapine group. Neurocognitive data were reduced through a principal components analysis that yielded a three-factor solution. The factors were general cognitive functioning, executive functioning, and verbal learning. For general cognitive functioning, both groups improved from baseline and the effects were relatively stable over the 26-week protocol. There were no differential treatment effects. For executive functioning, neither group improved significantly from baseline. For verbal learning, the aripiprazole group improved significantly from baseline to the 8th and 26th week of assessment, and there was a between-group effect favoring aripiprazole over olanzapine that was largely attributable to the differences in performance within the 8th week. Separate analyses were conducted for a measure of sustained attention (Continuous Performance Test-Identical Pairs). There were no differential treatment effects on this measure. Conclusions The findings from this open-label study suggest that the neurocognitive effects of aripiprazole are at least as good as those of olanzapine. C1 VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Geffen Sch Med, Los Angeles, CA 90024 USA. Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs VISN 22, Los Angeles, CA USA. Albert Einstein Coll Med, Bronx, NY 10467 USA. Zucker Hillside Hosp, N Shore Long Isl Jewish Med Ctr, Glen Oaks, NY USA. Bristol Myers Squibb Co, Wallingford, CT 06492 USA. Otsuka Amer Pharmaceut Inc, Princeton, NJ USA. Otsuka Maryland Res Inst, Rockville, MD USA. RP Kern, RS (reprint author), VA Greater Los Angeles Healthcare Ctr, 11301 Wilshire Blvd,MIRECC 210A, Los Angeles, CA 90073 USA. EM rkern@ucla.edu NR 51 TC 80 Z9 86 U1 2 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD AUG PY 2006 VL 187 IS 3 BP 312 EP 320 DI 10.1007/s00213-006-0428-x PG 9 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 082VQ UT WOS:000240415700009 PM 16810506 ER PT J AU Harvey, PD Green, MF Bowie, C Loebel, A AF Harvey, Philip D. Green, Michael F. Bowie, Christopher Loebel, Antony TI The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements SO PSYCHOPHARMACOLOGY LA English DT Article DE schizophrenia; clinical effectiveness; cognitive function; antipsychotic; treatment ID ACUTELY ILL INPATIENTS; DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; 1ST-EPISODE PSYCHOSIS; SUPPORTED EMPLOYMENT; FACTORIAL STRUCTURE; NEGATIVE SYMPTOMS; RATING-SCALE; OLANZAPINE; ZIPRASIDONE AB Background As cognitive impairments are related to deficits in everyday functioning in schizophrenia, treatment of these impairments may have the potential to reduce these functional deficits. To determine if treatments truly reduce cognitive impairment, it is important to discriminate direct cognitive effects of treatment from generalized treatment benefits on the multiple clinical dimensions of schizophrenia. Thus, this study used a database from an existing clinical trial and examined the relationships between changes in clinical symptoms and cognitive deficits with several different strategies. Materials and methods Two hundred and seventy stable but symptomatic outpatients with schizophrenia entered a study where they were switched from previous treatment to open-label ziprasidone. The present data are from the 6-month endpoint (n=184). Patients were examined at baseline and the 6-month endpoint with ratings of clinical symptoms based on the Positive and Negative Syndrome Scale (PANSS) and a neuropsychological (NP) assessment battery including aspects of cognitive functioning known to be related to functional outcome in schizophrenia. Results Changes on the individual PANSS items and NP test scores were examined with two separate principal components analyses, revealing four dimensions of clinical change (psychosis, negative symptoms, affective symptoms, and agitation) and two dimensions of NP improvement. Pearson correlations between changes in the (1) factors derived from the analyses, (2) individual NP items based the four clinical dimensions of change, and (3) the 30 PANSS items and the two NP dimensions of change suggested minimal relationships (largest r=0.15). Implications This sample was selected because previous findings suggested that clinical and NP symptoms of schizophrenia significantly improved from baseline after a switch to ziprasidone treatment. While four dimensions of change in clinical symptoms and two dimensions of cognitive improvements were identified, clinical changes, regardless of how they were defined, were not related to NP improvements. C1 CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Univ Calif Los Angeles, VA Greater Los Angles Healthcare Syst, Inst Neuropsychiat, Los Angeles, CA USA. Pfizer Inc, New York, NY 10016 USA. RP Harvey, PD (reprint author), CUNY Mt Sinai Sch Med, Dept Psychiat, 1425 Madison Ave, New York, NY 10029 USA. EM philipdharvey1@cs.com NR 44 TC 29 Z9 34 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD AUG PY 2006 VL 187 IS 3 BP 356 EP 363 DI 10.1007/s00213-006-0432-1 PG 8 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 082VQ UT WOS:000240415700013 PM 16783539 ER PT J AU Lorenz, KA Cunningham, WE Spritzer, KL Hays, RD AF Lorenz, Karl A. Cunningham, William E. Spritzer, Karen L. Hays, Ron D. TI Changes in symptoms and health-related quality of life in a nationally representative sample of adults in treatment for HIV SO QUALITY OF LIFE RESEARCH LA English DT Article DE health; longitudinal studies; quality of life; symptoms ID LOW-PREVALENCE DISEASES; MENTAL-HEALTH; SERVICES UTILIZATION; PROBABILITY SAMPLES; COST; ASSOCIATIONS; PERFORMANCE; OUTPATIENTS; INFECTION; CARE AB Patient-centered measures of functioning and well-being are needed to monitor and improve health for HIV-infected persons. We estimated the associations between HRQOL and symptoms over time in HIV-infected persons, adjusting for demographic and clinical characteristics using a longitudinal study of a nationally representative cohort of 2267 patients in care for HIV infection surveyed in 1996 and again in 1998. We used two global measures of HRQOL (overall health and overall quality of life) scored to have a mean of 50 and standard deviation of 10 in the sample. The total number of symptoms decreased (-1.29, p < 0.001 for the difference), and overall health (1.09, p < 0.001 for the difference) and overall quality of life (1.31, p < 0.001 for the difference) improved over the period. Controlling for baseline symptoms and HRQOL, each additional symptom at follow-up (B=-1.14, p < 0.001) was associated with worsened overall health and worsened overall quality of life (B=-0.95, p < 0.001). The association of two additional symptoms with lower global HRQOL was similar in magnitude to the effect of having significant depressive symptoms or the diagnosis of AIDS. In conclusion, among HIV-infected patients, symptoms are significantly related to HRQOL over time. The functioning and well-being of patients with HIV is inextricably linked to the symptoms they experience. C1 VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Program, Div Gen Internal Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. RP Lorenz, KA (reprint author), VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Program, Div Gen Internal Med, 11301 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA. EM karl.lorenz@med.va.gov RI Hays, Ronald/D-5629-2013 FU AHRQ HHS [U-01HS08578]; ASC OASH HHS [R01AS10227]; NIA NIH HHS [AG-02-004]; NIMHD NIH HHS [P20-MD00148-01] NR 20 TC 48 Z9 51 U1 2 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 J9 QUAL LIFE RES JI Qual. Life Res. PD AUG PY 2006 VL 15 IS 6 BP 951 EP 958 DI 10.1007/s11136-005-6010-x PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 073CE UT WOS:000239719400002 PM 16900276 ER PT J AU Saam, T Cai, J Ma, L Cai, YQ Ferguson, MS Polissar, NL Hatsukami, TS Yuan, C AF Saam, Tobias Cai, Jianming Ma, Lin Cai, You-Quan Ferguson, Marina S. Polissar, Nayak L. Hatsukami, Thomas S. Yuan, Chun TI Comparison of symptomatic and asymptomatic atherosclerotic carotid plaque features with in vivo MR imaging SO RADIOLOGY LA English DT Article ID SUDDEN CORONARY DEATH; INTRAPLAQUE HEMORRHAGE; INVERSION-RECOVERY; CEREBRAL-ISCHEMIA; ARTERY STENOSIS; RUPTURE; LESIONS; CLASSIFICATION; PROGRESSION; IDENTIFICATION AB Purpose: To retrospectively determine if in vivo magnetic resonance (MR) imaging can simultaneously depict differences between symptomatic and asymptomatic carotid atherosclerotic plaque. Materials and Methods: Institutional review board approval and informed consent were obtained for this HIPAA-compliant study. Twenty-three patients (21 men, two women; mean age, 66.1 years +/- 11.0 [standard deviation]) with unilateral symptomatic carotid disease underwent 1.5-T time-of-flight MR angiography and 1.5-T T1-, intermediate-, and T2-weighted MR imaging. Both carotid arteries were reviewed. One observer recorded quantitative and morphologic information, which included measurement of the area of the lumen, artery wall, and main plaque components; fibrous cap status (thick, thin, or ruptured); American Heart Association (AHA) lesion type (types I-VIII); and location (juxtaluminal vs intraplaque) and type of hemorrhage. Plaques associated with neurologic symptoms and asymptomatic plaques were compared with Wilcoxon signed rank and McNemar tests. Results: Compared with asymptomatic plaques, symptomatic plaques had a higher incidence of fibrous cap rupture (P=.007), juxtaluminal hemorrhage or thrombus (P=.039), type I hemorrhage (P=.021), and complicated AHA type VI lesions (P=-.004) and a lower incidence of uncomplicated AHA type IV and V lesions (P=.005). Symptomatic plaques also had larger hemorrhage (P=.003) and loose matrix (P=.014) areas and a smaller lumen area (P=.008). No significant differences between symptomatic and asymptomatic plaques were found for quantitative measurements of the lipid-rich necrotic core, calcification, and the vessel wall or for the occurrence of intraplaque hemorrhage or type II hemorrhage. Conclusion: This study revealed significant differences between symptomatic and asymptomatic plaques in the same patient. (c) RSNA, 2006. C1 Univ Washington, Dept Radiol, Seattle, WA 98109 USA. Univ Washington, Dept Surg, Seattle, WA 98109 USA. Peoples Liberat Army Gen Hosp, Dept Radiol, Beijing, Peoples R China. Mt Whisper Light Stat Consulting, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Saam, T (reprint author), Univ Washington, Dept Radiol, 815 Mercer St,Box 358050, Seattle, WA 98109 USA. EM Tobias.Saam@med.uni-muenchen.de FU NHLBI NIH HHS [P01HL072262, R01 HL056874, R01 HL073401, R01HL073401, P01 HL072262, R01HL56874] NR 36 TC 122 Z9 134 U1 2 U2 7 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD AUG PY 2006 VL 240 IS 2 BP 464 EP 472 DI 10.1148/radiol.2402050390 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 066PO UT WOS:000239242600019 PM 16864672 ER PT J AU El-Serag, HB Tran, T Richardson, P Ergun, G AF El-Serag, Hashem B. Tran, Thomas Richardson, Peter Ergun, Gulchin TI Anthropometric correlates of intragastric pressure SO SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY LA English DT Article DE BMI; GERD; obesity; risk factor; waist circumference ID GASTROESOPHAGEAL-REFLUX DISEASE; BODY-MASS INDEX; RISK-FACTORS; ESOPHAGUS; OBESITY; ADENOCARCINOMA; ASSOCIATION; PREGNANCY; SYMPTOMS; ASCITES AB Objective. Obesity may increase intra-abdominal pressure on the stomach leading to an increase in intragastric pressure, which in turn induces lower esophageal sphincter relaxation, with subsequent reflux. However, the association between anthropometric measures of total body as well as abdominal obesity and intragastric pressure has not been examined. Material and methods. This prospective cross-sectional study included consecutive patients undergoing manometry at an open access Reflux Center. Standardized measurements of body-weight, height, and waist and hip circumference were prospectively obtained. To assess the intragastric pressure, the perfusion port levels of the catheter were verified to be at the same vertical height (0 mmHg) inside the patient as they were outside the patient during calibration. Correlation between gastric pressure and anthropometric measures was calculated and adjusted for demographic features and presenting symptoms. Results. A total of 322 patients (67% women) with a mean age of 52.5 years were enrolled. The mean values for weight, height, and body mass index (BMI) were 77.2 kg, 168 cm, and 27.5 kg/m(2), respectively (range 16.0-52.0, median 27.0). The mean intragastric pressure was 2.9 cm H2O (SD: 1.7). There was a weak, positive correlation between gastric pressure and both BMI (r = 0.11, p = 0.05) and waist circumference (r = 0.11, p = 0.06). The associations between gastric pressure and both BMI and waist circumference were relatively unaffected by adjusting for several variables including age, indications for manometry, race, and gender in a multivariable linear regression model. For each unit increase in BMI, there was approximately a 10% increase in intragastric pressure. Conclusions. In this study of consecutive patients with wide-ranging BMI values, there was a weak, positive correlation between intragastric pressure and both BMI and waist circumference. This indicates that obesity operates to increase the risk of gastroesophageal reflux disease (GERD) at least partly by increasing intragastric pressure. C1 Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 16 TC 71 Z9 76 U1 0 U2 2 PU TAYLOR & FRANCIS AS PI OSLO PA PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY SN 0036-5521 J9 SCAND J GASTROENTERO JI Scand. J. Gastroenterol. PD AUG PY 2006 VL 41 IS 8 BP 887 EP 891 DI 10.1080/00365520500535402 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 067BH UT WOS:000239275100003 PM 16803686 ER PT J AU Morgenthaler, TI Kapen, S Lee-Chiong, T Alessi, C Boehlecke, B Brown, T Coleman, J Friedman, L Kapur, V Owens, J Pancer, J Swick, T AF Morgenthaler, Timothy I. Kapen, Sheldon Lee-Chiong, Teofilo Alessi, Cathy Boehlecke, Brian Brown, Terry Coleman, Jack Friedman, Leah Kapur, Vishesh Owens, Judith Pancer, Jeffrey Swick, Todd TI Practice parameters for the medical therapy of obstructive sleep apnea SO SLEEP LA English DT Article DE obstructive sleep apnea; medical therapy; weight reduction; bariatric surgery; positional therapy; supplementary oxygen; selective serotonergic uptake inhibitors ID POSITIVE AIRWAY PRESSURE; HORMONE-REPLACEMENT THERAPY; BARIATRIC SURGERY; HYPOPNEA SYNDROME; WEIGHT-LOSS; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; NASAL CPAP; APNEA/HYPOPNEA SYNDROME; DAYTIME SLEEPINESS AB Therapies for obstructive sleep apnea other than positive airway pressure, oral appliances, and surgical modifications of the upper airway are reviewed in this practice parameter. Several of these therapies such as weight loss and positional therapy hold some promise. Others, such as serotonergic agents, may gain credibility in the future but lack well-designed clinical trials. No practice parameters could be developed for a number of possible therapeutic modalities that had little or no evidence-based data on which to form a conclusion. The role of an organized, targeted weight-loss program either as a single therapy or as a supplement to PAP needs to be clarified. Although bariatric surgery is increasingly performed for refractory medically complicated obesity, its long-term effectiveness in treatment of obstructive sleep apnea in morbidly obese patients is not yet demonstrated. Positional therapy, or methods for preventing sleep in the supine position, has probably been undenutilized due to lack of easily measured predictive factors and randomized controlled trials. C1 Mayo Clin, Sleep Disorders Ctr, Rochester, MN 55905 USA. Detroit VA Med Ctr, Detroit, MI USA. Natl Jewish Med & Res Ctr, Denver, CO USA. Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, Sepulveda, CA USA. Univ N Carolina, Chapel Hill, NC 27515 USA. St Joseph Mem Hosp, Murphysboro, IL USA. Stanford Univ, Stanford, CA 94305 USA. Univ Washington, Seattle, WA 98195 USA. Rhode Isl Hosp, Providence, RI 02903 USA. Houston Sleep Ctr, Houston, TX USA. RP Morgenthaler, TI (reprint author), Mayo Clin, Sleep Disorders Ctr, 200 1st St SW, Rochester, MN 55905 USA. EM thaler.timothy@mayo.edu RI Kapur, Vishesh/K-1054-2014 OI Kapur, Vishesh/0000-0002-5417-1097; Morgenthaler, Timothy/0000-0002-2614-3793 NR 64 TC 101 Z9 105 U1 1 U2 3 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD AUG 1 PY 2006 VL 29 IS 8 BP 1031 EP 1035 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 077RB UT WOS:000240046400006 PM 16944671 ER PT J AU Swarztrauber, K Graf, E Cheng, E AF Swarztrauber, Kari Graf, Eric Cheng, Eric TI The quality of care delivered to Parkinson's disease patients in the US Pacific Northwest Veterans Health System SO BMC NEUROLOGY LA English DT Article ID NURSING-HOME PLACEMENT; DEPRESSION; FALLS AB Background: Parkinson's disease (PD) is the second most common chronic neurological disorder of the elderly. Despite the fact that a comprehensive review of general health care in the United States showed that the quality of care delivered to patients usually falls below professional standards, there is limited data on the quality of care for patients with PD. Methods: Using the administrative database, the Pacific Northwest Veterans Health Administration (VHA) Data Warehouse, a population of PD patients with encounters from 10/1/98-12/31/04 were identified. A random sample of 350 patient charts underwent further review for diagnostic evaluation. All patients whose records revealed a physician diagnosis of definite or possible Idiopathic Parkinson's (IPD) disease (n=150) were included in a medical chart review to evaluate adherence to five evidence-based quality of care indicators. Results: For those care indicators with good inter-rater reliability, 16.6% of care received by PD patients was adherent for annual depression screening, 23.4% of care was adherent for annual fall screening and, 67.3% of care was adherent for management of urinary incontinence. Patients receiving specialty care were more likely to be adherent with fall screening than those not receiving specialty care OR=2.3, 95% CI=1.2-4.2, but less likely to be adherent with management of urinary incontinence, OR=0.3, 95% CI=0.1-0.8. Patients receiving care outside the VA system were more likely to be adherent with depression screening OR=2.4, 95% CI=>1.0-5.5 and fall screening OR=2.2, 95% CI=1.1-4.4. Conclusion: We found very low rates of adherence for annual screening for depression and falls for PD patients but reasonable adherence rates for management of urinary incontinence. Interestingly, receiving concurrent specialty care did not necessarily result in higher adherence for all care indicators suggesting some coordination and role responsibility confusion. The increased adherence in PD patients receiving care outside the VA system suggests that patients with outside care may demand better care within the VA system. C1 Providence Hlth Syst, Newberg, OR 97132 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. VA Greater Los Angeles Healthcare Syst, Parkinsons Dis Res Educ & Clin Ctr, Los Angeles, CA USA. RP Swarztrauber, K (reprint author), Providence Hlth Syst, Newberg, OR 97132 USA. EM swarztra@stanfordalumni.org; grafe@ohsu.edu; eric.cheng@med.va.gov NR 19 TC 3 Z9 4 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1471-2377 J9 BMC NEUROL JI BMC Neurol. PD JUL 28 PY 2006 VL 6 AR 26 DI 10.1186/1471-2377/6/26 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 074GA UT WOS:000239799500001 PM 16875503 ER PT J AU Gooz, M Gooz, P Luttrell, LM Raymond, JR AF Gooz, Monika Gooz, Pal Luttrell, Louis M. Raymond, John R. TI 5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PROTEIN-COUPLED RECEPTORS; DIPHTHERIA-TOXIN RECEPTOR; METALLOPROTEASE-DISINTEGRINS; LYSOPHOSPHATIDIC ACID; CARDIAC-HYPERTROPHY; TNF-ALPHA; BINDING; TRANSACTIVATION; EXPRESSION; CLEAVAGE AB In this study, we present multiple lines of evidence to support a critical role for heparin-boundEGF( epidermal growth factor)like growth factor (HB-EGF) and tumor necrosis factor-alpha-converting enzyme (TACE) (ADAM17) in the transactivation of EGF receptor (EGFR), ERK phosphorylation, and cellular proliferation induced by the 5-HT2A receptor in renal mesangial cells. 5-hydroxy-tryptamine (5-HT) resulted in rapid activation of TACE, HB-EGF shedding, EGFR activation, ERK phosphorylation, and longer term increases in DNA content in mesangial cells. ERK phosphorylation was attenuated by 1) neutralizing EGFR antibodies and the EGFR kinase inhibitor, AG1478, 2) neutralizing HB-EGF, but not amphiregulin, antibodies, heparin, or CM197, and 3) pharmacological inhibitors of matrix-degrading metalloproteinases or TACE small interfering RNA. Exogenously administered HB-EGF stimulated ERK phosphorylation. Additionally, TACE was co-immunoprecipitated with HB-EGF. Small interfering RNA against TACE also blocked 5-HT-induced increases in ERK phosphorylation, HB-EGF shedding, and DNA content. In aggregate, this work supports a pathway map that can be depicted as follows: 5-HT -> 5-HT2A receptor -> TACE -> HB-EGF shedding -> EGFR -> ERK -> increased DNA content. To our knowledge, this is the first time that TACE has been implicated in 5-HT-induced EGFR transactivation or in proliferation induced by a G protein-coupled receptor in native cells in culture. C1 Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA. Med Univ S Carolina, Div Rheumatol, Charleston, SC 29425 USA. Med Univ S Carolina, Div Endocrinol, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29425 USA. RP Gooz, M (reprint author), Med Univ S Carolina, Div Nephrol, CSB 829,96 Jonathan Lucas St, Charleston, SC 29425 USA. EM beckm@musc.edu FU NCRR NIH HHS [P20 RR016434]; NIDDK NIH HHS [DK070054-01, R01 DK55524]; NIGMS NIH HHS [R01 GM-63909] NR 50 TC 64 Z9 64 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUL 28 PY 2006 VL 281 IS 30 BP 21004 EP 21012 DI 10.1074/jbc.M512096200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 065VF UT WOS:000239187300037 PM 16737974 ER PT J AU Garcia-Osta, A Tsokas, P Pollonini, G Landau, EM Blitzer, R Alberini, CM AF Garcia-Osta, Ana Tsokas, Panayiotis Pollonini, Gabriella Landau, Emmanuel M. Blitzer, Robert Alberini, Cristina M. TI MuSK expressed in the brain mediates cholinergic responses, synaptic plasticity, and memory formation SO JOURNAL OF NEUROSCIENCE LA English DT Article DE MuSK; brain; long-term plasticity; memory; oscillatory response; C/EBP ID RECEPTOR TYROSINE KINASE; LONG-TERM POTENTIATION; HIPPOCAMPAL THETA-RHYTHM; ELEMENT-BINDING PROTEIN; MUSCLE-SPECIFIC KINASE; NEUROMUSCULAR-JUNCTION FORMATION; IN-VIVO; SIGNALING PATHWAY; MYASTHENIA-GRAVIS; RAT HIPPOCAMPUS AB Muscle-specific tyrosine kinase receptor (MuSK) has been believed to be mainly expressed and functional in muscle, in which it mediates the formation of neuromuscular junctions. Here we show that MuSK is expressed in the brain, particularly in neurons, as well as in non-neuronal tissues. We also provide evidence that MuSK expression in the hippocampus is required for memory consolidation, because temporally restricted knockdown after training impairs memory retention. Hippocampal disruption of MuSK also prevents the learning-dependent induction of both cAMP response element binding protein (CREB) phosphorylation and CCAAT enhancer binding protein beta(C/EBP beta) expression, suggesting that the role of MuSK during memory consolidation critically involves the CREB-C/EBP pathway. Furthermore, we found that MuSK also plays an important role in mediating hippocampal oscillatory activity in the theta frequency as well as in the induction and maintenance of long-term potentiation, two synaptic responses that correlate with memory formation. We conclude that MuSK plays an important role in brain functions, including memory formation. Therefore, its expression and role are broader than what was believed previously. C1 Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA. Bronx Vet Affairs Med Ctr, Psychiat Serv, Bronx, NY 10468 USA. RP Alberini, CM (reprint author), Mt Sinai Sch Med, Dept Neurosci, Box 1065, New York, NY 10029 USA. EM Cristina.Alberini@mssm.edu OI Garcia-Osta, Ana/0000-0001-6326-9064 FU NIMH NIH HHS [MH65635] NR 74 TC 47 Z9 48 U1 0 U2 1 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JUL 26 PY 2006 VL 26 IS 30 BP 7919 EP 7932 DI 10.1523/JNEUROSCI.1674-06.2006 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 068GP UT WOS:000239361200016 PM 16870737 ER PT J AU Tschanz, JT Welsh-Bohmer, KA Lyketsos, CG Corcoran, C Green, RC Hayden, K Norton, MC Zandi, PP Toone, L West, NA Breitner, JCS AF Tschanz, J. T. Welsh-Bohmer, K. A. Lyketsos, C. G. Corcoran, C. Green, R. C. Hayden, K. Norton, M. C. Zandi, P. P. Toone, L. West, N. A. Breitner, J. C. S. CA Cache County Investigators TI Conversion to dementia from mild cognitive disorder - The Cache County Study SO NEUROLOGY LA English DT Article; Proceedings Paper CT 31st Annual Meeting of the International-Neuropsychological-Society CY FEB 05-08, 2003 CL HONOLULU, HI SP Int Neuropsychol Soc ID ALZHEIMERS-DISEASE; ELDERLY POPULATION; NO DEMENTIA; IMPAIRMENT; PREVALENCE; DECLINE; QUESTIONNAIRE; PREDICTOR; EPSILON-4; CRITERIA AB Objective: To examine 3-year rates of conversion to dementia, and risk factors for such conversion, in a population-based sample with diverse types of cognitive impairment. Methods: All elderly (aged 65 or older) residents of Cache County, UT, were invited to undergo two waves of dementia screening and assessment. Three-year follow- up data were available for 120 participants who had some form of mild cognitive impairment at baseline. Of these, 51 had been classified at baseline with prodromal Alzheimer disease (proAD), and 69 with other cognitive syndromes (CS). Results: Three-year rates of conversion to dementia were 46% among those with cognitive impairment at baseline. By comparison, 3.3% without impairment converted to dementia in the interval. Among converters, AD was the most common type of dementia. In individuals with at least one APOE epsilon 4 allele, those with proAD or CS exhibited a 22- to 25-fold higher risk of dementia than cognitively unimpaired individuals (vs 5- to 10-fold higher risk in those without e4). Conclusions: Individuals with all types of mild cognitive impairment have an elevated risk of dementia over 3 years, more so in those with an APOE e4 allele. These results suggest value in dementia surveillance for broad groups of cognitively impaired individuals beyond any specific category, and utility of APOE genotyping as a prognostic method. C1 Utah State Univ, Dept Psychol, Logan, UT 84322 USA. Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. Utah State Univ, Dept Math & Stat, Logan, UT 84322 USA. Utah State Univ, Dept Family Consumer & Human Dev, Logan, UT 84322 USA. Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC USA. Johns Hopkins Univ, Div Geriatr Psychiat & Neuropsychiat, Dept Psychiat & Behav Sci, Sch Med, Baltimore, MD USA. Johns Hopkins Univ, Dept Mental Hlth, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA. Boston Univ, Sch Med, Dept Med Genet, Boston, MA 02215 USA. Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02215 USA. Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Tschanz, JT (reprint author), Utah State Univ, Dept Psychol, 4440 Old Main Hill, Logan, UT 84322 USA. EM joannt@cc.usu.edu RI Corcoran, Chris/F-2155-2010; Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013; Hayden, Kathleen/B-6442-2012 OI Hayden, Kathleen/0000-0002-7745-3513 FU NIA NIH HHS [R01-AG11380, R01-AG21136] NR 36 TC 73 Z9 77 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JUL 25 PY 2006 VL 67 IS 2 BP 229 EP 234 DI 10.1212/01.wnl.0000224748.48011.84 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 066NW UT WOS:000239237600009 PM 16864813 ER PT J AU Ghosh-Choudhury, N Singha, PK Woodruff, K St Clair, P Bsoul, S Werner, SL Choudhury, GG AF Ghosh-Choudhury, Nandini Singha, Prajjal K. Woodruff, Kathleen St Clair, Patricia Bsoul, Sameer Werner, Sherry L. Choudhury, Goutam Ghosh TI Concerted action of Smad and CREB-binding protein regulates bone morphogenetic protein-2-stimulated osteoblastic colony-stimulating factor-1 expression SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID OSTEOCLAST DIFFERENTIATION FACTOR; GROWTH-FACTOR-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION; HISTONE ACETYLTRANSFERASES; FAMILY-MEMBERS; CELL-FORMATION; STROMAL CELLS; OP/OP MICE AB Bone remodeling depends upon proper osteoblast and osteoclast function. Bone morphogenetic protein-2 (BMP-2) stimulates differentiation of osteoblasts from pluripotent precursors. Osteoclast formation depends on the concerted action of osteoblast-derived receptor activator of NF-kappa B ligand and colony-stimulating factor-1 (CSF-1). BMP-2 stimulates receptor activator of NF-kappa B ligand expression. However, the effect of BMP-2 on CSF-1 expression has not been studied. We investigated the role of BMP-2 in CSF-1 expression in osteogenic C2C12 cells. Incubation of C2C12 cells with BMP-2 supported osteoclastogenesis of spleen cells with a concomitant increase in expression of CSF-1 mRNA and protein. To determine the mechanism, we identified a BMP-responsive element between -627 bp and -509 bp in the CSF-1 promoter. DNase I footprint analysis revealed the presence of consensus Smad binding motif in this region. Electrophoretic mobility shift assay showed BMP-2-stimulated binding of proteins to this motif. Mutation of core sequence as well as its 5'- and 3'-flanking sequences abolished the DNA-protein interaction resulting in inhibition of CSF-1 transcription. Supershift analysis detects the presence of Smads 1, 5, and 4 and the transcriptional coactivator CREB-binding protein in the BMP-responsive element-protein complex. In addition, Smads 1 and 5 alone or in combination with Smad 4 increased CSF-1 transcription. Furthermore, CREB-binding protein markedly increased transcription of CSF-1. These data represent the first evidence that BMP-2 increases the osteoclas-togenic CSF-1 expression by a transcriptional mechanism using the canonical Smad pathway and provide a mechanism for BMP-2-induced osteoclast differentiation. C1 Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhury@uthscsa.edu FU NIAMS NIH HHS [R01 AR042306, R01-AR52425]; NIDDK NIH HHS [DK 55815, P50 DK061597, R01 DK 50190] NR 69 TC 30 Z9 35 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUL 21 PY 2006 VL 281 IS 29 BP 20160 EP 20170 DI 10.1074/jbc.M511071200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 063RV UT WOS:000239038200040 PM 16707491 ER PT J AU Fu, YC Luo, LH Luo, NL Garvey, WT AF Fu, Yuchang Luo, Liehong Luo, Nanlan Garvey, W. Timothy TI Proinflammatory cytokine production and insulin sensitivity regulated by overexpression of resistin in 3T3-L1 adipocytes SO NUTRITION & METABOLISM LA English DT Article ID ADIPOSE-TISSUE; GENE-EXPRESSION; PPAR-GAMMA; IN-VIVO; DIFFERENTIATION; GLUCOSE; OBESITY; ADIPOGENESIS; ADIPONECTIN; METABOLISM AB Resistin is secreted from adipocytes, and high circulating levels have been associated with obesity and insulin resistance. To investigate whether resistin could exert autocrine effects in adipocytes, we expressed resistin gene in 3T3-L1 fibroblasts using a lentiviral vector, and selected several stably-transduced cell lines under blasticidin selection. We observed that 3T3-L1 adipocytes expressing resistin have a decreased gene expression for related transcriptional factors (CCAAT/enhancer binding protein alpha(C/EBP alpha), peroxisome proliferator-activated receptor gamma (PPAR gamma), and adipocyte lipid binding protein (ALBP/aP2) which is one of target genes for the PPAR. during adipocyte differentiation,. Overexpression of resistin increased the levels of three proinflammatory cytokines, tumor necrosis factor alpha (TNF alpha), interleukin 6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1), which play important roles for insulin resistance, glucose and lipid metabolisms during adipogenesis. Furthermore, overexpressing resistin in adipocytes inhibits glucose transport 4 (GLUT4) activity and its gene expression, reducing insulin's ability for glucose uptake by 30 %. In conclusion, resistin overexpression in stably transduced 3T3-L1 cells resulted in: 1) Attenuation of programmed gene expression responsible for adipogenesis; 2) Increase in expression of proinflammatory cytokines; 3) Decrease in insulin responsiveness of the glucose transport system. These data suggest a new role for resistin as an autocrine/paracrine factor affecting inflammation and insulin sensitivity in adipose tissue. C1 Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Fu, YC (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. EM yfu@uab.edu; lhluo@uab.edu; nluo@uab.edu; garveyt@uab.edu FU NHLBI NIH HHS [P01 HL055782]; NIDDK NIH HHS [P30 DK056336, R01 DK038765] NR 27 TC 29 Z9 34 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-7075 J9 NUTR METAB JI Nutr. Metab. PD JUL 19 PY 2006 VL 3 AR 28 DI 10.1186/1743-7075-3-28 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 074JR UT WOS:000239809000001 PM 16854242 ER PT J AU Leung, JW Leung, FW AF Leung, JW Leung, FW TI Papillotomy Performance Scoring Scale - a pilot validation study focused on the cut axis SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID SPHINCTEROTOMY; COMPLICATIONS AB Background No published Papillotomy Performance Scoring Scale exists. Aim To develop such a scale and to apply it to stratify the quality of performance of recorded papillotomies. Method Expert biliary endoscopists were polled regarding their opinion of a 'perfect' biliary papillotomy and experience with complications in relation to the cut axis. Based on these responses a scoring scale encompassing two components - wire alignment and cut orientation, was proposed. This scoring scale was presented to experienced and trainee endoscopists, who scored recording of five biliary papillotomies. The mean final combined score was used for stratification. Results The experts' opinion of a 'perfect' biliary papillotomy is one cut along the axis of the distal bile duct and papilla. Their reported experience with complications occurring outside of the perfect axis validated their consensus. Application of the scoring scale stratified recorded papillotomies based on the mean final combined scores. Conclusion These pilot data support the hypothesis that a scoring scale focused on the cut axis can be constructed based on expert opinion, experience and consensus. The possibility of stratification of mean final combined scores that are significantly different validates application of the scoring scale for assessment of papillotomy performance. C1 Sacramento VA Med Ctr, Sect Gastroenterol 111 GI, Mather, CA 95655 USA. Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. Vet Affairs No Calif Healthcare Syst, Res & Med Serv, Sacramento Vet Affairs Med Ctr, Sacramento, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Sepulveda, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr & Nursing Home, Sepulveda, CA USA. RP Leung, JW (reprint author), Univ Calif Davis, Davis Sch Med, 10535 Hosp Way, Mather, CA 95655 USA. EM jwleung@ucdavis.edu NR 13 TC 3 Z9 3 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD JUL 15 PY 2006 VL 24 IS 2 BP 307 EP 312 DI 10.1111/j.1365-2036.2006.02978.x PG 6 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 057EQ UT WOS:000238579500012 PM 16842457 ER PT J AU Chiao, EY Giordano, TP Palefsky, JM Tyring, S El Serag, H AF Chiao, EY Giordano, TP Palefsky, JM Tyring, S El Serag, H TI Screening HIV-infected individuals for anal cancer precursor lesions: A systematic review SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID SQUAMOUS INTRAEPITHELIAL LESIONS; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-PAPILLOMAVIRUS INFECTION; HUMAN-IMMUNODEFICIENCY-VIRUS; POSITIVE MEN; CELL CARCINOMA; COST-EFFECTIVENESS; HIGH PREVALENCE; HOMOSEXUAL-MEN; RISK-FACTORS AB Individuals with human immunodeficiency virus ( HIV) infection are at increased risk for human papillomavirus-related squamous cell cancer of the anus. Screening HIV-infected patients for squamous cell cancer of the anus and human papillomavirus-related anal dysplasia may prevent excess morbidity and mortality. We have conducted a systematic review of the indirect evidence in the literature regarding the utility of anal Papanicolau ( Pap) smear screening of HIV-infected individuals in the highly active antiretroviral therapy era. Although there are no published studies evaluating the efficacy of anal Pap smear screening for preventing squamous cell cancer of the anus or anal intraepithelial neoplasia, we reviewed data regarding the burden of disease, anal Pap smear sensitivity and specificity, the prevalence of anal dysplasia, and 1 cost effectiveness study. The available evidence demonstrates that HIV-infected individuals have an increased risk for squamous cell cancer of the anus and anal intraepithelial neoplasia. This review identifies important areas for further study before routine anal Pap smear screening can be recommended. C1 Michael E DeBakey Vet Affairs Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Texas, Hlth Sci Ctr, Houston, TX USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Chiao, EY (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM echiao@bcm.tmc.edu FU NIMH NIH HHS [K23MH67505] NR 100 TC 154 Z9 159 U1 3 U2 8 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 15 PY 2006 VL 43 IS 2 BP 223 EP 233 DI 10.1086/505219 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 053WY UT WOS:000238338000016 PM 16779751 ER PT J AU Connor, NP Cohen, SB Kammer, RE Sullivan, PA Brewer, KA Hong, TS Chappell, RJ Harari, PM AF Connor, Nadine P. Cohen, Stacy B. Kammer, Rachael E. Sullivan, Paula A. Brewer, Kathryn A. Hong, Theodore S. Chappell, Richard J. Harari, Paul M. TI Impact of conventional radiotherapy on health-related quality of life and critical functions of the head and neck SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE head-and-neck neoplasms radiotherapy; radiotherapy-adverse events; quality of life; salivation-radiation effects; deglutition-radiation effects ID LARYNGEAL-CANCER PATIENTS; EUROPEAN ORGANIZATION; RADIATION-THERAPY; WEIGHT-LOSS; CROSS-VALIDATION; XEROSTOMIA; QUESTIONNAIRE; PREDICTORS; PRESERVATION; CHEMOTHERAPY AB Purpose: Head-and-neck radiotherapy is associated with significant morbidities. Our purpose was to document impact of morbidities by use of multiple objective measures and health-related quality of life (HR-QOL). Methods and Materials: Ten head-and-neck cancer patients were evaluated before receiving conventional head-and-neck radiotherapy and at 1 month and 6 months after treatment. We evaluated weight, saliva production, diet, swallow function, auditory function, and HR-QOL. Results: After radiotherapy, weight was reduced in 89% of subjects. Salivary function was significantly reduced and did not resolve by 6 months. Diet impairment and abnormalities in swallowing function persisted at 6 months. Perception of physical functioning was reduced after treatment, and swallowing, coughing, and dry-mouth symptoms increased. Very few changes were observed in auditory function. Conclusions: Conventional head-and-neck radiotherapy is associated with substantial functional deficits and diminished HR-QOL. Deficits reported here can serve as a baseline for comparison with results derived from new radiotherapy-treatment techniques. (c) 2006 Elsevier Inc. C1 Univ Wisconsin, Sch Med, Dept Otolaryngol Head & Neck Surg, Madison, WI USA. Univ Wisconsin, Dept Commun Disorders, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. Univ Wisconsin, Sch Med, Dept Human Oncol, Madison, WI USA. Univ Wisconsin, Sch Med, Dept Biostat & Med Informat, Madison, WI USA. RP Connor, NP (reprint author), Clin Sci Ctr K4-711,600 Highland Ave, Madison, WI 53792 USA. EM connor@surgery.wisc.edu FU NCI NIH HHS [P01 CA88960] NR 44 TC 40 Z9 42 U1 2 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JUL 15 PY 2006 VL 65 IS 4 BP 1051 EP 1062 DI 10.1016/j.ijrobp.2006.01.054 PG 12 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 061NH UT WOS:000238878800013 PM 16682129 ER PT J AU Maron, R Levine, D Dobbs, TE Geisler, WM AF Maron, Rhodemarie Levine, Deborah Dobbs, Thomas E. Geisler, William M. TI Two cases of Pott disease associated with bilateral psoas abscesses - Case report SO SPINE LA English DT Article DE Pott disease; vertebral osteomyelitis; psoas abscess ID SPINAL TUBERCULOSIS; DEVELOPED COUNTRY; INFECTION; DIAGNOSIS; FEATURES; ADULTS AB Study Design. Two case reports and a literature review of spinal osteomyelitis with bilateral psoas abscesses secondary to Mycobacterium tuberculosis. Objective. Describe the presentation, diagnosis, treatment, and outcome of spinal tuberculosis (i.e., Pott disease). Summary of Background Data. Pott disease is a well-known condition in unindustrialized countries causing multiple spinal deformities in children. However, its association with bilateral psoas abscesses in adults with minimal risk factors is not commonly recognized in industrialized countries. Methods. There are 2 adult cases of Pott disease with psoas abscesses presented, and the relevant literature is reviewed. Plain spine radiographs, spine magnetic resonance imaging ( MRI), routine bacterial and acid-fast bacilli cultures of infected material, and other diagnostic testing for M. tuberculosis were performed. Results. Plain radiographs and MRI of the spine showed vertebral osteomyelitis with compression fractures, and MRI also revealed bilateral psoas abscesses. Acid-fast bacilli culture and other M. tuberculosis diagnostic testing of psoas abscess specimens confirmed the diagnosis of M. tuberculosis. Conclusion. Although spinal osteomyelitis with psoas abscess is classically associated with Staphylococcus aureus infection, Pott disease should be considered in this clinical setting, and risk factor assessment and testing for tuberculosis should be performed. C1 Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Deep S Ctr Effect, Birmingham, AL USA. RP Geisler, WM (reprint author), Univ Alabama, Dept Med, ZRB Room 242,703 19th St S, Birmingham, AL 35294 USA. EM wgeisler@uab.edu NR 20 TC 8 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 J9 SPINE JI SPINE PD JUL 15 PY 2006 VL 31 IS 16 BP E561 EP E564 DI 10.1097/01.brs.0000225998.99872.7f PG 4 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 065YV UT WOS:000239197200031 PM 16845344 ER PT J AU Jafri, F El-Shewy, HM Lee, MH Kelly, M Luttrell, DK Luttrell, LM AF Jafri, Farahdiba El-Shewy, Hesham M. Lee, Mi-Hye Kelly, Margaret Luttrell, Deirdre K. Luttrell, Louis M. TI Constitutive ERK1/2 activation by a chimeric neurokinin 1 receptor-beta-arrestin1 fusion protein - Probing the composition and function of the G protein-coupled receptor "signalsome" SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID BETA-ARRESTIN; MAP KINASE; REGULATED KINASES; VISUAL ARRESTIN; EGF RECEPTOR; CANCER-CELLS; SUBSTANCE-P; BETA-ARRESTIN-2; DESENSITIZATION; UBIQUITINATION AB The beta-arrestins, a small family of G protein-coupled receptor (GPCR)-binding proteins involved in receptor desensitization, have been shown to bind extracellular signal-regulated kinases 1 and 2 (ERK1/2) and function as scaffolds for GPCR-stimulated ERK1/2 activation. To better understand the mechanism of beta-arrestin-mediated ERK1/2 activation, we compared ERK1/2 activation by the wild-type neurokinin 1 (NK1) receptor with a chimeric NK1 receptor having beta-arrestin1 fused to the receptor C terminus (NK1- beta Arr1). The NK1 receptor couples to both Gs and G(q/11), resides on the plasma membrane, and mediates rapid ERK1/2 activation and nuclear translocation in response to neurokinin A. In contrast, NK1-beta Arr1 is a G protein-uncoupled "constitutively desensitized" receptor that resides almost entirely in an intracellular endosomal compartment. Despite its inability to respond to neurokinin A, we found that NK1-beta Arr1 expression caused robust constitutive activation of cytosolic ERK1/2 and that endogenous Raf, MEK1/2, and ERK1/2 coprecipitated in a complex with NK1-beta Arr1. While agonist- dependent ERK1/2 activation by the NK1 receptor was independent of protein kinase A(PKA) or PKC activity, NK1-beta Arr1-mediated ERK1/2 activation was completely inhibited when basal PKA and PKC activity were blocked. In addition, the rate of ERK1/ 2 dephosphorylation was slowed in NK1-beta Arr1-expressing cells, suggesting that beta-arrestin-bound ERK1/2 is protected from mitogen-activated protein kinase phosphatase activity. These data suggest that beta-arrestin binding to GPCRs nucleates the formation of a stable "signalsome" that functions as a passive scaffold for the ERK1/2 cascade while confining ERK1/2 activity to an extranuclear compartment. C1 Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA. EM luttrell@musc.edu FU NIDDK NIH HHS [DK55524] NR 50 TC 22 Z9 22 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUL 14 PY 2006 VL 281 IS 28 BP 19346 EP 19357 DI 10.1074/jbc.M512643200 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 061BU UT WOS:000238847000050 PM 16670094 ER PT J AU Silverberg, MJ Wegner, SA Milazzo, MJ McKaig, RG Williams, CF Agan, BK Armstrong, AW Gange, SJ Hawkes, C O'Connell, RJ Ahuja, SK Dolan, MJ AF Silverberg, Michael J. Wegner, Scott A. Milazzo, Mark J. McKaig, Rosemary G. Williams, Carolyn F. Agan, Brian K. Armstrong, Adam W. Gange, Stephen J. Hawkes, Clifton O'Connell, Robert J. Ahuja, Sunil K. Dolan, Matthew J. CA Tri-Service AIDS Clinical TI Effectiveness of highly-active antiretroviral therapy by race/ethnicity SO AIDS LA English DT Article DE highly-active antiretroviral therapy; survival; AIDS; race/ethnicity; HIV seroconversion; effectiveness ID HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE PROGRESSION; POPULATION EFFECTIVENESS; AFRICAN-AMERICANS; AIDS PROGRESSION; GENE VARIANTS; HIV DISEASE; DRUG-USE; CCR5; RACE AB Objective: To determine the effectiveness of HAART by race/ethnicity. Design: Prospective multicenter cohort study. Methods: We studied 991 African-Americans and 911 European-Americans enrolled in the United States Military's Tri-Service AIDS Clinical Consortium Natural History Study who had dates of HIV seroconversion known within 5 years and followed between 1990 and 2002. We determined the rate of disease progression to AIDS and death for subjects in this cohort. Multivariable models evaluated race, pre-HAART (1990-1995) and HAART (1996-2002) eras, age, gender and military service. Results: In the pre-HAART era, African-Americans had a statistically nonsignificant trend towards better outcomes: the relative hazards (RH) of AIDS and death for African-Americans compared to European-Americans were 0.85 [95% confidence interval (CI), 0.68-1.051 and 0.77 (95% CI, 0.55-1.08), respectively. In the HAART era, outcomes were similar by race: 1.17 (95% CI, 0.86-1.61) for AIDS and 1.11 (95% CI, 0.81-1.53) for death with overlapping Kaplan-Meier curves. Relative to the pre-HAART era, the adjusted RH of AIDS in the HAART era was 0.41 (95% CI, 0.31-0.54) and 0.30 (95% CI, 0.22-0.40) for African-American and European-American participants, respectively. Analogous RH for death were 0.55 (95% CI, 0.38-0.80) and 0.38 (95% CI, 0.27-0.54). The precipitous declines in AIDS and death in the HAART era were not statistically different by race. Conclusions: In a large multi-racial cohort with equal access to health care, HIV treatment outcomes by race/ethnicity were similar. (c) 2006 Lippincott Williams & Wilkins. C1 Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. TACC, NHS, Rockville, MD USA. Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Div Retrovirol, Washington, DC 20307 USA. NIAID, Epidemiol Branch, Div AIDS, NIH,DHHS, Bethesda, MD 20892 USA. Wilford Hall USAF Med Ctr, Dept Infect Dis, Lackland AFB, TX 78236 USA. USN, Med Ctr, Portsmouth, VA USA. Walter Reed Army Med Ctr, Washington, DC 20307 USA. S Texas Vet Hlth Care Syst, Vet Adm Res Ctr Aids & HIV 1 Infect, San Antonio, TX USA. Univ Texas Hlth Ctr, Dept Med, San Antonio, TX USA. Def Inst Med Operat, Brooks AFB, TX USA. RP Dolan, MJ (reprint author), Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA. EM Matthew.Dolan@brooks.af.mil OI Gange, Stephen/0000-0001-7842-512X; Agan, Brian/0000-0002-5114-1669 FU NIAID NIH HHS [U01-AI-42590] NR 37 TC 35 Z9 36 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD JUL 13 PY 2006 VL 20 IS 11 BP 1531 EP 1538 DI 10.1097/01.aids.0000237369.41617.0f PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 076VE UT WOS:000239985400008 PM 16847408 ER PT J AU Barrett-Connor, E Mosca, L Collins, P Geiger, MJ Grady, D Kornitzer, M McNabb, MA Wenger, NK AF Barrett-Connor, E Mosca, L Collins, P Geiger, MJ Grady, D Kornitzer, M McNabb, MA Wenger, NK CA RUTH Trial Investigators TI Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ESTROGEN-REPLACEMENT THERAPY; RANDOMIZED CLINICAL-TRIAL; VERTEBRAL FRACTURE RISK; CORONARY-HEART-DISEASE; MULTIPLE OUTCOMES; PLUS PROGESTIN; TAMOXIFEN; REDUCTION; STROKE; OSTEOPOROSIS AB BACKGROUND: The effect of raloxifene, a selective estrogen-receptor modulator, on coronary heart disease (CHD) and breast cancer is not established. METHODS: We randomly assigned 10,101 postmenopausal women (mean age, 67.5 years) with CHD or multiple risk factors for CHD to 60 mg of raloxifene daily or placebo and followed them for a median of 5.6 years. The two primary outcomes were coronary events (i.e., death from coronary causes, myocardial infarction, or hospitalization for an acute coronary syndrome) and invasive breast cancer.) RESULTS: As compared with placebo, raloxifene had no significant effect on the risk of primary coronary events (533 vs. 553 events; hazard ratio, 0.95; 95 percent confidence interval, 0.84 to 1.07), and it reduced the risk of invasive breast cancer (40 vs. 70 events; hazard ratio, 0.56; 95 percent confidence interval, 0.38 to 0.83; absolute risk reduction, 1.2 invasive breast cancers per 1000 women treated for one year); the benefit was primarily due to a reduced risk of estrogen-receptor-positive invasive breast cancers. There was no significant difference in the rates of death from any cause or total stroke according to group assignment, but raloxifene was associated with an increased risk of fatal stroke (59 vs. 39 events; hazard ratio, 1.49; 95 percent confidence interval, 1.00 to 2.24; absolute risk increase, 0.7 per 1000 woman-years) and venous thromboembolism (103 vs. 71 events; hazard ratio, 1.44; 95 percent confidence interval, 1.06 to 1.95; absolute risk increase, 1.2 per 1000 woman-years). Raloxifene reduced the risk of clinical vertebral fractures (64 vs. 97 events; hazard ratio, 0.65; 95 percent confidence interval, 0.47 to 0.89; absolute risk reduction, 1.3 per 1000). CONCLUSIONS: Raloxifene did not significantly affect the risk of CHD. The benefits of raloxifene in reducing the risks of invasive breast cancer and vertebral fracture should be weighed against the increased risks of venous thromboembolism and fatal stroke. C1 Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA. Royal Brompton Hosp, Dept Cardiac Med, London, England. Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England. Lilly Res Labs, Indianapolis, IN USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Free Univ Brussels, Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Brussels, Belgium. Emory Univ, Sch Med, Atlanta, GA USA. RP Barrett-Connor, E (reprint author), Univ Calif San Diego, Dept Family & Prevent Med, 9500 Gilman Dr, La Jolla, CA 92093 USA. EM ebarrettconnor@ucsd.edu RI Boehm, Bernhard/F-8750-2015 NR 31 TC 543 Z9 564 U1 3 U2 14 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUL 13 PY 2006 VL 355 IS 2 BP 125 EP 137 DI 10.1056/NEJMoa062462 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 062UP UT WOS:000238970600004 PM 16837676 ER PT J AU Bibbins-Domingo, K Chertow, GM Fried, LF Odden, MC Newman, AB Kritchevsky, SB Harris, TB Satterfield, S Cummings, SR Shlipak, MG AF Bibbins-Domingo, Kirsten Chertow, Glenn M. Fried, Linda F. Odden, Michelle C. Newman, Anne B. Kritchevsky, Stephen B. Harris, Tamara B. Satterfield, Suzanne Cummings, Steven R. Shlipak, Michael G. TI Renal function and heart failure risk in older black and white individuals - The health, aging, and body composition study SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID GLOMERULAR-FILTRATION-RATE; FACTOR INTERVENTION TRIAL; CYSTATIN-C CONCENTRATION; CHRONIC KIDNEY-DISEASE; RACIAL-DIFFERENCES; UNITED-STATES; ATHEROSCLEROSIS RISK; EXPLANATORY FACTORS; AFRICAN-AMERICANS; ATTRIBUTABLE RISK AB Background: Chronic kidney disease is a risk factor for heart failure, an association that may be particularly important in blacks who are disproportionately affected by both processes. Our objective was to determine whether the association of chronic kidney disease with incident heart failure differs between blacks and whites. Methods: The study population comprised participants in the Health, Aging, and Body Composition Study without a diagnosis of heart failure (1124 black and 1676 white community-dwelling older persons). The main predictors were quintiles of cystatin C and creatinine concentrations and estimated glomerular filtration rate. The main outcome measure was incident heart failure. Results: Over a mean 5.7 years, 200 participants developed heart failure. High concentrations of cystatin C and low estimated glomerular filtration rate were each associated with heart failure, but the magnitude was greater for blacks than for whites (cystatin C concentration: adjusted hazard ratio for quintile 5 [>= 1.18 mg/dL] vs quintile 1 [< 0.84 mg/dL] was 3.0 [95% confidence interval 1.4-6.5] in blacks and 1.4 [95% confidence interval, 0.8-2.5] in whites; estimated glomerular filtration rate: adjusted hazard ratio for quintile 5 (< 59.2 mL/min) vs quintile 1 (> 86.7 mL/min) was 2.7 [95% confidence interval, 1.4-4.9] in blacks and 1.8 [95% confidence interval, 0.9-3.6] in whites). For cystatin C, this association was observed at more modest decrements in kidney function among blacks as well. The population attributable risk of heart failure was 47% for blacks with moderate or high concentrations of cystatin C (>= 0.94 mg/dL) (56% prevalence) but only 5% among whites (64% prevalence). Conclusion: The association of kidney dysfunction with heart failure appears stronger in blacks than for whites, particularly when cystatin C is used to measure kidney function. C1 Univ Calif San Francisco, Div Gen Internal Med, SFGH, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. Univ Pittsburgh, Div Renal & Electrolyte, Grad Sch Publ Hlth, Pittsburgh, PA USA. Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA 15261 USA. Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. Wake Forest Univ, Sch Med, Sticht Ctr Aging, Winston Salem, NC 27109 USA. NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA. Univ Tennessee, Dept Prevent Med, Memphis, TN 38163 USA. Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94115 USA. RP Bibbins-Domingo, K (reprint author), Univ Calif San Francisco, Div Gen Internal Med, SFGH, Box 1364, San Francisco, CA 94143 USA. EM bbinsk@medicine.ucsf.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NHLBI NIH HHS [N01-HC-95095, N01-HL073208-01]; NIA NIH HHS [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIDDK NIH HHS [R01 DK 06648] NR 34 TC 32 Z9 34 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JUL 10 PY 2006 VL 166 IS 13 BP 1396 EP 1402 DI 10.1001/archinte.166.13.1396 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 062AK UT WOS:000238916500009 PM 16832005 ER PT J AU Maynard, C Lowy, E Rumsfeld, J Sales, AE Sun, HL Kopjar, B Fleming, B Jesse, RL Rusch, R Fihn, SD AF Maynard, Charles Lowy, Elliott Rumsfeld, John Sales, Ann E. Sun, Haili Kopjar, Branko Fleming, Barbara Jesse, Robert L. Rusch, Roxane Fihn, Stephan D. TI The prevalence and outcomes of in-hospital acute myocardial infarction in the department of veterans affairs health system SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID MEDICAL-CENTERS; MORTALITY; CARE; PROJECT; US AB Background: Most studies of the epidemiology and treatment of acute myocardial infarction (AMI) have focused on patients who experienced onset of their symptoms in the community and then presented to the hospital. There are, however, patients whose symptoms of AMI begin after hospitalization for other medical conditions. The purposes of this study were to determine the prevalence of in-hospital AMI in the Veterans Health Administration (VHA) and to compare baseline characteristics, treatments, and outcomes according to whether individuals presented with AMI or had an in-hospital AMI. Methods: This was a retrospective cohort study of 7054 veterans who were hospitalized for AMI in 127 VHA medical centers between July 2003 and August 2004. The main outcome measure was 30-day mortality. Key covariates included age, body mass index, admission systolic blood pressure, heart rate, previous use of lipid-lowering drugs, elevated admission troponin value, prolonged and/or atypical chest pain on admission, and ST-segment elevation on the initial electrocardiogram. Results: There were 792 patients (11.2%) who had AMI while hospitalized for other medical conditions. These patients differed substantially from those who presented to the hospital with AMI. The odds of 30-day mortality were greater in the in-hospital group (odds ratio, 3.6; 95% confidence interval, 3.1-4.3; P < .001) and remained higher after statistical adjustment (odds ratio, 2.0; 95% confidence interval, 1.7-2.4; P < .001). Conclusion: Although most attention has been paid to patients with AMI admitted via the community emergency medical system or through the emergency department, AMI occurring during hospitalization for other medical problems is an important clinical problem. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. VA Eastern Colorado Hlth Care Syst, Dept Cardiol, Denver, CO USA. US Dept Vet Affairs, Off Qual & Performance, Washington, DC USA. Hunter Holmes McGuire Vet Affairs Med Ctr, Dept Cardiol, Richmond, VA USA. RP Maynard, C (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Mail Code 152,1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM cmaynard@u.washington.edu RI Sales, Anne/D-9678-2012; Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814; Sales, Anne/0000-0001-9360-3334 NR 21 TC 27 Z9 27 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JUL 10 PY 2006 VL 166 IS 13 BP 1410 EP 1416 DI 10.1001/archinte.166.13.1410 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 062AK UT WOS:000238916500011 PM 16832007 ER PT J AU Gopal, R Glasheen, JJ Miyoshi, TJ Prochazka, AV AF Gopal, Ravi Glasheen, Jeffrey J. Miyoshi, Tom J. Prochazka, Allan V. TI Resident hours in the pursuit of better health care - In reply SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter C1 Denver Vet Affairs Med Ctr, Dept Internal Med, Denver, CO 80220 USA. RP Gopal, R (reprint author), Denver Vet Affairs Med Ctr, Dept Internal Med, 1055 Clermont St,Box 11B, Denver, CO 80220 USA. EM ravi.gopal@med.va.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JUL 10 PY 2006 VL 166 IS 13 BP 1423 EP 1424 DI 10.1001/archinte.166.13.1423-b PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 062AK UT WOS:000238916500026 ER PT J AU Papay, R Gaivin, R Jha, A McCune, DF McGrath, JC Rodrigo, MC Simpson, PC Doze, VA Perez, DM AF Papay, R Gaivin, R Jha, A McCune, DF McGrath, JC Rodrigo, MC Simpson, PC Doze, VA Perez, DM TI Localization of the mouse alpha(1A)-adrenergic receptor (AR) in the brain: alpha(1A)AR is expressed in neurons, GABAergic interneurons, and NG2 oligodendrocyte progenitors SO JOURNAL OF COMPARATIVE NEUROLOGY LA English DT Article DE adrenergic receptor; in situ; localization; brain; transgenic ID IN-SITU HYBRIDIZATION; GLUTAMIC-ACID DECARBOXYLASE; ARTERIAL BLOOD-PRESSURE; MULTIPLE SYSTEM ATROPHY; CENTRAL-NERVOUS-SYSTEM; RAT SPINAL-CORD; ALPHA(1B)-ADRENERGIC RECEPTOR; ALPHA-1-ADRENERGIC RECEPTORS; SUBCELLULAR-LOCALIZATION; ALPHA-ADRENOCEPTORS AB alpha(1)-Adrenergic receptors (ARs) are not well defined in the central nervous system. The particular cell types and areas that express these receptors are uncertain because of the lack of high avidity antibodies and selective ligands. We have developed transgenic mice that either systemically overexpress the human alpha(1A)-AR subtype fused with the enhanced green fluorescent protein (EGFP) or express the EGFP protein alone under the control of the mouse alpha(1A)-AR promoter. We confirm our transgenic model against the alpha(1A)-AR knockout mouse, which expresses the LacZ gene in place of the coding region for the alpha(1A)-AR. By using these models, we have now determined cellular localization of the alpha(1A)-AR in the brain, at the protein level. The alpha(1A)-AR or the EGFP protein is expressed prominently in neuronal cells in the cerebral cortex, hippocampus, hypothalamus, midbrain, pontine olivary nuclei, trigeminal nuclei, cerebellum, and spinal cord. The types of neurons were diverse, and the alpha(1A)-AR colocalized with markers for glutamic acid decarboxylase (GAD), gamma-aminobutyric acid (GABA), and N-methyl-D-aspartate (NMDA) receptors. Recordings from alpha(1A)-AR EGFP-expressing cells in the stratum oriens of the hippocampal CA1 region confirmed that these cells were interneurons. We could not detect expression of the alpha(1A)-AR in mature astrocytes, oligodendrocytes, or cerebral blood vessels, but we could detect the alpha(1A)-AR in oligodendrocyte progenitors. We conclude that the alpha(1A)-AR is abundant in the brain, expressed in various types of neurons, and may regulate the function of oligodendrocyte progenitors, interneurons, GABA, and NMDA receptor containing neurons. C1 Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol NB50, Cleveland, OH 44195 USA. Univ N Dakota, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58201 USA. Univ Glasgow, Inst Biomed & Life Sci, Div Neurosci & Biomed Syst, Autonom Physiol Unit, Glasgow, Lanark, Scotland. San Francisco VA Med Ctr, Div Cardiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, CVRI, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Perez, DM (reprint author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol NB50, 9500 Euclid Ave, Cleveland, OH 44195 USA. EM perezd@ccf.org RI McGrath, John/G-6485-2012 OI McGrath, John/0000-0002-5276-0381 FU NCRR NIH HHS [5P20RR017699]; NHLBI NIH HHS [HL31113, R01 HL031113, R01HL61438]; PHS HHS [T32] NR 74 TC 52 Z9 53 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9967 J9 J COMP NEUROL JI J. Comp. Neurol. PD JUL 10 PY 2006 VL 497 IS 2 BP 209 EP 222 DI 10.1002/cne.20992 PG 14 WC Neurosciences; Zoology SC Neurosciences & Neurology; Zoology GA 050EC UT WOS:000238069300005 PM 16705673 ER PT J AU Knight, CL Fihn, SD AF Knight, Christopher L. Fihn, Stephan D. TI Update in general internal medicine SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID CONTROLLED-TRIALS; METAANALYSIS; PREVENTION; THERAPY; DISEASE; HEALTH; RISK C1 Univ Washington, Med Ctr, Seattle, WA 98105 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Knight, CL (reprint author), Univ Washington, Med Ctr, 4245 Roosevelt Way NE,Campus Box 354 760, Seattle, WA 98105 USA. EM clknight@u.washington.edu NR 16 TC 4 Z9 4 U1 1 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 4 PY 2006 VL 145 IS 1 BP 52 EP 61 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 062IS UT WOS:000238938400007 PM 16818929 ER PT J AU Ikonomidis, JS Jones, JA Barbour, JR Stroud, RE Clark, LL Kaplan, BS Zeeshan, A Bavaria, JE Gorman, JH Spinale, FG Gorman, RC AF Ikonomidis, JS Jones, JA Barbour, JR Stroud, RE Clark, LL Kaplan, BS Zeeshan, A Bavaria, JE Gorman, JH Spinale, FG Gorman, RC TI Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome SO CIRCULATION LA English DT Article; Proceedings Paper CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc DE aneurysm; aorta; Marfan; MMP; TIMP ID INTEGRIN ALPHA(V) SUBUNIT; FIBRILLIN-1; ACTIVATION; BINDING; CELLS; LOCALIZATION; ADHESION; MICE AB Background-Marfan syndrome (MFS) is known to cause ascending thoracic aortic aneurysms (ATAAs). Transforming growth factor beta (TGF-beta) has recently been implicated in this process. Imbalances between the matrix metalloproteinases ( MMPs) and their endogenous inhibitors (TIMPs) have also been shown to contribute to aneurysm formation. Whether and to what degree MMP, TIMP, and TGF-beta signaling profiles are altered in ATAAs in MFS compared with non-MFS patients remains unknown. Methods and Results-ATAA samples taken during aortic replacement from age-matched MFS (n = 9) and non-MFS (n = 18) patients were assessed for representative subtypes of all MMP classes, all 4 known TIMPs, and type 2 TGF-beta receptors (TGFBR2). Results were expressed as a percentage (mean +/- SEM) of reference control samples (100%; n = 18) obtained from patients without ATAA. In MFS, decreased MMP-2 ( 76 +/- 7; P < 0.05 versus control), increased MMP-12 (161 +/- 27% versus control; P < 0.05), and increased MT1-MMP 248 +/- 64% versus 91 +/- 21 non-MFS and control; P < 0.05) were observed. TIMP-3 (74 +/- 23%) was reduced compared with control values (P < 0.05) and TIMP-2 was elevated (128 +/- 31%) compared with non-MFS ( 3 +/- 19%; P < 0.05). In non-MFS samples, MMP-1 ( 70 +/- 16%), MMP-3 ( 7 +/- 18%), MMP-8 (75 +/- 11%), MMP-9 ( 69 +/- 14%), and MMP-12 (85 +/- 15%) were decreased compared with control (P < 0.05). TIMPs 1 to 3 were reduced in non-MFS compared with control values (P < 0.05). TGFBR2 were increased in MFS ( 193 +/- 32%) compared with non-MFS (95 +/- 16%) and controls (P < 0.05). Conclusions-A unique MMP and TIMP portfolio was observed in ATAAs from MFS compared with non-MFS patients. In addition, MFS samples showed evidence of increased TGF-beta signaling. These differences suggest disparate mechanisms of extracellular matrix remodeling between these 2 groups of patients. C1 Med Univ S Carolina, Div Cardiothorac Surg, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. Univ Penn, Div Cardiothorac Surg, Philadelphia, PA 19104 USA. RP Ikonomidis, JS (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Ralph H Johnson Vet Affairs Med Ctr, Suite 409 CSB,96 Jonathan Lucas St, Charleston, SC 29425 USA. EM ikonomij@musc.edu FU NHLBI NIH HHS [R01 HL 059165-07, R01 HL075488-01] NR 32 TC 42 Z9 42 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD JUL 4 PY 2006 VL 114 SU 1 BP I365 EP I370 DI 10.1161/CIRCULATIONAHA.105.000810 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 058TT UT WOS:000238688200059 PM 16820601 ER PT J AU Mukherjee, R Apple, KA Squires, CE Kaplan, BS McLean, JE Saunders, SM Stroud, RE Spinale, FG AF Mukherjee, R Apple, KA Squires, CE Kaplan, BS McLean, JE Saunders, SM Stroud, RE Spinale, FG TI Protein kinase C isoform activation and endothelin-1 mediated defects in myocyte contractility after cardioplegic arrest and reperfusion SO CIRCULATION LA English DT Article; Proceedings Paper CT 78th Annual Scientific Session of the American-Heart-Association CY NOV 13-16, 2005 CL Dallas, TX SP Amer Heart Assoc DE active relaxation; cardioplegia; endothelin; kinases; myocyte contractility ID CARDIOPULMONARY BYPASS; POSTOPERATIVE RECOVERY; VENTRICULAR MYOCYTES; HEART-FAILURE; CIRCULATION; CHANNELS AB Background-Endothelin-1 (ET-1) is released after hyperkalemic cardioplegic arrest (CA) and reperfusion and may contribute to contractile dysfunction. ET-1 receptor transduction causes activation of protein kinase C (PKC) isoforms, which can cause differential intracellular events. The goal of this study was to determine which PKC isoforms contribute to myocyte contractile dysfunction with ET-1 and CA. Methods and Results-Percent shortening (PERSHORT) and the time to 50% relaxation (T50) were measured in porcine (n = 22) left ventricular myocytes, randomized (minimum: 30 cells/group) to normothermia: (cell media for 2 hours/37 degrees C), and CA: (2 hours/4 degrees C, 24 mEq K+ solution followed by reperfusion in cell media), ET-1/CA: (100 pM ET-1 during CA). Studies were performed in the presence and absence of PKC inhibitors (500nM) against the classical (Beta-I, Beta-II, Gamma) and novel (Epsilon, Eta) isoforms (myocytes from a minimum of 3 pigs per inhibitor). CA reduced PERSHORT by approximate to 35% from normothermia (P < 0.05), which was further reduced with ET-1. PKC-Beta-II or PKC-Gamma inhibition increased PERSHORT from ET-1/CA as well as CA only (P < 0.05). CA prolonged T50 by approximate to 19% from normothermia (P < 0.05) and was further prolonged with ET-1. Inhibition of the classical PKC isoforms reduced T50 from ET-1/CA (P < 0.05). Inhibition of novel PKC isoforms did not yield similar effects on either PERSHORT or T50 with ET-1/CA. Conclusions-Inhibition of the classical PKC isoforms relieved the negative inotropic and lusitropic effects of ET-1 after CA. These findings provide mechanistic support for developing targeted inhibitory strategies with respect to ET-1 signaling and myocyte contractile dysfunction with cardioplegic arrest and reperfusion. C1 Med Univ S Carolina, Div Cardiothorac Surg Res, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Mukherjee, R (reprint author), Med Univ S Carolina, Div Cardiothorac Surg Res, 770 MUSC Complex,Suite 625, Charleston, SC 29425 USA. EM mukherr@musc.edu FU NHLBI NIH HHS [HL-97012, HL-66029, HL-45024]; PHS HHS [P01-48788] NR 23 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD JUL 4 PY 2006 VL 114 SU 1 BP I308 EP I313 DI 10.1161/CIRCULATIONAHA.105.001388 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 058TT UT WOS:000238688200050 PM 16820591 ER PT J AU Houston, TK Wall, T Allison, JJ Palonen, K Willett, LL Keife, CI Massie, FS Benton, EC Heudebert, GR AF Houston, Thomas K. Wall, Terry Allison, Jeroan J. Palonen, Katri Willett, Lisa L. Keife, Catarina I. Massie, F. Stanford Benton, E. Cason Heudebert, Gustavo R. TI Implementing achievable benchmarks in preventive health: A controlled trial in residency education SO ACADEMIC MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; MEDICAL-RECORD AUDIT; QUALITY IMPROVEMENT; PRACTICE GUIDELINES; GENERAL-PRACTICE; CHART AUDITS; CARE; PERFORMANCE; FEEDBACK; CALL AB Purpose To evaluate the Preventive Health Achievable Benchmarks Curriculum, a multifaceted improvement intervention that included an objective, practice-based performance evaluation of internal medicine and pediatric residents' delivery of preventive services. Method The authors conducted a nonranclonnized experiment of intervention versus control group residents with baseline and follow-up of performance audited for 2001-2004. All 130 internal medicine and 78 pediatric residents at two continuity clinics at the University of Alabama School of Medicine, Birmingham, participated. Performance of preventive care was assessed by structured chart review. The multifaceted feedback curriculum included individualized performance feedback, academic detailing by faculty, and collective didactic sessions. The main outcome was difference in receipt of preventive care for patients seen by intervention and control residents, comparing baseline and follow-up. Results Charts were reviewed for 3,958 patients Receipt of preventive care increased for patients of intervention residents, but not for patients of control residents. For the intervention group, significant increases occurred for five of six indicators in internal medicine: smoking screening, quit smoking advice, colon cancer screening, pneumonia vaccine, and lipid screening; and four of six in pediatrics: parental quit smoking advice, car seats, car restraints, and eye alignment (P < .05 for all). For control residents, no consistent improvements were seen. There was greater improvement for intervention than for control residents for four of six indicators in internal medicine, and two of six in pediatrics. Conclusions Using a multifaceted feedback curriculum, the authors taught residents about the care they provide and improved documented patient care. C1 Univ Alabama, Sch Med, Div Gen Internal Med, Birmingham, AL 35294 USA. Univ Alabama, Sch Med, Div Prevent Med, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Deep S Ctr Effectiveness Res, Birmingham, AL USA. Univ Alabama, Sch Med, Ctr Outcomes & Effectiveness Res, Birmingham, AL 35233 USA. Univ Alabama, Sch Med, Div Gen Pediat, Birmingham, AL 35294 USA. RP Houston, TK (reprint author), Univ Alabama, Sch Med, Div Gen Internal Med, 1530 3rd Ave S,FOT 720, Birmingham, AL 35294 USA. EM thouston@uab.edu RI Houston, Thomas/F-2469-2013 OI Allison, Jeroan/0000-0003-4472-2112 NR 37 TC 11 Z9 12 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD JUL PY 2006 VL 81 IS 7 BP 608 EP 616 DI 10.1097/01.ACM.0000232410.97399.8f PG 9 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 061UU UT WOS:000238899100004 PM 16799281 ER PT J AU Weissmann, PF Branch, WT Gracey, CF Haidet, P Frankel, RM AF Weissmann, Peter F. Branch, William T. Gracey, Catherine F. Haidet, Paul Frankel, Richard M. TI Role modeling humanistic behaviour: Learning bedside manner from the experts SO ACADEMIC MEDICINE LA English DT Article ID COMMUNICATION-SKILLS; PATIENT SATISFACTION; ATTENDING-PHYSICIAN; HIDDEN CURRICULUM; MEDICAL-EDUCATION; HUMAN DIMENSIONS; CARE; STUDENTS; RESIDENTS; SETTINGS AB Purpose Humanistic care is regarded as important by patients and professional accrediting agencies, but little is known about how attitudes and behaviors in this domain are taught in clinical settings. To answer this question, the authors studied how excellent clinical teachers impart the behaviors and attitudes consistent with humanistic care to their learners. Method Using an observational, qualitative methodology, the authors studied 12 clinical faculty identified by the medical residents enrolled from 2003 to 2004 as excellent teachers of humanistic care on the inpatient medical services at four medical universities in the United States (University of Minnesota Medical School, Emory University, University of Rochester School of Medicine, and Baylor College of Medicine). Observations were conducted by the authors using standardized field notes. After each encounter, the authors debriefed patients, learners (residents and medical students), and the teaching physicians in semistructured interviews. Results Clinical teachers taught primarily by role modeling. Although they were highly aware of their significance as role models, they did not typically address the human dimensions of care overtly. Despite the common themes of role modeling identified, each clinical teacher exhibited unique teaching strategies. These clinical teachers identified self-reflection as the primary method by which they developed and refined their teaching strategies. Conclusions Role modeling is the primary method by which excellent clinical teachers try to teach medical residents humanistic aspects of medical care. Although clinical teachers develop unique teaching styles and strategies, common themes are shared and could be used for the future development of clinical faculty. C1 Univ Minnesota, Dept Med, Hennepin Cty Med Ctr, Sch Med, Minneapolis, MN 55415 USA. Emory Univ, Sch Med, Div Gen Internal Med, Atlanta, GA USA. Univ Rochester, Med Ctr, Sch Med & Dent, Rochester, NY 14642 USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Indiana Univ, Sch Med, Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA. Richard L Roudebush Vet Affairs Med Ctr, Ctr Implementing Evidence Based Practice, Indianapolis, IN 46202 USA. RP Weissmann, PF (reprint author), Univ Minnesota, Dept Med, Hennepin Cty Med Ctr, Sch Med, 701 Pk Ave S, Minneapolis, MN 55415 USA. EM weiss017@umn.edu NR 43 TC 68 Z9 69 U1 0 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD JUL PY 2006 VL 81 IS 7 BP 661 EP 667 DI 10.1097/01.ACM.0000232423.81299.fe PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 061UU UT WOS:000238899100012 PM 16799294 ER PT J AU Tache, Y AF Tache, Yvette TI New CRF antagonists: A new approach to IBS SO ACTA PHARMACOLOGICA SINICA LA English DT Meeting Abstract DE CRF; CRFl receptor; gut function; visceral pain C1 Univ Calif Los Angeles, Digest Dis Res Ctr, David Geffen Sch Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1671-4083 J9 ACTA PHARMACOL SIN JI Acta Pharmacol. Sin. PD JUL PY 2006 VL 27 SU 1 BP 6 EP 6 PG 1 WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy SC Chemistry; Pharmacology & Pharmacy GA 071HI UT WOS:000239590000037 ER PT J AU Becker, HC Myrick, H Veatch, LM AF Becker, HC Myrick, H Veatch, LM TI Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal SO ALCOHOL AND ALCOHOLISM LA English DT Article ID PLACEBO-CONTROLLED TRIAL; GENERALIZED ANXIETY DISORDER; ETHANOL WITHDRAWAL; DOUBLE-BLIND; POSTHERPETIC NEURALGIA; NONCONVULSIVE SEIZURES; ADJUNCTIVE THERAPY; DOSE-RESPONSE; GABAPENTIN; CALCIUM AB Aims: Pregabalin has been shown to possess anticonvulsant, analgesic, and anxiolytic properties in a variety of testing situations. This study was designed to evaluate the ability of pregabalin to exert its anticonvulsant effects against behavioral and electrographic measures of CNS hyperexcitability associated with alcohol withdrawal in a mouse model of ethanol dependence. Methods: Adult mice were chronically exposed to ethanol and, upon withdrawal, were tested for behavioral signs of seizure activity (handling-induced convulsions) or abnormalities in spontaneous EEG activity recorded from cortical and subcortical sites. Results: Pregabalin (50-200 mg/kg) administered 1 and 4 h into withdrawal dose dependently reduced severity of handling-induced convulsions in comparison to vehicle-treated mice. Similarly, pregabalin reduced the frequency in which EEG activity was interrupted by trains of high-voltage synchronous activity in a dose-related fashion. Finally, pregabalin treatment of repeated withdrawals was effective in blocking the development of withdrawal sensitization observed in vehicle-treated mice. Conclusions: Collectively, these results suggest that pregabalin may be an effective therapeutic agent for medical management of alcohol detoxification. C1 Inst Psychiat, Ctr Drug & Alcohol Programs, Charleston Alcohol Res Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Dept Vet Affairs, Charleston, SC USA. RP Becker, HC (reprint author), Inst Psychiat, Ctr Drug & Alcohol Programs, Charleston Alcohol Res Ctr, 67 President St, Charleston, SC 29425 USA. EM beckerh@musc.edu FU NIAAA NIH HHS [P50-AA10761] NR 57 TC 17 Z9 20 U1 3 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0735-0414 J9 ALCOHOL ALCOHOLISM JI Alcohol Alcohol. PD JUL-AUG PY 2006 VL 41 IS 4 BP 399 EP 406 DI 10.1093/alcalc/ag1029 PG 8 WC Substance Abuse SC Substance Abuse GA 059VC UT WOS:000238759300009 PM 16636010 ER PT J AU Shaib, YH Davila, JA El-Serag, B AF Shaib, Y. H. Davila, J. A. El-Serag, B. TI The epidemiology of pancreatic cancer in the United States: changes below the surface SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID SURVIVAL; PANCREATICODUODENECTOMY; STATISTICS; CARCINOMA; AMERICANS; WHITES AB Background Pancreatic cancer is the fourth leading cause of cancer death in the United States. Aim To examine temporal changes in the incidence and survival of patients with pancreatic adenocarcinoma. Methods Using data from nine registries of the Surveillance, Epidemiology and End Results programme, age-adjusted incidence rates per 100 000 and survival rates were calculated for pancreatic cancer between 1977 and 2001. Results We identified 58 655 cases of pancreatic cancer. The age-adjusted incidence rate remained stable during the study period (11.3 in 1977-1981 and 10.9 in 1997-2001). Overall, men were 30% more affected than women (age-adjusted incidence rate of 13.0 in men and 9.8 in women). The age-adjusted incidence rates were almost 50% higher among Blacks (16.4) than Whites (10.8) and people of other races (9.8). Over time the proportions of patients with localized disease decreased from 12.3% to 7.4% and those with regional disease increased from 18.6% to 25.8%, while metastatic disease remained stable (52.5% vs. 49.8%). The 1-year relative survival increased from 15.2% in 1977-1981 to 21.6% in 1997-2001. Conclusions The incidence of pancreatic cancer is stable. A shift from localized to regional disease was observed over time. The overall survival remains poor despite important improvements among patients with early stage disease. C1 Michael E Debakey Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. Michael E Debakey Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Shaib, YH (reprint author), Michael E Debakey Vet Affairs Med Ctr, Sect Hlth Serv Res, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM yshaib@bcm.tmc.edu RI qiao, zhixin/I-3408-2012 NR 18 TC 87 Z9 96 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD JUL 1 PY 2006 VL 24 IS 1 BP 87 EP 94 DI 10.1111/j.1365-2036.2006.02961.x PG 8 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 053LH UT WOS:000238306100008 PM 16803606 ER PT J AU Lieber, CS Weiss, DG Morgan, TR Paronetto, F AF Lieber, CS Weiss, DG Morgan, TR Paronetto, F TI Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID CHRONIC HEPATITIS-C; BIOPSY; CIRRHOSIS; POLYENYLPHOSPHATIDYLCHOLINE; VARIABILITY; FIBROTEST; DIAGNOSIS; DISEASE; TESTS; APRI AB OBJECTIVE: Aspartate aminotransferase (AST) to platelet ratio index (APRI) has been proposed as an easily determined and accurate noninvasive marker of liver fibrosis in chronic hepatitis C. To validate APRI in hepatitis C and to determine its usefulness in other liver diseases, we evaluated APRI in patients with liver fibrosis due to excessive alcohol consumption with or without viral hepatitis C. METHODS: A total of 1,308 subjects from two VA cooperative studies of alcoholic liver disease were evaluated. Liver biopsy was available from 781 noncirrhotic patients while a history of decompensation was present in 527. Alcohol intake was determined by self-report. Hepatitis C was confirmed by PCR. RESULTS: Ninety-eight percent were men with a mean age of 51.5 yr. Alcohol intake averaged 19 drinks/day for 20.6 yr. One hundred thirty-three (10.2%) were hepatitis C positive. In the HCV-positive subgroup, APRI had a sensitivity of 35.6% and a specificity of 29.7% for significant fibrosis. Of 64 patients classified as significant fibrosis, 21 (32.8%) were incorrectly classified. In the 507 HCV negative patients with biopsy confirmed fibrosis, the sensitivity of APRI for significant fibrosis was 13.2% and the specificity was 77.6%. Twenty percent were classified incorrectly. CONCLUSION: APRI has low sensitivity and specificity for the diagnosis of significant fibrosis in patients with alcoholic liver disease, including patients who have hepatitis C. Given the frequent history of alcohol use in patients with hepatitis C, APRI may be of limited usefulness in the diagnosis of fibrosis in many patients. C1 James J Peters VA Med Ctr, Alcohol Dependency Treatment Practice, Bronx, NY 10468 USA. James J Peters VA Med Ctr, Ctr Alcohol Res & Treatment, Sect Liver Dis & Nutr, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Med, New York, NY USA. Vet Affaird Maryland Hlth Care Syst, Perry Point, MD USA. Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. Vet Affairs Long Beach Healthcare Syst, Long Beach, CA USA. Univ Calif Irvine, Sch Med, Div Gastroenterol, Irvine, CA 92717 USA. RP Lieber, CS (reprint author), James J Peters VA Med Ctr, Alcohol Dependency Treatment Practice, 151-2,130 W Kingsbridge Rd, Bronx, NY 10468 USA. FU NIAAA NIH HHS [AA014326] NR 21 TC 55 Z9 57 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JUL PY 2006 VL 101 IS 7 BP 1500 EP 1508 DI 10.1111/j.1572-0241.2006.00610.x PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 058GU UT WOS:000238654300016 PM 16863553 ER PT J AU Monto, A Kakar, S Dove, LM Bostrom, A Miller, EL Wright, TL AF Monto, A Kakar, S Dove, LM Bostrom, A Miller, EL Wright, TL TI Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; CO-INFECTED PATIENTS; LIVER FIBROSIS; ANTIRETROVIRAL THERAPY; PROGRESSION; IMPACT; STEATOSIS; CIRRHOSIS; ALCOHOL; DISEASE AB OBJECTIVES: The aim of this study was to further explore the severity of liver disease and its predictors in a cohort of hepatitis C virus (HCV) infected patients, some of whom were coinfected with the human immunodeficiency virus (HIV). METHODS: This is a retrospective, cross-sectional study of patients undergoing liver biopsy to stage HCV disease prior to consideration of anti-HCV therapy. RESULTS: A total of 92 HIV-HCV coinfected and 372 HCV monoinfected patients were included. As might be expected, coinfected patients differed from monoinfected patients in a number of ways, including having lower body mass index (BMI), and lower alcohol intake. Liver disease was very similar between the two groups, with mean fibrosis score of 1.45 u for coinfected and 1.53 u for monoinfected (p = NS). Histological inflammation score dominated multivariate models of fibrosis when it was included in them. When only clinical predictors were used in multivariate models, BMI and type 2 diabetes had independent associations in monoinfected patients, whereas low CD4 count, current or nadir, was the only variable with an independent association in coinfected patients. CONCLUSIONS: Coinfected patients do not have uniformly worse liver disease than monoinfected patients. Immune compromise plays an important role in liver disease in coinfected patients, and the role of other clinical factors in liver disease may differ between these two groups, as well. C1 San Francisco Vet Affairs Med Ctr, Dept Pathol, San Francisco, CA 94121 USA. Vet Affairs Med Ctr, Gastroenterol Sect, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Monto, A (reprint author), San Francisco Vet Affairs Med Ctr, Dept Pathol, 4150 Clement St,111B, San Francisco, CA 94121 USA. FU NIDA NIH HHS [DA-13737] NR 21 TC 21 Z9 21 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JUL PY 2006 VL 101 IS 7 BP 1509 EP 1515 DI 10.1111/j.1572-0241.2006.00613.x PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 058GU UT WOS:000238654300017 PM 16863554 ER PT J AU Painter, P Johansen, KL AF Painter, Patricia Johansen, Kirsten L. TI Improving physical functioning: Time to be a part of routine care SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Editorial Material ID EXERCISE CAPACITY; HEMODIALYSIS; DIALYSIS; MORTALITY; SURVIVAL; ASSOCIATION; PATIENT; PROGRAM; HEALTH C1 Univ Minnesota, Dept Internal Med, Div Renal Dis & Hypertens, Minneapolis, MN 55455 USA. Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, Div Nephrol, San Francisco, CA 94143 USA. RP Painter, P (reprint author), Univ Minnesota, Dept Internal Med, Div Renal Dis & Hypertens, Minneapolis, MN 55455 USA. NR 26 TC 33 Z9 34 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JUL PY 2006 VL 48 IS 1 BP 167 EP 170 DI 10.1053/j.ajkd.2006.05.004 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 060UD UT WOS:000238826200021 PM 16797401 ER PT J AU Menon, V Rumsfeld, JS Roe, MT Cohen, MG Peterson, ED Brindis, RG Chen, AY Pollack, CV Smith, SC Gibler, WB Ohman, EM AF Menon, Venu Rumsfeld, John S. Roe, Matthew T. Cohen, Mauricio G. Peterson, Eric D. Brindis, Ralph G. Chen, Anita Y. Pollack, Charles V., Jr. Smith, Sidney C., Jr. Gibler, W. Brian Ohman, E. Magnus TI Regional outcomes after admission for high-risk non ST-segment elevation acute coronary syndromes SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE acute coronary syndromes; non-ST elevation myocardial infarction; outcomes; regional variation ID ACUTE MYOCARDIAL-INFARCTION; COOPERATIVE CARDIOVASCULAR PROJECT; PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; MEDICARE BENEFICIARIES; THROMBOLYTIC THERAPY; AMERICAN-COLLEGE; UNSTABLE ANGINA; CARE; MANAGEMENT AB PURPOSE: An analysis of reginal variation across the United States in the treatment and outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) has not been previously performed. SUBJECTS AND METHODS: We assessed contemporary practice and outcomes in 56,466 high-risk patients with NSTE ACS (positive cardiac markers and/or ischemic ST-segment changes) admitted to 310 hospitals across four defined regions in the United States from January 1, 2001, to September 30, 2003. Patient clinical characteristics, acute (< 24 hours) and discharge medications, in-hospital procedures, and in-hospital case-fatality rates were evaluated. RESULTS: Statistically significant but clinically small differences in baseline characteristics including age, gender, rates of diabetes, hypertension, and smoking, as well as medical treatment, including a greater than 5% variation in acute use of beta-blockers, clopidogrel, and statins use, were noted across regions. Adjusted rates of revascularization were similar across regions. Overall in-hospital case- fatality rate was 4.1%, with the highest rates in the Midwest (4.6%) and the lowest in the Northeast (3.5%). Adjusted odds ratios (OR) (95% confidence interval [CI] for death were significantly higher in the Midwest (OR 1.42, CI 1.19-1.70), West (OR 1.40 CI 1.05-1.87), and South (OR 1.33, CI 1.08-1.62), compared with the Northeast. CONCLUSIONS: Management of high-risk patients with NSTE ACS is relatively uniform across the United States. However, in-hospital case- fatality rates vary significantly by region, and the differences are not explained by adjustment for standard clinical variables. (c) 2006 Elsevier Inc. All rights reserved. C1 Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA. Denver VA Med Ctr, Cardiol Sect, Denver, CO USA. Duke Univ, Med Ctr, Div Cardiol, Durham, NC USA. Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. Univ N Carolina, Sch Med, Div Cardiol, Chapel Hill, NC USA. Oakland Kaiser Permanente Hosp, San Francisco, CA USA. Univ Penn, Sch Med & Dent, Dept Emergency Med, Philadelphia, PA 19104 USA. Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH USA. RP Menon, V (reprint author), Cleveland Clin Fdn, Dept Cardiol, 9500 Euclid Ave,F-15, Cleveland, OH 44195 USA. EM menonv@ccf.org OI Cohen, Mauricio/0000-0003-2038-6070 NR 17 TC 8 Z9 8 U1 0 U2 2 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JUL PY 2006 VL 119 IS 7 BP 584 EP 590 DI 10.1016/j.amjmed.2006.01.018 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 060XP UT WOS:000238835500010 PM 16828630 ER PT J AU Schnapp, LM Donohoe, S Chen, JZ Sunde, DA Kelly, PM Ruzinski, J Martin, T Goodlett, DR AF Schnapp, LM Donohoe, S Chen, JZ Sunde, DA Kelly, PM Ruzinski, J Martin, T Goodlett, DR TI Mining the acute respiratory distress syndrome proteome: Identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injury SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID BRONCHOALVEOLAR LAVAGE FLUID; IDIOPATHIC PULMONARY-FIBROSIS; TANDEM MASS-SPECTROMETRY; III PROCOLLAGEN PEPTIDE; IGF BINDING PROTEIN-3; FACTOR-I; FIBROBLAST PROLIFERATION; NEUTROPHIL APOPTOSIS; STATISTICAL-MODEL; CELL APOPTOSIS AB To obtain a more complete protein profile of the airspace milieu in acute respiratory distress syndrome (ARDS) and to identify new mediators, we analyzed bronchoalveolar lavage fluid (BALF) by shotgun proteomics. Using BALF from three patients, we identified a total of 870 different proteins, a nearly 10-fold increase from previous reports. Among the proteins identified were known markers of lung injury, such as surfactant, proteases, and serum proteins. We also identified several biologically interesting proteins not previously identified in patients with ARDS, including insulin-like growth factor-binding protein-3 (IGFBP-3). Because of the known role of IGFBP-3 in regulating cell survival, we measured IGFBP-3 levels by enzyme-linked imnumosorbent assay in ARDS BALF. Normal controls had low levels of IGFBP-3, whereas patients with early ARDS had a significant increase in IGFBP-3. The IGF pathway, acting through the type 1 IGF-receptor, repressed apoptosis of lung fibroblasts but not lung epithelial cells. Furthermore, depletion of IGF in ARDS BALF led to enhanced fibroblast apoptosis. Our data suggest that the IGFBP-3/IGF pathway is involved in the pathogenesis of lung injury, illustrating the power of shotgun proteomics to catalog proteins present in complex biological fluids, such as BALF, from which hypotheses can be developed and tested. C1 Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, Seattle, WA 98104 USA. Inst Syst Biol, Seattle, WA USA. Univ Washington, Dept Med Chem, Seattle, WA 98104 USA. Vet Affairs Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA USA. RP Schnapp, LM (reprint author), Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, 325 9Th Ave, Seattle, WA 98104 USA. EM lschnapp@u.washington.edu FU NHLBI NIH HHS [R01 HL73028, R01 HL073028, P50 HL073996, N01-HV-28179, N01HV28179]; NIAID NIH HHS [U54 AI057141, 1U54AI57141-01]; NIEHS NIH HHS [5P30ES007033-10, P30 ES007033] NR 51 TC 44 Z9 44 U1 0 U2 0 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD JUL PY 2006 VL 169 IS 1 BP 86 EP 95 DI 10.2353/ajpath.2006.050612 PG 10 WC Pathology SC Pathology GA 058KU UT WOS:000238664700008 PM 16816363 ER PT J AU Cattaruzza, F Cenac, N Barocelli, E Impicciatore, M Hyun, E Vergnolle, N Sternini, C AF Cattaruzza, F Cenac, N Barocelli, E Impicciatore, M Hyun, E Vergnolle, N Sternini, C TI Protective effect of proteinase-activated receptor 2 activation on motility impairment and tissue damage induced by intestinal ischemia/reperfusion in rodents SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID ISCHEMIA-REPERFUSION INJURY; GENE-RELATED PEPTIDE; MAST-CELL TRYPTASE; NITRIC-OXIDE; MOLECULAR-CLONING; SUBSTANCE-P; NECROTIZING ENTEROCOLITIS; PARACELLULAR PERMEABILITY; NEUROGENIC MECHANISM; SUGGESTIVE EVIDENCE AB We hypothesized that proteinase-activated receptor-2 (PAR(2)) modulates intestinal injuries induced by ischemia/reperfusion. Ischemia (I hour) plus reperfusion (6 hours) significantly delayed gastrointestinal transit (GIT) compared with sham operation. Intraduodenal injection of PAR(2)-activating peptide SLIGRL-NH2 Significantly accelerated transit in ischemia/reperfusion but not in sham-operated rats. GIT was significantly delayed in ischemia/reperfusion and sham-operated PAR(2)(-/-) mice compared with PAR(2)(+/+) SIJGRL-NH2 Significantly accelerated transit in ischemia/reperfusion in PAR2+/+ but not in PAR(2)(+/+) mice. Prevention of mast cell degranulation with cromolyn, ablation of visceral afferents; with capsaicin, and antagonism of calcitonin gene-related peptide (CGRP) and neurokinin-1 receptors with CGRP(8-37) and RP67580, respectively, abolished the SLIGRL-NH2-induced stimulatory effect on transit in ischemia/reperfusion. Tissue damage was significantly reduced by SLIGRL-NH2; this effect was not observed in cromolyn-, capsaicin-, or RP67580-treated rats but was detected following CGRP(8-37). lntestinal PARI mRNA levels were not affected by SLIGRL-NH2 in ischemia/reperfusion. We propose that PAR2 modulates GIT and tissue damage in intestinal ischemia/reperfusion by a mechanism dependent on mast cells and visceral afferents. PAR, effect on transit might be mediated by CGRP and substance P, whereas the effect on tissue damage appears to involve substance P but not CGRP. PAR, might he a signaling system in the neuroimmune communication in intestinal ischemia/reperfusion. C1 Vet Affairs Greater Los Angeles Hlth Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Ctr Ulcer Res & Educ, Digest Dis Res Ctr, David Geffen Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Div Digest Dis, Dept Med, David Geffen Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Div Digest Dis, Dept Neurobiol, David Geffen Sch Med, Los Angeles, CA USA. Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB, Canada. Univ Parma, Dept Pharmacol Biol & Appl Chem Sci, I-43100 Parma, Italy. RP Sternini, C (reprint author), Vet Affairs Greater Los Angeles Hlth Syst, 11301 Wilshire Blvd,CURE Bldg 115,Rm 224, Los Angeles, CA 90073 USA. EM csternin@ucla.edu RI Barocelli, Elisabetta/C-4509-2013 FU NCI NIH HHS [F32 CA090073]; NIDDK NIH HHS [DK 41301, DK 51455, DK 57037] NR 67 TC 39 Z9 42 U1 0 U2 1 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD JUL PY 2006 VL 169 IS 1 BP 177 EP 188 DI 10.2353/ajpath.2006.051098 PG 12 WC Pathology SC Pathology GA 058KU UT WOS:000238664700016 PM 16816371 ER PT J AU Inagami, S Cohen, DA Finch, BK Asch, SM AF Inagami, Sanae Cohen, Deborah A. Finch, Brian Karl Asch, Steven M. TI You are where you shop - Grocery store locations, weight, and neighborhoods SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SOCIOECONOMIC DIFFERENCES; MULTILEVEL ANALYSIS; RISK-FACTORS; ENVIRONMENT; SUPERMARKETS; DEPRIVATION; CONSUMPTION; MORTALITY; PREGNANCY; OBESITY AB Background: Residents in poor neighborhoods have higher body mass index (BMI) and eat less healthfully. One possible reason might be the quality of available foods in their area. Location of grocery stores where individuals shop and its association with BMI were examined. Methods: The 2000 U.S. Census data were linked with the Los Angeles Family and Neighborhood Study (L.A.FANS) database, which consists of 2620 adults sampled from 65 neighborhoods in Los Angeles County between 2000 and 2002. In 2005, multilevel linear regressions were used to estimate the associations between BMI and socioeconomic characteristics of grocery store locations after adjustment for individual-level factors and socioeconomic characteristics of residential neighborhoods. Results: Individuals have higher BMI if they reside in disadvantaged areas and in areas where the average person frequents grocery stores located in more disadvantaged neighborhoods. Those who own cars and travel farther to their grocery stores also have higher BMI. When controlling for grocery store census tract socioeconomic status (SES), the association between residential census tract SES and BMI becomes stronger. Conclusions: Where people shop for groceries and distance traveled to grocery stores are independently associated with BMI. Exposure to grocery store mediates and suppresses the association of residential neighborhoods with BMI and could explain why previous studies may not have found robust associations between residential neighborhood predictors and BMI. C1 VA Greater Los Angeles Hlth Care Syst, Vet Affairs Hlth Serv & Res Dev, Div Gen Int Med 111G, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. San Diego State Univ, Social Sci Res Lab, San Diego, CA 92182 USA. RP Inagami, S (reprint author), VA Greater Los Angeles Hlth Care Syst, Vet Affairs Hlth Serv & Res Dev, Div Gen Int Med 111G, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM sinagami@ucla.edu RI Mavoa, Suzanne/B-5372-2010 FU NIMHD NIH HHS [R40MD00303] NR 36 TC 151 Z9 152 U1 0 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUL PY 2006 VL 31 IS 1 BP 10 EP 17 DI 10.1016/j.amepre.2006.03.019 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 059GM UT WOS:000238721300002 PM 16777537 ER PT J AU Silveira, MJ Copeland, LA Feudtner, C AF Silveira, MJ Copeland, LA Feudtner, C TI Likelihood of home death associated with local rates of home birth: Influence of local area healthcare preferences on site of death SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID OF-HOSPITAL BIRTHS; PLACE; TRENDS AB Objectives. We tested whether local cultural and social values regarding the use of health care are associated with the likelihood of home death, using variation in local rates of home births as a proxy for geographic variation in these values. Methods. For each of 351110 adult decedents in Washington state who died from 1989 through 1998, we calculated the home birth rate in each zip code during the year of death and then used multivariate regression modeling to estimate the relation between the likelihood of home death and the local rate of home births. Results. Individuals residing in local areas with higher home birth rates had greater adjusted likelihood of dying at home (odds ratio [OR] = 1.04 for each percentage point increase in home birth rate; 95% confidence interval [CI] = 1.03, 1.05). Moreover, the likelihood of dying at home increased with local wealth (OR = 1.04 per $10000; 95% CI = 1.02, 1.06) but decreased with local hospital bed availability (OR = 0.96 per 1000 beds; 95% CI = 0.95, 0.97). Conclusions. The likelihood of home death is associated with local rates of home births, suggesting the influence of health care use preferences. C1 VA Hlth Serv Res & Dev Ctr Excellence, VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. Univ Michigan, Div Gen Med, Ann Arbor, MI 48109 USA. Univ Michigan, Bioeth Program, Ann Arbor, MI 48109 USA. Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, VERDICT Res Program, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Pediat Generalist Res Grp, Dept Pediat, Ctr Bioeth,Leonard Davis Inst, Philadelphia, PA 19104 USA. RP Silveira, MJ (reprint author), 300 N Ingalls Bldg,Room 7C27,Box 0429, Ann Arbor, MI 48109 USA. EM mariajs@umich.edu FU AHRQ HHS [K08 HS000002, KO8-HS0000002] NR 24 TC 2 Z9 2 U1 2 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUL PY 2006 VL 96 IS 7 BP 1243 EP 1248 DI 10.2105/AJPH.2005.063057 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 058IO UT WOS:000238658900025 PM 16735639 ER PT J AU Woodworth, BA Lathers, D Neal, JG Skinner, M Richardson, M Young, MR Schlosser, RJ AF Woodworth, Bradford A. Lathers, Deanne Neal, Jeffery G. Skinner, Margaret Richardson, Mary Young, M. Rita Schlosser, Rodney J. TI Immunolocalization of surfactant protein A and D in sinonasal mucosa SO AMERICAN JOURNAL OF RHINOLOGY LA English DT Article ID PSEUDOMONAS-AERUGINOSA; ALVEOLAR MACROPHAGES; HOST-DEFENSE; IN-VIVO; EXPRESSION; LOCALIZATION; PHAGOCYTOSIS; COLLECTINS; CELLS; INFECTION AB Background: Surfactant-associated proteins (SP) A and D are in the family of collectin proteins that play an integral part in the innate defense system. SP-A and SP-D expression and function are altered in a variety of inflammatory and infectious diseases of the lungs, such as asthma, allergies, and cystic fibrosis. Our prior studies are the first to identify the presence of these proteins in the human sinonasal cavity. The objective of this study was to immunolocalize SP-A and SP-D in human sinonasal tissue. Methods: Sinonasal mucosal biopsies were performed in patients with various forms of chronic hyperplastic rhinosinusitis with nasal polyposis and nondiseased mucosa from patients undergoing transsphenoidal hypophysectomy. (n = 10) Immunolocalization of surfactant proteins was performed with antibodies to SP-A and SP-D using immunoperoxidase staining technique, Isotype-negative controls were performed on all, specimens. Results: Analyses of mucosal biopsy specimens from human sinonasal tissue reveals staining within respiratory and intermediate (metaplastic)-type surface unit. In addition, staining was intense in the submucosal ductal epithelium of the seromucinous glands. These properties appear to be consistent regardless of disease state and location within the sinuses. Conclusion: This is the first study to immunolocalize SP-A and SP-D in sinonasal human mucosa. These are secreted proteins that are intricately involved in innate immunity in the lungs. Their secretion in the upper airway indicates that future studies may allow manipulation of these proteins and development of novel treatments for sinonasal pathology. C1 Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med & Immunol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Woodworth, BA (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,Suite 1130,POB 250550, Charleston, SC 29425 USA. EM woodwort@musc.edu NR 27 TC 24 Z9 27 U1 0 U2 1 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1050-6586 J9 AM J RHINOL JI Am. J. Rhinol. PD JUL-AUG PY 2006 VL 20 IS 4 BP 461 EP 465 DI 10.2500/ajr.2006.20.2892 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA 077RJ UT WOS:000240047200019 PM 16955780 ER PT J AU Schumacher, HR Becker, MA Wortmann, RL Lloyd, E MacDonald, PA Joseph-Ridge, N AF Schumacher, H. R. Becker, M. A. Wortmann, R. L. Lloyd, E. MacDonald, P. A. Joseph-Ridge, N. TI The focus trial 48-month interim analysis: Long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open-label extension study SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT Annual European Congress of Rheumatology (EULAR 2006) CY JUN 21-24, 2006 CL Amsterdam, NETHERLANDS C1 Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Chicago, Chicago, IL 60637 USA. Univ Oklahoma, Tulsa, OK USA. TAP, Lake Forest, England. NR 2 TC 2 Z9 3 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUL PY 2006 VL 65 SU 2 BP 93 EP 93 PG 1 WC Rheumatology SC Rheumatology GA 209ET UT WOS:000249372500276 ER PT J AU Becker, MA Schumacher, HR Wortmann, RL Lloyd, E Streit, J Joseph-Ridge, N AF Becker, M. A. Schumacher, H. R. Wortmann, R. L. Lloyd, E. Streit, J. Joseph-Ridge, N. TI The long-term clinical benefits of febuxostat vs allopurinol in subjects with gout: Interim analysis of the excel trial, an ongoing phase 3, open-label extension study SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT Annual European Congress of Rheumatology (EULAR 2006) CY JUN 21-24, 2006 CL Amsterdam, NETHERLANDS C1 Univ Chicago, Chicago, IL 60637 USA. Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Oklahoma, Tulsa, OK USA. TAP, Lake Forest, IL USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUL PY 2006 VL 65 SU 2 BP 431 EP 431 PG 1 WC Rheumatology SC Rheumatology GA 209ET UT WOS:000249372501662 ER PT J AU Rashad, SMOH Schumacher, RH Williams, GH Mahmoud, EABD AF Rashad, S. M. O. H. Schumacher, R. H. Williams, G. H. Mahmoud, E. A. B. D. TI A calcified intraarticular mass in a man with severe shoulder osteoarthritis. What are the implications? SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT Annual European Congress of Rheumatology (EULAR 2006) CY JUN 21-24, 2006 CL Amsterdam, NETHERLANDS C1 Assiut Univ Hosp, Assiut, Egypt. Univ Penn, Sch Med, Vet Affairs Med Ctr, Div Rheumatol, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Vet Affairs Med Ctr, Div Rheumatol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUL PY 2006 VL 65 SU 2 BP 436 EP 437 PG 2 WC Rheumatology SC Rheumatology GA 209ET UT WOS:000249372501682 ER PT J AU Keith, RL Geraci, MW Nana-Sinkam, SP Breyer, RM Hudish, TM Meyer, AM Malkinson, AM Dwyer-Nield, LD AF Keith, Robert L. Geraci, Mark W. Nana-Sinkam, S. Patrick Breyer, Richard M. Hudish, Tyler M. Meyer, Amy M. Malkinson, Alvin M. Dwyer-Nield, Lori D. TI Prostaglandin E-2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis SO ANTICANCER RESEARCH LA English DT Article DE EP2; two-stage carcinogenesis; chronic pulmonary inflammation; downstream prostaglandin receptors ID BUTYLATED HYDROXYTOLUENE BHT; PHASE-II TRIAL; PULMONARY INFLAMMATION; COLON CARCINOGENESIS; CANCER CELLS; RECEPTOR; CELECOXIB; E-2; EXPRESSION; CYCLOOXYGENASE-2 AB Background: Manipulating prostaglandin (PG) production modulates tumor development. Elevated PGI(2) production prevents murine lung cancer, while decreasing PGE(2) content protects against colon cancer. PGE(2) receptor subtype 2 (EP2)-deficient mice were hypothesized to be resistant to lung tumorigenesis. Materials and Methods: EP2 null BALB/c mice and their wild-type littermates were exposed to an initiation-promotion carcinogenesis protocol and lung tumorigenesis was examined. Chronic lung inflammation was induced to determine whether EP2 ablation influenced inflammatory cell infiltration. Results: Tumor multiplicity in EP2 null mice was 34% lower than in their wild-type littermates (21.9 +/- 3.0 vs. 14.5 +/- 2.9 tumors/mouse,p < 0.001). The lung tumor burden, anindicator of growth rate, also declined (57%, p < 0.05). All the mice exhibited similar inflammatory cell infiltration. Conclusion: PGE(2), acting through EP2, enhanced lung tumorigenesis through a mechanism that may be distinct from its pro-inflammatory activity. Thus, EP2 is a potential target for novel chemoprevention strategies. C1 Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA. Denver VA Med Ctr, Div Pulm Sci & Crit Care Med, Dept Med, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Dept Med, Denver, CO 80262 USA. Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol, Nashville, TN 37232 USA. RP Dwyer-Nield, LD (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, 4200 E 9th Ave, Denver, CO 80262 USA. FU NCI NIH HHS [CA 33497] NR 43 TC 16 Z9 16 U1 0 U2 0 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE SN 0250-7005 J9 ANTICANCER RES JI Anticancer Res. PD JUL-AUG PY 2006 VL 26 IS 4B BP 2857 EP 2861 PG 5 WC Oncology SC Oncology GA 096QJ UT WOS:000241391600011 PM 16886605 ER PT J AU Belogrudov, GI AF Belogrudov, GI TI Bovine factor B: Cloning, expression, and characterization SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article DE factor B; energy coupling; proton leaks vicinal dithiol; mitochondria; oxidative phosphorylation; ATP synthase ID MITOCHONDRIAL ATP SYNTHASE; COUPLING FACTOR-B; F-1-ATPASE; PROTEIN; PHOSPHORYLATION; INHIBITOR; SEQUENCE AB Bovine factor B, a polypeptide required for the coupled activity of the mitochondrial ATP synthase complex, was cloned. A novel expression system for overproducing the recombinant bovine factor B was developed, which yielded the recombinant polypeptide at a level of 12-15 mg of protein per liter of bacterial culture. Reconstitution of the recombinant polypeptide with factor B-depleted ammonia, EDTA-treated submitochondrial particles (AE-SMP) restored the formation of substrate-driven Delta pH gradient across vesicular membranes, presumably by blocking a proton leak. The proton leak in the AE-SMP could also be blocked by the F-0 inhibitors oligomycin and dicyclohexylcarbodiimide, but not the F-1-ATPase inhibitors efrapeptin and aurovertin B. The six factor B thiols titrated rapidly with Ellman's reagent, and two of these, presumably Cys92 and Cys94, gained protection following treatment of factor B with a vicinal dithiol-specific reagent phenylarsine oxide (PAO). Similarly, Cd, whose binding to factor B is believed to also involve a vicinal dithiol, and PAO, protected similar to 2 Cys residues against labeling with sulfhydryl-specific fluorescent reagent fluorescein-5'-maleimide. The circular dichroism spectra showed that binding of Cd2+ and Zn2+, but not Ca2+ to bovine factor B caused small but reproducible changes in the secondary structure elements of the polypeptide. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Belogrudov, GI (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM gbclo@ucla.edu FU NIGMS NIH HHS [GM66085] NR 21 TC 8 Z9 11 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD JUL 1 PY 2006 VL 451 IS 1 BP 68 EP 78 DI 10.1016/j.abb.2006.02.021 PG 11 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 060IT UT WOS:000238796600009 PM 16579955 ER PT J AU Profit, J Zupancic, JAF McCormick, MC Richardson, DK Escobar, GJ Tucker, J Tarnow-Mordi, W Parry, G AF Profit, J. Zupancic, J. A. F. McCormick, M. C. Richardson, D. K. Escobar, G. J. Tucker, J. Tarnow-Mordi, W. Parry, G. TI Moderately premature infants at Kaiser Permanente Medical Care Program in California are discharged home earlier than their peers in Massachusetts and the United Kingdom SO ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION LA English DT Article ID NEONATAL INTENSIVE-CARE; MANAGED CARE; NHS; MORTALITY; INDEX; SEVERITY; OUTCOMES; DOLLAR; APNEA; PRICE AB Objective: To compare gestational age at discharge between infants born at 30-34(+6) weeks gestational age who were admitted to neonatal intensive care units (NICUs) in California, Massachusetts, and the United Kingdom. Design: Prospective observational cohort study. Setting: Fifty four United Kingdom, five California, and five Massachusetts NICUs. Subjects: A total of 4359 infants who survived to discharge home after admission to an NICU. Main outcome measures: Gestational age at discharge home. Results: The mean (SD) postmenstrual age at discharge of the infants in California, Massachusetts, and the United Kingdom were 35.9 (1.3), 36.3 (1.3), and 36.3 (1.9) weeks respectively (p = 0.001). Compared with the United Kingdom, adjusted discharge of infants occurred 3.9 (95% confidence interval (CI) 1.4 to 6.5) days earlier in California, and 0.9 (95% CI - 1.2 to 3.0) days earlier in Massachusetts. Conclusions: Infants of 30-34(+6) weeks gestation at birth admitted and cared for In hospitals in California have a shorter length of stay than those in the United Kingdom. Certain characteristics of the integrated healthcare approach pursued by the health maintenance organisation of the NICUs in California may foster earlier discharge. The California system may provide opportunities for identifying practices for reducing the length of stay of moderately premature infants. C1 Childrens Hosp Boston, Harvard Newborn Med Program, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Sect Neonatol, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Dept Vet Affairs, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. Kaiser Permanente Med Care Program, Perinatal Res Unit, Oakland, CA 94612 USA. Univ Aberdeen, Dept Obstet & Gynaecol, Dugald Baird Ctr Res Womens Hlth, Aberdeen AB25 2ZL, Scotland. Univ Sydney, Westmead Hosp, Westmead & Childrens Hosp, Wentworthville, NSW, Australia. Univ Sheffield, Sch Hlth & Related Res, Hlth Serv Res, Sheffield, S Yorkshire, England. RP Profit, J (reprint author), Houston Ctr Qual Care & Utilizat Studies, Div Hlth Policy & Qual, VA HSR&D 152, 2002 Holcombe, Houston, TX 77030 USA. EM profit@bcm.edu OI McCormmick, Marie/0000-0002-3938-1707; Zupancic, John/0000-0003-1734-7193 FU AHRQ HHS [R01 HS010131, T32 HS000063, R01 HS10131] NR 47 TC 17 Z9 17 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1359-2998 J9 ARCH DIS CHILD-FETAL JI Arch. Dis. Child.-Fetal Neonatal Ed. PD JUL PY 2006 VL 91 IS 4 BP F245 EP F250 DI 10.1136/adc.2005.075093 PG 6 WC Pediatrics SC Pediatrics GA 061BI UT WOS:000238845800003 PM 16449257 ER PT J AU Brody, AL Mandelkern, MA Olmstead, RE Scheibal, D Hahn, E Shiraga, S Zamora-Paja, E Farahi, J Saxena, S London, ED McCracken, JT AF Brody, Arthur L. Mandelkern, Mark A. Olmstead, Richard E. Scheibal, David Hahn, Emily Shiraga, Sharon Zamora-Paja, Eleanor Farahi, Judah Saxena, Sanjaya London, Edythe D. McCracken, James T. TI Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 11th Annual Duke Nicotine Research Conference CY NOV 10, 2005 CL Durham, NC ID POSITRON-EMISSION-TOMOGRAPHY; D2 RECEPTOR GENE; RAT NUCLEUS-ACCUMBENS; CEREBRAL-BLOOD-FLOW; FREELY MOVING RATS; CIGARETTE-SMOKING; TRANSPORTER GENE; CONTINUOUS-INFUSION; HEALTHY-VOLUNTEERS; IN-VIVO AB Context: Preclinical studies demonstrate that nicotine administration leads to dopamine release in the ventral striatum. However, human studies reveal considerable interindividual variability in the extent of smoking-induced dopamine release. Objective: To determine whether common gene variants of the brain dopamine pathway explain this observed phenotypic variability in humans. Design: Blood samples were drawn to determine gene variants of dopamine system components, and positron emission tomography scanning with the radiotracer raclopride labeled with radioactive carbon (C-11) was performed to measure smoking-induced dopamine release. Setting: Academic brain imaging center. Participants: Forty-five tobacco-dependent smokers. Interventions: Subjects either smoked a cigarette (n=35) or did not smoke (n=10) during positron emission tomography scanning. Main Outcome Measures: Gene variants of dopamine system components (the dopamine transporter variable nucleotide tandem repeat, D-2 receptor Taq A(1)/A(2), D-4 receptor variable nucleotide tandem repeat, and catechol-O-methyltransferase Val158Met polymorphisms) and change in [C-11] raclopride binding potential in the ventral caudate/nucleus accumbens on positron emission tomography scans. Results: For subjects who smoked during scanning, those with at least one 9 allele of the dopamine transporter variable nucleotide tandem repeat, fewer than 7 repeats of the D-4 variable nucleotide tandem repeat, and the Val/Val catechol-O-methyltransferase genotype had greater decreases in binding potential (an indirect measure of dopamine release) with smoking than those with the alternate genotypes. An overall decrease in ventral caudate/nucleus accumbens binding potential in those who smoked compared with those who did not smoke was also found but was smaller in magnitude than previously reported. Conclusions: Smokers with genes associated with low resting dopamine tone have greater smoking-induced (phasic) dopamine release than those with alternate genotypes. These findings suggest that dopamine system genotype variabilities explain a significant proportion of the interindividual variability in smoking-induced dopamine release and indicate that smoking-induced dopamine release has a genetic predisposition. C1 Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst, Positron Emiss Tomog Ctr, Los Angeles, CA USA. Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP Brody, AL (reprint author), Univ Calif Los Angeles, Dept Psychiat & Behav Sci, 300 UCLA Med Pl,Suite 2200, Los Angeles, CA 90095 USA. EM abrody@ucla.edu FU NIDA NIH HHS [DA14093, DA20872, R01 DA014093, R01 DA015059, R01 DA015059-04, R01 DA020872, R01 DA020872-02, R01 DA15059]; NIMH NIH HHS [K24 MH001805, K24 MH01805] NR 98 TC 137 Z9 141 U1 4 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD JUL PY 2006 VL 63 IS 7 BP 808 EP 816 DI 10.1001/archpsyc.63.7.808 PG 9 WC Psychiatry SC Psychiatry GA 059RJ UT WOS:000238749600013 PM 16818870 ER PT J AU Peskind, ER Li, G Shofer, J Quinn, JF Kaye, JA Clark, CM Farlow, MR DeCarli, C Raskind, MA Schellenberg, GD Lee, VMY Galasko, DR AF Peskind, Elaine R. Li, Ge Shofer, Jane Quinn, Joseph F. Kaye, Jeffrey A. Clark, Chris M. Farlow, Martin R. DeCarli, Charles Raskind, Murray A. Schellenberg, Gerard D. Lee, Virginia M. -Y. Galasko, Douglas R. TI Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition SO ARCHIVES OF NEUROLOGY LA English DT Article ID AMYLOID-BETA PROTEIN; APOE EPSILON-4 ALLELE; ALZHEIMERS-DISEASE; A-BETA; TAU; CSF; BRAIN; A-BETA-42(43) AB Background: Decreased cerebrospinal fluid (CSF) beta-amyloid 42 (A beta(42)) concentration, but not A beta(40) concentration, is a biomarker for Alzheimer disease. This A beta(42) concentration decrease in CSF likely reflects precipitation of A beta(42) in amyloid plaques in brain parenchyma. This pathogenic plaque deposition begins years before the clinical expression of dementia in Alzheimer disease. Normal aging and the presence of the apolipoprotein E (APOE*4) allele are the most important known risk factors for Alzheimer disease. Objective: To estimate the interactive effects of normal aging and presence of the APOE*4 allele on CSF A beta(42) concentration in adults with normal cognition across the life span. Design: The CSF was collected in the morning after an overnight fast using Sprotte 24-g atraumatic spinal needles. The CSF A beta(42) and A beta(40) concentrations were measured in the 10th milliliter of CSF collected by sandwich enzyme-linked immunosorbent assay. The APOE genotype was determined by a restriction digest method. Subjects: One hundred eighty-four community volunteers with normal cognition aged 21 to 88 years. Results: The CSF A beta(42), but not the A beta(40), concentration decreased significantly with age. There was a sharp decrease in CSF A beta(42) concentration beginning in the sixth decade in subjects with the APOE*4 allele. This age-associated decrease in CSF A beta(42) concentration was significantly and substantially greater in subjects with the APOE*4 allele compared with those without the APOE*4 allele. Conclusion: These CSF A beta(42) findings are consistent with acceleration by the APOE*4 allele of pathogenic A beta(42) brain deposition starting in later middle age in persons with normal cognition. C1 VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. Univ Washington, Ctr Geriatr Res Educ & Clin, Sch Med, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. Univ Penn, Dept Neurol, Inst Aging, Philadelphia, PA 19104 USA. Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA. Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA. Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. VA Med Ctr, San Diego, CA USA. RP Peskind, ER (reprint author), VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, S-116MIRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM peskind@u.washington.edu RI DeCarli, Charles/B-5541-2009 OI Kaye, Jeffrey/0000-0002-9971-3478 FU NCRR NIH HHS [M01 RR00034]; NIA NIH HHS [AG05136, AG08017, AG08419, AG10124, AG10133, AG23185] NR 22 TC 86 Z9 89 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD JUL PY 2006 VL 63 IS 7 BP 936 EP 939 DI 10.1001/archneur.63.7.936 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 062AQ UT WOS:000238917100003 PM 16831961 ER PT J AU Yaffe, K Vittinghoff, E Ensrud, KE Johnson, KC Diem, S Hanes, V Grady, D AF Yaffe, Kristine Vittinghoff, Eric Ensrud, Kristine E. Johnson, Karen C. Diem, Susan Hanes, Vladimir Grady, Deborah TI Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life SO ARCHIVES OF NEUROLOGY LA English DT Article ID ESTROGEN PLUS PROGESTIN; RANDOMIZED CONTROLLED-TRIAL; CONJUGATED EQUINE ESTROGENS; SURGICALLY MENOPAUSAL WOMEN; ALZHEIMERS-DISEASE CERAD; POSTMENOPAUSAL WOMEN; INITIATIVE MEMORY; ESTROGEN/PROGESTIN REPLACEMENT; HORMONE-THERAPY; CLINICAL-TRIAL AB Background: Several small trials and many observational studies suggest that estrogen treatment in postmenopausal women improves cognition, but 2 large randomized trials have shown harm. The effect of an ultra low- dose of unopposed transdermal estradiol on cognition and health-related quality of life is unknown. Objective: To investigate the effect of unopposed ultra low- dose transdermal estradiol on cognitive function and quality of life in postmenopausal women. Design: Randomized, placebo-controlled, double-blind trial with 2-year follow-up. The main outcome of the trial was change in bone density. Changes in cognitive function and quality of life were preplanned secondary outcomes of the trial. Setting: Nine clinical centers in the United States. Participants: Postmenopausal women (N = 417), aged 60 to 80 years, with a normal bone density for age and an intact uterus. Intervention: A weekly transdermal patch that delivers estradiol, 0.014 mg/d (n = 208), or placebo (n = 209). Main Outcome Measures: Seven standardized cognitive tests (a total of 10 scores) administered at baseline and years 1 and 2 to test global cognitive function, verbal and visuospatial memory, language, executive function, and semantic memory. The 36-Item Short-Form General Health Survey was administered to assess health-related quality of life in physical and mental domains. The sample size provided 80% power to detect a standardized effect of 0.29 SD, a small-to-moderate difference. Results: Baseline characteristics were similar in the 2 treatment groups. At 2 years of follow-up, we found no statistically significant differences between treatment groups in change on any of the cognitive test scores or on the 36-Item Short- Form General Health Survey (P > .12 for all). There was no consistent evidence that the effect of treatment on change in cognitive or 36-Item Short-Form General Health Survey scores depended on the level of baseline endogenous estradiol. Conclusion: Postmenopausal treatment with ultra-lowdose unopposed transdermal estradiol for 2 years had no effect on change in cognitive function or in health-related quality of life over 2 years of treatment. C1 Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. Univ Calif San Francisco, Womens Hlth Clin Res Ctr, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Minnesota, Dept Med, Div Epidemiol, Minneapolis, MN 55455 USA. Vet Adm Med Ctr, Minneapolis, MN 55417 USA. Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. Berlex Inc, Montville, NJ USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, Campus Box 181,4150 Clement St, San Francisco, CA 94121 USA. EM kristine.yaffe@ucsf.edu RI Diem, Susan/B-6479-2013 FU NIA NIH HHS [R01 AG021918] NR 32 TC 56 Z9 62 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD JUL PY 2006 VL 63 IS 7 BP 945 EP 950 DI 10.1001/archneur.63.7.945 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 062AQ UT WOS:000238917100005 PM 16831962 ER PT J AU Weintraub, D Siderowf, AD Potenza, MN Goveas, J Morales, KH Duda, JE Moberg, PJ Stern, MB AF Weintraub, Daniel Siderowf, Andrew D. Potenza, Marc N. Goveas, Joseph Morales, Knashawn H. Duda, John E. Moberg, Paul J. Stern, Matthew B. TI Association of dopamine agonist use with impulse control disorders in Parkinson disease SO ARCHIVES OF NEUROLOGY LA English DT Article ID THERAPY AB Objective: To determine the frequency and correlates of impulse control disorders (ICDs) in Parkinson disease (PD). Design: An unstructured screening interview for ICDs (compulsive gambling, buying, and sexual behavior) followed by a telephone-administered structured interview for screen- positive patients. Setting: Two university-affiliated movement disorders centers. Participants: A convenience sample of 272 patients with idiopathic PD who were screened for psychiatric complications. Main Outcome Measures: Presence of compulsive gambling, buying, or sexual behavior as assessed by the Minnesota Impulsive Disorders Interview. Results: Eighteen patients (6.6%) with PD met criteria for an ICD at some point during the course of PD, including (4.0%) with an active ICD. Compulsive gambling and compulsive sexual behavior were equally common. In a multivariate model, treatment with a dopamine agonist (P = .01) and a history of ICD symptoms prior to PD onset (P = .02) predicted current ICD. There were no differences between the dopamine agonists in their association with ICDs (P = .21), and daily doses of dopamine agonists were higher in patients with an ICD than in dopamine agonist-treated patients without an ICD (P < .001). Conclusions: Patients with PD treated with a dopamine agonist should be made aware of the risk of developing an ICD and monitored clinically. Because dopamine agonists are increasingly being used for other indications, future research should assess the dopamine agonist-associated risk for ICDs in other populations. C1 Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Educ & Clin Ctr, Philadelphia, PA USA. Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. RP Weintraub, D (reprint author), 3535 Market St,Room 3003, Philadelphia, PA 19104 USA. EM weintrau@mail.med.upenn.edu FU NIMH NIH HHS [K23 MH067894, K23MH067894] NR 15 TC 337 Z9 344 U1 3 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD JUL PY 2006 VL 63 IS 7 BP 969 EP 973 DI 10.1001/archneur.63.7.969 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 062AQ UT WOS:000238917100010 PM 16831966 ER PT J AU McCarthy, ML Dikmen, SS Langlois, JA Selassie, AW Gu, JK Horner, MD AF McCarthy, ML Dikmen, SS Langlois, JA Selassie, AW Gu, JK Horner, MD TI Self-reported psychosocial health among adults with traumatic brain injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE brain injuries; rehabilitation ID QUALITY-OF-LIFE; HEAD-INJURY; PSYCHIATRIC-DISORDERS; SURVEY SF-36; SOCIOECONOMIC-STATUS; DEPRESSION; VALIDITY; 1-YEAR; PRODUCTIVITY; INDIVIDUALS AB Objective: To measure the subjective psychosocial health of a population-based sample of adults with traumatic brain injury (TBI). Design: Retrospective, cohort study involving a 1-year postinjury interview. Setting: Sixty-two acute care, nonfederal hospitals in South Carolina. Participants: Persons (>= 15y) hospitalized with TBI. Interventions: Not applicable. Main Outcome Measure: The psychosocial health scales of the Medical Outcomes Study 36-Item Short-Form Health Survey. Results: Of the 7612 participants, 29% reported poor psychosocial health. Factors associated with poor psychosocial well-being included younger age, female sex, Medicaid coverage, no health insurance, inadequate or moderate social support, comorbidities (eg, a preinjury substance abuse problem), cognitive complaints, and some or a lot of limitation with activities of daily living. Only 36% of participants who reported poor psychosocial health reported receiving any mental health services. Conclusions: A substantial proportion of persons hospitalized with TBI reported poor psychosocial health at 1 year postinjury. To optimize recovery, clinicians need to ensure that patients' psychosocial health needs are addressed during the postacute period. C1 Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21209 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. RP McCarthy, ML (reprint author), Johns Hopkins Univ, Sch Med, Dept Emergency Med, 5801 Smith Ave,Davis Bldg,Ste 3220, Baltimore, MD 21209 USA. EM mmccarth@jhmi.edu FU PHS HHS [U17/CCU421926] NR 76 TC 52 Z9 52 U1 8 U2 17 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUL PY 2006 VL 87 IS 7 BP 953 EP 961 DI 10.1016/j.apmr.2006.03.007 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 059MY UT WOS:000238738100011 PM 16813783 ER PT J AU Williams, RM Turner, AP Orendurff, M Segal, AD Klute, GK Pecoraro, J Czerniecki, J AF Williams, RM Turner, AP Orendurff, M Segal, AD Klute, GK Pecoraro, J Czerniecki, J TI Does having a computerized prosthetic knee influence cognitive performance during amputee walking? SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE amputees; artificial limbs; attention; memory; mental fatigue; rehabilitation ID LOWER-LIMB AMPUTATION; LOWER-EXTREMITY AMPUTATION; ATTENTIONAL DEMANDS; BALANCE CONFIDENCE; POSTURAL CONTROL; TASK; QUESTIONNAIRE; INDIVIDUALS; PROFILE; PEOPLE AB Objective: To compare objective cognitive performance and perception of cognitive burden during walking tasks using 2 different prosthetic knees: a computerized hydraulic knee (Otto Bock C-leg) and a noncomputerized hydraulic knee (Ossur Mauch SNS). Design: Two-group crossover trial, with participants randomly assigned to order of prosthesis. Participants completed assessments under 2 conditions, a self-selected speed walk and a controlled speed walk, on 2 separate occasions (precrossover, postcrossover). Setting: Veterans Health Administration hospital. Participants: Eight transfemoral amputees. Intervention: Computerized versus noncomputerized prosthetic knee. Main Outcome Measures: Objective cognitive performance measures included verbal fluency (Controlled Oral Word Association Test, Category Test), attention and working memory (serial subtraction), and walking speed during cognitive tasks. Measures of perceived cognitive burden included subjective attentional requirements of walking and cognitive tasks and subjective general cognitive burden of prosthesis. Results: There were no significant differences in objective cognitive performance on any task between prostheses, nor did walking speed vary by prosthesis during the free-speed walk. Participants reported that walking required less attention while wearing the C-leg and that the C-leg was less of a cognitive burden than the noncomputerized prosthesis. Conclusions: In nondemanding walking conditions with experienced amputees. participants reported that the more costly C-leg required less cognitive attention than the noncomputerized knee. However, this subjective experience did not translate to improved performance on neuropsychologic screening instruments or on walking speed. Noncomputerized prostheses may be adequate for a majority of amputees, and further research is needed to identify particular groups of amputees (ie, new amputees, amputees with complex physical or cognitive demands) who may benefit from computerized prostheses. C1 VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. Ctr Excellence Limb Loss Prevent & Prosthet Engn, Dept Vet Affairs, Seattle, WA USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. RP Williams, RM (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-1117 S Columbian Way, Seattle, WA 98108 USA. EM Rhonda.Williams1@med.va.gov OI Turner, Aaron/0000-0001-6897-8003 NR 32 TC 16 Z9 16 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUL PY 2006 VL 87 IS 7 BP 989 EP 994 DI 10.1016/j.apmr.2006.03.006 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 059MY UT WOS:000238738100016 PM 16813788 ER PT J AU Qing, XP Zavadil, J Crosby, MB Hogarth, MP Hahn, BH Mohan, C Gilkeson, GS Bottinger, EP Putterman, C AF Qing, Xiaoping Zavadil, Jiri Crosby, Michelle B. Hogarth, Mark P. Hahn, Bevra H. Mohan, Chandra Gilkeson, Gary S. Bottinger, Erwin P. Putterman, Chaim TI Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells SO ARTHRITIS AND RHEUMATISM LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; NITRIC-OXIDE SYNTHASE; GELATINASE-ASSOCIATED LIPOCALIN; GROWTH-FACTOR-BETA; AUTOIMMUNE GLOMERULONEPHRITIS; STRUCTURAL CHARACTERISTICS; ALPHA-ACTININ; RENAL INJURY; AUTOANTIBODIES; MICE AB Objective. Lupus-associated IgG anti-double-stranded DNA antibodies are thought to be pathogenic in the kidney due to cross-reaction with glomerular antigens, leading subsequently to immune complex formation in situ and complement activation. We undertook this study to determine if pathogenic anti-DNA antibodies may also contribute to renal damage by directly influencing mesangial gene expression. Methods. Complementary DNA microarray gene profiling was performed in primary mesangial cells (derived from lupus-prone MRL/lpr mice) treated with pathogenic, noncomplexed anti-DNA antibodies. Significant gene up-regulation induced by anti-DNA antibodies as determined by microarray analysis was further investigated by real-time polymerase chain reaction and methods to detect the relevant proteins. Induction of proinflammatory genes by pathogenic antibodies was confirmed by comparing gene expression in glomeruli of old versus young MRL/lpr mice, and by antibody injection in vivo. Results. Pathogenic, but not nonpathogenic, antibodies significantly induced a number of transcripts, including CXCL1/KC, LCN2, iNOS, CX3CL1/fractalkine, SERPINA3G, and I kappa B alpha ("marker genes"). Blocking of Fc gamma receptors or using Fc gamma chain-knockout mesangial cells had no effect on the gene regulation effect of the pathogenic antibody R4A, indicating a non-Fc-dependent mechanism. The glomerular expression of these marker genes increased over time with the development of glomerular antibody deposition and active nephritis in MRL/lpr mice. Moreover, injection of R4A into SCID mice in vivo significantly up-regulated glomerular marker gene expression. Conclusion. These findings indicate that the renal pathogenicity of anti-DNA antibodies may be attributed in part to their ability to directly modulate gene expression in kidney mesangial cells through both Fc-dependent and non-Fc-dependent mechanisms. C1 Albert Einstein Coll Med, Div Rheumatol, Bronx, NY 10461 USA. NYU, Sch Med, New York, NY USA. Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Med Res Serv, Charleston, SC USA. Austin & Repatriat Med Ctr, Heidelberg, Germany. Univ Calif Los Angeles, Los Angeles, CA USA. Univ Texas, SW Med Ctr, Dallas, TX USA. Mt Sinai Sch Med, New York, NY USA. RP Putterman, C (reprint author), Albert Einstein Coll Med, Div Rheumatol, Forchheimer 701N,1300 Morris Pk Ave, Bronx, NY 10461 USA. EM putterma@aecom.yu.edu OI Zavadil, Jiri/0000-0003-0640-5562 FU NIAID NIH HHS [P01-AI-51392, R37-AI/AR-46776]; NIAMS NIH HHS [R01-AR-48692]; NIDDK NIH HHS [DK-58768-02] NR 42 TC 50 Z9 52 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD JUL PY 2006 VL 54 IS 7 BP 2198 EP 2210 DI 10.1002/art.21934 PG 13 WC Rheumatology SC Rheumatology GA 062IY UT WOS:000238939000018 PM 16804897 ER PT J AU Nowling, TK Gilkeson, GS AF Nowling, Tamara K. Gilkeson, Gary S. TI Regulation of Fli1 gene expression and lupus SO AUTOIMMUNITY REVIEWS LA English DT Article; Proceedings Paper CT 9th International Workshop on Autoantibodies and Autoimmunity CY SEP 29-OCT 02, 2005 CL Gainesville, FL DE Ets; Fli1 gene expression; transcription; lupus; lymphocytes ID MURINE LEUKEMIA-VIRUS; ETS FAMILY; TRANSCRIPTION FACTOR; RENAL-DISEASE; DNA-BINDING; PROMOTER; ERYTHROLEUKEMIA; PROTEIN; MEMBER; CELLS AB Ets transcription factors function throughout development in such varied processes as cellular proliferation, apoptosis, differentiation and migration. Many have been implicated to play important roles in hematopoiesis, vasculogenesis/angiogenesis and myogenesis. Fli1 is an Ets family member that is essential for development and increasing evidence suggests modulating Fli1 gene expression impacts lymphocyte function and is important in the autoimmune disease lupus. Presently, it is unknown how Fli1 gene expression is controlled in lymphocytes. Identifying upstream regulators of Fli1 in lymphocytes will be critical for understanding lymphocyte development and the consequences of dysregulation and may be of value in developing future treatments for Jupus. Published by Elsevier B.V. C1 Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Med Res Serv, Charleston, SC 29425 USA. RP Gilkeson, GS (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol, 96 Jonathan Lucas St,Ste 912 CSB, Charleston, SC 29425 USA. EM gilkeson@musc.edu FU NIAMS NIH HHS [AR47451] NR 23 TC 10 Z9 10 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1568-9972 J9 AUTOIMMUN REV JI Autoimmun. Rev. PD JUL PY 2006 VL 5 IS 6 BP 377 EP 382 DI 10.1016/j/autrev.2005.10.005 PG 6 WC Immunology SC Immunology GA 079KL UT WOS:000240174700004 PM 16890890 ER PT J AU Yang, CC Porter, MP Penson, DF AF Yang, Claire C. Porter, Michael P. Penson, David F. TI Comparison of the International Index of Erectile Function erectile domain scores and nocturnal penile tumescence and rigidity measurements: does one predict the other? SO BJU INTERNATIONAL LA English DT Article DE RigiScan; International Index of Erectile Function; nocturnal penile tumescence and rigidity; erectile function; impotence ID FUNCTION IIEF; DYSFUNCTION; POTENT; ULTRASONOGRAPHY; CAVERNOSOMETRY; DIAGNOSIS; IMPOTENCE; CRITERIA; MEN AB OBJECTIVE To describe the relationship between the International Index of Erectile Function (IIEF) erectile domain score, and nocturnal penile tumescence and rigidity values measured by RigiScan (Timm Medical Technologies, Eden Prairie, MN). PATIENTS AND METHODS In all, 73 men were evaluated with the IIEF and 2 nights of continuous penile monitoring with the RigiScan. Twenty-six men were evaluated before and after prostatectomy, for a total of 99 pairs of data points. We dichotomized the RigiScan results as 'adequate' (no erectile dysfunction, ED), or 'inadequate' (having ED), based on the 'best erectile event' over the 2 nights of monitoring. Two separate criteria for adequate erectile function were used, one of > 70% rigidity for >= 10 min, and the other > 600/6 rigidity for >= 10 min. The erectile domain score of the IIEF was calculated in the standard fashion. RESULTS Using both the 70% and the 60% rigidity criteria, there was a statistically significant association between the IIEF erectile domain scores and the RigiScan data (r= 0.27, P = 0.008 and r = 0.29, P = 0.003, respectively). However, the sensitivity of the IIEF to predict ED based on RigiScan results using the 70% rigidity criteria was 68.90/6, and the specificity was 57.1%. When the IIEF was used as a continuous predictor of RigiScan results, the area under the receiver-operating characteristic (ROC) curve was 0.66. Using the 60% criteria, the sensitivity was 55.8% and the specificity was 73.2%; the area under the ROC curve was 0.72. CONCLUSIONS IIEF erectile domain scores and nocturnal penile tumescence and rigidity measurements are weakly associated, and the clinical utility of one test to predict the other is limited. However, because of the differences in the measured outcomes (perception of erectile function vs physiological capacity), a weak association does not disqualify either test's individual utility. C1 Univ Washington, Dept Urol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA 90089 USA. Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA. RP Yang, CC (reprint author), Univ Washington, Dept Urol, Box 356510, Seattle, WA 98195 USA. EM cyang@u.washington.edu FU NIDDK NIH HHS [1R21DK069315] NR 22 TC 13 Z9 15 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1464-4096 J9 BJU INT JI BJU Int. PD JUL PY 2006 VL 98 IS 1 BP 105 EP 109 DI 10.1111/j.1464-410X.2006.06246.x PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 062MJ UT WOS:000238948900024 PM 16831153 ER PT J AU Wells, WA Schwartz, GN Morganelli, PM Cole, BF Gibson, JJ Kinlaw, WB AF Wells, Wendy A. Schwartz, Gary N. Morganelli, Peter M. Cole, Bernard F. Gibson, Jennifer J. Kinlaw, William B. TI Expression of "Spot 14" (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE chromosome 11q13; gene amplification; lipogenesis; tumor markers ID FATTY-ACID SYNTHESIS; CYCLIN D1; LIPID-SYNTHESIS; CELL-DEATH; PROTEIN; GENE; AMPLIFICATION; INHIBITION; PROGNOSIS; SYNTHASE AB Most breast cancers are "lipogenic'', defined by high fatty acid synthase (FAS) content and dependence on fatty acid synthesis for growth and survival. S14 (Spot 14; THRSP) is a nuclear protein that activates genes required for fatty acid synthesis. The S14 gene is amplified in (similar to)15% of breast cancers, but clinical correlates of its expression were unknown. We analyzed 131 breast cancers by immunohistochemistry for S14 and FAS. Staining was graded 0, 1, or 2+, and scores were correlated with traditional tumor markers, histological features, and outcome. S14 and FAS staining were related to tumor size (p = 0.05 for S14, p = 0.038 for FAS), but not to stage. S14 but not FAS scores correlated with tumor grade in both DCIS (p = 0.003) and invasive cases (p < 0.001). Invasive cases (pooled node) and +) with weak S14 staining (n = 21) showed no recurrence over 3000 d follow-up, including 10 cases with lymph node involvement, whereas 32% of 67 strongly-staining tumors recurred ( log rank p < 0.0001). S14 scores did not cosegregate with sex steroid receptors, Her2/neu, or cyclin D1. Low level S14 expression is associated with prolonged disease-free survival in invasive cases, including those with nodal metastasis. High-level expression of S14 identifies a subset of high-risk breast cancers that is not specified by analysis of sex steroid receptors, Her2/neu, or cyclin D1, and provides a molecular correlate to histologic features that predict recurrence. C1 Dartmouth Coll Sch Med, Div Endocrinol & Metab, Dept Pathol, Lebanon, NH 03756 USA. Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA. Dartmouth Coll Sch Med, Dept Med, Lebanon, NH 03756 USA. VA Hosp, US Dept Vet Affairs, White River Jct, VT USA. Dartmouth Coll Sch Med, Dept Community & Family Med, Lebanon, NH 03756 USA. RP Kinlaw, WB (reprint author), Dartmouth Coll Sch Med, Div Endocrinol & Metab, Dept Pathol, 606 Rubin Bldg,1 Med Ctr Dr, Lebanon, NH 03756 USA. EM william.kinlaw@hitchcock.org FU NIDDK NIH HHS [R01 DK 058961, R01 DK058961] NR 35 TC 26 Z9 29 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD JUL PY 2006 VL 98 IS 2 BP 231 EP 240 DI 10.1007/s10549-005-9154-z PG 10 WC Oncology SC Oncology GA 071IL UT WOS:000239593700015 PM 16552628 ER PT J AU Walters, DK Mercher, T Gu, TL O'Hare, T Tyner, JW Loriaux, M Goss, VL Lee, KA Eide, CA Wong, MJ Stoffregen, EP McGreevey, L Nardone, J Moore, SA Crispino, J Boggon, TJ Heinrich, MC Deininger, MW Polakiewicz, RD Gilliland, DG Druker, BJ AF Walters, Denise K. Mercher, Thomas Gu, Ting-Lei O'Hare, Thomas Tyner, Jeffrey W. Loriaux, Marc Goss, Valerie L. Lee, Kimberly A. Eide, Christopher A. Wong, Matthew J. Stoffregen, Eric P. McGreevey, Laura Nardone, Julie Moore, Sandra A. Crispino, John Boggon, Titus J. Heinrich, Michael C. Deininger, Michael W. Polakiewicz, Roberto D. Gilliland, D. Gary Druker, Brian J. TI Activating alleles of JAK3 in acute megakaryoblastic leukemia SO CANCER CELL LA English DT Article ID ACUTE MYELOID-LEUKEMIA; TYROSINE KINASE JAK2; MICE LACKING JAK3; POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE DISORDERS; CONSTITUTIVE ACTIVATION; JANUS KINASE; CELL-LINES; PSEUDOKINASE DOMAIN; ALLOGRAFT-REJECTION AB Tyrosine kinases are aberrantly activated in numerous malignancies, including acute myeloid leukemia (AML). To identify tyrosine kinases activated in AML, we developed a screening strategy that rapidly identifies tyrosine-phosphorylated proteins using mass spectrometry. This allowed the identification of an activating mutation (A572V) in the JAK3 pseudokinase domain in the acute megakaryoblastic leukemia (AMKL) cell line CMK. Subsequent analysis identified two additional JAK3 alleles, V722I and P132T, in AMKL patients. JAK3(A572V), JAK3(P132T), and JAK3P132T each transform Ba/F3 cells to factor-independent growth, and JAK3 A572V confers features of megakaryoblastic leukemia in a murine model. These findings illustrate the biological importance of gain-of-function JAK3 mutations in leukemogenesis and demonstrate the utility of proteomic approaches to identifying clinically relevant mutations. C1 Howard Hughes Med Inst, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Hematol & Med Oncol, Portland, OR 97239 USA. Harvard Univ, Sch Med, Howard Hughes Med Inst, Brigham & Womens Hosp, Boston, MA 02115 USA. Cell Signaling Technol Inc, Danvers, MA 01923 USA. Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA. Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA. RP Druker, BJ (reprint author), Howard Hughes Med Inst, Portland, OR 97239 USA. EM drukerb@ohsu.edu RI Mercher, Thomas/J-2446-2014 OI Mercher, Thomas/0000-0003-1552-087X; Tyner, Jeffrey/0000-0002-2133-0960; Crispino, John/0000-0002-8182-8306 FU NCI NIH HHS [R01 CA101774, R01 CA101774-04] NR 66 TC 188 Z9 191 U1 0 U2 5 PU CELL PRESS PI CAMBRIDGE PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA SN 1535-6108 J9 CANCER CELL JI Cancer Cell PD JUL PY 2006 VL 10 IS 1 BP 65 EP 75 DI 10.1016/j.ccr.2006.06.002 PG 11 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 066AW UT WOS:000239202800009 PM 16843266 ER PT J AU Dang, H Dehghan, PL Goodwiler, K Chen, S Zardeneta, G Zhang, BX Yeh, CK AF Dang, Howard Dehghan, Parastou Lizeth Goodwiler, Kai Chen, Shuo Zardeneta, Gustavo Zhang, Bin-Xian Yeh, Chih-Ko TI Inhibition of CD95-mediated apoptosis through beta 1 integrin in the HSG epithelial cell line SO CELL COMMUNICATION AND ADHESION LA English DT Article DE salivary gland; Bcl-2; apoptosis; CD95; integrins; p63 ID SUBMANDIBULAR-GLAND; SALIVARY-GLAND; EGF RECEPTOR; SURVIVAL; ANOIKIS; PROTEIN; INTEGRINS; P63; ACTIVATION; MECHANISMS AB The HSG cell line serves as a model for salivary gland epithelial progenitor cell differentiation. In order for a progenitor cell to differentiate, the cell must maintain viability within its niche. Studies were designed to elucidate the mechanism for integrin-mediated HSG cell survival. HSG cells, grown on Matrigel(R), were resistant to CD95-mediated apoptosis. Western blot analysis showed that Matrigel(R) induced the expression of bcl-2, bcl-xL, p63, and Delta Np63. This induction occurred by as early as 2 hrs and remained for 24 hrs. CD95-mediated apoptosis resistance was dependent, however, upon the expression of the bcl-2 family. Furthermore, Matrigel(R) induced bcl-2 family expression was dependent on the transactivation of the EGF receptor pathway since PD98059 and AG1478 inhibited Matrigel(R) induced bcl-2 family expression and caused HSG cells to be sensitive to CD95-mediated apoptosis. Activation of the EGF receptor pathway, by itself, however, was not sufficient to inhibit apoptosis. Blocking antibody showed that bcl-2 family expression was mediated through beta 1 integrin. These studies show that salivary progenitor epithelial cell survival is integrin dependent and involves the transactivation of the EGF receptor pathway. C1 Univ Texas, Hlth Sci Ctr, Dept Community Dent, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Pediat Dent, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Oral & Maxillofacial Surg, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Res Serv, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Dang, H (reprint author), Univ Texas, Hlth Sci Ctr, Dept Community Dent, Mail Code 7917, San Antonio, TX 78229 USA. EM dang@uthscsa.edu FU NIDCR NIH HHS [DE-017333, DE-15381] NR 34 TC 2 Z9 3 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1541-9061 J9 CELL COMMUN ADHES JI Cell Commun. Adhes. PD JUL-AUG PY 2006 VL 13 IS 4 BP 223 EP 232 DI 10.1080/15419060600848532 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 074OC UT WOS:000239820700003 PM 16916750 ER PT J AU Felsenfeld, AJ Levine, BS AF Felsenfeld, Arnold J. Levine, Barton S. TI Milk alkali syndrome and the dynamics of calcium homeostasis SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID SENSING RECEPTOR REGULATION; GASTRIC-ACID SECRETION; EXTRACELLULAR CA2+-SENSING RECEPTOR; PARATHYROID-HORMONE LEVELS; CHRONIC METABOLIC-ACIDOSIS; CONVOLUTED TUBULE CELLS; CHRONIC-RENAL-FAILURE; THICK ASCENDING LIMB; RAT PROXIMAL TUBULE; PEAK BONE MASS C1 Univ Calif Los Angeles, Los Angeles, CA USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. RP Felsenfeld, AJ (reprint author), Va Greater Los Angeles Healthcare Syst, Nephrol Sect 111L, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Arnold.Felsenfeld@med.va.gov NR 134 TC 33 Z9 34 U1 0 U2 0 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JUL PY 2006 VL 1 IS 4 BP 641 EP 654 DI 10.2215/CJN.01451005 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA 108LQ UT WOS:000242241700006 PM 17699269 ER PT J AU Karayiannis, NB Tao, GZ Frost, JD Wise, MS Hrachovy, RA Mizrahi, EM AF Karayiannis, Nicolaos B. Tao, Guozhi Frost, James D., Jr. Wise, Merrill S. Hrachovy, Richard A. Mizrahi, Eli M. TI Automated detection of videotaped neonatal seizures based on motion segmentation methods SO CLINICAL NEUROPHYSIOLOGY LA English DT Article DE clustering; motion segmentation; motion strength signal; neonatal seizure; optical flow; quantitative feature; velocity field; videorecording ID MOTOR-ACTIVITY SIGNALS; QUANTIFYING MOTION; OPTICAL-FLOW; RECORDINGS; EEG; EXTRACTION; NEWBORN AB Objective: This study was aimed at the development of a seizure detection system by training neural networks using quantitative motion information extracted by motion segmentation methods from short video recordings of infants monitored for seizures. Methods: The motion of the infants' body parts was quantified by temporal motion strength signals extracted from video recordings by motion segmentation methods based on optical flow computation. The area of each frame occupied by the infants' moving body parts was segmented by direct thresholding, by clustering of the pixel velocities, and by clustering the motion parameters obtained by fitting an affine model to the pixel velocities. The computational tools and procedures developed for automated seizure detection were tested and evaluated on 240 short video segments selected and labeled by physicians from a set of video recordings of 54 patients exhibiting myoclonic seizures (80 segments), focal clonic seizures (80 segments), and random infant movements (80 segments). Results: The experimental study described in this paper provided the basis for selecting the most effective strategy for training neural networks to detect neonatal seizures as well as the decision scheme used for interpreting the responses of the trained neural networks. Depending on the decision scheme used for interpreting the responses of the trained neural networks, the best neural networks exhibited sensitivity above 90% or specificity above 90%. Conclusions: The best among the motion segmentation methods developed in this study produced quantitative features that constitute a reliable basis for detecting myoclonic and focal clonic neonatal seizures. The performance targets of this phase of the project may be achieved by combining the quantitative features described in this paper with those obtained by analyzing motion trajectory signals produced by motion tracking methods. Significance: A video system based upon automated analysis potentially offers a number of advantages. Infants who are at risk for seizures could be monitored continuously using relatively inexpensive and non-invasive video techniques that supplement direct observation by nursery personnel. This would represent a major advance in seizure surveillance and offers the possibility for earlier identification of potential neurological problems and subsequent intervention. (c) 2006 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved. C1 Univ Houston, Dept Elect & Comp Engn, Houston, TX 77204 USA. Baylor Coll Med, Dept Neurol, Peter Kellaway Sect Neurophysiol, Houston, TX 77030 USA. Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Karayiannis, NB (reprint author), Univ Houston, Dept Elect & Comp Engn, N308 Engn Bldg 1, Houston, TX 77204 USA. EM karayiannis@uh.edu FU NIBIB NIH HHS [1 R01 EB00183]; NINDS NIH HHS [N01-NS-2316] NR 24 TC 24 Z9 24 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1388-2457 J9 CLIN NEUROPHYSIOL JI Clin. Neurophysiol. PD JUL PY 2006 VL 117 IS 7 BP 1585 EP 1594 DI 10.1016/j.clinph.2005.12.030 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 066KB UT WOS:000239227100022 PM 16684619 ER PT J AU Bromley, E Johnson, JG Cohen, P AF Bromley, Elizabeth Johnson, Jeffrey G. Cohen, Patricia TI Personality strengths in adolescence and decreased risk of developing mental health problems in early adulthood SO COMPREHENSIVE PSYCHIATRY LA English DT Article ID STRESSFUL LIFE EVENTS; EGO-RESILIENCY; 5-FACTOR MODEL; CHILDHOOD PERSONALITY; SUICIDE ATTEMPTS; CHILDREN; DISORDERS; ADAPTATION; PREDICTORS; DEPRESSION AB The aim of this study was to investigate whether personality strengths during adolescence are associated with decreased risk of developing psychiatric disorders, educational or occupational problems, violent or criminal behaviors, and interpersonal difficulties during early adulthood. A representative community sample of 688 mothers from upstate New York and their offspring was interviewed in the period of 1985-1986 (mean offspring age = 16 years) and in that of 1991-1993 (mean offspring age = 22 years). Results showed that youths with numerous personality strengths at the mean age of 16 years were at a decreased risk of developing psychiatric disorders, educational and occupational problems, interpersonal difficulties, and criminal behaviors at the mean age of 22 years. These associations remained significant after controlling for age, sex, socioeconomic status, verbal intelligence, preexisting psychiatric disorders, and corresponding problems at the mean age of 16 years. Although youths with fewer personality strengths who experienced numerous stressful events were at elevated risk of developing psychiatric disorders during early adulthood, those with a higher number of personality strengths at the mean age of 16 years did not share this vulnerability. We conclude that personality strengths during adolescence may contribute to a decreased risk of developing a wide range of adverse outcomes during early adulthood. Systematic evaluation of character strengths may improve the clinical assessment of adolescents. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90024 USA. Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA. VA Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. Columbia Univ, New York, NY USA. New York State Psychiat Inst & Hosp, New York, NY 10032 USA. RP Bromley, E (reprint author), Univ Calif Los Angeles, Dept Anthropol, 911 Broxton Plaza,3rd Floor, Los Angeles, CA 90024 USA. EM ebromley@ucla.edu NR 59 TC 5 Z9 5 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0010-440X J9 COMPR PSYCHIAT JI Compr. Psychiat. PD JUL-AUG PY 2006 VL 47 IS 4 BP 317 EP 326 DI 10.1016/j.comppsych.2005.11.003 PG 10 WC Psychiatry SC Psychiatry GA 058BL UT WOS:000238639000012 ER PT J AU Peralta, CA Kurella, M Lo, JC Chertow, GM AF Peralta, Carmen A. Kurella, Manjula Lo, Joan C. Chertow, Glenn M. TI The metabolic syndrome and chronic kidney disease SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION LA English DT Editorial Material DE chronic kidney disease; hyperglycemia; hypertension; metabolic syndrome; microalbuminuria; obesity ID GLOMERULAR-FILTRATION-RATE; TARGET ORGAN DAMAGE; INSULIN-RESISTANCE; US ADULTS; RENAL-DISEASE; RHESUS-MONKEYS; OBESITY; HYPERINSULINEMIA; ASSOCIATION; RISK AB Purpose of review The metabolic syndrome is a constellation of physical and laboratory abnormalities including hypertension, hyperglycemia, hyperlipidemia and abdominal obesity. Over the past decade, the metabolic syndrome has emerged as a critically important risk factor for cardiovascular disease. Recent findings A large population-based cross-sectional analysis (the National Health and Nutrition Evaluation Survey III) found that the presence of the metabolic syndrome was associated with chronic kidney disease, defined as an estimated glomerular filtration rate of less than 60 ml/min per 1.73 m(2) and was also associated with proteinuria. More recently, a prospective cohort study found that the presence of the metabolic syndrome was associated with incident chronic kidney disease by the same definition, even when excluding individuals with diabetes mellitus and hypertension. More studies are required to determine whether the relationship between the metabolic syndrome and chronic kidney disease is mainly mediated by hyperglycemia (with insulin resistance) and hypertension, or other metabolic or hemodynamic factors. Summary The metabolic syndrome is associated with chronic kidney disease. Efforts aimed at determining the mechanisms underlying this association and strategies for the prevention of chronic kidney disease (or slowing the progression of chronic kidney disease) in affected patients should be research priorities in the future. C1 Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Biostat & Epidemiol, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Div Endocrinol, San Francisco, CA 94143 USA. Kaiser Permanente No Calif, Div Res, Oakland, CA USA. RP Chertow, GM (reprint author), Dept Med Res, UCSF Laurel Hts,Suite 430,3333 Calif St, San Francisco, CA 94118 USA. EM chertowg@medicine.ucsf.edu RI Kurella Tamura, Manjula/C-8284-2014 OI Kurella Tamura, Manjula/0000-0001-5227-2479 NR 24 TC 43 Z9 45 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1062-4821 EI 1473-6543 J9 CURR OPIN NEPHROL HY JI Curr. Opin. Nephrol. Hypertens. PD JUL PY 2006 VL 15 IS 4 BP 361 EP 365 DI 10.1097/01.mnh.0000232875.27846.7e PG 5 WC Urology & Nephrology; Peripheral Vascular Disease SC Urology & Nephrology; Cardiovascular System & Cardiology GA 064QA UT WOS:000239103000002 PM 16775449 ER PT J AU Mahimainathan, L Das, F Venkatesan, B Choudhury, GG AF Mahimainathan, L Das, F Venkatesan, B Choudhury, GG TI Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN SO DIABETES LA English DT Article ID GROWTH-FACTOR-BETA; DIABETIC RENAL HYPERTROPHY; ACTIVATED PROTEIN-KINASE; LHERMITTE-DUCLOS-DISEASE; TGF-BETA; PHOSPHOINOSITIDE 3-KINASE; GENE-EXPRESSION; TRANSFORMING GROWTH-FACTOR-BETA-1; FIBRONECTIN EXPRESSION; INSULIN-RESISTANCE AB Diabetic nephropathy is characterized early in its course by glomerular hypertrophy and, importantly, mesangial hypertrophy, which correlate with eventual glomerulosclerosis. The mechanism of hypertrophy, however, is not known. Gene disruption of the tumor suppressor PTEN, a negative regulator of the phosphatidylinositol 3-kinase/Akt pathway, in fruit flies and mice demonstrated its role in size control in a cell-specific manner. Here, we investigated the mechanism of mesangial hypertrophy in response to high extracellular glucose. We link early renal hypertrophy with significant reduction in PTEN expression in the streptozotocin-induced diabetic kidney cortex and glomeruli, concomitant with activation of Akt. Similarly, exposure of mesangial cells to high concentrations of glucose also decreased PTEN expression and its phosphatase activity, resulting in increased AM activity. Expression of PTEN inhibited high-glucose-induced mesangial cell hypertrophy, and expression of dominant-negative PTEN was sufficient to induce hypertrophy. In diabetic nephropathy, the hypertrophic effect of hyperglycemia is thought to be mediated by transforming growth factor-beta (TGF-beta). TGF-beta significantly reduced PTEN expression in mesangial cells, with a reduction in its phosphatase activity and an increase in Akt activation. PTEN and dominant-negative Akt attenuated TGF-beta-induced hypertrophy of mesangial cells. Finally, we show that inhibition of TGF-beta signal transduction blocks the effect of high glucose on PTEN downregulation. These data identify a novel mechanism placing PTEN as a key regulator of diabetic mesangial hypertrophy involving TGF-beta signaling. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu OI /0000-0001-5077-3552 FU NIDDK NIH HHS [R01 DK 55815, R01 DK50190] NR 71 TC 90 Z9 105 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD JUL PY 2006 VL 55 IS 7 BP 2115 EP 2125 DI 10.2337/db05-1326 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 059XD UT WOS:000238764600027 PM 16804083 ER PT J AU McHorney, CA Martin-Harris, B Robbins, J Rosenbek, J AF McHorney, Colleen A. Martin-Harris, Bonnie Robbins, JoAnne Rosenbek, John TI Clinical validity of the SWAL-QOL and SWAL-CARE outcome tools with respect to bolus flow measures SO DYSPHAGIA LA English DT Article DE deglutition disorders; quality of life; swallowing; patient satisfaction; deglutition ID QUALITY-OF-LIFE; OROPHARYNGEAL DYSPHAGIA; RHEUMATOID-ARTHRITIS; PROGNOSTIC VALUE; HEALTH; ADULTS; SCALE; FATIGUE; DISEASE; RELIABILITY AB The aim of this study was to quantify the association between a dysphagia-specific quality of life (SWAL-QOL) and quality of care (SWAL-CARE) questionnaire and four measures of bolus flow. Three hundred eighty-six people with oropharyngeal dysphagia completed a videofluoroscopic examination of their swallowing structure and physiology. They also completed the SWAL-QOL and SWAL-CARE surveys. Measures of bolus flow patterns for each swallow were analyzed from videofluoroscopic recordings and correlated with the SWAL-QOL and SWAL-CARE scale scores. The SWAL-QOL and SWAL-CARE scales were modestly related to the four measures of the bolus flow. The SWAL-QOL and SWAL-CARE were most related to measures of oral transit duration and total swallow duration. The SWAL-QOL and SWAL-CARE scales were least related to pharyngeal transit duration. Results were stronger for semisolid trials than for liquid trials. Results were generally weak for the Penetration Aspiration Scale. For all of the significant relationships, the greater the bolus flow severity, the worse the quality of life. The observed modest correlations suggest that patient-centered quality-of-life measures and clinician-driven bolus flow measures provide distinct yet complementary information about oropharyngeal dysphagia. Both sets of measures should be used in dysphagia effectiveness and outcomes research. C1 Merck & Co Inc, West Point, PA 19486 USA. Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, MUSC Evelyn Trammell Inst Voice & Swalowing, Charleston, SC 29425 USA. Med Univ S Carolina, Coll Hlth Profess, Charleston, SC 29425 USA. Univ Wisconsin, Sch Med, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. Univ Florida, Dept Communicat Disorders, Gainesville, FL USA. Univ Florida, Sch Med, Dept Neurol, Gainesville, FL USA. RP McHorney, CA (reprint author), Merck & Co Inc, WP39-166,770 Sumneytown Pike, West Point, PA 19486 USA. EM colleen_mchorney@merck.com FU NIA NIH HHS [R01 AG022067] NR 44 TC 33 Z9 38 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0179-051X J9 DYSPHAGIA JI Dysphagia PD JUL PY 2006 VL 21 IS 3 BP 141 EP 148 DI 10.1007/s00455-005-0026-9 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA 081HL UT WOS:000240307800001 PM 16715210 ER PT J AU Huang, DS Khoe, M Ilic, D Bryer-Ash, M AF Huang, DS Khoe, M Ilic, D Bryer-Ash, M TI Reduced expression of focal adhesion kinase disrupts insulin action in skeletal muscle cells SO ENDOCRINOLOGY LA English DT Article ID PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; RECEPTOR SUBSTRATE-1 PHOSPHORYLATION; TOKUSHIMA FATTY RAT; GLUCOSE-TRANSPORT; PLASMA-MEMBRANE; GLYCOGEN-SYNTHESIS; TYROSINE PHOSPHATASE; DNA-SYNTHESIS; IN-VIVO; STIMULATION AB Integrins mediate interactions between cells and extracellular matrix proteins that modulate growth factor signaling. Focal adhesion kinase (FAK) is a key multifunctional integrin pathway protein. We recently reported that disruption of FAK impairs insulin-mediated glycogen synthesis in hepatocytes. To test the hypothesis that FAK regulates skeletal muscle insulin action, we reduced FAK expression in L6 myotubes using FAK antisense. In untransfected myotubes, insulin stimulated both FAK tyrosine phosphorylation and kinase activity. Cells treated with antisense FAK showed 78 and 53% reductions in FAK mRNA and FAK protein, respectively, whereas insulin receptor substrate 1/2 and paxillin abundance were unaffected. Insulin-stimulated U-14C-glucose incorporation into glycogen was abolished by FAK antisense, and 2-deoxy-glucose uptake and glucose transporter 4 (GLUT4) translocation were both markedly attenuated. Antisense FAK did not alter GLUT1 or GLUT3 protein abundance. Immunofluorescence staining showed decreased FAK Tyr(397) phosphorylation and reduced actin stress fibers. Thus, in skeletal myotubes, FAK regulates the insulin-mediated cytoskeletal rearrangement essential for normal glucose transport and glycogen synthesis. Integrin signaling may play an important regulatory role in muscle insulin action. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Gonda Goldschmied Diabet Ctr, W Los Angeles Vet Adm Med Ctr, Los Angeles, CA 90095 USA. Univ Calif San Francisco, Dept Stomatol & Anat, San Francisco, CA 94143 USA. RP Bryer-Ash, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, 900 Vet Ave,Warren Hall Room 24-130, Los Angeles, CA 90095 USA. EM mbryerash@mednet.ucla.edu NR 51 TC 26 Z9 26 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD JUL PY 2006 VL 147 IS 7 BP 3333 EP 3343 DI 10.1210/en.2005-0382 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 053NS UT WOS:000238312400022 PM 16574795 ER PT J AU Handforth, A DeSalles, AAF Krahl, SE AF Handforth, Adrian DeSalles, Antonio A. F. Krahl, Scott E. TI Deep brain stimulation of the subthalamic nucleus as adjunct treatment for refractory epilepsy SO EPILEPSIA LA English DT Article DE epilepsy; deep brain stimulation; subthalamus; STN; DBS ID SUBSTANTIA-NIGRA; ENTOPEDUNCULAR NUCLEUS; SEIZURES; ACID; SITE; RATS AB Purpose: We studied the efficacy and safety of bilateral subthalamic deep brain stimulation (DBS) for refractory partial-onset epilepsy in two cases. Methods: This was an open treatment pilot study for subjects who had failed numerous medications and had seizure injuries. Seizure counts and adverse events were collected during a 3-4 month baseline, and for 26-32 months after DBS surgery, with AEDs held constant. Results: Case 1, age 45, with bitemporal seizures, had about half the seizure frequency but still fell with injuries. Case 2, age 46, with left frontal encephalomalacia, had a frequency reduction of about one-third, but a more meaningful reduction of seizure severity and injuries. Conclusions: Subthalamic DBS partly reduced partial-onset seizures, but the quality of life was more affected by seizure-related injuries. C1 VA Greater Los Angeles Healthcare Syst, Neurol Serv, Dept Neurol, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Dept Neurosurg, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Dev Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90024 USA. RP Handforth, A (reprint author), VA Greater Los Angeles Healthcare Syst, Neurol Serv, Dept Neurol, W127,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM charles.handforth@med.va.gov NR 10 TC 61 Z9 66 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD JUL PY 2006 VL 47 IS 7 BP 1239 EP 1241 DI 10.1111/j.1528-1167.2006.00563.x PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 064WD UT WOS:000239119700019 PM 16886990 ER PT J AU Gudavalli, MR Cambron, JA McGregor, M Jedlicka, J Keenum, M Ghanayem, AJ Patwardhan, AG AF Gudavalli, Maruti Ram Cambron, Jerrilyn A. McGregor, Marion Jedlicka, James Keenum, Michael Ghanayem, Alexander J. Patwardhan, Avinash G. TI A randomized clinical trial and subgroup analysis to compare flexion-distraction with active exercise for chronic low back pain SO EUROPEAN SPINE JOURNAL LA English DT Article DE low back pain; chiropractic; physical therapy; chronic pain; randomized clinical trial ID STABILIZING EXERCISE; SPINAL MANIPULATION; PREDICTION RULE; THERAPY AB Many clinical trials on chiropractic management of low back pain have neglected to include specific forms of care. This study compared two well-defined treatment protocols. The objective was to compare the outcome of flexion-distraction (FD) procedures performed by chiropractors with an active trunk exercise protocol (ATEP) performed by physical therapists. A randomized clinical trial study design was used. Subjects, 18 years of age and older, with a primary complaint of low back pain (> 3 months) were recruited. A 100 mm visual analogue scale (VAS) for perceived pain, the Roland Morris (RM) Questionnaire for low back function, and the SF-36 for overall health status served as primary outcome measures. Subjects were randomly allocated to receive either FD or ATEP. The FD intervention consisted of the application of flexion and traction applied to specific regions in the low back, with the aid of a specially designed manipulation table. The ATEP intervention included stabilizing and flexibility exercises, the use of modalities, and cardiovascular training. A total of 235 subjects met the inclusion/exclusion criteria and signed the informed consent. Of these, 123 were randomly allocated to FD and 112 to the ATEP. Study patients perceived significantly less pain and better function after intervention, regardless of which group they were allocated to (P < 0.01). Subjects randomly allocated to the flexion-distraction group had significantly greater relief from pain than those allocated to the exercise program (P=0.01). Subgroup analysis indicated that subjects categorized as chronic, with moderate to severe symptoms, improved most with the flexion-distraction protocol. Subjects categorized with recurrent pain and moderate to severe symptoms improved most with the exercise program. Patients with radiculopathy did significantly better with FD. There were no significant differences between groups on the Roland Morris and SF-36 outcome measures. Overall, flexion-distraction provided more pain relief than active exercise; however, these results varied based on stratification of patients with and without radiculopathy and with and without recurrent symptoms. The subgroup analysis provides a possible explanation for contrasting results among randomized clinical trials of chronic low back pain treatments and these results also provide guidance for future work in the treatment of chronic low back pain. C1 Palmer Coll Chiropract, Davenport, IA USA. Natl Univ Hlth Sci, Lombard, IL USA. Orthosport Phys Therapy, Forest Pk, IL USA. Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Gudavalli, MR (reprint author), Palmer Coll Chiropract, Davenport, IA USA. EM gudavalli_r@palmer.edu FU BHP HRSA HHS [R18 AH 10001] NR 34 TC 48 Z9 48 U1 2 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0940-6719 J9 EUR SPINE J JI Eur. Spine J. PD JUL PY 2006 VL 15 IS 7 BP 1070 EP 1082 DI 10.1007/s00586-005-0021-8 PG 13 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 063SG UT WOS:000239039300005 PM 16341712 ER PT J AU Wanahita, A Davis, B Hamill, RJ Goldsmith, EA Rodgers, JR Cook, RG Lamphear, JG Musher, DM AF Wanahita, A Davis, B Hamill, RJ Goldsmith, EA Rodgers, JR Cook, RG Lamphear, JG Musher, DM TI Clostridium difficile lacks detectable superantigen activity SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY LA English DT Article DE Clostridium difficile; superantigen; leukocytosis ID PERFRINGENS ENTEROTOXIN; TOXIN-A; LEUKOCYTOSIS; INFECTION; DIARRHEA; ACTIVATION; CELLS AB Clostridium difficile colitis causes striking leukocytosis. We examined the possibility that toxins A or B, or other nontoxin products of C. difficile, act as superantigens, thereby stimulating leukocytosis. Our results failed to show major histocompatibility complex class II-dependent T lymphocyte proliferation, the hallmark of superantigen activity. Elevated white blood cell counts in C. difficile colitis are probably due to increased generation of cytokines such as interleukin-6 (IL-6) or IL-8. C1 Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA. RP Musher, DM (reprint author), Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. EM musher@med.va.gov FU NIAID NIH HHS [R01 AI30036, T32-AI07495] NR 18 TC 0 Z9 1 U1 1 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0928-8244 J9 FEMS IMMUNOL MED MIC JI FEMS Immunol. Med. Microbiol. PD JUL PY 2006 VL 47 IS 2 BP 275 EP 277 DI 10.1111/j.1574-695X.2006.00089.x PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 059VY UT WOS:000238761500014 PM 16831215 ER PT J AU Asmis, R Qiao, M Rossi, RR Cholewa, J Xu, L Asmis, LM AF Asmis, R Qiao, M Rossi, RR Cholewa, J Xu, L Asmis, LM TI Adriamycin promotes macrophage dysfunction in mice SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE adriamycin; macrophage; thiol oxidation; cell death; wound healing; protein-S-glutathionylation ID NF-KAPPA-B; TRANSCRIPTION FACTOR; CARDIOLIPIN REQUIREMENT; OXIDATIVE STRESS; DB/DB MICE; IN-VITRO; CARDIOTOXICITY; NUCLEAR; REDOX; MOUSE AB Impaired wound healing contributes to the morbidity and mortality associated with adriamycin chemotherapy. Macrophages are essential for tissue repair and loss of macrophage function leads to impaired wound healing. We recently showed that adriamycin is a potent inducer of thiol oxidation and cell injury in cultured macrophages (FASEB J. 19:1866-1868; 2005). Here we tested the hypothesis that adriamycin also promotes oxidative stress and macrophage dysfunction in vivo. We treated FVB mice twice a week either with low doses of adriamycin (4 mg/kg) or with the same volume of saline by tail vein injection for a total of 8 injections. Wound healing was significantly delayed in adriamycin-treated mice. The number of resident peritoneal macrophages was decreased by 30% and macrophage recruitment in response to thiogycolate stimulation was decreased by 46% in mice treated with adriamycin. LPS-induced TNF alpha and IL-1 beta secretion from macrophages of adriamycin-treated mice was decreased by 28.7 and 29.5%, respectively, compared to macrophages isolated from saline-injected mice. Peritoneal macrophages isolated from adriamycin-treated mice also showed increased formation of reactive oxygen species and enhanced protein-S-glutathionylation. In summary, our results show that low cumulative doses of adriamycin are sufficient both to promote sustained thiol oxidative stress and macrophage dysfunction in vivo and to delay tissue repair, suggesting that macrophage dysfunction contributes to impaired wound healing associated with adriamycin chemotherapy. (c) 2006 Elsevier Inc. All fights reserved. C1 Univ Texas, Hlth Sci Ctr, Div Nephrol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Univ Rochester, Med Ctr, Rochester, NY 14642 USA. Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY USA. Univ Zurich Hosp, Div Hematol, CH-8091 Zurich, Switzerland. RP Asmis, R (reprint author), Univ Texas, Hlth Sci Ctr, Div Nephrol, 7703 Floyd Curl Dr,MSC 7882, San Antonio, TX 78229 USA. EM asmis@uthscsa.edu FU NHLBI NIH HHS [R01 HL-70963] NR 41 TC 15 Z9 15 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD JUL 1 PY 2006 VL 41 IS 1 BP 165 EP 174 DI 10.1016/j.freeradbiomed.2006.03.027 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 058LV UT WOS:000238667400018 PM 16781464 ER PT J AU Akiba, Y Ghayouri, S Takeuchi, T Mizumori, M Guth, PH Engel, E Swenson, ER Kaunitz, JD AF Akiba, Yasutada Ghayouri, Sara Takeuchi, Tetsu Mizumori, Misa Guth, Paul H. Engel, Eli Swenson, Erik R. Kaunitz, Jonathan D. TI Carbonic anhydrases and mucosal vanilloid receptors help mediate the hyperemic response to luminal CO2 in rat duodenum SO GASTROENTEROLOGY LA English DT Article ID AVIAN INTRAPULMONARY CHEMORECEPTORS; STIMULATED HCO3-SECRETION; GASTRIC-ACID-SECRETION; BLOOD-FLOW; GASTROINTESTINAL-TRACT; INTRACELLULAR PH; BICARBONATE SECRETION; AFFERENT NEURONS; ALKALINE SECRETION; EPITHELIAL-CELLS AB Background & Aims: The duodenal mucosa is exposed to PCO2 > 200 mm Hg due to the luminal mixture of gastric acid with secreted bicarbonate, which augments mucosal protective mechanisms. We examined the hyperemic response to elevated luminal PCO2 in the duodenum of anesthetized rats luminally exposed to high CO2 saline to help elucidate luminal acid-sensing mechanisms. Methods: Blood flow was measured by laser Doppler, and intracellular pH of epithelial cells by measured by ratio microimaging. The permeant carbonic anhydrase (CA) inhibitor methazolamide, relatively impermeant CA inhibitor benzolamide, vanilloid receptor antagonist capsazepine, or sodium-hydrogen exchanger 1 (NHE-1) inhibitor dimethyl amiloride were perfused with or without the high CO2 solution. Results: The high CO2 solution increased duodenal blood flow, which was abolished by pretreatment with methazolamide or capsazepine or by dimethyl amiloride coperfusion. Sensory denervation with capsaicin also abolished the CO2 effects. Benzolamide dose-dependently inhibited CO2-induced hyperemia and at 100 nmol/L inhibited CO2-induced intracellular acidification. The membrane-bound CA isoforms IV, IX, XII, and XIV and cytosolic CA II and the vanilloid receptor 1 (TRPV1) were expressed in duodenum and stomach. Dorsal root ganglion and no-dose ganglion expressed all isoforms except for CA IX. Conclusions: The duodenal hyperemic response to luminal CO2 is dependent on cytosolic and membrane-bound CA isoforms, NHE-1, and TRPV1. CO2-induced intracellular acidification was inhibited by selective extracellular CA inhibition, suggesting that CO2 diffusion across the epithelial apical membrane is mediated by extracellular CA. NHE-1 activation preceding TRPV1 stimulation suggests that luminal CO2 is sensed as H+ in the subepithelium. C1 W Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [P30 DK0413, R01 DK54221] NR 76 TC 36 Z9 43 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JUL PY 2006 VL 131 IS 1 BP 142 EP 152 DI 10.1053/j.gastro.2006.04.018 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 062YQ UT WOS:000238983300023 PM 16831598 ER PT J AU Boockvar, K AF Boockvar, Kenneth TI Transitional care: Governmental regulation versus provider oversight? SO GERIATRICS LA English DT Letter C1 CUNY Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY 10029 USA. RP Boockvar, K (reprint author), CUNY Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY 10029 USA. OI Boockvar, Kenneth/0000-0003-1165-5558 NR 4 TC 0 Z9 0 U1 0 U2 0 PU ADVANSTAR COMMUNICATIONS PI DULUTH PA 131 W FIRST ST, DULUTH, MN 55802 USA SN 0016-867X J9 GERIATRICS JI Geriatrics PD JUL PY 2006 VL 61 IS 7 BP 8 EP 8 PG 1 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 064XR UT WOS:000239124500001 PM 16827608 ER PT J AU Farwell, DG Kezirian, EJ Heydt, JL Yueh, B Futran, ND AF Farwell, DG Kezirian, EJ Heydt, JL Yueh, B Futran, ND TI Efficacy of small reconstruction plates in vascularized bone graft mandibular reconstruction SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article; Proceedings Paper CT 6th International Conference on Head and Neck Cancer CY AUG 07-11, 2004 CL Washington, DC SP Amer Head & Neck Soc DE reconstruction; mandible; locking; plate; complication ID HYPERBARIC-OXYGEN THERAPY; FREE-FLAP; OROMANDIBULAR RECONSTRUCTION; OSTEORADIONECROSIS; FIXATION; COMPLICATIONS; SURGERY; SYSTEM; THORP; NECK AB Background: Utilization of vascularized bone grafts rigidly fixated with titanium reconstruction plates is the method of choice for reconstruction of segmental mandibular defects. We hypothesized that the use of the newer 2.0-mm locking reconstruction plate (LRP) is not associated with higher rates of complications when compared with larger, previously used plating systems. Methods: A retrospective case series of 184 patients undergoing 185 vascularized bone graft reconstruction procedures of the mandible was conducted. Results. There were 37 plate complications. There was no significant difference in complication rates for the 2 most used plate types (14.5% with the 2.0-mm LRP and 22.2% with the 2.4-mm LRP). Conclusions: Use of the smaller 2.0-mm LRP was not associated with an increase in the complications of plate fracture, exposure, infection, or nonunion, Because of its lower profile and ease of application, the 2.0-mm LRP is our plate of choice for mandibular reconstruction. (c) 2006 Wiley Periodicals, Inc. C1 Univ Calif Davis, Dept Otolaryngol Head & Neck Surg, Sacramento, CA 95817 USA. Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA. Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. VA Puget Sound Healthcare Syst, Surg & Perioperat Care Serv, Seattle, WA USA. RP Farwell, DG (reprint author), Univ Calif Davis, Dept Otolaryngol Head & Neck Surg, 2521 Stockton Blvd,Suite 7200, Sacramento, CA 95817 USA. OI Yueh, Bevan/0000-0003-1380-1053 NR 24 TC 9 Z9 9 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1043-3074 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD JUL PY 2006 VL 28 IS 7 BP 573 EP 579 DI 10.1002/hed.20455 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 058UM UT WOS:000238690100001 PM 16755584 ER PT J AU Nath, N Prasad, R Giri, S Singh, AK Singh, I AF Nath, N Prasad, R Giri, S Singh, AK Singh, I TI T-bet is essential for the progression of experimental autoimmune encephalomyelitis SO IMMUNOLOGY LA English DT Article DE EAE; T-bet; T-cells; IL-10; autoimmunity ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; CELL-DIFFERENTIATION; MULTIPLE-SCLEROSIS; BALB/C MICE; GAMMA; IL-4-DEFICIENT; CHEMOKINES; INDUCTION; IL-10 AB Experimental autoimmune encephalomyelitis (EAE) is mediated by myelin-specific CD4(+) T helper 1 (Th1) cells, while recovery from the disease is associated with the presence of Th2 cells. Here we used animals with targeted deletion of the T-bet gene to determine its role in the progression of EAE. T-bet regulates the production of interferon-gamma (IFN-gamma) in CD4(+) and natural killer cells, and CD4(+) T cells from T-bet-deficient mice were unable to differentiate into a Th1 phenotype. Moreover BALB/c mice deficient in T-bet were resistant to the induction of EAE disease, with minimal inflammatory infiltrates in the central nervous system. These mice were resistant to EAE induction even when PLP(180-199) peptide specific effector T cells from BALB/c wild type were transferred to BALB/c T-bet-deficient mice. This resistance to EAE is may be caused by the production of the anti-inflammatory cytokine interleukin-10 (IL-10) from the spleen cells upon ex vivo stimulation with PLP(180-199) peptide and in vivo presence in the central nervous system. There was no difference in the recall responses in spleen cells from T-bet-deficient and wild type mice; however, less secretion of IFN-gamma was observed from primed splenocytes. The expression of IFN-gamma was less in the central nervous system of T-bet-deficient mice whereas IL-10 was significantly higher in T-bet-deficient as compared to wild type mice. These data indicate that T-bet genes play a critical role in maintaining the encephalitogenic nature of CD4(+) T cells in autoimmune responses during EAE disease progression. C1 Med Univ S Carolina, Childrens Res Inst, Dept Pediat, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Childrens Res Inst, Dept Pediat, 173 Ashley Ave,505 Childrens Res Inst, Charleston, SC 29425 USA. EM singhi@musc.edu FU NINDS NIH HHS [NS-22576, NS-34741, NS-37766, NS-40144, NS-40810] NR 32 TC 40 Z9 41 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0019-2805 J9 IMMUNOLOGY JI Immunology PD JUL PY 2006 VL 118 IS 3 BP 384 EP 391 DI 10.1111/j.1365-2567.2006.02385.x PG 8 WC Immunology SC Immunology GA 054RR UT WOS:000238396800011 PM 16827899 ER PT J AU Young, MRI AF Young, MRI TI Cytokine-containing gelfoam implants at a postsurgical tumor excision site to stimulate local immune reactivity SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE CD34(+) cells; chemoattraction; dendritic cells; differentiation; GM-CSF; immunotherapy; tumor; VEGF ID ENDOTHELIAL GROWTH-FACTOR; CD34(+) PROGENITOR CELLS; IMMATURE MYELOID CELLS; DENDRITIC CELLS; PROSTATE-CANCER; NECK-CANCER; CLINICAL-RESPONSES; PERIPHERAL-BLOOD; PHASE-II; T-CELLS AB We previously demonstrated increased numbers of CD34(+) progenitor cells in the peripheral blood of tumor bearers. Also demonstrated was the feasibility of chemoattracting these cells by sponge implants containing VEGF. The present study used a murine Lewis lung carcinoma (LLC) model to test if CD34(+) cells that are chemoattracted to a tumor excision site can be differentiated in situ into dendritic cells and whether this leads to increased local immune reactivity. After surgically excising established LLC tumors, mice received at the excision site gelatin sponge implants containing VEGF to chemoattract CD34(+) cells, and/or GM-CSF plus SCF to induce CD34(+) cell differentiation into dendritic cells. In some studies, lysates of GFP-transfected LLC cells (LLCGFP) were also included in the implants as a source of tumor antigen. After 2 weeks, implants and local lymph nodes were removed and analyzed. Implants containing VEGF, GM-CSF/SCF or VEGF/GM:CSF/SCF had a higher proportion of CD34(+) cells compared to control implants. However, the number of dendritic cells,vas higher in implants containing GM-CSF/SCF or VEGF/GM-CSF/SCF than those containing either VEGF or diluent. Regional lymph node from mice containing GM-CSF/SCF or VEGF/GM-CSF/SCF implants showed increased dendritic cell levels. However, when lysates from LLCGFP were added to the implants, the highest proportion of dendritic cells associated with GFP was in lymph nodes of mice containing GM-CSF/SCF implants. Lymph node cells from mice with GM-CSF/SCF or VEGF/GM-CSF/SCF had a higher level of proliferation and IFN-gamma secretion in response to in vitro LLC lysate challenge, with the greatest response being from lymph node cells of mice with GM-CSF/SCF implants. These results suggest the feasibility of using GM-CSF/SCF-containing implants to increase dendritic cell levels, uptake of tumor antigens, trafficking to lymph nodes and stimulation of immune reactivity at tumor excision sites with residual tumor. (c) 2006 Wiley-Liss, Inc. C1 Ralph H Johnson VA Med Ctr, Res Serv 151, Dept Res Serv, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv 151, Dept Res Serv, 109 Bee St, Charleston, SC 29401 USA. EM rita.young@med.va.gov FU NCI NIH HHS [CA-97813, CA-85266] NR 34 TC 0 Z9 1 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD JUL 1 PY 2006 VL 119 IS 1 BP 133 EP 138 DI 10.1002/ijc.21806 PG 6 WC Oncology SC Oncology GA 041CH UT WOS:000237430200018 PM 16450395 ER PT J AU Lam, MM Corless, CL Goldblum, JR Heinrich, MC Downs-Kelly, E Rubin, BP AF Lam, Maggie M. Corless, Christopher L. Goldblum, John R. Heinrich, Michael C. Downs-Kelly, Erinn Rubin, Brian P. TI Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: A diagnostic pitfall SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY LA English DT Article DE gastrointestinal stromal tumor; GIST; vulvovaginal septum ID SOFT-TISSUE; AGGRESSIVE ANGIOMYXOMA; C-KIT; MUTATIONS; EFFICACY; NEOPLASM; SAFETY; VAGINA; KINASE; VULVA AB Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. Most GISTs arise in the stomach and small bowel, whereas a small number occur elsewhere in the GI tract. Rare cases are identified outside the GI tract and are collectively known as extragastrointestinal stromal tumors (EGISTs). Because of their malignant potential and recent advances in the management of GISTs with imatinib mesylate (Gleevec, Glivec), it is imperative that these tumors are diagnosed correctly. In this study, we reviewed the clinical and pathologic characteristics of 3 cases of EGIST presenting as vulvovaginal/rectovaginal septal masses that were originally misdiagnosed, presumably due to their unusual anatomic locations. The original diagnoses were leiomyoma in one case and leiomyosarcoma in 2 cases. The lesions were localized to the rectovaginal septum (1) or vagina (2) and ranged from 4 to 8 cm in diameter. All 3 lesions had a spindle cell morphology that mimicked a smooth muscle tumor. Mitotic figures numbered from 12/50 to 16/50 high power fields (HPFs; median 15). Immunohistochemistry revealed that all 3 cases were strongly positive for KIT (CD 117) and CD34 and negative for smooth muscle actin, desmin, pan-cytokeratin, and estrogen receptor. KIT sequence analysis revealed oncogenic mutations in all 3 cases. The first tumor recurred at 2 years and the second tumor recurred at 10 years; the third case is too recent for meaningful follow-up. EGISTs that present as gynecologic masses are rare but may be more common than is currently recognized. Misdiagnosis may lead to inappropriate therapy because conventional chemotherapy and radiotherapy are not effective in the treatment of GISTs, whereas imatimb mesylate (Gleevec, Glivec) has a proven role in managing these tumors. Thus, it is imperative to consider EGISTs in the differential diagnosis of mesenchymal neoplasms in the vulvovaginal/rectovaginal septum. C1 Univ Washington, Med Ctr, Dept Pathol Anat, Seattle, WA 98195 USA. Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Div Hematol Oncol, Inst Canc, Portland, OR 97201 USA. Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA. Portland VA Med Ctr, Portland, OR USA. RP Rubin, BP (reprint author), Univ Washington, Med Ctr, Dept Pathol Anat, 1959 NE Pacific St,Box 356100, Seattle, WA 98195 USA. EM bprubin@u.washington.edu NR 22 TC 43 Z9 45 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-1691 J9 INT J GYNECOL PATHOL JI Int. J. Gynecol. Pathol. PD JUL PY 2006 VL 25 IS 3 BP 288 EP 292 DI 10.1097/01.pgp.0000215291.22867.18 PG 5 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA 061JV UT WOS:000238869100014 PM 16810068 ER PT J AU Marder, SR Crandall, D Pultz, J Carson, WH Gutierrez-Esteinou, R Tran, QV Marcus, RN AF Marder, S. R. Crandall, D. Pultz, J. Carson, W. H. Gutierrez-Esteinou, R. Tran, Q. -V. Marcus, R. N. TI The effectiveness of the novel atypical antipsychotic aripiprazole according to levels of agitation at baseline in patients with acute schizophrenia SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 25th CINP Congress CY JUL 09-13, 2006 CL Chicago, IL SP CINP C1 W Los Angeles VA Med Ctr, Los Angeles, CA USA. Bristol Myers Squibb Co, New York, NY 10154 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD JUL PY 2006 VL 9 SU 1 BP S277 EP S277 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 070BO UT WOS:000239495501470 ER PT J AU Monkul, ES Matsuo, K Nicoletti, MA Brambilla, R Sassi, RB Hatch, JP Mallinger, AG Keshavan, MS Soares, JC AF Monkul, E. S. Matsuo, K. Nicoletti, M. A. Brambilla, R. Sassi, R. B. Hatch, J. P. Mallinger, A. G. Keshavan, M. S. Soares, J. C. TI Dorsolateral prefrontal gray matter increases in healthy individuals after lithium treatment: A voxel-based morphometry study SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 25th Congress of the Collegium-Internationale-Neuro-Psychopharmacologicum (CINP)/29th Annual Meeting of the Canadian-College-of-Neuropsychopharmacology CY JUL 09-13, 2006 CL Chicago, IL SP Collegium Int Neuro Psychopharmacol, Canadian Coll Neuro Psychopharmacol C1 Univ Texas, Hlth Sci Ctr San Antonio, Dept Psychiat, Div Mood & Anxiety Disorders,MOOD CNS Program, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. Univ Udine, Sect Psychiat, Dept Pathol & Expt & Clin Med, I-33100 Udine, Italy. Sci Inst IRCCS E, Medea, Italy. Univ Sao Paulo, Sch Med, Dept Psychiat, BR-05508 Sao Paulo, Brazil. Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15260 USA. Univ Texas, Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78285 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD JUL PY 2006 VL 9 SU 1 BP S180 EP S180 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 070BO UT WOS:000239495501120 ER PT J AU Ho, AY Atencio, DP Peters, S Stock, RG Formenti, SC Cesaretti, JA Green, S Haffty, B Drumea, K Leitzin, L Kuten, A Azria, D Ozsahin, M Overgaard, J Andreassen, CN Trop, CS Park, J Rosenstein, BS AF Ho, AY Atencio, DP Peters, S Stock, RG Formenti, SC Cesaretti, JA Green, S Haffty, B Drumea, K Leitzin, L Kuten, A Azria, D Ozsahin, M Overgaard, J Andreassen, CN Trop, CS Park, J Rosenstein, BS TI Genetic predictors of adverse radiotherapy effects: The gene-pare project SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Review DE genetic predictors; adverse radiotherapy effects; breast cancer; prostate cancer ID BREAST-CANCER PATIENTS; PERFORMANCE LIQUID-CHROMATOGRAPHY; SINGLE-NUCLEOTIDE POLYMORPHISMS; ATAXIA-TELANGIECTASIA GENE; NORMAL-TISSUE RADIOSENSITIVITY; ATM SEQUENCE VARIANTS; DNA-REPAIR GENE; RADIATION SENSITIVITY; IN-VITRO; MUTATION DETECTION AB Purpose: The development of adverse effects resulting from the radiotherapy of cancer limits the use of this treatment modality. The validation of a test capable of predicting which patients would be most likely to develop adverse responses to radiation treatment, based on the possession of specific genetic variants, would therefore be of value. The purpose of the Genetic Predictors of Adverse Radiotherapy Effects (Gene-PARE) project is to help achieve this goal. Methods and Materials: A continuously expanding biorepository has been created consisting of frozen lymphocytes and DNA isolated from patients treated with radiotherapy. In conjunction with this biorepository, a database is maintained with detailed clinical information pertaining to diagnosis, treatment, and outcome. The DNA samples are screened using denaturing high performance liquid chromatography (DHPLC) and the Surveyor nuclease assay for variants in ATM, TGFB1, XRCC1, XRCC3, SOD2, and hHR21. It is anticipated that additional genes that control the biologic response to radiation will be screened in future work. Results: Evidence has been obtained that possession of variants in genes, the products of which play a role in radiation response, is predictive for the development of adverse effects after radiotherapy. Conclusions: It is anticipated that the Gene-PARE project will yield information that will allow radiation oncologists to use genetic data to optimize treatment on an individual basis. (c) 2006 Elsevier Inc. C1 Mt Sinai Sch Med, Dept Radiat Oncol, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Dermatol, New York, NY 10029 USA. NYU, Sch Med, Dept Radiat Oncol, New York, NY USA. Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA. Rambam Med Ctr, Dept Oncol, Haifa, Israel. CRLC Val Aurelle, Dept Radiat Oncol, Montpellier, France. CHUV, Dept Radiat Oncol, Lausanne, Switzerland. Aarhus Univ Hosp, Dept Expt Clin Oncol, DK-8000 Aarhus, Denmark. Bronx Vet Adm Med Ctr, Dept Urol, Bronx, NY USA. Bronx Vet Adm Med Ctr, Dept Radiat Oncol, Bronx, NY USA. RP Rosenstein, BS (reprint author), Mt Sinai Sch Med, Dept Radiat Oncol, Box 1236,1 Gustave Levy Pl, New York, NY 10029 USA. EM bariy.rosenstein@mssm.edu RI Rosenstein, Barry/A-7420-2009 NR 128 TC 78 Z9 81 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JUL 1 PY 2006 VL 65 IS 3 BP 646 EP 655 DI 10.1016/j.ijrobp.2006.03.006 PG 10 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 052ON UT WOS:000238243100003 PM 16751059 ER PT J AU Baird, JD Arroyo, LG Vengust, M McGurrin, MKJ Rodriguez-Palacios, A Kenney, DG Aravagiri, M Maylin, GA AF Baird, JD Arroyo, LG Vengust, M McGurrin, MKJ Rodriguez-Palacios, A Kenney, DG Aravagiri, M Maylin, GA TI Adverse extrapyramidal effects in four horse given fluphenazine decanoate SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Article ID NEUROLEPTIC MALIGNANT SYNDROME; ANTIPSYCHOTIC-DRUGS; PLASMA; MANAGEMENT; PRIAPISM AB Case Description-4 racehorses were examined because of markedly abnormal behavior following administration of fluphenazine decanoate. Clinical Findings-Clinical signs included restlessness, agitation, profuse sweating, hypermetria, aimless circling, intense pawing and striking with the thoracic limbs, and rhythmic swinging of the head and neck alternating with episodes of severe stupor. Fluphenazine was detected in serum or plasma from all 4 horses. The dose of fluphenazine decanoate administered to 3 of the 4 horses was within the range (25 to 50 mg) routinely administered to adult humans. Treatment and Outcome-In 2 horses, there was no response to IV administration of diphenhydramine hydrochloride, but the abnormal behavior in these 2 horses appeared to resolve following administration of benztropine mesylate, and both horses returned to racing. The other 2 horses responded to diphenhydramine administration. One returned to racing. The other was euthanized because of severe neurologic signs, respiratory failure, and acute renal failure. Clinical Relevance-Findings indicate that adverse extrapyramical effects may occur in horses given fluphenazine decanoate. These effects appear to be unpredictable and may be severe and life threatening. Use of fluphenazine decanoate as an anxiolytic in performance horses is not permitted in many racing and horse show jurisdictions, and analytic procedures are now available to detect the presence of fluphenazine in serum or plasma. C1 Univ Guelph, Ontario Vet Coll, Dept Clin Studies, Guelph, ON N1G 2W1, Canada. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 91311 USA. Cornell Univ, Coll Vet Med, Dept Populat Med & Diagnost Sci, Equine Drug Testing & Res Program, Ithaca, NY 14850 USA. RP Baird, JD (reprint author), Univ Guelph, Ontario Vet Coll, Dept Clin Studies, Guelph, ON N1G 2W1, Canada. RI Rodriguez-Palacios, Alex/C-2191-2011 OI Rodriguez-Palacios, Alexander/0000-0003-0713-5605 NR 37 TC 12 Z9 12 U1 0 U2 3 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD JUL 1 PY 2006 VL 229 IS 1 BP 104 EP 110 DI 10.2460/javma.229.1.104 PG 7 WC Veterinary Sciences SC Veterinary Sciences GA 058TN UT WOS:000238687600036 PM 16817724 ER PT J AU Pumbwe, L Ueda, O Yoshimura, F Chang, A Smith, RL Wexler, HM AF Pumbwe, Lilian Ueda, Ohmi Yoshimura, Fuminobu Chang, Abraham Smith, Rachel L. Wexler, Hannah M. TI Bacteroides fragilis BmeABC efflux systems additively confer intrinsic antimicrobial resistance SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE membrane proteins; co-expression; susceptibility ID MULTIPLE ANTIBIOTIC-RESISTANCE; PSEUDOMONAS-AERUGINOSA PAO1; EXTENSIVE DNA INVERSIONS; MEXC-MEXD-OPRJ; ANAEROBIC-BACTERIA; ESCHERICHIA-COLI; DRUG-RESISTANCE; MULTIDRUG-RESISTANCE; CAMPYLOBACTER-JEJUNI; SPIRAL GRADIENT AB Objectives: To determine the prevalence of expression and function(s) of Bacteroides fragilis RND family efflux transport systems (bmeABC1-16). Methods: The mRNA transcripts of bmeB efflux pump genes were detected in a wild-type strain ADB77 by RT-PCR and expression in different strains was quantified by comparative quantitative real-time RT-PCR. In order to determine independent or additive functions, BmeB 1, 3, 12 and 15 (the first efflux pumps identified) were deleted as singles, doubles, triples or quadruples by the double cross-over technique with pAD13242 and antimicrobial susceptibility was assayed by the spiral gradient endpoint technique. Results: All efflux pumps except bmeB9 were expressed in the wild-type parental strain. Susceptibility to beta-lactams, fluoroquinolones, ethidium bromide, SDS and triclosan was increased in ADB77 Delta bmeB3 (up to 3-fold) and ADB77 Delta bmeB1 Iota bmeB3 Delta bmeB12 (up to 5-fold). Expression of bmeB9 was increased and that of bmeB11 repressed in the latter deletant. A quadruple deletant (ADB77 Delta bmeB1 Delta bmeB3 Delta b-bmeB12 Delta bmeB15) had similar changes as well as a 2-fold increase in expression of bmeB16 and norfloxacin resistance. Expression of bmeB3 was increased in two triple deletants ADB77 Delta bmeB1 Delta bbmeB12 Delta bmeB15-type I (2-fold) and ADB77 Delta bmeB1 Delta bmeB12 Delta bmeB15-type II (5.8-fold). Antimicrobial MICs were also increased in the latter deletant; ampicillin (2.6-fold), cefoperazone (3.4-fold), cefoxitin (1.8-fold), tetracycline (36.4-fold), SDS (1.7-fold) and triclosan (2-fold). Conclusions: These data demonstrate that constitutive bmeB expression is prevalent in B. fragilis. At least seven BmeB efflux pumps are functional in transporting antimicrobials and have overlapping substrate profiles, and at least four confer intrinsic resistance. C1 Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Matsumoto Dent Univ, Dept Oral Microbiol, Shiojiri, Japan. Aichi Gakuin Univ, Sch Dent, Dept Microbiol, Nagoya, Aichi 464, Japan. RP Wexler, HM (reprint author), Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA. EM hwexler@ucla.edu NR 40 TC 28 Z9 30 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD JUL PY 2006 VL 58 IS 1 BP 37 EP 46 DI 10.1093/jac/dkl202 PG 10 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 071UF UT WOS:000239628700007 PM 16757501 ER PT J AU Bliziotes, M Sibonga, JD Turner, RT Orwoll, E AF Bliziotes, M Sibonga, JD Turner, RT Orwoll, E TI Periosteal remodeling at the femoral neck in nonhuman primates SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article; Proceedings Paper CT 24th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 20-24, 2002 CL SAN ANTONIO, TX SP Amer Soc Bone & Mineral Res DE primate; osteoblasts; modeling and remodeling; bone histomorphometry; bone mineralization; periosteum ID INTRACAPSULAR HIP FRACTURE; BONE HISTOMORPHOMETRY; CORTICAL BONE; PROXIMAL FEMUR; OSTEOPOROSIS; SIZE; WOMEN; FRAGILITY; POROSITY; DENSITY AB Introduction: Bone size is an important determinant of bone strength, and cellular events at the periosteal surface could alter bone dimensions. We characterized periosteal cellular activity with dynamic histomorphometric studies of nonhuman primate femoral neck and shaft. Materials and Methods: Femur specimens from 16 intact adult male and female nonhuman primates (Rhesus [Macaca mulatta, n = 9] and Japanese Macaque [Macaca fuscata, n = 7]) were analyzed. Animals were double-labeled with tetracycline, and necropsy was performed 2-7 days after the last dose. We characterized periosteal resorptive activity in an additional group of five intact and four castrate female animals. Multiple group comparisons in intact animals were performed by one-way ANOVA followed by a Fisher PLSD posthoc test. In gonadectomized animals, Fisher's exact test was used for dichotomous and Mann-Whitney U-test for continuous variables. Results: Bone turnover in the periosteum of the femoral neck in intact animals was more rapid than at the femoral shaft but slower than in femoral neck cancellous bone. Similarly, in these intact animals, the eroded surface of cortical bone at the femoral neck periosteal surface was significantly greater than in the cancellous bone compartment (p < 0.0001) or on the femoral shaft (p < 0.0001). Gonadectomized female animals showed an increase in osteoclast number on the periosteal surface compared with intact controls (p < 0.01). Conclusions: We documented intramembranous periosteal bone turnover in the femoral neck by histomorphometric analyses. The tissue level bone formation rate was sufficient to add substantively to femoral neck size over time. Periosteal osteoclastic activity was not the result of the emergence of intracortical tunneling at the bone surface. Sex steroid deficiency produced an increase in osteoclast numbers at the periosteal surface. This is the first systematic documentation of periosteal turnover at the femoral neck. C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR 97201 USA. Univ Space Res Assoc, Johnson Space Ctr, Div Space Life Sci, Houston, TX USA. Mayo Clin, Rochester, MN USA. Oregon State Univ, Dept Nutr & Exercise Sci, Corvallis, OR 97331 USA. RP Bliziotes, M (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA. EM bliziote@ohsu.edu OI Orwoll, Eric/0000-0002-8520-7355 FU NIAMS NIH HHS [AR48833] NR 32 TC 20 Z9 20 U1 0 U2 1 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD JUL PY 2006 VL 21 IS 7 BP 1060 EP 1067 DI 10.1359/JBMR.060414 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 057MW UT WOS:000238600900014 PM 16813526 ER PT J AU Vallarta-Ast, N Krueger, D Binkley, N AF Vallarta-Ast, Nellie Krueger, Diane Binkley, Neil TI Addition of right lateral decubitus positioning improves vertebral visualization with VFA in selected patients SO JOURNAL OF CLINICAL DENSITOMETRY LA English DT Article DE VFA; DXA; vertebral fracture ID X-RAY ABSORPTIOMETRY; FRACTURE ASSESSMENT; DENSITOMETRY; DEFORMITY AB Densitometric vertebral fracture assessment (VFA) allows detection of clinically unappreciated vertebral fracture. However, vertebral visualization using VFA can be suboptimal. In such individuals, alternative spine positioning may enhance visualization. Consistent with this, we observed that reversal of positioning (right lateral decubitus rather than standard left lateral decubitus, subsequently referred to as "reverse" positioning) improved visualization in patients with suboptimal vertebral visualization. This report describes 33 such individuals (i.e., 30 men and 3 women); their mean age and their lowest T-score (L1-L4 spine, proximal femur or 0.3 radius) was 69.9 yr and 2.2. respectively. All images were acquired using a GE Healthcare Lunar Prodigy densitometer (GE Healthcare, Madison, WI). Reverse VIA increased the number of visualized vertebrae in 82% of these patients (27 of 33; p < 0.0001). Specifically, only 62% of vertebrae from T4-L5 were visualized using the standard left lateral position. Addition of either full or partial reverse VFA increased (p < 0.0001) the number of visualized vertebrae to 83% (384 of 462). In this cohort, reverse positioning allowed detection of 4 additional vertebral fractures, including two in patients without previously identified fractures. We conclude that in selected patients with suboptimal vertebral visualization on VFA, addition of reverse positioning improves visualization and may enhance vertebral fracture detection. C1 Univ Wisconsin, Osteoporosis Res Program, Madison, WI 53705 USA. Univ Wisconsin, Osteoporosis Clin Ctr, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Vallarta-Ast, N (reprint author), Univ Wisconsin, Osteoporosis Res Program, 2870 Univ Ave,Suite 100, Madison, WI 53705 USA. EM vallarta-ast@med.va.gov NR 13 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1094-6950 J9 J CLIN DENSITOM JI J. Clin. Densitom. PD JUL-SEP PY 2006 VL 9 IS 3 BP 375 EP 379 DI 10.1016/j.jocd.2006.05.009 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 081MH UT WOS:000240321200019 PM 16931359 ER PT J AU Halvas, EK Aldrovandi, GM Balfe, P Beck, IA Boltz, VF Coffin, JM Frenkel, LM Hazelwood, JD Johnson, VA Kearney, M Kovacs, A Kuritzkes, DR Metzner, KJ Nissley, DV Nowicki, M Palmer, S Ziermann, R Zhao, RY Jennings, CL Bremer, J Brambilla, D Mellors, JW AF Halvas, Elias K. Aldrovandi, Grace M. Balfe, Peter Beck, Ingrid A. Boltz, Valerie F. Coffin, John M. Frenkel, Lisa M. Hazelwood, J. Darren Johnson, Victoria A. Kearney, Mary Kovacs, Andrea Kuritzkes, Daniel R. Metzner, Karin J. Nissley, Dwight V. Nowicki, Marek Palmer, Sarah Ziermann, Rainer Zhao, Richard Y. Jennings, Cheryl L. Bremer, James Brambilla, Don Mellors, John W. TI Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID REVERSE-TRANSCRIPTASE; IN-VIVO; MUTATIONS; THERAPY; POPULATIONS; INTERRUPTION; INHIBITORS; GENOTYPE; MULTIPLE; PROTEASE AB We determined the abilities of 10 technologies to detect and quantify a common drug-resistant mutant of human immunodeficiency virus type 1 (lysine to asparagine at codon 103 of the reverse transcriptase) using a blinded test panel containing mutant-wild-type mixtures ranging from 0.01% to 100% mutant. Two technologies, allele-specific reverse transcriptase PCR and a Ty1HRT yeast system, could quantify the mutant down to 0.1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy. C1 Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA 15261 USA. Childrens Hosp Los Angeles, Keck Sch Med, Los Angeles, CA 90027 USA. Columbia Univ, New York, NY USA. Univ Washington, Seattle, WA 98195 USA. NCI, HIV Drug Resistance Program, Frederick, MD 21701 USA. Birmingham VA Med Ctr, Birmingham, AL USA. Univ Alabama, Birmingham, AL USA. Univ So Calif, Los Angeles, CA USA. Brigham & Womens Hosp, Sect Retroviral Therapeut, Boston, MA 02115 USA. Harvard Univ, Sch Med, Div AIDS, Boston, MA USA. Univ Erlangen Nurnberg, Erlangen, Germany. NCI, Basic Res Program, SAIC Frederick, Frederick, MD 21701 USA. Bayer Healthcare Diagnost, Berkeley, CA USA. Univ Maryland, Sch Med, Baltimore, MD 21201 USA. Rush Med Coll, Chicago, IL 60612 USA. New England Res Inst, Watertown, MA 02172 USA. RP Mellors, JW (reprint author), Univ Pittsburgh, Dept Med, Div Infect Dis, S818 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM Mellors@msx.dept-med.pitt.edu RI Metzner, Karin/G-5319-2011 OI Metzner, Karin/0000-0003-4862-1503 FU NCI NIH HHS [N01-CO-12400, N01CO12400]; NIAID NIH HHS [N01AI85354, AI-60354, N01-AI-85354, P30 AI027767, P30 AI060354, P30AI27767, U01 AI038858, U01AI38858, UM1 AI106716]; NICHD NIH HHS [HD 40777, R01 HD040777] NR 20 TC 85 Z9 89 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JUL PY 2006 VL 44 IS 7 BP 2612 EP 2614 DI 10.1128/JCM.00449-06 PG 3 WC Microbiology SC Microbiology GA 065JY UT WOS:000239157400053 PM 16825395 ER PT J AU Coulter, ID Hardy, ML Morton, SC Hilton, LG Tu, WL Valentine, D Shekelle, PG AF Coulter, Ian D. Hardy, Mary L. Morton, Sally C. Hilton, Lara G. Tu, Wenli Valentine, Di Shekelle, Paul G. TI Antioxidants vitamin C and vitamin E for the prevention and treatment of cancer SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE vitamin C; vitamin E; systematic review; cancer; antioxidant ID NUTRITION INTERVENTION TRIALS; SUPPLEMENTAL ALPHA-TOCOPHEROL; RANDOMIZED CONTROLLED-TRIAL; DISEASE-SPECIFIC MORTALITY; BETA-CAROTENE; MINERAL SUPPLEMENTATION; COLORECTAL ADENOMAS; CLINICAL-TRIALS; ASCORBIC-ACID; MALE SMOKERS AB OBJECTIVE: To evaluate the evidence of the supplements vitamin C and vitamin E for treatment and prevention of cancer. METHODS: Systematic review of trials and meta-analysis. DATA SOURCES AND MAIN RESULTS: Thirty-eight studies showed scant evidence that vitamin C or vitamin E beneficially affects survival. In the ATBC Cancer Prevention Study Group, no statistically significant effect of treatment was seen for any cancer individually, and our pooled relative risk (regardless of tumor type) for a-tocopherol alone was 0.91 (95% confidence interval [CI]: 0.74, 1.12). All cause mortality was not significant. In the Linxian General Population Trial, the relative risks for cancer death for vitamin C (combined with molybdenum) was 1.06 (95% CI: 0.92, 1.21) and for vitamin E (combined with beta-carotene and selenium) was 0.87 (95% CI: 0.76, 1.00). We identified only 3 studies that reported statistically significant beneficial results: vitamin C (in combination with BCG) was found to be beneficial in a single trial of bladder cancer and vitamin E (in combination with omega-3 fatty acid) increased survival in patients with advanced cancer. In the ATBC trial, in analyses of 6 individual cancers, the prevention of prostate cancer in subjects treated with alpha-tocopherol was statistically significant (RR = 0.64, 95% CI: 0.44, 0.94). CONCLUSIONS: The systematic review of the literature does not support the hypothesis that the use of supplements of vitamin C or vitamin E in the doses tested helps prevent and/or treat cancer in the populations tested. There were isolated findings of benefit, which require confirmation. C1 RAND Corp, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. Univ So Calif, Los Angeles, CA 90089 USA. Cedars Sinai Integrat Med Med Grp Inc, Los Angeles, CA USA. RAND Corp, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Samuell Inst Informat Biol, Alexandria, VA USA. RP Coulter, ID (reprint author), 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM coulter@rand.org FU PHS HHS [290-97-0001] NR 46 TC 62 Z9 66 U1 0 U2 15 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2006 VL 21 IS 7 BP 735 EP 744 DI 10.1111/j.1525-1497.2006.0483.x PG 10 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 053NX UT WOS:000238313000012 PM 16808775 ER PT J AU Labarere, J Stone, RA Obrosky, DS Yealy, DM Meehan, TP Auble, TE Fine, JM Graff, LG Fine, MJ AF Labarere, J Stone, RA Obrosky, DS Yealy, DM Meehan, TP Auble, TE Fine, JM Graff, LG Fine, MJ TI Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE pneumonia; community-acquired infections; patient admission; risk factors; emergency service; hospital ID PREDICTION RULE; OUTCOMES; GUIDELINES; MANAGEMENT; COST; CARE AB BACKGROUND: Many low-risk patients with pneumonia are hospitalized despite recommendations to treat such patients in the outpatient setting. OBJECTIVE: To identify the factors associated with the hospitalization of low-risk patients with pneumonia. METHODS: We analyzed data collected by retrospective chart review for 1,889 low-risk patients (Pneumonia Severity Index [PSI] risk classes I to III without evidence of arterial oxygen desaturation) enrolled in a cluster-randomized trial conducted in 32 emergency departments. RESULTS: Overall, 845 (44.7%) of all low-risk patients were treated as inpatients. Factors independently associated with an increased odds of hospitalization included PSI risk classes II and III, the presence of medical or psychosocial contraindications to outpatient treatment, comorbid conditions that were not contained in the PSI (cognitive impairment, history of coronary artery disease, diabetes mellitus, or pulmonary disease), multilobar radiographic infiltrates, and home therapy with oxygen, corticosteroids, or antibiotics before presentation. While 32.8% of low-risk inpatients had a contraindication to outpatient treatment and 47.1% had one or more preexisting treatments, comorbid conditions, or radiographic abnormalities not contained in the PSI, 20.1% had no identifiable risk factors for hospitalization other than PSI risk class II or III. CONCLUSIONS: Hospital admission appears justified for one-third of low-risk inpatients based upon the presence of one or more contraindications to outpatient treatment. At least one-fifth of low-risk inpatients did not have a contraindication to outpatient treatment or an identifiable risk factor for hospitalization, suggesting that treatment of a larger proportion of such low-risk patients in the outpatient setting could be achieved without adversely affecting patient outcomes. C1 VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. UJF, Grenoble Univ Hosp, UMR CNRS 5525, ThEMAS TIMC IMAG, Grenoble, France. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15260 USA. Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA. Qualidigm, Middletown, CT USA. Norwalk Hosp, Pulm & Crit Care Med Sect, Norwalk, CT 06856 USA. Univ Connecticut, Sch Med, Dept Emergency Med, Farmington, CT USA. New Britain Gen Hosp, Dept Emergency Med, New Britain, CT USA. Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. RP Fine, MJ (reprint author), VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Univ Dr C,Bldg 28,1A102, Pittsburgh, PA 15240 USA. EM Michael.Fine@med.va.gov RI Labarere, Jose/N-1688-2014 OI Labarere, Jose/0000-0001-7621-6586 FU AHRQ HHS [R01 HS010049, R01 HS10049]; NIAID NIH HHS [5K24 AI01769, K24 AI001769] NR 25 TC 22 Z9 23 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2006 VL 21 IS 7 BP 745 EP 752 DI 10.1111/j.1525-1497.2006.00510.x PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 053NX UT WOS:000238313000013 PM 16808776 ER PT J AU Lewinsohn, DM Grotzke, JE Heinzel, AS Zhu, L Ovendale, PJ Johnson, M Alderson, MR AF Lewinsohn, DM Grotzke, JE Heinzel, AS Zhu, L Ovendale, PJ Johnson, M Alderson, MR TI Secreted proteins from mycobacterium tuberculosis gain access to the cytosolic MHC class-1 antigen-processing pathway SO JOURNAL OF IMMUNOLOGY LA English DT Article ID CD8(+) T-CELLS; CLASS-I PRESENTATION; ENHANCED PROTECTION; CROSS-PRESENTATION; DENDRITIC CELLS; CALMETTE-GUERIN; INFECTED-CELLS; LYMPHOCYTES; MACROPHAGES; PHAGOSOMES AB CD8(+) T cells play an important role in the host response to infection with Mycobacterium tuberculosis (Mtb). Mtb resides in an arrested phagosome that is phenotypically similar to an early endosome. The mechanisms by which Mtb-derived Ags gain access to the HLA-I-processing pathway are incompletely characterized. Studies with CD8(+) T cell lines have suggested that Mtb Ags gain access to the HLA-I pathway in an alternate vacuolar pathway that is both brefeldin A (BFA) and TAP independent. To define the requirements of entry of Ag into the HLA-I pathway, we have used human CD8(+) T cell clones specific for the secreted Mtb Ag CFP10. Human monocyte-derived dendritic cells were pulsed with CFP10 expressed in a recombinant adenovirus, surface adsorbed to microspheres, or in its native form by Mtb. When delivered by adenovirus, processing and presentation of CFP10 were blocked by both BFA and the proteasomal blocker lactacystin. In contrast, processing of CFP10 adsorbed to the surface of microspheres was not affected by either of these Ag-processing inhibitors. BFA, lactacystin, and TAP inhibition blocked the recognition of Mtb-infected dendritic cells, suggesting that processing was via a cytosolic pathway for this secreted protein Ag. We conclude that secreted proteins from Mtb can be processed in a BFA- and proteasome-dependent manner, consistent with egress of Ag into the cytosol and subsequent loading of proteasomally derived peptides. C1 Oregon Hlth Sci Univ, R&D 11, Portland VA Med Ctr, Div Pulm & Crit Care Med, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. Corixa, Seattle, WA 98104 USA. RP Lewinsohn, DM (reprint author), Oregon Hlth Sci Univ, R&D 11, Portland VA Med Ctr, Div Pulm & Crit Care Med, 3710 US Vet Rd, Portland, OR 97239 USA. EM lewinsod@OHSU.edu FU NIAID NIH HHS [R01 AI 48090, 1K08 AI 01644] NR 36 TC 41 Z9 41 U1 0 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JUL 1 PY 2006 VL 177 IS 1 BP 437 EP 442 PG 6 WC Immunology SC Immunology GA 055ST UT WOS:000238471400053 PM 16785540 ER PT J AU Giri, S Khan, M Rattan, R Singh, I Singh, AK AF Giri, S. Khan, M. Rattan, R. Singh, I. Singh, A. K. TI Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death SO JOURNAL OF LIPID RESEARCH LA English DT Article DE twitcher; apopoptosis; sPLA2 inhibitor; LPC ID HUMAN T-LYMPHOCYTES; INDUCED THYMOCYTE APOPTOSIS; NF-KAPPA-B; ARACHIDONIC-ACID; TWITCHER MOUSE; FACTOR RECEPTOR; LATE-ONSET; OXIDATIVE STRESS; POTENTIAL ROLE; GLIAL-CELLS AB Globoid cell leukodystrophy (Krabbe disease) is an inherited neurological disorder caused by the pathogenomic accumulation of psychosine (galactosylsphingosine), a substrate for the deficient enzyme galactocerebroside beta-galactosidase. This study underscores the mechanism of action of psychosine in the regulation of oligodendrocyte cell death via the generation of lysophosphatidylcholine (LPC) and arachidonic acid (AA) by the activation of secretory phospholipase A2 (sPLA2). There was a significant increase in the level of LPC, indicating a phospholipase A2 (PLA2)dependent pathobiology, in the brains of Krabbe disease patients and those of twitcher mice, an animal model of Krabbe disease. In vitro studies of the treatment of primary oligodendrocytes and the oligodendrocyte MO3.13 cell line with psychosine also showed the generation of LPC and the release of AA in a dose- and time-dependent manner, indicating psychosine- induced activation of PLA2. Studies with various pharmacological inhibitors of cytosolic phospholipase A2 and sPLA2 and psychosine-mediated induction of sPLA2 enzymatic activity in media supernatant suggest that psychosine- induced release of AA and generation of LPC is mainly contributed by sPLA2. An inhibitor of sPLA2, 7,7-dimethyl eicosadienoic acid, completely attenuated the psychosine-mediated accumulation of LPC levels, release of AA, and generation of reactive oxygen species, and blocked oligodendroyte cell death, as evident from cell survival, DNA fragmentation, and caspase 3 activity assays. This study documents for the first time that psychosine-induced cell death is mediated via the sPLA2 signaling pathway and that inhibitors of sPLA2 may hold a therapeutic potential for protection against oligodendrocyte cell death and resulting demyelination in Krabbe disease. C1 Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA. Med Univ S Carolina, Charles P Darby Childrens Res Inst, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Charles P Darby Childrens Res Inst, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Singh, AK (reprint author), Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA. EM singhi@musc.edu FU NINDS NIH HHS [NS-34741, NS-40810, NS-22576, NS-37766] NR 80 TC 59 Z9 61 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD JUL PY 2006 VL 47 IS 7 BP 1478 EP 1492 DI 10.1194/jlr.M600084-JLR200 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 064SW UT WOS:000239110400016 PM 16645197 ER PT J AU Ran, QT Gu, MJ Van Remmen, H Strong, R Roberts, JL Richardson, A AF Ran, Qitao Gu, Mingjun Van Remmen, Holly Strong, Randy Roberts, James L. Richardson, Arlan TI Glutathione peroxidase 4 protects cortical neurons from oxidative injury and amyloid toxicity SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE Gpx4; oxidative stress; cortical neurons; beta-amyloid ID MEMBRANE LIPID-PEROXIDATION; BETA-PEPTIDE; A-BETA; NEURODEGENERATIVE DISORDERS; ALDEHYDIC PRODUCT; HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; CYTOCHROME-C; CELL-DEATH; HYDROPEROXIDE AB Polyunsaturated fatty acids (PUFA) in membrane lipids are prone to attack by reactive oxygen species (ROS), and the resulting lipid peroxidation can cause injury and death of cells. Glutathione peroxidase 4 (Gpx4) is an antioxidant defense enzyme that can directly detoxify lipid hydroperoxides generated by ROS. Overexpression of Gpx4 has been shown to be protective against oxidative damage in several cell lines. We examined in this study the stress response of neurons with increased expression of Gpx4, because neurons are especially vulnerable to oxidative injury as a result of their high content of PUFA. Our results show that primary culture cortical neurons derived from Gpx4 transgenic mice, which had increased expression of Gpx4, had increased cell survival and reduced level of apoptosis after exposure to t-butyl hydroperoxide and hydrogen peroxide. We also studied the protective role of Gpx4 against P-amyloid toxicity, because P-amyloid-induced neural toxicity is believed to be mediated through lipid peroxidation. Primary culture cortical neurons from Gpx4 transgenic mice had significantly less cell toxicity than their wildtype counterparts after exposure to A beta(25-35) and A beta(1-40) peptides, and apoptosis induced by A beta(25-35) was attenuated in neurons from Gpx4 transgenic mice. Our data demonstrate that overexpression of Gpx4 protects neurons against oxidative injury and P-amyloid-induced cytotoxicity. (c) 2006 Wiley-Liss, Inc. C1 Univ Texas, Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr San Antonio, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. RP Ran, QT (reprint author), Univ Texas, Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM ran@uthscsa.edu FU NIA NIH HHS [K01 AG22014] NR 45 TC 43 Z9 47 U1 2 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD JUL PY 2006 VL 84 IS 1 BP 202 EP 208 DI 10.1002/jnr.20868 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 061UD UT WOS:000238897400018 PM 16673405 ER PT J AU Yaffe, K Blackwell, T Whitmer, RA Krueger, K Barrett-Connor, E AF Yaffe, K. Blackwell, T. Whitmer, R. A. Krueger, K. Barrett-Connor, E. TI Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women SO JOURNAL OF NUTRITION HEALTH & AGING LA English DT Article DE dementia; diabetes; mild cognitive impairment; glucose ID INSULIN-DEGRADING ENZYME; ALZHEIMERS-DISEASE; ELDERLY POPULATION; GLUCOSE-TOLERANCE; RISK-FACTORS; MEN; PERFORMANCE; DECLINE; HEALTH; ADULTS AB Background: Biological mechanisms linking diabetes and cognition continue to grow, yet the association remains controversial in elders. Whether glycosylated hemoglobin (HbA(1c)) level, a marker of glucose control, is predictive of the development of cognitive impairment or dementia is unknown. We determined the association between HbA(1c) level and risk of developing cognitive impairment in older women, mostly without diabetes. Methods: We studied 1983 postmenopausal women (mean age, 67.2 years) with osteoporosis who had HbA(1c) level measured at baseline. Development of mild cognitive impairment (MCI) or dementia over 4 years was determined as part of a dementia ancillary study. We analyzed risk of MCI or dementia for every 1% of HbA(1c) as well as risk associated with HbA(1c) >= 7%. Results: The mean level of HbA(1c) was 5.8% (range 3.0% to 12.1%) and 86 (4.3%) women developed MCI or dementia. For every 1% increase in HbA(1c), women had a greater age-adjusted likelihood of developing MCI (OR= 1.50; 95% Cl 1.14-1.97) and of developing MCI or dementia (OR=1.40; 95% Cl 1.08 - 1.83). For those with HbA(1c) level >= 7% (n=49), the age-adjusted risk for developing MCI was increased nearly 4-fold (OR= 3.70; 95% Cl 1.51-9.09) and was increased nearly 3-fold for developing MCI or dementia (OR=2.86; 95% Cl 1.17-6.98). When we excluded women with diagnosed diabetes (n=53), the association between HbA(1c) and MCI lessened somewhat but remained elevated (unadjusted OR=1.59; 95% Cl 1.01-2.50; age-adjusted OR=1.42; 95% Cl 0.89-2.28). Multivariate analyses adjusted for age, education, race, depression, alcohol use and treatment with raloxifene yielded similar results. Interpretation: We found an association between HbA(1c) level and risk of developing MCI or dementia in postmenopausal osteoporotic women primarily without diabetes. Our findings support the hypothesis that glucose dysregulation is a predictor for cognitive impairment. C1 Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Calif Pacific Med Ctr, San Francisco, CA 94115 USA. Kaiser Permanente, Div Res, Oakland, CA 94612 USA. Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, Box 181,4150 Clement St, San Francisco, CA 94121 USA. EM Kristine.Yaffe@ucsf.edu NR 26 TC 11 Z9 11 U1 2 U2 5 PU SERDI EDITION PI PARIS PA 320 RUE SAINT-HONORE, PARIS, 75001, FRANCE SN 1279-7707 J9 J NUTR HEALTH AGING JI J. Nutr. Health Aging PD JUL-AUG PY 2006 VL 10 IS 4 BP 292 EP 295 PG 4 WC Geriatrics & Gerontology; Nutrition & Dietetics SC Geriatrics & Gerontology; Nutrition & Dietetics GA 080NX UT WOS:000240255700010 ER PT J AU Garrett, N Roumanas, ED Blackwell, KE Freymiller, E Abemayor, E Wong, WK Gerratt, B Berke, G Beumer, J Kapur, KK AF Garrett, Neal Roumanas, Eleni D. Blackwell, Keith E. Freymiller, Earl Abemayor, Elliot Wong, Weng Kee Gerratt, Bruce Berke, Gerald Beumer, John, III Kapur, Krishan K. TI Efficacy of conventional and implant-supported mandibular resection prostheses: Study overview and treatment outcomes SO JOURNAL OF PROSTHETIC DENTISTRY LA English DT Article; Proceedings Paper CT 6th Meeting of the International-Society-for-Maxillofacial-Rehabilitation CY JUN, 2004 CL Maastricht, NETHERLANDS SP Int Soc Maxillofacial Rehabilitat ID FOREARM FLAP RECONSTRUCTION; COOPERATIVE-DENTAL-IMPLANT; REMOVABLE PARTIAL DENTURES; POORLY FITTING DENTURES; BLADE-VENT IMPLANTS; MASTICATORY FUNCTION; OROMANDIBULAR RECONSTRUCTION; OSSEOINTEGRATED IMPLANTS; DIABETIC-PATIENTS; PRIMARY CLOSURE AB Statement of problem. While surgical restoration of mandibular resections has advanced dramatically with free-flap techniques, oral function and patient perceptions of function, as well as treatment outcomes, often indicate significant impairment. Purpose. This longitudinal prospective study was designed to determine whether conventional prostheses (CP) or implant-supported prostheses (IP) and current surgical reconstructive procedures restore patients' oral functions and quality of life to their status prior to segmental mandibulectomy with immediate fibula free-flap reconstruction. Study, design and implementation, characteristics of the study sample, treatment completion rates, and selected presurgical and postsurgical functional and perceptual outcomes are presented. Material and methods. Forty-six subjects were enrolled. Longitudinal evaluations of medical and dental histories, oromaxillofacial examinations, questionnaires, and sensory and functional tests were planned before and after surgery and after CP and IP treatment. Sample characteristics are described with descriptive statistics and comparisons of subject responses to questionnaire items at entry and postsurgical intervals were made with Fisher exact tests (alpha = .05). Results. Conventional prostheses were completed in 33 of 46 subjects, and 16 of 33 CP subjects were treated with IP. Reasons for noncompletion of IP were recurrent/metastatic disease (16), refusal of implant therapy (7), lost to follow-up (4), treatment with a reconstruction plate (1), excessive radiation at implant sites (1), and death (1). AD 16 recurrences/metastases occurred within 13 months of surgery. Only 3 of the 58 implants placed in 17 participants were considered failures. One failed due to lack of integration 31 weeks following placement, and 2 were buried due to unacceptable positioning for prosthetic restoration during denture fabrication. The remaining 55 implants were successful at final evaluation, ranging from 58 to 123 weeks following implant placement (mean duration = 78.9 +/- 16.0 weeks). Conclusions. While 72% (33/46) of the subjects enrolled were able and willing to complete treatment with CP, only 35% (16/46) completed IP treatment. Careful consideration must be given to selection of the type of prosthetic rehabilitation and the timing of implant placement if an IP is planned. C1 Univ Calif Los Angeles, Sch Dent, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Div Adv Prosthodont Biomat & Hosp Dent, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Head & Neck Surg, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Dent Res Lab, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Dent, Sect Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. RP Garrett, N (reprint author), Univ Calif Los Angeles, Sch Dent, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Div Adv Prosthodont Biomat & Hosp Dent, 10833 Le Conte Ave,B3-087 CHS, Los Angeles, CA 90095 USA. EM ngarrett@ucla.edu OI Gerratt, Bruce/0000-0001-7032-1051 FU NCRR NIH HHS [C06 RR 14529-01]; NIDCR NIH HHS [1R01 DE 11255] NR 59 TC 54 Z9 54 U1 0 U2 4 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0022-3913 J9 J PROSTHET DENT JI J. Prosthet. Dent. PD JUL PY 2006 VL 96 IS 1 BP 13 EP 24 DI 10.1016/j.prosdent.2006.05.010 PG 12 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 070CW UT WOS:000239498900003 PM 16872926 ER PT J AU Chen, DC Agopian, VG Avansino, JR Lee, JK Farley, SM Stelzner, M AF Chen, David C. Agopian, Vatche G. Avansino, Jeffrey R. Lee, Jane K. Farley, Steven M. Stelzner, Matthias TI Optical tissue window: A novel model for optimizing engraftment of intestinal stem cell organoids SO JOURNAL OF SURGICAL RESEARCH LA English DT Article; Proceedings Paper CT 39th Annual Meeting of the Association-for-Academic-Surgery CY FEB 07-11, 2005 CL San Diego, CA SP Assoc Acad Surg DE intestinal stem cell; transplantation; dorsal skin fold chamber; polyglycolic acid ID ENGINEERED SMALL-INTESTINE; SHORT-BOWEL SYNDROME; CHAMBER; MANAGEMENT; ANGIOGENESIS AB Background. Intestinal malabsorption disorders and short bowel syndrome lead to significant morbidity. We recently demonstrated that grafting of intestinal organoids can grow a bioengineered intestinal neomucosa and cure bile acid malabsorption in rats. Now we have developed a novel system that permits direct observation of intestinal organoids in vivo to optimize conditions for engraftment. Methods. Optical Windows were created in C57BL/6J mice by externalizing an omental pedicle into a dorsal skin flap chamber. Following creation of windows, 5000 intestinal organoids from green-fluorescent protein transgene (GFP)(+) donor mice were seeded directly either on omentum or on polyglycolic acid (PGA) disks that had been placed on omentum at 1 or 5 days. Engraftment of green fluorescent cells was evaluated on postseeding days 1, 3, 5, 7, 10, 12, and 21 using fluorescence microscopy. Results. An initial group had seeding onto omentum (n = 5) or biopolymer disks (n = 5) on postoperative day 1. After 7 days, there was mucosal cell engraftment onto omental tissue and biopolymers. GFP(+) organoids engrafted significantly better when seeded onto biopolymers compared to omentum (P < 0.05). In a second study with increased sample size (n = 24) up to day 12, all four groups demonstrated adherence and growth. However, GFP(+) organoids seeded onto delayed PGA biopolymer demonstrated significantly better engraftment (P < 0.05). Conclusions. This novel system allows continuous in vivo observation of engrafted cells that are seeded on externalized omentum. The use of PGA mesh biopolymer may improve engraftment of intestinal organoids. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, Dept Surg, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90024 USA. Univ Washington, VA Puget Sound Hlth Care Syst, Dept Surg, Seattle, WA 98195 USA. RP Chen, DC (reprint author), Univ Calif Los Angeles, Dept Surg, VA Greater Los Angeles Hlth Care Syst, 10833 Le Conte Ave, Los Angeles, CA 90024 USA. EM dcchen@mednet.ucla.edu NR 24 TC 7 Z9 7 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD JUL PY 2006 VL 134 IS 1 BP 52 EP 60 DI 10.1016/j.jss.2006.03.029 PG 9 WC Surgery SC Surgery GA 062FE UT WOS:000238929200007 PM 16697415 ER PT J AU Vaughan, N Storzbach, D Furukawa, I AF Vaughan, Nancy Storzbach, Daniel Furukawa, Izumi TI Sequencing versus nonsequencing working memory in understanding of rapid speech by older listeners SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article DE aging; cognition; memory; speech recognition ID ORDERED POINTING TASK; ADULT AGE-DIFFERENCES; HEARING-AID FITTINGS; PROCESSING RESOURCES; COGNITIVE-ABILITIES; IMPAIRED CHILDREN; SERIAL ORDER; LANGUAGE; RECOGNITION; ATTENTION AB The goal of this study was to identify specific neurocognitive deficits that are associated with older listeners' difficulty understanding rapid speech. Older listeners performed speech recognition tests comprised of time-compressed sentences with and without context, and on a neurocognitive battery aimed specifically at testing working memory, processing speed, and attention. A principle component analysis identified three main cognitive components as follows: a sequencing working memory (WM-S) component, a nonsequencing working memory (WM-NS) component, and a processing speed (PS) component. Each of the cognitive component scores was divided into high, mid, and low categories. Sentence performance of the cognitive subgroups was compared within each component. The results showed that, with hearing loss and age accounted for, the cognitive score groups differed similarly on the sentence condition scores also at 50 and 60% time compression, particularly on the subgroups of the WM-S component. The results suggest that deficits in a separate working memory function identified as sequencing were associated with differences in ability to understand time-compressed speech in this study. C1 Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. RP Vaughan, N (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. EM nancy.vaughan@med.va.gov NR 54 TC 19 Z9 19 U1 1 U2 5 PU AMER ACADEMY OF AUDIOLOGY PI RESTON PA 11730 PLAZA DRIVE, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD JUL-AUG PY 2006 VL 17 IS 7 BP 506 EP 518 DI 10.3766/jaaa.17.7.6 PG 13 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 091JO UT WOS:000241023600006 PM 16927515 ER PT J AU Francis, S Kozak, KZ Heilig, L Lundahl, K Bowland, T Hester, E Best, A Dellavalle, RP AF Francis, S Kozak, KZ Heilig, L Lundahl, K Bowland, T Hester, E Best, A Dellavalle, RP TI Dermatology Internet Yellow Page advertising SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article; Proceedings Paper CT 63rd Annual Meeting of the American-Academy-of-Dermatology CY FEB 18-22, 2005 CL New Orleans, LA SP Amer Acad Dermatol ID PHYSICIANS AB Background: Patients may use Internet Yellow Pages to help select a physician. Objective. We sought to describe dermatology Internet Yellow Page advertising. Methods: Dermatology advertisements in Colorado, California, New York, and Texas at 3 Yellow Page World Wide Web sites were systematically examined. Results. Most advertisements (76%; 223/292) listed only one provider, 56 listed more than one provider, and 13 listed no practitioner names. Five advertisements listed provider names without any credentialing letters, 265 listed at least one doctor of medicine or osteopathy, and 9 listed only providers with other credentials (6 doctors of podiatric medicine and 3 registered nurses). Most advertisements (61%; 179/292) listed a doctor of medicine or osteopathy claiming board certification, 78% (139/179) in dermatology and 22% (40/179) in other medical specialties. Four (1%; 4/292) claims of board certification could not be verified (one each in dermatology, family practice, dermatologic/cosmetologic surgery, and laser surgery). Board certification could be verified for most doctors of medicine and osteopathy not advertising claims of board certification (68%; 41/60; 32 dermatology, 9 other specialties). A total of 50 advertisements (17%) contained unverifiable or no board certification information, and 47 (16%) listed a physician with verifiable board certification in a field other than dermatology. Limitations: All Internet Yellow Page World Wide Web sites and all US states were not examined. Conclusion: Nonphysicians, physicians board certified in medical specialties other than dermatology, and individuals without verifiable board certification in any medical specialty are advertising in dermatology Internet Yellow Pages. Many board-certified dermatologists are not advertising this certification. C1 Denver Vet Affairs Med Ctr, Dept Dermatol, Denver, CO 80220 USA. Univ Colorado, Dept Dermatol, Denver, CO 80202 USA. Hlth Sci Ctr, Aurora, CO USA. St Elizabeth Hosp, Utica, NY USA. Univ Denver, Sturm Coll Law, Denver, CO 80208 USA. RP Dellavalle, RP (reprint author), Denver Vet Affairs Med Ctr, Dept Dermatol, 1055 Clermont St,Mail Stop 165, Denver, CO 80220 USA. EM robert.dellavalle@uchsc.edu RI Dellavalle, Robert/L-2020-2013 OI Dellavalle, Robert/0000-0001-8132-088X FU NCI NIH HHS [K-07CA92550]; NIAMS NIH HHS [T32 AR07411] NR 12 TC 1 Z9 1 U1 1 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD JUL PY 2006 VL 55 IS 1 BP 67 EP 70 DI 10.1016/j.jaad.2006.03.021 PG 4 WC Dermatology SC Dermatology GA 058BV UT WOS:000238640200008 PM 16781294 ER PT J AU Hickman, D King-Herbert, A Murphy, SJ AF Hickman, Debra King-Herbert, Angela Murphy, Stephanie J. TI The Laboratory Animal Boards Study Group: A multifaceted tool for preparation for the American College of Laboratory Animal Medicine board examination SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE LA English DT Article AB Preparation for the specialty board examination for the American College of Laboratory Animal Medicine (ACLAM) is an intensive process that is facilitated by geographic regions where many people studying for the exam are located in close proximity. However, many people work at institutions that are distant from these 'study centers.' Approximately 10 y ago, the Laboratory Animal Boards Study Group (LABSG) online journal club was established to provide a forum for journal review for examination preparation. Over the years, the mission of this group has expanded to include practice examinations and practicals, questions from common resources, and summaries and questions from common laboratory animal science journals. These study aids are beneficial for those preparing for the ACLAM certification examination. They are also beneficial for those preparing for the technician and manager certification examinations offered by the American Association for Laboratory Animal Science (AALAS). This article is intended to be an introduction to the variety of study aids available through the LABSG online journal review club and the LABSG web page (www.labsg.org). It also provides details on the demographics of participants and an exploration of how this resource enhances examination preparation. C1 Portland VA Med Ctr, Portland, OR USA. Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA. Oregon Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. RP Hickman, D (reprint author), Portland VA Med Ctr, Portland, OR USA. EM Debra.Hickman@med.va.gov RI Hickman, Debra/D-3289-2009 NR 6 TC 2 Z9 2 U1 0 U2 0 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1060-0558 J9 J AM ASSOC LAB ANIM JI J. Amer. Assoc. Lab. Anim. Sci. PD JUL PY 2006 VL 45 IS 4 BP 33 EP 39 PG 7 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 068DL UT WOS:000239352300007 PM 16884177 ER PT J AU Saint, S Kaufman, SR Rogers, MAM Baker, PD Ossenkop, K Lipsky, BA AF Saint, Sanjay Kaufman, Samuel R. Rogers, Mary A. M. Baker, Paul D. Ossenkop, Kathleen Lipsky, Benjamin A. TI Condom versus indwelling urinary catheters: A randomized trial SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE urinary catheter; urinary tract infection; bacteriuria; cognitive impairment ID NURSING-HOME PATIENTS; LONG-TERM-CARE; TRACT-INFECTIONS; SPECIMEN COLLECTION; PATIENT SAFETY; BACTERIURIA; MEN; PREVALENCE; INCONTINENCE; HOSPITALS AB OBJECTIVES: To compare condom and indwelling urinary catheters in terms of infection risk and patient satisfaction. DESIGN: A prospective, randomized, unblinded, controlled trial. SETTING: An academically affiliated Veterans Affairs Medical Center. PARTICIPANTS: Hospitalized men aged 40 and older who required a urinary collection device. MEASUREMENTS: The incidence of adverse outcomes (bacteriuria, symptomatic urinary tract infection (UTI), or death) and patient device-related satisfaction as determined according to a questionnaire. Dementia status was recorded to assess effect modification by the presence of dementia. RESULTS: Seventy-five subjects were randomized: 41 receiving an indwelling catheter and 34 a condom catheter. The incidence of an adverse outcome was 131/1,000 patient-days with an indwelling catheter and 70/1,000 patient-days with a condom catheter (P = .07). The median time to an adverse event was 7 days in the indwelling group and 11 days in the condom group. After adjusting for other risk factors, it was found that condom catheter use reduced adverse outcomes (P = .04). Patients without dementia who had an indwelling catheter were approximately five times as likely to develop bacteriuria or symptomatic UTI or to die (hazard ratio = 4.84, 95% confidence interval = 1.46-16.02) as those with a condom catheter (P = .01). Patients reported that condom catheters were more comfortable (P = .02) and less painful (P = .02) than indwelling catheters. CONCLUSION: The use of condom catheters is less likely to lead to bacteriuria, symptomatic UTI, or death than the use of indwelling catheters. This protection is especially apparent in men without dementia. C1 Ann Arbor Dept Vet Affairs Hlth Serv, Res & Dev Ctr Excellence, Ctr Practice Management & Outcomes Res, Ann Arbor, MI USA. Univ Michigan, Div Gen Med, Dept Internal Med, Ann Arbor, MI USA. Univ Michigan, Dept Vet Affairs, Patient Safety Enhancement Program, Ann Arbor, MI USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Saint, S (reprint author), Room 7E08,300 NIB,Campus Box 0429, Ann Arbor, MI 48109 USA. EM saint@umich.edu RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 31 TC 65 Z9 66 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUL PY 2006 VL 54 IS 7 BP 1055 EP 1061 DI 10.1111/j.1532-5415.2006.00785.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 062XB UT WOS:000238978900004 PM 16866675 ER PT J AU Shannon, GR Wilber, KH Allen, D AF Shannon, George R. Wilber, Kathleen H. Allen, Douglas TI Reductions in costly healthcare service utilization: Findings from the Care Advocate Program SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE managed care; care management; home- and community-based services ID LONG-TERM-CARE; MANAGED CARE; OLDER-PEOPLE; INTERVENTION; EXPENDITURES; MORTALITY; OUTCOMES; SYSTEMS; ELDERS AB OBJECTIVES: To determine whether a telephone care-management intervention for high-risk Medicare health maintenance organization (HMO) health plan enrollees can reduce costly medical service utilization. DESIGN: Randomized, controlled trial measuring health-care services utilization over three 12-month periods (pre-, during, and postintervention). SETTING: Two social service organizations partnered with a Medicare HMO and four contracted medical groups in southern California. PARTICIPANTS: Eight hundred twenty-three patients aged 65 and older; eligibility was determined using an algorithm to target older adults with high use of insured healthcare services. INTERVENTION: After assessment, members in the intervention group were offered mutually agreed upon referrals to home- and community-based services (HCBS), medical groups, or Medicare HMO health plan and followed monthly for 1 year. MEASUREMENTS: Insured medical service utilization was measured across three 12-month periods. Acceptance and utilization of Care Advocate (CA) referrals were measured during the 12-month intervention period. RESULTS: CA intervention members were significantly more likely than controls to use primary care physician services (odds ratio (OR) 2.05, P < .001), and number of hospital admissions (OR 0.43, P < .01) and hospital days (OR = 0.39, P < .05) were significantly more stable for CA group members than for controls. CONCLUSION: Results suggest that a modest intervention linking older adults to HCBS may have important cost-saving implications for HMOs serving community-dwelling older adults with high healthcare service utilization. Future studies, using a national sample, should verify the role of telephone care management in reducing the use of costly medical services. C1 VA Greater Los Angeles Ctr Excellence, Sepulveda, CA 91343 USA. Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA. Greater Newport Physicians IPA, Newport Beach, CA USA. RP Shannon, GR (reprint author), VA Greater Los Angeles Ctr Excellence, 16111 Plummer St 152,Bldg 25, Sepulveda, CA 91343 USA. EM gshannon@usc.edu NR 28 TC 16 Z9 16 U1 2 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUL PY 2006 VL 54 IS 7 BP 1102 EP 1107 DI 10.1111/j.1532-5415.20066.00799.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 062XB UT WOS:000238978900011 PM 16866682 ER PT J AU Keith, RL Geraci, MW AF Keith, Robert L. Geraci, Mark W. TI Prostacyclin in lung cancer SO JOURNAL OF THORACIC ONCOLOGY LA English DT Editorial Material ID SMOOTH-MUSCLE CELLS; PROLIFERATOR-ACTIVATED RECEPTORS; PROSTAGLANDIN ENDOPEROXIDES; SYNTHASE; STIMULATION; EXPRESSION; GENE; MITOGEN; GROWTH C1 Denver VA Med Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. RP Keith, RL (reprint author), Denver VA Med Ctr, Dept Med, Div Pulm Sci & Crit Care Med, 1055 Clermont St,Box 111A, Denver, CO 80220 USA. NR 23 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD JUL PY 2006 VL 1 IS 6 BP 503 EP 505 DI 10.1097/01243894-200607000-00001 PG 3 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 065WT UT WOS:000239191500001 PM 17409908 ER PT J AU Blutt, SE Fenaux, M Warfield, KL Greenberg, HB Conner, ME AF Blutt, SE Fenaux, M Warfield, KL Greenberg, HB Conner, ME TI Active viremia in rotavirus-infected mice SO JOURNAL OF VIROLOGY LA English DT Article ID EXTRAINTESTINAL SPREAD; HISTOLOGIC DISTRIBUTION; HETEROLOGOUS ROTAVIRUS; RHESUS ROTAVIRUS; NEONATAL MOUSE; CHILDREN; MODEL; GASTROENTERITIS; ANTIGENEMIA; PROTECTION AB Rotavirus circulates extraintestinally in animals used as models for rotavirus infection and in children. Rotavirus infection in mice was used to define host or viral factors that affect rotavirus viremia. Antigenemia was observed with homologous and heterologous rotaviruses, and neither age nor mouse strain genetics altered the occurrence of rotavirus antigenemia or viremia. Rotavirus RNA and infectious virus were present in sera and associated with the plasma fraction of blood in all infected mice. These findings indicate that antigenemia/viremia occurs routinely in rotavirus infections and imply that infectious rotavirus has access to any extraintestinal cell within contact of blood. C1 Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. Stanford Univ, Sch Med, Dept Gastroenterol, Palo Alto, CA 94304 USA. Michael E Debakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Conner, ME (reprint author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA. EM mconner@bcm.tmc.edu FU NIAID NIH HHS [AI 24998, R56 AI021362, R01 AI021362, F32 AI010604, R37 AI021362, AI 21362, R21 AI024998, AI 10604, R01 AI024998]; NIDDK NIH HHS [P30 DK056338, DK 56338] NR 31 TC 31 Z9 34 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JUL PY 2006 VL 80 IS 13 BP 6702 EP 6705 DI 10.1128/JVI.00329-06 PG 4 WC Virology SC Virology GA 054MJ UT WOS:000238380700053 PM 16775359 ER PT J AU Chang, VW AF Chang, V. W. TI Residential racial isolation and body mass index among U.S. adults SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 VAMC, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD JUL PY 2006 VL 15 IS 6 BP 677 EP 678 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 079LG UT WOS:000240177200020 ER PT J AU Fried, LF Shlipak, MG Stehman-Breen, C Mittalhenkle, A Seliger, S Samak, M Robbins, J Siscovick, D Harris, TB Newman, AB Cauley, JA AF Fried, Linda F. Shlipak, Michael G. Stehman-Breen, Catherine Mittalhenkle, Anuja Seliger, Stephen Samak, Mark Robbins, John Siscovick, David Harris, Tamara B. Newman, Anne B. Cauley, Jane A. TI Kidney function predicts the rate of bone loss in older individuals: The cardiovascular health study SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article; Proceedings Paper CT 37th Annual Meeting of the American-Society-of-Nephrology CY OCT 27-NOV 01, 2004 CL St Louis, MO SP Amer Soc Nephrol ID SERUM CYSTATIN-C; GLOMERULAR-FILTRATION-RATE; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; RENAL-INSUFFICIENCY; HIP FRACTURE; ELDERLY-MEN; OSTEOPOROSIS; RISK; ALENDRONATE AB Background. Results of cross-sectional analyses of the association of kidney function with bone mineral density (BMD) have been conflicting. We examined the association of cystatin-C, a new marker of kidney function that is unrelated to lean mass, with initial and follow-up BMD, in an ancillary study of the Cardiovascular Health Study, a population-based cohort of individuals >= 65 years old. Methods. Two years after measurement of cystatin-C and other covariates, the first BMD was measured in Pittsburgh, Pennsylvania and Davis, California, by using dual energy x-ray absorptiometry. Follow-up BMD was measured in Pittsburgh 4 years later. Associations of cystatin-C with initial BMD and the change in BMD (%/y) at the hip were examined with linear regression. Analyses were conducted separately for men and women. Results. In 1519 participants who had cystatin-C and initial BMD assessed, 614 had follow-up BMD. The percent annual change in BMD at the total hip by cystatin-C quartiles was -0.24, -0.13, -0.40, and -0.66%/y (first to fourth quartile) in women and -0.02, -0.30, -0.18, and -0.94%/y in men. After adjusting for potential confounders, cystatin-C was marginally associated with initial BMD in men but not women. Cystatin-C was associated with bone loss in men; after adjustment for weight loss, cystatin-C was not associated with bone loss in women. Conclusion. Kidney dysfunction, as assessed by cystatin-C, is associated with a more rapid loss of BMD at the hip, especially in men. Further studies are needed to confirm these findings and to determine whether this loss leads to an elevated risk of fracture. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA. VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Amgen Inc, Thousand Oaks, CA USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA. Univ Maryland, Dept Med, College Pk, MD 20742 USA. Tufts Univ, New England Med Ctr, Dept Med, Boston, MA 02111 USA. Univ Calif Davis, Dept Med, Davis, CA 95616 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. NIA, NIH, Bethesda, MD 20892 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. RP Fried, LF (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Mailstop 111F-U, Pittsburgh, PA 15240 USA. EM linda.fried@med.va.gov RI Newman, Anne/C-6408-2013; Cauley, Jane/N-4836-2015 OI Newman, Anne/0000-0002-0106-1150; Cauley, Jane/0000-0003-0752-4408 FU NHLBI NIH HHS [N01-HC-35129, N01 HC-15103, N01-HC-85079, N01-HC-85086] NR 31 TC 27 Z9 27 U1 0 U2 1 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JUL PY 2006 VL 61 IS 7 BP 743 EP 748 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 071ZO UT WOS:000239642600017 PM 16870638 ER PT J AU Baumgarten, M Margolis, DJ Localio, AR Kagan, SH Lowe, RA Kinosian, B Holmes, JH Abbuhl, SB Kavesh, W Ruffin, A AF Baumgarten, Mona Margolis, David J. Localio, A. Russell Kagan, Sarah H. Lowe, Robert A. Kinosian, Bruce Holmes, John H. Abbuhl, Stephanie B. Kavesh, William Ruffin, Althea TI Pressure ulcers among elderly patients early in the hospital stay SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID NURSING-HOME RESIDENTS; RISK-FACTORS; PREDICTIVE-VALIDITY; NATIONAL-HEALTH; SORE PREVENTION; BRADEN SCALE; INCONTINENCE AB Background. Pressure ulcers among elderly hospital patients diminish quality of life and increase the cost of hospital care. Evidence suggests that pressure ulcers can arise after only a few hours of immobility. The goals of this study were to estimate the incidence of hospital-acquired pressure ulcers in the first 2 days of the hospital stay and to identify patient characteristics associated with higher incidence. Methods. A prospective cohort study was performed between 1998 and 2001. A total of 3233 patients 65 years old or older admitted through the Emergency Department to the inpatient Medical Service at two study hospitals were examined by a research nurse on the third day of hospitalization. Pressure ulcers were ascertained using standard criteria and were classified as either preexisting, possibly hospital-acquired, or definitely hospital-acquired. Results. There were 201 patients with one or more possibly or definitely hospital-acquired pressure ulcers for a cumulative incidence of 6.2% (95% confidence interval, 5.4%-7.1%). Most of the pressure ulcers were stage 2, and the majority were in the sacral area or on the heels. In multivariable analysis, pressure ulcer incidence was significantly associated with increasing age, male gender, dry skin, urinary and fecal incontinence, difficulty turning in bed, nursing home residence prior to admission, recent hospitalization, and poor nutritional status. Conclusions. A small but significant proportion of elderly emergently admitted hospital patients acquire pressure ulcers soon after their admission. New models of care may be required to ensure that preventive interventions are provided very early in the elderly person's hospital stay. C1 Univ Maryland, Sch Med, Baltimore, MD 21201 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Baumgarten, M (reprint author), Univ Maryland, Sch Med, 660 W Redwood St,Suite 200, Baltimore, MD 21201 USA. EM mbaumgar@epi.umaryland.edu FU NIA NIH HHS [R01-AG-14127] NR 52 TC 63 Z9 65 U1 1 U2 7 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JUL PY 2006 VL 61 IS 7 BP 749 EP 754 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 071ZO UT WOS:000239642600018 PM 16870639 ER PT J AU Almeida, JS Oates, JC Arthur, JM AF Almeida, J. S. Oates, J. C. Arthur, J. M. TI Response to urinary protein markers in lupus nephritis: The need for concurrent calibration and discrimination statistics in predictive models SO KIDNEY INTERNATIONAL LA English DT Letter C1 Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA. Ralph H Johnson VA Med Ctr, Dept Med, Charleston, SC USA. Med Univ S Carolina, Charleston, SC 29425 USA. RP Almeida, JS (reprint author), Univ Texas, MD Anderson Canc Ctr, Unit 447, 1515 Holcombe Blvd, Houston, TX 77030 USA. EM jalmeida@mdanderson.org NR 7 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JUL PY 2006 VL 70 IS 1 BP 231 EP 232 DI 10.1038/sj.ki.5001519 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 062UD UT WOS:000238969300042 ER PT J AU Kellum, J Palevsky, PM AF Kellum, John Palevsky, Paul M. TI Renal support in acute kidney injury SO LANCET LA English DT Editorial Material ID CONTINUOUS VENOVENOUS HEMOFILTRATION; CRITICALLY-ILL PATIENTS; REPLACEMENT THERAPY; FAILURE; INTERMITTENT; DIALYSIS; TRIAL; HEMODIALYSIS; GUIDELINES C1 Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Kellum, J (reprint author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA. EM kellumja@ccm.upmc.edu NR 14 TC 13 Z9 13 U1 0 U2 0 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0140-6736 J9 LANCET JI Lancet PD JUL-AUG PY 2006 VL 368 IS 9533 BP 344 EP 345 DI 10.1016/S0140-6736(06)69084-3 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 069JJ UT WOS:000239441900006 PM 16876645 ER PT J AU Steinman, MA Ranji, SR Shojania, KG Gonzales, R AF Steinman, Michael A. Ranji, Sumant R. Shojania, Kaveh G. Gonzales, Ralph TI Improving antibiotic selection - A systematic review and quantitative analysis of quality improvement strategies SO MEDICAL CARE LA English DT Article DE quality improvement; antibiotic use; meta analysis ID RANDOMIZED CONTROLLED-TRIAL; RESPIRATORY-TRACT INFECTIONS; GENERAL-PRACTICE; PRIMARY-CARE; EDUCATIONAL INTERVENTION; PRESCRIBER FEEDBACK; DRUG-TREATMENT; OTITIS-MEDIA; HEALTH-CARE; PRESCRIPTION AB Objective: We sought to assess which interventions are most effective at improving the prescribing of recommended antibiotics for acute outpatient infections. Design and Methods: We undertook a systematic review with quantitative analysis of the Cochrane Registry Effective Practice and Organization of Care (EPOC) database, supplemented by MEDLINE and hand-searches. Inclusion criteria included clinical trials with contemporaneous or strict historical controls that reported data on antibiotic selection in acute outpatient infections. The effect size of studies with different intervention types were compared using nonparametric statistics. To maximize comparability between studies, quantitative analysis was restricted to studies that reported absolute changes in the amount of or percent compliance with recommended antibiotic prescribing. Results: Twenty-six studies reporting 33 trials met inclusion criteria. Most interventions used clinician education alone or in combination with audit and feedback. Among the 22 comparisons amenable to quantitative analysis, recommended antibiotic prescribing improved by a median of 10.6% (interquartile range [IQR] 3.4-18.2%). Trials evaluating clinician education alone reported larger effects than interventions combining clinician education with audit and feedback (median effect size 13.9% [IQR 8.6-21.6%] vs. 3.4% [IQR 1.8-9.7%], P = 0.03). This result was confounded by trial sample size, as trials having a smaller number of participating clinicians reported larger effects and were more likely to use clinician education alone. Active forms of education, sustained interventions, and other features traditionally associated with successful quality improvement interventions were not associated with effect size and showed no evidence of confounding the association between clinician education-only strategies and outcome. Conclusions: Multidimensional interventions using audit and feedback to improve antibiotic selection were less effective than interventions using clinician education alone. Although confounding may partially account for this finding, our results suggest that enhancing the intensity of a focused intervention may be preferable to a less intense, multidimensional approach. C1 Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. Univ Ottawa, Ottawa, ON K1N 6N5, Canada. Ottawa Hlth Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada. RP Steinman, MA (reprint author), Univ Calif San Francisco, Dept Med, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu NR 50 TC 37 Z9 39 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JUL PY 2006 VL 44 IS 7 BP 617 EP 628 DI 10.1097/01.mlr.0000215846.25591.22 PG 12 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 060MM UT WOS:000238806300003 PM 16799356 ER PT J AU Egede, LE AF Egede, Leonard E. TI Disease-focused or integrated treatment: Diabetes and depression SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article ID INTERNATIONAL PRIMARY-CARE; PLACEBO-CONTROLLED TRIAL; MAJOR DEPRESSION; MEDICATION ADHERENCE; COMORBID DEPRESSION; GLYCEMIC CONTROL; ANTIDEPRESSANT TREATMENT; RANDOMIZED-TRIAL; CHRONIC ILLNESS; OLDER PATIENTS AB Diabetes and depression are chronic debilitating conditions that are associated with significant morbidity, mortality, and health care costs. Most patients who have diabetes are treated in primary care settings; however, multiple studies have shown that recognition and treatment of depression is less than optimal in this setting. This article reviews the literature on the adverse health outcomes of the coexistence of diabetes and depression, the challenges of treating coexisting diabetes and depression in a fragmented health care system, and the need for integrated care as a strategy to improve the quality of care for patients with complex medical illnesses (eg, patients who have coexisting diabetes and depression). C1 Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Charleston VA Targeted Res Enhancement Program, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU AHRQ HHS [5K08HS11418] NR 88 TC 10 Z9 10 U1 3 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD JUL PY 2006 VL 90 IS 4 BP 627 EP + DI 10.1016/j.mcna.2006.04.001 PG 21 WC Medicine, General & Internal SC General & Internal Medicine GA 071QB UT WOS:000239615600008 PM 16843766 ER PT J AU Wecht, JM Marsico, R Weir, JP Spungen, AM Bauman, WA De Meersman, RE AF Wecht, Jill M. Marsico, Robert Weir, Joseph P. Spungen, Ann M. Bauman, William A. De Meersman, Ronald E. TI Autonomic recovery from peak arm exercise in fit and unfit individuals with paraplegia SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article DE vagal cardiac control; spinal cord injury; endurance training; postexercise sympathetic response ID HEART-RATE-VARIABILITY; CARDIOVASCULAR CONTROL; CARDIAC-OUTPUT; DIFFUSING-CAPACITY; SPECTRUM ANALYSIS; MORTALITY; SEDENTARY; ACETYLENE; STANDARDS; FITNESS AB Introduction: Altered autonomic cardiovascular control in persons with paraplegia may reflect peripheral sympathetic denervation caused by the injury or deconditioning due to skeletal muscle paralysis. Parameters of autonomic cardiovascular control may be improved in fit persons with paraplegia similar to effects reported in the noninjured population. Purpose: To determine differences in resting and recovery HR and cardiac autonomic control in fit and unfit individuals with paraplegia. Methods: Eighteen healthy males with paraplegia below T-6 were studied; nine participated in aerobic exercise conditioning (fit: >= 30 min-d(-1), 3 d-wk(-1), >= 6 months), and nine were sedentary (unfit). Analysis of heart rate variability (HRV) was used to determine spectral power (In transformed) in the high-(lnHF) and low-frequency (lnLF) bandwidths, and the LF/HF ratio was calculated. Data were collected at baseline (BL) and at 2, 10, 30, 60, and 90 min of recovery from peak arm cycle ergometry. Results: The relative intensity achieved on the peak exercise test was comparable between the groups (i.e., 88% peak predicted HR). However, peak watts (P < 0.001) and oxygen consumption (P < 0.01) were higher in the fit compared with the unfit group (56 and 51%, respectively). Recovery lnHF was increased (P < 0,05), and recovery lnLF (P < 0.01) and LF/HF (P < 0.05) were reduced in the fit compared with the unfit group. Mean recovery autonomic activity was not different from BL in the fit group. In the unfit group, mean recovery lnHF was reduced, and mean recovery lnLF and LF/HF remained elevated above BL. Conclusion: These data suggest that fit individuals with paraplegia have improved cardiac autonomic control during the postexercise recovery period compared with their unfit counterparts. C1 James J Peters Med Ctr, Spinal Cord Damage Res Ctr, Bronx, NY 10468 USA. VA RR&D Serv Ctr Excellence, Bronx, NY 10468 USA. CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. Des Moines Univ, Osteopath Med Ctr, Des Moines, IA USA. Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. Columbia Univ Teachers Coll, New York, NY 10032 USA. RP Wecht, JM (reprint author), James J Peters Med Ctr, Spinal Cord Damage Res Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM jm.wecht@med.va.gov NR 29 TC 9 Z9 9 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD JUL PY 2006 VL 38 IS 7 BP 1223 EP 1228 DI 10.1249/01.mss.0000227306.34149.ba PG 6 WC Sport Sciences SC Sport Sciences GA 062UU UT WOS:000238971100005 PM 16826018 ER PT J AU Zeber, JE Copeland, LA Grazier, KL AF Zeber, John E. Copeland, Laurel A. Grazier, Kyle L. TI Serious mental illness, aging, and utilization patterns among Veterans SO MILITARY MEDICINE LA English DT Article; Proceedings Paper CT Annual Research Meeting of the Department-of-Veterans-Affairs CY FEB 12-14, 2003 CL Washington, DC SP Dept Veterans Affairs ID HEALTH-CARE UTILIZATION; QUALITY-OF-LIFE; OLDER-ADULTS; EMERGENCY-DEPARTMENT; SOCIOECONOMIC-STATUS; MEDICAL-SERVICES; MAINTENANCE ORGANIZATION; MAJOR DEPRESSION; BIPOLAR DISORDER; TREATMENT COSTS AB As veterans age, chronic physical and psychiatric conditions increasingly challenge the Veterans Health Administration. We examine influences of age and diagnosis on health care utilization, within the context of the 1995 deinstitutionalization policy of the Veterans Health Administration. Veterans were hospitalized repeatedly over 5 years with diagnoses of schizophrenia, bipolar disorder, depression, or alcohol dependence (N = 7,719). Inpatient days decreased 14% from baseline while outpatient (OP) visits increased 63%, consistent with deinstitutionalization. In adjusted models, OP utilization greatly increased with age, but psychiatric visits-notably alcohol treatment-dropped sharply. Emergency visits rose after 1997, particularly for ethnic minorities. Individuals ages 35-49 and 50-64 years were the greatest consumers of OP care; these large, aging cohorts will continue to require additional services, taxing a burdened system. Utilization patterns evolve across the life course, requiring foresight to address changing demographic demands. Careful attention to mental health utilization patterns may help policy makers and providers understand psychiatric needs in older patients. C1 S Texas Vet Hlth Care Syst HSR&D, Dept Vet Affairs, Vet Evidence Based Res Disseminat Implementat Res, San Antonio, TX 78229 USA. Univ Michigan, Sch Publ Hlth, Dept Hlth Policy & Management, Ann Arbor, MI 48109 USA. RP Zeber, JE (reprint author), S Texas Vet Hlth Care Syst HSR&D, Dept Vet Affairs, Vet Evidence Based Res Disseminat Implementat Res, San Antonio, TX 78229 USA. OI Copeland, Laurel/0000-0002-9478-0209 NR 74 TC 6 Z9 6 U1 3 U2 5 PU ASSN MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD JUL PY 2006 VL 171 IS 7 BP 619 EP 626 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 061IG UT WOS:000238864300011 PM 16895128 ER PT J AU Fogel, B Wu, M Kremen, S Murthy, K Jackson, G Vanek, Z AF Fogel, Brent Wu, Mark Kremen, Sarah Murthy, Kolar Jackson, George Vanek, Zeba TI Creutzfeldt-Jakob disease presenting with alien limb sign SO MOVEMENT DISORDERS LA English DT Article DE Creutzfeldt-Jakob; magnetic resonance imaging; alien limb; video; corticobasal degeneration ID MIMICKING CORTICOBASAL DEGENERATION; HAND SYNDROME AB Creutzfeldt-Jakob disease is a fatal spongiform encephalopathy, which typically presents with a rapidly progressing dementia and additional neurological findings that can be quite variable and diverse. Here we report the unusual case of a patient who presented with left alien limb sign without overt cognitive impairment and was ultimately diagnosed with pathologically confirmed Creutzfeldt-Jakob disease. (C) 2006 Movement Disorder Society. C1 Univ Calif Los Angeles, Dept Neurol, Med Ctr, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Ctr, Dept Neurol, Los Angeles, CA USA. RP Fogel, B (reprint author), Univ Calif Los Angeles, Dept Neurol, Med Ctr, 710 Westwood Plaza, Los Angeles, CA 90095 USA. EM bfogel@ucla.edu NR 13 TC 7 Z9 7 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD JUL PY 2006 VL 21 IS 7 BP 1040 EP 1042 DI 10.1002/mds.20858 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 067EW UT WOS:000239285600027 PM 16552737 ER PT J AU de Vasconcelos, AP Riban, V Wasterlain, C Nehlig, A AF de Vasconcelos, AP Riban, V Wasterlain, C Nehlig, A TI Role of endothelial nitric oxide synthase in cerebral blood flow changes during kainate seizures: A genetic approach using knockout mice SO NEUROBIOLOGY OF DISEASE LA English DT Article DE endothelial nitric oxide synthase; knockout mice; kainate seizures; intrahippocampal injection; cerebral blood flow ID TEMPORAL-LOBE EPILEPSY; HIPPOCAMPAL SCLEROSIS; LIMBIC SEIZURES; L-ARGININE; RAT; STIMULATION; HYPEREMIA; AUTOREGULATION; INHIBITION; LACKING AB The role of endothelial nitric oxide (NO) in the cerebrovascular response to partial seizures was investigated in mice deleted for the endothelial NO synthase gene (eNOS-/-) and in their paired wild-type (WT) congeners. Local cerebral blood flow (LCBF, quantitative [C-14] iodoantipyrine method) was measured 3-6 h after unilateral kainate (KA) injection in the dorsal hippocampus; controls received saline. In WT mice, KA seizures induced a 22 to 50% LCBF increase restricted to the ipsilateral hippocampus, while significant LCBF decreases (15-33%) were noticed in 22% of the contralateral areas, i.e., the parietal cortex, amygdala and three basal ganglia areas, compared to satine-injected WT mice. In eNOS-/- mice, no LCBF increases were recorded within the epileptic focus and generalized contralateral LCBF decreases (22-46%) were noticed in 2/3 of the brain areas, compared to saline-injected eNOS-/- mice. Thus, endothelial NO is the mediator of the cerebrovascular response within the epileptic focus and participates in the maintenance of LCBF in distant areas. (c) 2006 Elsevier Inc. All rights reserved. C1 INSERM, Fac Med, U 398, F-67085 Strasbourg, France. Univ Calif Los Angeles, Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Brain Res Inst, Los Angeles, CA 90095 USA. RP de Vasconcelos, AP (reprint author), INSERM, Fac Med, U 398, 11 Rue Humann, F-67085 Strasbourg, France. EM Pereira@neurochem.u-strasbg.fr NR 61 TC 7 Z9 7 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD JUL PY 2006 VL 23 IS 1 BP 219 EP 227 DI 10.1016/j.nbd.2006.03.002 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 057YY UT WOS:000238632300021 ER PT J AU Yenari, MA Han, HS AF Yenari, MA Han, HS TI Influence of hypothermia on post-ischemic inflammation: Role of nuclear factor kappa B (NF kappa B) SO NEUROCHEMISTRY INTERNATIONAL LA English DT Article; Proceedings Paper CT 36th Annual Meeting of the American-Society-for-Neurochemistry CY JUN 25-29, 2005 CL Madison, WI SP Amer Soc Neurochem DE hypothermia; NF kappa B target genes; TNF-alpha ID FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; GLOBAL BRAIN ISCHEMIA; MILD HYPOTHERMIA; ARTERY OCCLUSION; EXPERIMENTAL STROKE; MICROGLIAL ACTIVATION; MODERATE HYPOTHERMIA; RAT-BRAIN AB Mild hypothermia is one of the most robust neuroprotectant studied in the laboratory to date. The reasons for this protective effect are likely multifactorial, but work from our laboratory and others have shown that this protection is associated with remarkable suppression of the inflammatory response that accompanies brain ischemia. Consistently, laboratories have shown that small decreases in brain temperature to 30-34 degrees C result in reduced inflammatory cell infiltrate, less microglial activation, and reduction of a variety of inflammatory mediators such as nitric oxide, inflammatory cytokines and superoxide. Nuclear factor-kappa B (NF kappa B) is a transcription factor that is activated after cerebral ischemia. NF kappa B activation leads to the expression of many inflammatory genes involved in the pathogenesis of stroke. Our laboratory has shown that hypothermia decreases NF kappa B translocation and binding activity, by affecting NF kappa B regulatory proteins. Mild hypothermia appears to suppress phosphorylation of NF kappa B's inhibitory protein (I kappa B-alpha) by decreasing expression and activity of I kappa B kinase-gamma (IKK). As a consequence, hypothermia suppressed gene expression of two NF kappa B target genes, inducible nitric oxide synthase and TNF-alpha. These data suggest that the protective effect of hypothermia on cerebral injury is, in part, related to NF kappa B inhibition due to decreased activity of IKK. (c) 2006 Elsevier Ltd. All rights reserved. C1 Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Kyungpook Natl Univ, Sch Med, Dept Physiol, Taegu, South Korea. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu FU NINDS NIH HHS [R01 NS 40516] NR 84 TC 62 Z9 72 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0197-0186 J9 NEUROCHEM INT JI Neurochem. Int. PD JUL PY 2006 VL 49 IS 2 BP 164 EP 169 DI 10.1016/j.neuint.2006.03.016 PG 6 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 059XB UT WOS:000238764400008 PM 16750872 ER PT J AU Nemeroff, CB Mayberg, HS Krahl, SE McNamara, J Frazer, A Henry, TR George, MS Charney, DS Brannan, SK AF Nemeroff, CB Mayberg, HS Krahl, SE McNamara, J Frazer, A Henry, TR George, MS Charney, DS Brannan, SK TI VNS therapy in treatment-resistant depression: Clinical evidence and putative neurobiological mechanisms SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE vagus nerve stimulation; treatment-resistant depression; mechanism of action; vagus nerve; neuroimaging; research ID VAGUS NERVE-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; MEDICALLY INTRACTABLE SEIZURES; RANDOMIZED CONTROLLED-TRIAL; ELECTROCONVULSIVE-THERAPY; BLOOD-FLOW; PARTIAL EPILEPSY; BRAIN-STIMULATION; MAJOR DEPRESSION; LONG-TERM AB Currently available therapeutic interventions for treatment-resistant depression, including switch, combination, and augmentation strategies, are less than ideal. Observations of mood elevation during vagus nerve stimulation (VNS) therapy for pharmacoresistant epilepsy suggested a role for VNS therapy in refractory major depression and prompted clinical investigation of this neurostimulation modality. The VNS Therapy System (TM) has been available for treatment of pharmacoresistant epilepsy since 1997 and was approved by the US Food and Drug Administration for treatment-resistant depression in July, 2005. The physiology of the vagus nerve, mechanics of the VNS Therapy System (TM), and efficacy and safety in pharmacoresistant epilepsy are reviewed. Promising results of VNS therapy for treatment-resistant depression have been forthcoming from both acute and long-term studies, evidenced in part by progressive improvements in depression rating scale scores during the 1st year of treatment with maintenance of response thereafter. VNS therapy is well tolerated in patients with either pharmacoresistant epilepsy or treatment-resistant depression. As in epilepsy, the mechanisms of VNS therapy of treatment-resistant depression are incompletely understood. However, evidence from neuroimaging and other studies suggests that VNS therapy acts via innervation of the nucleus tractus solitarius, with secondary projections to limbic and cortical structures that are involved in mood regulation, including brainstem regions that contain serotonergic (raphe nucleus) and noradrenergic (locus ceruleus) perikarya that project to the forebrain. Mechanisms that mediate the beneficial effects of VNS therapy for treatment-resistant depression remain obscure. Suggestions for future research directions are described. C1 Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. Mt Sinai Sch Med, New York, NY USA. Duke Univ, Med Ctr, Durham, NC USA. Univ Texas, Hlth Sci Ctr San Antonio, San Antonio, TX 78285 USA. Med Univ S Carolina, Charleston, SC 29425 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Cyberonics Inc, Houston, TX USA. RP Nemeroff, CB (reprint author), Emory Univ, Sch Med, Dept Psychiat & Behav Sci, 101 Woodruff Circle,Suite 4000, Atlanta, GA 30322 USA. EM cnemero@emory.edu OI Henry, Thomas/0000-0002-5708-903X NR 78 TC 159 Z9 162 U1 2 U2 13 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JUL PY 2006 VL 31 IS 7 BP 1345 EP 1355 DI 10.1038/sj.npp.1301082 PG 11 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 054ZR UT WOS:000238418700001 PM 16641939 ER PT J AU Houldin, AD Lewis, FM AF Houldin, Arlene D. Lewis, Frances Marcus TI Salvaging their normal lives: A qualitative study of patients with recently diagnosed advanced colorectal cancer SO ONCOLOGY NURSING FORUM LA English DT Article ID OF-LIFE; COLON-CANCER; HEALTH; SURVIVORS; ADJUSTMENT; SURGERY; DISEASE; COUPLES AB Purpose/Objectives: To describe the experiences of patients living with newly diagnosed stage III or IV colorectal cancer. Research Approach: Qualitative; inductive coding methods were used to identity open codes that were analyzed, compared, and grouped into categories. Setting: An urban ambulatory cancer center in the northeastern United States. Participants: 14 patients newly diagnosed with stage III or stage IV colorectal cancer. Methodologic Approach: Semistructured interviews were recorded on audiotape. Interviewers asked participants to describe their experiences with the diagnosis and treatment of colorectal cancer. Content analysis with inductive coding was used to code the transcribed interview data. Categories were reviewed and organized into larger groupings, from which the core category was derived. Main Research Variables: Experiences of living with a diagnosis of colorectal cancer, impact on daily living, quality of life, coping strategies used, level of preparedness, and impact on children. Findings: The coded interview data yielded six domains: feeling life is disrupted, experiencing physicians, feeling unprepared for everything, rethinking parenting, Wondering "why me?," and dealing with it. The core category that explained study participants' experiences with recently diagnosed colorectal cancer was "salvaging their normal lives." Conclusions: The dominant experience of the study participants focused on four aspects of their illness experience: (a) framing it in ways that enabled them to recreate a semblance of normalcy or of their preillness state, (b) trying to tell children about the illness in stabilizing ways, (c) generating or maintaining a positive outlook no matter what, and (d) concretely managing the distress of the illness and its symptoms. Interpretation: Targeted assessment is important in the six dimensions of the study domains. Clinicians who work with patients with cancer should offer support as patients search for meanings to explain this potentially devastating life event. Teaching active coping strategies as patients with advanced cancer struggle to come to terms with the demands of the disease while attempting to live their lives as fully and as normally as possible is important. C1 Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. Univ Penn, Adult Nurse Practitioner Oncol Adv Practice Nursi, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Palliat Care Serv, Philadelphia, PA 19104 USA. Univ Washington, Sch Nursing, Seattle, WA 98195 USA. RP Houldin, AD (reprint author), Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. EM houldin@nursing.upenn.edu NR 39 TC 16 Z9 16 U1 1 U2 4 PU ONCOLOGY NURSING SOCIETY PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD JUL PY 2006 VL 33 IS 4 BP 719 EP 725 DI 10.1188/06.ONF.719-725 PG 7 WC Oncology; Nursing SC Oncology; Nursing GA 061PC UT WOS:000238883600015 PM 16858452 ER PT J AU Gallagher, RM Polomano, R AF Gallagher, Rollin M. Polomano, Rosemary TI Early, continuous, and restorative pain management in injured soldiers: The challenge ahead SO PAIN MEDICINE LA English DT Editorial Material ID NEUROPATHIC PAIN; MECHANISMS; DIAGNOSIS; MORPHINE; FREEDOM; RAT C1 Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 14 TC 6 Z9 6 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD JUL-AUG PY 2006 VL 7 IS 4 BP 284 EP 286 DI 10.1111/j.1526-4637.2006.00188.x PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 065LS UT WOS:000239162000001 PM 16898936 ER PT J AU Risner, ME Saunders, AM Altman, JFB Ormandy, GC Craft, S Foley, IM Zvartau-Hind, ME Hosford, DA Roses, AD AF Risner, M. E. Saunders, A. M. Altman, J. F. B. Ormandy, G. C. Craft, S. Foley, I. M. Zvartau-Hind, M. E. Hosford, D. A. Roses, A. D. CA Rosiglitazone Alzheimer's Dis Stud TI Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease SO PHARMACOGENOMICS JOURNAL LA English DT Article DE rosiglitazone; Alzheimer's disease; apolipoprotein E; clinical trial; pharmacogenetics; ADAS-Cog ID ACTIVATED RECEPTOR-GAMMA; APOLIPOPROTEIN-E; TRANSGENIC MICE; TYPE-4 ALLELE; DEMENTIA; ASSOCIATION; THIAZOLIDINEDIONE; RISK; METABOLISM; EPSILON-4 AB Mild-to-moderate AD patients were randomized to placebo or rosiglitazone (RSG) 2, 4 or 8 mg. Primary end points at Week 24 were mean change from baseline in AD Assessment Scale-Cognitive (ADAS-Cog) and Clinician's Interview-Based Impression of Change Plus Caregiver Input global scores in the intention-to-treat population (N=511), and results were also stratified by apolipoprotein E (APOE) genotype (n=323). No statistically significant differences on primary end points were detected between placebo and any RSG dose. There was a significant interaction between APOE epsilon(4) allele status and ADAS-Cog (P=0.014). Exploratory analyses demonstrated significant improvement in ADAS-Cog in APOE epsilon(4)-negative patients on 8mg RSG (P=0.024; not corrected for multiplicity). APOE epsilon 4-positive patients did not show improvement and showed a decline at the lowest RSG dose (P=0.012; not corrected for multiplicity). Exploratory analyses suggested that APOE epsilon 4 non-carriers exhibited cognitive and functional improvement in response to RSG, whereas APOE epsilon 4 allele carriers showed no improvement and some decline was noted. These preliminary findings require confirmation in appropriate clinical studies. C1 GlaxoSmithKline Inc, Res & Dev, World Wide Dept, Res Triangle Pk, NC 27709 USA. GlaxoSmithKline Inc, Res & Dev, Genet Res, Res Triangle Pk, NC 27709 USA. GlaxoSmithKline Inc, Res & Dev, World Wide Dev, Harlow, Essex, England. GlaxoSmithKline Inc, Res & Dev, World Wide Dev, Greenford, Middx, England. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, VA Puget Sound,Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Risner, ME (reprint author), GlaxoSmithKline Inc, Res & Dev, World Wide Dept, 5 Moore Dr,MAI-C4497, Res Triangle Pk, NC 27709 USA. EM Marc.E.Risner@gsk.com NR 42 TC 386 Z9 412 U1 6 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1470-269X J9 PHARMACOGENOMICS J JI Pharmacogenomics J. PD JUL-AUG PY 2006 VL 6 IS 4 BP 246 EP 254 DI 10.1038/sj.tpj.6500369 PG 9 WC Genetics & Heredity; Pharmacology & Pharmacy SC Genetics & Heredity; Pharmacology & Pharmacy GA 067NH UT WOS:000239309400004 PM 16446752 ER PT J AU Lambert, MT Copeland, LA Sampson, N Duffy, SA AF Lambert, MT Copeland, LA Sampson, N Duffy, SA TI New-onset type-2 diabetes associated with atypical antipsychotic medications SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY LA English DT Review DE atypical antipsychotic agents; body mass index; type-2 diabetes mellitus ID SCHIZOPHRENIA; RISPERIDONE; OLANZAPINE; MELLITUS; DATABASE; GLUCOSE; RISK AB Purpose: This study compared the one-year incidence of new-onset type-2 diabetes mellitus (DM) and changes in weight in patients with a variety of psychiatric diagnoses prescribed olanzapine, risperidone, or quetiapine, compared to a reference group receiving haloperidol and no other antipsychotic medication. Research design and methods: Data was abstracted from charts of subjects newly initiated and then maintained for one year on olanzapine (n = 112), risperidone (n = 100), quetiapine (n = 100), and haloperidol (it = 100). Baseline and one-year DM status, height, and weight were collected, as well as concurrent psychotropic medications, medical and psychiatric comorbidities. Findings: Using a multivariate model, logistic regression identified a significant association between olanzapine (but not other atypical agents) and the development of diabetes compared to haloperidol over the one-year period (odds ratio 8.4, 95% CI 1.8-38.7). Baseline obesity was independently associated with new-onset DM, but only marginally greater weight gain was found among olanzapine users. Conclusions: The middle-aged American veterans in this study cohort were highly vulnerable to the diabetogenic effects of olanzapine, but a close correlation with weight change was not found. Patients administered olanzapine should receive careful laboratory monitoring for elevated plasma, glucose in addition to weight measurement. Published by Elsevier Inc. C1 Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. VA Ann Arbor Hlth Serv Res & Dev, Ann Arbor, MI USA. Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA. Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Lambert, MT (reprint author), Univ Texas, SW Med Ctr, Ft Worth Outpatient Mental Hlth Clin, Ft Worth VA Mental Hlth Clin,Dept Psychiat, 6000 Western Pl,Suite 300, Ft Worth, TX 76107 USA. EM Michael.Lambert2@med.va.gov OI Copeland, Laurel/0000-0002-9478-0209 NR 22 TC 33 Z9 33 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-5846 J9 PROG NEURO-PSYCHOPH JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry PD JUL PY 2006 VL 30 IS 5 BP 919 EP 923 DI 10.1016/j.pnpbp.2006.02.007 PG 5 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 055NU UT WOS:000238458200017 PM 16581171 ER PT J AU Porter, MP Stanford, JL Lange, PH AF Porter, MP Stanford, JL Lange, PH TI The distribution of serum prostate-specific antigen levels among American men: Implications for prostate cancer prevalence and screening SO PROSTATE LA English DT Article DE prostate-specific antigen; prostate cancer; screening; prevalence ID REFERENCE RANGES; CLINICAL-EVIDENCE; BLOOD-PRESSURE; UNITED-STATES; TRENDS; ADOLESCENTS; POPULATION; INSTITUTE; CHILDREN; ADULTS AB BACKGROUND. The purpose of this study was to describe the distribution of serum prostate-specific antigen (PSA) among American men and to estimate the number of prevalent cases of biopsy detectable prostate cancer among men with normal serum PSA. METHODS. We analyzed data of the National Health and Nutrition Examination Survey 2001-2002 (NHANES 2001-2002) data and combined these results with published data from the Prostate Cancer Prevention Trial (PCPT). RESULTS. Most men in the US have a serum PSA <= 4.0 ng/ml, and mean and median serum PSA values rise steadily with age. There are an estimated 1,607,585 (95% CI 1,370,848 - 1,844,322) prevalent cases of biopsy detectable prostate cancer in men aged 62-85 years with a serum PSA <= 4 ng/ml. Among men aged 62-75 years, there are an estimated 1,252,143 (95% CI 1,054,677-1,449,609) prevalent cases, including an estimated 195,499 (95% CI 140,234-250,764) high-grade tumors. CONCLUSION. A large number of prevalent cases of biopsy detectable prostate cancer exist in American men with a normal PSA. C1 VA Puget Sound Hlth Care Syst, Urol Sect, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. Fred Hutchinson Canc Res Ctr, Program Epidemiol, Div Publ Hlth Sci, Seattle, WA 98104 USA. RP Porter, MP (reprint author), VA Puget Sound Hlth Care Syst, Urol Sect, S-112-GU,1660 S Columbian Way, Seattle, WA 98108 USA. EM mporter@u.washington.edu NR 32 TC 13 Z9 13 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD JUL 1 PY 2006 VL 66 IS 10 BP 1044 EP 1051 DI 10.1002/pros.20417 PG 8 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 053SH UT WOS:000238324900004 PM 16598738 ER PT J AU Bauer, MS McBride, L Williford, WO Glick, H Kinosian, B Altshuler, L Beresford, T Kilbourne, AM Sajatovic, M AF Bauer, MS McBride, L Williford, WO Glick, H Kinosian, B Altshuler, L Beresford, T Kilbourne, AM Sajatovic, M CA Cooperative Studies Program 430 St TI Collaborative care for bipolar disorder: Part I. Intervention and implementation in a randomized effectiveness trial SO PSYCHIATRIC SERVICES LA English DT Article; Proceedings Paper CT 18th Mental Health Services Research Conference CY JUL 18-19, 2005 CL Washington, DC SP NIMH ID ASSERTIVE COMMUNITY TREATMENT; TREATMENT ENHANCEMENT PROGRAM; CLINICAL-PRACTICE GUIDELINES; IMPROVING PRIMARY-CARE; COGNITIVE THERAPY; CHRONIC ILLNESS; HEALTH-CARE; STEP-BD; RELAPSE PREVENTION; SELF-MANAGEMENT AB Outcome for bipolar disorder remains suboptimal despite the availability of efficacious treatments. To improve treatment effectiveness in clinical practice, a Veterans Affairs study team created a care model conceptually similar to the lithium clinics of the 1970s but augmented by principles of more recent collaborative care models for chronic medical illnesses. This intervention consists of improving patients' self-management skills through psychoeducation; supporting providers' decision making through simplified practice guidelines; and enhancing access to care, continuity of care, and information flow through the use of a nurse care coordinator. In this article, which is part I of a two-part report, the authors summarize the conceptual background and development of the intervention, describe the design of a three-year, 11-site randomized effectiveness trial, and report data describing its successful implementation. Trial design emphasized aspects of effectiveness to support generalizability of the findings and eventual dissemination of the intervention. Part II (see companion article, this issue) reports clinical, functional, and overall cost outcomes of the trial. C1 VAMC, Providence, RI 02908 USA. Brown Univ, Dept Psychiat, Providence, RI 02912 USA. VA Cooperat Studies Program, Perry Point, MD USA. Univ Maryland, Dept Biostat, College Pk, MD 20742 USA. Univ Penn, Sect Gen Med, Philadelphia, PA 19104 USA. Philadelphia VAMC, Philadelphia, PA USA. W Los Angeles VAMC, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA. Denver VAMC, Denver, CO USA. Univ Colorado, Dept Psychiat, Sch Med, Denver, CO 80202 USA. Pittsburgh VAMC, Pittsburgh, PA USA. Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA. RP Bauer, MS (reprint author), VAMC, 116R,830 Chalkstone Ave, Providence, RI 02908 USA. EM mark.bauer@med.va.gov RI Sajatovic, Martha/I-8001-2014 NR 86 TC 91 Z9 92 U1 1 U2 15 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUL PY 2006 VL 57 IS 7 BP 927 EP 936 DI 10.1176/appi.ps.57.7.927 PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 059AX UT WOS:000238706800003 PM 16816276 ER PT J AU Bauer, MS McBride, L Williford, WO Glick, H Kinosian, B Altshuler, L Beresford, T Kilbourne, AM Sajatovic, M AF Bauer, MS McBride, L Williford, WO Glick, H Kinosian, B Altshuler, L Beresford, T Kilbourne, AM Sajatovic, M CA Cooperative Studies Program 430 St TI Collaborative care for bipolar disorder: Part II. Impact on clinical outcome, function, and costs SO PSYCHIATRIC SERVICES LA English DT Article; Proceedings Paper CT 18th Mental Health Services Research Conference CY JUL 18-19, 2005 CL Washington, DC SP NIMH ID ASSERTIVE COMMUNITY TREATMENT; RANDOMIZED CONTROLLED-TRIAL; LITHIUM MAINTENANCE TREATMENT; CONTROLLED 18-MONTH TRIAL; LONG-TERM EFFECTIVENESS; COGNITIVE THERAPY; DISEASE-MANAGEMENT; RELAPSE-PREVENTION; QUALITY IMPROVEMENT; DEPRESSED-PATIENTS AB Objective: The study addressed whether a collaborative model for chronic care, described in part I ( this issue), improves outcome for bipolar disorder. Methods: The intervention was designed to improve outcome by enhancing patient self-management skills with group psychoeducation; providing clinician decision support with simplified practice guidelines; and improving access to care, continuity of care, and information flow via nurse care coordinators. In an effectiveness design veterans with bipolar disorder at 11 Veterans Affairs hospitals were randomly assigned to three years of care in the intervention or continued usual care. Blinded clinical and functional measures were obtained every eight weeks. Intention-to-treat analysis (N=306) with mixed-effects models addressed the hypothesis that improvements would accrue over three years, consistent with social learning theory. Results: The intervention significantly reduced weeks in affective episode, primarily mania. Broad-based improvements were demonstrated in social role function, mental quality of life, and treatment satisfaction. Reductions in mean manic and depressive symptoms were not significant. The intervention was cost-neutral while achieving a net reduction of 6.2 weeks in affective episode. Conclusions: Collaborative chronic care models can improve some long-term clinical outcomes for bipolar disorder. Functional and quality-of-life benefits also were demonstrated, with most benefits accruing in years 2 and 3. C1 VAMC, Providence, RI 02908 USA. Brown Univ, Providence, RI 02912 USA. VA Cooperat Studies Program, Perry Point, MD USA. Univ Maryland, College Pk, MD 20742 USA. Univ Penn, Sect Gen Med, Philadelphia, PA 19104 USA. Philadelphia VAMC, Philadelphia, PA USA. W Los Angeles VAMC, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Denver VAMC, Denver, CO USA. Univ Colorado, Sch Med, Boulder, CO 80309 USA. Pittsburgh VAMC, Pittsburgh, PA USA. Case Western Reserve Univ, Cleveland, OH 44106 USA. RP Bauer, MS (reprint author), VAMC, 116R,830 Chalkstone Ave, Providence, RI 02908 USA. EM mark.bauer@med.va.gov RI Sajatovic, Martha/I-8001-2014 NR 71 TC 143 Z9 144 U1 3 U2 20 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUL PY 2006 VL 57 IS 7 BP 937 EP 945 DI 10.1176/appi.ps.57.7.937 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 059AX UT WOS:000238706800004 PM 16816277 ER PT J AU Krahn, DD Bartels, SJ Coakley, E Oslin, DW Chen, HT McIntyre, J Chung, H Maxwell, J Ware, J Levkoff, SE AF Krahn, DD Bartels, SJ Coakley, E Oslin, DW Chen, HT McIntyre, J Chung, H Maxwell, J Ware, J Levkoff, SE TI PRISM-E: Comparison of integrated care and enhanced specialty referral models in depression outcomes SO PSYCHIATRIC SERVICES LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; LATE-LIFE DEPRESSION; COLLABORATIVE CARE; HEALTH-SERVICES; MENTAL-ILLNESS; UNITED-STATES; OLDER-ADULTS; DISABILITY; GUIDELINES; MANAGEMENT AB Objective: This study, entitled Primary Care Research in Substance Abuse and Mental Health for the Elderly, examined six-month outcomes for older primary care patients with depression who received different models of treatment. Methods: Clinical outcomes were compared for patients who were randomly assigned to integrated care or enhanced specialty referral. Integrated care consisted of mental health services co-located in primary care in collaboration with primary care physicians. Enhanced specialty referral consisted of referral to physically separate, clearly identified mental health or substance abuse clinics. Results: A total of 1,531 patients were included; their mean age was 73.9 years. Remission rates and symptom reduction for all depressive disorders were similar for the two models at the three- and six-month follow-ups. For the subgroup with major depression, the enhanced specialty referral model was associated with a greater reduction in depression severity than integrated care, but rates of remission and change in function did not differ across models of care for major depression. Conclusions: Six-month outcomes were comparable for the two models. For the subgroup with major depression, reduction in symptom severity was superior for those randomly assigned to the enhanced specialty referral group. C1 William S Middleton Mem Vet Adm Med Ctr, Dept Psychiat, Madison, WI USA. Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53705 USA. Dartmouth Coll, Dept Psychiat, Lebanon, NH 03756 USA. John Snow Inc, Hlth Serv Div, Boston, MA USA. Univ Penn, Dept Geriatr & Addict Psychiat, Philadelphia, PA 19104 USA. Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. Unity Hlth Syst, Dept Psychiat & Behav Hlth, Rochester, NY USA. Charles B Wang Community Hlth Ctr, Dept Res & Strateg Management, New York, NY USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RP Krahn, DD (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Psychiat, Madison, WI USA. EM krahn@med.va.gov NR 30 TC 56 Z9 57 U1 2 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUL PY 2006 VL 57 IS 7 BP 946 EP 953 DI 10.1176/appi.ps.57.7.946 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 059AX UT WOS:000238706800005 PM 16816278 ER PT J AU Oslin, DW Grantham, S Coakley, E Maxwell, J Miles, K Ware, J Blow, FC Krahn, DD Bartels, SJ Zubritsky, C AF Oslin, DW Grantham, S Coakley, E Maxwell, J Miles, K Ware, J Blow, FC Krahn, DD Bartels, SJ Zubritsky, C CA PRISM-E grp TI PRISM-E: Comparison of integrated care and enhanced specialty referral in managing at-risk alcohol use SO PSYCHIATRIC SERVICES LA English DT Article ID RANDOMIZED-TRIAL; INTERVENTIONS; PATTERNS AB Objective: This study was part of the Primary Care Research in Substance Abuse and Mental Health for the Elderly study (PRISM-E) and determined the relative effectiveness of two different models of care for reducing at-risk alcohol use among primary care patients aged 65 and older. Methods: This multisite study was a randomized clinical trial comparing integrated care with enhanced specialty referral for older primary care patients screened and identified to have at-risk drinking. Results: Before the study, the 560 participants consumed a mean of 17.9 drinks per week and had a mean of 21.1 binge episodes in the prior three months. At six months, both treatment groups reported lower levels of average weekly drinking (p <.001) and binge drinking (p <.001), despite low levels of treatment engagement. However, the declines did not differ significantly between treatment groups. Conclusions: These results suggest that older persons with at-risk drinking can substantially modify their drinking over time. Although no evidence suggested that the model of care was important in achieving this result, the magnitude of reduction in alcohol use was comparable with other intervention studies. C1 Univ Penn, Dept Psychiat, Philadelphia, PA USA. Philadelphia VAMC, Dept Psychiat, Philadelphia, PA USA. JSI Res & Training Inst, Boston, MA USA. New Hampshire Dartmouth Psychiat Res Ctr, Dept Psychiat, Concord, NH USA. Harvard Univ, Sch Publ Hlth, Dept Psychiat, Boston, MA 02115 USA. Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. William S Middleton Mem Vet Adm Med Ctr, Dept Psychiat, Madison, WI USA. Dartmouth Coll, Dept Psychiat, Lebanon, NH 03756 USA. RP Oslin, DW (reprint author), Univ Penn, Dept Psychiat, 3535 Market St,Room 3002, Philadelphia, PA USA. EM oslin@mail.med.upenn.edu FU NIMH NIH HHS [K08 MH001599-05, K08 MH001599] NR 13 TC 32 Z9 32 U1 2 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUL PY 2006 VL 57 IS 7 BP 954 EP 958 DI 10.1176/appi.ps.57.7.954 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 059AX UT WOS:000238706800006 PM 16816279 ER PT J AU Chen, L Chantra, PK Larsen, LH Barton, P Rohitopakarn, M Zhu, EQ Bassett, LW AF Chen, Lina Chantra, Prem K. Larsen, Linda H. Barton, Premsri Rohitopakarn, Montanan Zhu, Elise Q. Bassett, Lawrence W. TI Imaging characteristics of malignant lesions of the male breast SO RADIOGRAPHICS LA English DT Article; Proceedings Paper CT 90th Scientific Assembly and Annual Meeting of the Radiological-Society-of-North-America CY NOV 28-DEC 03, 2004 CL Chicago, IL SP Radiol Soc N Amer ID 1ST MANIFESTATION; CANCER; CARCINOMA; MANAGEMENT; FEATURES; DISEASE; GYNECOMASTIA; MAMMOGRAPHY AB Most men referred for breast imaging have palpable lumps, breast enlargement, or tenderness. Most of the evaluated lesions are benign. Male breast cancer accounts for less than 1% of total male breast lesions. Differentiation between benign and malignant masses is critical because it alleviates patient anxiety and allows unnecessary procedures to be avoided. Clinically suspicious lesions referred for imaging should first be evaluated with mammography. In patients with questionable findings at mammography and for lesions that are difficult to image with mammography, ultrasonography (US) is often useful for further characterization. A discrete mass at mammography or US is suspicious for malignancy. The relationship of the mass to the nipple should be carefully assessed; an eccentric location is highly suspicious for cancer. Secondary signs occur earlier in male patients because of smaller breast size. Such signs include nipple retraction, skin ulceration or thickening, increased breast trabeculation, and axillary adenopathy. US of the axillary region is helpful for staging. At pathologic analysis, cystic lesions commonly demonstrate malignant findings; therefore, all cysts and complex masses should be worked up as potentially malignant lesions. Benign conditions that may mimic male breast cancer include gynecomastia, lipoma, epidermal inclusion cyst, pseudoangiomatous stromal hyperplasia, and intraductal papilloma. (C) RSNA, 2006. C1 Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA 90095 USA. W Los Angeles Vet Adm Healthcare Syst, Dept Radiol, Los Angeles, CA USA. Univ So Calif, Med Ctr, Dept Radiol, Los Angeles, CA USA. Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA. RP Chen, L (reprint author), Univ Calif Los Angeles, Dept Radiol, 200 UCLA Med Plaza,Room 165-47, Los Angeles, CA 90095 USA. EM lchen_mail@yahoo.com NR 23 TC 45 Z9 48 U1 0 U2 1 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD JUL-AUG PY 2006 VL 26 IS 4 BP 993 EP 1006 DI 10.1148/rg.264055116 PG 14 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 067LY UT WOS:000239305400005 PM 16844928 ER PT J AU Subotnik, KL Nuechterlein, KH Green, MF Horan, WP Nienow, TM Ventura, J Nguyen, AT AF Subotnik, Kenneth L. Nuechterlein, Keith H. Green, Michael F. Horan, William P. Nienow, Tasha M. Ventura, Joseph Nguyen, Annie T. TI Neurocognitive and social cognitive correlates of formal thought disorder in schizophrenia patients SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; proverbs; neurocognition; social cognition; formal thought disorder; concrete thinking ID PROVERB INTERPRETATION; COMMUNICATION DISTURBANCES; IDIOSYNCRATIC THINKING; GERIATRIC-PATIENTS; PARTIAL RECOVERY; ATTENTION; SYMPTOMS; LANGUAGE; DEFICIT; VULNERABILITY AB The neurocognitive and social cognitive correlates of two types of formal thought disorder (i.e., bizarre-idiosyncratic and concrete thinking) were examined in 47 stable outpatients with schizophrenia. Both types of thinking disturbance were related to impairments in verbal learning, intrusions in verbal memory, immediate auditory memory, sustained attention, and social schema knowledge. Distractibility during an immediate memory task was associated with more frequent bizarre verbalizations but not concreteness. Impaired verbal learning rate and intrusions in verbal memory independently contributed to the prediction of bizarre responses, whereas intrusions in verbal memory and impaired immediate memory independently contributed to concrete thinking. This pattern of findings is consistent with the view that neurocognitive and, possibly, social cognitive deficits underlie these two aspects of formal thinking disturbance in schizophrenia. (c) 2006 Elsevier B.V All rights reserved. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Subotnik, KL (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Room 2240, Los Angeles, CA 90095 USA. EM ksubotnik@mednet.ucla.edu FU NIMH NIH HHS [MH30911, MH66286, MH37705] NR 52 TC 30 Z9 30 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JUL PY 2006 VL 85 IS 1-3 BP 84 EP 95 DI 10.1016/j.schres.2006.03.007 PG 12 WC Psychiatry SC Psychiatry GA 065AJ UT WOS:000239131500009 PM 16624529 ER PT J AU Byne, W Kidkardnee, S Tatusov, A Yiannoulos, G Buchsbaum, MS Haroutunian, V AF Byne, William Kidkardnee, Smith Tatusov, Alex Yiannoulos, Georgia Buchsbaum, Monte S. Haroutunian, Vahram TI Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; thalamus; anterior nucleus; oligodendrocyte; sex difference ID MULTIPLE BRAIN-REGIONS; CINGULATE CORTEX; EFFERENT CONNECTIONS; MEDIODORSAL NUCLEUS; GENE-EXPRESSION; MEDIAL THALAMUS; POSTMORTEM; VOLUME; ABNORMALITIES; MYELINATION AB The anterior principal thalamic nucleus provides a nodal link for intralimbic circuits involved in the execution of multiple complex functions that are impaired in schizophrenia (SZ). Using stereoloic sampling procedures. we assessed the volume and the number of neurons and oligodendrocytes in this nucleus in well-characterized postmortem material from 23 neuroleptic treated subjects with chronic SZ (SZs) and 12 comparison subjects (Cs) with no psychiatric history. Volume was decreased on average by 17% in SZ, but this difference was not statistically significant. For neuronal number. there was a signifcant sex by diagnosis interaction with neuronal number being lower in male (p = .002) but not female (p = .374) SZs relative to their respective Cs. For the number of oligodendrocytes, there was a main effect of diagnosis and a diagnosis by sex interaction such that number was significantly reduced in male SZs (p < .001) with a similar trend in female SZs (p = .051) relative to their respective controls. The ratio of oligodendrocytes to neurons was signifcantly decreased in SZs (p = .045) with no sex by diagnosis interaction. These findings are consistent with a previous report of reduced neuronal number in the anterior principal nucleus of finale SZs and add to a growing body of evidence implicating oligodendrocyte abnormalities in SZ. (c) 2006 Elsevier B.V. All rights reserved. C1 Bronx Vet Affairs Med Ctr, Div Bas & Lab Res, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. RP Byne, W (reprint author), Bronx Vet Affairs Med Ctr, Div Bas & Lab Res, 130 W Kingsbridge Rd,Rm 2F37,Res Bldg, Bronx, NY 10468 USA. EM william.byne@mssm.edu FU NIMH NIH HHS [MH66998, MH45212] NR 59 TC 49 Z9 49 U1 3 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JUL PY 2006 VL 85 IS 1-3 BP 245 EP 253 DI 10.1016/j.schres.2006.03.029 PG 9 WC Psychiatry SC Psychiatry GA 065AJ UT WOS:000239131500025 PM 16730162 ER PT J AU Bagby, GC AF Bagby, Grover C. TI Constitutional marrow failure: Introduction SO SEMINARS IN HEMATOLOGY LA English DT Editorial Material C1 Oregon Hlth Sci Univ, Inst Canc, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. RP Bagby, GC (reprint author), Oregon Hlth Sci Univ, Inst Canc, Portland, OR 97201 USA. OI Bagby, Grover/0000-0001-6830-2046 NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0037-1963 J9 SEMIN HEMATOL JI Semin. Hematol. PD JUL PY 2006 VL 43 IS 3 BP 145 EP 146 DI 10.1053/j.seminhematol.2006.04.007 PG 2 WC Hematology SC Hematology GA 063BZ UT WOS:000238992300001 PM 16822456 ER PT J AU Cai, GP Sidhu, GS Wieczorek, R Gu, X Herrera, GA Cubukcu-Dimopulo, O Kahn, T AF Cai, Guoping Sidhu, Gurdip S. Wieczorek, Rosemary Gu, Xin Herrera, Guillermo A. Cubukcu-Dimopulo, Olcay Kahn, Thomas TI Plasma cell dyscrasia with kappa light-chain crystals in proximal tubular cells: A histological, immunofluorescent, and ultrastructural study SO ULTRASTRUCTURAL PATHOLOGY LA English DT Article DE crystal; immunoelectron microscopy; kappa light-chain; plasma cell dyscrasia; proximal tubulopathy; ultrastructure ID FANCONIS-SYNDROME; IMMUNOELECTRON MICROSCOPY; CYTOPLASMIC CRYSTALS; RENAL-DISEASE; MYELOMA; DEPOSITION AB This is a case report of a 56-year-old man with plasma cell dyscrasia who presented with proximal tubulopathy manifested as kappa light-chain crystal deposition in the proximal convoluted tubular cells. This was associated with mild cellular damage. The crystals were seen as negative images with the hematoxylin-eosin and periodic acid-Schiff (PAS) stains. They were identified as kappa light-chains by immunofluorescent imaging and confirmed by immunoelectron microscopy. Ultrastructurally, the crystals appear to be located within lysosomes. No deposits of light-chains were seen elsewhere in the kidney biopsy. C1 NY Harbor Healthcare Syst, Dept Pathol, New York, NY 10010 USA. NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA. Louisiana State Univ, Ctr Hlth Sci, Dept Pathol, Shreveport, LA 71105 USA. Bronx Vet Adm Med Ctr, Dept Pathol, New York, NY USA. Bronx Vet Adm Med Ctr, Dept Med, New York, NY USA. RP Sidhu, GS (reprint author), NY Harbor Healthcare Syst, Dept Pathol, Manhattan Campus,423 East 23d St, New York, NY 10010 USA. EM deepsidhu@optonline.net NR 19 TC 12 Z9 13 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0191-3123 J9 ULTRASTRUCT PATHOL JI Ultrastruct. Pathol. PD JUL-AUG PY 2006 VL 30 IS 4 BP 315 EP 319 DI 10.1080/019131290945727 PG 5 WC Microscopy; Pathology SC Microscopy; Pathology GA 083XD UT WOS:000240490600010 PM 16971357 ER PT J AU Wolden-Hanson, T AF Wolden-Hanson, Tami TI Mechanisms of the anorexia of aging in the Brown Norway rat SO PHYSIOLOGY & BEHAVIOR LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-for-the-Study-of-Ingestive-Behavior CY JUL 12-17, 2005 CL Pittsburgh, PA SP Soc Study Ingestive Behavior DE anorexia of aging; rat; aging; leptin; ghrelin; insulin; testosterone; neuropeptides; senescence; food intake; fasting ID HYPOTHALAMIC NEUROPEPTIDE-Y; AGOUTI-RELATED PROTEIN; REDUCED FEEDING RESPONSE; AGE-ASSOCIATED CHANGES; NPY GENE-EXPRESSION; BODY-COMPOSITION; ARCUATE NUCLEUS; FOOD-INTAKE; ENERGY HOMEOSTASIS; PARAVENTRICULAR NUCLEUS AB Aging is associated with a loss of the ability to maintain homeostasis in response to physiologic and environmental disturbances. Age-related dysregulation of food intake and energy balance appears to be the result of impaired responsiveness of hypothalamic integrative circuitry to metabolic cues, which can lead to lack of appropriate food intake (the anorexia of aging) and thus to inappropriate weight loss in response to acute or chronic illness or other stressors. Using the Brown Norway (BN) male rat model, we have shown that old animals fail to appropriately increase food intake after the metabolic challenge of a 72 h fast, resulting in the failure to re-gain lost body weight upon refeeding. Leptin levels increase with adiposity and age, and remain elevated above levels of young animals even after a 72 h fast, suggesting that hyperleptinemia may be influencing the energy balance dysregulation. It is unclear whether this age-related response is due to a failure of the network of hypothalamic neurons to appropriately integrate hormonal and neural inputs, or due to a failure of the neurons to produce the appropriate neuropeptides. We hypothesize that sequential, age-related alterations in the expression patterns of neuropeptides that maintain melanocortinergic tone, and in the hormone mediators that inform the system of the state of energy balance, result in a diminished ability to maintain energy homeostasis with increasing age. We have undertaken a number of interventional approaches to test this hypothesis, including manipulations of the hormones ghrelin, insulin and testosterone, and direct application of neuropeptides to the central nervous system in these animals. Published by Elsevier Inc. C1 VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA. RP Wolden-Hanson, T (reprint author), VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, S-182-GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM twh@u.washington.edu NR 88 TC 27 Z9 27 U1 2 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD JUN 30 PY 2006 VL 88 IS 3 BP 267 EP 276 DI 10.1016/j.physbeh.2006.05.032 PG 10 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 061JU UT WOS:000238868900008 PM 16781740 ER PT J AU Rubin, RT Miller, TH Rhodes, ME Czambel, RK AF Rubin, RT Miller, TH Rhodes, ME Czambel, RK TI Adrenal cortical responses to low- and high-dose ACTH(1-24) administration in major depressives vs. matched controls SO PSYCHIATRY RESEARCH LA English DT Article DE hypothalamo-pituitary-adrenocortical axis; cortisol; major depressive disorder ID DEXAMETHASONE SUPPRESSION TEST; ACTH STIMULATION TEST; GLAND VOLUME; ADRENOCORTICAL SENSITIVITY; HEALTHY-VOLUNTEERS; PITUITARY; CORTISOL; CORTICOTROPIN; WEIGHT; SUICIDE AB Increased hypothalamo-pituitary-adrenocortical (HPA) axis activity occurs in 30-50% of patients with major depression. This includes normal-to-increased adrenal cortical hormone (cortisol) secretion in spite of reduced corticotropin (ACTH) stimulation. A possible explanation is increased adrenal responsiveness to ACTH. Supporting this possibility is the finding of increased adrenal volume, which reverts to normal with successful treatment. Eight female and six male patients with major depression, and eight female and six male individually matched controls, underwent two test sessions 5-7 days apart. On the first day, a low ACTH, 24 dose (0.014 mu g/kg i.v.), equivalent to 1 mu g in a 70-kg individual, was given. On the second day, a supramaximal stimulating dose (250 mu g i.v.) was given. Serial blood samples were analyzed for immunoreactive (IR-)ACTH, ACTH(1-39), and cortisol. There were no significant sex or patient-control differences in IR-ACTH areas under the curve (AUCs) following low-dose ACTH(1-24), and the correlation between patient and matched control AUCs was +0.71, indicating good correspondence in the amount of circulating ACTH(1-24) available for adrenal stimulation. There were no significant sex or patient-control differences in cortisol response and no significant interaction between dose and subject group, indicating that patients did not differ from controls in their cortisol responses to either low- or high-dose ACTH(1-24). These findings do not indicate increased adrenal cortical responsiveness in patients with major depression. Neurochemical/neurohormonal and neural stimulatory factors other than ACTH might be responsible for the increased adrenal gland size and cortisol secretion, in spite of reduced pituitary ACTH secretion, that has been reported in this illness. Published by Elsevier Ireland Ltd. C1 VA Greater Los Angeles Healthcare Syst, Dept Psychiat & Mental Hlth 116, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Drexel Univ, Coll Med, Neurosci Res Ctr, Pittsburgh, PA 15212 USA. RP Rubin, RT (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Psychiat & Mental Hlth 116, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM robert.rubin@med.va.gov FU NIMH NIH HHS [MH28380] NR 42 TC 12 Z9 12 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD JUN 30 PY 2006 VL 143 IS 1 BP 43 EP 50 DI 10.1016/j.psychres.2005.10.003 PG 8 WC Psychiatry SC Psychiatry GA 059RD UT WOS:000238749000006 PM 16707164 ER PT J AU Lindsey, ML Escobar, P Mukherjee, R Goshorn, DK Sheats, NJ Bruce, JA Mains, IM Hendrick, JK Hewett, KW Gourdie, RG Matrisian, LM Spinale, FG AF Lindsey, ML Escobar, P Mukherjee, R Goshorn, DK Sheats, NJ Bruce, JA Mains, IM Hendrick, JK Hewett, KW Gourdie, RG Matrisian, LM Spinale, FG TI Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction SO CIRCULATION LA English DT Article DE infarction; leukocytes; metalloproteinases; myocardial infarction; remodeling ID SURFACE-PLASMON RESONANCE; HEART-FAILURE; GAP-JUNCTIONS; VENTRICULAR-TACHYCARDIA; IMPULSE PROPAGATION; BORDER ZONE; MATRILYSIN; MICE; MODEL; RAT AB Background-Matrix metalloproteinases ( MMPs) contribute to left ventricular remodeling after myocardial infarction (MI). Specific causative roles of particular MMPs, however, remain unclear. MMP-7 is abundant in cardiomyocytes and macrophages, but MMP-7 function after MI has not been defined. Methods and Results-Wild-type (WT; n=55) and MMP-7-null (MMP-7(-/-); n=32) mice underwent permanent coronary artery ligation for 7 days. MI sizes were similar, but survival was greatly improved in MMP-7(-/-) mice. The survival difference could not be attributed to differences in left ventricular dilation because end-diastolic volumes increased similarly. ECG analysis revealed a prolonged PR interval in WT but not in MMP-7(-/-) post-MI mice. Post-MI conduction velocity, determined by optically mapping electrical wavefront propagation, decreased to 78 +/- 6% of control for WT and was normalized in MMP-7(-/-) mice. In WT mice, slower conduction velocity correlated with a 53% reduction in the gap junction protein connexin-43. Direct binding of MMP-7 to connexin-43, determined by surface plasmon resonance technology, occurred in a dose-dependent manner. Connexin-43 processing by MMP-7 was confirmed by in silico and in vitro substrate analyses and MMP-7 infusion induced arrhythmias in vivo. Conclusions-MMP-7 deletion results in improved survival and myocardial conduction patterns after MI. This is the first report to implicate MMP-7 in post-MI remodeling and to demonstrate that connexin-43 is a novel MMP-7 substrate. C1 Univ Texas, Hlth Sci Ctr San Antonio, Dept Med, Div Cardiol, San Antonio, TX 78229 USA. Med Univ S Carolina, Div Cardiothorac Surg Res, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA. Vanderbilt Univ, Dept Canc Biol, Nashville, TN USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Lindsey, ML (reprint author), Univ Texas, Hlth Sci Ctr San Antonio, Dept Med, Div Cardiol, 7703 Floyd Curl Dr,Mail Code 7872, San Antonio, TX 78229 USA. EM lindseym@uthscsa.edu RI Lindsey, Merry/B-2650-2012 FU NHLBI NIH HHS [HL-10337, HL-36059, HL-45024, HL-56728, HL-66029, HL-75360, HL-97012, R01 HL075360]; NICHD NIH HHS [HD-39946]; PHS HHS [P01-48788] NR 36 TC 77 Z9 82 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD JUN 27 PY 2006 VL 113 IS 25 BP 2919 EP 2928 DI 10.1161/CIRCULATIONAHA.106.612960 PG 10 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 057CG UT WOS:000238572100011 PM 16769909 ER PT J AU Chin, PS Berg, AT Spencer, SS Lee, ML Shinnar, S Sperling, MR Langfitt, JT Walczak, TS Pacia, SV Bazil, CW Vassar, S Vickrey, BG AF Chin, PS Berg, AT Spencer, SS Lee, ML Shinnar, S Sperling, MR Langfitt, JT Walczak, TS Pacia, SV Bazil, CW Vassar, S Vickrey, BG TI Patient-perceived impact of resective epilepsy surgery SO NEUROLOGY LA English DT Article ID QUALITY-OF-LIFE; ANTERIOR TEMPORAL LOBECTOMY; TERM FOLLOW-UP; REFRACTORY EPILEPSY; SATISFACTION; MULTICENTER; OUTCOMES; ADJUSTMENT AB Objective: To evaluate the patient-perceived impact of resective epilepsy surgery, a key outcome to consider in evaluating such a highly invasive, elective procedure. Methods: Impact measures obtained from 396 patients in a multicenter cohort study of resective epilepsy surgery included (1) willingness to undergo surgery if that decision could be made again and (2) the overall impact of surgery on the patient's life. Predictors of impact were analyzed using multivariate ordinal logistic regression. Results: Of study participants, 73.8%, 77.4%, and 75.5% would definitely undergo surgery again and 78.2%, 80.2%, and 79.1% reported a very strong or strong positive overall impact of surgery at 3, 12, and 24 months. Multivariate ordinal logistic regression showed that seizure freedom predicted more positive perceptions at 3, 12, and 24 months (all p < 0.04). Becoming employed was uniquely associated with willingness to undergo surgery again and with overall impact at 24 months (all p < 0.05), but only a net 7% of the cohort improved their employment status. Right-sided resection (at 12 and 24 months, p < 0.005) and female gender ( at 3 and 12 months, p = 0.006) were each positively associated with perceived overall impact. Conclusions: Most epilepsy surgery patients report a positive overall impact of the procedure on their lives and a high willingness to undergo surgery again if that choice could be made. Seizure-free individuals express consistently more positive perceptions of the procedure. Findings suggest that it is important to make early efforts to reintegrate epilepsy surgery patients into employment. C1 Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Dept Neurol, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA. NIU, BIOS, De Kalb, IL USA. Yale Univ, Sch Med, Dept Neurol, New Haven, CT USA. Univ Calif Los Angeles, Sepulveda, CA USA. VA Med Ctr, HSR&D Field Program, Ctr Study Healthcare Provider Behav, Sepulveda, CA USA. Albert Einstein Coll Med, Montefiore Med Ctr, Dept Neurol, Bronx, NY 10467 USA. Albert Einstein Coll Med, Montefiore Med Ctr, Dept Pediat, Bronx, NY 10467 USA. Thomas Jefferson Univ, Sch Med, Dept Neurol, Philadelphia, PA 19107 USA. Univ Rochester, Dept Neurol, Rochester, NY USA. Minnesota Comprehens Epilepsy Program, Minneapolis, MN USA. NYU, Dept Neurol, New York, NY USA. Columbia Univ, Sch Med, Dept Neurol, New York, NY USA. Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA. RP Chin, PS (reprint author), Genentech Inc, Hlth Econ & Outcomes Res, 1 DNA Way,MS 241A, San Francisco, CA 94080 USA. EM neuroepi@yahoo.com FU PHS HHS [R01 32375-06] NR 30 TC 27 Z9 29 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JUN 27 PY 2006 VL 66 IS 12 BP 1882 EP 1887 DI 10.1212/01.wnl.0000219729.08924.54 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 057CJ UT WOS:000238572400020 PM 16801655 ER PT J AU Lyamin, OI Pryaslova, J Lance, V Siegel, JM AF Lyamin, OI Pryaslova, J Lance, V Siegel, JM TI Sleep behaviour - Reply SO NATURE LA English DT Letter ID RETICULAR-FORMATION; CETACEANS; STATE; EYE C1 Univ Calif Los Angeles, Sepulveda, CA 91343 USA. Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. Utrish Dolphinarium, Moscow 119071, Russia. San Diego State Univ, San Diego, CA 92182 USA. RP Lyamin, OI (reprint author), Univ Calif Los Angeles, Sepulveda, CA 91343 USA. EM jsiegel@ucla.edu NR 12 TC 4 Z9 5 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD JUN 22 PY 2006 VL 441 IS 7096 BP E11 EP E11 DI 10.1038/nature04900 PG 1 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 055AT UT WOS:000238422300033 ER PT J AU Spertus, JA Kettelkamp, R Vance, C Decker, C Jones, PG Rumsfeld, JS Messenger, JC Khanal, S Peterson, ED Bach, RG Krumholz, HM Cohen, DJ AF Spertus, JA Kettelkamp, R Vance, C Decker, C Jones, PG Rumsfeld, JS Messenger, JC Khanal, S Peterson, ED Bach, RG Krumholz, HM Cohen, DJ TI Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement results from the PREMIER registry SO CIRCULATION LA English DT Article DE angioplasty; anticoagulants; mortality; revascularization; stents ID PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; ST-SEGMENT ELEVATION; MYOCARDIAL-INFARCTION; ANTIPLATELET THERAPY; AMERICAN-COLLEGE; LATE THROMBOSIS; POOLED ANALYSIS; ARTERY-DISEASE AB Background - Although drug-eluting stents (DES) significantly reduce restenosis, they require 3 to 6 months of thienopyridine therapy to prevent stent thrombosis. The rate and consequences of prematurely discontinuing thienopyridine therapy after DES placement for acute myocardial infarction (MI) are unknown. Methods and Results - We used prospectively collected data from a 19-center study of MI patients to examine the prevalence and predictors of thienopyridine discontinuation 30 days after DES treatment. We then compared the mortality and cardiac hospitalization rates for the next 11 months between those who stopped and those who continued thienopyridine therapy. Among 500 DES-treated MI patients who were discharged on thienopyridine therapy, 68 (13.6%) stopped therapy within 30 days. Those who stopped were older, less likely to have completed high school or be married, more likely to avoid health care because of cost, and more likely to have had preexisting cardiovascular disease or anemia at presentation. They were also less likely to have received discharge instructions about their medications or a cardiac rehabilitation referral. Patients who stopped thienopyridine therapy by 30 days were more likely to die during the next 11 months (7.5% versus 0.7%, P < 0.0001; adjusted hazard ratio = 9.0; 95% confidence interval = 1.3 to 60.6) and to be rehospitalized (23% versus 14%, P = 0.08; adjusted hazard ratio = 1.5; 95% confidence interval = 0.78 to 3.0). Conclusions - Almost 1 in 7 MI patients who received a DES were no longer taking thienopyridines by 30 days. Prematurely stopping thienopyridine therapy was strongly associated with subsequent mortality. Strategies to improve the use of thienopyridines are needed to optimize the outcomes of MI patients treated with DES. C1 Mid Amer Heart Inst, Kansas City, MO 64111 USA. Univ Missouri, Kansas City, MO 64110 USA. Univ Colorado Hosp, Denver VA Med Ctr, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. Henry Ford Hlth Syst, Detroit, MI USA. Duke Univ, Durham, NC USA. Barnes Jewish Hosp, St Louis, MO 63110 USA. Washington Univ, Sch Med, St Louis, MO 63110 USA. Yale Univ, New Haven, CT USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Spertus, JA (reprint author), Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA. EM spertusj@umkc.edu NR 36 TC 558 Z9 594 U1 4 U2 18 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD JUN 20 PY 2006 VL 113 IS 24 BP 2803 EP 2809 DI 10.1161/CIRCULATIONAHA.106.618066 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 054NY UT WOS:000238385800008 PM 16769908 ER PT J AU Srinivas, S Stadler, WM Bukowski, R Figlin, R Hayes, T Yankee, EW Jonasch, E AF Srinivas, S. Stadler, W. M. Bukowski, R. Figlin, R. Hayes, T. Yankee, E. W. Jonasch, E. TI Talactoferrin alfa may prolong progression-free survival in advanced renal carcinoma patients. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT 42nd Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 02-06, 2006 CL Atlanta, GA SP Amer Soc Clin Oncol C1 Stanford Med Ctr, Stanford, CA USA. Univ Chicago, Chicago, IL 60637 USA. Cleveland Clin, Cleveland, OH 44106 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. VA Med Ctr, Houston, TX USA. Agennix, Houston, TX USA. Univ Texas, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUN 20 PY 2006 VL 24 IS 18 SU S BP 241S EP 241S PN 1 PG 1 WC Oncology SC Oncology GA 063HN UT WOS:000239009401397 ER PT J AU Graff, J Mori, M Li, H Garzotto, M Penson, D Potosky, A Beer, TM AF Graff, J. Mori, M. Li, H. Garzotto, M. Penson, D. Potosky, A. Beer, T. M. TI Predictors of overall and cancer-specific survival in patients with clinically localized prostate cancer (PC) treated with primary androgen deprivation therapy (PADT): Results from the Prostate Cancer Outcomes Study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT 42nd Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 02-06, 2006 CL Atlanta, GA SP Amer Soc Clin Oncol C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR 97201 USA. Univ So Calif, Los Angeles, CA 90089 USA. NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUN 20 PY 2006 VL 24 IS 18 SU S BP 244S EP 244S PN 1 PG 1 WC Oncology SC Oncology GA 063HN UT WOS:000239009401408 ER PT J AU Garzotto, M Mongoue-Tchokote, S Shannon, J Peters, L Sokoloff, MH Beer, TM Mori, M AF Garzotto, M. Mongoue-Tchokote, S. Shannon, J. Peters, L. Sokoloff, M. H. Beer, T. M. Mori, M. TI Effect of obesity on PSA density (PSAD): A new clinical predictor of prostate cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT 42nd Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 02-06, 2006 CL Atlanta, GA SP Amer Soc Clin Oncol C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUN 20 PY 2006 VL 24 IS 18 SU S BP 245S EP 245S PN 1 PG 1 WC Oncology SC Oncology GA 063HN UT WOS:000239009401415 ER PT J AU O'Brien, CA Mongoue-Tchokote, S Collins, L Spurgeon, S Peters, L Beer, TM Mori, M Garzotto, M AF O'Brien, C. A. Mongoue-Tchokote, S. Collins, L. Spurgeon, S. Peters, L. Beer, T. M. Mori, M. Garzotto, M. TI Assessment of PSA and digital rectal examination (DRE) for the detection of Gleason >= 7 prostate cancer in a referral population. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT 42nd Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 02-06, 2006 CL Atlanta, GA SP Amer Soc Clin Oncol C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUN 20 PY 2006 VL 24 IS 18 SU S BP 249S EP 249S PN 1 PG 1 WC Oncology SC Oncology GA 063HN UT WOS:000239009401431 ER PT J AU Merrick, DT Kittelson, J Winterhalder, R Kotantoulas, G Ingeberg, S Keith, RL Kennedy, TC Miller, YE Franklin, WA Hirsch, FR AF Merrick, D. T. Kittelson, J. Winterhalder, R. Kotantoulas, G. Ingeberg, S. Keith, R. L. Kennedy, T. C. Miller, Y. E. Franklin, W. A. Hirsch, F. R. TI Analysis of c-erb-1 (EGFR) and c-erb-2 (HER2) expression in bronchial dysplasia: Evaluation of potential targets for chemoprevention of lung cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT 42nd Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 02-06, 2006 CL Atlanta, GA SP Amer Soc Clin Oncol C1 Univ Colorado, Denver VAMC, Denver, CO 80202 USA. Univ Zurich Hosp, CH-8091 Zurich, Switzerland. Athens Chest Hosp, Athens, Greece. Naestved Hosp, Naestved, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUN 20 PY 2006 VL 24 IS 18 SU S MA 7070 BP 381S EP 381S PN 1 PG 1 WC Oncology SC Oncology GA 063HN UT WOS:000239009402394 PM 27953156 ER PT J AU Chang, C Knight, SJ Bennett, CL AF Chang, C. Knight, S. J. Bennett, C. L. TI Effects of depression on quality of life in Medicare beneficiaries with prostate cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT 42nd Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 02-06, 2006 CL Atlanta, GA SP Amer Soc Clin Oncol C1 Northwestern Univ, Chicago, IL 60611 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RI Bennett, Charles/C-2050-2008 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUN 20 PY 2006 VL 24 IS 18 SU S MA 8510 BP 470S EP 470S PN 1 PG 1 WC Oncology SC Oncology GA 063HN UT WOS:000239009403182 PM 27954170 ER PT J AU Xie, YM Massa, SM Ensslen-Craig, SE Major, DL Yang, T Tisi, MA Derevyanny, VD Runge, WO Mehta, BP Moore, LA Brady-Kalnay, SM Longo, FM AF Xie, YM Massa, SM Ensslen-Craig, SE Major, DL Yang, T Tisi, MA Derevyanny, VD Runge, WO Mehta, BP Moore, LA Brady-Kalnay, SM Longo, FM TI Protein-tyrosine phosphatase (PTP) wedge domain peptides - A novel approach for inhibition of PTP function and augmentation of protein-tyrosine kinase function SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NERVE GROWTH-FACTOR; NEURITE OUTGROWTH; PC12 CELLS; SIGNAL-TRANSDUCTION; HOMOPHILIC BINDING; CATALYTIC-ACTIVITY; CRYSTAL-STRUCTURE; RECEPTOR; LAR; MU AB Inhibition of protein-tyrosine phosphatases (PTPs) counterbalancing protein-tyrosine kinases (PTKs) offers a strategy for augmenting PTK actions. Conservation of PTP catalytic sites limits development of specific PTP inhibitors. A number of receptor PTPs, including the leukocyte common antigen-related (LAR) receptor and PTP mu, contain a wedge-shaped helix-loop-helix located near the first catalytic domain. Helix-loop-helix domains in other proteins demonstrate homophilic binding and inhibit function; therefore, we tested the hypothesis that LAR wedge domain peptides would exhibit homophilic binding, bind to LAR, and inhibit LAR function. Fluorescent beads coated with LAR or PTP mu wedge peptides demonstrated PTP-specific homophilic binding, and LAR wedge peptide-coated beads precipitated LAR protein. Administration of LAR wedge Tat peptide to PC12 cells resulted in increased proliferation, decreased cell death, increased neurite outgrowth, and augmented Trk PTK-mediated responses to nerve growth factor (NGF), a phenotype matching that found in PC12 cells with reduced LAR levels. PTP mu wedge Tat peptide had no effect on PC12 cells but blocked the PTP mu-dependent phenotype of neurite outgrowth of retinal ganglion neurons on a PTP mu substrate, whereas LAR wedge peptide had no effect. The survival- and neurite-promoting effect of the LAR wedge peptide was blocked by the Trk inhibitor K252a, and reciprocal co-immunoprecipitation demonstrated LAR/ TrkA association. The addition of LAR wedge peptide inhibited LAR co-immunoprecipitation with TrkA, augmented NGF-induced activation of TrkA, ERK, and AKT, and in the absence of exogenous NGF, induced activation of TrkA, ERK, and AKT. PTP wedge domain peptides provide a unique PTP inhibition strategy and offer a novel approach for augmenting PTK function. C1 Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA. Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Lab Computat Neurochem & Drug Discovery, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA. Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA. RP Longo, FM (reprint author), Stanford Univ, Dept Neurol & Neurol Sci, 300 Pasteur Dr, Stanford, CA 94305 USA. EM longo@stanford.edu FU NEI NIH HHS [R01 EY 12251, P01 EY 11373]; NIA NIH HHS [R01 AG 09873] NR 57 TC 37 Z9 38 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 16 PY 2006 VL 281 IS 24 BP 16482 EP 16492 DI 10.1074/jbc.M603131200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 051MR UT WOS:000238165700038 PM 16613844 ER PT J AU Ghebranious, N Burmester, JK Glurich, I McPherson, E Ivacic, L Kislow, J Rasmussen, K Kumar, V Raggio, CL Blank, RD Jacobsen, FS Faciszewski, T Womack, J Giampietro, PF AF Ghebranious, N Burmester, JK Glurich, I McPherson, E Ivacic, L Kislow, J Rasmussen, K Kumar, V Raggio, CL Blank, RD Jacobsen, FS Faciszewski, T Womack, J Giampietro, PF TI Evaluation of SLC35A3 as a candidate gene for human vertebral malformations SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Letter ID N-ACETYLGLUCOSAMINE TRANSPORTER; HOLSTEIN CALVES C1 Marshfield Clin Fdn Med Res & Educ, Mol Diagnost Genotyping Lab, Marshfield, WI USA. Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA. Marshfield Clin Res Fdn, Off Res Facil, Marshfield, WI USA. Marshfield Clin Fdn Med Res & Educ, Dept Pediat, Marshfield, WI USA. Hosp Special Surg, Dept Pediat Orthoped, New York, NY 10021 USA. Univ Wisconsin, Sch Med, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. Marshfield Clin Fdn Med Res & Educ, Dept Orthoped Spine Surg, Marshfield, WI USA. Texas A&M Univ, College Stn, TX USA. Marshfield Clin Fdn Med Res & Educ, Dept Med Genet Serv, Marshfield, WI 54449 USA. RP Giampietro, PF (reprint author), Marshfield Clin Fdn Med Res & Educ, Dept Med Genet Serv, 1000 N Oak Ave, Marshfield, WI 54449 USA. EM giampietro.philip@marshfieldclinic.org NR 9 TC 9 Z9 9 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4825 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD JUN 15 PY 2006 VL 140A IS 12 BP 1346 EP 1348 DI 10.1002/ajmg.a.31307 PG 3 WC Genetics & Heredity SC Genetics & Heredity GA 049BL UT WOS:000237990400019 PM 16691598 ER PT J AU Berrios-Rivera, JP Street, RL Popa-Lisseanu, MGG Kallen, MA Richardson, MN Janssen, NM Marcus, DM Reveille, JD Warner, NB Suarez-Almazor, ME AF Berrios-Rivera, JP Street, RL Popa-Lisseanu, MGG Kallen, MA Richardson, MN Janssen, NM Marcus, DM Reveille, JD Warner, NB Suarez-Almazor, ME TI Trust in physicians and elements of the medical interaction in patients with rheumatoid arthritis and systemic lupus erythematosus SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article DE physician trust; communication; rheumatoid arthritis; systemic lupus erythematosus ID QUALITY-OF-LIFE; PRIMARY-CARE; PREVENTIVE SERVICES; ETHNIC DISPARITIES; HEALTH-CARE; RACE; SCALE; SATISFACTION; PERCEPTIONS; PROFESSION AB Objective. To identify components of the patient-doctor relationship associated with trust in physicians. Methods. We assessed 102 patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) seen at publicly funded hospitals in Houston, Texas. Patients completed a self-response survey examining patient perceptions of the medical encounter and trust in their physicians. Evaluated components of physicians' behaviors included: informativeness, sensitivity to concerns, reassurance and support, patient-centeredness, and participatory decision-making style. Scales were scored 0 to 10, with higher numbers indicating more positive perceptions of communication. Results. Seventy patients had RA and 32 SLE; 25% were white, 43% Latino, 31% African American, and 75% were female. Mean scores for the medical interaction and trust scales ranged from 6.2-7.1, indicating moderate degrees of positive perceptions. All components were highly and positively correlated with each other, and with trust, suggesting that these traits are all elements of a positive style of doctor-patient communication. In multivariate analysis, ethnicity, physicians' informativeness, physicians' sensitivity to concerns, patient-centeredness, disease activity, and patient trust in the US health care system were independent predictors of trust in physicians. A separate model examined the predictors of patient disclosure of information. Patient perceptions of physicians' patient-centeredness and severity of disease activity were independently predictive of patient disclosure of information. Conclusion. In patients with SLE and RA, trust in physicians is significantly associated with patients' ethnicity and their perceptions about specific components of physicians' communication style. Trust in physicians can be improved by using a patient-centered approach, being sensitive to patient concerns, and providing adequate clinical information. Furthermore, patients appear to be more willing to disclose concerns when physicians use a patient-centered communication style. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Texas A&M Univ, College Stn, TX USA. Univ Texas, Hlth Sci Ctr, Houston, TX USA. RP Suarez-Almazor, ME (reprint author), Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mes@bcm.tmc.edu FU NIAMS NIH HHS [R01 AR 47858] NR 47 TC 58 Z9 59 U1 3 U2 11 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD JUN 15 PY 2006 VL 55 IS 3 BP 385 EP 393 DI 10.1002/art.21988 PG 9 WC Rheumatology SC Rheumatology GA 051PL UT WOS:000238172900008 PM 16739207 ER PT J AU Shen, KZ Johnson, SW AF Shen, Ke-Zhong Johnson, Steven W. TI Subthalamic stimulation evokes complex EPSCs in the rat substantia nigra pars reticulata in vitro SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID BASAL GANGLIA CIRCUITRY; GABAERGIC INHIBITION; MICROSCOPIC ANALYSIS; PARKINSONS-DISEASE; NEURONS; NUCLEUS; TRANSMISSION; RESPONSES; LESIONS; RECEPTORS AB The subthalamic nucleus (STN) plays an important role in movement control by exerting its excitatory influence on the substantia nigra pars reticulata (SNR), a major output structure of the basal ganglia. Moreover, excessive burst firing of SNR neurons seen in Parkinson's disease has been attributed to excessive transmission in the subthalamonigral pathway. Using the 'blind' whole-cell patch clamp recording technique in rat brain slices, we found that focal electrical stimulation of the STN evoked complex, long-duration excitatory postsynaptic currents (EPSCs) in SNR neurons. Complex EPSCs lasted 200-500 ms and consisted of an initial monosynaptic EPSC followed by a series of late EPSCs superimposed on a slow inward shift in holding current. Focal stimulation of regions outside the STN failed to evoke complex EPSCs. The late component of complex EPSCs was markedly reduced by ionotropic glutamate receptor antagonists (2-amino-5-phosphonopentanoic acid and 6-cyano-7-nitro-quinoxalone) and by a GABA(A) receptor agonist (isoguvacine) when these agents were applied directly to the STN using a fast-flow microapplicator. Moreover, the complex EPSC was greatly enhanced by bath application of the GABAA receptor antagonists picrotoxin or bicuculline. These data suggest that recurrent glutamate synapses in the STN generate polysynaptic, complex EPSCs that are under tonic inhibition by GABA. Because complex EPSCs are expected to generate bursts of action potentials in SNR neurons, we suggest that complex EPSCs may contribute to the pathological burst firing that is associated with the symptoms of Parkinson's disease. C1 Portland VA Med Ctr, R&D 61, Portland, OR 97207 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. RP Johnson, SW (reprint author), Portland VA Med Ctr, R&D 61, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM johnsost@ohsu.edu FU NINDS NIH HHS [R01 NS038175, NS 38175] NR 46 TC 25 Z9 25 U1 0 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD JUN 15 PY 2006 VL 573 IS 3 BP 697 EP 709 DI 10.1113/jphysiol.2006.110031 PG 13 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 065IU UT WOS:000239154200008 PM 16613871 ER PT J AU Mizumori, M Meyerowitz, J Takeuchi, T Lim, S Lee, P Supuran, CT Guth, PH Engel, E Kaunitz, JD Akiba, Y AF Mizumori, Misa Meyerowitz, Justin Takeuchi, Tetsu Lim, Shu Lee, Paul Supuran, Claudiu T. Guth, Paul H. Engel, Eli Kaunitz, Jonathan D. Akiba, Yasutada TI Epithelial carbonic anhydrases facilitate P-CO2 and pH regulation in rat duodenal mucosa SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID ZOLLINGER-ELLISON SYNDROME; APICAL CL-/HCO3-EXCHANGER; NA+/H+ EXCHANGER; BICARBONATE SECRETION; ACID LOSS; INTRACELLULAR PH; HCO3-SECRETION; ISOZYME-IX; GASTROINTESTINAL-TRACT; ALKALINE SECRETION AB The duodenum is the site of mixing of massive amounts of gastric H+ with secreted HCO3-, generating CO2 and H2O accompanied by the neutralization of H+. We examined the role of membrane-bound and soluble carbonic anhydrases (CA) by which H+ is neutralized, CO2 is absorbed, and HCO3- is secreted. Rat duodena were perfused with solutions of different pH and P-CO2 with or without a cell-permeant CA inhibitor methazolamide (MTZ) or impermeant CA inhibitors. Flow-through pH and P-CO2 electrodes simultaneously measured perfusate and effluent pH and P-CO2. High CO2 (34.7 kPa) perfusion increased net CO2 loss from the perfusate compared with controls (pH 6.4 saline, P-CO2 approximate to 0) accompanied by portal venous (PV) acidification and P-CO2 increase. Impermeant CA inhibitors abolished net perfusate CO2 loss and increased net HCO3- gain, whereas all CA inhibitors inhibited PV acidification and PCO2 increase. The changes in luminal and PV pH and [CO2] were also inhibited by the Na+-H+ exchanger-1 (NHE1) inhibitor dimethylamiloride, but not by the NHE3 inhibitor S3226. Luminal acid decreased total CO2 output and increased H+ loss with PV acidification and P-CO2 increase, all inhibited by all CA inhibitors. During perfusion of a 30% CO2 buffer, loss Of CO2 from the lumen was CA dependent as was transepithelial transport of perfused (CO2)-C-13. H+ and CO2 loss from the perfusate were accompanied by increases of PV H+ and tracer CO2, but unchanged PV total CO2, consistent with CA-dependent transmucosal. H+ and CO2 movement. Inhibition of membrane-bound CAs augments the apparent rate of net basal HCO3- secretion. Luminal H+ traverses the apical membrane as CO2, is converted back to cytosolic H+, which is extruded via NHE1. Membrane-bound and cytosolic CAs cooperatively facilitate secretion of HCO3 into the lumen and CO2 diffusion into duodenal mucosa, serving as important acid-base regulators. C1 Univ Calif Los Angeles, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90024 USA. Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA. Harvard Westlake Sch, Los Angeles, CA 90073 USA. Harbor UCLA Med Ctr, Stable Isotope Facil, Torrance, CA 90509 USA. Univ Florence, Dipartimento Chim, Lab Chim Bioinorgan, Florence, Italy. RP Kaunitz, JD (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu RI Supuran, Claudiu/A-5151-2008 OI Meyerowitz, Justin/0000-0001-7194-8286 FU BLRD VA [I01 BX001245]; NIDDK NIH HHS [P30 DK0413, R01 DK054221, R01 DK54221] NR 59 TC 39 Z9 42 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD JUN 15 PY 2006 VL 573 IS 3 BP 827 EP 842 DI 10.1113/jphysiol.2006.107581 PG 16 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 065IU UT WOS:000239154200018 PM 16556652 ER PT J AU Roostaeian, J Carlsen, B Simhaee, D Jarrahy, R Huang, WB Ishida, K Rudkin, GH Yamaguchi, DT Miller, TA AF Roostaeian, J Carlsen, B Simhaee, D Jarrahy, R Huang, WB Ishida, K Rudkin, GH Yamaguchi, DT Miller, TA TI Characterization of growth and osteogenic differentiation of rabbit bone marrow stromal cells SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE rabbit; bone marrow stromal cells; growth; differentiation; BNW; TGF-beta; osteogenesis; tissue engineering ID MESENCHYMAL STEM-CELLS; FACTOR-BETA; OSTEOBLASTIC CELLS; GENE-EXPRESSION; IN-VITRO; TISSUE; REGENERATION; OSTEOPONTIN; DEFECTS; PROLIFERATION AB Background. The rabbit is recognized as an excellent model to study the repair of bony defects with tissue engineered constructs. However, the use of rabbit bone marrow stromal. cells (RBMSCs) has been limited despite the proven benefits of autologous BMSCs in the formation of bone. The purpose of this study was to characterize the growth and differentiation pattern of RBMSCs and their response to growth factors. Material and methods. BMSCs were isolated from New Zealand White rabbits and cultured. Serial cell counts of parallel cultures were taken daily to determine cell growth. Response of RBMSCs to varying doses of recombinant human BMP-2 (rhBMP-2) and their time course was gauged by alkaline phosphatase (ALP) activity. The osteoblastic differentiation potential of RBMSCs in response to rhBMP-2 treatment was determined by evaluating the expression pattern of various genes involved with osteogensis using northern analysis. Von Kossa staining was performed to determine the effect of rhBMP-2 on the mineralization capabilities of RBMSCs. Results. The growth rate of RBMSCs severely declined after first passage and this rate was further suppressed by TGF-ss 1. The optimal dose response of rhBMP-2 was determined to be 50 ng/ml and its time course displayed increasing alkaline phosphatase activity over time. Two osteogenic markers, collagen I and osteopontin, were up regulated by rhBMP-2 treatment. Finally, the mineralization capability of RBMSCs was determined to be enhanced by rhBMP-2 treatment. Conclusion. Our work indicates that RBMSCs possess strong osteogenic potential and can be successfully applied toward bone tissue engineering in a rabbit model. (c) 2006 Elsevier Inc. All rights reserved. C1 VA Greater LA Healthcare Syst, Plast Surg Lab, Plast Surg Sect, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Surg, Div Plast Surg, Los Angeles, CA USA. RP Miller, TA (reprint author), VA Greater LA Healthcare Syst, Plast Surg Lab, Plast Surg Sect, Room 221,Bldg 114,11301 Whilshire Blvd, Los Angeles, CA 90073 USA. EM millerlab@hotmail.com NR 53 TC 19 Z9 23 U1 2 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD JUN 15 PY 2006 VL 133 IS 2 BP 76 EP 83 DI 10.1016/j.jss.2005.09.026 PG 8 WC Surgery SC Surgery GA 052OM UT WOS:000238243000003 PM 16360178 ER PT J AU Watson, GS Craft, S AF Watson, GS Craft, S TI Insulin resistance, inflammation, and cognition in Alzheimer's Disease: Lessons for multiple sclerosis SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article; Proceedings Paper CT Symposium on Cognitive Decline in Multiple Sclerosis CY NOV 11-13, 2004 CL Taormina, ITALY SP European Charcot Fdn DE Alzheimer's disease; cognition; diabetes; inflammation; insulin; insulin resistance; multiple sclerosis; PPAR gamma ID PROLIFERATOR-ACTIVATED RECEPTOR; AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; IMPAIRED GLUCOSE-TOLERANCE; APOLIPOPROTEIN-E GENOTYPE; NECROSIS-FACTOR-ALPHA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; STREPTOZOTOCIN-DIABETIC RATS; BLOOD-BRAIN-BARRIER AB Insulin resistance (reduced ability of insulin to stimulate glucose utilization) is common in North American and Europe, where as many as one third of all older adults suffer from prodromal or clinical type 2 diabetes mellitus. It has long been known that insulin-resistant conditions adversely affect general health status. A growing body of findings suggests that insulin contributes to normal brain functioning and that peripheral insulin abnormalities increase the risk for memory loss and neurodegenerative disorders such as Alzheimer's disease. Potential mechanisms for these effects include insulin's role in cerebral glucose metabolism, peptide regulation, modulation of neurotransmitter levels, and modulation of many aspects of the inflammatory network. An intriguing question is whether insulin abnormalities also influence the pathophysiology of multiple sclerosis (MS), an autoimmune disorder characterized by elevated inflammatory biomarkers, central nervous system white matter lesions, axonal degeneration, and cognitive impairment. MS increases the risk for type I diabetes mellitus. Furthermore, the lack of association between MS and type 2 diabetes may suggest that insulin resistance affects patients with MS and the general population at the same alarming rate. Therefore, insulin resistance may exacerbate phenomena that are common to MS and insulin-resistant conditions, such as cognitive impairments and elevated inflammatory responses. Interestingly, the thiazolidinediones, which are used to treat patients with type 2 diabetes, have been proposed as potential therapeutic agents for both Alzheimer's disease and MS. The agents improve insulin sensitivity, reduce hyperinsulinemia, and exert anti-inflammatory actions. Ongoing studies will determine whether thiazolidinediones improve cognitive functioning for patients with type 2 diabetes or Alzheimer's disease. Future studies are needed to examine the effects of thiazolidinediones on patients with MS. (c) 2006 Elsevier B.V. All rights reserved. C1 Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S182,Dept Psychiat &, Seattle, WA 98108 USA. RP Watson, GS (reprint author), Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S182,Dept Psychiat &, 1660 S Columbian Way, Seattle, WA 98108 USA. EM gswatson@u.washington.edu FU NIA NIH HHS [R01 AG-10880]; NIDDK NIH HHS [R01 DK-61606] NR 149 TC 52 Z9 52 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD JUN 15 PY 2006 VL 245 IS 1-2 SI SI BP 21 EP 33 DI 10.1016/j.jns.2005.08.017 PG 13 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 055PK UT WOS:000238462500005 PM 16631207 ER PT J AU Asch, SM Kerr, EA McGlynn, EA AF Asch, SM Kerr, EA McGlynn, EA TI Who is at greatest risk for receiving poor-quality health care? Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI 48105 USA. RAND Hlth, Santa Monica, CA 90407 USA. RP Asch, SM (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. NR 3 TC 0 Z9 0 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 15 PY 2006 VL 354 IS 24 BP 2618 EP 2619 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 052KU UT WOS:000238233400028 ER PT J AU Bearden, CE Glahn, DC Monkul, ES Barrett, J Najt, P Villarreal, V Soares, JC AF Bearden, Carrie E. Glahn, David C. Monkul, E. Serap Barrett, Jennifer Najt, Pablo Villarreal, Veronica Soares, Jair C. TI Patterns of memory impairment in bipolar disorder and unipolar major depression SO PSYCHIATRY RESEARCH LA English DT Article DE mood disorder; clinical state; declarative memory; cognition; bipolar depression; unipolar depression ID MOOD DISORDERS; VERBAL MEMORY; COGNITIVE IMPAIRMENT; HIPPOCAMPAL VOLUME; SUSTAINED ATTENTION; DECLARATIVE MEMORY; CLINICAL-FEATURES; EUTHYMIC PATIENTS; RATING-SCALE; ILLNESS AB Unipolar and bipolar depression are known to exert detrimental effects on learning and memory processes. However, few comparisons have been undertaken between bipolar and unipolar patients with comparable illness histories, and predictors of impairment are not well understood. Adult outpatients with unipolar major depressive illness (UP, n = 30) and bipolar disorder (BP, n = 30), group-matched for illness duration and severity of depressive symptomatology (16% clinically remitted, 42% partially remitted, 42% depressed), and 30 demographically matched controls completed measures of general cognitive functioning and declarative memory. Despite comparable general intellectual abilities, BP and UP patients exhibited significant memory deficits relative to healthy controls. A similar deficit profile was observed in both patient groups, involving poorer verbal recall and recognition. Impairments were not secondary to strategic processing deficits or rapid forgetting. Although depression severity was not associated with neurocognitive performance, number of hospitalizations and family history of mood disorder significantly affected memory function in BP, but not UP, patients. Results suggest qualitatively similar patterns of memory impairment in BP and UP patients, consistent with a primary encoding deficit. These impairments do not appear to be secondary to clinical state, but rather suggest a similar underlying pathophysiology involving medial temporal dysfunction. (c) 2005 Elsevier Ireland Ltd. All rights reserved. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Schizophrenia & Related Disorders, San Antonio, TX 78229 USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, TR-35340 Izmir, Turkey. Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. RP Bearden, CE (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 300 Bldg Med Pl,Suite 2265, Los Angeles, CA 90095 USA. EM cbearden@mednet.ucla.edu FU NCRR NIH HHS [M01-RR-01346]; NIMH NIH HHS [MH01736] NR 56 TC 83 Z9 86 U1 1 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD JUN 15 PY 2006 VL 142 IS 2-3 BP 139 EP 150 DI 10.1016/j.psychres.2005.08.010 PG 12 WC Psychiatry SC Psychiatry GA 057WM UT WOS:000238625900003 PM 16631256 ER PT J AU Walter, LC Lindquist, K O'Hare, AM Johansen, KL AF Walter, LC Lindquist, K O'Hare, AM Johansen, KL TI Targeting screening mammography according to life expectancy among women undergoing dialysis SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID STAGE RENAL-DISEASE; MEDICARE CLAIMS DATA; BREAST-CANCER; OLDER WOMEN; SURVIVAL; POPULATION; PROSTATE; CHOICE; RATES; CARE AB Background: Screening guidelines recommend that mammography be targeted to women likely to live longer than 5 years. Because women undergoing dialysis have a reduced but variable life expectancy, their appropriate use of screening is controversial. Therefore, we conducted this study to describe national mammography rates among women undergoing dialysis with differing prognostic factors and to determine whether screening is targeted to healthier women who live longer. Methods: Using the US Renal Data System, we identified 17 090 women aged 50 years or older who started dialysis in 1997. We tracked women for 5 years to ascertain their use of screening mammography or death. Results: The 5-year survival rate was 25%. The biennial screening mammography rate was 25%, ranging from 12% for women aged 80 years or older to 69% for women who were ever on the transplant list. Women who were screened in the past year had a lower death rate than those who were not ( hazards ratio, 0.55; 95% confidence interval, 0.51-0.59). Yet, 2198 women (13%) who died within 5 years underwent screening, and 2004 women (12%) who lived more than 5 years while receiving dialysis did not undergo screening. Conclusions: Screening mammography rates are appropriately low among women undergoing dialysis because the 5-year survival rate is low. Screening is being targeted to women who are healthier and live longer. However, targeting could be improved by increasing screening in the few women undergoing dialysis with substantial life expectancies while decreasing screening in most women undergoing dialysis who live less than 5 years. C1 San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Walter, LC (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Mailcode 181G, San Francisco, CA 94121 USA. EM Louise.Walter@ucsf.edu FU NIDDK NIH HHS [DK-56182] NR 38 TC 12 Z9 12 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JUN 12 PY 2006 VL 166 IS 11 BP 1203 EP 1208 DI 10.1001/archinte.166.11.1203 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 051YS UT WOS:000238198200008 PM 16772248 ER PT J AU Marracci, GH Marquardt, WE Strehlow, A McKeon, GP Gross, J Buck, DC Kozell, LB Bourdette, DN AF Marracci, GH Marquardt, WE Strehlow, A McKeon, GP Gross, J Buck, DC Kozell, LB Bourdette, DN TI Lipoic acid downmodulates CD4 from human T lymphocytes by dissociation of p56(Lck) SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE CD4; p56(Lck); lipoic acid ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; VIRUS TYPE-1 NEF; MULTIPLE-SCLEROSIS; SERINE PHOSPHORYLATION; RAPID INTERNALIZATION; CD4-P56(LCK) COMPLEX; OXIDATIVE STRESS; CYTOPLASMIC TAIL; CELL-ACTIVATION AB Lipoic acid is an antioxidant that suppresses and treats a model of multiple sclerosis, experimental autoimmune encephalomyelitis. We now demonstrate that treatment of human PBMC and T cell lines with LA downmodulated CD4 expression in a concentration-dependent manner. LA treatment of Con A stimulated PBMC specifically removed CD4 from the T-cell surface, but not CD3. Epitope masking by LA was excluded by using monoclonal antibodies targeting different domains of CD4. Incubation on ice inhibited CD4 removal following LA treatment, suggesting that endocytosis was involved in its downmodulation. LA is in a unique category of compounds that induce CD4 downmodulation by various mechanisms (e.g., gangliosides). We hypothesized that LA might induce dissociation of p56(Lek) from CD4. thus leading to its downmodulation. Immunoblot analyses demonstrated reduced co-precipitation of p56(Lck) from Jurkat T-cells following LA treatment and precipitation of CD4. This unique immunomodulatory effect of LA warrants further investigation. Published by Elsevier Inc. C1 Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA. RP Marracci, GH (reprint author), Portland Vet Affairs Med Ctr, R&D 65,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM marracci@ohsu.edu OI Kozell, Laura/0000-0003-3059-2046 FU NCCIH NIH HHS [P50 AT00066-01] NR 49 TC 9 Z9 9 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD JUN 9 PY 2006 VL 344 IS 3 BP 963 EP 971 DI 10.1016/j.bbrc.2006.03.172 PG 9 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 043FI UT WOS:000237585000038 PM 16631599 ER PT J AU Packer, M Abraham, WT Mehra, MR Yancy, CW Lawless, CE Mitchell, JE Smart, FW Bijou, R O'Connor, CM Massie, BM Pina, IL Greenberg, BH Young, JB Fishbein, DP Hauptman, PJ Bourge, RC Strobeck, JE Murali, S Schocken, D Teerlink, JR Levy, WC Trupp, RJ Silver, MA AF Packer, M Abraham, WT Mehra, MR Yancy, CW Lawless, CE Mitchell, JE Smart, FW Bijou, R O'Connor, CM Massie, BM Pina, IL Greenberg, BH Young, JB Fishbein, DP Hauptman, PJ Bourge, RC Strobeck, JE Murali, S Schocken, D Teerlink, JR Levy, WC Trupp, RJ Silver, MA CA PREDICT Study Investigators TI Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID ELECTRICAL-IMPEDANCE; CARDIAC-OUTPUT; BIOIMPEDANCE; THERMODILUTION; CARDIOMYOPATHY; PRESSURE AB OBJECTIVES This study sought to assess the potential utility of impedance cardiography (ICG) in predicting clinical deterioration in ambulatory patients with heart failure (HF). BACKGROUND Impedance cardiography uses changes in thoracic electrical impedance to estimate hemodynamic variables, but its ability to predict clinical events has not been evaluated. METHODS We prospectively evaluated 212 stable patients with HF and a recent episode of clinical decompensation who underwent serial clinical evaluation and blinded ICG testing every 2 weeks for 26 weeks and were followed up for the occurrence of death or worsening HF requiring hospitalization or emergent care. RESULTS During the study, 59 patients experienced 104 episodes of decompensated HF (16 deaths, 78 hospitalizations, and 10 emergency visits). Multivariate analysis identified 6 clinical and ICG variables that independently predicted an event within 14 days of assessment. These included three clinical variables (visual analog score, New York Heart Association functional class, and systolic blood pressure) and three ICG parameters (velocity index, thoracic fluid content index, and left ventricular ejection time). The three ICG parameters combined into a composite score was a powerful predictor of an event during the next 14 days (p = 0.0002). Visits with a high-risk composite score had 2.5 times greater likelihood and those with a low-risk score had a 70% lower likelihood of a near-term event compared with visits at intermediate risk. CONCLUSIONS These results suggest that when performed at regular intervals in stable patients with HF with a recent episode of clinical decompensation, ICG can identify patients at increased near-term risk of recurrent decompensation. C1 Univ Texas, SW Med Ctr, Dallas, TX 75390 USA. Ohio State Univ, Ctr Heart, Columbus, OH 43210 USA. Univ Maryland, Sch Med, Baltimore, MD 21201 USA. DuPage Med Grp, Chicago, IL USA. SUNY, Downstate Med Ctr, New York, NY USA. St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX 77030 USA. Columbia Presbyterian Med Ctr, New York, NY 10032 USA. Duke Univ, Med Ctr, Durham, NC USA. San Francisco Vet Adm Med Ctr, San Francisco, CA USA. Case Western Reserve Univ, Cleveland, OH 44106 USA. Univ Calif San Diego, San Diego, CA 92103 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Univ Washington, Seattle, WA 98195 USA. St Louis Univ, St Louis, MO 63103 USA. Univ Alabama, Birmingham, AL USA. Heart Lung Associates Amer, Hawthorne, NJ USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. Univ S Florida, Tampa, FL USA. Advocate Christ Med Ctr, Oak Lawn, IL USA. RP Packer, M (reprint author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd,Room E5-506P, Dallas, TX 75390 USA. EM Milton.Packer@UTSouthwestern.edu RI Teerlink, John/D-2986-2012 OI Mehra, Mandeep/0000-0001-8683-7044 NR 26 TC 101 Z9 107 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JUN 6 PY 2006 VL 47 IS 11 BP 2245 EP 2252 DI 10.1016/j.jacc.2005.12.071 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 048YC UT WOS:000237981500015 PM 16750691 ER PT J AU Malm, T Ortt, M Tahtivaara, L Jukarainen, N Goldsteins, G Puolivali, J Nurmi, A Pussinen, R Ahtoniemi, T Miettinen, TK Kanninen, K Leskinen, S Vartiainen, N Yrjanheikki, J Laatikainen, R Harris-White, ME Koistinaho, M Fralutschy, SA Bures, J Koistinaho, J AF Malm, T Ortt, M Tahtivaara, L Jukarainen, N Goldsteins, G Puolivali, J Nurmi, A Pussinen, R Ahtoniemi, T Miettinen, TK Kanninen, K Leskinen, S Vartiainen, N Yrjanheikki, J Laatikainen, R Harris-White, ME Koistinaho, M Fralutschy, SA Bures, J Koistinaho, J TI beta-amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE aging; cerebrospinal fluid; learning; oxidative stress; Alzheimer's disease ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARBOXYL-TERMINAL FRAGMENT; ALZHEIMERS-DISEASE BRAIN; APP TRANSGENIC MICE; PRECURSOR PROTEIN; RAT-BRAIN; MICROGLIAL ACTIVATION; IN-VIVO; SUPEROXIDE-DISMUTASE; COGNITIVE DEFICITS AB beta-Amyloid (A beta) polypeptide plays a critical role in the pathogenesis of Alzheimer's disease (AD), which is characterized by progressive decline of cognitive functions, formation of A beta deposits and neurofibrillary tangles, and loss of neurons. Increased genetic production or direct intracerebral administration of A beta in animal models results in A beta deposition, gliosis, and impaired cognitive functions. Whether aging renders the brain prone to A beta and whether inflammation is required for A beta-induced learning deficits is unclear. We show that intraventricular infusion of A beta(1-42) results in learning deficits in 9-month-old but not 2.5-month-old mice. Deficits that become detectable 12 weeks after the infusion are associated with a slight reduction in Cu,Zn superoxide dismutase activity but do not correlate with A beta deposition and are not associated with gliosis. In rats, A beta infusion induced learning deficits that were detectable 6 months after the infusion. Approximately 20% of the A beta immunoreactivity in rats was associated with astrocytes. NMR spectrum analysis of the animals cerebrospinal fluid revealed a strong reduction trend in several metabolites in All-infused rats, including lactate and myo-inositol, supporting the idea of dysfunctional astrocytes. Even a subtle increase in brain A beta(1-42) concentration may disrupt normal metabolism of astrocytes, resulting in altered neuronal functions and age-related development of learning deficits independent of A beta deposition and inflammation. C1 Kuopio Univ Hosp, Dept Oncol, FI-70211 Kuopio, Finland. Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland. Univ Kuopio, Dept Chem, FIN-70211 Kuopio, Finland. Acad Sci Czech Republ, Inst Physiol, Prague 14220 4, Czech Republic. Charles Univ, Dept Psychiat, Prague 12128 2, Czech Republic. Cerebricon Ltd, FI-70210 Kuopio, Finland. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. Geriatr Res Educ & Clin Core, North Hills, CA 91343 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. RP Bures, J (reprint author), Kuopio Univ Hosp, Dept Oncol, POB 1627, FI-70211 Kuopio, Finland. EM bures@biomed.cas.cz; jari.koistinaho@uku.fi FU BLRD VA [I01 BX000542]; NIA NIH HHS [P50 AG016570, R01 AG010685, R01 AG013741] NR 61 TC 35 Z9 36 U1 1 U2 2 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD JUN 6 PY 2006 VL 103 IS 23 BP 8852 EP 8857 DI 10.1073/pnas.0602896103 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 053BK UT WOS:000238278400049 PM 16723396 ER PT J AU Chandrasekar, B Mummidi, S Mahimainathan, L Patel, DN Bailey, SR Imam, SZ Greene, WC Valente, AJ AF Chandrasekar, B Mummidi, S Mahimainathan, L Patel, DN Bailey, SR Imam, SZ Greene, WC Valente, AJ TI Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappa B- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; C-REACTIVE PROTEIN; ARM ASCOT-LLA; MATRIX METALLOPROTEINASES; SIGNALING PATHWAY; STATIN THERAPY; INVASIVENESS; CHOLESTEROL; DISEASE; EVENTS AB The proliferation and migration of arterial smooth muscle cells (SMCs) are key events in the vascular restenosis that frequently follows angioplasty. Furthermore, SMC migration and neointimal hyperplasia are promoted by degradation of the extracellular matrix by matrix metalloproteinases ( MMPs). Because we demonstrated previously that the proinflammatory and proatherogenic cytokine interleukin-18 (IL-18) stimulates SMC proliferation ( Chandrasekar, B., Mummidi, S., Valente, A. J., Patel, D. N., Bailey, S. R., Freeman, G. L., Hatano, M., Tokuhisa, T., and Jensen, L. E. ( 2005) J. Biol. Chem. 280, 26263 - 26277), we investigated whether IL-18 induces SMC migration in an MMP-dependent manner and whether the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin can inhibit this response. IL-18 treatment increased both mRNA and protein expression of MMP9 in human coronary artery SMCs. Gel shift, enzyme-linked immunosorbent, and chromatin immunoprecipitation assays revealed a strong induction of IL-18-mediated AP-1 (c-Fos, c-Jun, and Fra-1) and NF-kappa B (p50 and p65) activation and stimulation of MMP9 promoter-dependent reporter gene activity in an AP-1- and NF-kappa B-dependent manner. Ectopic expression of p65, c-Fos, c-Jun, and Fra-1 induced MMP9 promoter activity. Specific antisense or small interfering RNA reagents for these transcription factors reduced IL-18-mediated MMP9 transcription. Furthermore, IL-18 stimulated SMC migration in an MMP9-dependent manner. Atorvastatin effectively suppressed IL-18-mediated AP-1 and NF-kappa B-activation, MMP9 expression, and SMC migration. Together, our results indicate for the first time that the proatherogenic cytokine IL-18 induces human coronary artery SMC migration in an MMP9-dependent manner. Atorvastatin inhibits IL-18-mediated aortic SMC migration and has therapeutic potential for attenuating the progression of atherosclerosis and restenosis. C1 S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Calif San Francisco, Gladstone Inst Virol & Immunol, Dept Immunol & Microbiol, San Francisco, CA 94158 USA. RP Chandrasekar, B (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med Cardiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM chandraseka@uthscsa.edu RI Mummidi, Srinivas/C-1004-2008 OI Mummidi, Srinivas/0000-0002-4068-6380 FU NHLBI NIH HHS [HL68020] NR 43 TC 129 Z9 149 U1 1 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 2 PY 2006 VL 281 IS 22 BP 15099 EP 15109 DI 10.1074/jbc.M600200200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 048BI UT WOS:000237922200012 PM 16554298 ER PT J AU Gregg, J Saha, S AF Gregg, J Saha, S TI Losing culture on the way to competence: The use and misuse of culture in medical education SO ACADEMIC MEDICINE LA English DT Article ID MYOCARDIAL-INFARCTION; ALTERNATIVE MEDICINE; COMMUNITY-MEDICINE; CONTROLLED-TRIAL; HEALTH; OSTEOARTHRITIS; CURRICULUM; DISEASE; SURGERY; KNEE AB Most cultural competence programs are based on traditional models of cross-cultural education that were motivated primarily by the desire to alleviate barriers to effective health care for immigrants, refugees, and others on the sociocultural margin. The main driver of renewed interest in cultural competence in the health professions has been the call to eliminate racial and ethnic disparities in the quality of health care. This mismatch between the motivation behind the design of cross-cultural education programs and the motivation behind their current application creates significant problems. First, in trying to define cultural boundaries or norms, programs may inadvertently reinforce racial and ethnic biases and stereotypes while doing little to clarify the actual complex sociocultural contexts in which patients live. Second, in attempting to address racial and ethnic disparities through cultural competence training, educators too often conflate these distinct concepts. To make this argument, the authors first discuss the relevance of culture to health and health care generally, and to disparities in particular. They then examine the concept of culture, paying particular attention to how it has been used (and misused) in cultural competence training. Finally, they discuss the implications of these ideas for health professions education. C1 Oregon Hlth & Sci Univ, Div Gen Internal Med, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. RP Gregg, J (reprint author), Oregon Hlth & Sci Univ, Div Gen Internal Med, 3181 SW Sam Jackson Pk Rd,L-475, Portland, OR 97201 USA. EM greggj@ohsu.edu NR 43 TC 74 Z9 77 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD JUN PY 2006 VL 81 IS 6 BP 542 EP 547 DI 10.1097/01.ACM.0000225218.15207.30 PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 048RB UT WOS:000237963100008 PM 16728802 ER EF